<SEC-DOCUMENT>0001193125-16-670851.txt : 20160804
<SEC-HEADER>0001193125-16-670851.hdr.sgml : 20160804
<ACCEPTANCE-DATETIME>20160804061106
ACCESSION NUMBER:		0001193125-16-670851
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		55
CONFORMED PERIOD OF REPORT:	20160630
FILED AS OF DATE:		20160804
DATE AS OF CHANGE:		20160804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		161805621

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d220080d10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML><HEAD>
<TITLE>Form 10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington,&nbsp;D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 10-Q
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the quarterly period ended June 30, 2016 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period from
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to
<U></U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File No.&nbsp;000-21392 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Amarin
Corporation plc </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>England and Wales</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Incorporation or Organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>2 Pembroke House, Upper Pembroke Street 28-32</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Dublin 2, Ireland</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: +353 (0)&nbsp;1 6699 020 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past
90&nbsp;days.&nbsp;&nbsp;&nbsp;&nbsp;YES&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;NO&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required
to be submitted and posted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T (&#167;229.405 of this chapter) during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to submit and post such
files).&nbsp;&nbsp;&nbsp;&nbsp;YES&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;NO&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See
the definitions of &#147;large accelerated filer,&#148; accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the Exchange Act. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;(Do not check if smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the
Act).&nbsp;&nbsp;&nbsp;&nbsp;YES&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;NO&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">183,448,877 shares held as American Depository Shares (ADSs), each representing one Ordinary Share, 50 pence par value per share, and 1,836,886 ordinary
shares, were outstanding as of August&nbsp;1, 2016. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>INDEX TO FORM 10-Q </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD COLSPAN="3" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B><A HREF="#tx220080_1">PART&nbsp;I &#150; Financial Information </A></B></TD>
<TD VALIGN="top"><B><A HREF="#tx220080_1"></A>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Financial Statements (unaudited):</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx220080_3">Condensed Consolidated Balance Sheets as of June 30, 2016 and December 31, 2015</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx220080_4">Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2016 and 2015</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx220080_5">Condensed Consolidated Statement of Changes in Stockholders&#146; Deficit for the six months ended June 30, 2016</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx220080_6">Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2016 and 2015</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx220080_7">Notes to Condensed Consolidated Financial Statements</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx220080_8">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx220080_9">Quantitative and Qualitative Disclosures about Market Risk</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx220080_10">Controls and Procedures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B><A HREF="#tx220080_11">PART&nbsp;II &#150; Other Information </A></B></TD>
<TD VALIGN="top"><B><A HREF="#tx220080_11"></A>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx220080_12">Legal Proceedings</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1A.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx220080_13">Risk Factors</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx220080_14">Exhibits</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx220080_15">SIGNATURES </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx220080_1"></A>PART I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx220080_3"></A>A<SMALL>MARIN</SMALL> C<SMALL>ORPORATION</SMALL> <SMALL>PLC</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited, in thousands, except share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible asset, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">147,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">173,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIABILITIES AND STOCKHOLDERS&#146; DEFICIT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-Term Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchangeable senior notes, net of discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note&nbsp;7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; Deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A Convertible Preferred Stock, &pound;0.05&nbsp;par, unlimited authorized; 328,184,640
shares issued and outstanding as of June&nbsp;30, 2016 and December&nbsp;31, 2015 (equivalent to 32,818,464 ordinary shares upon future consolidation and redesignation at a 10:1 ratio)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, &pound;0.50&nbsp;par, unlimited authorized; 185,274,511 issued, 184,551,164
outstanding as of June&nbsp;30, 2016; 183,577,765 issued, 183,403,263 outstanding as of December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">822,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">816,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treasury stock; 723,347 shares as of June&nbsp;30, 2016; 174,502 shares as of December&nbsp;31,
2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,160,779</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,117,654</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(164,416</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127,552</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL LIABILITIES AND STOCKHOLDERS&#146; DEFICIT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">147,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">173,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx220080_4"></A>A<SMALL>MARIN</SMALL> C<SMALL>ORPORATION</SMALL> <SMALL>PLC</SMALL>
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited, in thousands, except per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Three&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">58,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensing revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Cost of goods sold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,394</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,786</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain (loss) on change in fair value of derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(136</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,616</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,807</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,692</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations before taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,382</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,049</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,647</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefit from income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,354</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,512</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,638</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock purchase option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock beneficial conversion feature</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss applicable to common shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,354</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(62,853</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(43,125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(94,847</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss per share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.07</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.07</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx220080_5"></A>A<SMALL>MARIN</SMALL> C<SMALL>ORPORATION</SMALL> <SMALL>PLC</SMALL>
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited, in thousands, except share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Treasury<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>Paid-<BR>in&nbsp;Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Treasury<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>December&nbsp;31, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>328,184,640</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>183,577,765</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(174,502</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;24,364</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;149,978</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;816,171</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(411</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,119,293</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(129,191</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative-effect adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>January&nbsp;1, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>328,184,640</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>183,577,765</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(174,502</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24,364</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>149,978</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>816,171</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(411</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,117,654</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(127,552</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting of restricted stock units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,613,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(548,845</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(786</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>June&nbsp;30, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>328,184,640</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>185,274,511</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(723,347</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>24,364</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>151,183</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>822,013</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,197</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,160,779</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(164,416</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx220080_6"></A>A<SMALL>MARIN</SMALL> C<SMALL>ORPORATION</SMALL> <SMALL>PLC</SMALL>
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited, in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CASH FLOWS FROM OPERATING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(43,125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(62,638</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on sale of fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation&#151;warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of debt discount and debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangible asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on change in fair value of derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,846</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(731</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,813</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventories</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,321</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,766</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other non-current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued interest payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,416</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other non-current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,260</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CASH FLOWS FROM INVESTING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CASH FLOWS FROM FINANCING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of preferred stock, net of transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of stock options, net of transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of warrants, net of transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes paid related to stock-based awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments under capital leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(669</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,470</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CASH AND CASH EQUIVALENTS, END OF PERIOD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">136,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Supplemental disclosure of cash flow information:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid during the year for:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash transactions:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer of preferred stock purchase option derivative liability to equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of Series A Convertible Preferred Stock into common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of preferred stock beneficial conversion feature</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to condensed consolidated financial statements.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx220080_7"></A>A<SMALL>MARIN</SMALL> C<SMALL>ORPORATION</SMALL> <SMALL>PLC</SMALL>
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES&nbsp;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this Quarterly Report on Form 10-Q, our ordinary shares may also be referred to as &#147;common shares&#148; or &#147;common stock&#148;. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(1)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Nature of Business and Basis of Presentation </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Nature of Business
</U></I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc (&#147;Amarin&#148; or the &#147;Company&#148;) is a biopharmaceutical company with expertise in lipid science focused
on the commercialization and development of therapeutics to improve cardiovascular health. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s lead product, Vascepa<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) capsules, is approved by the U.S. Food and Drug Administration, or FDA, for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe (TG
<U>&gt;</U>500 mg/dL) hypertriglyceridemia. Vascepa is available in the United States by prescription only. In January 2013, the Company began selling and marketing Vascepa in the United States. In August 2015, in addition to marketing Vascepa for
severe hypertriglyceridemia, the Company commenced marketing Vascepa for use in adult patients with mixed dyslipidemia, as an adjunct to diet and an add-on to statin therapy in patients who despite statin therapy have high triglycerides (TGs
<U>&gt;</U>200 mg/dL and &lt;500 mg/dL), which the Company also refers to as persistently high triglycerides. This expanded promotion of Vascepa commenced pursuant to a federal court order and is continuing pursuant to an agreement among the
Company, the FDA and the U.S. government. The Company sells Vascepa principally to a limited number of major wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its Distributors or its customers,
that in turn resell Vascepa to retail pharmacies for subsequent resale to patients and healthcare providers. The Company markets Vascepa through its sales force of approximately 150 sales professionals, including sales representatives and their
managers. In May 2014, Kowa Pharmaceuticals America, Inc. commenced co-promotion of Vascepa in accordance with a co-promotion agreement with the Company. Kowa Pharmaceuticals America, Inc. co-promotes Vascepa through its no less than 250 sales
representatives who now devote a substantial portion of their time to promoting Vascepa in conjunction with the promotion of Kowa Pharmaceutical America, Inc.&#146;s primary product, a branded statin for patients with high cholesterol. The Company
operates in one business segment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is also developing Vascepa for FDA approval of potential additional indications for use. In particular, the
Company is conducting a cardiovascular outcomes study of Vascepa, titled REDUCE-IT (Reduction of Cardiovascular Events with EPA&#151;Intervention Trial). The REDUCE-IT study, which commenced in 2011 and reached its approximately 8,000 patient
enrollment target in March 2016, is designed to evaluate the efficacy of Vascepa in reducing major cardiovascular events in a high-risk patient population on statin therapy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Basis of Presentation </U></I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
condensed consolidated financial statements included herein have been prepared by the Company, without audit, in accordance with accounting principles generally accepted in the United States of America (the &#147;U.S.&#148; or the &#147;United
States&#148;) and pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. Certain information in the footnote disclosures of the financial statements has been condensed or omitted where it substantially
duplicates information provided in the Company&#146;s latest audited consolidated financial statements, in accordance with the rules and regulations of the SEC. These condensed consolidated financial statements should be read in conjunction with the
Company&#146;s audited consolidated financial statements and notes included in its Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2015, or the 2015 Form 10-K, filed with the SEC. The consolidated balance sheet amounts at
December&nbsp;31, 2015 in this report were derived from the Company&#146;s audited 2015 consolidated financial statements included in the 2015 Form 10-K. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The condensed consolidated financial statements reflect all adjustments of a normal and recurring nature that, in the opinion of management, are necessary to
present fairly the Company&#146;s financial position, results of operations and cash flows for the periods indicated. The preparation of the Company&#146;s condensed consolidated financial statements in conformity with U.S. Generally Accepted
Accounting Principles (&#147;GAAP&#148;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and
the reported amounts of revenues and expenses during the reporting period. The results of operations for the three and six months ended June&nbsp;30, 2016 and June&nbsp;30, 2015, respectively, are not necessarily indicative of the results for the
entire fiscal year or any future period. Certain numbers presented throughout this document may not add precisely to the totals provided due to rounding. Absolute and percentage changes are calculated using the underlying amounts in thousands.
Certain prior year balances have been reclassified to conform to current year presentation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements of the Company and subsidiaries have been prepared on a basis
which assumes that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2016, the Company had current assets of $116.5 million, including cash and cash equivalents of $72.5&nbsp;million. The Company&#146;s
condensed consolidated balance sheets also include derivative liabilities as well as long-term debt and exchangeable senior notes. The outstanding January 2012 exchangeable senior notes, or the 2012 Notes, may be redeemed by the Company on or after
January&nbsp;19, 2017 and may be put back to the Company by the holders on each of January&nbsp;19, 2017, 2022 and 2027 for cash equal to 100% of the principal amount of $15.1 million plus any accrued and unpaid interest. The outstanding May 2014
exchangeable senior notes, or the 2014 Notes, and the outstanding November 2015 exchangeable senior notes, or the 2015 Notes, may be redeemed by the Company on or after January&nbsp;19, 2019 at the option of the holders and are not puttable by the
holders prior to this date except upon the occurrence of certain contingent events. The 2012 Notes are exchangeable under certain circumstances into cash, American Depository Shares, or ADSs, or a combination of cash and ADSs, at the Company&#146;s
election. The 2014 Notes and 2015 Notes are exchangeable under certain circumstances into ADSs. Accordingly, the 2012 Notes represent a short-term obligation while the long-term debt, 2014 Notes, and 2015 Notes do not represent a short-term claim on
the liquid assets of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company believes its cash and cash equivalents will be sufficient to fund its projected operations for at least the
next twelve months. Depending on the level of cash generated from operations, additional capital will likely be required to sustain operations. The Company anticipates that quarterly net cash outflows in future periods will be variable. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(2)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Significant Accounting Policies </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Principles of Consolidation </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and
transactions have been eliminated in consolidation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Use of Estimates </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounting estimates are based on historical experience and other factors that are considered reasonable under the circumstances. Estimates are used in
determining such items as provisions for sales returns, rebates and incentives, chargebacks, and other sales allowances; depreciable/amortizable lives; asset impairments; valuation allowance on deferred taxes; probabilities of achievement of
performance conditions for certain equity awards; amounts recorded for licensing revenue; contingencies and accruals; and valuations of derivative and long-term debt instruments. Because of the uncertainties inherent in such estimates, actual
results may differ from these estimates. Management periodically evaluates estimates used in the preparation of the condensed consolidated financial statements for continued reasonableness. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Use of Forecasted Financial Information in Accounting Estimates </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The use of forecasted financial information is inherent in many of the Company&#146;s accounting estimates including, but not limited to, determining the
estimated fair values of derivatives, debt instruments and intangible assets, and evaluating the need for valuation allowances for deferred tax assets. Such forecasted financial information is comprised of numerous assumptions regarding the
Company&#146;s future revenues, cash flows, and operational results. Management believes that its financial forecasts are reasonable and appropriate based upon current facts and circumstances. Because of the inherent nature of forecasts, however,
actual results may differ from these forecasts. Management regularly reviews the information related to these forecasts and adjusts the carrying amounts of the applicable assets prospectively, if and when actual results differ from previous
estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Revenue Recognition </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company sells Vascepa principally to a limited number of major wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or
collectively, its Distributors or its customers, that in turn resell Vascepa to retail pharmacies for subsequent resale to patients and healthcare providers. Patients are required to have a prescription in order to purchase Vascepa. In accordance
with GAAP, the Company&#146;s revenue recognition policy requires that: (i)&nbsp;there is persuasive evidence that an arrangement exists between the Company and the Distributor, (ii)&nbsp;delivery has occurred, (iii)&nbsp;collectability is
reasonably assured and (iv)&nbsp;the price is fixed or determinable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has contracts with its primary Distributors and delivery generally
occurs when a Distributor receives Vascepa. The Company evaluates the creditworthiness of each of its Distributors to determine whether revenues can be recognized upon delivery, subject to satisfaction of the other requirements, or whether
recognition is required to be delayed until receipt of payment. In order to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conclude that the price is fixed or determinable, the Company must be able to (i)&nbsp;calculate its gross product revenues from the sales to Distributors and (ii)&nbsp;reasonably estimate its
net product revenues. The Company calculates gross product revenues generally based on the wholesale acquisition cost that the Company charges its Distributors for Vascepa. The Company estimates its net product revenues by deducting from its gross
product revenues (a)&nbsp;trade allowances, such as invoice discounts for prompt payment and distributor fees, (b)&nbsp;estimated government and private payor rebates, chargebacks and discounts, such as Medicaid reimbursements, (c)&nbsp;reserves for
expected product returns and (d)&nbsp;estimated costs of incentives offered to certain indirect customers, including patients. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Trade Allowances: </I>The Company generally provides invoice discounts on Vascepa sales to its Distributors for prompt
payment and pays fees for distribution services, such as fees for certain data that Distributors provide to the Company. The payment terms for sales to Distributors generally include a 2% discount for payment within 30&nbsp;days while the fees for
distribution services are based on contractual rates agreed with the respective Distributors. Based on judgment and experience, the Company expects its Distributors to earn these discounts and fees, and deducts the full amount of these discounts and
fees from its gross product revenues and accounts receivable at the time such revenues are recognized. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Rebates,
Chargebacks and Discounts: </I>The Company contracts with Medicaid, other government agencies and various private organizations, or collectively, Third-party Payors, so that Vascepa will be eligible for purchase by, or partial or full reimbursement
from, such Third-party Payors. The Company estimates the rebates, chargebacks and discounts it will provide to Third-party Payors and deducts these estimated amounts from its gross product revenues at the time the revenues are recognized. The
Company estimates the rebates, chargebacks and discounts that it will provide to Third-party Payors based upon (i)&nbsp;the Company&#146;s contracts with these Third-party Payors, (ii)&nbsp;the government-mandated discounts applicable to
government-funded programs, (iii)&nbsp;information obtained from the Company&#146;s Distributors and (iv)&nbsp;information obtained from other third parties regarding the payor mix for Vascepa. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Product Returns: </I>The Company&#146;s Distributors have the right to return unopened unprescribed Vascepa during the
18-month period beginning six months prior to the labeled expiration date and ending twelve months after the labeled expiration date. The expiration date for Vascepa is three years after it has been converted into capsule form, which is the last
step in the manufacturing process for Vascepa and generally occurs within a few months before Vascepa is delivered to Distributors. The Company estimates future product returns on sales of Vascepa based on: (i)&nbsp;data provided to the Company by
its Distributors (including weekly reporting of Distributors&#146; sales and inventory held by Distributors that provided the Company with visibility into the distribution channel in order to determine what quantities were sold to retail pharmacies
and other providers), (ii)&nbsp;information provided to the Company from retail pharmacies, (iii)&nbsp;data provided to the Company by a third party data provider which collects and publishes prescription data, and other third parties,
(iv)&nbsp;historical industry information regarding return rates for similar pharmaceutical products, (v)&nbsp;the estimated remaining shelf life of Vascepa previously shipped and currently being shipped to Distributors and (vi)&nbsp;contractual
agreements intended to limit the amount of inventory maintained by the Company&#146;s Distributors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Other Incentives:
</I>Other incentives that the Company offers to indirect customers include co-pay mitigation rebates provided by the Company to commercially insured patients who have coverage for Vascepa and who reside in states that permit co-pay mitigation
programs. The Company&#146;s co-pay mitigation program is intended to reduce each participating patient&#146;s portion of the financial responsibility for Vascepa&#146;s purchase price to a specified dollar amount. Based upon the terms of the
program and information regarding programs provided for similar specialty pharmaceutical products, the Company estimates the average co-pay mitigation amounts and the percentage of patients that it expects to participate in the program in order to
establish its accruals for co-pay mitigation rebates and deducts these estimated amounts from its gross product revenues at the time the revenues are recognized. The Company adjusts its accruals for co-pay mitigation rebates based on actual
redemption activity and estimates regarding the portion of issued co-pay mitigation rebates that it estimates will be redeemed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables summarize activity in each of the net product revenue allowance and reserve categories
described above for the six months ended June&nbsp;30, 2016 and 2015: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>In thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Trade<BR>Allowances</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Rebates,<BR>Chargebacks<BR>and&nbsp;Discounts</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Product<BR>Returns</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other<BR>Incentives</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 4,296</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 9,881</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 535</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 1,084</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 15,796</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision related to current period sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision related to prior period sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(466</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Credits/payments made for current period sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,415</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,910</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,075</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Credits/payments made for prior period sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,180</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,284</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,187</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of June&nbsp;30, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,662</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19,113</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>566</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,504</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>25,845</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>In thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Trade<BR>Allowances</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Rebates,<BR>Chargebacks<BR>and&nbsp;Discounts</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Product<BR>Returns</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other<BR>Incentives</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 2,207</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 3,610</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;481</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 792</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 7,090</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision related to current period sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision related to prior period sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Credits/payments made for current period sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,810</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,149</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Credits/payments made for prior period sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,531</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(792</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,376</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of June&nbsp;30, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,289</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,749</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>743</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,542</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,323</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such net product revenue allowances and reserves are included within accrued expenses and other current liabilities within the
condensed consolidated balance sheets, with the exception of trade allowances and chargebacks, which are included within accounts receivable, net as discussed below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Multiple-Element Arrangements and Licensing Revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When evaluating multiple-element arrangements, the Company identifies the deliverables included within the agreement and evaluates which deliverables represent
separate units of accounting based on whether the delivered element has stand-alone value to the customer or if the arrangement includes a general right of return for delivered items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consideration received is allocated between each of the separable elements in the arrangement using the relative selling price method. The selling price
used for each separable element will be based on vendor specific objective evidence (&#147;VSOE&#148;) if available, third-party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third-party evidence is available.
Revenue is then recognized as each of the separable elements to which the revenue has been allocated is delivered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may receive up-front,
non-refundable payments when licensing its intellectual property in conjunction with research, development and commercialization agreements. In determining the units of accounting, management evaluates whether the license has stand-alone value from
the undelivered elements to the collaborative partner based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the stage of development of the license delivered,
research and development capabilities of the partner and the ability of partners to develop and commercialize Vascepa independent of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When
management believes the license to its intellectual property does not have stand-alone value from the other deliverables to be provided in the arrangement, the Company generally recognizes revenue attributable to the license over the Company&#146;s
contractual or estimated performance period. Any unrecognized portion of license revenue is classified within deferred revenue in the accompanying condensed consolidated balance sheets. When management believes the license to its intellectual
property has stand-alone value, the Company recognizes revenue attributed to the license upon delivery. The periods over which revenue is recognized is subject to estimates by management and may change over the course of the agreement. Such a change
could have a material impact on the amount of revenue the Company records in future periods. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Milestones </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contingent consideration from activities that is earned upon the achievement of a substantive milestone is recognized in its entirety in the period in which
the milestone is achieved. At the inception of each arrangement that includes milestone payments, the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
evaluates whether each milestone is substantive. This evaluation includes an assessment of whether: (a)&nbsp;the consideration is commensurate with either (1)&nbsp;the entity&#146;s performance
to achieve the milestone, or (2)&nbsp;the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity&#146;s performance to achieve the milestone, (b)&nbsp;the consideration relates solely to past
performance and (c)&nbsp;the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must
be overcome to achieve the respective milestone, the level of effort and investment required and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 10&#151;Development, Commercialization and Supply Agreement for further information regarding licensing revenue and milestones related to the
Company&#146;s multiple-element arrangement with Eddingpharm (Asia) Macao Commercial Offshore Limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Distribution Costs
</U></I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records distribution costs related to shipping product to its customers, primarily through the use of common carriers or external
distribution services, in cost of goods sold. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Cash and Cash Equivalents and Restricted Cash </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents consist of cash, deposits with banks and short-term highly liquid money market instruments with remaining maturities at the date of
purchase of 90&nbsp;days or less. Restricted cash represents cash and cash equivalents pledged to guarantee repayment of certain expenses which may be incurred for business travel under corporate credit cards held by employees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Accounts Receivable, net </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounts receivable, net, comprised of trade receivables, are generally due within 30 days and are stated at amounts due from customers. The Company does not
currently maintain an allowance for doubtful accounts and has not historically experienced any credit losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the impact
of accounts receivable reserves on the gross trade accounts receivable balances as of June&nbsp;30, 2016 and December&nbsp;31, 2015: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>In thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross trade accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade allowances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,662</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chargebacks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(227</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(148</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Inventory </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective April 2016, the Company adopted ASU No.&nbsp;2015-11, <I>Inventory (Topic 330)&#151;Simplifying the Measurement of Inventory</I>, which simplifies
the subsequent measurement of inventories by replacing the lower of cost or market test with a lower of cost and net realizable value test and, as such, began to state inventories at the lower of cost or net realizable value. Such adoption had no
impact on the carrying value of inventory. Cost is determined based on actual cost using the average cost method. An allowance is established when management determines that certain inventories may not be saleable. If inventory cost exceeds expected
net realizable value due to obsolescence, damage, quantities in excess of expected demand, changes in price levels or other causes, the Company will reduce the carrying value of such inventory to net realizable value and recognize the difference as
a component of cost of goods sold in the period in which it occurs. The Company capitalizes inventory purchases of saleable product from approved suppliers while inventory purchases from suppliers prior to regulatory approval are included as a
component of research and development expense. The Company expenses inventory identified for use as marketing samples when they are packaged. The average cost reflects the actual purchase price of Vascepa active pharmaceutical ingredient, or API.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Property, Plant and Equipment </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company provides for depreciation and amortization using the straight-line method by charges to operations in amounts that depreciate the cost of the fixed
asset over its estimated useful life. The estimated useful lives, by asset classification, are as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:66.30pt; font-size:8pt; font-family:Times New Roman"><B>Asset Classification</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Useful&nbsp;Lives</B></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3&nbsp;-&nbsp;5&nbsp;years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5&nbsp;years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Lesser&nbsp;of&nbsp;useful&nbsp;life&nbsp;or&nbsp;lease&nbsp;term</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon retirement or sale of assets, the cost of the assets disposed and the related accumulated depreciation are removed from
the condensed consolidated balance sheet and any resulting gain or loss is credited or expensed to operations. Repairs and maintenance costs are expensed as incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Long-Lived Asset Impairment </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not
be recoverable. Recoverability of these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to their carrying amount. If impairment is indicated, the assets are written down to
fair value. Fair value is determined based on discounted forecasted cash flows or appraised values, depending on the nature of the assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Intangible Asset, net </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intangible asset, net consists of a milestone payment paid to the former shareholders of Laxdale Limited related to the 2004 acquisition of the rights to
Vascepa, which is the result of Vascepa receiving marketing approval for the first indication and is amortized over its estimated useful life on a straight-line basis. See Note 7&#151;Commitments and Contingencies for further information regarding
other obligations related to the acquisition of Laxdale Limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Beneficial Conversion Features </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company issued Series A preference shares in a private placement transaction executed in two tranches that each contain a conversion feature whereby such
shares are convertible into ordinary shares at a fixed rate. The conversion price on the date of issuance was less than the market price of the Company&#146;s ordinary shares. It was determined that these discounts represent contingent beneficial
conversion features, which were valued based on the difference between the conversion price and the market price of the ordinary shares on the date of issuance, which is the commitment date. These features are analogous to preference dividends and
were each recorded as a non-cash return to preferred shareholders through accumulated deficit upon the earliest possible date of conversion, which occurred in the three months ended June&nbsp;30, 2015 upon effectiveness of the related resale
Registration Statement on Form S-3 and in the three months ended September&nbsp;30, 2015 upon shareholder approval received at the Company&#146;s Annual General Meeting of Shareholders. See Note 8&#151;Equity for further discussion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Costs for Patent Litigation and Legal Proceedings </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs for patent litigation or other legal proceedings are expensed as incurred and included in selling, general and administrative expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Research and Development Costs </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company charges research and development costs to operations as incurred. Research and development expenses are comprised of costs incurred by the Company
in performing research and development activities, including: salary and benefits; stock-based compensation expense; laboratory supplies and other direct expenses; contractual services, including clinical trial and pharmaceutical development costs;
commercial supply investment in its drug candidates; and infrastructure costs, including facilities costs and depreciation expense. In addition, research and development costs include the costs of product supply received from suppliers when such
receipt by the Company is prior to regulatory approval of the supplier. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Selling, General and Administrative Costs
</U></I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company charges selling, general and administrative costs to operations as incurred. Selling, general and administrative costs include
costs of salaries, programs and infrastructure necessary for the general conduct of the Company&#146;s business, including those incurred as a result of the commercialization of Vascepa in the United States as well as co-promotion fees payable to
Kowa Pharmaceuticals America, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Income Taxes </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred tax assets and liabilities are recognized for the future tax consequences of differences between the carrying amounts and tax bases of assets and
liabilities and operating loss carryforwards and other attributes using enacted rates expected to be in effect when those differences reverse. Valuation allowances are provided against deferred tax assets that are not more likely than not to be
realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company provides reserves for potential payments of tax to various tax authorities or does not recognize tax benefits related to uncertain
tax positions and other issues. Tax benefits for uncertain tax positions are based on a determination of whether a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized, assuming that the matter in
question will be decided based on its technical merits. The Company&#146;s policy is to record interest and penalties in the provision for income taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company regularly assesses its ability to realize deferred tax assets. Changes in historical earnings performance and future earnings projections, among
other factors, may cause the Company to adjust its valuation allowance on deferred tax assets, which would impact the Company&#146;s income tax expense in the period in which it is determined that these factors have changed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2016, the Company adopted ASU No.&nbsp;2016-09, <I>Compensation&#151;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment
Accounting,</I> which changes the accounting for certain aspects of share-based payments to employees. One aspect of the standard requires that excess tax benefits and deficiencies that arise upon vesting or exercise of share-based payments be
recognized as an income tax benefit and expense in the income statement. Previously, such amounts were recognized as an increase and decrease in additional paid-in capital. This aspect of the standard was adopted prospectively, and accordingly, the
benefit from income taxes for the three and six months ended June&nbsp;30, 2016, includes $0.1 million and $0.2 million, respectively, of excess tax deficiencies arising from share-based payments. Additionally, the new standard requires that
historical excess tax benefits that were not previously recognized because the related tax deduction had not reduced current taxes payable should be recognized on a modified retrospective basis as a cumulative-effect adjustment to retained earnings
as of the beginning of the annual period of adoption. Consequently, the Company recognized deferred tax assets of approximately $1.6 million relating to excess tax benefits of stock-based compensation outstanding as of December&nbsp;31, 2015, with a
corresponding cumulative-effect adjustment to accumulated deficit. The new standard also amends the presentation of employee share-based payment-related items in the statement of cash flows by requiring that: (i)&nbsp;excess income tax benefits and
deficiencies be classified in cash flows from operating activities, and (ii)&nbsp;cash paid to taxing authorities arising from the withholding of shares from employees be classified as cash flows from financing activities. The Company adopted the
aspects of the standard affecting cash flow presentation retrospectively and, accordingly, reclassified $0.6 million of excess tax provision from cash flows provided by financing activities to cash flows used in operating activities in the condensed
consolidated statement of cash flows for the six months ended June&nbsp;30, 2015 to conform to the current year presentation. The presentation requirement for cash flows related to taxes paid for withheld shares had no impact to any of the periods
presented in the condensed consolidated statement of cash flows since such payments have historically been presented as a financing activity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company&#146;s and its subsidiaries&#146; income tax returns are periodically examined by various tax authorities. The Company is currently under audit by the United States Internal Revenue Service (IRS) for the years 2012 to 2013. Although the
outcome of tax audits is always uncertain and could result in significant cash tax payments, the Company does not believe the outcome of these audits will have a material adverse effect on the Company&#146;s consolidated financial position or
results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Derivative Instruments </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derivative financial liabilities are recorded at fair value, with gains and losses arising for changes in fair value recognized in the condensed consolidated
statement of operations at each period end while such instruments are outstanding. If the Company issues shares to discharge the liability, the derivative financial liability is derecognized and common stock and additional paid-in capital are
recognized on the issuance of those shares. Warrants are valued using a Black-Scholes option pricing model. The long-term debt redemption features are valued using probability-weighted models incorporating management estimates for potential change
in control, and by determining the fair value of the debt with and without the change in control provision included. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the terms of warrants that
initially require the warrant to be classified as a derivative financial liability lapse, the derivative financial liability is reclassified out of financial liabilities into equity at its fair value on that date. The cash proceeds received from
exercises of warrants are recorded in common stock and additional paid-in capital. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Loss per Share </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period. Diluted net loss per
share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as common stock options and warrants
calculated using the treasury stock method and convertible notes using the &#147;if-converted&#148; method. In periods with reported net operating losses, all common stock options and warrants are deemed anti-dilutive such that basic net loss per
share and diluted net loss per share are equal. However, in certain periods in which there is a gain recorded pursuant to the change in fair value of the warrant derivative liability, for diluted net loss per share purposes, the impact of such gains
is reversed and the treasury stock method is used to determine diluted net loss per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s preferred stock is entitled to receive dividends on an as-if-converted basis in the same form
as dividends actually paid on common shares. Accordingly, the preferred stock is considered a participating security and the Company is required to apply the two-class method to consider the impact of the preferred stock on the calculation of basic
and diluted earnings per share. The Company is currently in a net loss position and is therefore not required to present the two-class method, however, in the event the Company is in a net income position, the two-class method must be applied by
allocating all earnings during the period to common shares and preferred stock based on their contractual entitlements assuming all earnings were distributed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The calculation of net loss and the number of shares used to compute basic and diluted net loss per share for the three and six months ended June&nbsp;30,
2016 and 2015 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Three&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>In thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,354</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(31,512</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(43,125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(62,638</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock purchase option (see Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock beneficial conversion feature (see Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss applicable to common shareholders&#151;basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,354</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,853</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,847</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on warrant derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss&#151;diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,354</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,853</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94,966</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.07</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the three and six months ended&nbsp;June 30, 2016 and 2015, the following potentially dilutive securities were not
included in the computation of net loss per share because the effect would be anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Three months ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Six months ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>In thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock and restricted stock units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchangeable senior notes (if converted)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock (if converted)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Debt Instruments </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Debt instruments are initially recorded at fair value, with coupon interest and amortization of debt issuance discounts recognized in the condensed
consolidated statement of operations as interest expense each period in which such instruments are outstanding. If the Company issues shares to discharge the liability, the debt obligation is derecognized and common stock and additional paid-in
capital are recognized on the issuance of those shares. The conversion features in the 2012 Notes, 2014 Notes, and 2015 Notes qualify for the exception from derivative accounting in accordance with ASC 815-40. The 2012 Notes may be settled, at the
Company&#146;s discretion, in any combination of ADSs or cash upon conversion and have been accounted for in accordance with ASC 470-20. Under ASC 470-20, the fair value of the liability component of the 2012 Notes was determined and deducted from
the initial proceeds to determine the proceeds allocated to the conversion option, which has been recorded in equity. The difference between the initial fair value of the liability component and the amount repayable was amortized over the expected
term of the instrument. The conversion features in the 2014 Notes and 2015 Notes may only be settled in ADSs upon conversion and have been accounted for as part of the debt host. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conversion options in the 2012 Notes, 2014 Notes, and 2015 Notes continue to be evaluated on a quarterly basis to determine if they still receive an
exception from derivative accounting in accordance with ASC 815-40. The 2014 Notes were recognized initially at fair value as part of an extinguishment of a portion of the 2012 Notes. As a result, the 2014 Notes were initially recognized at a
discount of $27.9 million. The 2015 Notes were recognized initially at fair value as part of the issuance of new debt in November 2015. As a result, the 2015 Notes were initially recognized at a discount of $3.8 million. These discounts are being
amortized through interest expense over the expected terms of the 2014 Notes and 2015 Notes, which is through January 2019 for each. See Note 6&#151;Debt for further discussion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Stock-Based Compensation </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock-based compensation cost is generally measured at the grant date, based on the fair value of the award, and is recognized as compensation expense over the
requisite service period. For awards with performance conditions, if the achievement of the performance conditions is deemed probable, the Company recognizes compensation expense based on the fair value of the award over the estimated service
period. The Company reassesses the probability of achievement of the performance conditions for such awards each reporting period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Concentration of Credit Risk </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company
maintains substantially all of its cash and cash equivalents in financial institutions believed to be of high-credit quality. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A significant portion of
the Company&#146;s sales are to wholesalers in the pharmaceutical industry. The Company monitors the creditworthiness of customers to whom it grants credit terms and has not experienced any credit losses. The Company does not require collateral or
any other security to support credit sales. The Company&#146;s top three customers accounted for 95% of gross product sales for each of the six months ending June&nbsp;30, 2016 and 2015 and represented 94% and 96% of the gross accounts receivable
balance as of June&nbsp;30, 2016 and 2015, respectively. The Company has not experienced any write-offs of its accounts receivable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Concentration of Suppliers </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has contractual freedom to source the API for Vascepa and has entered into supply agreements with multiple suppliers. The Company&#146;s supply of
product for commercial sale and clinical trials is dependent upon relationships with third-party manufacturers and key suppliers, in particular three suppliers of API for Vascepa. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company cannot provide assurance that its efforts to procure uninterrupted supply of Vascepa API to meet market demand will continue to be successful or
that it will be able to renew current API supply agreements on favorable terms or at all. Significant alteration to or termination of the Company&#146;s current API supply chain or its failure to enter into new and similar agreements, if needed,
could have a material adverse effect on its business, condition (financial and other), prospects or results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company currently has
manufacturing agreements with three FDA-approved commercial API encapsulators for Vascepa manufacturing. Each of these companies has qualified its manufacturing processes and is capable of manufacturing Vascepa. There can be no guarantee that these
or other suppliers with which the Company may contract in the future to encapsulate API will continue to be qualified to manufacture the product to its specifications or that these and any future suppliers will have the manufacturing capacity to
meet anticipated demand for Vascepa. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Foreign Currency </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All subsidiaries use the U.S. dollar as the functional currency. Monetary assets and liabilities denominated in a foreign currency are remeasured into U.S.
dollars at period-end exchange rates. Gains and losses from the remeasurement are included in other (expense) income, net in the condensed consolidated statements of operations. For transactions settled during the applicable period, gains and losses
are included in other (expense) income, net in the condensed consolidated statements of operations. Certain amounts payable pursuant to supply contracts are denominated in currencies other than the U.S. dollar. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Debt Issuance Costs </U></I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior
to January 2016, debt issuance costs were initially recorded as a deferred cost and amortized to interest expense using the effective interest method over the expected term of the related debt. Effective January 2016, the Company adopted ASU
No.&nbsp;2015-03, <I>Interest&#151;Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</I>, and as such began recording debt issuance costs related to a recognized debt liability in the condensed
consolidated balance sheet as a direct deduction from the carrying amount of that debt liability and amortized to interest expense using the effective interest method over the expected term of the related debt. As the standard is required to be
adopted on a retrospective basis, the Company reclassified $1.9 million of underwriters&#146; fees and offering costs related to the 2014 and 2015 exchangeable notes from other long-term assets to exchangeable senior notes, net of discount, within
the condensed consolidated balance sheet as of December&nbsp;31, 2015. Unamortized debt issuance costs related to the extinguishment of debt are expensed at the time the debt is extinguished and recorded in other (expense) income, net in the
condensed consolidated statements of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Fair Value of Financial Instruments </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company provides disclosure of financial assets and financial liabilities that are carried at fair value based on the price that would be received upon
sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&nbsp;Fair value measurements may be classified based on the amount of subjectivity associated with the inputs to fair
valuation of these assets and liabilities using the following three levels: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level 1&#151;Inputs are unadjusted quoted prices in active markets for
identical assets or liabilities that the Company has the ability to access at the measurement date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level 2&#151;Inputs include quoted prices for similar
assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield
curves, etc.) and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level 3&#151;Unobservable inputs that reflect the Company&#146;s estimates of the assumptions that market participants would use in pricing the asset or
liability.&nbsp;The Company develops these inputs based on the best information available, including its own data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables present
information about the Company&#146;s assets and liabilities as of June&nbsp;30, 2016 and December&nbsp;31, 2015 that are measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques the Company
utilized to determine such fair value: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30, 2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>In thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Asset:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents&#151;money markets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>In thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Asset:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents&#151;money markets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying amounts of cash, cash equivalents, accounts payable and accrued liabilities approximate fair value because of
their short-term nature. The carrying amounts and the estimated fair values of debt instruments as of June&nbsp;30, 2016 and December&nbsp;31, 2015 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30, 2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>In thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt&#151;December 2012 financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">89,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">91,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2012 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2014 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The estimated fair value of the long-term debt pursuant to the December 2012 financing is calculated utilizing the same Level
3 inputs utilized in valuing the related derivative liability (see Long-Term Debt Redemption Features below).&nbsp;The estimated fair value of the 2012 Notes and 2014 Notes is calculated based on Level 1 quoted bond prices, while the estimated fair
value of the 2015 Notes is calculated based on Level 2 quoted bond prices for the 2014 Notes.&nbsp;The carrying value of the 2012 Notes as of June&nbsp;30, 2016 and December&nbsp;31, 2015 does not include a debt discount, as it had been fully
amortized as non-cash interest expense over the expected term of the 2012 Notes, which was calculated to be a period of twenty-four months. The carrying value of the 2014 Notes as of June&nbsp;30, 2016 and December&nbsp;31, 2015 includes a debt
discount of $20.7 million and $24.1 million, respectively, which is being amortized as non-cash interest expense over the expected term of the 2014 Notes, through January 2019. The carrying value of the 2015 Notes as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of June&nbsp;30, 2016 and December&nbsp;31, 2015 includes a debt discount of $3.6 million and $4.2 million, respectively, which is being amortized as non-cash interest expense over the expected
term of the 2015 Notes, through January 2019. The carrying values and related debt discounts of the 2014 Notes and 2015 Notes as of December&nbsp;31, 2015 reflect the retroactive reclassification of debt issuance costs per adoption of ASU
No.&nbsp;2015-03 as described in Note 6&#151;Debt. The change in the estimated fair values of these liabilities from December&nbsp;31, 2015 to June&nbsp;30, 2016 is largely related to changes in the quoted bond prices. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Derivative Liabilities </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Warrant Derivative Liability </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company&#146;s warrant derivative liability (discussed in Note 5&#151;Warrants and Warrant Derivative Liability) was carried at fair value and was classified as Level 3 in the fair value hierarchy due to the use of significant unobservable inputs.
During the six months ended June&nbsp;30, 2015, of the 8,087,388 warrants outstanding as of December&nbsp;31, 2014, 1,844,585 warrants were exercised while the remaining 6,242,803 warrants expired, and the related derivative liability was
extinguished. As such, no warrants were outstanding as of June&nbsp;30, 2016 and December&nbsp;31, 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Long-Term Debt Redemption
Features </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s December 2012 financing agreement with BioPharma Secured Debt Fund II Holdings Cayman LP (discussed in
Note&nbsp;6&#151;Debt) contains a redemption feature whereby, upon a change of control, the Company would be required to repay $150 million, less any previously repaid amount. The Company determined this redemption feature to be an embedded
derivative, which is carried at fair value and is classified as Level 3 in the fair value hierarchy due to the use of significant unobservable inputs.&nbsp;The fair value of the embedded derivative was calculated using a probability-weighted model
incorporating management estimates of future revenues and for a potential change in control, and by determining the fair value of the debt with and without the change in control provision included. The difference between the two was determined to be
the fair value of the embedded derivative. As of June&nbsp;30, 2016, the fair value of the derivative was determined to be $2.8 million, and the debt was valued by comparing debt issues of similar companies with (i)&nbsp;remaining terms of between
1.6 and 5.9 years, (ii)&nbsp;coupon rates of between 6.6% and 12.5% and (iii)&nbsp;market yields of between 11.0% and 27.7%. As of December&nbsp;31, 2015, the fair value of the derivative was determined to be $5.5 million, and the debt was valued by
comparing debt issues of similar companies with (i)&nbsp;remaining terms of between 2.0 and 7.3 years, (ii)&nbsp;coupon rates of between 6.6% and 12.5% and (iii)&nbsp;market yields of between 13.0% and 30.7%. As such, the Company recognized a $2.7
million gain on change in fair value of derivative liability for the six months ended June&nbsp;30, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s 2014 Notes and 2015 Notes
each contain a redemption feature whereby, upon occurrence of a change in control, the Company would be required to repurchase the notes. The Company determined these redemption features to be embedded derivatives, requiring bifurcation in
accordance with ASC 815. The derivatives are carried at fair value and are classified as Level 3 in the fair value hierarchy due to the use of significant unobservable inputs.&nbsp;The fair value of each embedded derivative was calculated using a
probability-weighted model incorporating management estimates of the probability of a change in control occurring, and by determining the fair value of the debt with and without the change in control provision included. The difference between the
two was determined to be the fair value of the embedded derivative. As of June&nbsp;30, 2016, the fair values of the derivatives related to the 2014 Notes and 2015 Notes were determined to be $0.6 million and $0.2 million, respectively, and the
debts were valued by using (i)&nbsp;the estimated remaining term of the notes, (ii)&nbsp;a bond yield of 20.6%, (iii)&nbsp;a risk-free interest rate of 2.0% and (iv)&nbsp;volatility of 86.0%. As of December&nbsp;31, 2015, the fair values of the
derivatives related to the 2014 Notes and 2015 Notes were determined to be $2.1 million and $0.6 million, respectively, and the debts were valued by using (i)&nbsp;the estimated remaining term of the notes, (ii)&nbsp;a bond yield of 25.6%,
(iii)&nbsp;a risk-free interest rate of 2.9% and (iv)&nbsp;volatility of 89.0%. As such, the Company recognized a $1.5 million gain and $0.4 million gain on change in fair value of derivative liability for the 2014 Notes and 2015 Notes,
respectively, for the six months ended June&nbsp;30, 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Preferred Stock Purchase Option Derivative Liability </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to a pre-existing contractual right to participate in certain private placement transactions effected by the Company in connection with the
subscription agreement executed on March&nbsp;5, 2015, the Company determined that such right represented a derivative liability (see Note 8). This preferred stock purchase option derivative liability was carried at fair value and classified as
Level 3 in the fair value hierarchy due to the use of significant unobservable inputs. The fair value of this liability was calculated using a Black-Scholes model and was determined to be $0.9 million at inception. On March&nbsp;30, 2015, this right
was exercised and the liability was marked to fair value through such date. The liability was then reclassified to permanent equity on such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any
changes in the assumptions used to value the derivative liabilities, including the probability of a change in control, could result in a material change to the carrying value of such liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The change in the fair value of derivative liabilities for the six months ended June&nbsp;30, 2016 and 2015 is as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>In thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October<BR>2009<BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Long-Term&nbsp;Debt</FONT><BR>Derivative<BR>Liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred&nbsp;Stock<BR>Purchase&nbsp;Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Totals</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 8,170</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 8,170</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on change in fair value of derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of June&nbsp;30, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,610</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,610</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>In thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October<BR>2009<BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Long-Term&nbsp;Debt</FONT><BR>Derivative<BR>Liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred&nbsp;Stock<BR>Purchase&nbsp;Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Totals</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 119</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;7,400</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> &#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 7,519</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Record derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on change in fair value of derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation income for change in fair value of warrants issued to former employees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer derivative liability to equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,814</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,814</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of June&nbsp;30, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,700</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,700</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Segment and Geographical Information </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by
the chief operating decision-maker, or decision making group, in deciding how to allocate resources to an individual segment and in assessing performance of the segment. The Company currently operates in one business segment, which is the
development and commercialization of Vascepa. A single management team that reports to the Company&#146;s chief decision-maker, who is the Chief Executive Officer, comprehensively manages the business. Accordingly, the Company does not have
separately reportable segments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Recent Accounting Pronouncements </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, and are early adopted by the Company or
adopted as of the specified effective date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2016, the Company adopted ASU No.&nbsp;2015-03, <I>Interest&#151;Imputation of Interest (Subtopic
835-30): Simplifying the Presentation of Debt Issuance Costs</I>, which provides guidance on simplifying the presentation of debt issuance costs on the balance sheet. To simplify presentation of debt issuance costs, the amendments in ASU
No.&nbsp;2015-03 require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with the treatment of debt discounts. The
recognition and measurement guidance for debt issuance costs are not affected by the amendments in this update. In accordance with ASU No.&nbsp;2015-03, the Company applied the new guidance on a retrospective basis, wherein the condensed
consolidated balance sheet of each individual period presented was adjusted to reflect the period-specific effects of applying the new guidance. See Note 6<I>&#151;</I>Debt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2016, the Company adopted ASU No.&nbsp;2015-11, <I>Inventory (Topic 330): Simplifying the Measurement of Inventory</I>, which simplifies the
subsequent measurement of inventories by replacing the lower of cost or market test with a lower of cost or net realizable value test. When evidence exists that the net realizable value of inventory is less than its cost (due to damage, physical
deterioration, obsolescence, changes in price levels or other causes), the Company will recognize the difference as a component of cost of goods sold in the period in which it occurs. In accordance with ASU No.&nbsp;2015-11, the Company applied the
new guidance on a prospective basis with no impact on the carrying amount of inventory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also in April 2016, the Company adopted ASU No.&nbsp;2016-09,
<I>Compensation&#151;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,</I> which changes the accounting for certain aspects of share-based payments to employees. One aspect of the standard requires that excess
tax benefits and deficiencies that arise upon vesting or exercise of share-based payments be recognized as an income tax benefit and expense in the income statement. Previously, such amounts were recognized as an increase and decrease in additional
paid-in capital. This aspect of the standard was adopted prospectively, and accordingly, the benefit from income taxes for the three and six months ended June&nbsp;30, 2016, includes $0.1 million and $0.2 million, respectively, of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
excess tax deficiencies arising from share-based payments. Additionally, the new standard requires that historical excess tax benefits that were not previously recognized because the related tax
deduction had not reduced current taxes payable should be recognized on a modified retrospective basis as a cumulative-effect adjustment to retained earnings as of the beginning of the annual period of adoption. Consequently, the Company recognized
deferred tax assets of approximately $1.6 million relating to excess tax benefits on stock-based compensation outstanding as of December&nbsp;31, 2015, with a corresponding cumulative-effect adjustment to accumulated deficit. The new standard also
amends the presentation of employee share-based payment-related items in the statement of cash flows by requiring that: (i)&nbsp;excess income tax benefits and deficiencies be classified in cash flows from operating activities, and (ii)&nbsp;cash
paid to taxing authorities arising from the withholding of shares from employees be classified as cash flows from financing activities. The Company adopted the aspects of the standard affecting cash flow presentation retrospectively and,
accordingly, reclassified $0.6 million of excess tax provision from cash flows provided by financing activities to cash flows used in operating activities in the condensed consolidated statement of cash flows for the six months ended June&nbsp;30,
2015 to conform to the current year presentation. The presentation requirement for cash flows related to taxes paid for withheld shares had no impact to any of the periods presented in the condensed consolidated statement of cash flows since such
payments have historically been presented as a financing activity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also considered the following recent accounting pronouncements which were
not yet adopted as of June&nbsp;30, 2016: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued ASU No.&nbsp;2014-09, <I>Revenue from Contracts with Customers (Topic 606)</I>.
This amendment provides principles for recognizing revenue for the transfer of promised goods or services to customers with the consideration to which the entity expects to be entitled in exchange for those goods or services, and is effective for
annual periods beginning after December&nbsp;15, 2016 (the original effective date). In April 2015, the FASB issued a proposal, which was subsequently adopted in July 2015, to defer the original effective date of this standard by one year, such that
the amendment is effective for the Company&#146;s fiscal year beginning January&nbsp;1, 2018. Early adoption is permitted, but not before the original effective date. The Company is currently evaluating the accounting, transition and disclosure
requirements of the standard and cannot currently estimate the financial statement impact of adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2014, the FASB issued ASU
No.&nbsp;2014-15, <I>Presentation of Financial Statements&#151;Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern</I>. ASU 2014-15 requires management to assess an entity&#146;s
ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the ASU (i)&nbsp;provides a definition of the term substantial doubt, (ii)&nbsp;requires an
evaluation every reporting period including interim periods, (iii)&nbsp;provides principles for considering the mitigating effect of management&#146;s plans, (iv)&nbsp;requires certain disclosures when substantial doubt is alleviated as a result of
consideration of management&#146;s plans, (v)&nbsp;requires an express statement and other disclosures when substantial doubt is not alleviated and (vi)&nbsp;requires an assessment for a period of one year after the date that the financial
statements are issued (or available to be issued). This standard is effective for fiscal years ending after December&nbsp;15, 2016, and for annual and interim periods thereafter. Early application is permitted. The Company has determined that this
standard would not have a material impact on its condensed consolidated financial statements based on the assessment of its ability to continue as a going concern as of June&nbsp;30, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2016, the FASB issued ASU No.&nbsp;2016-01, <I>Financial Instruments&#151;Overall (Subtopic 825-10): Recognition and Measurement of Financial
Assets and Financial Liabilities</I>. The new guidance is intended to improve the recognition and measurement of financial instruments by requiring separate presentation of financial assets and financial liabilities by measurement category and form
of financial asset (i.e., securities or loans and receivables) within the balance sheet or the accompanying notes to the financial statements, eliminating the requirement for public business entities to disclose the method(s) and significant
assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost within the balance sheet, requiring public business entities to use the exit price notion when measuring the fair value
of financial instruments for disclosure purposes, requiring equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) to be measured at fair value with changes in
fair value recognized in net income, and requiring a reporting organization to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific
credit risk (also referred to as &#147;own credit&#148;) when the organization has elected to measure the liability at fair value in accordance with the fair value option for financial instruments, among others. The new guidance is effective for
fiscal years beginning after December&nbsp;15, 2017, including interim periods within those fiscal years. The new guidance permits early adoption of the own credit provision. The Company is currently evaluating the accounting, transition and
disclosure requirements of the standard and cannot currently estimate the financial statement impact of adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU
No.&nbsp;2016-02,<I> Leases (Topic 842)</I>. The new guidance will require lessees to recognize a right-of-use asset and a lease liability for virtually all of their leases (other than leases that meet the definition of a short-term lease). The
liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for initial direct costs. Under the new guidance, lessor accounting is largely unchanged but certain targeted
improvements were made to align, where necessary, lessor accounting with the lessee accounting model and Topic 606, Revenue from Contracts with Customers. The new lease guidance also simplified the accounting for sale and leaseback transactions
primarily because lessees must recognize </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
lease assets and lease liabilities and therefore, will no longer be provided with a source of off-balance sheet financing. The new guidance is effective for fiscal years beginning after
December&nbsp;15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the accounting, transition and disclosure requirements of the standard and cannot currently estimate the
financial statement impact of adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2016, the FASB issued ASU No.&nbsp;2016-08, <I>Revenue from Contracts with Customers (Topic 606):
Principal versus Agent Considerations (Reporting Revenue Gross versus Net)</I>, which clarifies that an entity is a principal when it controls the specified good or service before that good or service is transferred to the customer, and is an agent
when it does not control the specified good or service before it is transferred to the customer. The new guidance is intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations.
In April 2016, the FASB issued ASU No.&nbsp;2016-10<I>, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,</I> which clarifies the following two aspects of Topic 606: (a)&nbsp;identifying
performance obligations; and (b)&nbsp;the licensing implementation guidance. Further, in May 2016, the FASB issued ASU No.&nbsp;2016-12, <I>Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients,</I>
which provides clarifying guidance in certain narrow areas and adds some practical expedients. The amendments do not change the core principles of the guidance in Topic 606 and are effective for the Company&#146;s fiscal year beginning
January&nbsp;1, 2018. Early application is permitted only as of annual reporting periods beginning after December&nbsp;15, 2016, including interim reporting periods within that reporting period. The Company is currently evaluating the accounting,
transition and disclosure requirements of these standards and cannot currently estimate the financial statement impact of adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company believes
that the impact of other recently issued but not yet adopted accounting pronouncements will not have a material impact on the Company&#146;s consolidated financial position, results of operations, and cash flows, or do not apply to the
Company&#146;s operations. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(3)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Intangible Assets </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intangible assets consist of the historical acquisition cost of certain technology
rights for Vascepa and have an estimated remaining useful life of 14.1 years. The carrying value as of June&nbsp;30, 2016 and December&nbsp;31, 2015 is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>In thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Technology rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,529</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,207</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(4)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Inventory </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company capitalizes its purchases of saleable inventory of Vascepa from suppliers that
have been qualified by the FDA. Inventories as of June&nbsp;30, 2016 and December&nbsp;31, 2015 consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>In thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Raw materials</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Work in process</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finished goods</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(5)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Warrants and Warrant Derivative Liability </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;16, 2009, the Company completed a $70.0
million private placement with both existing and new investors resulting in $62.3 million in net proceeds and an additional $3.6 million from bridge notes converted in conjunction with the private placement. In consideration for the $62.3 million in
net cash proceeds Amarin issued 66.4&nbsp;million units, each unit consisting of (i)&nbsp;one ADS (representing one ordinary share) at a purchase price of $1.00 and (ii)&nbsp;a warrant with a five year term to purchase 0.5 (one half) of an ADS at an
exercise price of $1.50 per ADS. In consideration for the conversion of $3.6 million of convertible bridge notes, Amarin issued 4.0&nbsp;million units, each unit consisting of (i)&nbsp;one ADS (representing one ordinary share) at a purchase price of
$0.90 and (ii)&nbsp;a warrant with a five year term to purchase 0.5 (one half) of an ADS at an exercise price of $1.50 per ADS. The total number of warrants issued in conjunction with the financing was 35.2&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In conjunction with the October 2009 financing, the Company issued an additional 0.9&nbsp;million warrants to three former officers. The warrants issued in
connection with the October 2009 financing contained a pricing variability feature which provided for an increase </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the exercise price if the exchange rate between the U.S. dollar and British pound adjusts such that the warrants could be exercised at a price less than the &pound;0.5 par value of the common
stock&#151;that is, if the exchange rate exceeded U.S. $3.00 per &pound;1.0 sterling. Due to the potential variable nature of the exercise price, the warrants were not considered to be indexed to the Company&#146;s common stock. Accordingly, the
warrants did not qualify for the exception to classify the warrants within equity and were classified as a derivative liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of this
warrant derivative liability was remeasured at each reporting period, with changes in fair value recognized in the condensed consolidated statement of operations. Upon exercise, the fair value of the warrants exercised was remeasured and
reclassified from warrant derivative liability to additional paid-in-capital. Although the warrants contained a pricing variability feature, the number of warrants issuable remained fixed. Therefore, the maximum number of common shares issuable as a
result of the October 2009 private placement was 36.1 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2014, the Company and the holders of the remaining October 2009 warrants
mutually agreed to extend the expiration date of such warrants from October&nbsp;16, 2014 to February&nbsp;27, 2015. During the six months ended June&nbsp;30, 2015, of the 8,087,388 warrants outstanding as of December&nbsp;31, 2014, 1,844,585
warrants were exercised, resulting in net proceeds to the Company of $2.7 million, the remaining 6,242,803 warrants expired, and the related derivative liability was extinguished. As such, no warrants were outstanding as of June&nbsp;30, 2016 and
December&nbsp;31, 2015. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(6)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Debt </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Long-Term Debt&#151;December 2012 Financing </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;6, 2012, the Company entered into an agreement with BioPharma Secured Debt Fund II Holdings Cayman LP, or BioPharma. Under this agreement, the
Company granted to BioPharma a security interest in future receivables associated with the Vascepa patent rights, in exchange for $100 million received at the closing of the agreement which occurred in December 2012. Under these terms, the Company
continues to own all Vascepa intellectual property rights, however, such rights, as described below, could be used by BioPharma as collateral for repayment of the remaining unpaid balance under this agreement if the Company defaults on making
required payments. In the agreement, the Company agreed to repay BioPharma up to $150&nbsp;million with such repayment based on a portion of revenues and receivables generated from Vascepa. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2016, the remaining amount to be repaid to BioPharma is $132.1 million. During the three and six months ended June&nbsp;30, 2016, the
Company made repayments under the agreement of $2.5 million and $5.2 million, respectively, to BioPharma and an additional $3.3 million is scheduled to be paid in August 2016 for the second quarter of 2016. These payments were calculated based on
the threshold limitation, as described below, as opposed to the scheduled quarterly repayments. Additional quarterly repayments, subject to the threshold limitation, are scheduled to be paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The maximum quarterly amounts which could be due for payment, except upon a change of control and subject each quarter to the threshold limitation, are as
follows: $15.0 million in the fourth quarter of 2016 and first quarter of 2017, and a payment of $13.0 million scheduled for payment in May 2017. All such payments reduce the remainder of the $150 million in aggregate payments to BioPharma. These
quarterly payments are subject to a quarterly threshold amount whereby, if a calculated threshold, based on quarterly Vascepa revenues, is not achieved, the quarterly payment payable in that quarter can at the Company&#146;s election be reduced,
with the reduction carried forward without interest for payment in a future period. The payment of any carried forward amount is subject to similarly calculated threshold repayment amounts based on Vascepa revenue levels. Except upon a change of
control in Amarin, the agreement does not expire until $150 million in aggregate has been repaid. Except in the event of the Company&#146;s default, there is no compounding of interest and no scheduled cliff payment due under this agreement. Rather,
payment will be made, subject to the threshold limitation, until $150 million in aggregate has been repaid, including payments made previously. The Company can prepay an amount equal to $150 million less any previously repaid amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company currently estimates that its Vascepa revenue levels will not be high enough in each quarter to support repayment to BioPharma in accordance with
the maximum quarterly amounts in the repayment schedule. For each quarterly period since the inception of the debt, revenues were below the contractual threshold amount such that cash payments were calculated for each period reflecting the optional
reduction amount as opposed to the contractual threshold payment due for each quarterly period. In accordance with the agreement with BioPharma, quarterly differences between the calculated optional reduction amounts and the repayment schedule
amounts are rescheduled for payment beginning in the second quarter of 2017. Any such deferred repayments will remain subject to continued application of the quarterly ceiling in amounts due established by the calculated threshold limitation based
on quarterly Vascepa revenues. No additional interest expense or liability is incurred as a result of such deferred repayments. These estimates will be reevaluated each reporting period by the Company and adjusted if necessary, prospectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determined the redemption feature upon a change of control to be an embedded derivative requiring bifurcation. The fair value of the embedded
derivative was calculated by determining the fair value of the debt with the change in control provision </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
included and also without the change in control provision. The difference between the two fair values of the debt was determined to be the fair value of the embedded derivative, and upon closing
the Company recorded a derivative liability of $14.6 million as a reduction to the note payable. The fair value of this derivative liability is remeasured at each reporting period, with changes in fair value recognized in the condensed consolidated
statement of operations and any changes in the assumptions used in measuring the fair value of the derivative liability could result in a material increase or decrease in its carrying value. The Company recognized a $2.7 million gain and a $0.8
million loss on change in fair value of derivative liability during the six months ended June&nbsp;30, 2016 and 2015, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30,
2016 and December&nbsp;31, 2015, the carrying value of the BioPharma debt, net of the unamortized debt discount and issuance costs, was $92.5 million and $91.5 million, respectively. During the six months ended June&nbsp;30, 2016, the Company
recorded cash and non-cash interest expense of $3.4 million and $1.0 million, respectively, in connection with the BioPharma debt. During the six months ended June&nbsp;30, 2015, the Company recorded cash and non-cash interest expense of $3.2
million and $0.9 million, respectively, in connection with the BioPharma debt. The Company will periodically evaluate the remaining term of the agreement and the effective interest rate is recalculated each period based on the Company&#146;s most
current estimate of repayment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To secure the obligations under the agreement with BioPharma, the Company granted BioPharma a security interest in the
Company&#146;s patents, trademarks, trade names, domain names, copyrights, know-how and regulatory approvals related to the covered products, all books and records relating to the foregoing and all proceeds of the foregoing, referred to collectively
as the collateral. If the Company (i)&nbsp;fails to deliver a payment when due and does not remedy that failure within a specific notice period, (ii)&nbsp;fails to maintain a first-priority perfected security interest in the collateral in the United
States and does not remedy that failure after receiving notice of such failure or (iii)&nbsp;becomes subject to an event of bankruptcy, then BioPharma may attempt to collect the maximum amount payable by the Company under this agreement (after
deducting any payments the Company has already made). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Purchase and Sale Agreement with BioPharma, the Company is restricted from paying
dividends on its common shares, unless it has cash and cash equivalents in excess of a specified amount after such payment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>January
2012 Exchangeable Senior Notes </U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2012, the Company issued $150.0 million in principal amount of 3.5% exchangeable senior notes due 2032
(the &#147;2012 Notes&#148;), a portion of which was subsequently exchanged and a portion of which was extinguished (see discussion of May 2014 and November 2015 Exchangeable Senior Notes below). The 2012 Notes were issued by Corsicanto Limited, an
Irish limited company acquired by Amarin in January 2012. Corsicanto Limited is a wholly-owned subsidiary of Amarin. The general, unsecured, senior obligations are fully and unconditionally guaranteed by Amarin but not by any of the Company&#146;s
other subsidiaries. Corsicanto Limited has no assets, operations, revenues or cash flows other than those related to the issuance, administration and repayment of the 2012 Notes and 2014 Notes.&nbsp;There are no significant restrictions on the
ability of Amarin to obtain funds from Corsicanto Limited in the form of cash dividends, loans, or advances.&nbsp;Net proceeds to the Company, after payment of underwriting fees and expenses, were approximately $144.3 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2012 Notes have a stated interest rate of 3.5%&nbsp;per year, payable semiannually in arrears on January&nbsp;15 and July&nbsp;15 of each year beginning
on July&nbsp;15, 2012, and ending upon the 2012 Notes&#146; maturity on January&nbsp;15, 2032. The 2012 Notes are subject to repurchase by the Company at the option of the holders on each of January&nbsp;19, 2017,&nbsp;January&nbsp;19, 2022, and
January&nbsp;19, 2027, at a price equal to 100% of the principal amount of the 2012 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the repurchase date. The 2012 Notes are exchangeable under certain circumstances into
cash, ADSs, or a combination of cash and ADSs, at the Company&#146;s election, with an initial exchange rate of 113.4752 ADSs per $1,000 principal amount of 2012 Notes (equivalent to an initial exchange price of approximately $8.8125 per ADS),
subject to adjustment in certain circumstances, including adjustment if the Company pays cash dividends. If the Company elected physical settlement, the net remaining outstanding portion of the 2012 Notes would be exchangeable into 1,714,270 ADSs.
Based on the closing price of the Company&#146;s stock as of June&nbsp;30, 2016, the principal amount of the 2012 Notes would exceed the value of the shares if converted on that date by $11.4 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional covenants include: (i)&nbsp;limitations on future indebtedness under certain circumstances, (ii)&nbsp;the timely filing of documents and reports
pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 with both the SEC and the Trustee and (iii)&nbsp;maintaining the tradability of the 2012 Notes. The Company is required to use commercially reasonable efforts to maintain
the listing of the 2012 Notes on the Global Exchange Market operated under the supervision of the Irish Stock Exchange (or other recognized stock exchange as defined in the 2012 Notes indenture). If the 2012 Notes are not freely tradable, as a
result of restrictions pursuant to U.S. securities law or the terms of the 2012 Notes indenture or the 2012 Notes, the Company shall pay additional interest on the 2012 Notes at the rate of 0.50%&nbsp;per annum of the principal amount of 2012 Notes
outstanding for each day during such period for which the Company&#146;s failure to file has occurred and is continuing or for which the 2012 Notes are not freely tradable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may not redeem the 2012 Notes prior to January&nbsp;19, 2017, other than in connection with certain changes in the tax law of a relevant taxing
jurisdiction that results in additional amounts becoming due with respect to payments and/or deliveries on the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2012 Notes. On or after January&nbsp;19, 2017 and prior to the maturity date, the Company may redeem for cash all or part of the 2012 Notes at a redemption price equal to 100% of the principal
amount of the 2012 Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. There is no prepayment penalty or sinking fund provided for the 2012 Notes. If the Company undergoes a change in control, holders may
require the Company to repurchase for cash all or part of their 2012 Notes at a repurchase price equal to 100% of the principal amount of the 2012 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the change in control
repurchase date. The 2012 Notes are the Company&#146;s senior unsecured obligations and rank senior in right of payment to the Company&#146;s future indebtedness that is expressly subordinated in right of payment to the 2012 Notes and equal in right
of payment to the Company&#146;s future unsecured indebtedness that is not so subordinated. The 2012 Notes are effectively junior in right of payment to future secured indebtedness to the extent of the value of the assets securing such indebtedness.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2012 Notes are exchangeable under certain circumstances. At the time of issuance, the Company calculated the fair value of the liability component of
the outstanding 2012 Notes to be $126.2 million, and the excess of the principal amount of the debt over the liability component of $23.8 million was allocated to the conversion option resulting in a discount on the debt and corresponding increase
in equity as a result of the cash settlement feature. The discount created from allocating proceeds to the conversion option was amortized to interest expense using the effective interest method over the 2012 Notes&#146; estimated remaining life,
which was calculated to be a period of twenty-four months. As of both June&nbsp;30, 2016 and December&nbsp;31, 2015, the discount created from the allocation of the proceeds to the conversion option was fully amortized and the carrying amount of the
conversion option was $11.5 million. The conversion option will not be subsequently remeasured as long as it continues to meet the criteria for equity classification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also recorded a debt discount to reflect the value of the underwriter&#146;s discounts and offering costs. A portion of the debt discount from
underwriter&#146;s discounts and offering costs was allocated to the equity and liability components of the 2012 Notes in proportion to the proceeds allocated to each component. The portion of the debt discount from underwriter&#146;s discounts and
offering costs allocated to the liability component was amortized as interest expense over the estimated life of the 2012 Notes of twenty-four months. As of both June&nbsp;30, 2016 and December&nbsp;31, 2015, the debt discount was fully amortized
and the carrying value of the 2012 Notes was $15.1 million after an exchange and repayment of a portion of the 2012 Notes (see below for further discussion of the May 2014 Notes and November 2015 Notes). The outstanding 2012 Notes may be put to the
Company (at the holders&#146; option, upon fundamental change or an event of default), or converted by holders and the holders have the option to put the 2012 Notes back to the Company on each of January&nbsp;19, 2017, 2022 and 2027 for cash equal
to 100% of the principal amount plus accrued and unpaid interest. As a result, the carrying value of the 2012 Notes of $15.1 million is classified as a current liability as of June&nbsp;30, 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>May 2014 Exchangeable Senior Notes </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2014, the Company entered into separate, privately negotiated exchange agreements with certain holders of the 2012 Notes pursuant to which Corsicanto
exchanged $118.7 million in aggregate principal amount of the existing 2012 Notes for $118.7 million in aggregate principal amount of new 3.5%&nbsp;May 2014 Exchangeable Senior Notes due 2032 (the &#147;2014 Notes&#148;), following which $31.3
million in aggregate principal amount of the 2012 Notes remained outstanding with terms unchanged (the 2012 Notes and 2014 Notes are referred to collectively as the &#147;Notes&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2014 Notes have a stated interest rate of 3.5%&nbsp;per year, payable semiannually in arrears on January&nbsp;15 and July&nbsp;15 of each year beginning
on July&nbsp;15, 2014, and ending upon the 2014 Notes&#146; maturity on January&nbsp;15, 2032, unless earlier repurchased or redeemed by Corsicanto or exchanged by the holders. At any time after the issuance of the 2014 Notes and prior to the close
of business on the second business day immediately preceding January&nbsp;15, 2032, holders may exchange the 2014 Notes at their option. If prior to January&nbsp;15, 2018, a make-whole fundamental change (as defined in the 2014 Notes indenture)
occurs or the Company elects to redeem the 2014 Notes in connection with certain changes in tax law, in each case as described in the 2014 Notes indenture, and a holder elects to exchange its 2014 Notes in connection with such make-whole fundamental
change or election, as the case may be, such holder may be entitled to an increase in the exchange rate as described in the 2014 Notes indenture. In the event of physical settlement, the 2014 Notes would be exchangeable into 45,666,925 ADSs. The
initial exchange rate is 384.6154 ADSs per $1,000 principal amount of the 2014 Notes (equivalent to an initial exchange price of approximately $2.60 per ADS, or the Exchange Price), subject to adjustment in certain circumstances. The exchange rate
is subject to adjustment from time to time upon the occurrence of certain events, including, but not limited to, the payment of cash dividends. Based on the closing price of the Company&#146;s stock as of June&nbsp;30, 2016, the principal amount of
the 2014 Notes would exceed the value of the shares if converted on that date by $20.1 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to January&nbsp;19, 2018, the Company may not
redeem the 2014 Notes at its option other than in connection with certain changes in the tax law of a relevant taxing jurisdiction that results in additional amounts (as defined in the 2014 Notes indenture) becoming due with respect to payments
and/or deliveries on the 2014 Notes. On or after January&nbsp;19, 2018, the Company may redeem for cash all or a portion of the 2014 Notes at a redemption price of 100% of the aggregate principal amount of the 2014 Notes to be redeemed, plus accrued
and unpaid interest to, but not including, the redemption date. If a fundamental change (as defined in the 2014 Notes indenture) occurs, holders may require the Company to repurchase all or part of their 2014 Notes for cash at a fundamental change
repurchase price equal to 100% of the aggregate principal amount of the 2014 Notes to be repurchased, plus accrued and unpaid </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interest to, but not including, the fundamental change repurchase date. In addition, holders of the 2014 Notes may require the Company to repurchase all or any portion of the 2014 Notes on each
of January&nbsp;19, 2019,&nbsp;January&nbsp;19, 2024 and January&nbsp;19, 2029 for cash at a price equal to 100% of the aggregate principal amount of the 2014 Notes to be repurchased, plus accrued and unpaid interest to, but not including, the
repurchase date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may elect at its option to cause all or any portion of the 2014 Notes to be mandatorily exchanged in whole or in part at any
time prior to the close of business on the business day preceding January&nbsp;15, 2032 if the Daily VWAP (as defined in the 2014 Notes indenture) equals or exceeds 110% of the Exchange Price then in effect for at least 20 VWAP Trading Days (as
defined in the 2014 Notes indenture) in any 30 VWAP Trading Day period. The Company may only exercise its optional exchange rights upon satisfaction of specified equity conditions, including that the ADSs issuable upon exchange of the 2014 Notes be
eligible for resale without registration by non-affiliates and listed on The NASDAQ Global Market, its related exchanges or the New York Stock Exchange. If Corsicanto elects to exercise its optional exchange rights on or prior to January&nbsp;15,
2018, each holder whose 2014 Notes are exchanged will upon exchange receive a specified number of additional ADSs as set forth in the 2014 Notes indenture. Upon such a declaration of acceleration, such principal and accrued and unpaid interest, if
any, will be due and payable immediately. Upon the occurrence of certain events of bankruptcy, insolvency or reorganization involving Corsicanto, 100% of the principal of and accrued and unpaid interest, if any, on all of the 2014 Notes will become
due and payable automatically. Notwithstanding the foregoing, the 2014 Notes indenture provides that, to the extent Corsicanto elects and for up to 360 days, the sole remedy for an event of default relating to certain failures by Corsicanto or the
Company, as the case may be, to comply with certain reporting covenants in the 2014 Notes indenture consists exclusively of the right to receive additional interest on the 2014 Notes. Additional covenants pertaining to the 2012 Notes (as described
above for the January 2012 Exchangeable Senior Notes) are also applicable to the May 2014 Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the note exchange (as described above),
the Company assessed both quantitative and qualitative aspects of the features of the 2014 Notes as compared to the 2012 Notes. Such assessment resulted in the conclusion that the features of the 2014 Notes represent a substantive modification from
the 2012 Notes as the terms of the exchange resulted in a substantive modification to the embedded conversion feature within the 2012 Notes, and as such should be accounted for as an extinguishment of debt. In accordance with ASC 470-20, the Company
extinguished the 2012 Notes by recording a gain on extinguishment of the liability component of $38.0 million and repurchase of the conversion option in equity through a reduction to additional paid-in capital of $10.1 million. The 2014 Notes were
recorded at fair value of $90.8 million representing a $27.9 million discount to par. In addition, the Company recognized $2.5 million in underwriter&#146;s fees and offering costs and initially recognized those costs as deferred assets. Effective
January 2016, the Company adopted ASU No.&nbsp;2015-03, <I>Interest&#151;Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</I>, which requires that debt issuance costs related to a recognized debt
liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with the treatment of debt discounts. As the standard is required to be adopted on a retrospective basis, the Company
reclassified $1.8 million of underwriters&#146; fees and offering costs related to the 2014 Notes from other long-term assets to exchangeable senior notes, net of discount, within the condensed consolidated balance sheet as of December&nbsp;31,
2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company further allocated $3.5 million of the $90.8 million fair value of the 2014 Notes to the derivative liability related to the fundamental
change redemption feature (as described above). The fair value of this derivative liability is remeasured at each reporting period, with changes in fair value recognized in the condensed consolidated statement of operations and any changes in the
assumptions used in measuring the fair value of the derivative liability could result in a material increase or decrease in its carrying value. The Company recognized a $1.5 million gain on the change in fair value of the redemption feature in each
of the six months ended June&nbsp;30, 2016 and 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because the conversion option in the 2014 Notes receives an exception from derivative accounting and
only requires gross physical settlement in shares, the embedded option does not require separate accounting and is therefore accounted for as part of the debt host at amortized cost. The debt discount is being amortized as interest expense over the
estimated life of the 2014 Notes and recognized in the condensed consolidated statement of operations as interest expense. As of June&nbsp;30, 2016 and December&nbsp;31, 2015, the carrying value of the 2014 Notes, net of the unamortized debt
discount and issuance costs, was $98.0 million and $94.6 million, respectively. During the six months ended June&nbsp;30, 2016, the Company recognized aggregate interest expense of $5.7 million related to the Notes, of which $3.4 million represents
non-cash interest and $2.3 million represents contractual coupon interest. During the six months ended June&nbsp;30, 2015, the Company recognized aggregate interest expense of $5.6 million related to the Notes, of which $3.0 million represents
non-cash interest and $2.6 million represents contractual coupon interest. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>November 2015 Exchangeable Senior Notes </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2015, the Company entered into a privately negotiated subscription agreement with one of its existing investors (the &#147;Investor&#148;),
pursuant to which the Investor agreed to purchase approximately $31.3 million in aggregate principal amount of new 3.5%&nbsp;November 2015 Exchangeable Senior Notes due 2032 (the &#147;2015 Notes&#148;) for approximately $27.5 million. Approximately
$15.9 million of such proceeds were used to finance the repayment of a portion of the 2012 Notes and the remainder will be used for working capital and general corporate purposes. The 2015 Notes have substantially identical terms to the 2014 Notes,
except that the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2015 Notes were issued by Amarin Corporation plc and are not guaranteed by any entity. In the event of physical settlement, the 2015 Notes would be exchangeable into 12,025,385 ADSs. The initial
exchange rate is 384.6154 ADSs per $1,000 principal amount of 2015 Notes (equivalent to an initial exchange price of approximately $2.60 per ADS), provided that exchanges will be prohibited if, as a result, the holder of such 2015 Notes and its
affiliates would beneficially own more than 4.99% of the total number of the Company&#146;s ordinary shares or ADSs outstanding following such exchange (the &#147;Beneficial Ownership Limitation&#148;). By written notice to the Company, a holder may
from time to time increase or decrease the Beneficial Ownership Limitation to any other percentage not in excess of 19.9% (the &#147;Beneficial Ownership Cap&#148;) specified in such notice; provided that any such increase will not be effective
until the sixty-first (61st)&nbsp;day after such notice is delivered to the Company. The exchange rate is subject to adjustment from time to time upon the occurrence of certain events, including, but not limited to, the payment of cash dividends.
Based on the closing price of the Company&#146;s stock as of June&nbsp;30, 2016, the principal amount of the 2015 Notes would exceed the value of the shares if converted on that date by $5.3 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2015 Notes are the senior unsecured obligations of the Company. The 2015 Notes bear interest at a rate of 3.5%&nbsp;per annum from, and including,
November&nbsp;24, 2015, payable semi-annually in arrears on January&nbsp;15 and July&nbsp;15 of each year, beginning on January&nbsp;15, 2016. The 2015 Notes mature on January&nbsp;15, 2032, unless earlier repurchased or redeemed by the Company or
exchanged by the holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2015 Notes were recorded at fair value of $27.5 million representing a $3.8 million discount to par. In addition, the
Company recognized $0.1 million in offering costs and initially recognized those costs as deferred assets. As described for the 2014 Notes above, effective January 2016, the Company adopted ASU No.&nbsp;2015-03, <I>Interest&#151;Imputation of
Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.</I> As the standard is required to be adopted on a retrospective basis, the Company reclassified $0.1 million of underwriters&#146; fees and offering costs related to
the 2015 Notes from other long-term assets to exchangeable senior notes, net of discount, within the condensed consolidated balance sheet as of December&nbsp;31, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company further allocated $0.5 million of the $27.5 million fair value of the 2015 Notes to the derivative liability related to the fundamental change
redemption feature (as described under the 2014 Notes above). The fair value of this derivative liability is remeasured at each reporting period, with changes in fair value recognized in the condensed consolidated statement of operations and any
changes in the assumptions used in measuring the fair value of the derivative liability could result in a material increase or decrease in its carrying value. During the six months ended June&nbsp;30, 2016, the Company recognized a gain on the
change in fair value of the redemption feature of $0.4 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because the conversion option in the 2015 Notes receives an exception from derivative
accounting and only requires gross physical settlement in shares, the embedded option does not require separate accounting and is therefore accounted for as part of the debt host at amortized cost. The debt discount is being amortized as interest
expense over the estimated life of the 2015 Notes and recognized in the condensed consolidated statement of operations as interest expense. As of June&nbsp;30, 2016 and December&nbsp;31, 2015, the carrying value of the 2015 Notes, net of the
unamortized debt discount and issuance costs, was $27.6 million and $27.0 million, respectively. During the six months ended June&nbsp;30, 2016, the Company recognized aggregate interest expense of $1.2 million related to the 2015 Notes, of which
$0.6 million represents non-cash interest and $0.6 million represents contractual coupon interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent with the issuance of the 2015 Notes,
Corsicanto Limited and the Company entered into separate, privately negotiated purchase agreements with certain holders of the 2012 Notes pursuant to which the Company purchased (the &#147;2012 Notes Purchase&#148;) approximately $16.2 million in
aggregate principal amount of the 2012 Notes for $15.9 million, which included accrued but unpaid interest on such 2012 Notes. The 2012 Notes Purchase was funded by the issuance of the 2015 Notes. Following the closing of the 2012 Notes Purchase,
Corsicanto had approximately $15.1 million in aggregate principal amount of 2012 Notes outstanding. The 2012 Notes Purchase was accounted for as an extinguishment of debt and the Company recorded a gain of $1.3 million upon extinguishment during the
fourth quarter of 2015, which represents the reacquisition of the conversion option at fair value and a negotiated discount on the purchase of the notes partially offset by legal and transaction advisory costs incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2016 and December&nbsp;31, 2015, the Company had total accrued interest on the notes of $2.7 million and $2.3 million, respectively, which
is included in current portion of long-term debt. The Company made the contractual interest payments due on the notes during the six months ended June&nbsp;30, 2016 and 2015 of $2.5 million and $2.6 million, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(7)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Commitments and Contingencies </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Litigation </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, the Company is from time to time involved in lawsuits, claims, investigations, proceedings, and threats of litigation
relating to intellectual property, commercial arrangements and other matters. &#147;Item 3. Legal Proceedings&#148; of the Company&#146;s Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2015, and &#147;Item 1. Legal
Proceedings&#148; of the Company&#146;s Quarterly Report on Form 10-Q for the quarter ended March&nbsp;31, 2016, include discussions of the Company&#146;s current legal proceedings. There have been no material changes to those disclosures as of the
date of this filing other than as set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;26, 2016, the U.S. District Court for the District of New Jersey granted a motion to
dismiss in favor of the Company and related defendants in the putative consolidated class action lawsuit captioned&nbsp;<I>In re Amarin Corporation plc, Securities Litigation,</I>&nbsp;No.&nbsp;3:13-cv-06663 (D.N.J. Nov. 1, 2013). The class action
was dismissed without prejudice with leave for plaintiffs to file an amended complaint. The lawsuit seeks unspecified monetary damages and attorneys&#146; fees and costs alleging that the Company and certain of its current and former officers and
directors made misstatements and omissions regarding the FDA&#146;s willingness to approve Vascepa&#146;s ANCHOR indication and related contributing factors and the potential relevance of data from the ongoing REDUCE-IT trial to that potential
approval. The April 2016 dismissal was the second motion to dismiss granted in favor of the Company and related defendants in this litigation. The first motion to dismiss in this litigation was granted in June 2015 in response to the original
complaint and related amendment. On May&nbsp;24, 2016, plaintiffs notified the court they would not file another amended complaint and, on May&nbsp;26, 2016, filed a notice of appeal of the most recent dismissal to the Third Circuit Court of
Appeals. The Company plans a vigorous defense to this appeal. The Company has insurance coverage that is anticipated to cover any significant loss exposure that may arise from this action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;31, 2016, FDA granted five-year, new chemical entity exclusivity with respect to Vascepa in connection with Vascepa&#146;s July&nbsp;26, 2012 FDA
approval. Following such exclusivity grant, on June&nbsp;7, 2016, Watson Laboratories Inc., or Watson, moved for voluntarily dismissal of its own appeal to the United States Court of Appeals (case no. 2016-1596) of the January&nbsp;22, 2016 U.S.
District Court for the District of New Jersey order of dismissal of the abbreviated new drug application, or ANDA, patent infringement litigation (case no. 14-CV-3259) related to Vascepa. The Watson motion for voluntary dismissal, to which the
Company consented, was granted on June&nbsp;8, 2016. There is no pending patent litigation related to Vascepa. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Milestone and Supply
Purchase Obligations </U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company entered into long-term supply agreements with multiple FDA-approved API suppliers and encapsulators. Certain
supply agreements require annual minimum volume commitments by the Company and certain volume shortfalls may require payments for such shortfalls, as detailed below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company entered into its initial Vascepa API supply agreement with Nisshin Pharma, Inc. (&#147;Nisshin&#148;) in 2010. In 2011, the Company entered into
agreements with two additional suppliers, Chemport, Inc. (&#147;Chemport&#148;) and BASF (formerly Equateq Limited), for the supply of API. In 2012, the Company agreed to terms with a fourth API supplier, a consortium of companies led by Slanmhor
Pharmaceutical, Inc. (&#147;Slanmhor&#148;). The API supply agreement with BASF terminated in February 2014. In July 2014, the Company terminated the supply agreement with Slanmhor and subsequently, in July 2015, entered into a new supply agreement
with Finorga SAS (&#147;Novasep&#148;). These agreements included requirements for the suppliers to meet certain product specifications and qualify their materials and facilities with applicable regulatory authorities including the FDA. The Company
has incurred certain costs associated with the qualification of product produced by these suppliers as described below. Nisshin, Chemport and Novasep are currently the three manufacturers from which the Company purchases API. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chemport was approved by the FDA to manufacture API for commercial sale in April 2013 and the Company began purchasing commercial supply from Chemport in
2013. The agreement with Chemport contains a provision requiring the Company to pay Chemport in cash for any shortfall in the minimum purchase obligations. The Company began purchasing commercial supply from Novasep in 2015. API manufactured by
Novasep was previously approved by the FDA in July 2014. The 2015 supply agreement with Novasep includes commitments for the Company to fund API purchases and contains a provision requiring the Company to pay Novasep a cash remedy for any shortfall
in the minimum purchase obligations. The Company continues to meet its contractual purchase obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the 2004 share repurchase agreement with
Laxdale Limited (&#147;Laxdale&#148;) upon receipt of marketing approval in Europe for the first indication for Vascepa (or first indication of any product containing Amarin Neuroscience Limited intellectual property acquired from Laxdale in 2004),
the Company must make an aggregate stock or cash payment to the former shareholders of Laxdale (at the sole option of each of the sellers) of &pound;7.5&nbsp;million (approximately $10.0 million as of June&nbsp;30, 2016). Also under the Laxdale
agreement, upon receipt of a marketing approval in the United States or Europe for a further indication of Vascepa (or further indication of any other product using Amarin Neuroscience Limited intellectual property), the Company must make an
aggregate stock or cash payment (at the sole option of each of the sellers) of &pound;5&nbsp;million (approximately $6.7 million as of June&nbsp;30, 2016) for each of the two potential market approvals (i.e. &pound;10&nbsp;million maximum, or
approximately $13.4 million as of June&nbsp;30, 2016). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has no provision for any of the obligations above since the amounts are either not probable or able
to be estimated as of June&nbsp;30, 2016. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(8)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Equity </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Warrants </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2015, the Company issued 1,844,585 shares upon the exercise of warrants, resulting in gross and net proceeds of $2.8
million and $2.7 million, respectively. There was no warrant activity during the six months ended June&nbsp;30, 2016 and no warrants remained outstanding as of June&nbsp;30, 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Incentive Equity Awards </U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June
2014, the FASB issued guidance for accounting for share-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period. The standard states that a performance target in a share-based
payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition. As such, the performance target should not be reflected in estimating the grant-date fair value of the
award. The guidance became effective for all entities during the first quarter of fiscal 2016. The Company previously accounted for awards in a manner consistent with the new guidance and as such, adoption of the guidance did not have any impact on
the Company&#146;s condensed consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2016, the FASB issued ASU No.&nbsp;2016-09, <I>Compensation&#151;Stock
Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</I>. The Company early adopted this standard during the quarter ended June&nbsp;30, 2016, without electing to change its existing accounting policy of accounting for
forfeitures based on expected vesting. The new standard requires that excess tax benefits and deficiencies that arise upon vesting or exercise of share-based payments be recognized as an income tax benefit and expense in the income statement, and
also that historical excess tax benefits that were not previously recognized because the related tax deduction had not reduced current taxes payable should be recognized on a modified retrospective basis as a cumulative-effect adjustment to retained
earnings as of the beginning of the annual period of adoption. Further, the new standard amends the presentation of employee share-based payment-related items in the statement of cash flows by requiring that: (i)&nbsp;excess income tax benefits and
deficiencies be classified in cash flows from operating activities, and (ii)&nbsp;cash paid to taxing authorities arising from the withholding of shares from employees be classified as cash flows from financing activities. Refer to Note 2 above for
additional discussion on the Company&#146;s adoption of the new standard. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2016, there were an aggregate of 20,641,123 stock options
and 10,361,147 restricted stock units (&#147;RSUs&#148;) outstanding, representing approximately 8% and 4%, respectively, of outstanding shares (including common and preferred shares) on a fully diluted basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2016 and 2015, the Company issued 83,020 and 18,020 shares, respectively, as a result of the exercise of stock
options, resulting in gross and net proceeds of $0.1 million during the six months ended June&nbsp;30, 2016 and $31 thousand during the six months ended June&nbsp;30, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;1, 2016, the Company granted a total of 1,607,500 RSUs and 2,442,000 stock options to employees under the Amarin Corporation plc Stock
Incentive Plan (the &#147;2011 Plan&#148;). The RSUs vest annually over a three year period and the stock options vest monthly over a four year period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;6, 2015, the Company granted a total of 1,455,000 RSUs and 5,470,000 stock options to employees under the 2011 Plan. The RSUs granted vest over a
four year period. Of the total stock options granted, 3,670,000 stock options vest over a four year period while the remaining 1,800,000 stock options vest upon the achievement of certain performance conditions. During the six months ended
June&nbsp;30, 2016, the Company issued 181,874 common shares related to the vesting of these RSUs, of which 77,405 shares were retained as treasury shares as settlement of employee tax obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on July&nbsp;6, 2015, the Company granted a total of 413,500 RSUs and 288,657 stock options to members of the Company&#146;s Board of Directors under the
2011 Plan. Of the total awards granted, 283,500 RSUs and 121,506 stock options vest in equal installments over a three year period upon the earlier of the one-year anniversary of the grant date or the Company&#146;s annual general meeting of
shareholders in such anniversary year, while the remaining 130,000 RSUs and 167,151 stock options vest in full upon the earlier of the one-year anniversary of the grant date or the Company&#146;s annual general meeting of shareholders in such
anniversary year. Upon termination of service to the Company or upon a change of control, each Director shall be entitled to a payment equal to the fair market value of one share of Amarin common stock, which is required to be made in shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;29, 2015, the Company granted a total of 2,564,251 RSUs and 1,622,500 stock options to employees
under the 2011 Plan. The RSUs vest annually over a three year period and the stock options vest monthly over a four year period. Also on January&nbsp;29, 2015, the Company granted 5,455,500 RSUs to employees under the 2011 Plan that vest upon the
achievement of certain performance conditions. The issuance of these performance RSUs was contingent upon shareholder approval to increase the aggregate number of shares authorized for issuance under the 2011 Plan, which was obtained at the
Company&#146;s Annual General Meeting of Shareholders held on July&nbsp;6, 2015. During the six months ended June&nbsp;30, 2016, the Company issued 818,352 common shares related to the vesting of these RSUs, of which 270,329 shares were retained as
treasury shares as settlement of employee tax obligations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>Preferred Stock </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;5, 2015, the Company entered into a subscription agreement with four institutional investors (the &#147;Purchasers&#148;), including both
existing and new investors, for the private placement of 352,150,790 restricted American Depositary Shares, each representing one (1)&nbsp;share of Amarin&#146;s Series A Convertible Preference Shares, par value &pound;0.05&nbsp;per share, in the
capital of the Company (&#147;Series A Preference Shares&#148;), resulting in gross proceeds to the Company of $52.8 million. The closing of the private placement occurred on March&nbsp;30, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For each restricted American Depositary Share, the Purchasers paid a negotiated price of $0.15 (equating to $1.50 on an as-if-converted-to-ordinary-shares
basis), resulting in $52.8 million in aggregate gross proceeds to the Company, before deducting estimated offering expenses of approximately $0.7 million. The net proceeds are reflected as preferred stock in the accompanying condensed consolidated
balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each ten (10)&nbsp;Series A Preference Shares may be consolidated and redesignated as one (1)&nbsp;ordinary share, par value
&pound;0.50&nbsp;per share, in the capital of the Company, each ordinary share to be represented by American Depositary Shares (&#147;ADSs&#148;), provided that consolidation will be prohibited if, as a result, the holder of such Series A Preference
Shares and its affiliates would beneficially own more than 4.99% of the total number of Amarin ordinary shares or ADSs outstanding following such redesignation (the &#147;Beneficial Ownership Limitation&#148;). By written notice to the Company, a
holder may from time to time increase or decrease the Beneficial Ownership Limitation to any other percentage not in excess of 19.9% specified in such notice; provided that any such increase will not be effective until the sixty-first
(61st)&nbsp;day after such notice is delivered to the Company. This consolidation and redesignation may be effected by a holder of Series A Preference Shares following the first to occur of the resale of the ADSs representing the ordinary shares
being registered for resale under the Securities Act pursuant to an effective registration statement, following any sale of the ADSs representing the ordinary shares pursuant to Rule 144 under the Securities Act, or if such ADSs representing the
ordinary shares are eligible for sale under Rule 144, following the expiration of the one-year holding requirement under Rule 144. Subsequently, at the request of the holders, a portion of the Series A Preference Shares were consolidated and
redesignated during the three months ended June&nbsp;30, 2015, resulting in the issuance of 6,283,333 ADSs such that a maximum of 32,818,464 ordinary shares remain issuable upon future consolidation and redesignation of the remaining Series A
Preference Shares as of June&nbsp;30, 2016, inclusive of the shares issued in July 2015 as discussed below, subject to certain adjustments for dilutive events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in the Series A Preference Share Terms or as required by applicable law, the Series A Preference Shares have no voting rights.
However, as long as any Series A Preference Shares are outstanding, the Company cannot, without the approval of the holders of seventy-five percent (75%)&nbsp;of the then outstanding Series A Preference Shares, alter or change adversely the powers,
preferences or rights attaching to the Series A Preference Shares or enter into any agreement with respect to the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of the Series A
Preference Shares are entitled to receive, and the Company is required to pay, dividends (other than dividends in the form of ordinary shares) on the Series A Preference Shares equal (on an as-if-converted-to-ordinary-shares basis) to and in the
same form as dividends (other than dividends in the form of ordinary shares) actually paid on ordinary shares when, as and if such dividends (other than dividends in the form of ordinary shares) are paid on the ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The restricted American Depositary Shares and Series A Preference Shares were sold in a transaction exempt from the registration requirements under the
Securities Act of 1933, as amended (the &#147;Securities Act&#148;). The Company filed a registration statement with the SEC covering the resale of the restricted American Depositary Shares and the ADSs representing ordinary shares created by the
consolidation and redesignation of the Series A Preference Shares (the &#147;Registrable Securities&#148;) on April&nbsp;9, 2015, which was declared effective by the SEC on May&nbsp;1, 2015. In addition, the Company agreed to use its commercially
reasonable best efforts to keep the registration, and any qualification, exemption or compliance under state securities laws which the Company determines to obtain, continuously effective, and to keep the Registration Statement free of any material
misstatements or omissions, until the earlier of (a)&nbsp;March 11, 2017 or (b)&nbsp;the date on which all Registrable Securities held by Purchasers may be sold or transferred in compliance with Rule 144 under the Securities Act, without any volume
or manner of sale restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Series A Preference Shares contain a contingent beneficial conversion feature (&#147;BCF&#148;) because they contain
a conversion feature at a fixed rate that was in-the-money when issued. The BCF was recorded in the three months ended June&nbsp;30, 2015 as a result of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
related Form S-3 Registration Statement being declared effective, which represents the resolution of the contingency to convert the Series A Preference Shares. The BCF was recognized in
stockholders&#146; deficit and was measured by allocating a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital. The effective purchase price of the ordinary shares into which the preferred shares are
convertible was $1.50, which was used to compute the intrinsic value. The intrinsic value was calculated as the difference between the effective purchase price of the ordinary shares and the market value ($2.39 per share) on the date the preferred
shares were issued, multiplied by the number of shares into which the preferred shares are convertible. The BCF resulting from the issuance of the Series A Preference Shares was determined to be $31.3 million. The BCF was recorded as a non-cash
dividend to preferred shareholders through accumulated deficit, and was therefore reflected as an adjustment to net loss applicable to common shareholders for earnings per common share purposes in accordance with GAAP for the three months ended
June&nbsp;30, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;30, 2015, in connection with the closing of the private placement, and pursuant to a pre-existing contractual right to
participate in certain private placement transactions effected by the Company, the Company entered into a separate subscription agreement with an existing investor, Sofinnova Venture Partners VII L.P. (Sofinnova), for the purchase of an additional
$5.8 million of restricted American Depositary Shares, each representing one (1)&nbsp;share of the Company&#146;s Series A Preference Shares, at the same price per share and otherwise on substantially the same terms as the initial private placement
(the &#147;Second Private Placement&#148;). In accordance with applicable marketplace rules of the NASDAQ Stock Market, the consummation of the Second Private Placement was conditioned upon approval by the Company&#146;s shareholders at a future
meeting of the Company&#146;s shareholders. Such approval was received at the Company&#146;s Annual General Meeting of Shareholders on July&nbsp;6, 2015 and as a result, the closing of the Second Private Placement occurred on July&nbsp;10, 2015. The
Company issued 38,867,180 restricted ADSs at that time, each representing one Series A Preference Share, which may be consolidated and redesignated from time to time up to a maximum of 3,886,718 ordinary shares, each ordinary share to be represented
by one ADS. For each restricted ADS, Sofinnova paid a negotiated price of $0.15 (equating to $1.50 on an as-if-converted-to-ordinary-shares basis) resulting in gross proceeds to the Company of $5.8 million. Dr.&nbsp;James Healy, a member of the
Company&#146;s Board, is a managing general partner of Sofinnova Management VII, L.L.C., which is the general partner of Sofinnova. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company filed
another registration statement with the SEC covering the resale of these restricted American Depositary Shares and the ADSs representing ordinary shares created by the consolidation and redesignation of the Series A Preference Shares (the
&#147;Sofinnova Registrable Securities&#148;) on July&nbsp;24, 2015, which was declared effective by the SEC on August&nbsp;7, 2015. In addition, the Company agreed to use its commercially reasonable best efforts to keep the registration, and any
qualification, exemption or compliance under state securities laws which the Company determines to obtain, continuously effective, and to keep the registration statement free of any material misstatements or omissions, until the earlier of
(a)&nbsp;July 10, 2017 or (b)&nbsp;the date on which all Sofinnova Registrable Securities held by Sofinnova may be sold or transferred in compliance with Rule 144 under the Securities Act, without any volume or manner of sale restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The existence of this preferred stock purchase option was determined to be a derivative liability effective March&nbsp;5, 2015, the date on which the private
placement was initially subscribed. The fair value of this liability was calculated using a Black-Scholes model and was determined to be $0.9 million at inception and was charged to accumulated deficit as a deemed non-cash dividend to Sofinnova. The
liability was then marked to fair value as of March&nbsp;30, 2015, the date on which the Company executed a subscription agreement with Sofinnova, resulting in a charge of $0.9 million through gain (loss) on change in fair value of derivatives. The
liability of $1.8 million was reclassified to permanent equity (additional paid-in capital) on such date. Subsequent to approval of the Second Private Placement at the Company&#146;s Annual General Meeting of Shareholders in July 2015, the Company
recorded the remaining value of the BCF related to this share issuance as a non-cash dividend to preferred shareholders through accumulated deficit. The value of the BCF was determined on the same basis as the first private placement and amounted to
$3.4 million less $1.8 million previously recorded for the preferred stock purchase option for a net non-cash charge of $1.6 million in the third quarter of 2015. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(9)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Co-Promotion Agreement </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;31, 2014, the Company entered into a Co-Promotion Agreement (the
Agreement) with Kowa Pharmaceuticals America, Inc. related to the commercialization of Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) capsules in the United States. Under the terms of the Agreement, Amarin
granted to Kowa Pharmaceuticals America, Inc. the right to be the sole co-promoter, together with the Company, of Vascepa in the United States during the term. The initial term of the Agreement extends through 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the term, Kowa Pharmaceuticals America, Inc. and Amarin have agreed to use commercially reasonable efforts to promote, detail and optimize sales of
Vascepa in the United States. The performance requirements include a negotiated minimum number of details to be delivered by each party in the first and second position, and the use of a negotiated number of minimum sales representatives from each
party, including no less than 250 Kowa Pharmaceuticals America, Inc. sales representatives. Kowa Pharmaceuticals America, Inc. has agreed to continue to bear the costs incurred for its sales force associated with the commercialization of Vascepa and
to pay for certain incremental costs associated with the use of its sales force, such as sample costs and costs for promotional and marketing materials. Amarin will continue to recognize all revenue from sales of Vascepa and will use commercially
reasonable efforts to maintain a minimum amount of inventory of Vascepa for use in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In exchange for Kowa Pharmaceuticals America, Inc.&#146;s co-promotional services, Kowa Pharmaceuticals America,
Inc. is entitled to a quarterly co-promotion fee based on aggregate Vascepa gross margin that increases during the term. The percentage of aggregate Vascepa gross margin earned by Kowa Pharmaceuticals America, Inc. was fifteen percent (15%)&nbsp;in
2015, is nineteen percent (19%)&nbsp;in 2016, and is scheduled to increase to low twenty percent levels in 2017 and 2018, subject to certain adjustments. The co-promotion fee also varies based on sales levels and whether the FDA has approved an
ANCHOR indication labeling expansion for Vascepa or has permitted the use of data generated to support obtaining FDA approval of the ANCHOR indication in the promotion of Vascepa, in which case the co-promotion fee would be decreased if specified
requirements are met. In certain circumstances, upon the earlier of the expiration or termination of the Agreement in accordance with its terms, Kowa Pharmaceuticals America, Inc. may be eligible for a co-promotion tail fee equal to declining
fractions of the co-promotion fee in effect prior to such expiration or termination for periods ranging from one to three years following such expiration or termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2016 and December&nbsp;31, 2015,&nbsp;the Company had a net payable of $2.7 million and $2.5 million, respectively, to Kowa
Pharmaceuticals America, Inc. representing co-promotion fees payable to Kowa Pharmaceuticals America, Inc. net of reimbursable amounts incurred for samples and other marketing expenses. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(10)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Development, Commercialization and Supply Agreement </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;26, 2015, the Company entered into
a Development, Commercialization and Supply Agreement (the &#147;DCS Agreement&#148;) with Eddingpharm (Asia) Macao Commercial Offshore Limited (&#147;Eddingpharm&#148;) related to the development and commercialization of Vascepa in Mainland China,
Hong Kong, Macau and Taiwan (the &#147;China Territory&#148;). Under the terms of the DCS Agreement, the Company granted to Eddingpharm an exclusive (including as to the Company) license with right to sublicense to develop and commercialize Vascepa
in the China Territory for uses that are currently commercialized and under development by the Company based on the Company&#146;s MARINE, ANCHOR and ongoing REDUCE-IT clinical trials of Vascepa. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the DCS Agreement, Eddingpharm will be solely responsible for development and commercialization activities in the China Territory and associated
expenses. The Company will provide development assistance and be responsible for supplying finished and later bulk drug product at defined prices under negotiated terms. The Company will retain all Vascepa manufacturing rights. Eddingpharm has
agreed to certain restrictions regarding the commercialization of competitive products globally and the Company has agreed to certain restrictions regarding the commercialization of competitive products in the China Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company and Eddingpharm agreed to form a joint development committee to oversee regulatory and development activities for Vascepa in the China Territory
in accordance with a negotiated development plan and to form a separate joint commercialization committee to oversee Vascepa commercialization activities in the China Territory. Development costs will be paid by Eddingpharm to the extent such costs
are incurred in connection with the negotiated development plan or otherwise incurred by Eddingpharm. Eddingpharm will be responsible for preparing and filing regulatory applications in all countries of the China Territory at Eddingpharm&#146;s cost
with the Company&#146;s assistance. The DCS Agreement also contains customary provisions regarding indemnification, packaging, record keeping, audit rights, reporting obligations, and representations and warranties that are customary for an
arrangement of this type. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term of the DCS Agreement expires, on a product-by-product basis, upon the later of (i)&nbsp;the date on which such product
is no longer covered by a valid claim under a licensed patent in the China Territory, or (ii)&nbsp;the twelfth (12th)&nbsp;anniversary of the first commercial sale of such product in Mainland China. The DCS Agreement may be terminated by either
party in the event of a bankruptcy of the other party and for material breach, subject to customary cure periods. In addition, at any time following the third anniversary of the first commercial sale of a product in Mainland China, Eddingpharm has
the right to terminate the DCS Agreement for convenience with twelve months&#146; prior notice. Neither party may assign or transfer the DCS Agreement without the prior consent of the other party, provided that the Company may assign the DCS
Agreement in the event of a change of control transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon closing of the DCS Agreement, the Company received a non-refundable $15.0 million
up-front payment, which it will recognize as revenue over the estimated period in which the Company is required to provide initial and on-going regulatory and development support and clinical supply for obtaining regulatory approvals in the China
Territory and through the estimated period in which the Company is required to provide commercial supply, which is currently estimated to be a period of approximately 16 years. In March 2016, Eddingpharm submitted its clinical trial application
(&#147;CTA&#148;) with respect to the MARINE indication for Vascepa to the Chinese regulatory authority. Following the CTA submission, the Company received a non-refundable $1.0 million milestone payment which it will recognize as revenue over the
estimated period in which the Company is required to provide on-going development support needed to support the successful approval for a new drug application, which is currently estimated to be a period of approximately four years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the non-refundable, up-front and regulatory milestone payments described above, the Company is
entitled to receive certain regulatory and sales-based milestone payments of up to an additional $153.0 million as well as tiered double-digit percentage royalties on net sales of Vascepa in the China Territory escalating to the high teens. The
regulatory milestone events relate to the submission and approval of certain applications to the applicable regulatory authority, such as a clinical trial application, clinical trial exemption, or import drug license application. The sales-based
milestone events occur when annual aggregate net sales of Vascepa in the territory equals or exceeds certain specified thresholds. Each such milestone payment shall be payable only once regardless of how many times the sales milestone event is
achieved. Each such milestone payment is non-refundable and non-creditable against any other milestone payments. The Company recognizes contingent consideration from activities that is earned upon the achievement of a substantive milestone in the
period in which the milestone is achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Licensing and deferred revenues currently consist of revenue attributable to receipt of up-front,
non-refundable payments and milestone payments related to the DCS Agreement and other licensing agreements outside the United States. Up-front and milestone payments under such agreements are typically recognized as licensing revenue over the
estimated period in which we are required to provide regulatory and development support and clinical and commercial supply pursuant to the agreements. During the six months ended June&nbsp;30, 2016 and 2015, the Company recognized $0.5 million and
$0.4 million of up-front and milestone payments as licensing revenue, respectively, and recorded $15.7 million as deferred revenue as of June&nbsp;30, 2016. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(11)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Subsequent Events </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events from June&nbsp;30, 2016 through the date
of the issuance of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx220080_8"></A>Item&nbsp;2.</B><B><I></I></B></TD>
<TD ALIGN="left" VALIGN="top"><B><I></I></B><B></B><B><I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</I></B><B> </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as
amended. These forward-looking statements reflect our plans, estimates and beliefs. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially
different from any future results, performances or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#147;anticipates,&#148; &#147;believes,&#148;
&#147;continue,&#148; &#147;could,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;plans,&#148; &#147;potential,&#148; &#147;predicts,&#148; &#147;projects,&#148; &#147;should,&#148; &#147;would&#148;
and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Because of these risks
and uncertainties, the forward-looking events and circumstances discussed in this report may not transpire. We discuss many of these risks in Part I, Item&nbsp;1A under the heading &#147;Risk Factors&#148; of our Annual Report on Form 10-K for the
fiscal year ended December&nbsp;31, 2015 and below under Part II, Item IA, &#147;Risk Factors&#148;. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Given these uncertainties, you should not
place undue reliance on these forward-looking statements. Also, forward-looking statements represent our estimates and assumptions only as of the date of this document. You should read this document with the understanding that our actual future
results may be materially different from what we expect. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statements contained in this report, whether as a result of new information,
future events or otherwise. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company with expertise in lipid science focused on the commercialization and development of therapeutics to improve
cardiovascular health. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our lead product, Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) capsules, is
approved by the U.S. Food and Drug Administration, or FDA, for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe (TG&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia. This
FDA-approved indication for Vascepa, known as the MARINE indication, is based primarily on the successful results from the MARINE study of Vascepa in this approved patient population. In considering this approval, FDA also reviewed the successful
results from our study of Vascepa in patients with high triglyceride levels (TG <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>200 mg/dL and &lt;500 mg/dL) who are also on statin therapy for elevated low-density lipoprotein cholesterol, or LDL-C,
levels which condition we refer to as mixed dyslipidemia or persistently high triglycerides. This study is known as the ANCHOR study. Safety data from both the MARINE and ANCHOR studies are reflected in FDA-approved labeling for Vascepa. In January
2013, we began selling and marketing Vascepa in the United States based on the FDA-approved MARINE indication. In August 2015, we also began marketing Vascepa in the United States for the treatment of the patient population studied in the ANCHOR
study based on the federal court declaration described below. In March 2016, we reached agreement with the FDA and U.S. government under which they agreed to be bound by the terms of the August 2015 judicial declaration. Vascepa is available in the
United States by prescription only. In May 2016, the FDA determined Vascepa to be eligible for five-year, new chemical entity (NCE) marketing exclusivity thereby providing Vascepa with the benefits of NCE exclusivity afforded by statute from its
July 2012 FDA approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We sell Vascepa principally to a limited number of major wholesalers, as well as selected regional wholesalers
and specialty pharmacy providers, or collectively, our Distributors or our customers, that in turn resell Vascepa to retail pharmacies for subsequent resale to patients and healthcare providers. We market Vascepa in the United States through our
sales force of approximately 150 sales professionals, including sales representatives and their managers. In March 2014, we entered into a co-promotion agreement in the United States with Kowa Pharmaceuticals America, Inc. under which no less than
250 Kowa Pharmaceuticals America, Inc. sales representatives began to devote a substantial portion of their time to promoting Vascepa starting in May 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have an exclusive agreement with Eddingpharm (Asia) Macao Commercial Offshore Limited, or Eddingpharm, to develop and commercialize Vascepa
capsules in Mainland China, Hong Kong, Macau and Taiwan, or the China Territory. We also have an agreement to register and commercialize Vascepa in countries within the Middle East and North Africa and are assessing other partnership opportunities
for licensing Vascepa in other territories outside of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Triglycerides are the main constituent of body fat in humans.
Hypertriglyceridemia refers to a condition in which patients have high levels of triglycerides in the bloodstream. It is estimated that over 70&nbsp;million adults in the United States have elevated triglyceride levels (TG&nbsp;<U>&gt;</U>150
mg/dL), approximately 40&nbsp;million adults in the United States have high triglyceride levels (TG <U>&gt;</U>200 mg/dL), and approximately 4.0&nbsp;million people in the United States have severely high triglyceride levels (TG <U>&gt;</U>500
mg/dL), commonly known as very high triglyceride levels. Many patients with high triglyceride levels also have diabetes and other lipid level abnormalities such as high cholesterol. The patient condition of having more than one lipid level
abnormality is referred to as mixed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dyslipidemia. According to <I>The&nbsp;American Heart Association Scientific Statement on Triglycerides and Cardiovascular Disease </I>(2011), triglycerides provide important information as a
marker associated with the risk for heart disease and stroke, especially when an individual also has low high-density lipoprotein cholesterol, or HDL-C (often referred to as &#147;good&#148; cholesterol), and elevated levels of LDL-C (often referred
to as &#147;bad&#148; cholesterol). Guidelines for the management of very high triglyceride levels suggest that reducing triglyceride levels is the primary goal in patients to reduce the risk of acute pancreatitis. The effect of Vascepa on
cardiovascular mortality and morbidity, or the risk for pancreatitis, in patients with hypertriglyceridemia has not been determined. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
are currently focused on completing the ongoing REDUCE-IT (Reduction of Cardiovascular Events with EPA&#151;Intervention Trial) cardiovascular outcomes study of Vascepa, which we started in December 2011. REDUCE-IT, a multinational, prospective,
randomized, double-blind, placebo-controlled study, is the first prospective cardiovascular outcomes study of any drug in a population of patients who, despite stable statin therapy, have elevated triglyceride levels. Based on the results of
REDUCE-IT, we plan to seek additional indicated uses for Vascepa. In REDUCE-IT, cardiovascular event rates for patients on stable statin therapy plus four grams per day of Vascepa will be compared to cardiovascular event rates for patients on stable
statin therapy plus placebo. In March 2016, we announced the REDUCE-IT enrollment target of approximately 8,000 patients was reached and we have since begun to wind down patient enrollment on a country-by-country basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The REDUCE-IT study is designed to be completed after reaching 1,612 aggregate cardiovascular events. Based on projected event rates, we
estimate the onset of the target aggregate number of cardiovascular events to be reached in or about the second half of 2017 with study results then expected to be available and published in 2018. In addition, since its inception in 2011, our
REDUCE-IT special protocol assessment (SPA) agreement with the FDA has provided for periodic safety reviews and an interim efficacy and safety analysis by the study&#146;s independent data monitoring committee (DMC) at approximately 60% of the
target aggregate number of primary cardiovascular events. In August 2016, we announced an amendment to our REDUCE-IT SPA agreement with FDA that reaffirmed FDA concurrence on key elements of the study, defined details of the statistical analysis
plan for the study, expanded to greater than 30 the pre-specified secondary and tertiary endpoints in the study, and added a second interim efficacy and safety analysis by the DMC at approximately 80% of the target aggregate number of primary
cardiovascular events. The periodic safety reviews and interim efficacy and safety analyses are conducted confidentially by the study&#146;s DMC. We remain blinded to all data from the study. Since patient enrollment commenced in 2011, more than
20,000 patient years of study experience have been accumulated in the REDUCE-IT study. Following each periodic review of safety data to date, the DMC has communicated to us that we should continue the study as planned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In March 2016, we announced that the onset of approximately 60% of the target aggregate number of primary cardiovascular events has triggered
preparation for the first pre-specified interim analysis of efficacy and safety results. We currently expect the 60% interim analysis to be conducted by the independent DMC in September or October 2016, which interim analysis will include the first
review of unblinded efficacy data by the DMC. In addition, assuming the 60% interim analysis results in a recommendation to continue the study, a second planned interim analysis will be triggered by the onset of approximately 80% of the target
aggregate number of primary cardiovascular events in the study. Based on historical event rates, we anticipate that the onset of approximately 80% of events will occur in the first half of 2017, with the second pre-specified interim efficacy and
safety analysis by the DMC expected around mid-2017. As is typical, the statistical threshold for defining overwhelming efficacy on the primary endpoint at interim analyses is considerably higher than the threshold for defining statistical
significance at the end of the study. In addition, we have requested the DMC to not recommend to us stopping the study early based only upon achieving statistical significance for the primary endpoint, but to ensure that supportive trends of benefit
are also consistently observed in certain secondary endpoints and subpopulations before recommending that the study be stopped early for overwhelming efficacy. Accordingly, it is our expectation that each of the 60% and 80% interim analyses will
result in a recommendation to continue the trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the successful Phase 3 MARINE and ANCHOR clinical trials, Vascepa was studied at a
daily dose of 2&nbsp;grams and 4 grams. We sought approval of Vascepa at the more efficacious 4-gram dose for use in each patient population. These trials demonstrated favorable results in their respective patient populations, particularly with the
4-gram dose of Vascepa, in reducing triglyceride levels without increasing LDL-C levels in the MARINE trial and with a statistically significant decrease in LDL-C levels in the ANCHOR trial, in each case, relative to placebo. These trials also
showed favorable results, particularly with the 4-gram dose of Vascepa, in other important lipid and inflammation biomarkers, including apolipoprotein B (apo B), non-high-density lipoprotein cholesterol (non-HDL-C), total-cholesterol (TC), very
low-density lipoprotein cholesterol (VLDL-C), lipoprotein-associated phospholipase A2 (Lp-PLA2), and high sensitivity C-reactive protein (hs-CRP). In these trials, the most commonly reported adverse reaction (incidence &gt;2% and greater than
placebo) in Vascepa-treated patients was arthralgia (joint pain) (2.3% for Vascepa vs. 1.0% for placebo). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In April 2015, we received a
Complete Response Letter, or CRL, from the FDA in response to our supplemental new drug application, or sNDA, that sought approval of Vascepa for use in patients with mixed dyslipidemia, based on the successful ANCHOR study. The CRL followed an
October 2013 rescission by the FDA of a special protocol assessment, or SPA, agreement and three failed attempts by us to appeal that rescission at FDA. The FDA has acknowledged the success of the ANCHOR study, which met all
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
primary and secondary endpoints. However, FDA determined that there were insufficient data to conclude that drug-induced changes in serum triglycerides could be recognized by the FDA as a valid
surrogate for reducing cardiovascular risk in the ANCHOR population for the purpose of regulatory approval of a drug targeted at a triglyceride-lowering indication in this population. The FDA has acknowledged that the standard of proof required by
the FDA for approval of a new drug indication is higher than that generally used to inform patient treatment guidelines and that used by physicians in clinical practice. The FDA did not determine that the drug-induced effects of Vascepa, which go
beyond triglyceride-lowering, would not actually reduce cardiovascular risk in this population and the FDA has encouraged us to complete the REDUCE-IT outcomes study. Based on our communications with the FDA, we expect that final positive results
from the REDUCE-IT outcomes study will be required for label expansion for Vascepa. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In May 2015, we and a group of independent physicians
filed a lawsuit in federal court to permit us to promote to healthcare professionals the use of Vascepa in patients with mixed dyslipidemia so long as the promotion is truthful and non-misleading. This use reflects recognized medical practice but is
not covered by current FDA-approved labeling for the drug. Historically, FDA has considered promotion of drug uses not covered by FDA-approved labelling to be illegal off-label promotion, even if such promotion is truthful and non-misleading. In
August 2015, we were granted preliminary relief in the form of a declaratory judgment in this lawsuit. The court declaration permitted us to promote to healthcare professionals the FDA-reviewed and agreed effects of Vascepa demonstrated in the
ANCHOR clinical trial and presentation of the current state of scientific research related to the potential of Vascepa to reduce the risk of cardiovascular disease including through use of peer-reviewed scientific publications of available data. In
August 2015, we began to promote Vascepa to healthcare professionals as permitted by this court declaration and in March 2016, the parties obtained court approval of negotiated settlement terms under which the FDA and the U.S. government agreed to
be bound by the court&#146;s conclusions from the August 2015 declaration that we may engage in truthful and non-misleading speech promoting the off-label use of Vascepa and that certain statements and disclosures that we proposed to make to
healthcare professionals were truthful and non-misleading. While we believe we are now permitted under applicable law to more broadly promote Vascepa, the FDA-approved labeling for Vascepa did not change as a result of this litigation and
settlement, and neither government nor other third-party coverage or reimbursement to pay for the off-label use of Vascepa promoted under the court declaration was required. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Commercialization &#150; United States </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We commenced the commercial launch of Vascepa in the United States in January 2013. We commenced sales and shipments of Vascepa at that time to
our network of U.S.-based wholesalers. We now market Vascepa in the United States through our sales force of approximately 150 sales professionals, including sales representatives and their managers. Commencing in May 2014, in addition to promotion
by our sales representatives, no less than 250 Kowa Pharmaceuticals America, Inc. sales representatives began promoting Vascepa. We also employ various marketing personnel to support our commercialization of Vascepa. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under our co-promotion agreement with Kowa Pharmaceuticals America, Inc., both parties have agreed to use commercially reasonable efforts to
promote, detail and optimize sales of Vascepa in the United States and have agreed to specific performance requirements detailed in the related agreement. The performance requirements include a negotiated minimum number of sales details to be
delivered by each party in the first and second position, the use of a negotiated number of minimum sales representatives from each party, including no less than 250 Kowa Pharmaceuticals America, Inc. sales representatives and the achievement of
minimum levels of Vascepa revenue in 2015 and beyond. First position refers to when a sales representative&#146;s primary purpose in detailing is related to Vascepa, while second position refers to when a sales representative&#146;s primary purpose
in detailing is to promote another product, but they also devote time in the same sales call to promote Vascepa. Kowa Pharmaceuticals America, Inc. has also agreed to continue to bear the costs incurred for its sales force associated with the
commercialization of Vascepa and to pay for certain incremental costs associated with the use of its sales force, such as sample costs and costs for promotional and marketing materials. We will continue to recognize all revenue from sales of
Vascepa. In exchange for Kowa Pharmaceuticals America, Inc.&#146;s co-promotional services, Kowa Pharmaceuticals America, Inc. is entitled to a quarterly co-promotion fee based on a percentage of aggregate Vascepa gross margin that increases during
the term. The percentage of aggregate Vascepa gross margin earned by Kowa Pharmaceuticals America, Inc. was fifteen percent (15%)&nbsp;in 2015, is nineteen percent (19%)&nbsp;in 2016, and is scheduled to increase to low twenty percent levels in 2017
and 2018, subject to certain adjustments. The term of this co-promotion agreement expires on December&nbsp;31, 2018, following which Kowa Pharmaceuticals America, Inc. will be entitled to earn tail royalties equal to declining fractions of the
co-promotion fee in effect prior to such expiration for periods ranging from one to three years following such expiration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on
monthly compilations of data provided by a third party, Symphony Health Solutions, the estimated number of normalized total Vascepa prescriptions for the three months ended June&nbsp;30, 2016 was approximately 230,000 compared to 201,000 and 148,000
in the three months ended March&nbsp;31, 2016 and June&nbsp;30, 2015, respectively. According to data from another third party, IMS Health, the estimated number of normalized total Vascepa prescriptions for the three months ended June&nbsp;30, 2016
was approximately 248,000 compared to 214,000 and 157,000 in the three months ended March&nbsp;31, 2016 and June&nbsp;30, 2015, respectively. Normalized total prescriptions represent the estimated total number of Vascepa prescriptions shipped to
patients, calculated on a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
normalized basis (i.e., total capsules shipped divided by 120&nbsp;capsules, or one month&#146;s supply). Growth in Vascepa prescriptions resulted in increased shipment volumes to wholesalers
during the three months ended June&nbsp;30, 2016. Inventory levels at wholesalers tend to fluctuate based on seasonal factors, prescription trends and other factors. For example, during the quarter ended March&nbsp;31, 2016, wholesalers decreased
inventory levels from year-end 2015. During the three months ended June&nbsp;30, 2016, the trend was reversed and wholesalers increased inventory levels. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The data reported above is based on information made available to us from third-party resources and may be subject to adjustment and may
overstate or understate actual prescriptions. Timing of shipments to wholesalers, as used for revenue recognition purposes, and timing of prescriptions as estimated by these third parties may differ from period to period. Although we believe these
data are prepared on a period-to-period basis in a manner that is generally consistent and that such results can be generally indicative of current prescription trends, these data are based on estimates and should not be relied upon as definitive.
While we expect to be able to grow Vascepa revenues over time, no guidance should be inferred from the operating metrics described above. We also anticipate that such sales growth will be inconsistent from period to period. We believe that investors
should view the above-referenced operating metrics with caution, as data for this limited period may not be representative of a trend consistent with the results presented or otherwise predictive of future results. Seasonal fluctuations in
pharmaceutical sales, for example, may affect future prescription trends of Vascepa, as could changes in prescriber sentiment, period-to-period Distributor purchasing habits and other factors. We believe investors should consider our results over
several quarters, or longer, before making an assessment about potential future performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The commercialization of pharmaceutical
products is a complex undertaking, and our ability to effectively and profitably commercialize Vascepa will depend in part on our ability to generate market demand for Vascepa through education, marketing and sales activities, our ability to achieve
market acceptance of Vascepa, our ability to generate product revenue and our ability to receive adequate levels of reimbursement from third-party payers. See &#147;<I>Risk Factors&#151;Risks Related to the Commercialization and Development of
Vascepa</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In August 2015, we and our co-promotion partner began communicating ANCHOR clinical trial data to targeted healthcare
professionals. Such qualified communications are being made pursuant to the August&nbsp;7, 2015 federal district court declaration and related settlement allowing truthful and non-misleading promotion of the FDA-reviewed and agreed effects of
Vascepa demonstrated in the ANCHOR clinical trial and presentation of the current state of scientific research related to the potential of Vascepa to reduce the risk of cardiovascular disease including through use of peer-reviewed scientific
publications of available data. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Commercialization &#150; Outside the United States </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In February 2015, we announced an exclusive agreement with Eddingpharm to develop and commercialize Vascepa capsules in what we refer to as the
China Territory, consisting of the territories of Mainland China, Hong Kong, Macau and Taiwan, for uses that are currently commercialized and under development by us in the United States based on the MARINE, ANCHOR and ongoing REDUCE-IT clinical
trials of Vascepa. Under the agreement, Eddingpharm is responsible for development and commercialization activities in the China Territory and associated expenses. We will provide development assistance and be responsible for supplying the product.
Terms of the agreement include up-front and milestone payments to us of up to $169.0 million, including a non-refundable $15.0 million up-front payment received at closing, a non-refundable milestone payment of $1.0 million received upon successful
submission of a clinical trial application with respect to the MARINE indication for Vascepa to the Chinese regulatory authority in March 2016, and future development, regulatory and sales-based milestone payments of up to an additional $153.0
million. Eddingpharm will also pay us tiered double-digit percentage royalties on net sales of Vascepa in the China Territory escalating to the high teens. We will supply finished product to Eddingpharm under negotiated terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also have an agreement to register and commercialize Vascepa in countries within the Middle East and North Africa. We continue to assess
other partnership opportunities for licensing Vascepa in other territories outside of the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">REDUCE-IT is the first prospective cardiovascular outcomes study of any drug in a population of patients who, despite stable statin
therapy, have elevated triglyceride levels. REDUCE-IT is a multinational, prospective, randomized, double-blind, placebo-controlled study designed to assess the cumulative effect on the rate of cardiovascular events for patients treated with Vascepa
as an add-on to statin therapy compared to the corresponding rate of cardiovascular events for patients treated with placebo on top of statin therapy. Based on the results of REDUCE-IT, we may seek additional indications for Vascepa beyond the
indications studied in the ANCHOR or MARINE trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">REDUCE-IT is designed to enroll approximately 8,000 patients. As announced in March
2016, this enrollment target has been reached and we have begun to wind down patient enrollment on a country-by-country basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Completion of the REDUCE-IT study is designed to occur after reaching an aggregate number of
cardiovascular events. Based on projected event rates, we estimate the onset of the target aggregate number of cardiovascular events to be reached in or about the second half of 2017 with study results then expected to be available in 2018. In
addition, since its inception in 2011, our REDUCE-IT special protocol assessment (SPA) agreement with the FDA has provided for periodic safety reviews and an interim efficacy and safety analysis by the independent DMC at approximately 60% of the
target aggregate number of primary cardiovascular events. In August 2016, we announced an amendment to our REDUCE-IT SPA agreement with FDA that reaffirmed FDA concurrence on key elements of the study, defined details of the statistical analysis
plan for the study, expanded to greater than 30 the pre-specified secondary and tertiary endpoints in the study, and added a second interim efficacy and safety analysis by the DMC at approximately 80% of the target aggregate number of primary
cardiovascular events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In March 2016, we announced that the onset of approximately 60% of the target aggregate number of primary
cardiovascular events has triggered preparation for the first pre-specified interim analysis of efficacy and safety results by the independent DMC. We currently expect this independent interim analysis to be conducted in September or October 2016.
In addition, assuming the 60% interim analysis results in a recommendation to continue the study, a second planned interim analysis will be triggered by the onset of approximately 80% of the target aggregate number of primary cardiovascular events
in the study. Based on historical event rates, we anticipate that the onset of approximately 80% of events will occur in the first half of 2017, with the second pre-specified interim efficacy and safety analysis by the DMC expected around mid-2017.
As is typical, the statistical threshold for defining overwhelming efficacy on the primary endpoint at interim analyses is considerably higher than the threshold for defining statistical significance at the end of the study. In addition, we have
requested the DMC to not recommend stopping the study early based only upon achieving statistical significance for the primary endpoint, but to ensure that supportive trends of benefit are also consistently observed in certain secondary endpoints
and subpopulations before recommending that the study be stopped early for overwhelming efficacy. Accordingly, it is our expectation that each of the 60% and 80% interim analyses will result in a recommendation to continue the trial. By design, it
is most common for cardiovascular outcomes studies not to be stopped upon an interim look. We remain blinded to all data from the study. Unless overwhelming efficacy and safety is declared by the DMC at an interim look or the study is halted due to
a patient safety concern, Amarin personnel will remain blinded to the efficacy and safety data from the REDUCE-IT study until the study is complete. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since patient enrollment commenced in 2011, more than 20,000 patient years of study experience have been accumulated in REDUCE-IT. The DMC has
reviewed unblinded safety data on a quarterly basis since initiation of the REDUCE-IT study in 2011 and, after each such meeting to date, the DMC has recommended to us that the study be continued as planned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our scientific rationale for the REDUCE-IT study is supported by (i)&nbsp;epidemiological data that suggests elevated triglyceride levels
correlate with increased cardiovascular disease risk, (ii)&nbsp;genetic data that suggests triglyceride and/or triglyceride-rich lipoproteins (as well as low-density lipoprotein cholesterol (LDL cholesterol), known as bad cholesterol) are
independently in the causal pathway for cardiovascular disease and (iii)&nbsp;clinical data that suggest substantial triglyceride reduction in patients with elevated baseline triglyceride levels correlates with reduced cardiovascular risk. Our
scientific rationale for the REDUCE-IT study is also supported by research on the putative cardioprotective effects of EPA as presented in scientific literature. It is possible that the effects of EPA may be due not to a single mode of action, such
as triglyceride lowering, but rather to multiple mechanisms working together. Studies in the scientific literature explore potentially beneficial effects of EPA on multiple atherosclerosis processes, including endothelial function, oxidative stress,
foam cell formation, inflammation/cytokines, plaque formation/progression, platelet aggregation, thrombus formation, and plaque rupture. The REDUCE-IT study is needed to determine the clinical benefit, if any, of EPA therapy in statin-treated
patients with elevated triglyceride levels. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Commercial Supply </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to 2015, all of our active pharmaceutical ingredient, or API, that has been utilized in product sold was manufactured by two suppliers:
Nisshin Pharma, Inc., or Nisshin, and Chemport, Inc., or Chemport. A significant portion of such API was purchased from Nisshin at a price that is higher than expected future average API costs. During 2015, we began purchasing API from a third
supplier, Finorga SAS, or Novasep. The amount of supply we seek to purchase in future periods will depend on the level of growth of Vascepa revenues and minimum purchase commitments with certain suppliers. While our current supply chain is scalable,
we continue efforts to expand, diversify and further enhance it. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Financial Position </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that our cash and cash equivalents of $72.5 million as of June&nbsp;30, 2016 will be sufficient to fund our projected operations for
at least the next twelve months. Depending on the level of cash generated from operations, additional capital will likely be required to sustain operations. We anticipate that quarterly net cash outflows in future periods will be variable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Operations Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Product Revenue, net.</I> All of our product revenue is derived from product sales of Vascepa, net of allowances, discounts, incentives,
rebates, chargebacks and returns. We sell product to a limited number of major wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, our Distributors or our customers, who resell the product to
retail pharmacies for purposes of their reselling the product to fill patient prescriptions. We commenced our commercial launch in the United States in January 2013. In accordance with GAAP, until we had the ability to reliably estimate returns of
Vascepa from our Distributors, revenue was recognized based on the resale of Vascepa for the purposes of filling patient prescriptions, and not based on our sales to such Distributors. In 2014, we concluded that we had developed sufficient history
such that we can reliably estimate returns and as a result, began to recognize revenue based on sales to our Distributors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Licensing
revenue.</I> Licensing revenue currently consists of revenue attributable to receipt of up-front, non-refundable payments and milestone payments related to license and distribution agreements for Vascepa outside the United States. Up-front and
milestone payments under such agreements are typically recognized as licensing revenue over the estimated period in which we are required to provide regulatory and development support and clinical and commercial supply pursuant to the agreements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Cost of Goods Sold.</I> Cost of goods sold includes the cost of API for Vascepa on which revenue was recognized during the period, as
well as the associated costs for encapsulation, packaging, shipment, supply management, quality assurance and insurance. The cost of the API included in cost of goods sold reflects the average cost method of inventory valuation and relief. This
average cost reflects the actual purchase price of Vascepa API. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Selling, General and Administrative Expense.</I> Selling, general and
administrative expense consists primarily of salaries and other related costs, including stock-based compensation expense, for personnel in our sales, marketing, executive, business development, finance and information technology functions, as well
as co-promotion fees payable to Kowa Pharmaceuticals America, Inc. Other costs primarily include facility costs and professional fees for accounting, consulting and legal services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expense.</I> Research and development expense consists primarily of fees paid to professional service providers in
conjunction with independent monitoring of our clinical trials and acquiring and evaluating data in conjunction with our clinical trials, fees paid to independent researchers, costs of qualifying contract manufacturers, services expenses incurred in
developing and testing products and product candidates, salaries and related expenses for personnel, including stock-based compensation expense, costs of materials, depreciation, rent, utilities and other facilities costs. In addition, research and
development expenses include the cost to support current development efforts, including patent costs and milestone payments, as well as costs of product supply received from suppliers when such receipt by us is prior to regulatory approval of the
supplier. We expense research and development costs as incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Gain (Loss) on Change in Fair Value of Derivative Liabilities.</I>
Gain (loss) on change in fair value of derivative liabilities is comprised of: (i)&nbsp;the change in fair value of the warrant derivative liability, (ii)&nbsp;the change in fair value of the derivative liability related to the change in control
provision associated with the December 2012 financing with BioPharma Secured Debt Fund II Holdings Cayman LP, or BioPharma, (iii)&nbsp;the change in fair value of the derivative liabilities related to the change in control provisions associated with
the May 2014 and November 2015 exchangeable senior notes; and (iv)&nbsp;the change in fair value of the derivative liability related to the preferred stock purchase option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Interest and Other (Expense) Income, Net.</I> Interest expense consists of interest incurred under lease obligations, interest incurred
under our 3.5% exchangeable notes and interest incurred under our December 2012 financing arrangement with BioPharma. Interest expense under our exchangeable notes includes the amortization of the conversion option related to our exchangeable debt,
the amortization of the related debt discounts and debt obligation coupon interest. Interest expense under our BioPharma financing arrangement is calculated based on an estimated repayment schedule. Interest income consists of interest earned on our
cash and cash equivalents. Other (expense) income, net, consists primarily of foreign exchange losses and gains. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and
Significant Judgments and Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our discussion and analysis of our financial condition and results of operations is based on our
condensed consolidated financial statements and notes, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and
judgments that affect the reported amounts of assets, liabilities, revenue and expenses. On an ongoing basis, we evaluate our estimates and judgments, including those related to derivative financial liabilities. We base our estimates on historical
experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from
other sources. Actual results may differ from these estimates under different assumptions or conditions. A summary of our significant accounting policies is contained in Note&nbsp;2 to our condensed consolidated financial statements included
elsewhere in this Quarterly Report on Form&nbsp;10-Q. We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Revenue Recognition</I>&#151;We sell Vascepa principally to a limited number of Distributors,
that in turn resell Vascepa to retail pharmacies that subsequently resell it to patients and healthcare providers. In accordance with GAAP, our revenue recognition policy requires that: (i)&nbsp;there is persuasive evidence that an arrangement
exists between us and the Distributor, (ii)&nbsp;delivery has occurred, (iii)&nbsp;collectability is reasonably assured and (iv)&nbsp;the price is fixed or determinable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We began recognizing revenue from the sale of Vascepa following our commercial launch in the United&nbsp;States in January 2013. Prior to
2013, we recognized no revenue from Vascepa sales. We sell Vascepa to Distributors. In accordance with GAAP, until we had the ability to reliably estimate returns of Vascepa from our Distributors, revenue was recognized based on the resale of
Vascepa for the purposes of filling patient prescriptions, and not based on our sales to such Distributors. In 2014, we concluded that we had developed sufficient history such that we can reliably estimate returns and as a result, began to recognize
revenue based on sales to our Distributors. Consequently, we recognized revenues of $58.1 million and $33.3 million based on sales to Distributors during the six months ended June&nbsp;30, 2016 and 2015, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have written contracts with our Distributors, and delivery occurs when a Distributor receives Vascepa. We evaluate the creditworthiness of
each of our Distributors to determine whether revenues can be recognized upon delivery, subject to satisfaction of the other requirements, or whether recognition is required to be delayed until receipt of payment. In order to conclude that the price
is fixed or determinable, we must be able to (i)&nbsp;calculate our gross product revenues from the sales to Distributors and (ii)&nbsp;reasonably estimate our net product revenues. We calculate gross product revenues based on the wholesale
acquisition cost that we charge our Distributors for Vascepa. We estimate our net product revenues by deducting from our gross product revenues (a)&nbsp;trade allowances, such as invoice discounts for prompt payment and distributor fees,
(b)&nbsp;estimated government and private payor rebates, chargebacks and discounts, such as Medicaid reimbursements, (c)&nbsp;reserves for expected product returns and (d)&nbsp;estimated costs of incentives offered to certain indirect customers,
including patients. The gross to net deductions are estimated based on available actual information, historical data, known trends, and levels of inventory in the distribution channel. We rely on resale data provided by our Distributors as well as
prescription data provided by Symphony Health Solutions and IMS Health in estimating the level of inventory held in the distribution channel. A hypothetical 5% change in estimated channel inventory would result in a change of less than 1% in net
product revenues reported during each of the three and six months ended June&nbsp;30, 2016 and 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">When evaluating multiple-element
arrangements, we identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on whether the delivered element has stand-alone value to the collaborator or if the arrangement
includes a general right of return for delivered items. We may receive up-front, non-refundable payments when licensing our intellectual property in conjunction with research and development agreements. In determining the units of accounting, we
evaluate whether the license has stand-alone value from the undelivered elements to the collaborative partner based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include
the stage of development of the license delivered, research and development capabilities of the partner and the ability of partners to develop and commercialize Vascepa independently. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">When we believe a license to our intellectual property does not have stand-alone value from the other deliverables to be provided in the
arrangement, we generally recognize revenue attributable to the license over the contractual or estimated performance period. Any unrecognized portion of license revenue is classified within deferred revenue in the accompanying condensed
consolidated balance sheets. When we believe a license to our intellectual property has stand-alone value, we recognize revenue attributed to the license upon delivery. The periods over which revenue is recognized is subject to estimates and may
change over the course of the agreement. Such a change could have a material impact on the amount of revenue we record in future periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Derivative Financial Liabilities</I>&#151;Derivative financial liabilities are initially recorded at fair value. They are subsequently held
at fair value, with gains and losses arising for changes in fair value recognized in the condensed consolidated statement of operations.&nbsp;The fair value of derivative financial liabilities is determined using various valuation techniques. We use
our judgment to select a variety of methods and make assumptions that are mainly based on market conditions existing at each balance sheet date, which include our projections for future estimated revenues, management estimates of the probability of
a change in control occurring, and the terms of debt issues of similar companies. Fluctuations in the assumptions used in the valuation model would result in adjustments to the fair value of the derivative liabilities reflected on our condensed
consolidated balance sheet and, therefore, our condensed consolidated statement of operations. If we issue shares to discharge the liability, the derivative financial liability is derecognized and common stock and additional paid-in capital are
recognized on the issuance of those shares. For options and warrants treated as derivative financial liabilities, at settlement date the carrying value of the options and warrants are transferred to equity.&nbsp;The cash proceeds received from
shareholders for additional shares are recorded in common stock and additional paid-in capital. We have recorded financial derivatives related to certain outstanding warrants (extinguished during the first quarter of 2015), the change in control
provision associated with our December 2012 debt financing, the change in control provisions associated with our May 2014 and November 2015 exchangeable senior notes, and a preferred stock purchase option (subsequently reclassified to permanent
equity). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Inventory</I>&#151;We capitalize purchases of saleable inventory of Vascepa from suppliers
that have been qualified by the FDA. During the periods presented, we purchased API for Vascepa from three FDA-approved suppliers. If we add a new API supplier, all Vascepa API purchased from such supplier is included as a component of research and
development expense until the new API supplier is approved. Upon sNDA approval of each additional supplier, we capitalize subsequent Vascepa API purchases from such supplier as inventory. In April 2016, we adopted ASU No.&nbsp;2015-11, Inventory
(Topic 330)&#151;<I>Simplifying the Measurement of Inventory</I>, and as such, began to state inventories at the lower of cost or net realizable market value (previously, we stated inventories at the lower of cost or market value). Cost is
determined based on actual cost using the average cost method. An allowance is established when management determines that certain inventories may not be saleable. If inventory cost exceeds expected net realizable value due to obsolescence, damage,
quantities in excess of expected demand, changes in price levels or other causes, then we will reduce the carrying value of such inventory to net realizable value and recognize the difference as a component of cost of goods sold in the period in
which it occurs. We expense inventory identified for use as marketing samples when they are packaged. The average cost reflects the actual purchase price of Vascepa API. Additionally, the determination of the classification of our inventory requires
the use of estimates in order to determine the portion of inventories anticipated to be utilized within twelve months of the balance sheet date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Income Taxes</I>&#151;Deferred tax assets and liabilities are recognized for the future tax consequences of differences between the
carrying amounts and tax bases of assets and liabilities and operating loss carryforwards and other attributes using enacted rates expected to be in effect when those differences reverse. Valuation allowances are provided against deferred tax assets
that are not more likely than not to be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We provide reserves for potential payments of tax to various tax authorities or do not
recognize tax benefits related to uncertain tax positions and other issues. Tax benefits for uncertain tax positions are based on a determination of whether a tax benefit taken by us in our tax filings or positions is more likely than not to be
realized, assuming that the matter in question will be decided based on its technical merits. Our policy is to record interest and penalties in the provision for income taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We assess our ability to realize deferred tax assets at each reporting period. The realization of deferred tax assets depends on generating
future taxable income during the periods in which the tax benefits are deductible or creditable. We have been historically profitable in the United States. When making our assessment about the realization of our U.S. deferred tax assets as of
June&nbsp;30, 2016, we considered all available evidence, placing particular weight on evidence that could be objectively verified. The evidence considered included the (i)&nbsp;historical profitability of our U.S. operations, (ii)&nbsp;sources of
future taxable income, giving weight to sources according to the extent to which they can be objectively verified and (iii)&nbsp;the risks to our business related to the commercialization and development of Vascepa. Based on our assessment, we
concluded that the U.S. deferred tax assets are more likely than not to be realizable as of June&nbsp;30, 2016. The majority of our deferred tax assets are held outside of the United States, for which we have established a full valuation allowance.
Changes in historical earnings performance and future earnings projections, among other factors, may cause us to adjust our valuation allowance on deferred tax assets, which would impact our income tax expense in the period in which we determine
that these factors have changed. In the event sufficient taxable income is not generated in future periods, additional valuation allowances could be required relating to these U.S. deferred tax assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In April 2016, we adopted ASU No.&nbsp;2016-09, Compensation&#151;<I>Stock Compensation (Topic 718): Improvements to Employee Share-Based
Payment Accounting</I>, which changes the accounting for certain aspects of share-based payments to employees. Refer to recent accounting pronouncements below for additional details on the impact of this recently adopted accounting guidance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">From
time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, and are early adopted by us or adopted as of the specified effective date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January 2016, we adopted ASU No.&nbsp;2015-03, <I>Interest&#151;Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of
Debt Issuance Costs</I>, which provides guidance on simplifying the presentation of debt issuance costs on the balance sheet. To simplify presentation of debt issuance costs, the amendments in ASU No.&nbsp;2015-03 require that debt issuance costs
related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with the treatment of debt discounts. The recognition and measurement guidance for debt
issuance costs are not affected by the amendments in this update. In accordance with ASU No.&nbsp;2015-03, we applied the new guidance on a retrospective basis, wherein the condensed consolidated balance sheet of each individual period presented was
adjusted to reflect the period-specific effects of applying the new guidance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In April 2016, we adopted ASU No.&nbsp;2015-11, <I>Inventory (Topic 330): Simplifying the
Measurement of Inventory</I>, which simplifies the subsequent measurement of inventories by replacing the lower of cost or market test with a lower of cost or net realizable value test. When evidence exists that the net realizable value of inventory
is less than its cost (due to damage, physical deterioration, obsolescence, changes in price levels or other causes), we will recognize the difference as a component of cost of goods sold in the period in which it occurs. In accordance with ASU
No.&nbsp;2015-11, we applied the new guidance on a prospective basis with no impact on the carrying amount of inventory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Also in April
2016, we adopted ASU No.&nbsp;2016-09, <I>Compensation&#151;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,</I> which changes the accounting for certain aspects of share-based payments to employees. One
aspect of the standard requires that excess tax benefits and deficiencies that arise upon vesting or exercise of share-based payments be recognized as an income tax benefit and expense in the income statement. Previously, such amounts were
recognized as an increase and decrease in additional paid-in capital. This aspect of the standard was adopted prospectively, and accordingly, the benefit from income taxes for the three and six months ended June&nbsp;30, 2016, includes $0.1 million
and $0.2 million, respectively, of excess tax deficiencies arising from share-based payments. Additionally, the new standard requires that historical excess tax benefits that were not previously recognized because the related tax deduction had not
reduced current taxes payable should be recognized on a modified retrospective basis as a cumulative-effect adjustment to retained earnings as of the beginning of the annual period of adoption. Consequently, we recognized deferred tax assets of
approximately $1.6 million relating to excess tax benefits on stock-based compensation outstanding as of December&nbsp;31, 2015, with a corresponding cumulative-effect adjustment to accumulated deficit. The new standard also amends the presentation
of employee share-based payment-related items in the statement of cash flows by requiring that: (i)&nbsp;excess income tax benefits and deficiencies be classified in cash flows from operating activities, and (ii)&nbsp;cash paid to taxing authorities
arising from the withholding of shares from employees be classified as cash flows from financing activities. We adopted the aspects of the standard affecting cash flow presentation retrospectively and, accordingly, reclassified $0.6 million of
excess tax provision from cash flows provided by financing activities to cash flows used in operating activities in the condensed consolidated statement of cash flows for the six months ended June&nbsp;30, 2015 to conform to the current year
presentation. The presentation requirement for cash flows related to taxes paid for withheld shares had no impact to any of the periods presented in the condensed consolidated statement of cash flows since such payments have historically been
presented as a financing activity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also considered the following recent accounting pronouncements which were not yet adopted as of
June&nbsp;30, 2016: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued ASU No.&nbsp;2014-09, <I>Revenue from Contracts with Customers (Topic 606)</I>. This
amendment provides principles for recognizing revenue for the transfer of promised goods or services to customers with the consideration to which the entity expects to be entitled in exchange for those goods or services, and is effective for annual
periods beginning after December&nbsp;15, 2016 (the original effective date). In April 2015, the FASB issued a proposal, which was subsequently adopted in July 2015, to defer the original effective date of this standard by one year, such that the
amendment is effective for our fiscal year beginning January&nbsp;1, 2018. Early adoption is permitted, but not before the original effective date. We are currently evaluating the accounting, transition and disclosure requirements of the standard
and cannot currently estimate the financial statement impact of adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In August 2014, the FASB issued ASU No.&nbsp;2014-15,
<I>Presentation of Financial Statements&#151;Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern</I>. ASU 2014-15 requires management to assess an entity&#146;s ability to
continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the ASU (i)&nbsp;provides a definition of the term substantial doubt, (ii)&nbsp;requires an evaluation
every reporting period including interim periods, (iii)&nbsp;provides principles for considering the mitigating effect of management&#146;s plans, (iv)&nbsp;requires certain disclosures when substantial doubt is alleviated as a result of
consideration of management&#146;s plans, (v)&nbsp;requires an express statement and other disclosures when substantial doubt is not alleviated and (vi)&nbsp;requires an assessment for a period of one year after the date that the financial
statements are issued (or available to be issued). This standard is effective for fiscal years ending after December&nbsp;15, 2016, and for annual and interim periods thereafter. Early application is permitted. We have determined that this standard
would not have a material impact on our condensed consolidated financial statements based on the assessment of our ability to continue as a going concern as of June&nbsp;30, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January 2016, the FASB issued ASU No.&nbsp;2016-01, <I>Financial Instruments&#151;Overall (Subtopic 825-10): Recognition and Measurement of
Financial Assets and Financial Liabilities</I>. The new guidance is intended to improve the recognition and measurement of financial instruments by requiring separate presentation of financial assets and financial liabilities by measurement category
and form of financial asset (i.e., securities or loans and receivables) within the balance sheet or the accompanying notes to the financial statements, eliminating the requirement for public business entities to disclose the method(s) and
significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost within the balance sheet, requiring public business entities to use the exit price notion when measuring
the fair value of financial instruments for disclosure purposes, requiring equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) to be measured at fair value with
changes in fair value recognized in net income, and requiring </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a reporting organization to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific
credit risk (also referred to as &#147;own credit&#148;) when the organization has elected to measure the liability at fair value in accordance with the fair value option for financial instruments, among others. The new guidance is effective for
fiscal years beginning after December&nbsp;15, 2017, including interim periods within those fiscal years. The new guidance permits early adoption of the own credit provision. We are currently evaluating the accounting, transition and disclosure
requirements of the standard and cannot currently estimate the financial statement impact of adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued
ASU No.&nbsp;2016-02,<I> Leases (Topic 842)</I>. The new guidance will require lessees to recognize a right-of-use asset and a lease liability for virtually all of their leases (other than leases that meet the definition of a short-term lease). The
liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for initial direct costs. Under the new guidance, lessor accounting is largely unchanged but certain targeted
improvements were made to align, where necessary, lessor accounting with the lessee accounting model and Topic 606, Revenue from Contracts with Customers. The new lease guidance also simplified the accounting for sale and leaseback transactions
primarily because lessees must recognize lease assets and lease liabilities and therefore, will no longer be provided with a source of off-balance sheet financing. The new guidance is effective for fiscal years beginning after December&nbsp;15,
2018, including interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the accounting, transition and disclosure requirements of the standard and cannot currently estimate the financial statement impact
of adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In March 2016, the FASB issued ASU No.&nbsp;2016-08, <I>Revenue from Contracts with Customers (Topic 606): Principal versus
Agent Considerations (Reporting Revenue Gross versus Net)</I>, which clarifies that an entity is a principal when it controls the specified good or service before that good or service is transferred to the customer, and is an agent when it does not
control the specified good or service before it is transferred to the customer. The new guidance is intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. In April 2016, the
FASB issued ASU No.&nbsp;2016-10<I>, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,</I> which clarifies the following two aspects of Topic 606: (a)&nbsp;identifying performance obligations; and
(b)&nbsp;the licensing implementation guidance. Further, in May 2016, the FASB issued ASU No.&nbsp;2016-12, <I>Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients,</I> which provides clarifying
guidance in certain narrow areas and adds some practical expedients. The amendments do not change the core principles of the guidance in Topic 606 and are effective for our fiscal year beginning January&nbsp;1, 2018. Early application is permitted
only as of annual reporting periods beginning after December&nbsp;15, 2016, including interim reporting periods within that reporting period. We is currently evaluating the accounting, transition and disclosure requirements of these standards and
cannot currently estimate the financial statement impact of adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that the impact of other recently issued but not yet
adopted accounting pronouncements will not have a material impact on our consolidated financial position, results of operations, and cash flows, or do not apply to our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of Three Months
Ended June&nbsp;30, 2016 and June&nbsp;30, 2015 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Product Revenue, net.</I> We recorded net product revenue of $32.8 million and
$17.7 million during the three months ended June&nbsp;30, 2016 and 2015, respectively, an increase of $15.1 million, or 85%. This increase in revenue was driven primarily by an increase in estimated normalized total Vascepa prescriptions as well as
an increase in the level of inventories held by our customers during the period. Based on data provided by Symphony Health Solutions and IMS Health, estimated normalized total Vascepa prescriptions increased by approximately 82,000 and 91,000,
respectively, over the three months ended June&nbsp;30, 2015, representing growth of 55% and 58%, respectively. The level of inventories held by our Distributors as of June&nbsp;30, 2016 increased as compared to inventories held as of year-end 2015
calculated based on estimated days of Vascepa sales on hand, resulting in a net overall increase in product revenues of approximately $1.5 million to $1.8 million during the first half of 2016. We estimate that revenues during the quarter ended
June&nbsp;30, 2016 include approximately $2.9 million to $3.2 million in product revenues resulting from a net overall increase in Distributor inventory levels during the period compared to a less than $0.5 million decrease in revenues due to net
inventory level changes in the corresponding period in 2015. The increase in Distributor inventory levels during the quarter ended June&nbsp;30, 2016 follows an estimated $1.2 million to $1.5 million decline in first quarter 2016 product revenues
due to reduced Distributor inventory levels during the first three months of 2016. All of our product revenue in the three months ended June&nbsp;30, 2016 and 2015 was derived from product sales of Vascepa, net of allowances, discounts, incentives,
rebates, chargebacks and returns. Timing of shipments to wholesalers, as used for revenue recognition, and timing of prescriptions as estimated by third-party sources such as Symphony Health Solutions and IMS Health may differ from period to period.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the quarters ended June&nbsp;30, 2016 and 2015, our net product revenue included an adjustment for co-pay mitigation rebates
provided by us to commercially insured patients. Such rebates are intended to offset the differential for patients of Vascepa not covered by commercial insurers at the time of launch on Tier 2 for formulary purposes, resulting in higher co-pay
amounts for such patients. Our cost for these co-payment mitigation rebates during the quarters ended June&nbsp;30, 2016 and 2015 was up to $70 per prescription filled. Since launch, certain third-party payors have added Vascepa to their Tier 2
coverage, which results in lower co-payments for patients covered by these third-party payors. In connection with such Tier 2 coverage, we have agreed to pay customary rebates to these third-party payors on the resale of Vascepa to patients covered
by these third-party payors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As is typical for the pharmaceutical industry, the majority of Vascepa sales are to major
commercial wholesalers which then resell Vascepa to retail pharmacies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Licensing Revenue.</I> Licensing revenue during the three
months ended June&nbsp;30, 2016 was $0.3 million. No licensing revenue was recorded during the three months ended June&nbsp;30, 2015. Licensing revenue relates primarily to the amortization of a $15.0 million up-front payment received in February
2015 and a $1.0 milestone payment achieved in March 2016, both associated with a Vascepa licensing agreement for the China Territory. The up-front and milestone payments are being recognized over the estimated period in which we are required to
provide regulatory and development support and clinical and commercial supply under the agreement. The amount of licensing revenue recorded may be variable from period to period based on changes in estimates of the timing and level of support
required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Cost of Goods Sold.</I> Cost of goods sold during the three months ended June&nbsp;30, 2016 and 2015 was $8.9 million and
$6.4&nbsp;million, respectively, an increase of $2.5 million, or 39%. Cost of goods sold includes the cost of API for Vascepa on which revenue was recognized during the period, as well as the associated costs for encapsulation, packaging, shipment,
supply management, insurance and quality assurance. The cost of the API included in cost of goods sold reflects the average cost of API included in inventory. This average cost reflects the actual purchase price of Vascepa API. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The API included in the calculation of the average cost of goods sold during the three months ended June&nbsp;30, 2016 and 2015 was sourced
from three API suppliers and two API suppliers, respectively. The contracted cost of supply from our initial API supplier was higher than the contracted cost from our other API suppliers. In the future, we anticipate making continued purchases from
this initial supplier and to make additional lower unit cost purchases of Vascepa API from other API suppliers, with the amount of such purchases dependent on the rate of our revenue growth. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our gross margin on product sales for the three months ended June&nbsp;30, 2016 and 2015 was 73% and 64%, respectively. This improvement was
primarily driven by lower unit cost API purchases. In addition, over time we expect continued lower average unit cost purchases of API. We also expect that API costs will be lower in the future due to advantages derived from the mix of our suppliers
and potential cost efficiency through increased volume. The average cost may be variable from period to period depending upon the timing and quantity of API purchased from each supplier. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Selling, General and Administrative Expense.</I> Selling, general and administrative expense for the three months ended June&nbsp;30, 2016
and 2015 was $26.1 million in each period. Selling, general and administrative expenses for the three months ended June&nbsp;30, 2016 and 2015 are summarized in the table below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>In thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expense (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Co-promotion fees (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash stock based compensation expense (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total selling, general and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Selling, general and administrative expense, excluding non-cash compensation charges for stock compensation and warrants and co-promotion fees, for the three months ended June&nbsp;30, 2016 and 2015 was $18.6 million
and $22.0 million, respectively, a decrease of $3.4 million, or 15%. The decrease is due primarily to lower legal costs following the favorable federal court declaration on August&nbsp;7, 2015 and related settlement on March&nbsp;8, 2016 allowing
communication of truthful and non-misleading ANCHOR clinical trial and related data to be communicated to healthcare professionals. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Co-promotion fees payable to Kowa Pharmaceuticals America, Inc. for the three months ended June&nbsp;30, 2016 and 2015 were $4.6 million and $1.7 million, respectively, an increase of $2.9 million, or 168%. The increase
is due primarily to an increase in gross margin on product sales in the second quarter of 2016 compared to the second quarter of 2015, coupled with an increase in the percentage of aggregate Vascepa gross margin earned by Kowa Pharmaceuticals
America, Inc. from 15% in 2015 to 19% in 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Stock-based compensation expense for the three months ended June&nbsp;30, 2016 and 2015 was $2.9 million and $2.4 million, respectively, an increase of $0.5 million, or 22%, primarily due to an increase in new stock
option and restricted stock awards granted to attract and retain qualified employees. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We currently anticipate that prior to REDUCE-IT data, our selling, general and administrative
costs in 2016 as a whole will be substantially consistent with that in 2015, with the exception of non-cash costs and anticipated increases in the co-promotion fees earned by Kowa Pharmaceuticals America, Inc. based on anticipated increases in net
product revenues and the terms of our co-promotion agreement with Kowa Pharmaceuticals America, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Research and Development
Expense.</I> Research and development expense for the three months ended June&nbsp;30, 2016 and 2015 was $12.6 million and $12.0&nbsp;million, respectively, an increase of $0.6 million, or 5%. Research and development expenses for the three months
ended June&nbsp;30, 2016 and 2015 are summarized in the table below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>In thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">REDUCE-IT study (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regulatory filing fees and expenses (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Internal staffing, overhead and other (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense, excluding non-cash expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash stock-based compensation (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The increase in research and development expenses for the quarter ended June&nbsp;30, 2016, as compared to the
prior year period, is primarily due to quarterly variability in costs related to the REDUCE-IT study. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">In December 2011, we announced commencement of patient dosing in our cardiovascular outcomes study of Vascepa, titled REDUCE-IT, which is designed to evaluate the efficacy of Vascepa in reducing major cardiovascular
events in a high risk patient population on statin therapy. The study duration is dependent on the rate of clinical events in the study, which rate may be affected by the number of patients enrolled in the study, the epidemiology of the patients
enrolled in the study, and the length of time that the enrolled patients are followed. We manage the study through a contract research organization (CRO) through which all costs for this outcomes study are incurred with the exception of costs for
clinical trial material (CTM) and costs for internal management. Our internal personnel are responsible for managing multiple projects and their costs are not specifically allocated to REDUCE-IT or any other individual project. For the three months
ended June&nbsp;30, 2016 and 2015, we incurred expenses through our CRO in connection with this trial of approximately $7.5 million and $7.2 million, respectively. Inclusive of CTM costs, the combined CRO and CTM costs during the three months ended
June&nbsp;30, 2016 and 2015 for REDUCE-IT were approximately $8.7 million and $8.1 million, respectively. The increase in expenses in 2016 as compared to 2015 is primarily the result of timing variability for REDUCE-IT costs. We expense costs for
CTM when allocated to clinical research. The aggregate cost of this outcomes study will depend on the rate of clinical events in the study. We currently estimate that we will incur $30 million to $40 million in annual costs through study completion
and the rate at which we incur such costs will vary from quarter to quarter. The study is designed to be completed after reaching 1,612 aggregate cardiovascular events. Based on projected event rates, we estimate the onset of the target aggregate
number of cardiovascular events to be reached in or about the second half of 2017 with study results then expected to be available and published in 2018. We anticipate that our costs for this outcomes study will continue to represent the most
significant component of our research and development expenditures. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The regulatory filing fees in each of the quarters ended June&nbsp;30, 2016 and 2015 included annual FDA fees for maintaining manufacturing sites. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Internal staffing, overhead and other research and development expenses primarily relate to the costs of our personnel employed to manage research, development and regulatory affairs activities and related overhead
costs including consulting and other professional fees that are not allocated to specific projects. Also included are costs related to qualifying suppliers and legal costs. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Non-cash stock-based compensation expense represents the costs associated with equity awards issued to internal staff supporting our research and development and regulatory functions. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Research and development costs, excluding non-cash costs, are expected to vary from quarter to quarter in 2016 due to the timing of REDUCE-IT
costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Gain (Loss) on Change in Fair Value of Derivative Liabilities</I>. Gain (loss) on change in fair value of derivative
liabilities for the three months ended June&nbsp;30, 2016 was a gain of $5.8 million versus a loss of $0.6&nbsp;million in the prior year period. Gain (loss) on change in fair value of derivative liabilities for the three months ended June&nbsp;30,
2016 and 2015 is comprised of (i)&nbsp;the change in fair value of the derivative liability related to the change in control provision associated with the December 2012 BioPharma financing, and (ii)&nbsp;the change in fair value of the derivative
liabilities related to the change in control provisions associated with the May 2014 and November 2015 exchangeable senior notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our December 2012 financing agreement with BioPharma contains a redemption feature whereby, upon
a change of control, we would be required to repay $150 million, less any previously repaid amount. The fair value of the derivative liability is recalculated at each reporting period using a probability-weighted model incorporating management
estimates for potential change in control, and by determining the fair value of the debt with and without the change in control provision included. The difference between the two fair values of the debt was determined to be the fair value of the
embedded derivative. As of March&nbsp;31, 2016, the fair value of the derivative was determined to be $5.9&nbsp;million, and as of June&nbsp;30, 2016, the fair value of the derivative was determined to be $2.8 million. As such, we recognized a $3.1
million gain on change in fair value of derivative liability for the three months ended June&nbsp;30, 2016. As of March&nbsp;31, 2015, the fair value of the derivative was determined to be $4.8&nbsp;million, and as of June&nbsp;30, 2015, the fair
value of the derivative was determined to be $5.6 million. As such, we recognized a $0.8 million loss on change in fair value of derivative liability for the three months ended June&nbsp;30, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our 2014 Notes, issued in May 2014, contain a redemption feature whereby, upon occurrence of a change in control, we would be required to
repurchase the notes. The fair value of the embedded derivative was calculated using a probability-weighted model incorporating management estimates of the probability of a change in control occurring, and by determining the fair value of the debt
with and without the change in control provision included. The difference between the two was determined to be the fair value of the embedded derivative. As of March&nbsp;31, 2016, the fair value of the derivative was determined to be $2.8 million,
and as of June&nbsp;30, 2016, the fair value of the derivative was determined to be $0.6 million. As such, we recognized a $2.2 million gain on change in fair value of derivative liability for the three months ended June&nbsp;30, 2016. As of
March&nbsp;31, 2015, the fair value of the derivative was determined to be $1.3 million, and as of June&nbsp;30, 2015, the fair value of the derivative was determined to be $1.1 million. As such, we recognized a $0.2 million gain on change in fair
value of derivative liability for the three months ended June&nbsp;30, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our 2015 Notes, issued in November 2015, contain the same
redemption feature as the 2014 Notes and the related derivative liability was calculated utilizing the same methodology. As of March&nbsp;31, 2016, the fair value of the derivative was determined to be $0.7 million, and as of June&nbsp;30, 2016, the
fair value of the derivative was determined to be $0.2 million. As such, we recognized a $0.6 million gain on change in fair value of derivative liability for the three months ended June&nbsp;30, 2016. There was no such change in fair value of
derivative liability for the three months ended June&nbsp;30, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The change in fair value of the derivative liability related to the
BioPharma financing agreement is largely related to our projections for future estimated revenues, management estimates of the probability of a change in control occurring, and the terms of debt issues of similar companies. The change in fair value
of the derivative liabilities related to the 2014 Notes and 2015 Notes is largely related to changes in quoted bond prices. Any changes in the assumptions used to value the derivative liabilities could result in a material change to the carrying
value of such liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Interest Expense, net.</I> Net interest expense for the three months ended June&nbsp;30, 2016 and 2015 was
$5.6 million and $4.8&nbsp;million, respectively, an increase of $0.8 million, or 17%. Net interest expense for the three months ended June&nbsp;30, 2016 and 2015 is summarized in the table below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>In thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchangeable senior notes (1):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of debt discounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contractual coupon interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total exchangeable senior notes interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt&#151;BioPharma financing (2):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-term debt interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(82</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total interest expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Cash and non-cash interest expense related to the exchangeable senior notes for the three months ended June&nbsp;30, 2016 and 2015 was $3.5 million and $2.9 million, respectively. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cash and non-cash interest expense related to the BioPharma financing for the three months ended June&nbsp;30,
2016 and 2015 was $2.2 million and $2.0 million, respectively. These amounts reflect the assumption that our Vascepa revenue levels will not be </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
high enough to support repayment to BioPharma in accordance with the repayment schedule without the optional reduction which is allowed to be elected by us if the threshold revenue levels are not
achieved. To date, our revenues have been below the contractual threshold amount each quarter such that each payment reflects the calculated optional reduction amount as opposed to the contractual threshold payments for each quarterly period.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Interest income represents income earned on cash balances. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Other (Expense) Income,
net</I>. Other (expense) income, net, for the three months ended June&nbsp;30, 2016 was expense of $0.2 million versus income of $0.1 million in the prior year period. Other (expense) income, net, primarily consists of gains and losses on foreign
exchange transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Benefit from Income Taxes.</I> Benefit from income taxes for the three months ended June&nbsp;30, 2016 and 2015
was $1.0 million and $0.5 million, respectively. The current benefit relates entirely to the U.S. subsidiary operations. We are profitable in the United States as a result of intercompany transactions between our U.S. subsidiary and our other
companies. In April 2016, we adopted ASU No.&nbsp;2016-09, <I>Compensation&#151;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,</I> which requires that excess tax benefits and deficiencies that arise upon
vesting or exercise of share-based payments be recognized as an income tax benefit and expense in the income statement. Previously, such amounts were recognized as an increase and decrease in additional paid-in capital. This aspect of the standard
was adopted prospectively, and accordingly, the benefit from income taxes for the three months ended June&nbsp;30, 2016, includes $0.1 million of excess tax deficiencies arising from share-based payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Preferred Stock Beneficial Conversion Feature. </I>In 2015, we issued Series A preference shares in a private placement transaction
executed in two tranches that each contain a conversion feature whereby such shares are convertible into ordinary shares at a fixed rate. The conversion price on the date of issuance was less than the market price of our ordinary shares on such
date. We determined that these discounts represent contingent beneficial conversion features, which were valued based on the difference between the conversion price and the market price of the ordinary shares on the date of issuance. These features
are analogous to preference dividends and were recorded as a non-cash return to preferred shareholders through accumulated deficit, and are therefore reflected as an adjustment to net loss applicable to common shareholders for earnings per common
share purposes in accordance with GAAP. During the three months ended June&nbsp;30, 2015, we recorded an adjustment to net loss applicable to common shareholders of $31.3 million upon effectiveness of the related resale Registration Statement on
Form S-3. There was no such adjustment to net loss in the three months ended June&nbsp;30, 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of Six Months Ended June&nbsp;30, 2016
and June&nbsp;30, 2015 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Product Revenue, net.</I> We recorded net product revenue of $58.1 million and $33.3 million during the
six months ended June&nbsp;30, 2016 and 2015, respectively, an increase of $24.9 million, or 75%. This increase in revenue was driven primarily by an increase in estimated normalized total Vascepa prescriptions as well as an increase in the level of
inventories held by our customers during the period. Based on data provided by Symphony Health Solutions and IMS Health, estimated normalized total Vascepa prescriptions increased by approximately 153,000 and 168,000, respectively, over the six
months ended June&nbsp;30, 2015, representing growth of 55% and 57%, respectively. The level of inventories held by our customers as of June&nbsp;30, 2016 increased as compared to inventories held as of year-end 2015 calculated based on estimated
days of Vascepa sales on hand. We estimate that revenues during the six months ended June&nbsp;30, 2016 include approximately $1.5 million to $1.8 million in product revenues resulting from a net overall increase in Distributor inventory levels
compared to a less than $1.0 million decrease in revenues due to net inventory level changes in the corresponding period in 2015. All of our product revenue in the six months ended June&nbsp;30, 2016 and 2015 was derived from product sales of
Vascepa, net of allowances, discounts, incentives, rebates, chargebacks and returns. Timing of shipments to wholesalers, as used for revenue recognition, and timing of prescriptions as estimated by third-party sources such as Symphony Health
Solutions and IMS Health may differ from period to period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2016 and 2015, our net product
revenue included an adjustment for co-pay mitigation rebates provided by us to commercially insured patients. Such rebates are intended to offset the differential for patients of Vascepa not covered by commercial insurers at the time of launch on
Tier 2 for formulary purposes, resulting in higher co-pay amounts for such patients. Our cost for these co-payment mitigation rebates during the six months ended June&nbsp;30, 2016 and 2015 was up to $70 per prescription filled. Since launch,
certain third-party payors have added Vascepa to their Tier 2 coverage, which results in lower co-payments for patients covered by these third-party payors. In connection with such Tier 2 coverage, we have agreed to pay customary rebates to these
third-party payors on the resale of Vascepa to patients covered by these third-party payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As is typical for the pharmaceutical
industry, the majority of Vascepa sales are to major commercial wholesalers which then resell Vascepa to retail pharmacies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Licensing Revenue.</I> Licensing revenue during the six months ended June&nbsp;30, 2016 and
2015 was $0.5 million and $0.4 million, respectively, an increase of $0.2. Licensing revenue relates to the amortization of a $15.0 million up-front payment received in February 2015 and a $1.0 million milestone payment achieved in March 2016, both
associated with a Vascepa licensing agreement for the China Territory. The up-front and milestone payments are being recognized over the estimated period in which we are required to provide regulatory and development support and clinical and
commercial supply under the agreement. The amount of licensing revenue recorded may be variable from period to period based on changes in estimates of the timing and level of support required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Cost of Goods Sold.</I> Cost of goods sold during the six months ended June&nbsp;30, 2016 and 2015 was $15.8 million and
$12.0&nbsp;million, respectively, an increase of $3.7 million, or 31%. Cost of goods sold includes the cost of API for Vascepa on which revenue was recognized during the period, as well as the associated costs for encapsulation, packaging, shipment,
supply management, insurance and quality assurance. The cost of the API included in cost of goods sold reflects the average cost of API included in inventory. This average cost reflects the actual purchase price of Vascepa API. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The API included in the calculation of the average cost of goods sold during the six months ended June&nbsp;30, 2016 and 2015 was sourced from
three API suppliers and two API suppliers, respectively. The contracted cost of supply from our initial API supplier was higher than the contracted cost from our other API suppliers. In the future, we anticipate making continued purchases from this
initial supplier and to make additional lower unit cost purchases of Vascepa API from other API suppliers, with the amount of such purchases dependent on the rate of our revenue growth. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our gross margin on product sales for the six months ended June&nbsp;30, 2016 and 2015 was 73% and 64%, respectively. This improvement was
primarily driven by lower unit cost API purchases. In addition, over time we expect continued lower average unit cost purchases of API. We also expect that API costs will be lower in the future due to advantages derived from the mix of our suppliers
and potential cost efficiency through increased volume. The average cost may be variable from period to period depending upon the timing and quantity of API purchased from each supplier. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Selling, General and Administrative Expense.</I> Selling, general and administrative expense for the six months ended June&nbsp;30, 2016
and 2015 was $54.1 million and $50.8&nbsp;million, respectively, an increase of $3.3 million, or 6%. Selling, general and administrative expenses for the six months ended June&nbsp;30, 2016 and 2015 are summarized in the table below:</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>In thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expense (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Co-promotion fees (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash stock based compensation expense (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash warrant related compensation income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total selling, general and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">54,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Selling, general and administrative expense, excluding non-cash compensation charges for stock compensation and warrants and co-promotion fees, for the six months ended June&nbsp;30, 2016 and 2015 was $40.3 million and
$43.0 million, respectively, decrease of $2.7 million, or 6%. The decrease is due primarily to lower legal costs following the favorable federal court declaration on August&nbsp;7, 2015 and related settlement on March&nbsp;8, 2016 allowing
communication of truthful and non-misleading ANCHOR clinical trial and related data to be communicated to healthcare professionals. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Co-promotion fees payable to Kowa Pharmaceuticals America, Inc. for the six months ended June&nbsp;30, 2016 and 2015 were $8.0 million and $3.2 million, respectively, an increase of $4.9 million, or 152%. The increase
is due primarily to an increase in gross margin on product sales in the second quarter of 2016 compared to the second quarter of 2015, coupled with an increase in the percentage of aggregate Vascepa gross margin earned by Kowa Pharmaceuticals
America, Inc. from 15% in 2015 to 19% in 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Stock-based compensation expense for the six months ended June&nbsp;30, 2016 and 2015 was $5.8 million and $4.6 million, respectively, an increase of $1.2 million, or 25%, primarily due to an increase in new stock
option and restricted stock awards granted to attract and retain qualified employees. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We currently anticipate that prior to
REDUCE-IT data, our selling, general and administrative costs in 2016 as a whole will be substantially consistent with that in 2015, with the exception of non-cash costs and anticipated increases in the co-promotion fees earned by Kowa
Pharmaceuticals America, Inc. based on anticipated increases in net product revenues and the terms of our co-promotion agreement with Kowa Pharmaceuticals America, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expense.</I> Research and development expense for the six months
ended June&nbsp;30, 2016 and 2015 was $26.3 million and $24.6&nbsp;million, respectively, an increase of $1.7 million, or 7%. Research and development expenses for the six months ended June&nbsp;30, 2016 and 2015 are summarized in the table below:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>In thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">REDUCE-IT study (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regulatory filing fees and expenses (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Internal staffing, overhead and other (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense, excluding non-cash expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash stock-based compensation (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The increase in research and development expenses for the six months ended June&nbsp;30, 2016, as compared to
the prior year period, is primarily due to quarterly variability in costs related to the REDUCE-IT study. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">In December 2011, we announced commencement of patient dosing in our cardiovascular outcomes study of Vascepa, titled REDUCE-IT, which is designed to evaluate the efficacy of Vascepa in reducing major cardiovascular
events in a high risk patient population on statin therapy. The study duration is dependent on the rate of clinical events in the study, which rate may be affected by the number of patients enrolled in the study, the epidemiology of the patients
enrolled in the study, and the length of time that the enrolled patients are followed. We manage the study through a contract research organization (CRO) through which all costs for this outcomes study are incurred with the exception of costs for
clinical trial material (CTM) and costs for internal management. Our internal personnel are responsible for managing multiple projects and their costs are not specifically allocated to REDUCE-IT or any other individual project. For the six months
ended June&nbsp;30, 2016 and 2015, we incurred expenses through our CRO in connection with this trial of approximately $15.1 million and $13.8 million, respectively. Inclusive of CTM costs, the combined CRO and CTM costs during the six months ended
June&nbsp;30, 2016 and 2015 for REDUCE-IT were approximately $18.1 million and $16.6 million, respectively. The increase in expenses in 2016 as compared to 2015 is primarily the result of timing variability for REDUCE-IT costs. We expense costs for
CTM when allocated to clinical research. The aggregate cost of this outcomes study will depend on the rate of clinical events in the study. We currently estimate that we will incur $30 million to $40 million in annual costs through study completion
and the rate at which we incur such costs will vary from quarter to quarter. The study is designed to be completed after reaching 1,612 aggregate cardiovascular events. Based on projected event rates, we estimate the onset of the target aggregate
number of cardiovascular events to be reached in or about the second half of 2017 with study results then expected to be available and published in 2018. We anticipate that our costs for this outcomes study will continue to represent the most
significant component of our research and development expenditures. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The regulatory filing fees in each of the six months ended June&nbsp;30, 2016 and 2015 included annual FDA fees for maintaining manufacturing sites. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Internal staffing, overhead and other research and development expenses primarily relate to the costs of our personnel employed to manage research, development and regulatory affairs activities and related overhead
costs including consulting and other professional fees that are not allocated to specific projects. Also included are costs related to qualifying suppliers and legal costs. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Non-cash stock-based compensation expense represents the costs associated with equity awards issued to internal staff supporting our research and development and regulatory functions. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Research and development costs, excluding non-cash costs, are expected to vary from quarter to quarter in 2016 due to the timing of REDUCE-IT
costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Gain (Loss) on Change in Fair Value of Derivative Liabilities</I>. Gain (loss) on change in fair value of derivative
liabilities for the six months ended June&nbsp;30, 2016 was a gain of $4.6 million versus a loss of $0.1&nbsp;million in the prior year period. Gain (loss) on change in fair value of derivative liabilities for the six months ended June&nbsp;30, 2016
and 2015 is comprised of (i)&nbsp;the change in fair value of the warrant derivative liability, (ii)&nbsp;the change in fair value of the derivative liability related to the change in control provision associated with the December 2012 BioPharma
financing, (iii)&nbsp;the change in fair value of the derivative liabilities related to the change in control provisions associated with the May 2014 and November 2015 exchangeable senior notes, and (iv)&nbsp;the change in fair value of the
derivative liability related to the preferred stock purchase option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The warrant derivative liability was related to the change in fair
value of warrants issued in conjunction with the October 2009 private placement. In October 2009 we issued 36.1&nbsp;million warrants at an exercise price of $1.50 per warrant and recorded a $48.3 million warrant derivative liability, representing
the fair value of the warrants issued. As these warrants were classified as a derivative liability, they were revalued at each reporting period, with changes in fair value recognized in the condensed consolidated
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statement of operations. Of the 8,087,388 warrants outstanding as of December&nbsp;31, 2014, 1,844,585 warrants were exercised and the remaining 6,242,803 warrants expired on February&nbsp;27,
2015. As such, no warrants were outstanding as of June&nbsp;30, 2015 and the derivative liability was extinguished. The fair value of the warrant derivative liability as of December&nbsp;31, 2014 was $0.1 million and we recognized a $0.1 million
gain on change in fair value of derivative liability for the six months ended June&nbsp;30, 2015. There was no such change in fair value of derivative liability for the six months ended June&nbsp;30, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our December 2012 financing agreement with BioPharma contains a redemption feature whereby, upon a change of control, we would be required to
repay $150 million, less any previously repaid amount. The fair value of the derivative liability is recalculated at each reporting period using a probability-weighted model incorporating management estimates for potential change in control, and by
determining the fair value of the debt with and without the change in control provision included. The difference between the two fair values of the debt was determined to be the fair value of the embedded derivative. As of December&nbsp;31, 2015,
the fair value of the derivative was determined to be $5.5&nbsp;million, and as of June&nbsp;30, 2016, the fair value of the derivative was determined to be $2.8 million. As such, we recognized a $2.7 million gain on change in fair value of
derivative liability for the six months ended June&nbsp;30, 2016. As of December&nbsp;31, 2014, the fair value of the derivative was determined to be $4.8&nbsp;million, and as of June&nbsp;30, 2015, the fair value of the derivative was determined to
be $5.6 million. As such, we recognized a $0.8 million loss on change in fair value of derivative liability for the six months ended June&nbsp;30, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our 2014 Notes, issued in May 2014, contain a redemption feature whereby, upon occurrence of a change in control, we would be required to
repurchase the notes. The fair value of the embedded derivative was calculated using a probability-weighted model incorporating management estimates of the probability of a change in control occurring, and by determining the fair value of the debt
with and without the change in control provision included. The difference between the two was determined to be the fair value of the embedded derivative. As of December&nbsp;31, 2015, the fair value of the derivative was determined to be $2.1
million, and as of June&nbsp;30, 2016, the fair value of the derivative was determined to be $0.6 million. As such, we recognized a $1.5 million gain on change in fair value of derivative liability for the six months ended June&nbsp;30, 2016. As of
December&nbsp;31, 2014, the fair value of the derivative was determined to be $2.6 million, and as of June&nbsp;30, 2015, the fair value of the derivative was determined to be $1.1 million. As such, we recognized a $1.5 million gain on change in
fair value of derivative liability for the six months ended June&nbsp;30, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our 2015 Notes, issued in November 2015, contain the same
redemption feature as the 2014 Notes and the related derivative liability was calculated utilizing the same methodology. As of December&nbsp;31, 2015, the fair value of the derivative was determined to be $0.6 million, and as of June&nbsp;30, 2016,
the fair value of the derivative was determined to be $0.2 million. As such, we recognized a $0.4 million gain on change in fair value of derivative liability for the six months ended June&nbsp;30, 2016. There was no such change in fair value of
derivative liability for the six months ended June&nbsp;30, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the closing of a private placement transaction in
early March 2015, we recorded a derivative liability pursuant to a pre-existing contractual right. This preferred stock purchase option was determined to be a derivative liability effective March&nbsp;5, 2015, the date in which the private placement
was initially subscribed. The fair value of this liability was calculated using a Black-Scholes model and was determined to be $0.9&nbsp;million at inception. The liability was charged to accumulated deficit as a deemed non-cash dividend and was
therefore reflected as an adjustment to net loss applicable to common shareholders for earnings per common share purposes in accordance with GAAP for the six months ended June&nbsp;30, 2015. The liability was then marked to fair value through
March&nbsp;30, 2015, the date on which we executed a separate subscription agreement with the investor, resulting in a charge of $0.9&nbsp;million through gain (loss) on change in fair value of derivatives in the six months ended June&nbsp;30, 2015.
The liability of $1.8 million was then reclassified to permanent equity on March&nbsp;30, 2015. There was no such change in fair value of derivative liability for the six months ended June&nbsp;30, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The change in fair value of the derivative liability related to the BioPharma financing agreement is largely related to our projections for
future estimated revenues, management estimates of the probability of a change in control occurring, and the terms of debt issues of similar companies. The change in fair value of the derivative liabilities related to the 2014 Notes and 2015 Notes
is largely related to changes in quoted bond prices. Any changes in the assumptions used to value the derivative liabilities could result in a material change to the carrying value of such liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Interest Expense, net.</I> Net interest expense for the six months ended June&nbsp;30, 2016 and 2015 was $11.2 million and
$9.7&nbsp;million, respectively, an increase of $1.5 million, or 16%. Net interest expense for the six months ended June&nbsp;30, 2016 and 2015 is summarized in the table below: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>In thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchangeable senior notes (1):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of debt discounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contractual coupon interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total exchangeable senior notes interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt&#151;BioPharma financing (2):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash interest&#151;current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash interest&#151;deferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-term debt interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(98</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total interest expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Cash and non-cash interest expense related to the exchangeable senior notes for the six months ended June&nbsp;30, 2016 and 2015 was $6.9 million and $5.6 million, respectively. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Cash and non-cash interest expense related to the BioPharma financing for the six months ended June&nbsp;30, 2016 and 2015 was $4.4 million and $4.1 million, respectively. These amounts reflect the assumption that our
Vascepa revenue levels will not be high enough to support repayment to BioPharma in accordance with the repayment schedule without the optional reduction which is allowed to be elected by us if the threshold revenue levels are not achieved. To date,
our revenues have been below the contractual threshold amount each quarter such that each payment reflects the calculated optional reduction amount as opposed to the contractual threshold payments for each quarterly period. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Interest income for the six months ended June&nbsp;30, 2016 and 2015 was $0.1 million in each period. Interest income represents income earned on cash balances. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Other (Expense) Income, net</I>. Other (expense) income, net, for the six months ended June&nbsp;30, 2016 was expense of $0.3 million
versus expense of $0.03 million in the prior year period. Other (expense) income, net, primarily consists of gains and losses on foreign exchange transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Benefit from Income Taxes.</I> Benefit from income taxes for the six months ended June&nbsp;30, 2016 and 2015 was $1.3 million and $1.0
million, respectively. The current benefit relates entirely to the U.S. subsidiary operations. We are profitable in the United States as a result of intercompany transactions between our U.S. subsidiary and our other companies. In April 2016, we
adopted ASU No.&nbsp;2016-09, <I>Compensation&#151;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,</I> which requires that excess tax benefits and deficiencies that arise upon vesting or exercise of
share-based payments be recognized as an income tax benefit and expense in the income statement. Previously, such amounts were recognized as an increase and decrease in additional paid-in capital. This aspect of the standard was adopted
prospectively, and accordingly, the benefit from income taxes for the six months ended June&nbsp;30, 2016, includes $0.2 million of excess tax deficiencies arising from share-based payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Preferred Stock Purchase Option. </I>In connection with the closing of a private placement transaction in early March 2015, we recorded a
derivative liability pursuant to a pre-existing contractual right. This preferred stock purchase option was determined to be a derivative liability effective March&nbsp;5, 2015, the date in which the private placement was initially subscribed. The
fair value of this liability was calculated using a Black-Scholes model and was determined to be $0.9&nbsp;million at inception. The liability was charged to accumulated deficit as a deemed non-cash dividend and was therefore reflected as an
adjustment to net loss applicable to common shareholders for earnings per common share purposes in accordance with GAAP for the six months ended June&nbsp;30, 2015. There was no such adjustment for the six months ended June&nbsp;30, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Preferred Stock Beneficial Conversion Feature. </I>In 2015, we issued Series A preference shares in a private placement transaction
executed in two tranches that each contain a conversion feature whereby such shares are convertible into ordinary shares at a fixed rate (see Note 8). The conversion price on the date of issuance was less than the market price of our ordinary shares
on such date. We determined that these discounts represent contingent beneficial conversion features, which were valued based on the difference between the conversion price and the market price of the ordinary shares on the date of issuance. These
features are analogous to preference dividends and were recorded as a non-cash return to preferred shareholders through accumulated deficit, and are therefore reflected as an adjustment to net loss applicable to common shareholders for earnings per
common share purposes in accordance with GAAP. During the six months ended June&nbsp;30, 2015, we recorded an adjustment to net loss applicable to common shareholders of $31.3 million upon effectiveness of the related resale Registration Statement
on Form S-3. There was no such adjustment to net loss in the three months ended June&nbsp;30, 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our sources of liquidity as of June&nbsp;30, 2016 include cash and cash equivalents of $72.5 million. Our projected uses of cash include
commercialization of Vascepa, the continued funding of the REDUCE-IT cardiovascular outcomes study, working capital and other general corporate activities. Our cash flows from operating, investing and financing activities, as reflected in the
condensed consolidated statements of cash flows, are summarized in the following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>In millions</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash (used in) provided by:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(33.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(38.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Decrease) increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(34.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities during the six months ended June&nbsp;30, 2016 compared to the six
months ended June&nbsp;30, 2015 decreased primarily as a result of increased collections resulting from higher revenues and decreased legal costs following the favorable federal court declaration on August&nbsp;7, 2015 and related settlement on
March&nbsp;8, 2016 allowing communication of truthful and non-misleading ANCHOR clinical trial and related data to be communicated to healthcare professionals, partially offset by receipt in 2015 of $15.0 million in up-front proceeds from the
Eddingpharm license agreement. Increased sales and marketing spend in 2016 in support of expanded Vascepa promotion was more than offset by higher collections from product sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;6, 2012 we entered into a financing agreement with BioPharma. Under this agreement, we granted to BioPharma a security
interest in future receivables and all related rights to Vascepa, in exchange for $100 million received at the closing of the agreement which closing occurred in December 2012. We have agreed to repay BioPharma up to $150 million of future revenue
and receivables. As of June&nbsp;30, 2016, the net remaining amount to be repaid to BioPharma is $132.1 million. To date, our revenues have been below the contractual threshold amount such that each payment made has reflected the calculated optional
reduction amount as opposed to the contractual threshold payments for each quarterly period. The maximum amount payable under the contractual threshold for 2016 is $23.4 million. The quarterly repayments through June&nbsp;30, 2016 represent interest
only. In accordance with the agreement with BioPharma, quarterly differences between the calculated optional reduction amounts and the repayment schedule amounts are rescheduled for payment beginning in the second quarter of 2017. Any such deferred
payments will remain subject to continued application of the quarterly ceiling in amounts due established by the calculated threshold based on quarterly Vascepa revenues. No additional interest expense or liability is incurred as a result of such
deferred repayments. The agreement does not expire until $150 million in aggregate has been repaid. We can prepay an amount equal to $150 million less any previously repaid amount. We currently estimate that Vascepa revenue levels will not be high
enough in each quarter to support repayment to BioPharma in accordance with threshold amounts in the repayment schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On
January&nbsp;9, 2012, through our wholly-owned subsidiary Corsicanto Limited, or Corsicanto, a private limited company incorporated under the laws of Ireland, we completed a private placement of $150.0 million in aggregate principal amount of 3.5%
exchangeable senior notes due 2032, or the 2012 Notes. The proceeds we received from the January 2012 debt offering were approximately $144.3 million, net of fees and transaction costs. On May&nbsp;20, 2014, we entered into separate, privately
negotiated exchange agreements with certain holders of the 2012 Notes pursuant to which Corsicanto exchanged $118.7 million in aggregate principal amount of the 2012 Notes for $118.7 million in aggregate principal amount of new 3.5%&nbsp;May 2014
Exchangeable Senior Notes due 2032, or the 2014 Notes. In November 2015, $16.2 million of the 2012 Notes was extinguished, following which $15.1 million in aggregate principal amount of the 2012 Notes remains outstanding with terms unchanged. We may
in the future seek to negotiate exchange agreements with the remaining holders of the outstanding 2012 Notes or to otherwise refinance this debt obligation on or before all or a portion of the $15.1 million is put to us. The outstanding 2012 Notes
may be converted by holders or put to us at the holders&#146; option upon fundamental change or an event of default. The holders also have the option to put the 2012 Notes back to us on each of January&nbsp;19, 2017, 2022 and 2027 for cash equal to
100% of the principal amount plus accrued and unpaid interest. As a result, the carrying value of the 2012 Notes of $15.1 million is classified as a current liability as of June&nbsp;30, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On November&nbsp;24, 2015, we entered into a privately negotiated subscription agreement with one of our existing investors, or the Investor,
pursuant to which the Investor agreed to purchase approximately $31.3 million in aggregate principal amount of new 3.5%&nbsp;November 2015 Exchangeable Senior Notes due 2032, or the 2015 Notes, for approximately $27.5 million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The 2012 Notes were issued pursuant to an indenture dated as of January&nbsp;9, 2012, by and
among Corsicanto, us as guarantor, and Wells Fargo Bank, National Association, as trustee. The notes are the senior unsecured obligations of Corsicanto and are guaranteed by us. The 2012 Notes bear interest at a rate of 3.5%&nbsp;per annum, payable
semi-annually in arrears on January&nbsp;15 and July&nbsp;15 of each year, beginning on July&nbsp;15, 2012. The notes mature on January&nbsp;15, 2032, unless earlier repurchased, redeemed or exchanged. On or after January&nbsp;19, 2017, we may elect
to redeem for cash all or a portion of the notes for the principal amount of the notes plus accrued and unpaid interest. On each of January&nbsp;19, 2017,&nbsp;January&nbsp;19, 2022 and January&nbsp;19, 2027, the holders of the notes may require
that we repurchase in cash the principal amount of the notes plus accrued and unpaid interest. At any time prior to January&nbsp;15, 2032, upon certain circumstances, which circumstances include our issuing a notice of redemption to the note
holders, the price of our shares trading above 130% of the exchange price, or certain other events defined in the note agreement, the holders of the notes may elect to convert the notes. The exchange rate for conversion is 113.4752 ADSs per $1,000
principal amount of the notes (equivalent to an initial exchange price of approximately $8.8125 per ADS), subject to adjustment in certain circumstances, including adjustment if we pay cash dividends. Upon exchange, the notes may be settled, at our
election, subject to certain conditions, in cash, ADSs or a combination of cash and ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The 2014 Notes were issued pursuant to an
indenture dated May&nbsp;20, 2014 by and among Corsicanto, us as guarantor, and Wilmington Trust, National Association, as trustee. The notes are the senior unsecured obligations of Corsicanto and are guaranteed by us. The 2014 Notes have a stated
interest rate of 3.5%&nbsp;per year, payable semiannually in arrears on January&nbsp;15 and July&nbsp;15 of each year beginning on July&nbsp;15, 2014, and ending upon the notes&#146; maturity on January&nbsp;15, 2032, unless earlier repurchased or
redeemed by Corsicanto or exchanged by the holders. On or after January&nbsp;19, 2018, we may elect to redeem for cash all or a portion of the notes for the principal amount of the notes plus accrued and unpaid interest. On each of January&nbsp;19,
2019,&nbsp;January&nbsp;19, 2024 and January&nbsp;19, 2029, the holders of the notes may require that we repurchase in cash the principal amount of the notes plus accrued and unpaid interest. At any time after the issuance of the 2014 Notes and
prior to the close of business on the second business day immediately preceding January&nbsp;15, 2032, holders may exchange their 2014 Notes at their option. If prior to January&nbsp;15, 2018, a make-whole fundamental change (as defined in the 2014
Notes indenture) occurs or we elect to redeem the 2014 Notes in connection with certain changes in tax law, in each case as described in the 2014 Notes indenture, and a holder elects to exchange its 2014 Notes in connection with such make-whole
fundamental change or election, as the case may be, such holder may be entitled to an increase in the exchange rate as described in the 2014 Notes indenture. The initial exchange rate is 384.6154 ADSs per $1,000 principal amount of the 2014 Notes
(equivalent to an initial exchange price of approximately $2.60 per ADS, or the Exchange Price), subject to adjustment in certain circumstances. The exchange rate is subject to adjustment from time to time upon the occurrence of certain events,
including, but not limited to, the payment of cash dividends. Upon exchange, the notes may only be settled in ADSs. The 2015 Notes have substantially identical terms to the 2014 Notes, except that the 2015 Notes were issued by us and are not
guaranteed by any entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2016, we had cash and cash equivalents of $72.5 million, a decrease of $8.9 million from
March&nbsp;31, 2016 and a decrease of $34.5 million from December&nbsp;31, 2015.&nbsp;The decrease during 2016 is primarily due to net cash used in operating activities in support of the commercialization of Vascepa and funding of REDUCE-IT, less
accounts receivable collections. We have incurred annual operating losses since our inception and, as a result, we had an accumulated deficit of $1.2 billion as of June&nbsp;30, 2016. We believe that our cash and cash equivalents will be sufficient
to fund our projected operations for at least the next twelve months. Depending on the level of cash generated from operations, additional capital will likely be required to sustain operations. We anticipate that quarterly net cash outflows in
future periods will be variable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have Vascepa API supply agreements with three independent companies from which we purchase qualified API supply: Nisshin, Chemport, and
Finorga SAS, or Novasep. We also have encapsulation agreements with three FDA-approved commercial API encapsulators for Vascepa manufacturing: Patheon, Inc. (formerly Banner Pharmacaps), Catalent Pharma Solutions, and Capsugel Pl&ouml;ermel SAS,
LLC, or Capsugel. Our agreements with Chemport, Novasep, Patheon and Capsugel contain minimum annual purchase levels to enable us to maintain certain supply exclusivity and also contain a provision that any shortfall in the minimum purchase
commitments may be payable in cash. Each supplier is required to meet certain performance obligations and the agreements may be terminated by us in the event of non-performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have operating lease costs consisting of leases for facilities in Dublin, Ireland and Bedminster, NJ, offset by sublease rental income.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement with BioPharma, we agreed to repay up to $150 million of future revenue and receivables. As of
June&nbsp;30, 2016, the net remaining amount to be repaid to BioPharma is $132.1 million. To date, each payment made has reflected the calculated optional reduction amount as opposed to the contractual threshold payments for each quarterly period.
The maximum amount payable under the contractual threshold for 2016 is $23.4 million. The quarterly repayments through June&nbsp;30, 2016 represent interest only. In accordance with the agreement with BioPharma, quarterly differences between the
calculated optional reduction amounts and the repayment schedule amounts are rescheduled for payment beginning in the second quarter of 2017. Any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such deferred payments will remain subject to continued application of the quarterly ceiling in amounts due established by the calculated threshold based on quarterly Vascepa revenues. No
additional interest expense or liability is incurred as a result of such deferred repayments and no cliff payment of the remaining balance is due except in the event of Company default or Company change of control. The agreement does not expire
until $150 million in aggregate has been repaid. We can prepay an amount equal to $150 million less any previously repaid amount. We currently estimate that Vascepa revenue levels will not be high enough in each quarter to support repayment to
BioPharma in accordance with threshold amounts in the repayment schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have scheduled interest payments due under the terms of the
2012 Notes, 2014 Notes, and 2015 Notes, assuming that the 2012 Notes remain outstanding through January&nbsp;19, 2017 and that the 2014 Notes and 2015 Notes remain outstanding through January&nbsp;19, 2019 and they have not been exchanged for ADSs.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Concurrent with our supply agreement with Chemport entered into in 2011 for the supply of API materials for Vascepa, we agreed to make a
non-controlling minority share equity investment in the supplier of up to $3.3 million. We invested $1.7 million under this agreement in July 2011 and the remaining $1.6 million during 2012. In September 2013, we entered into an equity sale and
purchase agreement between this supplier and a third party in which we agreed to sell approximately $1.3 million of our investment in the supplier to the third party at cost. This transaction closed in the first quarter of 2014. In August 2014, we
entered into a second equity sale and purchase agreement between this supplier and another third party in which we agreed to sell approximately $1.0 million of our remaining investment. This transaction closed in the fourth quarter of 2014. The
remaining carrying amount of $0.2 million as of both June&nbsp;30, 2016 and December&nbsp;31, 2015 is included in other long-term assets and is accounted for under the cost method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the 2004 share repurchase agreement with Laxdale Limited, or Laxdale, upon approval of Vascepa by the FDA on July&nbsp;26, 2012, we were
required to make a milestone payment to Laxdale of &pound;7.5&nbsp;million. We made this payment in 2012 and capitalized this Laxdale milestone payment of $11.6 million as a component of other long-term assets. This long-term asset is being
amortized over the estimated useful life of the intellectual property we acquired from Laxdale and we recognized amortization expense of $0.3 million in each of the six months ended June&nbsp;30, 2016 and 2015. Also under the Laxdale agreement, upon
receipt of marketing approval in Europe for the first indication for Vascepa (or first indication of any product containing Amarin Neuroscience Limited intellectual property acquired from Laxdale in 2004), we must make an aggregate stock or cash
payment to the former shareholders of Laxdale (at the sole option of each of the sellers) of &pound;7.5&nbsp;million (approximately $10.0 million as of June&nbsp;30, 2016). Additionally, upon receipt of a marketing approval in the United States or
Europe for a further indication of Vascepa (or further indication of any other product using Amarin&nbsp;Neuroscience Limited intellectual property), we must make an aggregate stock or cash payment (at the sole option of each of the sellers) of
&pound;5&nbsp;million (approximately $6.7 million as of June&nbsp;30, 2016) for each of the two potential market approvals (i.e. &pound;10&nbsp;million maximum, or approximately $13.4 million as of June&nbsp;30, 2016). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have recorded a liability of $0.1 million for uncertain tax positions in other long-term liabilities as of June&nbsp;30, 2016. We are not
able to reasonably estimate in which future periods these amounts will ultimately be settled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do not enter into financial instruments
for trading or speculative purposes. As of June&nbsp;30, 2016, we had no outstanding forward exchange contracts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Off-Balance Sheet Arrangements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do not have any special purpose entities or other off-balance sheet arrangements. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx220080_9"></A>Item&nbsp;3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>Quantitative and Qualitative Disclosures about Market Risk</I></B><B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There
have been no material changes with respect to the information appearing in PART II, Item&nbsp;7A &#147;Quantitative and Qualitative Disclosures about Market Risk&#148; of our Annual Report on Form 10-K filed with the Securities and Exchange
Commission on February&nbsp;25, 2016. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx220080_10"></A>Item&nbsp;4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>Controls and Procedures</I></B><B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Evaluation of Disclosure Controls and Procedures
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports
that we file or submit under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), is (1)&nbsp;recorded, processed, summarized, and reported within the time periods specified in the SEC&#146;s rules and forms and
(2)&nbsp;accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial Officer, to allow timely decisions regarding required disclosure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2016, our management, with the participation of our Principal Executive
Officer and Principal Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Our management recognizes that any controls and procedures, no
matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our
Principal Executive Officer and Principal Financial Officer has concluded, based upon the evaluation described above that, as of June&nbsp;30, 2016, our disclosure controls and procedures were effective at the reasonable assurance level. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes in Internal Control over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the quarter ended June&nbsp;30, 2016, there have been no changes in our internal control over financial reporting, as such term is
defined in Rules&nbsp;13a-15(f) and 15(d)-15(f) promulgated under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx220080_11"></A>PART II </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx220080_12"></A>Item&nbsp;1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>Legal Proceedings</I></B><B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, we are from
time to time involved in lawsuits, claims, investigations, proceedings, and threats of litigation relating to intellectual property, commercial arrangements and other matters. &#147;Item 3. Legal Proceedings&#148; of our Annual Report on Form 10-K
for the fiscal year ended December&nbsp;31, 2015 and &#147;Item 1. Legal Proceedings&#148; of our Quarterly Report on Form 10-Q for the quarter ended March&nbsp;31, 2016, include discussions of our current legal proceedings. There have been no
material changes to those disclosures as of the date of this filing other than as set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On April&nbsp;26, 2016, the U.S.
District Court for the District of New Jersey granted our motion to dismiss the putative consolidated class action lawsuit captioned&nbsp;<I>In re Amarin Corporation plc, Securities Litigation,</I>&nbsp;No.&nbsp;3:13-cv-06663 (D.N.J. Nov. 1, 2013).
The class action was dismissed without prejudice with leave for plaintiffs to file an amended complaint. The lawsuit seeks unspecified monetary damages and attorneys&#146; fees and costs alleging that we and certain of our current and former
officers and directors made misstatements and omissions regarding the FDA&#146;s willingness to approve Vascepa&#146;s ANCHOR indication and related contributing factors and the potential relevance of data from the ongoing REDUCE-IT trial to that
potential approval. The April 2016 dismissal was the second motion to dismiss granted in favor of Amarin and related defendants in this litigation. The first motion to dismiss in this litigation was granted in June 2015 in response to the original
complaint and related amendment. On May&nbsp;24, 2016, plaintiffs notified the court they would not file another amended complaint and on May&nbsp;26, 2016, filed a notice of appeal of the most recent dismissal to the Third Circuit Court of Appeals.
We plan a vigorous defense to this appeal. We have insurance coverage that is anticipated to cover any significant loss exposure that may arise from this action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On May&nbsp;31, 2016, FDA granted five-year, new chemical entity exclusivity with respect to Vascepa in connection with Vascepa&#146;s
July&nbsp;26, 2012, FDA approval. Following such exclusivity grant, on June&nbsp;7, 2016, Watson Laboratories Inc., or Watson, moved for voluntarily dismissal of its own appeal to the United States Court of Appeals (case no. 2016-1596) of the
January&nbsp;22, 2016, U.S. District Court for the District of New Jersey order of dismissal of the abbreviated new drug application, or ANDA, patent infringement litigation (case no. 14-CV-3259) related to Vascepa. The Watson motion for voluntary
dismissal, to which we consented, was granted on June&nbsp;8, 2016. There is no pending patent litigation related to Vascepa. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx220080_13"></A>Item&nbsp;1A.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>Risk Factors</I></B><B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This Quarterly Report on Form 10-Q contains forward-looking
information based on our current expectations. Because our actual results may differ materially from any forward-looking statements that we make or that are made on our behalf, this section includes a discussion of important factors that could
affect our actual future results, including, but not limited to, our ability to successfully commercialize Vascepa, our capital resources, the progress and timing of our clinical programs, the safety and efficacy of our product candidates, risks
associated with regulatory filings, the potential clinical benefits and market potential of our product candidates, commercial market estimates, future development efforts, patent protection, effects of healthcare reform, reliance on third parties,
and other risks set forth below. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Those risk factors below denoted with a &#147;*&#148; are newly added or have been materially updated from our
Annual Report on 10-K filed with the SEC on February&nbsp;25, 2016. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Commercialization and Development of Vascepa </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are substantially dependent upon sales of Vascepa in the United States. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a result of our reliance on a single product, Vascepa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) capsules,
and our primary focus on the U.S. market in the near-term, much of our near-term results and value as a company depends on our ability to execute our commercial strategy for Vascepa in the United States. If commercialization efforts for Vascepa are
not successful, our business will be materially and adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if we are able to successfully develop Vascepa outside the
United States or develop additional products from our research and development efforts, the development time cycle for products typically takes several years. This restricts our ability to respond to adverse business conditions for Vascepa. If we
are not successful with development, or if there is not adequate demand for Vascepa or the market for such product develops less rapidly than we anticipate, we may not have the ability to effectively shift our resources to the development of
alternative products or do so in a timely manner without suffering material adverse effects on our business. As a result, the lack of alternative markets and products we develop could constrain our ability to generate revenues and achieve
profitability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The uncertain effect of Vascepa on its ultimate targeted clinical benefit makes it more
difficult to achieve a level of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January 2013, we launched Vascepa based on FDA approval of our MARINE indication, for use as an adjunct to diet to reduce triglyceride
levels in adult patients with severe (TG <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia. Approximately 4.0&nbsp;million people in the United States have severely high triglyceride levels (TG <U>&gt;</U>500 mg/dL),
commonly known as very high triglyceride levels. Guidelines for the management of very high triglyceride levels suggest that reducing triglyceride levels is the primary goal in patients to reduce the risk of acute pancreatitis. A secondary goal for
this patient population is to reduce cardiovascular risk. The effect of Vascepa on cardiovascular mortality and morbidity, or the risk for pancreatitis, in patients with hypertriglyceridemia has not been determined and our FDA-approved labeling and
promotional efforts state these facts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In August 2015, based on a federal court order, we also began marketing Vascepa in the United
States to healthcare professionals for the treatment of patients with high (TG <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>200 mg/dL and &lt;500 mg/dL) triglyceride levels who are also on statin therapy for elevated low-density lipoprotein
cholesterol, or LDL-C, levels, based on results from the ANCHOR study of Vascepa. It is estimated that approximately 40&nbsp;million adults in the United States have high triglyceride levels (TG <U>&gt;</U>200 mg/dL), and many patients with high
triglycerides also have other lipid level abnormalities such as high cholesterol and are on statin therapy. FDA did not approve Vascepa for use in this population due to the uncertain effect of pharmaceutically induced triglyceride reduction in this
patient population on cardiovascular risk reduction, the ultimate targeted clinical benefit. Our promotional efforts disclose this fact and what we view as truthful and non-misleading information on the current state of research on both triglyceride
reduction and the active pharmaceutical ingredient, or API, in Vascepa, EPA, as each relate to the potential of Vascepa to reduce cardiovascular risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The uncertainties around the ultimate clinical benefit of Vascepa make it more difficult for Vascepa to gain market acceptance by physicians,
patients, healthcare payors and others in the medical community. If Vascepa does not achieve an adequate level of acceptance, we may not generate product revenues sufficient to become profitable. The degree of market acceptance of Vascepa for the
MARINE indication and in ANCHOR patients and any future approved indications will depend on a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the perceived efficacy, safety and potential advantages of Vascepa, as compared to alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to offer Vascepa for sale at competitive prices; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">convenience and ease of administration compared to alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, effectiveness and strength of product education, marketing and distribution support, including our sales and marketing team; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">publicity concerning Vascepa or competing products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to continually promote Vascepa in the United States outside of FDA-approved labeling and the related perception thereof; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sufficient third-party coverage or reimbursement for on-label use, and for permitted off-label use, the third-party coverage or reimbursement for which was not addressed in the scope of the August 2015 court
declaration; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the actual efficacy of the product and the prevalence and severity of any side effects, including any limitations or warnings contained in Vascepa&#146;s approved labeling. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our current and planned commercialization efforts may not be successful in increasing sales of Vascepa. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January 2013, we began selling and marketing Vascepa in the United States through our own, newly established sales and marketing teams and
through a newly established third-party commercial distribution infrastructure. We hired key personnel in these areas over the last several years and hired and trained a professional sales force in early January 2013. In October 2013, following an
FDA advisory committee recommendation against approval for the ANCHOR indication, we implemented a plan to reduce our workforce and our team of sales professionals in half. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In May 2014 we began co-promoting Vascepa in the United States with Kowa Pharmaceuticals America, Inc. under a co-promotion agreement we
entered into in March 2014. Under the agreement, no less than 250 Kowa Pharmaceuticals America, Inc. sales representatives devote a substantial portion of their time to promoting Vascepa with our approximately 150 sales professionals, including
sales representatives and their managers, based on a plan designed to increase both the number of sales targets reached and the frequency of sales calls on existing sales targets. However, the commercialization of pharmaceutical products is a
complex undertaking for a company to manage, and we have very limited experience as a company operating in this area and co-promoting a pharmaceutical product with a partner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are also expanding our commercialization activities to markets outside of the United States
through partnering arrangements. In February&nbsp;2015, we entered into a Development, Commercialization and Supply Agreement (the &#147;DCS Agreement&#148;) with Eddingpharm (Asia) Macao Commercial Offshore Limited (&#147;Eddingpharm&#148;) related
to the development and commercialization of Vascepa in Mainland China, Hong Kong, Macau and Taiwan, or the China Territory. Under the DCS Agreement, Eddingpharm will be solely responsible for development and commercialization activities in the China
Territory and associated expenses. Additionally, Eddingpharm may be required to conduct clinical trials in the China Territory to secure regulatory approval. Significant commercialization of Vascepa in the China Territory is several years away, if
at all. If Eddingpharm is not able to effectively develop and commercialize Vascepa in the China Territory, we may not be able to generate revenue from the DCS Agreement resulting from the sale of Vascepa in the China Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have limited experience working with ex-U.S. partners such as Eddingpharm to develop and market our products in foreign countries. In order
for Eddingpharm, or us, to market and sell Vascepa in any country outside of the United States for any indication, it will be necessary to obtain regulatory approval from the appropriate regulatory authorities. The requirements and timing for
regulatory approval, which may include conducting clinical trials, vary widely from country to country and may in some cases be different than or more rigorous than requirements in the United States. Any failure by us or Eddingpharm to obtain
approval for Vascepa in any countries outside of the United States in a timely manner may limit the commercial success of Vascepa and our ability to grow our revenues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also have an agreement to register and commercialize Vascepa in countries within the Middle East and North Africa. Development in this
region, as in China, is also several years away and subject to similar risks. We continue to assess other partnership opportunities for licensing Vascepa in other territories outside of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Factors related to building and managing a sales and marketing organization that can inhibit our efforts to successfully commercialize Vascepa
include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to attract and retain adequate numbers of effective sales and marketing personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to adequately train our sales and marketing personnel, in particular as it relates to various healthcare regulatory requirements applicable to the marketing and sale of pharmaceutical products and the
court declaration that we believe enables us to expand marketing efforts for Vascepa, and our inability to adequately monitor compliance with these requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability of our new sales personnel, working for us as a new market entrant, to obtain access to or persuade adequate numbers of physicians to prescribe Vascepa; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an inability by us or our partners to obtain regulatory and marketing approval or establish marketing channels in foreign jurisdictions; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unforeseen costs and expenses associated with operating a new independent sales and marketing organization. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we are not successful in our efforts to market and sell Vascepa, our anticipated revenues will be materially and negatively affected, and
we may not obtain profitability, may need to cut back on research and development activities or need to raise additional funding that could result in substantial dilution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>*We expect final positive results from the REDUCE-IT outcomes study will be required for FDA-approved label expansion for Vascepa.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since January 2013, we have marketed Vascepa for use in the FDA-approved MARINE indication in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In April 2015, we received a Complete Response Letter, or CRL, from the FDA on our supplemental new drug application (&#147;sNDA&#148;) that
sought approval for the use of Vascepa in patients with high triglyceride levels (TG <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>200 mg/dL and &lt;500 mg/dL) who are also on statin therapy, which we refer to as the ANCHOR indication. In regulatory
communications, the FDA acknowledged that the results of the ANCHOR trial as we presented them to FDA were valid and truthful in that, for example, Vascepa reduced triglyceride levels compared to placebo in patients treated in the ANCHOR study. The
clinical rationale for reducing serum triglycerides with Vascepa and modifying other lipid/lipoprotein parameters shown in ANCHOR among statin-treated patients with triglycerides 200-499 mg/dL is to reduce cardiovascular risk. In not approving our
ANCHOR sNDA, the FDA concluded that, for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory approval purposes, there were insufficient data to support a drug-induced change in serum triglycerides as a surrogate for reducing cardiovascular risk in the ANCHOR population. The
FDA did not determine that the drug-induced effects of Vascepa, which go beyond triglyceride-lowering, would not actually reduce cardiovascular risk in this population. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In August 2015, based on a federal court order, we began marketing Vascepa in the United States to healthcare professionals for the treatment
of patients in the ANCHOR population through use of a set of qualified statements that reflect the state of research related to this use. In March 2016, we settled the litigation related to this court order under terms by which the FDA and the U.S.
government agreed to be bound by the conclusions from the federal court order that we may engage in truthful and non-misleading speech promoting the off-label use of Vascepa and that certain statements and disclosures that we proposed to make to
healthcare professionals were truthful and non-misleading. An FDA-approved indication for this patient population has not been granted. Our ability to reach full potential in the commercialization of Vascepa in the United States is dependent upon
marketing claims associated with Vascepa that are granted with the approval of an indication statement by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on our
communications with the FDA, we expect that final positive results from the REDUCE-IT outcomes study will be required for FDA approval of a new indication or other label expansion for Vascepa. Any delay in obtaining, or an inability to obtain,
further expansion of our marketing approval rights with an FDA approval could prevent us from growing revenue at greater than our current pace and could therefore have a material adverse effect on our operations and financial condition, including
our ability to reach profitability. Even if we obtain additional regulatory approvals for Vascepa, the timing or scope of any approvals may prohibit or reduce our ability to commercialize the product successfully. For example, if the approval
process for any expanded indication takes too long, we may miss market opportunities and give other companies the ability to develop competing products or establish market dominance. If the FDA does not approve any expanded indication at all, it
could have a material impact on our future results of operations and financial condition. Additionally, the terms of any approvals beyond the approval received from the FDA in July 2012 for the MARINE indication may prove to not have the scope or
breadth needed for us to successfully commercialize Vascepa or become profitable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>*Our off-label promotion of Vascepa could subject
us to additional regulatory scrutiny and present unforeseen risks. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Federal Food, Drug, and Cosmetic Act, or FDCA, has been
interpreted by the FDA to make it illegal for pharmaceutical companies to promote their products for uses that have not been approved by the FDA. Companies that market drugs for so called off-label uses or indications have been subject to related
costly litigation, criminal penalties and civil liability under the False Claims Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In May 2015, we and a group of independent
physicians filed a lawsuit against the FDA seeking a federal court declaration that would permit us and our agents to promote to healthcare professionals the use of Vascepa in patients with mixed dyslipidemia and promote on the potential of Vascepa
to reduce the risk of cardiovascular disease so long as the promotion is truthful and non-misleading. This use of Vascepa at issue reflects recognized medical practice but was not approved by the FDA and is thus not covered by current FDA-approved
labeling for the drug. Promotion of a so-called off-label use is considered by the FDA to be illegal under the FDCA. The lawsuit, captioned <I>Amarin Pharma, Inc., et al. v. Food&nbsp;&amp; Drug Administration, et al.</I>, S.D.N.Y.
(1:15-cv-03588-PAE), was filed in the United States District Court for the Southern District of New York. In the lawsuit, we contended principally that FDA regulations limiting off-label promotion of truthful and non-misleading information are
unconstitutional under the freedom of speech clause of the First Amendment to the U.S. Constitution as applied in the case of our proposed promotion of Vascepa. The physicians in the suit regularly treat patients at risk of cardiovascular disease
and, as the complaint contended, have First Amendment rights to receive truthful and non-misleading information from Amarin. The suit was based on the principle that better informed physicians make better treatment decisions for their patients. The
FDA opposed this lawsuit but did not dispute the veracity of the subject ANCHOR clinical trial data, the safety data from which is already in FDA-approved labeling of Vascepa, or the peer-reviewed research related to Vascepa and the potential for
cardiovascular risk reduction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with this litigation, the FDA sent a detailed letter to us on June&nbsp;5, 2015 that
confirmed the validity of the ANCHOR trial results. The letter also sought to clarify how, in the FDA&#146;s view, applicable law and FDA policies apply to the communications proposed in our complaint. The FDA stated in this letter that it did not
have concerns with much of the information we proposed to communicate and provided us with guidance on the FDA&#146;s view of lawful, but limited paths for the dissemination and communication to healthcare professionals of the effects of Vascepa
demonstrated in the ANCHOR clinical trial and use of peer-reviewed scientific publications in the context of appropriate disclaimers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
August 2015, we were granted preliminary relief in this lawsuit through the court&#146;s declaratory judgment that confirmed we may engage in truthful and non-misleading speech promoting the off-label use of Vascepa to healthcare professionals,
i.e., to treat patients with persistently high triglycerides, and that such speech may not form the basis of a misbranding action under the FDCA. In August 2015, we began to promote Vascepa to healthcare professionals as permitted by this court
declaration. The FDA did not appeal the court&#146;s ruling. In March 2016, we settled this litigation under terms by which the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
FDA and the U.S. government agreed to be bound by the conclusions from the federal court order that we may engage in truthful and non-misleading speech promoting the off-label use of Vascepa and
that certain statements and disclosures that we proposed to make to healthcare professionals were truthful and non-misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">While we
believe we are now permitted under applicable law to more broadly promote Vascepa, the FDA-approved labeling for Vascepa did not change as a result of this litigation and settlement, and neither government nor other third-party coverage or
reimbursement to pay for the off-label use of Vascepa promoted under the court declaration was required. Based on our communications with the FDA, we expect that final positive results from the REDUCE-IT outcomes study will be required for label
expansion for Vascepa. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even though we have the benefit of a final settlement in this litigation, our promotion is still subject to a
high, perhaps abnormally high, degree of scrutiny to ensure that our promotion remains within the scope covered by the settlement. For example, under the settlement, we remain responsible for ensuring our speech is truthful and non-misleading.
Federal and state governments may also seek to find other means to prevent our promotion of unapproved truthful and non-misleading information about Vascepa. If our promotional activities or other operations are found to be in violation of any law
or governmental regulation through existing or new interpretations, we may be subject to prolonged litigation, penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations, any of which
could adversely affect our ability to operate our business and our results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>*We may not be able to compete
effectively against our competitors&#146; pharmaceutical products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries are highly
competitive. There are many pharmaceutical companies, biotechnology companies, public and private universities and research organizations actively engaged in the research and development of products that may be similar to our products. It is
probable that the number of companies seeking to develop products and therapies similar to our products will increase. Many of these and other existing or potential competitors have substantially greater financial, technical and human resources than
we do and may be better equipped to develop, manufacture and market products. These companies may develop and introduce products and processes competitive with or superior to ours. In addition, other technologies or products may be developed that
have an entirely different approach or means of accomplishing the intended purposes of our products, which might render our technology and products noncompetitive or obsolete. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our competitors both in the United States and Europe include large, well-established pharmaceutical companies, specialty pharmaceutical sales
and marketing companies, and specialized cardiovascular treatment companies. GlaxoSmithKline plc, which currently sells Lovaza<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, a prescription-only omega-3 fatty acid indicated for patients
with severe hypertriglyceridemia was approved by FDA in 2004 and has been on the market in the United States since 2005. As described below, multiple generic versions of Lovaza are now available in the United States. Other large companies with
competitive products include AbbVie, Inc., which currently sells Tricor<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Trilipix<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for the treatment of severe hypertriglyceridemia
and Niaspan<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, which is primarily used to raise HDL-C but is also used to lower triglycerides. Generic versions of Tricor, Trilipix, and Niaspan are also now available in the United States. In
addition, in May 2014, Epanova<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (omega-3-carboxylic acids) capsules, a free fatty acid form of omega-3 (comprised of 55% EPA and 20% DHA), was approved by the FDA for patients with severe
hypertriglyceridemia. Epanova was developed by Omthera Pharmaceuticals, Inc., and is now owned by AstraZeneca Pharmaceuticals LP (AstraZeneca). Also, in April 2014, Omtryg, another omega-3-acid fatty acid composition developed by Trygg Pharma AS,
received FDA approval for severe hypertriglyceridemia. Neither Epanova nor Omtryg have been commercially launched, but could launch at any time. Each of these competitors, other than potentially Trygg, has greater resources than we do, including
financial, product development, marketing, personnel and other resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Currently, six manufacturers have launched generic versions of
Lovaza. In April 2014, Teva Pharmaceuticals USA Inc., or Teva, launched a generic version of Lovaza after winning its patent litigation against Pronova BioPharma Norge AS, now owned by BASF, which owns such patents rights. In June 2014 and September
2014, Par Pharmaceutical Inc., or Par, and Apotex Inc., or Apotex, respectively, received FDA approval of their respective versions of generic Lovaza. In March 2011, Pronova/BASF entered into an agreement with Apotex to settle its patent litigation
in the United States related to Lovaza. Pursuant to the terms of the settlement agreement, Apotex launched a generic version of Lovaza in January 2015. Prasco Labs launched a generic version of Lovaza in March 2015 and AvKARE, Inc., or AvKARE,
launched its version in May 2015. AvKARE supplies government agencies and does not participate in the commercial marketplace. Amneal Pharmaceuticals launched a generic version of Lovaza in January 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, we are aware of other pharmaceutical companies that are developing products that, if approved and marketed, would compete with
Vascepa. We understand that Acasti Pharma, or Acasti, a subsidiary of Neptune Technologies&nbsp;&amp; Bioresources Inc., announced in December 2015 that it intends to pursue a regulatory pathway under section 505(b)(2) of the FDCA for its omega-3
prescription drug candidate, CaPre<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, derived from krill oil for the treatment of hypertriglyceridemia. Acasti plans to begin a pivotal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
bioavailability bridging study between CaPre and an omega-3 prescription drug to establish a scientific bridge between the two and determine the feasibility of a 505(b)(2) regulatory pathway.
Acasti intends to complete long-term toxicity studies in the next 6-9 months and follow these with a Phase 3 clinical program to assess the safety and efficacy of CaPre in patients with very high (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500
mg/dL) triglycerides. We believe Sancilio&nbsp;&amp; Company, or Sancilio, is also developing potential treatments for hypertriglyceridemia based on omega-3 fatty acids. To our knowledge, Sancilio is pursuing a regulatory pathway under section
505(b)(2) of the FDCA for its product and submitted an Investigational New Drug Application, or IND, in July 2015. Sancilio completed two pivotal pharmacokinetic studies, and we expect the company to initiate a pivotal clinical endpoint study as the
next step in development. In addition, we are aware that Matinas BioPharma, Inc. is developing an omega-3-based therapeutic for the treatment of severe hypertriglyceridemia and mixed dyslipidemia. Matinas BioPharma, Inc. has filed an IND with the
FDA to conduct a human study in the treatment of severe hypertriglyceridemia. Akcea Therapeutics/Ionis Pharmaceuticals (formerly Isis Pharmaceuticals) announced favorable Phase 2 results of volanesorsen (formerly ISIS-APOCIII<SUB
STYLE="font-size:85%; vertical-align:bottom">Rx</SUB>), a drug candidate administered through weekly subcutaneous injections, in patients with high triglycerides and type 2 diabetes and in patients with moderate to severe high triglycerides. Phase 3
trials are currently ongoing studying volanesorsen in patients with severe hypertriglyceridemia, familial chylomicronemia syndrome (FCS), and familial partial lipodystrophy (FPL) with data expected in 2017 and 2018. Madrigal Pharmaceuticals has
completed Phase 1 clinical testing of MGL-3196 for the treatment of high triglycerides and various lipid parameters in patients. We expect Madrigal to begin Phase 2 trials in homozygous familial hypercholesterolemia (HoFH) and heterozygous familial
hypercholesterolemia (HeFH) in 2016. Finally, Gemfire Therapeutics has initiated a Phase 2 trial to evaluate the safety and efficacy of gemcabene, an oral, once-daily pill, in the treatment of patients with homozygous familial hypercholesterolemia
(HoFH) on stable lipid-lowering therapy. The novel mechanism of action of gemcabene may support multiple indications including a potential severe triglyceride reduction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>*Vascepa&#146;s recently granted five-year, new chemical entity, or NCE, regulatory exclusivity from the FDA, based on its July 2012 FDA
approval, could be challenged by companies seeking to make generic versions of Vascepa or via a citizens&#146; petition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
timelines and conditions under the abbreviated new drug application, or ANDA process that permit the start of patent litigation and allow the FDA to approve generic versions of brand name drugs like Vascepa differ based on whether a drug receives
three-year, or five-year, new chemical entity (&#147;NCE&#148;) marketing exclusivity. The FDA typically makes a determination on marketing exclusivity in connection with an NDA approval of a drug for a new indication. FDA marketing exclusivity is
separate from, and in addition to, patent protection, trade secrets and manufacturing barriers to entry which also help protect Vascepa against generic competition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We applied to the FDA for five-year, NCE marketing exclusivity for Vascepa in connection with the NDA for our MARINE indication, which NDA was
approved by the FDA on July&nbsp;26, 2012. On February&nbsp;21, 2014, in connection with the July&nbsp;26, 2012 approval of the MARINE indication, the FDA denied a grant of five-year NCE marketing exclusivity to Vascepa and granted three-year
marketing exclusivity. Under applicable regulations, such three-year exclusivity would have extended through July&nbsp;25, 2015 and would have been supplemented by a 30-month stay triggered by patent litigation that would have extended into
September 2016, unless such patent litigation was resolved against us sooner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">NCE marketing exclusivity precludes approval during the
five-year exclusivity period of certain 505(b)(2) applications and ANDAs submitted by another company for another version of the drug. However, an application may be submitted after four years if it contains a certification of patent invalidity or
non-infringement. In this case, the pioneer drug company may be afforded the benefit of a 30-month stay against the launch of such a competitive product that would extend from the end of the five-year exclusivity period, and may also be afforded
other extensions under applicable regulations, including a six-month pediatric exclusivity extension or a judicial extension if applicable requirements are met. Another drug sponsor could also gain a form of marketing exclusivity under the
provisions of the FDCA, as amended by the Hatch-Waxman Amendments, if such company can, under certain circumstances, complete a human clinical trial process and obtain regulatory approval of its product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In contrast, a three-year period of exclusivity under the Hatch-Waxman Amendments is generally granted for a drug product that contains an
active moiety that has been previously approved, such as when the application contains reports of new clinical investigations (other than bioavailability studies) conducted by the sponsor that were essential to approval of the application.
Accordingly, we expect to receive three-year exclusivity in connection with any future regulatory approvals of Vascepa, such as an approval sought based on positive REDUCE-IT outcomes study results. Such three-year exclusivity protection precludes
the FDA from approving a marketing application for an ANDA, a product candidate that the FDA views as having the same conditions of approval as Vascepa (for example, the same indication and/or other conditions of use), or a 505(b)(2) NDA submitted
to the FDA with Vascepa as the reference product, for a period of three years from the date of FDA approval. The FDA may accept and commence review of such applications during the three-year exclusivity period. Such three-year exclusivity grant does
not prevent a company from challenging the validity of patents at any time, subject to any prior four-year period pending from a grant of five-year exclusivity. This three-year form of exclusivity may also not prevent the FDA from approving an NDA
that relies only on its own data to support the change or innovation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;27, 2014, we sued the FDA in the U.S. District Court for the District of
Columbia to challenge the agency&#146;s denial of five-year NCE exclusivity for Vascepa, based on our reading of the relevant statute, our view of FDA&#146;s inconsistency with its past actions in this area and the retroactive effect of what we
believe is a new policy at FDA as it relates to our situation. On May&nbsp;28, 2015, the court granted our motion for summary judgment. The decision vacated the FDA&#146;s denial of our claim for such exclusivity and remanded to the FDA for
proceedings consistent with the decision. On July&nbsp;22, 2015, Watson Laboratories Inc., the purported first Vascepa ANDA filer, sought to intervene and appeal the court&#146;s decision. We and FDA opposed this intervention effort. The applicable
courts denied Watson the relief sought and appeal periods have expired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On May&nbsp;31, 2016, in a reversal that FDA and we view as
consistent with the court&#146;s May&nbsp;28, 2015 summary judgment motion, FDA determined that Vascepa is eligible for five-year, NCE marketing exclusivity. This determination provides Vascepa with the benefits of NCE exclusivity afforded by
statute. NCE exclusivity for Vascepa runs from its date of&nbsp;FDA&nbsp;approval on&nbsp;July 26, 2012&nbsp;and extends until&nbsp;July 26, 2017. The statutory 30-month stay triggered by patent litigation following generic application submissions
permitted on&nbsp;July 26, 2016&nbsp;would continue until January&nbsp;26, 2020, seven-and-a-half years from&nbsp;FDA&nbsp;approval, unless such patent litigation was resolved against us sooner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">It is possible that FDA&#146;s NCE determination could be challenged by interested parties. If challenged, we plan to vigorously support
FDA&#146;s determination. Any such challenge could have a negative impact on our company and create uncertainty around the continued benefits associated with a five-year exclusivity status. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Generic company competitors are expected to again seek FDA approval of generic versions of Vascepa. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDCA, as amended by the Drug Price Competition and Patent Term Restoration Act of 1984, as amended, or the Hatch-Waxman Amendments, permits
the FDA to approve ANDAs for generic versions of brand name drugs like Vascepa. We refer to the process of generic drug applications as the &#147;ANDA process.&#148; The ANDA process permits competitor companies to obtain marketing approval for a
drug product with the same active ingredient, dosage form, strength, route of administration, and labeling as the approved brand name drug, but without having to conduct and submit clinical studies to establish the safety and efficacy of the
proposed generic product. In place of such clinical studies, an ANDA applicant needs to submit data demonstrating that its product is bioequivalent to the brand name product, usually based on pharmacokinetic studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Hatch-Waxman Amendments require an applicant for a drug product that relies, in whole or in part, on the FDA&#146;s prior approval of
Vascepa, to notify us of its application, a &#147;Paragraph IV&#148; notice, if the applicant is seeking to market its product prior to the expiration of the patents that claim Vascepa. A bona fide Paragraph IV notice may not be given under the
Hatch-Waxman Amendments until after the generic company receives from the FDA an acknowledgement letter stating that its ANDA is sufficiently complete to permit a substantive review. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Paragraph IV notice is required to contain a detailed factual and legal statement explaining the basis for the applicant&#146;s opinion
that the proposed product does not infringe our patents, that our patents are invalid, or both. After receipt of a valid notice, we would have the option of bringing a patent infringement suit in federal district court against any generic company
seeking approval for its product within 45 days from the date of receipt of each notice. If such a suit is commenced within this 45 day period, we will be entitled to receive a 30 month stay on FDA&#146;s ability to give final approval to any of the
proposed products that reference Vascepa that begins on the date we receive the Paragraph IV notice. The stay may be shortened or lengthened if either party fails to cooperate in the litigation and it may be terminated if the court decides the case
in less than 30 months. If the litigation is resolved in favor of the applicant before the expiration of the 30 month period, the stay will be immediately lifted and the FDA&#146;s review of the application may be completed. Such litigation is often
time-consuming and costly, and may result in generic competition if such patents are not upheld or if the generic competitor is found not to infringe such patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the first half of 2014, we received six Paragraph IV notices notifying us of accepted ANDAs to Vascepa under the Hatch-Waxman Amendments.
These ANDAs were submitted and accepted by FDA under the regulatory scheme adopted under the Hatch-Waxman Amendments based on the FDA&#146;s determination that we were entitled to three, and not five-year exclusivity. As a result from the first half
of 2014 until June 2015, we were engaged in costly litigation with the ANDA applicants to protect our patent rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on the
May&nbsp;28, 2015, District of Columbia court order granting our motion for summary judgment in the NCE litigation, on June&nbsp;26, 2015, the parties to the related Vascepa patent litigation that followed acceptance by FDA of ANDAs to Vascepa based
on a three-year regulatory exclusivity determination, agreed to a full stay of proceeding in that patent litigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Following the
May&nbsp;28, 2015 District of Columbia court order setting aside FDA&#146;s denial of NCE exclusivity for Vascepa, FDA notified the ANDA filers that FDA had changed the status of their ANDAs to submitted, but no longer accepted, and notified ANDA
filers that FDA had ceased review of the pending ANDAs. In rescinding acceptance of the ANDAs, the statutory basis for the patent litigation (accepted ANDAs) no longer existed. Thus, on July&nbsp;24, 2015, we moved to dismiss the pending patent
infringement lawsuits against each of the Vascepa ANDA applicants in the U.S. District Court for the District of New Jersey. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;22, 2016, the U.S. District Court for the District of New Jersey granted our
motion to dismiss all patent infringement litigation related to the 2014 acceptance by the FDA of ANDAs to Vascepa. An appeal of the court&#146;s dismissal was filed by one ANDA filer and, after FDA&#146;s May 2016 grant of Vascepa NCE exclusivity,
that appeal was withdrawn by the ANDA filer. With this dismissal and terminated appeal, there is no pending patent litigation related to Vascepa. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We plan to defend the exclusivity of Vascepa through patent litigation after the so called Paragraph IV notification from ANDA filers that FDA
has accepted their ANDA application related to Vascepa. We expect notification of new ANDA acceptances in the third quarter of 2016, given their eligibility for submission under the NCE regulatory structure, after the expiration of four years from
the July 2012 approval of Vascepa. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If an ANDA filer is ultimately successful in patent litigation against us, it meets the requirements
for a generic version of Vascepa to the satisfaction of the FDA under its ANDA (after the applicable regulatory exclusivity period and the litigation-related 30-month stay period ends), and is able to supply the product in significant commercial
quantities, the generic company could introduce a generic version of Vascepa. Such a market entry would likely limit our U.S. sales, which would have an adverse impact on our business and results of operations. In addition, even if a
competitor&#146;s effort to introduce a generic product is ultimately unsuccessful, the perception that such development is in progress and/or news related to such progress could materially affect the perceived value of our company and our stock
price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Vascepa is a prescription-only omega-3 fatty acid product. Omega-3 fatty acids are also marketed by other companies as
non-prescription dietary supplements. As a result, Vascepa is subject to non-prescription competition and consumer substitution. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our only current product, Vascepa, is a prescription-only omega-3 fatty acid. Mixtures of omega-3 fatty acids are naturally occurring
substances contained in various foods, including fatty fish. Omega-3 fatty acids are also marketed by others as non-prescription dietary supplements. We cannot be sure physicians will view the pharmaceutical grade purity and tested safety of Vascepa
as having a superior therapeutic profile to naturally occurring omega-3 fatty acids and dietary supplements. In addition, the FDA has not enforced what we view as illegal drug claims made by certain omega-3 fatty acid supplement manufacturers to the
extent we believe appropriate under applicable law and regulations, for example, claims that such supplements reduce triglyceride levels. Also, for more than a decade now, the FDA has expressly permitted dietary supplement manufacturers that sell
supplements containing the omega-3 fatty acids EPA and/or DHA to make the following qualified health claim directly to consumers: Supportive but not conclusive research shows that consumption of EPA and DHA omega-3 fatty acids may reduce the risk of
coronary heart disease. As a result of our First Amendment litigation and settlement, we may now make this claim to healthcare professionals subject to certain qualifications. These factors enable dietary supplements to effectively compete with
Vascepa. In addition, to the extent the net price of Vascepa after insurance and offered discounts is significantly higher than the prices of commercially available omega-3 fatty acids marketed by other companies as dietary supplements (through that
lack of coverage by insurers or otherwise), physicians and pharmacists may recommend these commercial alternatives instead of writing or filling prescriptions for Vascepa or patients may elect on their own to take commercially available omega-3
fatty acids. Either of these outcomes may adversely impact our results of operations by limiting how we price our product and limiting the revenue we receive from the sale of Vascepa due to reduced market acceptance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our Vascepa co-promotion effort with Kowa Pharmaceuticals America, Inc. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In March 2014, we entered into a co-promotion agreement with Kowa Pharmaceuticals America, Inc. to co-promote Vascepa in the United States
under which no less than 250 Kowa Pharmaceuticals America, Inc. sales representatives devote a substantial portion of their time to promoting Vascepa with our approximately 150 sales professionals, including sales representatives and their managers.
Co-promotion under the agreement commenced in May 2014 based on a plan designed to substantially increase both the number of sales targets reached and the frequency of sales calls on existing sales targets. While our agreement provides for minimum
performance criteria, we have little control over Kowa Pharmaceuticals America, Inc., and it may fail to devote the necessary resources and attention to promote Vascepa effectively. If that were to occur, depending on Vascepa revenues, we may have
to curtail the continued development of Vascepa for approval for additional indications or increase our planned expenditures and undertake additional development or commercialization activities at our own expense. Or, we may seek to terminate the
agreement and search for another commercialization partner. If we elect to increase our expenditures to fund development or commercialization activities on our own, depending on Vascepa&#146;s revenues, we may need to obtain additional capital,
which may not be available to us on acceptable terms, or at all, or which may not be possible due to our other financing arrangements. If we do not generate sufficient funds from the sale of Vascepa or, to the extent needed to supplement funds
generated from product revenue, cannot raise sufficient funds, we may not be able to devote resources sufficient to market and sell Vascepa on our own in a manner required to realize the full market potential of Vascepa. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The commercial value to us of current and sought marketing rights may be smaller than we
anticipate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There can be no assurance as to the adequacy for commercial success of the scope and breadth of the marketing rights
we currently have or, if approved, an indication based on a successful outcome of the REDUCE-IT study. Even if we obtain marketing approval for additional indications, the FDA may impose restrictions on the product&#146;s conditions for use,
distribution or marketing and in some cases may impose ongoing requirements for post-market surveillance, post-approval studies or clinical trials. Also, the number of actual patients with conditions within the scope of our marketing efforts may be
smaller than we anticipate. If any such marketing right or approved indication is narrower than we anticipate, the market potential for our product would suffer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>*Our special protocol assessment, or SPA, agreement for ANCHOR was rescinded and our SPA agreement for REDUCE-IT is not a guarantee of
FDA approval of Vascepa for the proposed REDUCE-IT indication. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A SPA is an evaluation by the FDA of a protocol with the goal of
reaching an agreement that the Phase 3 trial protocol design, clinical endpoints, and statistical analyses are acceptable to support regulatory approval of the drug product candidate with respect to effectiveness for the indication studied. The
ANCHOR trial was, and the REDUCE-IT trial is, being conducted under a SPA agreement with the FDA. In each case, the FDA agreed that, based on the information we submitted to the agency, the design and planned analysis of the trial is adequate to
support use of the conducted study as the primary basis for approval with respect to effectiveness. A SPA agreement is not a guarantee of approval. A SPA agreement is generally binding upon the FDA except in limited circumstances, such as if the FDA
identifies a substantial scientific issue essential to determining safety or efficacy after the study begins, or if the study sponsor fails to follow the protocol that was agreed upon with the FDA. The FDA reserves the right of final determinations
for approval based on its review of the entire data presented in a marketing application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In October 2013, the FDA notified us that it
rescinded the ANCHOR study SPA agreement because the FDA determined that a substantial scientific issue essential to determining the effectiveness of Vascepa in the studied population was identified after testing began. In April 2015, we received a
CRL from the FDA stating that the FDA determined not to approve label expansion reflecting the ANCHOR clinical trial efficacy data at this time. Thus, even though we have received regulatory approval of Vascepa for the MARINE indication under a SPA
agreement, our ANCHOR SPA agreement was rescinded and there is no assurance that the FDA will not rescind our REDUCE-IT SPA agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
August 2016, we announced an amendment to our REDUCE-IT SPA agreement with FDA that reaffirmed FDA concurrence on key elements of the study, defined details of the statistical analysis plan for the study, expanded to greater than 30 the
pre-specified secondary and tertiary endpoints in the study, and added a second interim efficacy and safety analysis by the independent DMC at approximately 80% of the target aggregate number of primary cardiovascular events. In this amended
REDUCE-IT SPA agreement, FDA agreed that, based on the information submitted to the agency, the critical elements of the revised REDUCE-IT protocol and analysis plans adequately address the objectives necessary to support a regulatory submission.
However, secondary and/or tertiary endpoints, their ordering in the statistical hierarchy, their clinical significance, or whether any would yield results appropriate for labeling are considered review issues and are not intended to be a binding
component of the REDUCE-IT SPA agreement. Further, matters such as endpoint adjudication procedures (including potential endpoint ascertainment, adjudication process, and detailed definitions) were specified by FDA as issues to be reviewed by the
agency as part of a drug approval application. Consistent with the May 2016 FDA SPA draft guidance, FDA stated that the SPA agreement does not necessarily indicate the agency&#146;s agreement with every detail of a protocol; instead, such an
agreement indicates FDA&#146;s concurrence with the elements critical to ensuring that the trial conducted under the protocol would have the potential to form the primary basis of an efficacy claim in a marketing application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The inability to obtain marketing approval in the ANCHOR or REDUCE-IT indications has prevented, and would continue to prevent us, from
growing revenue more significantly, and it has had, and could continue to have, a material adverse effect on our operations and financial condition, including our ability to reach profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The commercial value to us of sales of Vascepa outside the United States, such as under the DCS Agreement with Eddingpharm, may be
smaller than we anticipate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There can be no assurance as to the adequacy for commercial success of Vascepa outside the United
States. For example, even if we and Eddingpharm obtain marketing approval in countries within the China Territory, applicable regulatory agencies may impose restrictions on the product&#146;s conditions for use, distribution or marketing and in some
cases may impose ongoing requirements for post-market surveillance, post-approval studies or clinical trials. Also, with regard to any indications for which we may gain approval in territories outside the United States, the number of actual patients
with the condition included in such approved indication may be smaller than we anticipate. If any such approved indication is narrower than we anticipate, the market potential in these countries for our product would suffer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our products and marketing efforts are subject to extensive post-approval government
regulation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Once a product candidate receives FDA marketing approval, numerous post-approval requirements apply. Among other
things, the holder of an approved NDA is subject to periodic and other monitoring and reporting obligations enforced by the FDA and other regulatory bodies, including obligations to monitor and report adverse events and instances of the failure of a
product to meet the specifications in the approved application. Application holders must also submit advertising and other promotional material to regulatory authorities and report on ongoing clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">With respect to sales and marketing activities including direct-to-healthcare provider and direct-to-consumer advertising and promotional
activities involving the internet, advertising and promotional materials must comply with FDA rules in addition to other applicable federal and local laws in the United States and in other countries. The result of our First Amendment litigation and
settlement may cause the government to scrutinize our promotional efforts or otherwise monitor our business more closely. Industry-sponsored scientific and educational activities also must comply with FDA and other requirements. In the United
States, the distribution of product samples to physicians must comply with the requirements of the U.S. Prescription Drug Marketing Act. Manufacturing facilities remain subject to FDA inspection and must continue to adhere to the FDA&#146;s
pharmaceutical current good manufacturing practice requirements, or cGMPs. Application holders must obtain FDA approval for product and manufacturing changes, depending on the nature of the change. We also are subject to the new federal transparency
requirements under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, which require manufacturers of certain drugs, devices, biologics, and medical supplies to report to the Centers for
Medicare&nbsp;&amp; Medicaid Services, or CMS, information related to payments and other transfers of value to physicians and teaching hospitals and physician ownership and investment interests. We may also be subject, directly or indirectly through
our customers and partners, to various fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute, U.S. False Claims Act, and similar state laws, which impact, among other things, our proposed sales, marketing, and
scientific/educational grant programs. If we participate in the U.S. Medicaid Drug Rebate Program, the Federal Supply Schedule of the U.S. Department of Veterans Affairs, or other government drug programs, we will be subject to complex laws and
regulations regarding reporting and payment obligations. We must also comply with requirements to collect and report adverse events and product complaints associated with our products. For example, in September 2014, we participated in a routine
inspection from the FDA in which the FDA made observations on perceived deficiencies related to our processes for collection and processing of adverse events. We have responded to FDA with respect to these observations and continue to work with FDA
to show that we have improved related systems and, given we received communication from the FDA that it considers this matter to be closed, we believe that we have demonstrated to FDA that we have adequately responded to these observations. Our
activities are also potentially subject to U.S. federal and state consumer protection and unfair competition laws. Similar requirements exist in many of these areas in other countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Depending on the circumstances, failure to meet these post-approval requirements can result in criminal prosecution, fines or other penalties,
injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, or refusal to allow us to enter into supply contracts, including government contracts. We may also be
held responsible for the non-compliance of our partners, such as Kowa Pharmaceuticals America, Inc. In addition, even if we comply with FDA and other requirements, new information regarding the safety or effectiveness of a product could lead the FDA
to modify or withdraw a product approval. Adverse regulatory action, whether pre- or post-approval, can potentially lead to product liability claims and increase our product liability exposure. We must also compete against other products in
qualifying for coverage and reimbursement under applicable third-party payment and insurance programs. In addition, all of the above factors may also apply to any regulatory approval for Vascepa obtained within the China Territory under the DCS
agreement with Eddingpharm and in other territories outside the United States. Given our inexperience with marketing and commercializing products outside the United States, we will need to rely on third parties, such as Eddingpharm in China, to
assist us in dealing with any such issues. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The FDA and other regulatory agencies strictly regulate the promotional claims that may
be made about prescription products. If we or our partners are found to have improperly promoted uses of Vascepa, we may become subject to significant fines and other liability. The government may seek to find means to prevent our promotion of
truthful and non-misleading information beyond the current court ruling and litigation settlement. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA and other regulatory
agencies strictly regulate the promotional claims that may be made about prescription products. In particular, in general, the U.S. government&#146;s position has been that a product may not be promoted for uses that are not approved by the FDA as
reflected in the product&#146;s approved labeling. Even though we received FDA marketing approval for Vascepa for the MARINE indication and we believe the First Amendment court ruling and litigation settlement affords us a degree of protection for
other promotional efforts, physicians may still prescribe Vascepa to their patients for use in the treatment of conditions that are not included as part of the indication statement in our FDA-approved Vascepa label or our settlement. If we are found
to have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
promoted Vascepa outside the terms of the litigation settlement or in violation of what federal or state government may determine to be acceptable, we may become subject to significant government
fines and other related liability, such as under the False Claims Act or other theories of liability. Government may also seek to hold us responsible for the non-compliance of our co-promotion partner, Kowa Pharmaceuticals America, Inc., or our
ex-U.S. commercialization partner, Eddingpharm. For example, the Federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion.
The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, incentives exist under applicable laws that encourage competitors, employees and physicians to report violations of rules
governing promotional activities for pharmaceutical products. These incentives could lead to so-called whistleblower lawsuits as part of which such persons seek to collect a portion of moneys allegedly overbilled to government agencies due to, for
example, promotion of pharmaceutical products beyond labeled claims. These incentives could also lead to suits that we have mischaracterized a competitor&#146;s product in the marketplace and we may, as a result, be sued for alleged damages to our
competitors. Such lawsuits, whether with or without merit, are typically time-consuming and costly to defend. Such suits may also result in related shareholder lawsuits, which are also costly to defend. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even though we have a final settlement in our litigation related to promotion beyond FDA-approved labeling, our promotion would still be
subject to a high, perhaps abnormally high, degree of scrutiny to ensure that our promotion remains within the permitted scope. Likewise, federal or state government may seek to find other means to prevent our promotion of truthful and
non-misleading information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The REDUCE-IT cardiovascular outcomes trial may fail to show that Vascepa can reduce major
cardiovascular events in an at-risk patient population on statin therapy, and the long-term clinical results of Vascepa may not be consistent with the clinical results we observed in our Phase 3 clinical trial, in which case our sales of Vascepa may
then suffer. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In accordance with the SPA agreements for our MARINE and ANCHOR trials, efficacy was evaluated in these trials
compared to placebo at twelve weeks. No placebo-controlled studies have been conducted regarding the long-term effect of Vascepa on lipids, and no outcomes study has been conducted evaluating Vascepa. The REDUCE-IT study, which commenced in 2011 and
reached its approximately 8,000 patient enrollment target in March 2016, is designed to evaluate the efficacy of Vascepa in reducing major cardiovascular events in an at-risk patient population on statin therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Outcomes studies of certain other lipid-modifying therapies have failed to achieve the endpoints of such studies, even though they reduced
triglyceride levels and showed other favorable effects on parameters relevant to cardiovascular health in studied patients. For example, in 2010, the results of the ACCORD-Lipid trial were published. This trial studied the effect of adding
fenofibrate onto open-label simvastatin therapy on cardiovascular outcomes. The addition of fenofibrate did not show any treatment benefit on cardiovascular outcomes over simvastatin monotherapy in this study. In 2011, the results of the AIM-HIGH
trial were published. This trial studied the effect of adding a second lipid-altering agent, extended-release niacin, to simvastatin therapy on cardiovascular outcomes in people at high risk for cardiovascular events. No significant incremental
treatment benefit with extended-release niacin was observed. In addition, in September 2012, researchers published in the <I>Journal of the American Medical Association, </I>or<I> JAMA, </I>the results of a retrospective meta-analysis of twenty
previously conducted studies regarding the use of omega-3 supplements across various patient populations. This meta-analysis suggested that the use of such supplements was not associated with a lower risk of all-cause death, cardiac death, sudden
death, heart attack, or stroke. We believe the results of these studies may not be directly applicable to the use of Vascepa over time. For instance, the outcomes studies for fenofibrates and niacin were conducted in patient populations in which the
majority of patients studied had triglycerides below 200 mg/dL and fenofibrates and niacin are believed to work differently than Vascepa in the body and do not have as favorable a side-effect profile, and nineteen of the twenty studies included in
the <I>JAMA</I> meta-analysis involved the use of omega-3 supplements containing a mixture of EPA and DHA, and most were evaluated at relatively lower doses. In addition, in May 2013, <I>The New England Journal of Medicine</I> published the results
of an outcomes study of 1 gram per day of an omega-3 acid ethyl ester composition. In that study, the composition failed to show a benefit in reducing the rate of death from cardiovascular causes or hospitalization for cardiovascular causes when
administered to patients with cardiovascular risk factors under different study conditions than in the REDUCE-IT study. Vascepa is comprised of highly-pure ethyl-EPA, and has been approved by the FDA for use in adult patients with severe
hypertriglyceridemia at a dose of 4 grams per day and is being studied in REDUCE-IT at 4&nbsp;grams&nbsp;per day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The only other outcomes
study involving the use of a highly-pure formulation of ethyl-EPA, called the Japan EPA Lipid Intervention Study (JELIS), suggested that use of a highly-pure formulation of ethyl-EPA in Japan, when used in conjunction with statins, reduced
cardiovascular events by 19% compared to the use of statins alone. However, there are several limitations to the JELIS study. First, the patient population was exclusively Japanese, the majority of the participants were women, and at baseline
patients had a much higher LDL, limiting its generalizability to the intended target population. Also, a low dose of statins was used. It is unknown whether the positive treatment effects would have persisted if these patients had been optimally
treated with statins using </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contemporary LDL targets in the United States. In addition, JELIS was an open-label trial, which could influence patient and physician behavior and reporting of symptoms, decisions regarding
hospitalization, and referral of events for adjudication. This may be particularly relevant since hospitalization for unstable angina was a primary contributor of the overall positive result, and is considered a softer endpoint than fatal
cardiovascular events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Further, FDA determined that JELIS results could not be used as support for or against the use of triglyceride
levels as a surrogate for cardiovascular risk reduction. Patients treated with EPA and statin in JELIS achieved triglyceride levels that were only 5% lower, on average, than those achieved among patients treated with statin alone; however, the
reduction in cardiovascular risk in the primary endpoint analysis was 19%. Likewise, within the primary and secondary prevention sub-analyses, triglyceride levels were lowered only 5% on average in the EPA plus statin group compared with the statin
alone group; however, the relative risk reduction was 53% in the primary prevention population with elevated triglyceride (<U>&gt;</U> 150 mg/dL) and low HDL-C (<U>&lt;</U> 40 mg/dL) levels and 23% in the secondary prevention population with
established coronary artery disease. These large differences in magnitude between triglyceride reduction and risk reduction in JELIS suggest that the effects of EPA on triglyceride levels alone may not be responsible for, or predict, the observed
differences in cardiovascular events between treatment groups in JELIS. JELIS was not designed to evaluate primary and secondary prevention populations. It is possible that the putative cardioprotective effects of EPA observed in JELIS are due not
to a single mode of action, such as triglyceride lowering, but rather to multiple mechanisms working together, such as purported beneficial effects on multiple atherosclerosis processes, including endothelial function, oxidative stress, foam cell
formation, inflammation/cytokines, plaque formation/progression, platelet aggregation, thrombus formation, and plaque rupture. The REDUCE-IT study is needed to determine the clinical benefit, if any, of EPA therapy in statin-treated patients with
elevated triglyceride levels. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although we believe the results of the <I>JAMA</I> meta-analysis and other studies are not directly
applicable to the potential long-term clinical experience with Vascepa, there can be no assurance that the endpoints of the REDUCE-IT cardiovascular outcomes study will be achieved or that the lipid-modifying effects of Vascepa in REDUCE-IT or any
other study of Vascepa will not be subject to variation beyond twelve weeks. If the REDUCE-IT trial fails to achieve its clinical endpoints or if the results of these long-term studies are not consistent with the 12-week clinical results, it could
prevent us from expanding the labeled approval of Vascepa or even call into question the currently understood efficacy and safety profile of Vascepa. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>*The prospective 60% and 80% interim efficacy and safety analyses of the REDUCE-IT cardiovascular outcomes trial may not be completed in
the contemplated timeframes and may not demonstrate to the independent committee monitoring the study a sufficient benefit risk result to warrant the independent committee recommending stopping the study early for overwhelming efficacy. The
independent monitoring committee may, at its discretion, also recommend that the study be stopped for safety or related concerns. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In accordance with the SPA agreement for our REDUCE-IT cardiovascular outcomes trial, an interim analysis of the efficacy and safety results of
the trial is scheduled to occur upon reaching approximately 60% of the target aggregate number of cardiovascular events. We currently expect this interim analysis by the study&#146;s independent data monitoring committee (DMC) to occur in September
or October 2016 based on our understanding of the current event rates in the study and expected future event rates and will include the first review of unblinded efficacy data by the DMC. Assuming the REDUCE-IT study continues following the 60%
interim analysis, the second planned interim analysis will be triggered by the onset of approximately 80% of the target aggregate number of primary cardiovascular events in the study. Based on historical event rates, we anticipate that the onset of
approximately 80% of events will occur in the first half of 2017, with the second pre-specified interim efficacy and safety analysis by the DMC expected around mid-2017. It may actually take longer than anticipated for the DMC assessment of data for
the interim analysis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Further, as is typical of interim analyses, the statistical threshold for defining overwhelming efficacy on the
primary endpoint that would call for stopping the study early in connection with such analysis is considerably higher than the threshold for defining statistical significance after the expected completion of the study in or about the second half of
2017. We do not expect the study to be stopped due to overwhelming efficacy at these interim looks. We have requested the DMC to not recommend stopping the study early based only upon achieving statistical significance for the primary endpoint, but
to ensure that supportive trends of benefit are also consistently observed in certain secondary endpoints and subpopulations before recommending that the study be stopped early for overwhelming efficacy. For example, even if the appropriate studied
cardiovascular events in the trial occur at sufficiently low rates in the active, Vascepa, group as compared to the placebo group such that the study would be a success at completion, the more rigorous statistical analysis applied by the DMC at the
interim analysis may not warrant stoppage of the study for overwhelming efficacy in connection with the interim analysis. The study may also be stopped pursuant to recommendation by the DMC at this interim analysis due to low likelihood of obtaining
a favorable result at completion. Despite no formal futility analysis or boundary being pre-specified in the protocol, it is within the purview of the DMC to weigh all available information and recommend study stoppage or continuation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, it is the DMC that will make the formal recommendation as to whether to stop the study early or to continue as planned. We are
blinded to the interim analysis results and are informed by the DMC of the recommendation to stop the study or to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
continue as planned. The DMC may consider factors outside the pre-specified statistical analysis plan when assessing whether to recommend continuing the study as planned. For example, even if
study results are sufficiently positive at the interim analysis to demonstrate overwhelming efficacy, the DMC at its discretion may recommend continuation of the study as planned with the goal of arriving at more robust results at the planned study
completion if it believes that waiting for more robust results outweighs the potential medical benefit of stopping and unblinding the study early. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The DMC has multiple times per year assessed safety data generated in the ongoing study and has thus far recommended to continue the study as
planned. Thus, multiple safety reviews to date have not warranted study stoppage. Nevertheless, the study may be stopped at any time based on recommendations of the DMC due to safety concerns identified by the DMC during its ongoing and regularly
scheduled safety data assessments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in developing or marketing future products if we cannot meet the
extensive regulatory requirements of the FDA and other regulatory agencies for quality, safety and efficacy. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The success of our
research and development efforts is dependent in part upon our ability, and the ability of our partners or potential partners, to meet regulatory requirements in the jurisdictions where we or our partners or potential partners ultimately intend to
sell such products once approved. The development, manufacture and marketing of pharmaceutical products are subject to extensive regulation by governmental authorities in the United States and elsewhere. In the United States, the FDA generally
requires preclinical testing and clinical trials of each drug to establish its safety and efficacy and extensive pharmaceutical development to ensure its quality before its introduction into the market. Regulatory authorities in other jurisdictions
impose similar requirements. The process of obtaining regulatory approvals is lengthy and expensive and the issuance of such approvals is uncertain. The commencement and rate of completion of clinical trials and the timing of obtaining marketing
approval from regulatory authorities may be delayed by many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the lack of efficacy during clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to manufacture sufficient quantities of qualified materials under cGMPs for use in clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">slower than expected rates of patient recruitment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to observe patients adequately after treatment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in regulatory requirements for clinical trials or preclinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the emergence of unforeseen safety issues in clinical trials or preclinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay, suspension, or termination of a trial by the institutional review board responsible for overseeing the study at a particular study site; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unanticipated changes to the requirements imposed by regulatory authorities on the extent, nature or timing of studies to be conducted on quality, safety and efficacy; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">government or regulatory delays or &#147;clinical holds&#148; requiring suspension or termination of a trial; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">political instability affecting our clinical trial sites, such as the potential for political unrest affecting our REDUCE-IT clinical trial sites in the Ukraine and Russia. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if we obtain positive results from early stage preclinical studies or clinical trials, we may not achieve the same success in future
trials. Clinical trials that we or potential partners conduct may not provide sufficient safety and efficacy data to obtain the requisite regulatory approvals for product candidates. The failure of clinical trials to demonstrate safety and efficacy
for our desired indications could harm the development of that product candidate as well as other product candidates, and our business and results of operations would suffer. For example, the efficacy results of our Vascepa Phase 3 clinical trials
for the treatment of Huntington&#146;s disease were negative. As a result, we stopped development of that product candidate, revised our clinical strategy and shifted our focus to develop Vascepa for use in the treatment of cardiovascular disease.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any approvals that are obtained may be limited in scope, may require additional post-approval studies or may require the addition of
labeling statements focusing on product safety that could affect the commercial potential for our product candidates. Any of these or similar circumstances could adversely affect our ability to earn revenues from the sale of such products. Even in
circumstances where products are approved by a regulatory body for sale, the regulatory or legal requirements may change over time, or new safety or efficacy information may be identified concerning a product, which may lead to the withdrawal of a
product from the market or similar use restrictions. The discovery of previously unknown problems with a product or in connection with the manufacturer of products may result in restrictions on that product or manufacturer, including withdrawal of
the product from the market, which would have a negative impact on our potential revenue stream. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Legislative or regulatory reform of the healthcare system in the United States and foreign
jurisdictions may affect our ability to profitably sell Vascepa. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our ability to commercialize our future products successfully,
alone or with collaborators, will depend in part on the extent to which coverage and reimbursement for the products will be available from government and health administration authorities, private health insurers and other third-party payors. The
continuing efforts of the U.S. and foreign governments, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce healthcare costs may adversely affect our ability to set prices for our products
which we believe are fair, and our ability to generate revenues and achieve and maintain profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Specifically, in both the United
States and some foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. For example, the Patient Protection and
Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the PPACA, enacted in March 2010, substantially changed the way healthcare is financed by both governmental and private insurers. Among other
cost-containment measures, PPACA established: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">An annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A new Medicare Part D coverage gap discount program, in which pharmaceutical manufacturers who wish to have their drugs covered under Part D must offer discounts to eligible beneficiaries during their coverage gap
period; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A new formula that increases the rebates a manufacturer must pay under the Medicaid Drug Rebate Program. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect further federal and state proposals and healthcare reforms to continue to be proposed by legislators, which could limit the prices
that can be charged for the products we develop and may limit our commercial opportunity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The continuing efforts of government and other
third-party payors to further contain or reduce the costs of healthcare through various means may limit our commercial opportunity. It will be time consuming and expensive for us to go through the process of seeking coverage and reimbursement from
Medicare and private payors. Our products may not be considered cost effective, and government and third-party private health insurance coverage and reimbursement may not be available to patients for any of our future products or sufficient to allow
us to sell our products on a competitive and profitable basis. Our results of operations could be adversely affected by PPACA and by other healthcare reforms that may be enacted or adopted in the future. In addition, increasing emphasis on managed
care in the United States will continue to put pressure on the pricing of pharmaceutical products. Cost control initiatives could decrease the price that we or any potential collaborators could receive for any of our future products and could
adversely affect our profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In some foreign countries, including major markets in the European Union and Japan, the pricing of
prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take 6 to 12 months or longer after the receipt of regulatory marketing approval for a product. To obtain
reimbursement or pricing approval in some countries, we may be required to conduct a pharmacoeconomic study that compares the cost-effectiveness of Vascepa to other available therapies. Such pharmacoeconomic studies can be costly and the results
uncertain. Our business could be harmed if reimbursement of our products is unavailable or limited in scope or amount or if pricing is set at unsatisfactory levels. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>As we evolve from a company primarily involved in research and development to a company also focused on establishing an infrastructure
for commercializing Vascepa, we may encounter difficulties in managing our growth and expanding our operations successfully. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
hired and trained a professional sales force of approximately 275 sales representatives and commenced our commercial launch of Vascepa in the MARINE indication in the United States in early January 2013. The process of establishing a commercial
infrastructure is difficult, expensive and time-consuming. Our October 2013 worldwide reduction in force, which included the termination of approximately 50% of the then-staffed sales force, has made this process more difficult. As our operations
expand with the anticipated growth of our product sales, we expect that we will need to manage additional relationships with various collaborative partners, suppliers and other third parties. Future growth will impose significant added
responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional employees. Our future financial performance and our ability to commercialize Vascepa and to compete effectively will depend, in
part, on our ability to manage our future growth effectively. To that end, we must be able to manage our development efforts effectively, and hire, train, integrate and retain additional management, administrative and sales and marketing personnel.
We may not be able to accomplish these tasks, and our failure to accomplish any of them could prevent us from successfully growing our company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Reliance on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our supply of product for commercial supply and clinical trials is dependent upon relationships with third-party manufacturers and key
suppliers. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have no in-house manufacturing capacity and rely on contract manufacturers for our clinical and commercial product
supply. We cannot assure you that we will successfully manufacture any product we may develop, either independently or under manufacturing arrangements, if any, with our third-party manufacturers. Moreover, if any manufacturer should cease doing
business with us or experience delays, shortages of supply or excessive demands on their capacity, we may not be able to obtain adequate quantities of product in a timely manner, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any manufacturing problem, natural disaster affecting manufacturing facilities, or the loss of a contract manufacturer could be disruptive to
our operations and result in lost sales. Additionally, we will be reliant on third parties to supply the raw materials needed to manufacture Vascepa. Any reliance on suppliers may involve several risks, including a potential inability to obtain
critical materials and reduced control over production costs, delivery schedules, reliability and quality. Any unanticipated disruption to future contract manufacture caused by problems at suppliers could delay shipment of products, increase our
cost of goods sold and result in lost sales. If our suppliers were unable to supply us with adequate volumes of active pharmaceutical ingredient (drug substance) or encapsulated bulk product (drug product), it would have a material adverse effect on
our ability to continue to commercialize Vascepa. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We initially purchased all of our supply of the bulk compound (ethyl-EPA), which
constitutes the only API of Vascepa, from a single supplier, Nisshin Pharma, Inc., or Nisshin, located in Japan. Nisshin was approved by the FDA as a Vascepa API supplier as part of our FDA marketing approval for the MARINE indication in July 2012.
In April 2013, we announced the approval by the FDA of an NDA supplement for Chemport, Inc. and BASF (formerly Equateq Limited) as additional Vascepa API suppliers. We terminated our agreement with BASF due to its inability to meet the agreement
requirements, may enter into a new development and supply agreement with BASF, and may purchase API from BASF, as it remains an NDA-approved supplier. In 2014, we obtained sNDA approval for a fourth supplier of API, which includes the manufacturing
facility of Finorga SAS (Novasep). We currently purchase and use commercial supply from Novasep, Chemport, and Nisshin. Each of the API manufacturers obtains supply of the key raw material to manufacture API from other third-party sources of supply.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">While we have contractual freedom to source the API for Vascepa and have entered into supply agreements with multiple suppliers who also
rely on other third-party suppliers of the key raw material to manufacture the API for Vascepa, Novasep, Nisshin and Chemport currently supply all of our API for Vascepa. Our strategy in adding API suppliers beyond Nisshin has been to expand
manufacturing capacity and to partially mitigate the risk of reliance on any single supplier. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Expanding manufacturing capacity and
qualifying such capacity is difficult and subject to numerous regulations and other operational challenges. The resources of our suppliers vary and are limited; costs associated with projected expansion and qualification can be significant. For
example, Chemport, which was approved as one of our API suppliers in April 2013, is a privately-held company and their commitment to Vascepa supply has required them to seek additional resources. There can be no assurance that the expansion plans of
any of our suppliers will be successful. Our aggregate capacity to produce API is dependent upon the qualification of our API suppliers. Each of our API suppliers has outlined plans for potential further capacity expansion. If no additional API
supplier is approved by the FDA as part of an sNDA, our API supply will be limited to the API we purchase from previously approved suppliers. If our third-party manufacturing capacity is not expanded and compliant with applicable regulatory
requirements, we may not be able to supply sufficient quantities of Vascepa to meet anticipated demand. We cannot assure you that we can contract with any future manufacturer on acceptable terms or that any such alternative supplier will not require
capital investment from us in order for them to meet our requirements. Alternatively, our purchase of supply may exceed actual demand for Vascepa. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We currently have encapsulation agreements with three commercial API encapsulators for the encapsulation of Vascepa: Patheon, Inc. (formerly
Banner Pharmacaps), Catalent Pharma Solutions, and Capsugel Pl&ouml;ermel SAS. These companies have qualified their manufacturing processes and are capable of manufacturing Vascepa. There can be no guarantee that additional other suppliers with
which we have contracted to encapsulate API will be qualified to manufacture the product to our specifications or that these and any future suppliers will have the manufacturing capacity to meeting anticipated demand for Vascepa. We cannot assure
you that we can contract with any future manufacturer on acceptable terms or that any such alternative supplier will not require capital investment from us in order for them to meet our requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to maintain our exclusivity with our certain third-party Vascepa suppliers if we do not meet minimum purchase
obligations due to lower than anticipated sales of Vascepa. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Certain of our agreements with our suppliers include minimum purchase
obligations and limited exclusivity provisions based on such minimum purchase obligations. If we do not meet the respective minimum purchase obligations in our supply agreements, our suppliers, in certain cases, will be free to sell the active
pharmaceutical ingredient of Vascepa to potential competitors. Similarly if we terminate certain of our supply agreements, such suppliers may be free to sell the active pharmaceutical ingredient of Vascepa to potential competitors of Vascepa. While
we anticipate that intellectual property barriers and FDA regulatory exclusivity will be the primary means to protect the commercial potential of Vascepa, the availability of Vascepa active pharmaceutical ingredient from our suppliers to our
potential competitors would make our competitors&#146; entry into the market easier and more attractive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have limited experience with the commercial sale of Vascepa, and such inexperience may
cause us to purchase too much or not enough supply to satisfy actual demand, which could have a material adverse effect on our financial results and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Certain of our agreements with our suppliers include minimum purchase obligations and limited exclusivity provisions. These purchases are
generally made on the basis of rolling twelve-month forecasts which in part are binding on us and the balance of which are subject to adjustment by us subject to certain limitations. Certain of our agreements also include contractual minimum
purchase commitments regardless of the rolling twelve-month forecasts. We have limited experience with the commercial sale of Vascepa, and as such expectations regarding expected demand may be wrong. We may not purchase sufficient quantities of
Vascepa to meet actual demand or our purchase of supply may exceed actual demand. In either case, such event could have a material adverse effect on our financial results and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The manufacture, packaging and distribution of pharmaceutical products such as Vascepa are subject to FDA requirements and those of
similar foreign regulatory bodies. If we or our third-party manufacturers fail to satisfy these requirements, our product development and commercialization efforts may be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The manufacture, packaging and distribution of pharmaceutical products, such as Vascepa, are regulated by the FDA and similar foreign
regulatory bodies and must be conducted in accordance with the FDA&#146;s pharmaceutical current good manufacturing practices, or cGMPs, and comparable requirements of foreign regulatory bodies. There are a limited number of manufacturers that
operate under these cGMPs regulations who are both capable of manufacturing Vascepa and willing to do so. Failure by us or our third-party manufacturers to comply with applicable regulations, requirements, or guidelines could result in sanctions
being imposed on us, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our products, delays, suspension or withdrawal of approvals, license revocation, seizures or voluntary recalls of
product, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect our business. If we are not able to manufacture Vascepa to required specifications through our current and potential API suppliers, we
may be delayed in successfully supplying the product to meet anticipated demand and our anticipated future revenues and financial results may be materially adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Changes in the manufacturing process or procedure, including a change in the location where the product is manufactured or a change of a
third-party manufacturer, may require prior FDA review and approval of the manufacturing process and procedures in accordance with the FDA&#146;s cGMPs. Any new facility may be subject to a pre-approval inspection by the FDA and would again require
us to demonstrate product comparability to the FDA. There are comparable foreign requirements. This review may be costly and time consuming and could delay or prevent the launch of a product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Furthermore, the FDA and foreign regulatory agencies require that we be able to consistently produce the API and the finished product in
commercial quantities and of specified quality on a repeated basis, including proven product stability, and document our ability to do so. This requirement is referred to as process validation. This includes stability testing, measurement of
impurities and testing of other product specifications by validated test methods. If the FDA does not consider the result of the process validation or required testing to be satisfactory, the commercial supply of Vascepa may be delayed, or we may
not be able to supply sufficient quantities of Vascepa to meet anticipated demand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA and similar foreign regulatory bodies may also
implement new requirements, or change their interpretation and enforcement of existing requirements, for manufacture, packaging or testing of products at any time. If we are unable to comply, we may be subject to regulatory, civil actions or
penalties which could significantly and adversely affect our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to conduct our clinical trials, and
those third parties may not perform satisfactorily, including failing to meet established deadlines for the completion of such clinical trials. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our reliance on third parties for clinical development activities reduces our control over these activities. However, if we sponsor clinical
trials, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trials. Moreover, the FDA requires us to comply with requirements, commonly referred to
as good clinical practices, for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are
protected. Our reliance on third parties does not relieve us of these responsibilities and requirements. Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties
do not successfully carry out their contractual duties or meet expected deadlines, we may be delayed in obtaining regulatory approvals for our product candidates and may be delayed in our efforts to successfully commercialize our product candidates
for targeted diseases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are dependent upon our collaboration with Eddingpharm and others to commercialize
Vascepa in certain regions outside of the United States, and if such third parties fail to successfully fulfill their obligations, or are ineffective in their commercialization of Vascepa, or if our collaborations are terminated, our plans to
commercialize Vascepa outside of the United States may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In February 2015, we entered into the DCS Agreement
with Eddingpharm, under which we granted exclusive rights to Eddingpharm to develop and commercialize Vascepa in the China Territory. We are dependent on Eddingpharm for certain regulatory filings outside of the United States with respect to
Vascepa, which may require conducting clinical trials in the China Territory to secure regulatory approval, as well as the commercialization of Vascepa outside of the United States. If Eddingpharm fails to perform its obligations under the DCS
Agreement or is ineffective in its commercialization of Vascepa in the China Territory or if we fail to effectively manage our relationship with Eddingpharm, our ability to and the extent to which we commercialize and obtain certain regulatory
approvals of Vascepa outside of the United States would be significantly harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, Eddingpharm has the right to terminate the
agreement under certain conditions. If Eddingpharm terminates the DCS Agreement, we would be required to either enter into alternative arrangements with third parties to commercialize Vascepa in the China Territory, which we may be unable to do, or
to increase our internal infrastructure, both of which would likely result in significant additional expense and delay or termination of our Vascepa clinical development programs outside of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also have an agreement to register and commercialize Vascepa in countries within the Middle East and North Africa. Development in this
region, as in China, is subject to similar third party risk. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are dependent on patents, proprietary rights and confidentiality to protect the commercial potential of Vascepa. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our success depends in part on our ability to obtain and maintain intellectual property protection for our drug candidates, technology and
know-how, and to operate without infringing the proprietary rights of others. Our ability to successfully implement our business plan and to protect our products with our intellectual property will depend in large part on our ability to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain, defend and maintain patent protection and market exclusivity for our current and future products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preserve any trade secrets relating to our current and future products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acquire patented or patentable products and technologies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">operate without infringing the proprietary rights of third parties. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have prosecuted, and
are currently prosecuting, multiple patent applications to protect the intellectual property developed during the Vascepa development program. As of the date of this report, we had 47&nbsp;patent applications in the United States that have been
either issued or allowed and more than 30 additional patent applications are pending in the United States. Such 47 allowed and issued applications include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2 issued U.S. patents directed to a pharmaceutical composition of Vascepa in a capsule that have terms that expire in 2020 and 2030, respectively, </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1 issued U.S. patent covering a composition containing highly pure EPA that expires in 2021, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">36 U.S. patents covering the use of Vascepa in either the MARINE or anticipated ANCHOR indication that have terms that expire in 2030, </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">3 additional patents related to the use of a pharmaceutical composition comprised of free fatty acids to treat the ANCHOR patient population with a term that expires in 2030, </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2 additional patents related to the use of a pharmaceutical composition comprised of free fatty acids to treat the MARINE patient population with a term that expires in 2030, </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1 additional patent related to a pharmaceutical composition comprised of free fatty acids and uses thereof to treat both the MARINE and ANCHOR patient populations with a term that expires in 2030, </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1 additional patent related to a formulation of EPA/DHA and uses thereof with a term that expires in 2030, and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1 additional patent related to the use of Vascepa to treat obesity with a term that expires in 2030. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A Notice of Allowance is issued after the USPTO makes a determination that a patent can be
granted from an application. A Notice of Allowance does not afford patent protection until the underlying patent is issued by the USPTO. No assurance can be given that applications with issued notices of allowance will be issued as patents or that
any of our pending patent applications will issue as patents. No assurance can be given that, if and when issued, our patents will prevent competitors from competing with Vascepa. For example, we may choose to not assert all issued patents in patent
litigation and patents or claims within patents may be determined to be invalid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are also pursuing patent applications related to
Vascepa in multiple jurisdictions outside the United States. We may be dependent in some cases upon third-party licensors to pursue filing, prosecution and maintenance of patent rights or applications owned or controlled by those parties. It is
possible that third parties will obtain patents or other proprietary rights that might be necessary or useful to us. In cases where third parties are first to invent a particular product or technology, or first to file after various provisions of
the America Invents Act of 2011 went into effect on March&nbsp;16, 2013, it is possible that those parties will obtain patents that will be sufficiently broad so as to prevent us from utilizing such technology or commercializing our current and
future products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although we intend to make reasonable efforts to protect our current and future intellectual property rights and to
ensure that any proprietary technology we acquire or develop does not infringe the rights of other parties, we may not be able to ascertain the existence of all potentially conflicting claims. Therefore, there is a risk that third parties may make
claims of infringement against our current or future products or technologies. In addition, third parties may be able to obtain patents that prevent the sale of our current or future products or require us to obtain a license and pay significant
fees or royalties in order to continue selling such products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may in the future discover the existence of products that infringe
patents that we own or that have been licensed to us. If we were to initiate legal proceedings against a third party to stop such an infringement, such proceedings could be costly and time consuming, regardless of the outcome. No assurances can be
given that we would prevail, and it is possible that, during such a proceeding, our patent rights could be held to be invalid, unenforceable or both. Although we intend to protect our trade secrets and proprietary know-how through confidentiality
agreements with our manufacturers, employees and consultants, we may not be able to prevent parties subject to such confidentiality agreements from breaching these agreements or third parties from independently developing or learning of our trade
secrets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We anticipate that competitors may from time to time oppose our efforts to obtain patent protection for new technologies or to
submit patented technologies for regulatory approvals. Competitors may seek to oppose our patent applications to delay the approval process or to challenge our granted patents, for example, by requesting a reexamination of our patent at the USPTO,
or by filing an opposition in a foreign patent office, even if the opposition or challenge has little or no merit. For example, one of our patents was revoked in an opposition proceeding in Europe due to a determination of improper claim amendments
under a provision of law not applicable in the United States. Such proceedings are generally highly technical, expensive, and time consuming, and there can be no assurance that such a challenge would not result in the narrowing or complete
revocation of any patent of ours that was so challenged. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our issued patents may not prevent competitors from competing with
Vascepa, even if we seek to enforce our patent rights. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We plan to vigorously defend our rights under issued patents. For example,
in March 2014, we filed a patent infringement suit against Omthera Pharmaceuticals, Inc., and its parent company, AstraZeneca Pharmaceuticals LP. The suit sought injunctive relief and monetary damages for infringement of our U.S. Patent
No.&nbsp;8,663,662. The complaint alleged infringement of the patent arising from the expected launch of Epanova, a product that is expected to compete with Vascepa in the United States. The patent covers methods of lowering triglycerides by
administering a pharmaceutical composition that includes amounts of EPA as free acid, and no more than about 30% DHA. In November 2014, based on a representation from AstraZeneca Pharmaceuticals LP that the commercial launch of Epanova was not
imminent, the court dismissed our complaint, without prejudice (i.e., preserving our ability to later re-file the suit). The court required the defendant to notify us before any product launch. We intend to pursue this litigation vigorously and
aggressively protect its intellectual property rights. However, patent litigation is a time-consuming and costly process. There can be no assurance that we will be successful in enforcing this patent or that it will not be successfully challenged
and invalidated. Even if we are successful in enforcing this patent, the process could take years to reach conclusion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Other drug
companies may challenge the validity, enforceability, or both of our patents and seek to design its products around our issued patent claims and gain marketing approval for generic versions of Vascepa or branded competitive products based on new
clinical studies. The pharmaceutical industry is highly competitive and many of our competitors have greater experience and resources than we have. Any such competition could undermine sales, marketing and collaboration efforts for Vascepa, and thus
reduce, perhaps materially, the revenue potential for Vascepa. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if we are successful in enforcing our issued patents, we may incur substantial costs and
divert management&#146;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. Patent litigation is costly and time consuming, and we may not have sufficient resources to bring these actions to a
successful conclusion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>There can be no assurance that any of our pending patent applications relating to Vascepa or its use will
issue as patents. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have filed and are prosecuting numerous families of patent applications in the United States and
internationally with claims designed to protect the proprietary position of Vascepa. For certain of these patent families, we have filed multiple patent applications. Collectively the patent applications include numerous independent claims and
dependent claims. Several of our patent applications contain claims that are based upon what we believe are unexpected and favorable findings from the MARINE and ANCHOR trials. If granted, many of the resulting granted patents would expire in 2030
or beyond. However, no assurance can be given that these additional MARINE and ANCHOR patents or any of our pending patent applications intended to cover an indication based on future results from the REDUCE-IT clinical trial will be granted or, if
they grant, that they will prevent competitors from competing with Vascepa. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Securing patent protection for a product is a complex process
involving many legal and factual questions. The patent applications we have filed in the United States and internationally are at varying stages of examination, the timing of which is outside our control. The process to getting a patent granted can
be lengthy and claims initially submitted are often modified in order to satisfy the requirements of the patent office. This process includes written and public communication with the patent office. The process can also include direct discussions
with the patent examiner. There can be no assurance that the patent office will accept our arguments with respect to any patent application or with respect to any claim therein. The timing of the patent review process is independent of and has no
effect on the timing of the FDA&#146;s review of our NDA or sNDA submissions. We cannot predict the timing or results of any patent application. In addition, we may elect to submit, or the patent office may require, additional evidence to support
certain of the claims we are pursuing. Furthermore, third parties may attempt to submit publications for consideration by the patent office during examination of our patent applications. Providing such additional evidence and publications could
prolong the patent office&#146;s review of our applications and result in us incurring additional costs. We cannot be certain what commercial value any granted patent in our patent estate will provide to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Despite the use of confidentiality agreements and/or proprietary rights agreements, which themselves may be of limited effectiveness, it
may be difficult for us to protect our trade secrets. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to our patent portfolio and strategy, we will also rely upon
trade secrets and know-how to help protect our competitive position. We rely on trade secrets to protect technology in cases when we believe patent protection is not appropriate or obtainable. However, trade secrets are difficult to protect. While
we require certain of our academic collaborators, contractors and consultants to enter into confidentiality agreements, we may not be able to adequately protect our trade secrets or other proprietary information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>*If
the estimates we make, or the assumptions on which we rely, in preparing our projected guidance prove inaccurate, our actual results may vary from those reflected in our projections and accruals. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January 2016, we issued financial and business guidance, including expected fiscal year 2016 total net revenue, which is based on estimates
and the judgment of management. In August 2016, we updated this guidance based on new information. Because of the inherent nature of estimates, there could be significant differences between our estimates and the actual amount of product demand. If,
for any reason, we are unable to realize our currently projected 2016 revenue, we may not realize our publicly announced financial guidance. If we fail to realize or if we change or update any element of our publicly disclosed financial guidance or
other expectations about our business, our stock price could decline in value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We and certain of our current and former executive
officers were named as defendants in a class action lawsuit that could result in substantial costs and divert management&#146;s attention. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The market price of our American Depositary Shares, or ADSs, declined significantly after the October 2013 decision by the FDA Advisory
Committee to recommend against approval of Vascepa in the ANCHOR indication. We and certain of our current and former executive officers and directors were named as defendants in a class action lawsuit that generally alleged that we and certain of
our current and former officers and directors violated Sections 10(b) and/or 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by making allegedly false and/or misleading statements or material omissions concerning
the ANCHOR sNDA and related FDA regulatory approval process in an effort to lead investors to believe that Vascepa would receive approval from the FDA in the ANCHOR indication. The complaints sought unspecified damages, interest, attorneys&#146;
fees, and other costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We engaged in a vigorous defense of this lawsuit. On June&nbsp;29, 2015, the court granted our
first motion to dismiss the class action litigation without prejudice. The court held that the plaintiffs failed to state a claim upon which relief could be granted and plaintiffs were given 30 days to refile an amended complaint. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;29, 2015, the plaintiffs filed an amended complaint and we again moved to dismiss. On April&nbsp;26, 2016, the court granted a
second motion to dismiss, again without prejudice, with leave for plaintiffs to file an amended complaint. On May&nbsp;24, 2016, plaintiffs notified the court they would not file another amended complaint and on May&nbsp;26, 2016, filed a notice of
appeal of the most recent dismissal to the Third Circuit Court of Appeals. We plan a vigorous defense to this appeal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are unable to
predict the ultimate outcome of this matter at this time. While we expect insurance to cover any financial exposure from this litigation, the conclusion of this matter in a manner adverse to us could have a material adverse effect on our financial
condition and business. For example, we could incur substantial costs not covered by our directors&#146; and officers&#146; liability insurance, suffer a significant adverse impact on our reputation and divert management&#146;s attention and
resources from other priorities, including the execution of business plans and strategies that are important to our ability to grow our business, any of which could have a material adverse effect on our business. In addition, any of these matters
could require payments that are not covered by, or exceed the limits of, our available directors&#146; and officers&#146; liability insurance, which could have a material adverse effect on our operating results or financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Potential technological changes in our field of business create considerable uncertainty. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are engaged in the biopharmaceutical field, which is characterized by extensive research efforts and rapid technological progress. New
developments in research are expected to continue at a rapid pace in both industry and academia. We cannot assure you that research and discoveries by others will not render some or all of our programs or product candidates uncompetitive or
obsolete. Our business strategy is based in part upon new and unproven technologies to the development of therapeutics to improve cardiovascular health. We cannot assure you that unforeseen problems will not develop with these technologies or
applications or that any commercially feasible products will ultimately be developed by us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to potential product
liability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Following the commercial launch of Vascepa, we will be subject to the potential risk of product liability claims
relating to the manufacturing and marketing of Vascepa. Any person who is injured as a result of using Vascepa may have a product liability claim against us without having to prove that we were at fault. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, we could be subject to product liability claims by persons who took part in clinical trials involving our current or former
development stage products. A successful claim brought against us could have a material adverse effect on our business. We cannot guarantee that a product liability claim will not be asserted against us in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may become subject to liability in connection with the wind-down of our EN101 program. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In 2007, we purchased Ester Neurosciences Limited, an Israeli pharmaceutical company, and its lead product candidate, EN101, an AChE-R mRNA
inhibitor for the treatment of myasthenia gravis, or MG, a debilitating neuromuscular disease. In connection with the acquisition, we assumed a license to certain intellectual property assets related to EN101 from the Yissum Research Development
Company of The Hebrew University of Jerusalem. In keeping with our 2009 decision to re-focus our efforts on developing improved treatments for cardiovascular disease and cease development of all product candidates outside of our cardiovascular
disease focus, we amended the terms of our acquisition agreement with the original shareholders of Ester. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Following our decision to cease
development of EN101, Yissum terminated its license agreement with us. In June 2011, Yissum announced that it had entered into a license agreement with BiolineRX Ltd for the development of EN101 in a different indication, inflammatory bowel disease.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In 2011 and early 2012, but not after, we received several communications on behalf of the former shareholders of Ester asserting that we
are in breach of our agreement with them as it relates to alleged rights to share in the value of EN101 due to the fact that Yissum terminated its license. We do not believe the circumstances presented constitute a breach of the agreement. If the
dispute arises again, we plan to defend our position vigorously, but there can be no assurance as to the outcome of this dispute. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>*A change in our tax residence could have a negative effect on our future profitability.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under current UK legislation, a company incorporated in England and Wales, or which is centrally managed and controlled in the UK,
is regarded as resident in the UK for taxation purposes. Under current Irish legislation, a company is regarded as resident for tax purposes in Ireland if it is centrally managed and controlled in Ireland, or, in certain circumstances, if it is
incorporated in Ireland. Where a company is treated as tax resident under the domestic laws of both the UK and Ireland then the provisions of article 4(3) of the Double Tax Convention between the UK and Ireland provides that such enterprise shall be
treated as resident only in the jurisdiction in which its place of effective management is situated. We have sought to conduct our affairs in such a way so as to be resident only in Ireland for tax purposes by virtue of having our place of effective
management situated in Ireland. Trading income of an Irish company is generally taxable at the Irish corporation tax rate of 12.5%. Non-trading income of an Irish company (e.g., interest income, rental income or other passive income) is taxable at a
rate of 25%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">However, we cannot assure you that we are or will continue to be resident only in Ireland for tax purposes. It is possible
that in the future, whether as a result of a change in law or the practice of any relevant tax authority or as a result of any change in the conduct of our affairs, we could become, or be regarded as having become resident in a jurisdiction other
than Ireland. Our and our subsidiaries&#146; income tax returns are periodically examined by various tax authorities. We are currently under audit by the United States Internal Revenue Service (IRS) for the years 2012 to 2013. Although the outcome
of tax audits is always uncertain and could result in significant cash tax payments, we do not believe the outcome of these audits will have a material adverse effect on our consolidated financial position or results of operations. The ultimate
resolution may result in a payment that is materially different from our current estimate of the tax liabilities. Should we cease to be an Irish tax resident, we may be subject to a charge to Irish capital gains tax on our assets. Similarly, if the
tax residency of any of our subsidiaries were to change from their current jurisdiction for any of the reasons listed above, we may be subject to a charge to local capital gains tax charge on the assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The loss of key personnel could have an adverse effect on our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are highly dependent upon the efforts of our senior management. The loss of the services of one or more members of senior management could
have a material adverse effect on us. As a small company with a streamlined management structure, the departure of any key person could have a significant impact and would be potentially disruptive to our business until such time as a suitable
replacement is hired. Furthermore, because of the specialized nature of our business, as our business plan progresses we will be highly dependent upon our ability to attract and retain qualified scientific, technical and key management personnel. As
we evolve from a development stage company to a commercial stage company we may experience turnover among members of our senior management team. We may have difficulty identifying and integrating new executives to replace any such losses. There is
intense competition for qualified personnel in the areas of our activities. In this environment, we may not be able to attract and retain the personnel necessary for the development of our business, particularly if we do not achieve profitability.
The failure to recruit key scientific, technical and management personnel would be detrimental to our ability to implement our business plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We could be adversely affected by our exposure to customer concentration risk. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A significant portion of our sales are to wholesalers in the pharmaceutical industry. Our top three customers accounted for 95% of gross
product sales for each of the six months ended June&nbsp;30, 2016 and 2015 and represented 94% and 96% of the gross accounts receivable balance as of June&nbsp;30, 2016 and 2015, respectively. There can be no guarantee that we will be able to
sustain our accounts receivable or gross sales levels from our key customers. If, for any reason, we were to lose, or experience a decrease in the amount of business with our largest customers, whether directly or through our distributor
relationships, our financial condition and results of operations could be negatively affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Financial Position and Capital
Requirements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I></I></B>*<B><I>We have a history of operating losses and anticipate that we will incur continued losses for an
indefinite period of time. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have not yet reached profitability. For the fiscal years ended December&nbsp;31, 2015, 2014, and
2013, we reported losses of approximately $149.1 million, $56.4 million, and $166.2 million, respectively, and we had an accumulated deficit as of December&nbsp;31, 2015 of $1.1 billion. For the six months ended June&nbsp;30, 2016 and 2015, we
reported losses of approximately $43.1 million and $94.8 million, respectively and we had an accumulated deficit as of June&nbsp;30, 2016 of $1.2 billion. Substantially all of our operating losses resulted from costs incurred in connection with our
research and development programs, from general and administrative costs associated with our operations, costs related to the commercialization of Vascepa, and from non-cash losses on changes in the fair value of warrant derivative liabilities.
Additionally, as a result of our significant expenses relating to research and development and to commercialization, we expect to continue to incur significant operating losses for an indefinite period. Because of the numerous risks and
uncertainties associated with developing and commercializing pharmaceutical products, we are unable to predict the magnitude of these future losses. Our historic losses, combined with expected future losses, have had and will continue to have an
adverse effect on our cash resources, shareholders&#146; deficit and working capital. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Although we began generating revenue from Vascepa in January 2013, we may never be
profitable. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our ability to become profitable depends upon our ability to generate revenue. In January 2013, we began to generate
revenue from the marketing of Vascepa for use in the MARINE indication, but we may not be able to generate sufficient revenue to attain profitability. Our ability to generate profits on sales of Vascepa is subject to the market acceptance and
commercial success of Vascepa and our ability to manufacture commercial quantities of Vascepa through third parties at acceptable cost levels, and may also depend upon our ability to enter into one or more strategic collaborations to effectively
market and sell Vascepa. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even though Vascepa has been approved by the FDA for marketing in the United States in the MARINE indication, it
may not gain market acceptance or achieve commercial success and it may never be approved for the ANCHOR indication or any other indication. In addition, we anticipate continuing to incur significant costs associated with commercializing Vascepa. We
may not achieve profitability soon after generating product sales, if ever. If we are unable to generate sufficient product revenues, we will not become profitable and may be unable to continue operations without continued funding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our historical financial results do not form an accurate basis for assessing our current business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a consequence of the many years developing Vascepa for commercialization and the commercial launch of Vascepa in 2013 in the United States,
our historical financial results do not form an accurate basis upon which investors should base their assessment of our business and prospects. In addition, we expect that our costs will increase substantially as we continue to commercialize Vascepa
in the MARINE indication and with ANCHOR data and seek to obtain additional regulatory approval of Vascepa from continuation of the REDUCE-IT cardiovascular outcomes study. Accordingly, our historical financial results reflect a substantially
different business from that currently being conducted and from that expected in the future. In addition, we have a limited history of obtaining regulatory approval for, and no demonstrated ability to successfully commercialize, a product candidate.
Consequently, any predictions about our future performance may not be as accurate as they could be if we had a history of successfully developing and commercializing pharmaceutical products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>*Our operating results are unpredictable and may fluctuate. If our operating results are below the expectations of securities analysts
or investors, the trading price of our stock could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our operating results are difficult to predict and will likely
fluctuate from quarter to quarter and year to year, and Vascepa prescription figures will likely fluctuate from month to month. Vascepa sales are difficult to predict from period to period and as a result, you should not rely on Vascepa sales
results in any period as being indicative of future performance, and sales of Vascepa may be below the expectation of securities analysts or investors in the future. We believe that our quarterly and annual results of operations may be affected by a
variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the level of demand for Vascepa, including due to changes in prescriber sentiment or period-to-period Distributor purchasing habits; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which coverage and reimbursement for Vascepa is available from government and health administration authorities, private health insurers, managed care programs and other third-party payers;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing, cost and level of investment in our sales and marketing efforts to support Vascepa sales and the resulting effectiveness of those efforts with our new co-promotion partner, Kowa Pharmaceuticals America,
Inc.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and ability of Eddingpharm to development and commercialize Vascepa in the China Territory and other territories outside the United States, including obtaining necessary regulatory approvals and establishing
marketing channels; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additional developments regarding our intellectual property portfolio and regulatory exclusivity protections, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and nature of results of the REDUCE-IT study or post-approval studies for Vascepa; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">outcomes of litigation and other legal proceedings, including our pending FDA determination on regulatory exclusivity, shareholder litigation, regulatory matters and tax matters; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our regulatory dialogue on the REDUCE-IT study. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I></I></B>*<B><I>We will likely require
substantial additional resources to fund our operations. If we cannot find additional capital resources, we will have difficulty in operating as a going concern and growing our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We currently operate with limited resources. We believe that our cash and cash equivalents balance of $72.5 million as of June&nbsp;30, 2016
will be sufficient to fund our projected operations for at least the next twelve months. Depending on the level of cash generated from operations, additional capital will likely be required to sustain operations. We anticipate that quarterly net
cash outflows in future periods will be variable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In order to fully realize the market potential of Vascepa, we may need to enter into a new
strategic collaboration or raise additional capital. We may also need additional capital to fully complete our REDUCE-IT cardiovascular outcomes trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our future capital requirements will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing, amount and consistency of revenue generated from the commercial sale of Vascepa; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs associated with commercializing Vascepa in the United States and for additional indications in the United States and in jurisdictions in which we receive regulatory approval, if any, including the cost of
sales and marketing capabilities with our new co-promotion partner, Kowa Pharmaceuticals America, Inc., and the cost and timing of securing commercial supply of Vascepa and the timing of entering into any new strategic collaboration with others
relating to the commercialization of Vascepa, if at all, and the terms of any such collaboration; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the continued cost associated with our REDUCE-IT cardiovascular outcomes study; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continued costs associated with litigation and other legal proceedings; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the time and costs involved in obtaining additional regulatory approvals for Vascepa; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which we continue to develop internally, acquire or in-license new products, technologies or businesses; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we require additional funds and adequate funds are not available to us in amounts or on terms acceptable to us or on a timely basis, or at
all, our commercialization efforts for Vascepa may suffer materially, and we may need to delay the advancement of the REDUCE-IT cardiovascular outcomes trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Continued negative economic conditions would likely have a negative effect on our ability to obtain financing on acceptable terms.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">While we may seek additional funding through public or private financings, we may not be able to obtain financing on acceptable
terms, or at all. There can be no assurance that we will be able to access equity or credit markets in order to finance our current operations or expand development programs for Vascepa, or that there will not be a further deterioration in financial
markets and confidence in economies. We may also have to scale back or further restructure our operations. If we are unable to obtain additional funding on a timely basis, we may be required to curtail or terminate some or all of our research or
development programs or our commercialization strategies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our existing
shareholders, restrict our operations or require us to relinquish rights. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To the extent we are permitted under our Purchase and
Sale Agreement with BioPharma Secured Debt Fund II Holdings Cayman LP, or BioPharma, we may seek additional capital through a combination of private and public equity offerings, debt financings and collaboration, strategic and licensing
arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your
rights as a shareholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January 2012, we issued $150 million in aggregate principal amount of 3.5% exchangeable senior notes due
2032, or the 2012 Notes, $16.2 million of which was subsequently repaid. In May 2014, we entered into separate, privately negotiated exchange agreements with certain holders of the 2012 Notes pursuant to which Corsicanto exchanged $118.7 million in
aggregate principal amount of the existing 2012 Notes for $118.7 million in aggregate principal amount of new 3.5%&nbsp;May 2014 Exchangeable Senior Notes due 2032, or the 2014 Notes. In the event of physical settlement, the remaining 2012 Notes and
2014 Notes would be exchangeable into a total of 1,714,270 ADSs and 45,666,925 ADSs, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In November 2015, we issued $31.3
million in aggregate principal amount of 3.5% exchangeable senior notes due 2032, or the 2015 Notes. In the event of physical settlement, the 2015 Notes would be exchangeable into a total of 12,025,385 ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions such
as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaboration, strategic alliance and licensing arrangements with third parties, we may have to relinquish valuable rights to our
technologies, Vascepa or product candidates beyond the rights we have already relinquished, or grant licenses on terms that are not favorable to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Potential business combinations or other strategic transactions may disrupt our business or
divert management&#146;s attention. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On a regular basis, we explore potential business combination transactions, including an
acquisition of us by a third party, exclusive licenses of Vascepa or other strategic transactions or collaborations with third parties. For example, in March 2014, we entered into a co-promotion agreement with Kowa Pharmaceuticals America, Inc.
related to the commercialization of Vascepa in the United States. The consummation and performance of any such future transactions or collaborations will involve risks, such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">diversion of managerial resources from day-to-day operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exposure to litigation from the counterparties to any such transaction, other third parties or our shareholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">misjudgment with respect to the value; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">higher than expected transaction costs; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an inability to successfully consummate any such transaction or collaboration. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a result of
these risks, we may not be able to achieve the expected benefits of any such transaction or collaboration or deliver the value thereof to our shareholders. If we are unsuccessful in consummating any such transaction or collaboration, we may be
required to reevaluate our business only after we have incurred substantial expenses and devoted significant management time and resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks
Related to Ownership of our ADSs and Common Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The price of our ADSs and common shares may be volatile. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The stock market has from time to time experienced significant price and volume fluctuations that may be unrelated to the operating performance
of particular companies. In addition, the market prices of the securities of many pharmaceutical and medical technology companies have been especially volatile in the past, and this trend is expected to continue in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of August&nbsp;1, 2016 we had 185,285,763 common shares outstanding including 183,448,877 shares held as ADSs and 1,836,886 held as common
shares (which are not held in the form of ADSs). There is a risk that there may not be sufficient liquidity in the market to accommodate significant increases in selling activity or the sale of a large block of our securities. Our ADSs have
historically had limited trading volume, which may also result in volatility. If any of our large investors, such as the participants in our March 2015 private placement, seek to sell substantial amounts of our ADSs, particularly if these sales are
in a rapid or disorderly manner, or other investors perceive that these sales could occur, the market price of our ADSs could decrease significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The market price of our ADSs and common shares may also be affected by factors such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments or disputes concerning ongoing patent prosecution efforts and any future patent or proprietary rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">litigation and regulatory developments in the United States affecting our Vascepa promotional rights, and regulatory developments in the European Union or other countries; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or potential medical results relating to our products or our competitors&#146; products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">interim failures or setbacks in product development; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">innovation by us or our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">currency exchange rate fluctuations; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">period-to-period variations in our results of operations. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The number of our ordinary
shares, or ADSs representing such ordinary shares, outstanding may increase substantially as a result of our March 2015 private placement and the later consolidation and redesignation of the Series A Preference Shares represented by Preference ADSs
issued thereunder, and some of the investors may then beneficially own significant blocks of our ordinary shares; the ordinary shares and Series A Preference Shares resulting from the private placement will be generally available for resale in the
public market upon registration under the Securities Act. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In March and July 2015, we completed a private placement of American Depositary Shares in two
tranches representing 352,150,790 and 38,867,180 Series A Preference Shares, respectively, each ten (10)&nbsp;of which may be consolidated and redesignated into one (1)&nbsp;ordinary share in our capital. During the three months ended June&nbsp;30,
2015, 62,833,330 preferred shares were converted, resulting in the issuance of 6,283,333 ordinary shares. The consolidation and redesignation of the Series A Preference Shares currently outstanding would result in an additional 32,818,464 ordinary
shares outstanding, resulting in substantial dilution to shareholders who held our ordinary shares or ADSs representing such ordinary shares prior to the private placement. Although the Series A Preference Shares do not have voting rights, in
general, upon consolidation and redesignation into ordinary shares some of the investors in the private placement could then have significant influence over the outcome of any shareholder vote, including the election of directors and the approval of
mergers or other business combination transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the securities subscription agreements that we entered into with the
investors in the private placement, we agreed to file with the SEC a registration statement to register the resale of the Series A Preference Shares represented by American Depositary Shares issued in the private placement and the ordinary shares
issuable upon the consolidation and consolidation and redesignation of such Series A Preference Shares. Upon such registration and subsequent consolidation and redesignation, these securities will become generally available for immediate resale in
the public market. The market price of our ordinary shares could fall as a result of an increase in the number of shares available for sale in the public market. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Failure to comply with our obligations under the March 2015 securities subscription agreements could result in our becoming liable for
damages to certain investors under these agreements, including specified liquidated damages, which could be material in amount. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the terms of the March 2015 securities subscription agreements, we are subject to various obligations, failure to comply with which could
result in our becoming liable to certain investors under these agreement for damages, which could be material in amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For example,
under each of these agreements we have agreed to file and maintain the effectiveness of certain resale registration statements for ADSs representing the ordinary shares underlying the Series A Preference shares we issued and sold under these
agreements. Specifically, we have agreed to pay liquidated damages to the investors in the respective private placements if (a)&nbsp;the applicable resale registration statements we are required to file are not declared effective within 120 days
after the closing of the applicable private placement, or (b)&nbsp;after effectiveness and subject to certain specified exceptions, we suspend the use of the applicable registration statement or the registration statement ceases to remain
continuously effective as to all the securities for which it is required to be effective. We refer to each of these events as a registration default. Subject to the specified exceptions, for each 30-day period or portion thereof during which a
registration default remains uncured, we are obligated to pay liquidated damages to each investor in cash in an amount equal to 1% of the aggregate subscription price paid by each such investor in the private placement, up to a maximum of 8% of such
aggregate subscription price. These amounts could be material, and any liquidated damages we are required to pay could have a material adverse effect on our financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, under the securities subscription agreement dated as of March&nbsp;5, 2015, we are required to offer to certain investors party
to that agreement an opportunity to participate in future equity and debt financings we may conduct from time to time, and to not publicly disclose the identity of the investors party to that agreement, subject to certain exceptions for disclosures
required in securities filings and under applicable law. If we fail to comply with these obligations we could become liable to these investors for damages, including specified liquidated damages. For example, following certain public statements made
by us on a quarterly conference call concerning the 2015 private placement, we agreed to specified liquidated damages in the event we are found to have violated the confidentiality provisions of the subscription agreement in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>A share price of less than $1.00 may impact our NASDAQ listing. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If our closing bid price is less than $1.00 for 30 consecutive trading days, we would receive a NASDAQ staff deficiency letter indicating that
we are not in compliance with the minimum bid price requirement for continued listing. Such a letter would trigger an automatic 180 calendar day period within which the company could regain compliance. Compliance is regained at any time during this
period if the Amarin closing bid price is $1.00 per share or more for a minimum of 10 consecutive trading days. If we do not regain compliance during this period, our ADSs could be delisted from The NASDAQ Global Market, transferred to a listing on
The NASDAQ Capital Market, or delisted from the NASDAQ markets altogether. The failure to maintain our listing on The NASDAQ Global Market could harm the liquidity of our ADSs and could have an adverse effect on the market price of our ADSs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Actual or potential sales of our common shares by our employees, including members of our
senior management team, pursuant to pre-arranged stock trading plans could cause our stock price to fall or prevent it from increasing for numerous reasons, and actual or potential sales by such persons could be viewed negatively by other investors.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In accordance with the guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934 and our policies regarding
stock transactions, a number of our directors and employees, including members of our senior management team, have adopted and may continue to adopt pre-arranged stock trading plans to sell a portion of our common stock. Generally, sales under such
plans by members of our senior management team and directors require public filings. Actual or potential sales of our ADSs by such persons could cause the price of our ADSs to fall or prevent it from increasing for numerous reasons. For example, a
substantial amount of our ADSs becoming available (or being perceived to become available) for sale in the public market could cause the market price of our ADSs to fall or prevent it from increasing. Also, actual or potential sales by such persons
could be viewed negatively by other investors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may be a passive foreign investment company, or PFIC, which would result in
adverse U.S. federal tax consequences to U.S. investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc and certain of our subsidiaries may be classified
as &#147;passive foreign investment companies,&#148; or PFICs, for U.S. federal income tax purposes. The tests for determining PFIC status for a taxable year depend upon the relative values of certain categories of assets and the relative amounts of
certain kinds of income. The application of these factors depends upon our financial results, which are beyond our ability to predict or control, and which may be subject to legal and factual uncertainties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe it is prudent to assume that we were classified as a PFIC in 2012. We do not believe that we were classified as a PFIC in 2013,
2014 or 2015. Our status as a PFIC is subject to change in 2016 and future years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we are a PFIC, U.S. holders of notes, ordinary
shares or ADSs would be subject to adverse U.S. federal income tax consequences, such as ineligibility for any preferred tax rates on capital gains or on actual or deemed dividends, interest charges on certain taxes treated as deferred, and
additional reporting requirements under U.S. federal income tax laws and regulations. Whether or not U.S. holders of our ADSs make a timely &#147;QEF election&#148; or &#147;mark-to-market election&#148; may affect the U.S. federal income tax
consequences to U.S. holders with respect to the acquisition, ownership and disposition of Amarin ADSs and any distributions such U.S. holders may receive. A QEF election and other elections that may mitigate the effect of our being classified as a
PFIC are unavailable with respect to the notes. Investors should consult their own tax advisors regarding all aspects of the application of the PFIC rules to the notes, ordinary shares and ADSs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Failure to meet our obligations under our Purchase and Sale Agreement with BioPharma could adversely affect our financial results and
liquidity. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to our December 2012 Purchase and Sale Agreement with BioPharma, we are obligated to make payments to
BioPharma based on the amount of our net product sales of Vascepa and any future products based on ethyl-EPA, or covered products, subject to certain quarterly caps. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to this agreement, we may not, among other things: (i)&nbsp;incur indebtedness greater than a specified amount, which we refer to as
the Indebtedness Covenant; (ii)&nbsp;pay a dividend or other cash distribution, unless we have cash and cash equivalents in excess of a specified amount after such payment; (iii)&nbsp;amend or restate our memorandum and articles of association
unless such amendments or restatements do not affect BioPharma&#146;s interests under the transaction; (iv)&nbsp;encumber any of the collateral securing our performance under the agreement; and (v)&nbsp;abandon certain patent rights, in each case
without the consent of BioPharma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon a transaction resulting in a change of control of Amarin, as defined in the agreement, BioPharma
will be automatically entitled to receive any amounts not previously paid, up to our maximum repayment obligation. As defined in the agreement, &#147;change of control&#148; includes, among other things, (i)&nbsp;a greater than 50 percent change in
the ownership of Amarin, (ii)&nbsp;a sale or disposition of any collateral securing our debt with BioPharma and (iii), unless BioPharma has been paid a certain amount under the indebtedness, certain licensings of Vascepa to a third party for sale in
the United States. The acceleration of the payment obligation in the event of a change of control transaction may make us less attractive to potential acquirers, and the payment of such funds out of our available cash or acquisition proceeds would
reduce acquisition proceeds for our shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To secure our obligations under the agreement, we granted BioPharma a security interest
in our rights in patents, trademarks, trade names, domain names, copyrights, know-how and regulatory approvals related to the covered products, all books and records relating to the foregoing and all proceeds of the foregoing, which we refer to as
the collateral. If we (i)&nbsp;fail to deliver a payment when due and do not remedy that failure within specific notice period, (ii)&nbsp;fail to maintain a first-priority perfected security interest in the collateral in the United States and do not
remedy that failure after receiving notice of such failure or (iii)&nbsp;become subject to an event of bankruptcy, then BioPharma may attempt to collect the maximum amount payable by us under this agreement (after deducting any payments we have
already made). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There can be no assurance that we will not breach the covenants or other terms of, or that an
event of default will not occur under, this agreement and, if a breach or event of default occurs, there can be no assurance that we will be able to cure the breach within the time permitted. Any failure to pay our obligations when due, any breach
or default of our covenants or other obligations, or any other event that causes an acceleration of payment at a time when we do not have sufficient resources to meet these obligations, could have a material adverse effect on our business, results
of operations, financial condition and future viability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our existing indebtedness could adversely affect our financial condition.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our existing indebtedness consists of $165.1 million in aggregate principal amount of 3.5% exchangeable senior notes due 2032,
$15.1 million of which relates to the 2012 Notes with a provision for such notes to be put to us by the holders on each of January&nbsp;19, 2017,&nbsp;January&nbsp;19, 2022 and January&nbsp;19, 2027, and $118.7 million of which relates to the 2014
Notes and $31.3 million of which relates to the 2015 Notes, both with a provision for such notes to be put to us by the holders on each of January&nbsp;19, 2019,&nbsp;January&nbsp;19, 2024 and January&nbsp;19, 2029. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our indebtedness and the related annual debt service requirements may adversely impact our business, operations and financial condition in the
future. For example, they could: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increase our vulnerability to general adverse economic and industry conditions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limit our ability to raise additional funds by borrowing or engaging in equity sales in order to fund future working capital, capital expenditures, research and development and other general corporate requirements;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require us to dedicate a substantial portion of our cash to service payments on our debt; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limit our flexibility to react to changes in our business and the industry in which we operate or to pursue certain strategic opportunities that may present themselves. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The accounting for convertible debt securities that may be settled in cash, such as our notes, could have a material effect on our
reported financial results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the FASB Accounting Standards Codification, or ASC, we are required to separately account for
the liability and equity components of the convertible debt instruments that may be settled entirely or partially in cash upon conversion in a manner that reflects the issuer&#146;s economic interest cost. The effect of ASC on the accounting for our
outstanding convertible notes may be that the equity component is required to be included in the additional paid-in capital section of stockholders&#146; equity on our condensed consolidated balance sheets and the value of the equity component would
be treated as original issue discount for purposes of accounting for the debt component of the notes. As a result, we are required to record non-cash interest expense as a result of the amortization of the discounted carrying value of the notes to
their face amount over the term of the notes. We may be required to report higher interest expense in our financial results because ASC may require interest to include both the current period&#146;s amortization of the debt discount and the
instrument&#146;s coupon interest, which could adversely affect our reported or future financial results and the trading price of our ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Servicing our debt may require a significant amount of cash, and we may not have sufficient cash flow from our business to provide the funds
sufficient to pay our substantial debt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our ability to make scheduled payments of the principal, to pay interest on or to refinance our
indebtedness, including the notes, depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not continue to generate cash flow from operations in the future
sufficient to service our debt and make necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity
capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in
these activities on desirable terms, which could result in a default on our debt obligations, including the notes, and have a material adverse effect on the trading price of our ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may be able to incur substantial additional debt in the future, subject to the restrictions contained in our future debt instruments, if
any, which would intensify the risks discussed above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The conditional exchange feature of the notes, if triggered, may adversely
affect our financial condition and operating results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event the conditional exchange feature of the notes is triggered,
holders of notes will be entitled to exchange the notes at any time during specified periods at their option. If one or more holders elect to exchange their notes, unless we elect to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
satisfy its exchange obligation by delivering solely the ADSs (other than cash in lieu of any fractional ADS), we would be required to settle a portion or all of its exchange obligation through
the payment of cash, which could adversely affect our liquidity. In addition, even if holders do not elect to exchange their notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of
the notes as a current rather than long-term liability, which would result in a material reduction of our net working capital. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The
change in control repurchase feature of the notes may delay or prevent an otherwise beneficial takeover attempt of us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
indenture governing the notes will require us to repurchase the notes for cash upon the occurrence of a change in control of Amarin and, in certain circumstances, to increase the exchange rate for a holder that exchanges its notes in connection with
a make-whole fundamental change. A takeover of us may trigger the requirement that we purchase the notes and/or increase the exchange rate, which could make it more costly for a potential acquirer to engage in a combinatory transaction with us. Such
additional costs may have the effect of delaying or preventing a takeover of us that would otherwise be beneficial to investors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We
do not intend to pay cash dividends on the ordinary shares in the foreseeable future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have never paid dividends on ordinary
shares and do not anticipate paying any cash dividends on the ordinary shares in the foreseeable future. Under English law, any payment of dividends would be subject to relevant legislation and our Articles of Association, which requires that all
dividends must be approved by our Board of Directors and, in some cases, our shareholders, and may only be paid from our distributable profits available for the purpose, determined on an unconsolidated basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are incorporated under English law. The rights of holders of ordinary shares and, therefore, certain of the rights of holders of ADSs, are
governed by English law, including the provisions of the Companies Act 2006, and by our Articles of Association. These rights differ in certain respects from the rights of shareholders in typical U.S. corporations. The principal differences include
the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Under English law and our Articles of Association, each shareholder present at a meeting has only one vote unless demand is made for a vote on a poll, in which case each holder gets one vote per share owned. Under U.S.
law, each shareholder typically is entitled to one vote per share at all meetings. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Under English law, it is only on a poll that the number of shares determines the number of votes a holder may cast. You should be aware, however, that the voting rights of ADSs are also governed by the provisions of a
deposit agreement with our depositary bank. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Under English law, subject to certain exceptions and disapplications, each shareholder generally has preemptive rights to subscribe on a proportionate basis to any issuance of ordinary shares or rights to subscribe for,
or to convert securities into, ordinary shares for cash. Under U.S. law, shareholders generally do not have preemptive rights unless specifically granted in the certificate of incorporation or otherwise. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Under English law and our Articles of Association, certain matters require the approval of 75% of the shareholders who vote (in person or by proxy) on the relevant resolution (or on a poll shareholders representing 75%
of the ordinary shares voting (in person or by proxy)), including amendments to the Articles of Association. This may make it more difficult for us to complete corporate transactions deemed advisable by our board of directors. Under U.S. law,
generally only majority shareholder approval is required to amend the certificate of incorporation or to approve other significant transactions. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In the United Kingdom, takeovers may be structured as takeover offers or as schemes of arrangement. Under English law, a bidder seeking to acquire us by means of a takeover offer would need to make an offer for all of
our outstanding ordinary shares/ADSs. If acceptances are not received for 90% or more of the ordinary shares/ADSs under the offer, under English law, the bidder cannot complete a &#147;squeeze out&#148; to obtain 100% control of us. Accordingly,
acceptances of 90% of our outstanding ordinary shares/ADSs will likely be a condition in any takeover offer to acquire us, not 50% as is more common in tender offers for corporations organized under Delaware law. By contrast, a scheme of
arrangement, the successful completion of which would result in a bidder obtaining 100% control of us, requires the approval of a majority of shareholders voting at the meeting and representing 75% of the ordinary shares voting for approval.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Under English law and our Articles of Association, shareholders and other persons whom we know or have reasonable cause to believe are, or have been, interested in our shares may be required to disclose information
regarding their interests in our shares upon our request, and the failure to provide the required information could result in the loss or restriction of rights attaching to the shares, including prohibitions on certain transfers of the shares,
withholding of dividends and loss of voting rights. Comparable provisions generally do not exist under U.S. law. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The quorum requirement for a shareholders&#146; meeting is a minimum of two shareholders entitled to vote at the meeting and present in person or by proxy or, in the case of a shareholder which is a corporation,
represented by a duly authorized officer. Under U.S. law, a majority of the shares eligible to vote must generally be present (in person or by proxy) at a shareholders&#146; meeting in order to constitute a quorum. The minimum number of shares
required for a quorum can be reduced pursuant to a provision in a company&#146;s certificate of incorporation or bylaws, but typically not below one-third of the shares entitled to vote at the meeting. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>U.S. shareholders may not be able to enforce civil liabilities against us. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are incorporated under the laws of England and Wales, and our subsidiaries are incorporated in various jurisdictions, including foreign
jurisdictions. A number of the officers and directors of each of our subsidiaries are non-residents of the United States, and all or a substantial portion of the assets of such persons are located outside the United States. As a result, it may not
be possible for investors to affect service of process within the United States upon such persons or to enforce against them judgments obtained in U.S. courts predicated upon the civil liability provisions of the federal securities laws of the
United States. We have been advised by our English solicitors that there is doubt as to the enforceability in England in original actions, or in actions for enforcement of judgments of U.S. courts, of civil liabilities to the extent predicated upon
the federal securities laws of the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>U.S. holders of the ADSs or ordinary shares may be subject to U.S. federal income
taxation at ordinary income tax rates on undistributed earnings and profits. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There is a risk that we will be classified as a
controlled foreign corporation, or CFC, for U.S. federal income tax purposes. If we are classified as a CFC, any ADS holder or shareholder that is a U.S. person that owns directly, indirectly or by attribution, 10% or more of the voting power of our
outstanding shares may be subject to U.S. income taxation at ordinary income tax rates on all or a portion of our undistributed earnings and profits attributable to &#147;subpart F income.&#148; Such 10% holder may also be taxable at ordinary income
tax rates on any gain realized on a sale of ordinary shares or ADS, to the extent of our current and accumulated earnings and profits attributable to such shares. The CFC rules are complex and U.S. holders of the ordinary shares or ADSs are urged to
consult their own tax advisors regarding the possible application of the CFC rules to them in their particular circumstances. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Unregistered Sales of Equity Securities and Use of Proceeds </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Issuer Purchases of Equity Securities
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Shares purchased in the second quarter of 2016 are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:21.75pt; font-size:8pt; font-family:Times New Roman"><B></B><I>Period</I><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Number&nbsp;of<BR>Shares&nbsp;Purchased&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average&nbsp;Price<BR>Paid&nbsp;per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;1 &#150; 30, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May&nbsp;1 &#150; 31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;1 &#150; 30, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents shares withheld to satisfy tax withholding amounts due from employees related to the receipt of stock which resulted from the exercise or vesting of equity awards. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx220080_14"></A>Item&nbsp;6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Exhibits </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following exhibits are incorporated by reference or filed as part of this
report. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Letter Agreement with Mr. Michael Kalb, dated May 9, 2016 (incorporated herein by reference to Exhibit 10.1 to the Company&#146;s Current Report on Form 8-K filed June 30, 2016, File No. 000-21392)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of President and Chief Executive Officer (Principal Executive Officer) pursuant to Section 302 of Sarbanes-Oxley Act of 2002</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;31.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Senior Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) pursuant to Section 302 of Sarbanes-Oxley Act of 2002</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;32.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of President and Chief Executive Officer (Principal Executive Officer) and Senior Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) pursuant to Section 906 of
Sarbanes-Oxley Act of 2002</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;101.INS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Instance Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;101.SCH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;101.CAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Calculation Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;101.DEF</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Definition Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;101.LAB</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Label Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;101.PRE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Presentation Linkbase Document</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx220080_15"></A>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">A<SMALL>MARIN</SMALL> C<SMALL>ORPORATION</SMALL> P<SMALL>LC</SMALL></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/&nbsp;John F. Thero</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">John F. Thero</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Principal Executive Officer)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(On behalf of the
Registrant)</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: August&nbsp;4, 2016 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>d220080dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, John F. Thero, certify
that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this quarterly report on Form 10-Q of Amarin Corporation plc; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: August&nbsp;4, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">/s/&nbsp;&nbsp;&nbsp;&nbsp;John F. Thero&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">John F. Thero</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">President and Chief Executive Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Principal Executive Officer)</P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>d220080dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Michael W. Kalb,
certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this quarterly report on Form 10-Q of Amarin Corporation plc; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: August&nbsp;4, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">/s/&nbsp;&nbsp;&nbsp;&nbsp;Michael W. Kalb&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Michael W. Kalb</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Senior Vice President and Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(Principal Financial Officer and Principal Accounting Officer)</P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>d220080dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENT PURSUANT TO 18 U.S.C. &#167; 1350 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirement set forth in Rule&nbsp;13a-14(b) of the Securities Exchange Act of 1934, as amended, and Section&nbsp;1350 of Chapter&nbsp;63 of
Title 18 of the United States Code (18 U.S.C. &#167;1350), John F. Thero, President and Chief Executive Officer (Principal Executive Officer) of Amarin Corporation plc (the &#147;Company&#148;) and Michael W. Kalb, Senior Vice President and Chief
Financial Officer (Principal Financial Officer and Principal Accounting Officer) of the Company, each hereby certifies that, to the best of his knowledge: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s Quarterly Report on Form 10-Q for the period ended June&nbsp;30, 2016, to which this Certification is attached as Exhibit&nbsp;32.1 (the &#147;Quarterly Report&#148;) fully complies with the
requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John F. Thero</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: August 4, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">John F. Thero</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Executive Officer)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael W. Kalb</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: August 4, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Michael W. Kalb</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Vice President and Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Financial Officer and Principal Accounting Officer)</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange
Commission and is not incorporated by reference into any filing of Amarin Corporation plc under the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation
language contained in such filing. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>amrn-20160630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="yes" ?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version:  6.23.6 -->
<!-- Round: 3 -->
<!-- Creation date: 2016-08-03T22:03:39Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:amrn="http://www.amarincorp.com/20160630" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <xbrll:schemaRef xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="amrn-20160630.xsd" xlink:type="simple" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE46938---1610-Q0007_STD_0_20120131_0_1324529x1461424_1328615x1333865" decimals="INF" id="id_6038951_32D75A08-FD12-43FC-9ABE-3343C6704FC9_1002_1" unitRef="pure">0.035</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE46938---1610-Q0007_STD_0_20120131_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6038951_32D75A08-FD12-43FC-9ABE-3343C6704FC9_1002_0" unitRef="iso4217_USD">150000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent contextRef="eol_PE46938---1610-Q0007_STD_0_20120131_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6038951_186768D4-6CA6-4B9D-8BB4-551C02D62BBD_3001_0" unitRef="iso4217_USD">23800000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE46938---1610-Q0007_STD_0_20120131_0_1324529x1461424_1328615x1333865_1330096x1403450" decimals="4" id="id_6038951_AA371BFA-143A-4DAA-A51B-AE6F15E09FD4_4001_2" unitRef="iso4217_USD_per_shares">8.8125</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentFairValue contextRef="eol_PE46938---1610-Q0007_STD_0_20120131_0_1324529x1461424_1328615x1333865_1334996x1364094" decimals="-5" id="id_6038951_186768D4-6CA6-4B9D-8BB4-551C02D62BBD_4001_1" unitRef="iso4217_USD">126200000</us-gaap:DebtInstrumentFairValue>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE46938---1610-Q0007_STD_0_20151130_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6038951_0B66086E-A0DF-4566-8C35-FD6CF3551219_2001_2" unitRef="iso4217_USD">15100000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="eol_PE46938---1610-Q0007_STD_0_20151130_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6038951_0B66086E-A0DF-4566-8C35-FD6CF3551219_2001_0" unitRef="iso4217_USD">16200000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE46938---1610-Q0007_STD_0_20151130_0_1324529x1486557_1328615x1333865" decimals="INF" id="id_6038951_60A62C0D-177A-4669-86C4-DEF1FAF41842_6001_1" unitRef="pure">0.035</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="eol_PE46938---1610-Q0007_STD_0_20151130_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6038951_E743A84A-72A8-4DA5-B7B1-38F582C13171_2001_0" unitRef="iso4217_USD">500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE46938---1610-Q0007_STD_0_20151130_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6038951_60A62C0D-177A-4669-86C4-DEF1FAF41842_6001_0" unitRef="iso4217_USD">31300000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFairValue contextRef="eol_PE46938---1610-Q0007_STD_0_20151130_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6038951_3AE016AE-CDC4-4D7B-BF47-80CEFB700EAB_3001_0" unitRef="iso4217_USD">27500000</us-gaap:DebtInstrumentFairValue>
  <us-gaap:DeferredFinanceCostsGross contextRef="eol_PE46938---1610-Q0007_STD_0_20151130_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6038951_3AE016AE-CDC4-4D7B-BF47-80CEFB700EAB_3001_2" unitRef="iso4217_USD">100000</us-gaap:DeferredFinanceCostsGross>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE46938---1610-Q0007_STD_0_20151130_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6038951_300A9C20-9892-4ECF-BBCD-B6D516CF328F_2002_1" unitRef="iso4217_USD">3800000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE46938---1610-Q0007_STD_0_20151130_0_1324529x1486557_1328615x1333865_1330096x1403450" decimals="2" id="id_6038951_60A62C0D-177A-4669-86C4-DEF1FAF41842_7001_7" unitRef="iso4217_USD_per_shares">2.60</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE46938---1610-Q0007_STD_0_20150305_0" decimals="INF" id="id_6038951_34A17C75-E862-47A6-82B8-4BBCB04A527A_6001_0" unitRef="iso4217_GBP_per_shares">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE46938---1610-Q0007_STD_0_20150305_0" decimals="INF" id="id_6038951_34A17C75-E862-47A6-82B8-4BBCB04A527A_4001_3" unitRef="shares">0.1</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:SharePrice contextRef="eol_PE46938---1610-Q0007_STD_0_20150305_0" decimals="INF" id="id_6038951_AB0E477A-2F26-41DF-AF0A-88ED22510010_3_1" unitRef="iso4217_USD_per_shares">2.39</us-gaap:SharePrice>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE46938---1610-Q0007_STD_0_20150305_0_1330096x1335797" decimals="INF" id="id_6038951_360D217B-DE1A-4498-913E-ABE634540342_3001_2" unitRef="iso4217_GBP_per_shares">0.05</us-gaap:PreferredStockParOrStatedValuePerShare>
  <amrn:ConversionPricePerShare contextRef="eol_PE46938---1610-Q0007_STD_0_20150305_0_1330097x1393080" decimals="INF" id="id_6038951_44DABF76-3C5D-49AB-B8C7-A78855E86E67_1001_0" unitRef="iso4217_USD_per_shares">0.15</amrn:ConversionPricePerShare>
  <amrn:ConversionPricePerShare contextRef="eol_PE46938---1610-Q0007_STD_0_20150305_0_1330097x1400959" decimals="INF" id="id_6038951_44DABF76-3C5D-49AB-B8C7-A78855E86E67_2001_1" unitRef="iso4217_USD_per_shares">1.50</amrn:ConversionPricePerShare>
  <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="eol_PE46938---1610-Q0007_STD_0_20150305_0_1330125x1482162_1330926x1353534" decimals="-5" id="id_6038951_62CE8781-0CA8-4BF2-BBA3-8742054E9C6E_2001_0" unitRef="iso4217_USD">900000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="eol_PE46938---1610-Q0007_STD_0_20150305_0_1330926x1353534" decimals="-5" id="id_6038951_C9498043-B187-4FF7-8789-AB540A0D6DC2_1001_0" unitRef="iso4217_USD">900000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE46938---1610-Q0007_STD_0_20140531_0_1324529x1375482_1328615x1333865" decimals="INF" id="id_6038951_10BF13B3-4BC9-49C5-B079-5403CE1F4BC4_2001_1" unitRef="pure">0.035</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="eol_PE46938---1610-Q0007_STD_0_20140531_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6038951_D7D9551B-0EB9-45F8-A623-ED5904725C48_2003_0" unitRef="iso4217_USD">3500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE46938---1610-Q0007_STD_0_20140531_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6038951_10BF13B3-4BC9-49C5-B079-5403CE1F4BC4_2001_0" unitRef="iso4217_USD">118700000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFairValue contextRef="eol_PE46938---1610-Q0007_STD_0_20140531_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6038951_1F250133-B467-41B8-BB19-11E3049DC435_4001_1" unitRef="iso4217_USD">90800000</us-gaap:DebtInstrumentFairValue>
  <us-gaap:DeferredFinanceCostsGross contextRef="eol_PE46938---1610-Q0007_STD_0_20140531_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6038951_1F250133-B467-41B8-BB19-11E3049DC435_4001_3" unitRef="iso4217_USD">2500000</us-gaap:DeferredFinanceCostsGross>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE46938---1610-Q0007_STD_0_20140531_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6038951_300A9C20-9892-4ECF-BBCD-B6D516CF328F_1001_0" unitRef="iso4217_USD">27900000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE46938---1610-Q0007_STD_0_20140531_0_1324529x1375482_1328615x1333865_1330096x1403450" decimals="2" id="id_6038951_DCD753F6-986B-4B11-945C-7651F17A6D7C_4001_2" unitRef="iso4217_USD_per_shares">2.60</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE46938---1610-Q0007_STD_0_20140531_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6038951_10BF13B3-4BC9-49C5-B079-5403CE1F4BC4_3001_4" unitRef="iso4217_USD">31300000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE46938---1610-Q0007_STD_0_20140531_0_1324529x1461424_1328615x1333865_1330788x1464257" decimals="-5" id="id_6038951_10BF13B3-4BC9-49C5-B079-5403CE1F4BC4_4001_3" unitRef="iso4217_USD">118700000</us-gaap:DebtInstrumentFaceAmount>
  <amrn:ConversionPricePerShare contextRef="eol_PE46938---1610-Q0007_STD_0_20150710_0_1330096x1335797_1330097x1393080_1330125x1482162" decimals="INF" id="id_6038951_425BFE2D-ED7F-4922-86F6-56B6A3E6C4F7_2001_3" unitRef="iso4217_USD_per_shares">0.15</amrn:ConversionPricePerShare>
  <amrn:ConversionPricePerShare contextRef="eol_PE46938---1610-Q0007_STD_0_20150710_0_1330096x1335797_1330097x1400959_1330125x1482162" decimals="INF" id="id_6038951_425BFE2D-ED7F-4922-86F6-56B6A3E6C4F7_3001_4" unitRef="iso4217_USD_per_shares">1.50</amrn:ConversionPricePerShare>
  <amrn:PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding contextRef="eol_PE46938---1610-Q0007_STD_0_20150710_0_1330096x1335797_1330125x1482162" decimals="INF" id="id_6038951_425BFE2D-ED7F-4922-86F6-56B6A3E6C4F7_4001_2" unitRef="shares">3886718</amrn:PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE46938---1610-Q0007_STD_0_20160801_0_1330096x1403450" decimals="INF" id="id_6038951_7122CAB9-2953-466D-BF94-16FD51A80C1D_1002_500006" unitRef="shares">183448877</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE46938---1610-Q0007_STD_0_20160801_0_1330096x1433040" decimals="INF" id="id_6038951_7122CAB9-2953-466D-BF94-16FD51A80C1D_2002_500005" unitRef="shares">1836886</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE46938---1610-Q0007_STD_0_20091016_0_1324828x1419380_1328615x1330534_1330125x1468605_1333769x1451741" decimals="INF" id="id_6038951_5F697CDA-5B79-4A3F-A6BF-149F44AB0CE2_1002_14" unitRef="iso4217_USD_per_shares">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="eol_PE46938---1610-Q0007_STD_0_20091016_0_1324828x1419380_1328615x1330534_1330125x1468605_1333769x1451741" decimals="INF" id="id_6038951_5F697CDA-5B79-4A3F-A6BF-149F44AB0CE2_1002_13" unitRef="shares">0.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE46938---1610-Q0007_STD_0_20091016_0_1324828x1419380_1330125x1468605_1333769x1451741" decimals="INF" id="id_6038951_5F697CDA-5B79-4A3F-A6BF-149F44AB0CE2_2002_8" unitRef="iso4217_USD_per_shares">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="eol_PE46938---1610-Q0007_STD_0_20091016_0_1324828x1419380_1330125x1468605_1333769x1451741" decimals="INF" id="id_6038951_5F697CDA-5B79-4A3F-A6BF-149F44AB0CE2_2002_7" unitRef="shares">0.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <amrn:ClassOfWarrantOrRightIssued contextRef="eol_PE46938---1610-Q0007_STD_0_20091016_0_1326002x1332009_1330125x1468605" decimals="-5" id="id_6038951_E5C838E3-B79F-4EA5-9874-E54D2758BA20_2002_1" unitRef="shares">900000</amrn:ClassOfWarrantOrRightIssued>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE46938---1610-Q0007_STD_0_20091016_0_1328615x1330534_1330125x1468605" decimals="INF" id="id_6038951_5F697CDA-5B79-4A3F-A6BF-149F44AB0CE2_3002_11" unitRef="iso4217_USD_per_shares">0.90</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <amrn:ClassOfWarrantOrRightIssued contextRef="eol_PE46938---1610-Q0007_STD_0_20091016_0_1330125x1468605_1333769x1451741" decimals="-5" id="id_6038951_5F697CDA-5B79-4A3F-A6BF-149F44AB0CE2_8001_15" unitRef="shares">35200000</amrn:ClassOfWarrantOrRightIssued>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE46938---1610-Q0007_STD_0_20091016_0_1330125x1468605_1333769x1451741_1335482x1328677" decimals="-5" id="id_6038951_ED8C5196-ABFF-446C-9DDF-7E61ABCE9D14_1001_0" unitRef="shares">36100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1610-Q0007_STD_0_20150630_0" decimals="-3" id="id_6038951_E2DC3566-84DC-4350-9A4A-417787BC4F4E_3004_9" unitRef="iso4217_USD">6700000</us-gaap:DerivativeLiabilities>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-Q0007_STD_0_20150630_0" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_3005_12" unitRef="iso4217_USD">10323000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1610-Q0007_STD_0_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2002_33" unitRef="iso4217_USD">136050000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <amrn:PrivatePlacementIssuanceNumberOfTranches contextRef="eol_PE46938---1610-Q0007_STD_0_20150630_0" decimals="INF" id="id_6038951_DA90842A-06BE-4E3F-8529-C2D1B2AAE243_1_0" unitRef="Tranche">2</amrn:PrivatePlacementIssuanceNumberOfTranches>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-Q0007_STD_0_20150630_0_1327091x1327216" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_3003_12" unitRef="iso4217_USD">743000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-Q0007_STD_0_20150630_0_1327091x1327217" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_3001_12" unitRef="iso4217_USD">2289000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-Q0007_STD_0_20150630_0_1327091x1368196" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_3004_12" unitRef="iso4217_USD">1542000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-Q0007_STD_0_20150630_0_1327091x1397499" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_3002_12" unitRef="iso4217_USD">5749000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1610-Q0007_STD_0_20150630_0_1330926x1327893" decimals="-3" id="id_6038951_E2DC3566-84DC-4350-9A4A-417787BC4F4E_3002_9" unitRef="iso4217_USD">6700000</us-gaap:DerivativeLiabilities>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="INF" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_32" unitRef="shares">328184640</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:TreasuryStockShares contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="INF" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_40" unitRef="shares">723347</us-gaap:TreasuryStockShares>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="INF" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_37" unitRef="shares">184551164</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="INF" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1001_35" unitRef="iso4217_GBP_per_shares">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="INF" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_36" unitRef="shares">185274511</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="INF" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_31" unitRef="shares">328184640</us-gaap:PreferredStockSharesIssued>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="INF" id="id_6038951_66C93328-A825-4A07-992F-662C31506AE2_1001_1" unitRef="shares">10361147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="INF" id="id_6038951_66C93328-A825-4A07-992F-662C31506AE2_1001_0" unitRef="shares">20641123</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="INF" id="id_6038951_F026F2D1-A4BA-4CFE-A5C1-B7589FA810EB_1001_3" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="INF" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1001_30" unitRef="iso4217_GBP_per_shares">0.05</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:SeniorLongTermNotes contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_21" unitRef="iso4217_USD">125644000</us-gaap:SeniorLongTermNotes>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_41" unitRef="iso4217_USD">-1160779000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:PreferredStockValue contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_29" unitRef="iso4217_USD">24364000</us-gaap:PreferredStockValue>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_25" unitRef="iso4217_USD">268000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:LongTermDebtFairValue contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_6309153B-3F2F-4734-9186-828746BFA8F1_1_0" unitRef="iso4217_USD">89000000</us-gaap:LongTermDebtFairValue>
  <us-gaap:Liabilities contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_26" unitRef="iso4217_USD">312052000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_43" unitRef="iso4217_USD">147636000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_23" unitRef="iso4217_USD">3610000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_18" unitRef="iso4217_USD">1172000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_15" unitRef="iso4217_USD">14811000</us-gaap:AccountsPayableCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_42" unitRef="iso4217_USD">-164416000</us-gaap:StockholdersEquity>
  <us-gaap:LongTermDebtNoncurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_22" unitRef="iso4217_USD">90150000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_E2DC3566-84DC-4350-9A4A-417787BC4F4E_8004_3" unitRef="iso4217_USD">3610000</us-gaap:DerivativeLiabilities>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_24" unitRef="iso4217_USD">14529000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenue contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-5" id="id_6038951_5FF1F212-590F-42E9-B013-7BF45648AB7E_1001_1" unitRef="iso4217_USD">15700000</us-gaap:DeferredRevenue>
  <us-gaap:CommonStockValue contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_34" unitRef="iso4217_USD">151183000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_38" unitRef="iso4217_USD">822013000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_7005_6" unitRef="iso4217_USD">25845000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_F1D20E60-A0BE-46D8-A2A7-6C12CAF5F7A6_1_1" unitRef="iso4217_USD">2529000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-5" id="id_6038951_186768D4-6CA6-4B9D-8BB4-551C02D62BBD_2_3" unitRef="iso4217_USD">11500000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_27" unitRef="iso4217_USD" xsi:nil="true"/>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_16" unitRef="iso4217_USD">31052000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:LongTermDebtCurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_17" unitRef="iso4217_USD">30816000</us-gaap:LongTermDebtCurrent>
  <us-gaap:LongTermDebt contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_25395BD3-4DD3-4257-868D-0EB155889C18_1_0" unitRef="iso4217_USD">92533000</us-gaap:LongTermDebt>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_19" unitRef="iso4217_USD">77851000</us-gaap:LiabilitiesCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_7" unitRef="iso4217_USD">116512000</us-gaap:AssetsCurrent>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_022501C1-028F-41A1-AABA-E9DAE1CE552B_1_1" unitRef="iso4217_USD">2748000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_8" unitRef="iso4217_USD">137000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_2" unitRef="iso4217_USD">72491000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_9" unitRef="iso4217_USD">21718000</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <us-gaap:InventoryNet contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_5" unitRef="iso4217_USD">20306000</us-gaap:InventoryNet>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_4" unitRef="iso4217_USD">17639000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_3" unitRef="iso4217_USD">600000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableGrossCurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_3DD9C881-BBB4-4329-93E4-E774C7393794_1_0" unitRef="iso4217_USD">21528000</us-gaap:AccountsReceivableGrossCurrent>
  <us-gaap:Assets contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_12" unitRef="iso4217_USD">147636000</us-gaap:Assets>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_11" unitRef="iso4217_USD">9095000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_F1D20E60-A0BE-46D8-A2A7-6C12CAF5F7A6_1_0" unitRef="iso4217_USD">11624000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_022501C1-028F-41A1-AABA-E9DAE1CE552B_1_0" unitRef="iso4217_USD">8596000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_022501C1-028F-41A1-AABA-E9DAE1CE552B_1_2" unitRef="iso4217_USD">8962000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_10" unitRef="iso4217_USD">174000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_6" unitRef="iso4217_USD">5476000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:TreasuryStockValue contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_39" unitRef="iso4217_USD">1197000</us-gaap:TreasuryStockValue>
  <amrn:WriteOffsOfAccountsReceivables contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="INF" id="id_6038951_DA538F2D-9B24-45F9-BA03-48BAF678A727_3001_2" unitRef="iso4217_USD">0</amrn:WriteOffsOfAccountsReceivables>
  <amrn:CashDiscountPercent contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="2" id="id_6038951_74F636D7-EA93-4F41-BB3E-B115FE6B03DA_1001_0" unitRef="pure">0.02</amrn:CashDiscountPercent>
  <amrn:PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0" decimals="INF" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1_33" unitRef="shares">32818464</amrn:PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324093x1528669" decimals="-5" id="id_6038951_3F6849BD-D7D4-4677-A197-16E5D7F62D46_1004_1" unitRef="iso4217_USD">1600000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <amrn:PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324199x1331109" decimals="2" id="id_6038951_66C93328-A825-4A07-992F-662C31506AE2_2001_2" unitRef="pure">0.08</amrn:PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis>
  <amrn:PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324199x1335583" decimals="2" id="id_6038951_66C93328-A825-4A07-992F-662C31506AE2_3001_3" unitRef="pure">0.04</amrn:PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6038951_6D4583B3-AC09-464C-9701-513739DFDEAF_4001_0" unitRef="iso4217_USD">600000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:DebtInstrumentFairValue contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324529x1375482_1328615x1333865" decimals="-3" id="id_6038951_6309153B-3F2F-4734-9186-828746BFA8F1_1001_2" unitRef="iso4217_USD">122959000</us-gaap:DebtInstrumentFairValue>
  <us-gaap:ConvertibleDebt contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6038951_E80A76F1-63CB-46EA-9296-5170BC68CB70_3001_0" unitRef="iso4217_USD">98000000</us-gaap:ConvertibleDebt>
  <us-gaap:SeniorNotes contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324529x1375482_1328615x1333865" decimals="-3" id="id_6038951_25395BD3-4DD3-4257-868D-0EB155889C18_1001_2" unitRef="iso4217_USD">97994000</us-gaap:SeniorNotes>
  <amrn:ExcessPrincipalValueOverFairValue contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6038951_DCD753F6-986B-4B11-945C-7651F17A6D7C_3002_5" unitRef="iso4217_USD">20100000</amrn:ExcessPrincipalValueOverFairValue>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324529x1375482_1328615x1333865_1333245x1345793" decimals="-5" id="id_6038951_2DB18CD9-77CA-4B94-9785-9A7F990D70CC_2001_2" unitRef="iso4217_USD">20700000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:LongTermDebtCurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324529x1461424" decimals="-5" id="id_6038951_02A4B0D1-6CEB-4EDE-A213-01F278ECAB3F_2002_3" unitRef="iso4217_USD">15100000</us-gaap:LongTermDebtCurrent>
  <us-gaap:DebtInstrumentFairValue contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324529x1461424_1328615x1333865" decimals="-3" id="id_6038951_6309153B-3F2F-4734-9186-828746BFA8F1_2001_1" unitRef="iso4217_USD">14686000</us-gaap:DebtInstrumentFairValue>
  <us-gaap:ConvertibleDebt contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6038951_3C66D491-3A39-4445-8C9A-AA1BE3334369_3001_9" unitRef="iso4217_USD">15100000</us-gaap:ConvertibleDebt>
  <us-gaap:SeniorNotes contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324529x1461424_1328615x1333865" decimals="-3" id="id_6038951_25395BD3-4DD3-4257-868D-0EB155889C18_2001_1" unitRef="iso4217_USD">15107000</us-gaap:SeniorNotes>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324529x1461424_1328615x1333865" decimals="INF" id="id_6038951_2DB18CD9-77CA-4B94-9785-9A7F990D70CC_1001_0" unitRef="iso4217_USD">0</us-gaap:DebtInstrumentUnamortizedDiscount>
  <amrn:ExcessPrincipalValueOverFairValue contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6038951_AA371BFA-143A-4DAA-A51B-AE6F15E09FD4_1002_5" unitRef="iso4217_USD">11400000</amrn:ExcessPrincipalValueOverFairValue>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6038951_6D4583B3-AC09-464C-9701-513739DFDEAF_5001_1" unitRef="iso4217_USD">200000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:DebtInstrumentFairValue contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324529x1486557_1328615x1333865" decimals="-3" id="id_6038951_6309153B-3F2F-4734-9186-828746BFA8F1_3001_3" unitRef="iso4217_USD">32378000</us-gaap:DebtInstrumentFairValue>
  <us-gaap:ConvertibleDebt contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6038951_FD305EA1-2595-400A-922D-829A38A62F3E_1001_0" unitRef="iso4217_USD">27600000</us-gaap:ConvertibleDebt>
  <us-gaap:SeniorNotes contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324529x1486557_1328615x1333865" decimals="-3" id="id_6038951_25395BD3-4DD3-4257-868D-0EB155889C18_3001_3" unitRef="iso4217_USD">27650000</us-gaap:SeniorNotes>
  <amrn:ExcessPrincipalValueOverFairValue contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6038951_60A62C0D-177A-4669-86C4-DEF1FAF41842_6002_10" unitRef="iso4217_USD">5300000</amrn:ExcessPrincipalValueOverFairValue>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324529x1486557_1328615x1333865_1333245x1345793" decimals="-5" id="id_6038951_2DB18CD9-77CA-4B94-9785-9A7F990D70CC_4001_3" unitRef="iso4217_USD">3600000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324896x1324925_1331211x1328015" decimals="-3" id="id_6038951_EDEE05DE-6488-4554-8333-83ED54B555C3_4_3" unitRef="iso4217_USD">3610000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324896x1327983_1331211x1328015" decimals="-3" id="id_6038951_EDEE05DE-6488-4554-8333-83ED54B555C3_2_1" unitRef="iso4217_USD">14210000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1327036x1498782_1328480x1458944" decimals="-5" id="id_6038951_ADE3F0B6-0B9C-46AD-97A4-609A5B4C871D_1001_0" unitRef="iso4217_USD">2700000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1327091x1327216" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_7003_6" unitRef="iso4217_USD">566000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1327091x1327217" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_7001_6" unitRef="iso4217_USD">3662000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1327091x1366356" decimals="-3" id="id_6038951_3DD9C881-BBB4-4329-93E4-E774C7393794_2001_2" unitRef="iso4217_USD">227000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1327091x1368196" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_7004_6" unitRef="iso4217_USD">2504000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1327091x1397499" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_7002_6" unitRef="iso4217_USD">19113000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1328615x1333865" decimals="-5" id="id_6038951_E36B50A5-038F-45C3-9A4D-31D5B08AD71A_2001_0" unitRef="iso4217_USD">2700000</us-gaap:InterestPayableCurrent>
  <amrn:PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1330096x1433040" decimals="INF" id="id_6038951_34A17C75-E862-47A6-82B8-4BBCB04A527A_5002_5" unitRef="shares">32818464</amrn:PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1330097x1325837" decimals="INF" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_5001_400008" unitRef="shares">328184640</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1330097x1325837" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_5001_700008" unitRef="iso4217_USD">24364000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1330097x1326044" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_5008_1100008" unitRef="iso4217_USD">-1160779000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1330097x1327190" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_5006_900008" unitRef="iso4217_USD">822013000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1330097x1330220" decimals="INF" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_5003_600008" unitRef="shares">-723347</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1330097x1330220" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_5003_1000008" unitRef="iso4217_USD">-1197000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1330097x1333806" decimals="INF" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_5002_500008" unitRef="shares">185274511</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1330097x1333806" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_5002_800008" unitRef="iso4217_USD">151183000</us-gaap:StockholdersEquity>
  <amrn:ConversionPricePerShare contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1330097x1400959" decimals="INF" id="id_6038951_AB0E477A-2F26-41DF-AF0A-88ED22510010_2001_0" unitRef="iso4217_USD_per_shares">1.50</amrn:ConversionPricePerShare>
  <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1330125x1482162_1330926x1353534" decimals="-5" id="id_6038951_62CE8781-0CA8-4BF2-BBA3-8742054E9C6E_2002_4" unitRef="iso4217_USD">1800000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1330926x1327893" decimals="-3" id="id_6038951_E2DC3566-84DC-4350-9A4A-417787BC4F4E_8002_3" unitRef="iso4217_USD">3610000</us-gaap:DerivativeLiabilities>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1330926x1327893_1333242x1356609" decimals="-5" id="id_6038951_DB4BC3CD-3A87-41FF-AE0F-2D181F3A62CA_4003_7" unitRef="iso4217_USD">2800000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1331211x1328015" decimals="-3" id="id_6038951_EDEE05DE-6488-4554-8333-83ED54B555C3_1_3" unitRef="iso4217_USD">3610000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1331211x1328015" decimals="-3" id="id_6038951_EDEE05DE-6488-4554-8333-83ED54B555C3_1_1" unitRef="iso4217_USD">14210000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:OtherCommitment contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1333242x1356609" decimals="-5" id="id_6038951_48EB9B53-53EA-46D5-8390-75FBDA9FAE94_1001_0" unitRef="iso4217_USD">132100000</us-gaap:OtherCommitment>
  <us-gaap:ConvertibleDebt contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1333242x1356609" decimals="-5" id="id_6038951_BBD88633-2BB4-4D8C-A7DD-A310C02B9223_3001_0" unitRef="iso4217_USD">92500000</us-gaap:ConvertibleDebt>
  <amrn:FutureMinimumGuaranteePayments contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1333242x1356609_1367440x1347115" decimals="-5" id="id_6038951_48EB9B53-53EA-46D5-8390-75FBDA9FAE94_3001_2" unitRef="iso4217_USD">3300000</amrn:FutureMinimumGuaranteePayments>
  <amrn:FutureMinimumGuaranteePayments contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1333242x1356609_1367440x1358031" decimals="-5" id="id_6038951_BD781FF4-D008-4B34-A216-D4EC0CE909A7_1001_0" unitRef="iso4217_USD">15000000</amrn:FutureMinimumGuaranteePayments>
  <amrn:FutureMinimumGuaranteePayments contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1333242x1356609_1367440x1517729" decimals="-5" id="id_6038951_BD781FF4-D008-4B34-A216-D4EC0CE909A7_2001_1" unitRef="iso4217_USD">13000000</amrn:FutureMinimumGuaranteePayments>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1333245x1506247_1335482x1328677" decimals="INF" id="id_6038951_29098356-38B2-465C-900D-ADE5ED1C2AAD_1002_3" unitRef="iso4217_GBP">10000000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1333245x1506247_1335482x1328677" decimals="-5" id="id_6038951_29098356-38B2-465C-900D-ADE5ED1C2AAD_1001_3" unitRef="iso4217_USD">13400000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1333245x1506247_1512983x1364380" decimals="INF" id="id_6038951_29098356-38B2-465C-900D-ADE5ED1C2AAD_2002_2" unitRef="iso4217_GBP">5000000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1333245x1506247_1512983x1364380" decimals="-5" id="id_6038951_29098356-38B2-465C-900D-ADE5ED1C2AAD_2001_2" unitRef="iso4217_USD">6700000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1333245x1506247_1512983x1410232" decimals="INF" id="id_6038951_29098356-38B2-465C-900D-ADE5ED1C2AAD_3002_0" unitRef="iso4217_GBP">7500000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1333245x1506247_1512983x1410232" decimals="-5" id="id_6038951_29098356-38B2-465C-900D-ADE5ED1C2AAD_3001_0" unitRef="iso4217_USD">10000000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1333245x1506247_1512983x1493724" decimals="INF" id="id_6038951_29098356-38B2-465C-900D-ADE5ED1C2AAD_4002_1" unitRef="iso4217_GBP">5000000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1333245x1506247_1512983x1493724" decimals="-5" id="id_6038951_29098356-38B2-465C-900D-ADE5ED1C2AAD_4001_1" unitRef="iso4217_USD">6700000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1610-Q0007_STD_0_20160630_0_1333769x1451741" decimals="INF" id="id_6038951_5AD776DB-BE45-4427-B11A-9ECE2A56CA47_2003_6" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1610-Q0007_STD_0_20121206_0_1333242x1356609" decimals="-5" id="id_6038951_F7F2EBF9-0A3F-445D-B3F5-C5AC806D4324_2001_0" unitRef="iso4217_USD">14600000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:OtherCommitment contextRef="eol_PE46938---1610-Q0007_STD_0_20121206_0_1333242x1356609" decimals="-6" id="id_6038951_8648B229-098F-41C0-90B1-326C69B8102C_2001_1" unitRef="iso4217_USD">150000000</us-gaap:OtherCommitment>
  <us-gaap:OtherCommitment contextRef="eol_PE46938---1610-Q0007_STD_0_20121231_0_1330926x1327893_1333242x1356609" decimals="-6" id="id_6038951_DB4BC3CD-3A87-41FF-AE0F-2D181F3A62CA_4002_0" unitRef="iso4217_USD">150000000</us-gaap:OtherCommitment>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1610-Q0007_STD_0_20141231_0" decimals="-3" id="id_6038951_E2DC3566-84DC-4350-9A4A-417787BC4F4E_1004_4" unitRef="iso4217_USD">7519000</us-gaap:DerivativeLiabilities>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-Q0007_STD_0_20141231_0" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_1005_7" unitRef="iso4217_USD">7090000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1610-Q0007_STD_0_20141231_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_3001_32" unitRef="iso4217_USD">119539000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-Q0007_STD_0_20141231_0_1327091x1327216" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_1003_7" unitRef="iso4217_USD">481000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-Q0007_STD_0_20141231_0_1327091x1327217" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_1001_7" unitRef="iso4217_USD">2207000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-Q0007_STD_0_20141231_0_1327091x1368196" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_1004_7" unitRef="iso4217_USD">792000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-Q0007_STD_0_20141231_0_1327091x1397499" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_1002_7" unitRef="iso4217_USD">3610000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1610-Q0007_STD_0_20141231_0_1330926x1327893" decimals="-3" id="id_6038951_E2DC3566-84DC-4350-9A4A-417787BC4F4E_1002_4" unitRef="iso4217_USD">7400000</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1610-Q0007_STD_0_20141231_0_1330926x1451741" decimals="-3" id="id_6038951_E2DC3566-84DC-4350-9A4A-417787BC4F4E_1001_4" unitRef="iso4217_USD">119000</us-gaap:DerivativeLiabilities>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1610-Q0007_STD_0_20141231_0_1333769x1451741" decimals="INF" id="id_6038951_F10ADC19-9A50-4F10-80D7-48EDAB36163E_1002_0" unitRef="shares">8087388</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="INF" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_32" unitRef="shares">328184640</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:TreasuryStockShares contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="INF" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_40" unitRef="shares">174502</us-gaap:TreasuryStockShares>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="INF" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_37" unitRef="shares">183403263</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="INF" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1002_35" unitRef="iso4217_GBP_per_shares">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="INF" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_36" unitRef="shares">183577765</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="INF" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_31" unitRef="shares">328184640</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="INF" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_1002_30" unitRef="iso4217_GBP_per_shares">0.05</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:SeniorLongTermNotes contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_21" unitRef="iso4217_USD">136734000</us-gaap:SeniorLongTermNotes>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_41" unitRef="iso4217_USD">-1117654000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:PreferredStockValue contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_29" unitRef="iso4217_USD">24364000</us-gaap:PreferredStockValue>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_25" unitRef="iso4217_USD">335000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:LongTermDebtFairValue contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_6309153B-3F2F-4734-9186-828746BFA8F1_2_0" unitRef="iso4217_USD">87700000</us-gaap:LongTermDebtFairValue>
  <us-gaap:Liabilities contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_26" unitRef="iso4217_USD">300782000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_43" unitRef="iso4217_USD">173230000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_23" unitRef="iso4217_USD">8170000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_18" unitRef="iso4217_USD">923000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_15" unitRef="iso4217_USD">10832000</us-gaap:AccountsPayableCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_42" unitRef="iso4217_USD">-127552000</us-gaap:StockholdersEquity>
  <us-gaap:LongTermDebtNoncurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_22" unitRef="iso4217_USD">91512000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_E2DC3566-84DC-4350-9A4A-417787BC4F4E_6004_1" unitRef="iso4217_USD">8170000</us-gaap:DerivativeLiabilities>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_24" unitRef="iso4217_USD">13308000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_34" unitRef="iso4217_USD">149978000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_38" unitRef="iso4217_USD">816171000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_5005_1" unitRef="iso4217_USD">15796000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_F1D20E60-A0BE-46D8-A2A7-6C12CAF5F7A6_2_1" unitRef="iso4217_USD">2207000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-5" id="id_6038951_186768D4-6CA6-4B9D-8BB4-551C02D62BBD_3_3" unitRef="iso4217_USD">11500000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_27" unitRef="iso4217_USD" xsi:nil="true"/>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_16" unitRef="iso4217_USD">24226000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:LongTermDebtCurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_17" unitRef="iso4217_USD">14742000</us-gaap:LongTermDebtCurrent>
  <us-gaap:LongTermDebt contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_25395BD3-4DD3-4257-868D-0EB155889C18_2_0" unitRef="iso4217_USD">91512000</us-gaap:LongTermDebt>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_19" unitRef="iso4217_USD">50723000</us-gaap:LiabilitiesCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_7" unitRef="iso4217_USD">143524000</us-gaap:AssetsCurrent>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_022501C1-028F-41A1-AABA-E9DAE1CE552B_2_1" unitRef="iso4217_USD">1640000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_8" unitRef="iso4217_USD">243000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_2" unitRef="iso4217_USD">106961000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_9" unitRef="iso4217_USD">19872000</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <us-gaap:InventoryNet contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_5" unitRef="iso4217_USD">18985000</us-gaap:InventoryNet>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_4" unitRef="iso4217_USD">13826000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_3" unitRef="iso4217_USD">600000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableGrossCurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_3DD9C881-BBB4-4329-93E4-E774C7393794_2_0" unitRef="iso4217_USD">18270000</us-gaap:AccountsReceivableGrossCurrent>
  <us-gaap:Assets contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_12" unitRef="iso4217_USD">173230000</us-gaap:Assets>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_11" unitRef="iso4217_USD">9417000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_F1D20E60-A0BE-46D8-A2A7-6C12CAF5F7A6_2_0" unitRef="iso4217_USD">11624000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_022501C1-028F-41A1-AABA-E9DAE1CE552B_2_0" unitRef="iso4217_USD">9096000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_022501C1-028F-41A1-AABA-E9DAE1CE552B_2_2" unitRef="iso4217_USD">8249000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_10" unitRef="iso4217_USD">174000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_6" unitRef="iso4217_USD">3152000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:TreasuryStockValue contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="-3" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_39" unitRef="iso4217_USD">411000</us-gaap:TreasuryStockValue>
  <amrn:PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0" decimals="INF" id="id_6038951_7DBA1B9A-EEC5-4EE4-A760-EC151DB3FAEC_2_33" unitRef="shares">32818464</amrn:PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding>
  <us-gaap:SeniorLongTermNotes contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324093x1330360_1324529x1375482" decimals="-5" id="id_6038951_1F250133-B467-41B8-BB19-11E3049DC435_2002_6" unitRef="iso4217_USD">1800000</us-gaap:SeniorLongTermNotes>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324093x1330360_1324529x1375482_1328615x1333865" decimals="-5" id="id_6038951_1F250133-B467-41B8-BB19-11E3049DC435_3002_5" unitRef="iso4217_USD">-1800000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:SeniorLongTermNotes contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324093x1330360_1324529x1486557" decimals="-5" id="id_6038951_3AE016AE-CDC4-4D7B-BF47-80CEFB700EAB_1002_4" unitRef="iso4217_USD">100000</us-gaap:SeniorLongTermNotes>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324093x1330360_1324529x1486557_1328615x1333865" decimals="-5" id="id_6038951_3AE016AE-CDC4-4D7B-BF47-80CEFB700EAB_2002_3" unitRef="iso4217_USD">-100000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:UnamortizedDebtIssuanceExpense contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324093x1330360_1333245x1332467" decimals="-5" id="id_6038951_760429ED-426A-44D6-A3DD-5F462BF69771_1001_1" unitRef="iso4217_USD">1900000</us-gaap:UnamortizedDebtIssuanceExpense>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324093x1330360_1333245x1332467" decimals="-5" id="id_6038951_760429ED-426A-44D6-A3DD-5F462BF69771_1001_0" unitRef="iso4217_USD">-1900000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6038951_6D4583B3-AC09-464C-9701-513739DFDEAF_4002_0" unitRef="iso4217_USD">2100000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:DebtInstrumentFairValue contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324529x1375482_1328615x1333865" decimals="-3" id="id_6038951_6309153B-3F2F-4734-9186-828746BFA8F1_1002_2" unitRef="iso4217_USD">108034000</us-gaap:DebtInstrumentFairValue>
  <us-gaap:ConvertibleDebt contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6038951_E80A76F1-63CB-46EA-9296-5170BC68CB70_3002_0" unitRef="iso4217_USD">94600000</us-gaap:ConvertibleDebt>
  <us-gaap:SeniorNotes contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324529x1375482_1328615x1333865" decimals="-3" id="id_6038951_25395BD3-4DD3-4257-868D-0EB155889C18_1002_2" unitRef="iso4217_USD">94599000</us-gaap:SeniorNotes>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324529x1375482_1328615x1333865_1333245x1345793" decimals="-5" id="id_6038951_2DB18CD9-77CA-4B94-9785-9A7F990D70CC_2002_2" unitRef="iso4217_USD">24100000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:DebtInstrumentFairValue contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324529x1461424_1328615x1333865" decimals="-3" id="id_6038951_6309153B-3F2F-4734-9186-828746BFA8F1_2002_1" unitRef="iso4217_USD">13637000</us-gaap:DebtInstrumentFairValue>
  <us-gaap:ConvertibleDebt contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6038951_02A4B0D1-6CEB-4EDE-A213-01F278ECAB3F_3003_1" unitRef="iso4217_USD">15100000</us-gaap:ConvertibleDebt>
  <us-gaap:SeniorNotes contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324529x1461424_1328615x1333865" decimals="-3" id="id_6038951_25395BD3-4DD3-4257-868D-0EB155889C18_2002_1" unitRef="iso4217_USD">15107000</us-gaap:SeniorNotes>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324529x1461424_1328615x1333865" decimals="INF" id="id_6038951_2DB18CD9-77CA-4B94-9785-9A7F990D70CC_1002_0" unitRef="iso4217_USD">0</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6038951_6D4583B3-AC09-464C-9701-513739DFDEAF_5002_1" unitRef="iso4217_USD">600000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:DebtInstrumentFairValue contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324529x1486557_1328615x1333865" decimals="-3" id="id_6038951_6309153B-3F2F-4734-9186-828746BFA8F1_3002_3" unitRef="iso4217_USD">28448000</us-gaap:DebtInstrumentFairValue>
  <us-gaap:ConvertibleDebt contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6038951_FD305EA1-2595-400A-922D-829A38A62F3E_1002_0" unitRef="iso4217_USD">27000000</us-gaap:ConvertibleDebt>
  <us-gaap:SeniorNotes contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324529x1486557_1328615x1333865" decimals="-3" id="id_6038951_25395BD3-4DD3-4257-868D-0EB155889C18_3002_3" unitRef="iso4217_USD">27028000</us-gaap:SeniorNotes>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324529x1486557_1328615x1333865_1333245x1345793" decimals="-5" id="id_6038951_2DB18CD9-77CA-4B94-9785-9A7F990D70CC_4002_3" unitRef="iso4217_USD">4200000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324896x1324925_1331211x1328015" decimals="-3" id="id_6038951_2D03F903-84A4-40AD-8C9B-8716C676C841_4_3" unitRef="iso4217_USD">8170000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324896x1327983_1331211x1328015" decimals="-3" id="id_6038951_2D03F903-84A4-40AD-8C9B-8716C676C841_2_1" unitRef="iso4217_USD">14184000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1327036x1498782_1328480x1458944" decimals="-5" id="id_6038951_ADE3F0B6-0B9C-46AD-97A4-609A5B4C871D_1002_0" unitRef="iso4217_USD">2500000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1327091x1327216" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_5003_1" unitRef="iso4217_USD">535000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1327091x1327217" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_5001_1" unitRef="iso4217_USD">4296000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1327091x1366356" decimals="-3" id="id_6038951_3DD9C881-BBB4-4329-93E4-E774C7393794_2002_2" unitRef="iso4217_USD">148000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1327091x1368196" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_5004_1" unitRef="iso4217_USD">1084000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1327091x1397499" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_5002_1" unitRef="iso4217_USD">9881000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1328615x1333865" decimals="-5" id="id_6038951_E36B50A5-038F-45C3-9A4D-31D5B08AD71A_2002_0" unitRef="iso4217_USD">2300000</us-gaap:InterestPayableCurrent>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1325837" decimals="INF" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_1001_400003" unitRef="shares">328184640</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1325837" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_1001_700003" unitRef="iso4217_USD">24364000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1325837_1333245x1335616" decimals="INF" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_2001_400001" unitRef="shares">328184640</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1325837_1333245x1335616" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_2001_700001" unitRef="iso4217_USD">24364000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1326044" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_1008_1100003" unitRef="iso4217_USD">-1117654000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1326044_1333245x1335616" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_2008_1100001" unitRef="iso4217_USD">-1119293000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1327190" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_1006_900003" unitRef="iso4217_USD">816171000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1327190_1333245x1335616" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_2006_900001" unitRef="iso4217_USD">816171000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1330220" decimals="INF" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_1003_600003" unitRef="shares">-174502</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1330220" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_1003_1000003" unitRef="iso4217_USD">-411000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1330220_1333245x1335616" decimals="INF" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_2003_600001" unitRef="shares">-174502</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1330220_1333245x1335616" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_2003_1000001" unitRef="iso4217_USD">-411000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1333806" decimals="INF" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_1002_500003" unitRef="shares">183577765</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1333806" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_1002_800003" unitRef="iso4217_USD">149978000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1333806_1333245x1335616" decimals="INF" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_2002_500001" unitRef="shares">183577765</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1333806_1333245x1335616" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_2002_800001" unitRef="iso4217_USD">149978000</us-gaap:StockholdersEquity>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330926x1327893" decimals="-3" id="id_6038951_E2DC3566-84DC-4350-9A4A-417787BC4F4E_6002_1" unitRef="iso4217_USD">8170000</us-gaap:DerivativeLiabilities>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330926x1327893_1333242x1356609" decimals="-5" id="id_6038951_DB4BC3CD-3A87-41FF-AE0F-2D181F3A62CA_4001_7" unitRef="iso4217_USD">5500000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1331211x1328015" decimals="-3" id="id_6038951_2D03F903-84A4-40AD-8C9B-8716C676C841_1_3" unitRef="iso4217_USD">8170000</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1331211x1328015" decimals="-3" id="id_6038951_2D03F903-84A4-40AD-8C9B-8716C676C841_1_1" unitRef="iso4217_USD">14184000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:ConvertibleDebt contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1333242x1356609" decimals="-5" id="id_6038951_BBD88633-2BB4-4D8C-A7DD-A310C02B9223_3002_0" unitRef="iso4217_USD">91500000</us-gaap:ConvertibleDebt>
  <us-gaap:StockholdersEquity contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1333245x1335616" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_2009_1200001" unitRef="iso4217_USD">-129191000</us-gaap:StockholdersEquity>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE46938---1610-Q0007_STD_0_20151231_0_1333769x1451741" decimals="INF" id="id_6038951_5AD776DB-BE45-4427-B11A-9ECE2A56CA47_2006_6" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
  <amrn:LicensingAgreementTerm contextRef="eol_PE46938---1610-Q0007_STD_1_20150226_0_1512983x1440366" id="id_6038951_B573A080-6791-486C-B846-3A3BFE474F7A_2001_1">P16Y</amrn:LicensingAgreementTerm>
  <amrn:NonRefundableUpfrontPaymentsReceived contextRef="eol_PE46938---1610-Q0007_STD_1_20150226_0_1512983x1440366" decimals="-5" id="id_6038951_B573A080-6791-486C-B846-3A3BFE474F7A_2001_0" unitRef="iso4217_USD">15000000</amrn:NonRefundableUpfrontPaymentsReceived>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE46938---1610-Q0007_STD_1_20160201_0_1324199x1331109_1325804x1405848" id="id_6038951_455F3B43-9D95-4B90-A8FD-55CCAD6272A2_1001_3">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE46938---1610-Q0007_STD_1_20160201_0_1324199x1331109_1325804x1405848" decimals="INF" id="id_6038951_455F3B43-9D95-4B90-A8FD-55CCAD6272A2_1001_1" unitRef="shares">2442000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE46938---1610-Q0007_STD_1_20160201_0_1324199x1335583_1325804x1405848" id="id_6038951_455F3B43-9D95-4B90-A8FD-55CCAD6272A2_2001_2">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1610-Q0007_STD_1_20160201_0_1324199x1335583_1325804x1405848" decimals="INF" id="id_6038951_455F3B43-9D95-4B90-A8FD-55CCAD6272A2_2001_0" unitRef="shares">1607500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <amrn:PrivatePlacementClosingDate contextRef="eol_PE46938---1610-Q0007_STD_1_20150305_0" id="id_6038951_360D217B-DE1A-4498-913E-ABE634540342_1_3">2015-03-30</amrn:PrivatePlacementClosingDate>
  <us-gaap:PreferredStockConversionBasis contextRef="eol_PE46938---1610-Q0007_STD_1_20150305_0_1330096x1335797" id="id_6038951_360D217B-DE1A-4498-913E-ABE634540342_1001_1">American  Depositary Shares, each representing one (1) share of Amarin's Series A  Convertible Preference Shares</us-gaap:PreferredStockConversionBasis>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1610-Q0007_STD_1_20150305_0_1330096x1335797_1330097x1403450" decimals="INF" id="id_6038951_360D217B-DE1A-4498-913E-ABE634540342_2001_0" unitRef="shares">352150790</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE46938---1610-Q0007_STD_1_20150305_0_1330096x1335797_1330097x1403450" decimals="-5" id="id_6038951_360D217B-DE1A-4498-913E-ABE634540342_2001_4" unitRef="iso4217_USD">52800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <amrn:BeneficialOwnershipLimitationPercentage contextRef="eol_PE46938---1610-Q0007_STD_1_20150305_0_1330096x1335797_1335482x1328677" decimals="INF" id="id_6038951_34A17C75-E862-47A6-82B8-4BBCB04A527A_1001_2" unitRef="pure">0.199</amrn:BeneficialOwnershipLimitationPercentage>
  <amrn:BeneficialOwnershipLimitationPercentage contextRef="eol_PE46938---1610-Q0007_STD_1_20150305_0_1330096x1335797_1335482x1331874" decimals="INF" id="id_6038951_34A17C75-E862-47A6-82B8-4BBCB04A527A_2001_1" unitRef="pure">0.0499</amrn:BeneficialOwnershipLimitationPercentage>
  <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="eol_PE46938---1610-Q0007_STD_1_20150305_0_1330125x1482162_1330926x1353534" decimals="-5" id="id_6038951_62CE8781-0CA8-4BF2-BBA3-8742054E9C6E_1001_1" unitRef="iso4217_USD">-900000</us-gaap:DerivativeGainLossOnDerivativeNet>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE46938---1610-Q0007_STD_1_20150706_0_1324199x1331109_1325804x1405848" decimals="INF" id="id_6038951_A8FD6E71-FE9D-4C45-B45C-593469947C43_1001_1" unitRef="shares">5470000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE46938---1610-Q0007_STD_1_20150706_0_1324199x1331109_1325804x1405848_1330194x1334098" decimals="INF" id="id_6038951_4B3339D9-7476-4F40-A258-AA5678BA13E7_1001_1" unitRef="shares">288657</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE46938---1610-Q0007_STD_1_20150706_0_1324199x1331109_1325804x1405848_1330194x1334098_1336123x1454011" id="id_6038951_4B3339D9-7476-4F40-A258-AA5678BA13E7_2001_5">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE46938---1610-Q0007_STD_1_20150706_0_1324199x1331109_1325804x1405848_1330194x1334098_1336123x1454011" decimals="INF" id="id_6038951_4B3339D9-7476-4F40-A258-AA5678BA13E7_2001_3" unitRef="shares">121506</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE46938---1610-Q0007_STD_1_20150706_0_1324199x1331109_1325804x1405848_1330194x1334098_1336123x1487759" decimals="INF" id="id_6038951_4B3339D9-7476-4F40-A258-AA5678BA13E7_3001_7" unitRef="shares">167151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE46938---1610-Q0007_STD_1_20150706_0_1324199x1331109_1325804x1405848_1336123x1429469" id="id_6038951_A8FD6E71-FE9D-4C45-B45C-593469947C43_2001_4">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE46938---1610-Q0007_STD_1_20150706_0_1324199x1331109_1325804x1405848_1336123x1429469" decimals="INF" id="id_6038951_A8FD6E71-FE9D-4C45-B45C-593469947C43_2001_3" unitRef="shares">3670000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE46938---1610-Q0007_STD_1_20150706_0_1324199x1335583_1325804x1405848" id="id_6038951_A8FD6E71-FE9D-4C45-B45C-593469947C43_3001_2">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1610-Q0007_STD_1_20150706_0_1324199x1335583_1325804x1405848" decimals="INF" id="id_6038951_A8FD6E71-FE9D-4C45-B45C-593469947C43_3001_0" unitRef="shares">1455000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1610-Q0007_STD_1_20150706_0_1324199x1335583_1325804x1405848_1330194x1334098" decimals="INF" id="id_6038951_4B3339D9-7476-4F40-A258-AA5678BA13E7_4001_0" unitRef="shares">413500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE46938---1610-Q0007_STD_1_20150706_0_1324199x1335583_1325804x1405848_1330194x1334098_1336123x1454011" id="id_6038951_4B3339D9-7476-4F40-A258-AA5678BA13E7_5001_4">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1610-Q0007_STD_1_20150706_0_1324199x1335583_1325804x1405848_1330194x1334098_1336123x1454011" decimals="INF" id="id_6038951_4B3339D9-7476-4F40-A258-AA5678BA13E7_5001_2" unitRef="shares">283500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1610-Q0007_STD_1_20150706_0_1324199x1335583_1325804x1405848_1330194x1334098_1336123x1487759" decimals="INF" id="id_6038951_4B3339D9-7476-4F40-A258-AA5678BA13E7_6001_6" unitRef="shares">130000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE46938---1610-Q0007_STD_1_20150706_0_1324199x1456480_1325804x1405848_1336123x1425353" decimals="INF" id="id_6038951_A8FD6E71-FE9D-4C45-B45C-593469947C43_5001_5" unitRef="shares">1800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1610-Q0007_STD_1_20150710_0_1330096x1335797_1330097x1403450_1330125x1482162" decimals="INF" id="id_6038951_425BFE2D-ED7F-4922-86F6-56B6A3E6C4F7_1001_1" unitRef="shares">38867180</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE46938---1610-Q0007_STD_1_20150710_0_1330096x1335797_1330097x1403450_1330125x1482162" decimals="-5" id="id_6038951_425BFE2D-ED7F-4922-86F6-56B6A3E6C4F7_1001_0" unitRef="iso4217_USD">5800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <amrn:ClassOfWarrantOrRightTerm contextRef="eol_PE46938---1610-Q0007_STD_1_20091016_0_1324828x1419380_1328615x1330534_1330125x1468605_1333769x1451741" id="id_6038951_5F697CDA-5B79-4A3F-A6BF-149F44AB0CE2_1001_12">P5Y</amrn:ClassOfWarrantOrRightTerm>
  <amrn:ClassOfWarrantOrRightTerm contextRef="eol_PE46938---1610-Q0007_STD_1_20091016_0_1324828x1419380_1330125x1468605_1333769x1451741" id="id_6038951_5F697CDA-5B79-4A3F-A6BF-149F44AB0CE2_2001_6">P5Y</amrn:ClassOfWarrantOrRightTerm>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1610-Q0007_STD_1_20091016_0_1328615x1330534_1330125x1468605" decimals="-5" id="id_6038951_5F697CDA-5B79-4A3F-A6BF-149F44AB0CE2_3001_9" unitRef="shares">4000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="eol_PE46938---1610-Q0007_STD_1_20091016_0_1328615x1330534_1330125x1468605" decimals="-5" id="id_6038951_5F697CDA-5B79-4A3F-A6BF-149F44AB0CE2_3001_2" unitRef="iso4217_USD">3600000</us-gaap:DebtConversionOriginalDebtAmount1>
  <amrn:AmericanDepositorySharesToSharesRatio contextRef="eol_PE46938---1610-Q0007_STD_1_20091016_0_1328615x1330534_1330125x1468605" decimals="INF" id="id_6038951_5F697CDA-5B79-4A3F-A6BF-149F44AB0CE2_3001_10" unitRef="pure">1</amrn:AmericanDepositorySharesToSharesRatio>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE46938---1610-Q0007_STD_1_20091016_0_1330125x1468605" decimals="-5" id="id_6038951_5F697CDA-5B79-4A3F-A6BF-149F44AB0CE2_4001_3" unitRef="shares">66400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE46938---1610-Q0007_STD_1_20091016_0_1330125x1468605" decimals="-5" id="id_6038951_5F697CDA-5B79-4A3F-A6BF-149F44AB0CE2_4001_0" unitRef="iso4217_USD">70000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE46938---1610-Q0007_STD_1_20091016_0_1330125x1468605" decimals="-5" id="id_6038951_5F697CDA-5B79-4A3F-A6BF-149F44AB0CE2_4001_1" unitRef="iso4217_USD">62300000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <amrn:AmericanDepositorySharesToSharesRatio contextRef="eol_PE46938---1610-Q0007_STD_1_20091016_0_1330125x1468605" decimals="INF" id="id_6038951_5F697CDA-5B79-4A3F-A6BF-149F44AB0CE2_4001_4" unitRef="pure">1</amrn:AmericanDepositorySharesToSharesRatio>
  <amrn:EquityIssuancePerShareAmount1 contextRef="eol_PE46938---1610-Q0007_STD_1_20091016_0_1330125x1468605" decimals="INF" id="id_6038951_5F697CDA-5B79-4A3F-A6BF-149F44AB0CE2_4001_5" unitRef="iso4217_USD_per_shares">1.00</amrn:EquityIssuancePerShareAmount1>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="eol_PE46938---1610-Q0007_STD_1_20121206_0_1333242x1356609" decimals="-6" id="id_6038951_8648B229-098F-41C0-90B1-326C69B8102C_1001_0" unitRef="iso4217_USD">100000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE46938---1610-Q0007_STD_1_20150129_0_1324199x1331109_1325804x1405848" id="id_6038951_4EE230FA-CF6D-4C64-9E39-A1088A62EA42_1001_3">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE46938---1610-Q0007_STD_1_20150129_0_1324199x1331109_1325804x1405848" decimals="INF" id="id_6038951_4EE230FA-CF6D-4C64-9E39-A1088A62EA42_1001_1" unitRef="shares">1622500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE46938---1610-Q0007_STD_1_20150129_0_1324199x1335583_1325804x1405848" id="id_6038951_4EE230FA-CF6D-4C64-9E39-A1088A62EA42_2001_2">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1610-Q0007_STD_1_20150129_0_1324199x1335583_1325804x1405848" decimals="INF" id="id_6038951_4EE230FA-CF6D-4C64-9E39-A1088A62EA42_2001_0" unitRef="shares">2564251</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE46938---1610-Q0007_STD_1_20150129_0_1324199x1423313_1325804x1405848" decimals="INF" id="id_6038951_4EE230FA-CF6D-4C64-9E39-A1088A62EA42_4001_4" unitRef="shares">5455500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="2" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_4_21" unitRef="iso4217_USD_per_shares">-0.53</us-gaap:EarningsPerShareDiluted>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2_20" unitRef="iso4217_USD">-38260000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_4_24" unitRef="shares">178036000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_4_23" unitRef="shares">178036000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_938BD5E9-A023-4494-BBD9-FDB4D35A3605_4_8" unitRef="shares">178036000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="2" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_4_20" unitRef="iso4217_USD_per_shares">-0.53</us-gaap:EarningsPerShareBasic>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="INF" id="id_6038951_736EEF89-CDFA-4A38-9059-1DA96B98CDB3_2_0" unitRef="shares">18020</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="2" id="id_6038951_938BD5E9-A023-4494-BBD9-FDB4D35A3605_4_7" unitRef="iso4217_USD_per_shares">-0.53</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_4005_8" unitRef="iso4217_USD">21968000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:Revenues contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_4_2" unitRef="iso4217_USD">33640000</us-gaap:Revenues>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2_29" unitRef="iso4217_USD">5000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_4_11" unitRef="iso4217_USD">-9692000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2_15" unitRef="iso4217_USD">-318000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_4_0" unitRef="iso4217_USD">33265000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_4_9" unitRef="iso4217_USD">-53786000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_4_15" unitRef="iso4217_USD">-62638000</us-gaap:NetIncomeLoss>
  <us-gaap:InterestPaid contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2_36" unitRef="iso4217_USD">5829000</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2_13" unitRef="iso4217_USD">6766000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2_12" unitRef="iso4217_USD">2101000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2_28" unitRef="iso4217_USD">117000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:LicensesRevenue contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_4_1" unitRef="iso4217_USD">375000</us-gaap:LicensesRevenue>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2_37" unitRef="iso4217_USD">171000</us-gaap:IncomeTaxesPaid>
  <us-gaap:GrossProfit contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_4_4" unitRef="iso4217_USD">21632000</us-gaap:GrossProfit>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_4_10" unitRef="iso4217_USD">-136000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_4_12" unitRef="iso4217_USD">-33000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_4_18" unitRef="iso4217_USD">-94847000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_938BD5E9-A023-4494-BBD9-FDB4D35A3605_4_6" unitRef="iso4217_USD">-94966000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2_14" unitRef="iso4217_USD">-1325000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_4_13" unitRef="iso4217_USD">-63647000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_938BD5E9-A023-4494-BBD9-FDB4D35A3605_4_5" unitRef="iso4217_USD">-119000</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2_40" unitRef="iso4217_USD">4804000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2_10" unitRef="iso4217_USD">-731000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:Depreciation contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2_3" unitRef="iso4217_USD">85000</us-gaap:Depreciation>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_4_14" unitRef="iso4217_USD">-1009000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_E2DC3566-84DC-4350-9A4A-417787BC4F4E_4004_5" unitRef="iso4217_USD">868000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2_5" unitRef="iso4217_USD">6258000</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2_17" unitRef="iso4217_USD">14625000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2_19" unitRef="iso4217_USD">240000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2_25" unitRef="iso4217_USD">52149000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_4_6" unitRef="iso4217_USD">50795000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_4005_10" unitRef="iso4217_USD">12202000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2_7" unitRef="iso4217_USD">3688000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2_18" unitRef="iso4217_USD">6976000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2_16" unitRef="iso4217_USD">11000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2_30" unitRef="iso4217_USD">54771000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:PreferredStockConversionsInducements contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_4_17" unitRef="iso4217_USD">31341000</us-gaap:PreferredStockConversionsInducements>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2_27" unitRef="iso4217_USD">2713000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_4_7" unitRef="iso4217_USD">24623000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2_8" unitRef="iso4217_USD">323000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2_31" unitRef="iso4217_USD">16511000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_4_3" unitRef="iso4217_USD">12008000</us-gaap:CostOfGoodsSold>
  <us-gaap:OperatingExpenses contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_4_8" unitRef="iso4217_USD">75418000</us-gaap:OperatingExpenses>
  <us-gaap:PreferredStockDividendsAndOtherAdjustments contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_4_16" unitRef="iso4217_USD">868000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2_26" unitRef="iso4217_USD">31000</us-gaap:ProceedsFromStockOptionsExercised>
  <amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="INF" id="id_6038951_F026F2D1-A4BA-4CFE-A5C1-B7589FA810EB_2_0" unitRef="shares">1844585</amrn:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <amrn:DerivativeLiabilitiesTransferredToStockholdersEquity contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_E2DC3566-84DC-4350-9A4A-417787BC4F4E_4004_8" unitRef="iso4217_USD">1814000</amrn:DerivativeLiabilitiesTransferredToStockholdersEquity>
  <amrn:DerivativeLiabilitiesTransferredToEquityClassifications contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_2_39" unitRef="iso4217_USD">868000</amrn:DerivativeLiabilitiesTransferredToEquityClassifications>
  <amrn:ProvisionRelatedToPriorPeriodSales contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_4005_9" unitRef="iso4217_USD">-157000</amrn:ProvisionRelatedToPriorPeriodSales>
  <amrn:CreditsPaymentsMadeForPriorPeriodSales contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_4005_11" unitRef="iso4217_USD">6376000</amrn:CreditsPaymentsMadeForPriorPeriodSales>
  <amrn:ProceedsFromWarrantExercisesGross contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0" decimals="-5" id="id_6038951_F026F2D1-A4BA-4CFE-A5C1-B7589FA810EB_2_1" unitRef="iso4217_USD">2800000</amrn:ProceedsFromWarrantExercisesGross>
  <amrn:ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationOperatingActivities contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1324093x1528669_1333245x1332387" decimals="-5" id="id_6038951_3F6849BD-D7D4-4677-A197-16E5D7F62D46_2003_3" unitRef="iso4217_USD">600000</amrn:ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationOperatingActivities>
  <amrn:ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1324093x1528669_1333245x1335616" decimals="-5" id="id_6038951_3F6849BD-D7D4-4677-A197-16E5D7F62D46_3003_2" unitRef="iso4217_USD">-600000</amrn:ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6038951_D7D9551B-0EB9-45F8-A623-ED5904725C48_1002_1" unitRef="iso4217_USD">1500000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1327091x1327216" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_4003_8" unitRef="iso4217_USD">276000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <amrn:CreditsPaymentsMadeForPriorPeriodSales contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1327091x1327216" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_4003_11" unitRef="iso4217_USD">14000</amrn:CreditsPaymentsMadeForPriorPeriodSales>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1327091x1327217" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_4001_8" unitRef="iso4217_USD">6044000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1327091x1327217" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_4001_10" unitRef="iso4217_USD">3810000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <amrn:ProvisionRelatedToPriorPeriodSales contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1327091x1327217" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_4001_9" unitRef="iso4217_USD">-113000</amrn:ProvisionRelatedToPriorPeriodSales>
  <amrn:CreditsPaymentsMadeForPriorPeriodSales contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1327091x1327217" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_4001_11" unitRef="iso4217_USD">2039000</amrn:CreditsPaymentsMadeForPriorPeriodSales>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1327091x1368196" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_4004_8" unitRef="iso4217_USD">3691000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1327091x1368196" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_4004_10" unitRef="iso4217_USD">2149000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <amrn:CreditsPaymentsMadeForPriorPeriodSales contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1327091x1368196" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_4004_11" unitRef="iso4217_USD">792000</amrn:CreditsPaymentsMadeForPriorPeriodSales>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1327091x1397499" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_4002_8" unitRef="iso4217_USD">11957000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1327091x1397499" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_4002_10" unitRef="iso4217_USD">6243000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <amrn:ProvisionRelatedToPriorPeriodSales contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1327091x1397499" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_4002_9" unitRef="iso4217_USD">-44000</amrn:ProvisionRelatedToPriorPeriodSales>
  <amrn:CreditsPaymentsMadeForPriorPeriodSales contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1327091x1397499" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_4002_11" unitRef="iso4217_USD">3531000</amrn:CreditsPaymentsMadeForPriorPeriodSales>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1328615x1333865" decimals="-3" id="id_6038951_5BDFD6F6-6DE1-4246-B761-5D351FDA9212_1004_2" unitRef="shares">49215000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1328615x1333865" decimals="-5" id="id_6038951_E80A76F1-63CB-46EA-9296-5170BC68CB70_1004_3" unitRef="iso4217_USD">2600000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1328615x1333865" decimals="-5" id="id_6038951_E80A76F1-63CB-46EA-9296-5170BC68CB70_1004_1" unitRef="iso4217_USD">5600000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestPaid contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1328615x1333865_1333110x1404455" decimals="-5" id="id_6038951_E36B50A5-038F-45C3-9A4D-31D5B08AD71A_1003_1" unitRef="iso4217_USD">2600000</us-gaap:InterestPaid>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1328615x1333865_1333245x1345793" decimals="-5" id="id_6038951_E80A76F1-63CB-46EA-9296-5170BC68CB70_2004_2" unitRef="iso4217_USD">3000000</us-gaap:InterestExpenseDebt>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1330926x1327893" decimals="-3" id="id_6038951_E2DC3566-84DC-4350-9A4A-417787BC4F4E_4002_6" unitRef="iso4217_USD">700000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1330926x1353534" decimals="-3" id="id_6038951_E2DC3566-84DC-4350-9A4A-417787BC4F4E_4003_6" unitRef="iso4217_USD">-946000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1330926x1353534" decimals="-3" id="id_6038951_E2DC3566-84DC-4350-9A4A-417787BC4F4E_4003_5" unitRef="iso4217_USD">868000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
  <amrn:DerivativeLiabilitiesTransferredToStockholdersEquity contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1330926x1353534" decimals="-3" id="id_6038951_E2DC3566-84DC-4350-9A4A-417787BC4F4E_4003_8" unitRef="iso4217_USD">1814000</amrn:DerivativeLiabilitiesTransferredToStockholdersEquity>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1330926x1451741" decimals="-3" id="id_6038951_E2DC3566-84DC-4350-9A4A-417787BC4F4E_4001_6" unitRef="iso4217_USD">110000</us-gaap:UnrealizedGainLossOnDerivatives>
  <amrn:ShareBasedCompensationNet contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1330926x1451741_1331645x1336129" decimals="-3" id="id_6038951_E2DC3566-84DC-4350-9A4A-417787BC4F4E_5001_7" unitRef="iso4217_USD">-9000</amrn:ShareBasedCompensationNet>
  <amrn:ShareBasedCompensationNet contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1331645x1336129" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_1002_6" unitRef="iso4217_USD">-9000</amrn:ShareBasedCompensationNet>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1333242x1356609" decimals="-5" id="id_6038951_F7F2EBF9-0A3F-445D-B3F5-C5AC806D4324_1003_1" unitRef="iso4217_USD">-800000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1333242x1356609_1333245x1345793" decimals="-5" id="id_6038951_BBD88633-2BB4-4D8C-A7DD-A310C02B9223_1004_2" unitRef="iso4217_USD">900000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1333242x1356609_1333245x1417215" decimals="-5" id="id_6038951_BBD88633-2BB4-4D8C-A7DD-A310C02B9223_2004_1" unitRef="iso4217_USD">3200000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1333589x1330112" decimals="-3" id="id_6038951_5BDFD6F6-6DE1-4246-B761-5D351FDA9212_2004_0" unitRef="shares">11750000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1333589x1335583" decimals="-3" id="id_6038951_5BDFD6F6-6DE1-4246-B761-5D351FDA9212_3004_1" unitRef="shares">4046000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1333769x1451741" decimals="-5" id="id_6038951_5AD776DB-BE45-4427-B11A-9ECE2A56CA47_1005_4" unitRef="iso4217_USD">2700000</us-gaap:ProceedsFromWarrantExercises>
  <amrn:ClassOfWarrantOrRightExercisedInPeriod contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1333769x1451741" decimals="INF" id="id_6038951_F10ADC19-9A50-4F10-80D7-48EDAB36163E_1001_1" unitRef="shares">1844585</amrn:ClassOfWarrantOrRightExercisedInPeriod>
  <amrn:ClassOfWarrantOrRightExpiredInPeriod contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1333769x1451741" decimals="INF" id="id_6038951_F10ADC19-9A50-4F10-80D7-48EDAB36163E_1001_2" unitRef="shares">6242803</amrn:ClassOfWarrantOrRightExpiredInPeriod>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1333817x1329312_1333818x1324536_1334994x1501282" decimals="2" id="id_6038951_DA538F2D-9B24-45F9-BA03-48BAF678A727_1002_0" unitRef="pure">0.95</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1333817x1333518_1333818x1324536_1334994x1501282" decimals="2" id="id_6038951_DA538F2D-9B24-45F9-BA03-48BAF678A727_2002_1" unitRef="pure">0.96</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-Q0007_STD_181_20150630_0_1334996x1325837" decimals="-3" id="id_6038951_5BDFD6F6-6DE1-4246-B761-5D351FDA9212_4004_3" unitRef="shares">28932000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_B5971EA1-4D7D-4C8E-A0C5-AC610A000986_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Cash and Cash Equivalents and Restricted
 Cash&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Cash and cash equivalents consist of cash, deposits with banks and
 short-term highly liquid money market instruments with remaining
 maturities at the date of purchase of 90&amp;#xA0;days or less.
 Restricted cash represents cash and cash equivalents pledged to
 guarantee repayment of certain expenses which may be incurred for
 business travel under corporate credit cards held by employees.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_1DFB3BC8-60FA-4DAC-9B71-4B319E71C4D5_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;b&gt;(10)&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;b&gt;Development, Commercialization and
 Supply Agreement&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 On February&amp;#xA0;26, 2015, the Company entered into a Development,
 Commercialization and Supply Agreement (the &amp;#x201C;DCS
 Agreement&amp;#x201D;) with Eddingpharm (Asia) Macao Commercial Offshore
 Limited (&amp;#x201C;Eddingpharm&amp;#x201D;) related to the development and
 commercialization of Vascepa in Mainland China, Hong Kong, Macau
 and Taiwan (the &amp;#x201C;China Territory&amp;#x201D;). Under the terms of
 the DCS Agreement, the Company granted to Eddingpharm an exclusive
 (including as to the Company) license with right to sublicense to
 develop and commercialize Vascepa in the China Territory for uses
 that are currently commercialized and under development by the
 Company based on the Company&amp;#x2019;s MARINE, ANCHOR and ongoing
 REDUCE-IT clinical trials of Vascepa.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Under the DCS Agreement, Eddingpharm will be solely responsible for
 development and commercialization activities in the China Territory
 and associated expenses. The Company will provide development
 assistance and be responsible for supplying finished and later bulk
 drug product at defined prices under negotiated terms. The Company
 will retain all Vascepa manufacturing rights. Eddingpharm has
 agreed to certain restrictions regarding the commercialization of
 competitive products globally and the Company has agreed to certain
 restrictions regarding the commercialization of competitive
 products in the China Territory.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company and Eddingpharm agreed to form a joint development
 committee to oversee regulatory and development activities for
 Vascepa in the China Territory in accordance with a negotiated
 development plan and to form a separate joint commercialization
 committee to oversee Vascepa commercialization activities in the
 China Territory. Development costs will be paid by Eddingpharm to
 the extent such costs are incurred in connection with the
 negotiated development plan or otherwise incurred by Eddingpharm.
 Eddingpharm will be responsible for preparing and filing regulatory
 applications in all countries of the China Territory at
 Eddingpharm&amp;#x2019;s cost with the Company&amp;#x2019;s assistance. The
 DCS Agreement also contains customary provisions regarding
 indemnification, packaging, record keeping, audit rights, reporting
 obligations, and representations and warranties that are customary
 for an arrangement of this type.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The term of the DCS Agreement expires, on a product-by-product
 basis, upon the later of (i)&amp;#xA0;the date on which such product is
 no longer covered by a valid claim under a licensed patent in the
 China Territory, or (ii)&amp;#xA0;the twelfth (12th)&amp;#xA0;anniversary
 of the first commercial sale of such product in Mainland China. The
 DCS Agreement may be terminated by either party in the event of a
 bankruptcy of the other party and for material breach, subject to
 customary cure periods. In addition, at any time following the
 third anniversary of the first commercial sale of a product in
 Mainland China, Eddingpharm has the right to terminate the DCS
 Agreement for convenience with twelve months&amp;#x2019; prior notice.
 Neither party may assign or transfer the DCS Agreement without the
 prior consent of the other party, provided that the Company may
 assign the DCS Agreement in the event of a change of control
 transaction.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Upon closing of the DCS Agreement, the Company received a
 non-refundable $15.0 million up-front payment, which it will
 recognize as revenue over the estimated period in which the Company
 is required to provide initial and on-going regulatory and
 development support and clinical supply for obtaining regulatory
 approvals in the China Territory and through the estimated period
 in which the Company is required to provide commercial supply,
 which is currently estimated to be a period of approximately 16
 years. In March 2016, Eddingpharm submitted its clinical trial
 application (&amp;#x201C;CTA&amp;#x201D;) with respect to the MARINE
 indication for Vascepa to the Chinese regulatory authority.
 Following the CTA submission, the Company received a non-refundable
 $1.0 million milestone payment which it will recognize as revenue
 over the estimated period in which the Company is required to
 provide on-going development support needed to support the
 successful approval for a new drug application, which is currently
 estimated to be a period of approximately four years.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 In addition to the non-refundable, up-front and regulatory
 milestone payments described above, the Company is entitled to
 receive certain regulatory and sales-based milestone payments of up
 to an additional $153.0 million as well as tiered double-digit
 percentage royalties on net sales of Vascepa in the China Territory
 escalating to the high teens. The regulatory milestone events
 relate to the submission and approval of certain applications to
 the applicable regulatory authority, such as a clinical trial
 application, clinical trial exemption, or import drug license
 application. The sales-based milestone events occur when annual
 aggregate net sales of Vascepa in the territory equals or exceeds
 certain specified thresholds. Each such milestone payment shall be
 payable only once regardless of how many times the sales milestone
 event is achieved. Each such milestone payment is non-refundable
 and non-creditable against any other milestone payments. The
 Company recognizes contingent consideration from activities that is
 earned upon the achievement of a substantive milestone in the
 period in which the milestone is achieved.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Licensing and deferred revenues currently consist of revenue
 attributable to receipt of up-front, non-refundable payments and
 milestone payments related to the DCS Agreement and other licensing
 agreements outside the United States. Up-front and milestone
 payments under such agreements are typically recognized as
 licensing revenue over the estimated period in which we are
 required to provide regulatory and development support and clinical
 and commercial supply pursuant to the agreements. During the six
 months ended June&amp;#xA0;30, 2016 and 2015, the Company recognized
 $0.5 million and $0.4 million of up-front and milestone payments as
 licensing revenue, respectively, and recorded $15.7 million as
 deferred revenue as of June&amp;#xA0;30, 2016.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_FBA7E61B-2AC9-4436-8AC2-0A3DCCEBE4BC_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;b&gt;(7)&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;b&gt;Commitments and
 Contingencies&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;&lt;u&gt;Litigation&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 In the ordinary course of business, the Company is from time to
 time involved in lawsuits, claims, investigations, proceedings, and
 threats of litigation relating to intellectual property, commercial
 arrangements and other matters. &amp;#x201C;Item 3. Legal
 Proceedings&amp;#x201D; of the Company&amp;#x2019;s Annual Report on Form
 10-K for the fiscal year ended December&amp;#xA0;31, 2015, and
 &amp;#x201C;Item 1. Legal Proceedings&amp;#x201D; of the Company&amp;#x2019;s
 Quarterly Report on Form 10-Q for the quarter ended March&amp;#xA0;31,
 2016, include discussions of the Company&amp;#x2019;s current legal
 proceedings. There have been no material changes to those
 disclosures as of the date of this filing other than as set forth
 below.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 On April&amp;#xA0;26, 2016, the U.S. District Court for the District of
 New Jersey granted a motion to dismiss in favor of the Company and
 related defendants in the putative consolidated class action
 lawsuit captioned&amp;#xA0;&lt;i&gt;In re Amarin Corporation plc, Securities
 Litigation,&lt;/i&gt;&amp;#xA0;No.&amp;#xA0;3:13-cv-06663 (D.N.J. Nov. 1, 2013).
 The class action was dismissed without prejudice with leave for
 plaintiffs to file an amended complaint. The lawsuit seeks
 unspecified monetary damages and attorneys&amp;#x2019; fees and costs
 alleging that the Company and certain of its current and former
 officers and directors made misstatements and omissions regarding
 the FDA&amp;#x2019;s willingness to approve Vascepa&amp;#x2019;s ANCHOR
 indication and related contributing factors and the potential
 relevance of data from the ongoing REDUCE-IT trial to that
 potential approval. The April 2016 dismissal was the second motion
 to dismiss granted in favor of the Company and related defendants
 in this litigation. The first motion to dismiss in this litigation
 was granted in June 2015 in response to the original complaint and
 related amendment. On May&amp;#xA0;24, 2016, plaintiffs notified the
 court they would not file another amended complaint and, on
 May&amp;#xA0;26, 2016, filed a notice of appeal of the most recent
 dismissal to the Third Circuit Court of Appeals. The Company plans
 a vigorous defense to this appeal. The Company has insurance
 coverage that is anticipated to cover any significant loss exposure
 that may arise from this action.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 On May&amp;#xA0;31, 2016, FDA granted five-year, new chemical entity
 exclusivity with respect to Vascepa in connection with
 Vascepa&amp;#x2019;s July&amp;#xA0;26, 2012 FDA approval. Following such
 exclusivity grant, on June&amp;#xA0;7, 2016, Watson Laboratories Inc.,
 or Watson, moved for voluntarily dismissal of its own appeal to the
 United States Court of Appeals (case no. 2016-1596) of the
 January&amp;#xA0;22, 2016 U.S. District Court for the District of New
 Jersey order of dismissal of the abbreviated new drug application,
 or ANDA, patent infringement litigation (case no. 14-CV-3259)
 related to Vascepa. The Watson motion for voluntary dismissal, to
 which the Company consented, was granted on June&amp;#xA0;8, 2016.
 There is no pending patent litigation related to Vascepa.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;&lt;u&gt;Milestone and Supply Purchase Obligations&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company entered into long-term supply agreements with multiple
 FDA-approved API suppliers and encapsulators. Certain supply
 agreements require annual minimum volume commitments by the Company
 and certain volume shortfalls may require payments for such
 shortfalls, as detailed below.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company entered into its initial Vascepa API supply agreement
 with Nisshin Pharma, Inc. (&amp;#x201C;Nisshin&amp;#x201D;) in 2010. In 2011,
 the Company entered into agreements with two additional suppliers,
 Chemport, Inc. (&amp;#x201C;Chemport&amp;#x201D;) and BASF (formerly Equateq
 Limited), for the supply of API. In 2012, the Company agreed to
 terms with a fourth API supplier, a consortium of companies led by
 Slanmhor Pharmaceutical, Inc. (&amp;#x201C;Slanmhor&amp;#x201D;). The API
 supply agreement with BASF terminated in February 2014. In July
 2014, the Company terminated the supply agreement with Slanmhor and
 subsequently, in July 2015, entered into a new supply agreement
 with Finorga SAS (&amp;#x201C;Novasep&amp;#x201D;). These agreements included
 requirements for the suppliers to meet certain product
 specifications and qualify their materials and facilities with
 applicable regulatory authorities including the FDA. The Company
 has incurred certain costs associated with the qualification of
 product produced by these suppliers as described below. Nisshin,
 Chemport and Novasep are currently the three manufacturers from
 which the Company purchases API.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Chemport was approved by the FDA to manufacture API for commercial
 sale in April 2013 and the Company began purchasing commercial
 supply from Chemport in 2013. The agreement with Chemport contains
 a provision requiring the Company to pay Chemport in cash for any
 shortfall in the minimum purchase obligations. The Company began
 purchasing commercial supply from Novasep in 2015. API manufactured
 by Novasep was previously approved by the FDA in July 2014. The
 2015 supply agreement with Novasep includes commitments for the
 Company to fund API purchases and contains a provision requiring
 the Company to pay Novasep a cash remedy for any shortfall in the
 minimum purchase obligations. The Company continues to meet its
 contractual purchase obligations.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Under the 2004 share repurchase agreement with Laxdale Limited
 (&amp;#x201C;Laxdale&amp;#x201D;) upon receipt of marketing approval in
 Europe for the first indication for Vascepa (or first indication of
 any product containing Amarin Neuroscience Limited intellectual
 property acquired from Laxdale in 2004), the Company must make an
 aggregate stock or cash payment to the former shareholders of
 Laxdale (at the sole option of each of the sellers) of
 &amp;#xA3;7.5&amp;#xA0;million (approximately $10.0 million as of
 June&amp;#xA0;30, 2016). Also under the Laxdale agreement, upon receipt
 of a marketing approval in the United States or Europe for a
 further indication of Vascepa (or further indication of any other
 product using Amarin Neuroscience Limited intellectual property),
 the Company must make an aggregate stock or cash payment (at the
 sole option of each of the sellers) of &amp;#xA3;5&amp;#xA0;million
 (approximately $6.7 million as of June&amp;#xA0;30, 2016) for each of
 the two potential market approvals (i.e. &amp;#xA3;10&amp;#xA0;million
 maximum, or approximately $13.4 million as of June&amp;#xA0;30,
 2016).&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company has no provision for any of the obligations above since
 the amounts are either not probable or able to be estimated as of
 June&amp;#xA0;30, 2016.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_BA3A6215-CFF4-4E66-9004-D121F0B695FC_1_4">Q2</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_BA3A6215-CFF4-4E66-9004-D121F0B695FC_1_3">2016</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_BA3A6215-CFF4-4E66-9004-D121F0B695FC_1_0">10-Q</dei:DocumentType>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="2" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_3_21" unitRef="iso4217_USD_per_shares">-0.23</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_E48B6B08-D999-436F-BCE2-9F7FB29FD2F7_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Loss per Share&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Basic net loss per share is determined by dividing net loss by the
 weighted average shares of common stock outstanding during the
 period. Diluted net loss per share is determined by dividing net
 loss by diluted weighted average shares outstanding. Diluted
 weighted average shares reflects the dilutive effect, if any, of
 potentially dilutive common shares, such as common stock options
 and warrants calculated using the treasury stock method and
 convertible notes using the &amp;#x201C;if-converted&amp;#x201D; method. In
 periods with reported net operating losses, all common stock
 options and warrants are deemed anti-dilutive such that basic net
 loss per share and diluted net loss per share are equal. However,
 in certain periods in which there is a gain recorded pursuant to
 the change in fair value of the warrant derivative liability, for
 diluted net loss per share purposes, the impact of such gains is
 reversed and the treasury stock method is used to determine diluted
 net loss per share.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company&amp;#x2019;s preferred stock is entitled to receive
 dividends on an as-if-converted basis in the same form as dividends
 actually paid on common shares. Accordingly, the preferred stock is
 considered a participating security and the Company is required to
 apply the two-class method to consider the impact of the preferred
 stock on the calculation of basic and diluted earnings per share.
 The Company is currently in a net loss position and is therefore
 not required to present the two-class method, however, in the event
 the Company is in a net income position, the two-class method must
 be applied by allocating all earnings during the period to common
 shares and preferred stock based on their contractual entitlements
 assuming all earnings were distributed.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The calculation of net loss and the number of shares used to
 compute basic and diluted net loss per share for the three and six
 months ended June&amp;#xA0;30, 2016 and 2015 are as follows:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Six&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(13,354&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(31,512&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(43,125&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(62,638&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Preferred stock purchase option (see Note 8)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(868&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Preferred stock beneficial conversion feature (see Note 8)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(31,341&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(31,341&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Net loss applicable to common shareholders&amp;#x2014;basic&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(13,354&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(62,853&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(43,125&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(94,847&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Gain on warrant derivative liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(119&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Net loss&amp;#x2014;diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(13,354&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(62,853&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(43,125&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(94,966&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Net loss per share&amp;#x2014;basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.07&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.35&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.23&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.53&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Weighted average shares outstanding&amp;#x2014;basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;184,471&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,464&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;184,262&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;178,036&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 For the three and six months ended&amp;#xA0;June 30, 2016 and 2015, the
 following potentially dilutive securities were not included in the
 computation of net loss per share because the effect would be
 anti-dilutive:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three months
 ended&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Six months
 ended&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,641&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,750&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,641&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,750&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Restricted stock and restricted stock units&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,361&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,046&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,361&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,046&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Exchangeable senior notes (if converted)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;59,407&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;49,215&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;59,407&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;49,215&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Preferred stock (if converted)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32,818&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,932&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32,818&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,932&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <dei:EntityCentralIndexKey contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_7122CAB9-2953-466D-BF94-16FD51A80C1D_1_400002">0000897448</dei:EntityCentralIndexKey>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_959944E5-685F-4172-9DEE-D3538683656F_1_0">&lt;div&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Fair Value of Financial Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company provides disclosure of financial assets and financial
 liabilities that are carried at fair value based on the price that
 would be received upon sale of an asset or paid to transfer a
 liability in an orderly transaction between market participants at
 the measurement date.&amp;#xA0;Fair value measurements may be
 classified based on the amount of subjectivity associated with the
 inputs to fair valuation of these assets and liabilities using the
 following three levels:&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Level 1&amp;#x2014;Inputs are unadjusted quoted prices in active markets
 for identical assets or liabilities that the Company has the
 ability to access at the measurement date.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Level 2&amp;#x2014;Inputs include quoted prices for similar assets and
 liabilities in active markets, quoted prices for identical or
 similar assets or liabilities in markets that are not active,
 inputs other than quoted prices that are observable for the asset
 or liability (i.e., interest rates, yield curves, etc.) and inputs
 that are derived principally from or corroborated by observable
 market data by correlation or other means (market corroborated
 inputs).&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Level 3&amp;#x2014;Unobservable inputs that reflect the Company&amp;#x2019;s
 estimates of the assumptions that market participants would use in
 pricing the asset or liability.&amp;#xA0;The Company develops these
 inputs based on the best information available, including its own
 data.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The following tables present information about the Company&amp;#x2019;s
 assets and liabilities as of June&amp;#xA0;30, 2016 and
 December&amp;#xA0;31, 2015 that are measured at fair value on a
 recurring basis and indicate the fair value hierarchy of the
 valuation techniques the Company utilized to determine such fair
 value:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;June&amp;#xA0;30, 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Asset:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Cash equivalents&amp;#x2014;money markets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,210&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,210&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Liabilities:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Long-term debt derivative liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,610&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,610&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;December&amp;#xA0;31,
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Asset:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Cash equivalents&amp;#x2014;money markets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,184&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,184&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Liabilities:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Long-term debt derivative liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,170&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;$&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,170&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The carrying amounts of cash, cash equivalents, accounts payable
 and accrued liabilities approximate fair value because of their
 short-term nature. The carrying amounts and the estimated fair
 values of debt instruments as of June&amp;#xA0;30, 2016 and
 December&amp;#xA0;31, 2015 are as follows:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;June&amp;#xA0;30, 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;December&amp;#xA0;31,
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Carrying&lt;br /&gt;
 Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Estimated&lt;br /&gt;
 Fair&amp;#xA0;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Carrying&lt;br /&gt;
 Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Estimated&lt;br /&gt;
 Fair&amp;#xA0;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Long-term debt&amp;#x2014;December 2012 financing&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;92,533&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;89,000&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;91,512&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;87,700&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 2012 Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,107&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,686&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,107&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,637&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 2014 Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;97,994&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;122,959&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;94,599&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;108,034&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 2015 Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,650&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32,378&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,028&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,448&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The estimated fair value of the long-term debt pursuant to the
 December 2012 financing is calculated utilizing the same Level 3
 inputs utilized in valuing the related derivative liability (see
 Long-Term Debt Redemption Features below).&amp;#xA0;The estimated fair
 value of the 2012 Notes and 2014 Notes is calculated based on Level
 1 quoted bond prices, while the estimated fair value of the 2015
 Notes is calculated based on Level 2 quoted bond prices for the
 2014 Notes.&amp;#xA0;The carrying value of the 2012 Notes as of
 June&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015 does not include a
 debt discount, as it had been fully amortized as non-cash interest
 expense over the expected term of the 2012 Notes, which was
 calculated to be a period of twenty-four months. The carrying value
 of the 2014 Notes as of June&amp;#xA0;30, 2016 and December&amp;#xA0;31,
 2015 includes a debt discount of $20.7 million and $24.1 million,
 respectively, which is being amortized as non-cash interest expense
 over the expected term of the 2014 Notes, through January 2019. The
 carrying value of the 2015 Notes as of June&amp;#xA0;30, 2016 and
 December&amp;#xA0;31, 2015 includes a debt discount of $3.6 million and
 $4.2 million, respectively, which is being amortized as non-cash
 interest expense over the expected term of the 2015 Notes, through
 January 2019. The carrying values and related debt discounts of the
 2014 Notes and 2015 Notes as of December&amp;#xA0;31, 2015 reflect the
 retroactive reclassification of debt issuance costs per adoption of
 ASU No.&amp;#xA0;2015-03 as described in Note 6&amp;#x2014;Debt. The change
 in the estimated fair values of these liabilities from
 December&amp;#xA0;31, 2015 to June&amp;#xA0;30, 2016 is largely related to
 changes in the quoted bond prices.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_DEFE7AE0-1D0C-4B78-9683-E269E3B126D6_1_0">P14Y1M6D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:InventoryDisclosureTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_D319EB01-E937-4E9C-9B26-2D9859C3D6CC_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;(4)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Inventory&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company capitalizes its purchases of saleable inventory of
 Vascepa from suppliers that have been qualified by the FDA.
 Inventories as of June&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015
 consist of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&amp;#xA0;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Raw materials&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,596&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,096&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Work in process&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,748&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,640&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Finished goods&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,962&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,249&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total inventory&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,306&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,985&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:InventoryPolicyTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_37C4A1AD-91A0-49CE-A42C-9BB4576A7FDC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Inventory&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Effective April 2016, the Company adopted ASU No.&amp;#xA0;2015-11,
 &lt;i&gt;Inventory (Topic 330)&amp;#x2014;Simplifying the Measurement of
 Inventory&lt;/i&gt;, which simplifies the subsequent measurement of
 inventories by replacing the lower of cost or market test with a
 lower of cost and net realizable value test and, as such, began to
 state inventories at the lower of cost or net realizable value.
 Such adoption had no impact on the carrying value of inventory.
 Cost is determined based on actual cost using the average cost
 method. An allowance is established when management determines that
 certain inventories may not be saleable. If inventory cost exceeds
 expected net realizable value due to obsolescence, damage,
 quantities in excess of expected demand, changes in price levels or
 other causes, the Company will reduce the carrying value of such
 inventory to net realizable value and recognize the difference as a
 component of cost of goods sold in the period in which it occurs.
 The Company capitalizes inventory purchases of saleable product
 from approved suppliers while inventory purchases from suppliers
 prior to regulatory approval are included as a component of
 research and development expense. The Company expenses inventory
 identified for use as marketing samples when they are packaged. The
 average cost reflects the actual purchase price of Vascepa active
 pharmaceutical ingredient, or API.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_1_20" unitRef="iso4217_USD">-33780000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_E4CEC57C-4CC2-46A2-BCA9-01ACDCB0106F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Recent Accounting Pronouncements&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 From time to time, new accounting pronouncements are issued by the
 Financial Accounting Standards Board, or FASB, and are early
 adopted by the Company or adopted as of the specified effective
 date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In January 2016, the Company adopted ASU No.&amp;#xA0;2015-03,
 &lt;i&gt;Interest&amp;#x2014;Imputation of Interest (Subtopic 835-30):
 Simplifying the Presentation of Debt Issuance Costs&lt;/i&gt;, which
 provides guidance on simplifying the presentation of debt issuance
 costs on the balance sheet. To simplify presentation of debt
 issuance costs, the amendments in ASU No.&amp;#xA0;2015-03 require that
 debt issuance costs related to a recognized debt liability be
 presented in the balance sheet as a direct deduction from the
 carrying amount of that debt liability, consistent with the
 treatment of debt discounts. The recognition and measurement
 guidance for debt issuance costs are not affected by the amendments
 in this update. In accordance with ASU No.&amp;#xA0;2015-03, the
 Company applied the new guidance on a retrospective basis, wherein
 the condensed consolidated balance sheet of each individual period
 presented was adjusted to reflect the period-specific effects of
 applying the new guidance. See Note 6&lt;i&gt;&amp;#x2014;&lt;/i&gt;Debt.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In April 2016, the Company adopted ASU No.&amp;#xA0;2015-11,
 &lt;i&gt;Inventory (Topic 330): Simplifying the Measurement of
 Inventory&lt;/i&gt;, which simplifies the subsequent measurement of
 inventories by replacing the lower of cost or market test with a
 lower of cost or net realizable value test. When evidence exists
 that the net realizable value of inventory is less than its cost
 (due to damage, physical deterioration, obsolescence, changes in
 price levels or other causes), the Company will recognize the
 difference as a component of cost of goods sold in the period in
 which it occurs. In accordance with ASU No.&amp;#xA0;2015-11, the
 Company applied the new guidance on a prospective basis with no
 impact on the carrying amount of inventory.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Also in April 2016, the Company adopted ASU No.&amp;#xA0;2016-09,
 &lt;i&gt;Compensation&amp;#x2014;Stock Compensation (Topic 718): Improvements
 to Employee Share-Based Payment Accounting,&lt;/i&gt; which changes the
 accounting for certain aspects of share-based payments to
 employees. One aspect of the standard requires that excess tax
 benefits and deficiencies that arise upon vesting or exercise of
 share-based payments be recognized as an income tax benefit and
 expense in the income statement. Previously, such amounts were
 recognized as an increase and decrease in additional paid-in
 capital. This aspect of the standard was adopted prospectively, and
 accordingly, the benefit from income taxes for the three and six
 months ended June&amp;#xA0;30, 2016, includes $0.1 million and $0.2
 million, respectively, of excess tax deficiencies arising from
 share-based payments. Additionally, the new standard requires that
 historical excess tax benefits that were not previously recognized
 because the related tax deduction had not reduced current taxes
 payable should be recognized on a modified retrospective basis as a
 cumulative-effect adjustment to retained earnings as of the
 beginning of the annual period of adoption. Consequently, the
 Company recognized deferred tax assets of approximately $1.6
 million relating to excess tax benefits on stock-based compensation
 outstanding as of December&amp;#xA0;31, 2015, with a corresponding
 cumulative-effect adjustment to accumulated deficit. The new
 standard also amends the presentation of employee share-based
 payment-related items in the statement of cash flows by requiring
 that: (i)&amp;#xA0;excess income tax benefits and deficiencies be
 classified in cash flows from operating activities, and
 (ii)&amp;#xA0;cash paid to taxing authorities arising from the
 withholding of shares from employees be classified as cash flows
 from financing activities. The Company adopted the aspects of the
 standard affecting cash flow presentation retrospectively and,
 accordingly, reclassified $0.6 million of excess tax provision from
 cash flows provided by financing activities to cash flows used in
 operating activities in the condensed consolidated statement of
 cash flows for the six months ended June&amp;#xA0;30, 2015 to conform
 to the current year presentation. The presentation requirement for
 cash flows related to taxes paid for withheld shares had no impact
 to any of the periods presented in the condensed consolidated
 statement of cash flows since such payments have historically been
 presented as a financing activity.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company also considered the following recent accounting
 pronouncements which were not yet adopted as of June&amp;#xA0;30,
 2016:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In May 2014, the FASB issued ASU No.&amp;#xA0;2014-09, &lt;i&gt;Revenue from
 Contracts with Customers (Topic 606)&lt;/i&gt;. This amendment provides
 principles for recognizing revenue for the transfer of promised
 goods or services to customers with the consideration to which the
 entity expects to be entitled in exchange for those goods or
 services, and is effective for annual periods beginning after
 December&amp;#xA0;15, 2016 (the original effective date). In April
 2015, the FASB issued a proposal, which was subsequently adopted in
 July 2015, to defer the original effective date of this standard by
 one year, such that the amendment is effective for the
 Company&amp;#x2019;s fiscal year beginning January&amp;#xA0;1, 2018. Early
 adoption is permitted, but not before the original effective date.
 The Company is currently evaluating the accounting, transition and
 disclosure requirements of the standard and cannot currently
 estimate the financial statement impact of adoption.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In August 2014, the FASB issued ASU No.&amp;#xA0;2014-15,
 &lt;i&gt;Presentation of Financial Statements&amp;#x2014;Going Concern
 (Subtopic 205-40): Disclosure of Uncertainties about an
 Entity&amp;#x2019;s Ability to Continue as a Going Concern&lt;/i&gt;. ASU
 2014-15 requires management to assess an entity&amp;#x2019;s ability to
 continue as a going concern by incorporating and expanding upon
 certain principles that are currently in U.S. auditing standards.
 Specifically, the ASU (i)&amp;#xA0;provides a definition of the term
 substantial doubt, (ii)&amp;#xA0;requires an evaluation every reporting
 period including interim periods, (iii)&amp;#xA0;provides principles
 for considering the mitigating effect of management&amp;#x2019;s plans,
 (iv)&amp;#xA0;requires certain disclosures when substantial doubt is
 alleviated as a result of consideration of management&amp;#x2019;s
 plans, (v)&amp;#xA0;requires an express statement and other disclosures
 when substantial doubt is not alleviated and (vi)&amp;#xA0;requires an
 assessment for a period of one year after the date that the
 financial statements are issued (or available to be issued). This
 standard is effective for fiscal years ending after
 December&amp;#xA0;15, 2016, and for annual and interim periods
 thereafter. Early application is permitted. The Company has
 determined that this standard would not have a material impact on
 its condensed consolidated financial statements based on the
 assessment of its ability to continue as a going concern as of
 June&amp;#xA0;30, 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In January 2016, the FASB issued ASU No.&amp;#xA0;2016-01, &lt;i&gt;Financial
 Instruments&amp;#x2014;Overall (Subtopic 825-10): Recognition and
 Measurement of Financial Assets and Financial Liabilities&lt;/i&gt;. The
 new guidance is intended to improve the recognition and measurement
 of financial instruments by requiring separate presentation of
 financial assets and financial liabilities by measurement category
 and form of financial asset (i.e., securities or loans and
 receivables) within the balance sheet or the accompanying notes to
 the financial statements, eliminating the requirement for public
 business entities to disclose the method(s) and significant
 assumptions used to estimate the fair value that is required to be
 disclosed for financial instruments measured at amortized cost
 within the balance sheet, requiring public business entities to use
 the exit price notion when measuring the fair value of financial
 instruments for disclosure purposes, requiring equity investments
 (except those accounted for under the equity method of accounting,
 or those that result in consolidation of the investee) to be
 measured at fair value with changes in fair value recognized in net
 income, and requiring a reporting organization to present
 separately in other comprehensive income the portion of the total
 change in the fair value of a liability resulting from a change in
 the instrument-specific credit risk (also referred to as &amp;#x201C;own
 credit&amp;#x201D;) when the organization has elected to measure the
 liability at fair value in accordance with the fair value option
 for financial instruments, among others. The new guidance is
 effective for fiscal years beginning after December&amp;#xA0;15, 2017,
 including interim periods within those fiscal years. The new
 guidance permits early adoption of the own credit provision. The
 Company is currently evaluating the accounting, transition and
 disclosure requirements of the standard and cannot currently
 estimate the financial statement impact of adoption.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In February 2016, the FASB issued ASU No.&amp;#xA0;2016-02, &lt;i&gt;Leases
 (Topic 842)&lt;/i&gt;. The new guidance will require lessees to recognize
 a right-of-use asset and a lease liability for virtually all of
 their leases (other than leases that meet the definition of a
 short-term lease). The liability will be equal to the present value
 of lease payments. The asset will be based on the liability,
 subject to adjustment, such as for initial direct costs. Under the
 new guidance, lessor accounting is largely unchanged but certain
 targeted improvements were made to align, where necessary, lessor
 accounting with the lessee accounting model and Topic 606, Revenue
 from Contracts with Customers. The new lease guidance also
 simplified the accounting for sale and leaseback transactions
 primarily because lessees must recognize lease assets and lease
 liabilities and therefore, will no longer be provided with a source
 of off-balance sheet financing. The new guidance is effective for
 fiscal years beginning after December&amp;#xA0;15, 2018, including
 interim periods within those fiscal years. Early adoption is
 permitted. The Company is currently evaluating the accounting,
 transition and disclosure requirements of the standard and cannot
 currently estimate the financial statement impact of adoption.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In March 2016, the FASB issued ASU No.&amp;#xA0;2016-08, &lt;i&gt;Revenue
 from Contracts with Customers (Topic 606): Principal versus Agent
 Considerations (Reporting Revenue Gross versus Net)&lt;/i&gt;, which
 clarifies that an entity is a principal when it controls the
 specified good or service before that good or service is
 transferred to the customer, and is an agent when it does not
 control the specified good or service before it is transferred to
 the customer. The new guidance is intended to improve the
 operability and understandability of the implementation guidance on
 principal versus agent considerations. In April 2016, the FASB
 issued ASU No.&amp;#xA0;2016-10&lt;i&gt;, Revenue from Contracts with
 Customers (Topic 606): Identifying Performance Obligations and
 Licensing,&lt;/i&gt; which clarifies the following two aspects of Topic
 606: (a)&amp;#xA0;identifying performance obligations; and (b)&amp;#xA0;the
 licensing implementation guidance. Further, in May 2016, the FASB
 issued ASU No.&amp;#xA0;2016-12, &lt;i&gt;Revenue from Contracts with
 Customers (Topic 606): Narrow-Scope Improvements and Practical
 Expedients,&lt;/i&gt; which provides clarifying guidance in certain
 narrow areas and adds some practical expedients. The amendments do
 not change the core principles of the guidance in Topic 606 and are
 effective for the Company&amp;#x2019;s fiscal year beginning
 January&amp;#xA0;1, 2018. Early application is permitted only as of
 annual reporting periods beginning after December&amp;#xA0;15, 2016,
 including interim reporting periods within that reporting period.
 The Company is currently evaluating the accounting, transition and
 disclosure requirements of these standards and cannot currently
 estimate the financial statement impact of adoption.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company believes that the impact of other recently issued but
 not yet adopted accounting pronouncements will not have a material
 impact on the Company&amp;#x2019;s consolidated financial position,
 results of operations, and cash flows, or do not apply to the
 Company&amp;#x2019;s operations.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_46DD1C78-63C2-4AF7-925D-7057167D0F66_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 For the three and six months ended&amp;#xA0;June 30, 2016 and 2015, the
 following potentially dilutive securities were not included in the
 computation of net loss per share because the effect would be
 anti-dilutive:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three months
 ended&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Six months
 ended&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,641&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,750&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,641&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,750&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Restricted stock and restricted stock units&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,361&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,046&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,361&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,046&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Exchangeable senior notes (if converted)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;59,407&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;49,215&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;59,407&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;49,215&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Preferred stock (if converted)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32,818&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,932&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32,818&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,932&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_F1568217-BBF2-49D2-97A8-61FE3463162E_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Selling, General and Administrative Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company charges selling, general and administrative costs to
 operations as incurred. Selling, general and administrative costs
 include costs of salaries, programs and infrastructure necessary
 for the general conduct of the Company&amp;#x2019;s business, including
 those incurred as a result of the commercialization of Vascepa in
 the United States as well as co-promotion fees payable to Kowa
 Pharmaceuticals America, Inc.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_2C5D0A80-88CC-463F-80BD-95D030B592A0_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;(2)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Significant Accounting
 Policies&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Principles of Consolidation&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The condensed consolidated financial statements include the
 accounts of the Company and its wholly-owned subsidiaries. All
 intercompany accounts and transactions have been eliminated in
 consolidation.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Use of Estimates&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Accounting estimates are based on historical experience and other
 factors that are considered reasonable under the circumstances.
 Estimates are used in determining such items as provisions for
 sales returns, rebates and incentives, chargebacks, and other sales
 allowances; depreciable/amortizable lives; asset impairments;
 valuation allowance on deferred taxes; probabilities of achievement
 of performance conditions for certain equity awards; amounts
 recorded for licensing revenue; contingencies and accruals; and
 valuations of derivative and long-term debt instruments. Because of
 the uncertainties inherent in such estimates, actual results may
 differ from these estimates. Management periodically evaluates
 estimates used in the preparation of the condensed consolidated
 financial statements for continued reasonableness.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Use of Forecasted Financial Information in Accounting
 Estimates&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The use of forecasted financial information is inherent in many of
 the Company&amp;#x2019;s accounting estimates including, but not limited
 to, determining the estimated fair values of derivatives, debt
 instruments and intangible assets, and evaluating the need for
 valuation allowances for deferred tax assets. Such forecasted
 financial information is comprised of numerous assumptions
 regarding the Company&amp;#x2019;s future revenues, cash flows, and
 operational results. Management believes that its financial
 forecasts are reasonable and appropriate based upon current facts
 and circumstances. Because of the inherent nature of forecasts,
 however, actual results may differ from these forecasts. Management
 regularly reviews the information related to these forecasts and
 adjusts the carrying amounts of the applicable assets
 prospectively, if and when actual results differ from previous
 estimates.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company sells Vascepa principally to a limited number of major
 wholesalers, as well as selected regional wholesalers and specialty
 pharmacy providers, or collectively, its Distributors or its
 customers, that in turn resell Vascepa to retail pharmacies for
 subsequent resale to patients and healthcare providers. Patients
 are required to have a prescription in order to purchase Vascepa.
 In accordance with GAAP, the Company&amp;#x2019;s revenue recognition
 policy requires that: (i)&amp;#xA0;there is persuasive evidence that an
 arrangement exists between the Company and the Distributor,
 (ii)&amp;#xA0;delivery has occurred, (iii)&amp;#xA0;collectability is
 reasonably assured and (iv)&amp;#xA0;the price is fixed or
 determinable.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company has contracts with its primary Distributors and
 delivery generally occurs when a Distributor receives Vascepa. The
 Company evaluates the creditworthiness of each of its Distributors
 to determine whether revenues can be recognized upon delivery,
 subject to satisfaction of the other requirements, or whether
 recognition is required to be delayed until receipt of payment. In
 order to conclude that the price is fixed or determinable, the
 Company must be able to (i)&amp;#xA0;calculate its gross product
 revenues from the sales to Distributors and (ii)&amp;#xA0;reasonably
 estimate its net product revenues. The Company calculates gross
 product revenues generally based on the wholesale acquisition cost
 that the Company charges its Distributors for Vascepa. The Company
 estimates its net product revenues by deducting from its gross
 product revenues (a)&amp;#xA0;trade allowances, such as invoice
 discounts for prompt payment and distributor fees,
 (b)&amp;#xA0;estimated government and private payor rebates,
 chargebacks and discounts, such as Medicaid reimbursements,
 (c)&amp;#xA0;reserves for expected product returns and
 (d)&amp;#xA0;estimated costs of incentives offered to certain indirect
 customers, including patients.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Trade Allowances:&lt;/i&gt; The Company generally provides invoice
 discounts on Vascepa sales to its Distributors for prompt payment
 and pays fees for distribution services, such as fees for certain
 data that Distributors provide to the Company. The payment terms
 for sales to Distributors generally include a 2% discount for
 payment within 30&amp;#xA0;days while the fees for distribution
 services are based on contractual rates agreed with the respective
 Distributors. Based on judgment and experience, the Company expects
 its Distributors to earn these discounts and fees, and deducts the
 full amount of these discounts and fees from its gross product
 revenues and accounts receivable at the time such revenues are
 recognized.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Rebates, Chargebacks and Discounts:&lt;/i&gt; The Company contracts
 with Medicaid, other government agencies and various private
 organizations, or collectively, Third-party Payors, so that Vascepa
 will be eligible for purchase by, or partial or full reimbursement
 from, such Third-party Payors. The Company estimates the rebates,
 chargebacks and discounts it will provide to Third-party Payors and
 deducts these estimated amounts from its gross product revenues at
 the time the revenues are recognized. The Company estimates the
 rebates, chargebacks and discounts that it will provide to
 Third-party Payors based upon (i)&amp;#xA0;the Company&amp;#x2019;s
 contracts with these Third-party Payors, (ii)&amp;#xA0;the
 government-mandated discounts applicable to government-funded
 programs, (iii)&amp;#xA0;information obtained from the Company&amp;#x2019;s
 Distributors and (iv)&amp;#xA0;information obtained from other third
 parties regarding the payor mix for Vascepa.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Product Returns:&lt;/i&gt; The Company&amp;#x2019;s Distributors have the
 right to return unopened unprescribed Vascepa during the 18-month
 period beginning six months prior to the labeled expiration date
 and ending twelve months after the labeled expiration date. The
 expiration date for Vascepa is three years after it has been
 converted into capsule form, which is the last step in the
 manufacturing process for Vascepa and generally occurs within a few
 months before Vascepa is delivered to Distributors. The Company
 estimates future product returns on sales of Vascepa based on:
 (i)&amp;#xA0;data provided to the Company by its Distributors
 (including weekly reporting of Distributors&amp;#x2019; sales and
 inventory held by Distributors that provided the Company with
 visibility into the distribution channel in order to determine what
 quantities were sold to retail pharmacies and other providers),
 (ii)&amp;#xA0;information provided to the Company from retail
 pharmacies, (iii)&amp;#xA0;data provided to the Company by a third
 party data provider which collects and publishes prescription data,
 and other third parties, (iv)&amp;#xA0;historical industry information
 regarding return rates for similar pharmaceutical products,
 (v)&amp;#xA0;the estimated remaining shelf life of Vascepa previously
 shipped and currently being shipped to Distributors and
 (vi)&amp;#xA0;contractual agreements intended to limit the amount of
 inventory maintained by the Company&amp;#x2019;s Distributors.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 &lt;i&gt;Other Incentives:&lt;/i&gt; Other incentives that the Company offers
 to indirect customers include co-pay mitigation rebates provided by
 the Company to commercially insured patients who have coverage for
 Vascepa and who reside in states that permit co-pay mitigation
 programs. The Company&amp;#x2019;s co-pay mitigation program is intended
 to reduce each participating patient&amp;#x2019;s portion of the
 financial responsibility for Vascepa&amp;#x2019;s purchase price to a
 specified dollar amount. Based upon the terms of the program and
 information regarding programs provided for similar specialty
 pharmaceutical products, the Company estimates the average co-pay
 mitigation amounts and the percentage of patients that it expects
 to participate in the program in order to establish its accruals
 for co-pay mitigation rebates and deducts these estimated amounts
 from its gross product revenues at the time the revenues are
 recognized. The Company adjusts its accruals for co-pay mitigation
 rebates based on actual redemption activity and estimates regarding
 the portion of issued co-pay mitigation rebates that it estimates
 will be redeemed.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The following tables summarize activity in each of the net product
 revenue allowance and reserve categories described above for the
 six months ended June&amp;#xA0;30, 2016 and 2015:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Trade&lt;br /&gt;
 Allowances&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Rebates,&lt;br /&gt;
 Chargebacks&lt;br /&gt;
 and&amp;#xA0;Discounts&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Product&lt;br /&gt;
 Returns&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Other&lt;br /&gt;
 Incentives&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Balance as of December&amp;#xA0;31, 2015&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;4,296&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;9,881&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;535&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,084&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;15,796&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Provision related to current period sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,048&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,945&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;257&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,614&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44,864&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Provision related to prior period sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(87&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(466&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(553&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Credits/payments made for current period sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,415&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10,750&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,910&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(20,075&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Credits/payments made for prior period sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,180&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,497&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(226&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,284&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(14,187&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Balance as of June&amp;#xA0;30, 2016&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;3,662&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;19,113&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;566&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,504&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;25,845&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Trade&lt;br /&gt;
 Allowances&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Rebates,&lt;br /&gt;
 Chargebacks&lt;br /&gt;
 and&amp;#xA0;Discounts&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Product&lt;br /&gt;
 Returns&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Other&lt;br /&gt;
 Incentives&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Balance as of December&amp;#xA0;31, 2014&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,207&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;3,610&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#xA0;481&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;792&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;7,090&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Provision related to current period sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,044&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,957&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,691&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,968&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Provision related to prior period sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(113&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(44&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(157&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Credits/payments made for current period sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,810&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,243&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,149&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12,202&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Credits/payments made for prior period sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,039&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,531&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(792&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,376&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Balance as of June&amp;#xA0;30, 2015&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,289&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;5,749&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;743&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,542&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;10,323&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Such net product revenue allowances and reserves are included
 within accrued expenses and other current liabilities within the
 condensed consolidated balance sheets, with the exception of trade
 allowances and chargebacks, which are included within accounts
 receivable, net as discussed below.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Multiple-Element Arrangements and Licensing Revenue&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 When evaluating multiple-element arrangements, the Company
 identifies the deliverables included within the agreement and
 evaluates which deliverables represent separate units of accounting
 based on whether the delivered element has stand-alone value to the
 customer or if the arrangement includes a general right of return
 for delivered items.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The consideration received is allocated between each of the
 separable elements in the arrangement using the relative selling
 price method. The selling price used for each separable element
 will be based on vendor specific objective evidence
 (&amp;#x201C;VSOE&amp;#x201D;) if available, third-party evidence if VSOE is
 not available, or estimated selling price if neither VSOE nor
 third-party evidence is available. Revenue is then recognized as
 each of the separable elements to which the revenue has been
 allocated is delivered.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company may receive up-front, non-refundable payments when
 licensing its intellectual property in conjunction with research,
 development and commercialization agreements. In determining the
 units of accounting, management evaluates whether the license has
 stand-alone value from the undelivered elements to the
 collaborative partner based on the consideration of the relevant
 facts and circumstances for each arrangement. Factors considered in
 this determination include the stage of development of the license
 delivered, research and development capabilities of the partner and
 the ability of partners to develop and commercialize Vascepa
 independent of the Company.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 When management believes the license to its intellectual property
 does not have stand-alone value from the other deliverables to be
 provided in the arrangement, the Company generally recognizes
 revenue attributable to the license over the Company&amp;#x2019;s
 contractual or estimated performance period. Any unrecognized
 portion of license revenue is classified within deferred revenue in
 the accompanying condensed consolidated balance sheets. When
 management believes the license to its intellectual property has
 stand-alone value, the Company recognizes revenue attributed to the
 license upon delivery. The periods over which revenue is recognized
 is subject to estimates by management and may change over the
 course of the agreement. Such a change could have a material impact
 on the amount of revenue the Company records in future periods.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Milestones&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Contingent consideration from activities that is earned upon the
 achievement of a substantive milestone is recognized in its
 entirety in the period in which the milestone is achieved. At the
 inception of each arrangement that includes milestone payments, the
 Company evaluates whether each milestone is substantive. This
 evaluation includes an assessment of whether: (a)&amp;#xA0;the
 consideration is commensurate with either (1)&amp;#xA0;the
 entity&amp;#x2019;s performance to achieve the milestone, or
 (2)&amp;#xA0;the enhancement of the value of the delivered item(s) as a
 result of a specific outcome resulting from the entity&amp;#x2019;s
 performance to achieve the milestone, (b)&amp;#xA0;the consideration
 relates solely to past performance and (c)&amp;#xA0;the consideration
 is reasonable relative to all of the deliverables and payment terms
 within the arrangement. The Company evaluates factors such as the
 scientific, clinical, regulatory, commercial and other risks that
 must be overcome to achieve the respective milestone, the level of
 effort and investment required and whether the milestone
 consideration is reasonable relative to all deliverables and
 payment terms in the arrangement in making this assessment.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 See Note 10&amp;#x2014;Development, Commercialization and Supply
 Agreement for further information regarding licensing revenue and
 milestones related to the Company&amp;#x2019;s multiple-element
 arrangement with Eddingpharm (Asia) Macao Commercial Offshore
 Limited.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Distribution Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company records distribution costs related to shipping product
 to its customers, primarily through the use of common carriers or
 external distribution services, in cost of goods sold.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Cash and Cash Equivalents and Restricted
 Cash&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Cash and cash equivalents consist of cash, deposits with banks and
 short-term highly liquid money market instruments with remaining
 maturities at the date of purchase of 90&amp;#xA0;days or less.
 Restricted cash represents cash and cash equivalents pledged to
 guarantee repayment of certain expenses which may be incurred for
 business travel under corporate credit cards held by employees.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Accounts Receivable, net&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Accounts receivable, net, comprised of trade receivables, are
 generally due within 30 days and are stated at amounts due from
 customers. The Company does not currently maintain an allowance for
 doubtful accounts and has not historically experienced any credit
 losses.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following table summarizes the impact of accounts receivable
 reserves on the gross trade accounts receivable balances as of
 June&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&amp;#xA0;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Gross trade accounts receivable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,528&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,270&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade allowances&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,662&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,296&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Chargebacks&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(227&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(148&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accounts receivable, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,639&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,826&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Inventory&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Effective April 2016, the Company adopted ASU No.&amp;#xA0;2015-11,
 &lt;i&gt;Inventory (Topic 330)&amp;#x2014;Simplifying the Measurement of
 Inventory&lt;/i&gt;, which simplifies the subsequent measurement of
 inventories by replacing the lower of cost or market test with a
 lower of cost and net realizable value test and, as such, began to
 state inventories at the lower of cost or net realizable value.
 Such adoption had no impact on the carrying value of inventory.
 Cost is determined based on actual cost using the average cost
 method. An allowance is established when management determines that
 certain inventories may not be saleable. If inventory cost exceeds
 expected net realizable value due to obsolescence, damage,
 quantities in excess of expected demand, changes in price levels or
 other causes, the Company will reduce the carrying value of such
 inventory to net realizable value and recognize the difference as a
 component of cost of goods sold in the period in which it occurs.
 The Company capitalizes inventory purchases of saleable product
 from approved suppliers while inventory purchases from suppliers
 prior to regulatory approval are included as a component of
 research and development expense. The Company expenses inventory
 identified for use as marketing samples when they are packaged. The
 average cost reflects the actual purchase price of Vascepa active
 pharmaceutical ingredient, or API.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Property, Plant and Equipment&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company provides for depreciation and amortization using the
 straight-line method by charges to operations in amounts that
 depreciate the cost of the fixed asset over its estimated useful
 life. The estimated useful lives, by asset classification, are as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 66.3pt; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Asset Classification&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;Useful&amp;#xA0;Lives&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Computer equipment and software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;3&amp;#xA0;-&amp;#xA0;5&amp;#xA0;years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Furniture and fixtures&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5&amp;#xA0;years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 Lesser&amp;#xA0;of&amp;#xA0;useful&amp;#xA0;life&amp;#xA0;or&amp;#xA0;lease&amp;#xA0;term&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Upon retirement or sale of assets, the cost of the assets disposed
 and the related accumulated depreciation are removed from the
 condensed consolidated balance sheet and any resulting gain or loss
 is credited or expensed to operations. Repairs and maintenance
 costs are expensed as incurred.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Long-Lived Asset Impairment&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company reviews its long-lived assets for impairment whenever
 events or changes in circumstances indicate that the carrying
 amount of such assets may not be recoverable. Recoverability of
 these assets is determined by comparing the forecasted undiscounted
 net cash flows of the operation to which the assets relate to their
 carrying amount. If impairment is indicated, the assets are written
 down to fair value. Fair value is determined based on discounted
 forecasted cash flows or appraised values, depending on the nature
 of the assets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Intangible Asset, net&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Intangible asset, net consists of a milestone payment paid to the
 former shareholders of Laxdale Limited related to the 2004
 acquisition of the rights to Vascepa, which is the result of
 Vascepa receiving marketing approval for the first indication and
 is amortized over its estimated useful life on a straight-line
 basis. See Note 7&amp;#x2014;Commitments and Contingencies for further
 information regarding other obligations related to the acquisition
 of Laxdale Limited.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Beneficial Conversion Features&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company issued Series A preference shares in a private
 placement transaction executed in two tranches that each contain a
 conversion feature whereby such shares are convertible into
 ordinary shares at a fixed rate. The conversion price on the date
 of issuance was less than the market price of the Company&amp;#x2019;s
 ordinary shares. It was determined that these discounts represent
 contingent beneficial conversion features, which were valued based
 on the difference between the conversion price and the market price
 of the ordinary shares on the date of issuance, which is the
 commitment date. These features are analogous to preference
 dividends and were each recorded as a non-cash return to preferred
 shareholders through accumulated deficit upon the earliest possible
 date of conversion, which occurred in the three months ended
 June&amp;#xA0;30, 2015 upon effectiveness of the related resale
 Registration Statement on Form S-3 and in the three months ended
 September&amp;#xA0;30, 2015 upon shareholder approval received at the
 Company&amp;#x2019;s Annual General Meeting of Shareholders. See Note
 8&amp;#x2014;Equity for further discussion.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Costs for Patent Litigation and Legal
 Proceedings&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Costs for patent litigation or other legal proceedings are expensed
 as incurred and included in selling, general and administrative
 expenses.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Research and Development Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company charges research and development costs to operations as
 incurred. Research and development expenses are comprised of costs
 incurred by the Company in performing research and development
 activities, including: salary and benefits; stock-based
 compensation expense; laboratory supplies and other direct
 expenses; contractual services, including clinical trial and
 pharmaceutical development costs; commercial supply investment in
 its drug candidates; and infrastructure costs, including facilities
 costs and depreciation expense. In addition, research and
 development costs include the costs of product supply received from
 suppliers when such receipt by the Company is prior to regulatory
 approval of the supplier.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Selling, General and Administrative Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company charges selling, general and administrative costs to
 operations as incurred. Selling, general and administrative costs
 include costs of salaries, programs and infrastructure necessary
 for the general conduct of the Company&amp;#x2019;s business, including
 those incurred as a result of the commercialization of Vascepa in
 the United States as well as co-promotion fees payable to Kowa
 Pharmaceuticals America, Inc.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Income Taxes&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Deferred tax assets and liabilities are recognized for the future
 tax consequences of differences between the carrying amounts and
 tax bases of assets and liabilities and operating loss
 carryforwards and other attributes using enacted rates expected to
 be in effect when those differences reverse. Valuation allowances
 are provided against deferred tax assets that are not more likely
 than not to be realized.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company provides reserves for potential payments of tax to
 various tax authorities or does not recognize tax benefits related
 to uncertain tax positions and other issues. Tax benefits for
 uncertain tax positions are based on a determination of whether a
 tax benefit taken by the Company in its tax filings or positions is
 more likely than not to be realized, assuming that the matter in
 question will be decided based on its technical merits. The
 Company&amp;#x2019;s policy is to record interest and penalties in the
 provision for income taxes.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company regularly assesses its ability to realize deferred tax
 assets. Changes in historical earnings performance and future
 earnings projections, among other factors, may cause the Company to
 adjust its valuation allowance on deferred tax assets, which would
 impact the Company&amp;#x2019;s income tax expense in the period in
 which it is determined that these factors have changed.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In April 2016, the Company adopted ASU No.&amp;#xA0;2016-09,
 &lt;i&gt;Compensation&amp;#x2014;Stock Compensation (Topic 718): Improvements
 to Employee Share-Based Payment Accounting,&lt;/i&gt; which changes the
 accounting for certain aspects of share-based payments to
 employees. One aspect of the standard requires that excess tax
 benefits and deficiencies that arise upon vesting or exercise of
 share-based payments be recognized as an income tax benefit and
 expense in the income statement. Previously, such amounts were
 recognized as an increase and decrease in additional paid-in
 capital. This aspect of the standard was adopted prospectively, and
 accordingly, the benefit from income taxes for the three and six
 months ended June&amp;#xA0;30, 2016, includes $0.1 million and $0.2
 million, respectively, of excess tax deficiencies arising from
 share-based payments. Additionally, the new standard requires that
 historical excess tax benefits that were not previously recognized
 because the related tax deduction had not reduced current taxes
 payable should be recognized on a modified retrospective basis as a
 cumulative-effect adjustment to retained earnings as of the
 beginning of the annual period of adoption. Consequently, the
 Company recognized deferred tax assets of approximately $1.6
 million relating to excess tax benefits of stock-based compensation
 outstanding as of December&amp;#xA0;31, 2015, with a corresponding
 cumulative-effect adjustment to accumulated deficit. The new
 standard also amends the presentation of employee share-based
 payment-related items in the statement of cash flows by requiring
 that: (i)&amp;#xA0;excess income tax benefits and deficiencies be
 classified in cash flows from operating activities, and
 (ii)&amp;#xA0;cash paid to taxing authorities arising from the
 withholding of shares from employees be classified as cash flows
 from financing activities. The Company adopted the aspects of the
 standard affecting cash flow presentation retrospectively and,
 accordingly, reclassified $0.6 million of excess tax provision from
 cash flows provided by financing activities to cash flows used in
 operating activities in the condensed consolidated statement of
 cash flows for the six months ended June&amp;#xA0;30, 2015 to conform
 to the current year presentation. The presentation requirement for
 cash flows related to taxes paid for withheld shares had no impact
 to any of the periods presented in the condensed consolidated
 statement of cash flows since such payments have historically been
 presented as a financing activity.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company&amp;#x2019;s and its subsidiaries&amp;#x2019; income tax returns
 are periodically examined by various tax authorities. The Company
 is currently under audit by the United States Internal Revenue
 Service (IRS) for the years 2012 to 2013. Although the outcome of
 tax audits is always uncertain and could result in significant cash
 tax payments, the Company does not believe the outcome of these
 audits will have a material adverse effect on the Company&amp;#x2019;s
 consolidated financial position or results of operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Derivative Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Derivative financial liabilities are recorded at fair value, with
 gains and losses arising for changes in fair value recognized in
 the condensed consolidated statement of operations at each period
 end while such instruments are outstanding. If the Company issues
 shares to discharge the liability, the derivative financial
 liability is derecognized and common stock and additional paid-in
 capital are recognized on the issuance of those shares. Warrants
 are valued using a Black-Scholes option pricing model. The
 long-term debt redemption features are valued using
 probability-weighted models incorporating management estimates for
 potential change in control, and by determining the fair value of
 the debt with and without the change in control provision
 included.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 If the terms of warrants that initially require the warrant to be
 classified as a derivative financial liability lapse, the
 derivative financial liability is reclassified out of financial
 liabilities into equity at its fair value on that date. The cash
 proceeds received from exercises of warrants are recorded in common
 stock and additional paid-in capital.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Loss per Share&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Basic net loss per share is determined by dividing net loss by the
 weighted average shares of common stock outstanding during the
 period. Diluted net loss per share is determined by dividing net
 loss by diluted weighted average shares outstanding. Diluted
 weighted average shares reflects the dilutive effect, if any, of
 potentially dilutive common shares, such as common stock options
 and warrants calculated using the treasury stock method and
 convertible notes using the &amp;#x201C;if-converted&amp;#x201D; method. In
 periods with reported net operating losses, all common stock
 options and warrants are deemed anti-dilutive such that basic net
 loss per share and diluted net loss per share are equal. However,
 in certain periods in which there is a gain recorded pursuant to
 the change in fair value of the warrant derivative liability, for
 diluted net loss per share purposes, the impact of such gains is
 reversed and the treasury stock method is used to determine diluted
 net loss per share.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The Company&amp;#x2019;s preferred stock is entitled to receive
 dividends on an as-if-converted basis in the same form as dividends
 actually paid on common shares. Accordingly, the preferred stock is
 considered a participating security and the Company is required to
 apply the two-class method to consider the impact of the preferred
 stock on the calculation of basic and diluted earnings per share.
 The Company is currently in a net loss position and is therefore
 not required to present the two-class method, however, in the event
 the Company is in a net income position, the two-class method must
 be applied by allocating all earnings during the period to common
 shares and preferred stock based on their contractual entitlements
 assuming all earnings were distributed.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The calculation of net loss and the number of shares used to
 compute basic and diluted net loss per share for the three and six
 months ended June&amp;#xA0;30, 2016 and 2015 are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Six&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(13,354&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(31,512&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(43,125&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(62,638&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Preferred stock purchase option (see Note 8)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(868&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Preferred stock beneficial conversion feature (see Note 8)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(31,341&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(31,341&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss applicable to common shareholders&amp;#x2014;basic&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(13,354&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(62,853&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(43,125&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(94,847&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Gain on warrant derivative liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(119&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss&amp;#x2014;diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(13,354&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(62,853&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(43,125&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(94,966&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss per share&amp;#x2014;basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.07&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.35&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.23&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.53&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted average shares outstanding&amp;#x2014;basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;184,471&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,464&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;184,262&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;178,036&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 For the three and six months ended&amp;#xA0;June 30, 2016 and 2015, the
 following potentially dilutive securities were not included in the
 computation of net loss per share because the effect would be
 anti-dilutive:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three months
 ended&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Six months
 ended&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,641&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,750&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,641&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,750&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Restricted stock and restricted stock units&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,361&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,046&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,361&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,046&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exchangeable senior notes (if converted)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;59,407&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;49,215&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;59,407&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;49,215&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Preferred stock (if converted)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32,818&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,932&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32,818&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,932&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Debt Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Debt instruments are initially recorded at fair value, with coupon
 interest and amortization of debt issuance discounts recognized in
 the condensed consolidated statement of operations as interest
 expense each period in which such instruments are outstanding. If
 the Company issues shares to discharge the liability, the debt
 obligation is derecognized and common stock and additional paid-in
 capital are recognized on the issuance of those shares. The
 conversion features in the 2012 Notes, 2014 Notes, and 2015 Notes
 qualify for the exception from derivative accounting in accordance
 with ASC 815-40. The 2012 Notes may be settled, at the
 Company&amp;#x2019;s discretion, in any combination of ADSs or cash upon
 conversion and have been accounted for in accordance with ASC
 470-20. Under ASC 470-20, the fair value of the liability component
 of the 2012 Notes was determined and deducted from the initial
 proceeds to determine the proceeds allocated to the conversion
 option, which has been recorded in equity. The difference between
 the initial fair value of the liability component and the amount
 repayable was amortized over the expected term of the instrument.
 The conversion features in the 2014 Notes and 2015 Notes may only
 be settled in ADSs upon conversion and have been accounted for as
 part of the debt host.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The conversion options in the 2012 Notes, 2014 Notes, and 2015
 Notes continue to be evaluated on a quarterly basis to determine if
 they still receive an exception from derivative accounting in
 accordance with ASC 815-40. The 2014 Notes were recognized
 initially at fair value as part of an extinguishment of a portion
 of the 2012 Notes. As a result, the 2014 Notes were initially
 recognized at a discount of $27.9 million. The 2015 Notes were
 recognized initially at fair value as part of the issuance of new
 debt in November 2015. As a result, the 2015 Notes were initially
 recognized at a discount of $3.8 million. These discounts are being
 amortized through interest expense over the expected terms of the
 2014 Notes and 2015 Notes, which is through January 2019 for each.
 See Note 6&amp;#x2014;Debt for further discussion.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Stock-Based Compensation&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Stock-based compensation cost is generally measured at the grant
 date, based on the fair value of the award, and is recognized as
 compensation expense over the requisite service period. For awards
 with performance conditions, if the achievement of the performance
 conditions is deemed probable, the Company recognizes compensation
 expense based on the fair value of the award over the estimated
 service period. The Company reassesses the probability of
 achievement of the performance conditions for such awards each
 reporting period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Concentration of Credit Risk&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Financial instruments that potentially subject the Company to
 credit risk consist primarily of cash and cash equivalents and
 accounts receivable. The Company maintains substantially all of its
 cash and cash equivalents in financial institutions believed to be
 of high-credit quality.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 A significant portion of the Company&amp;#x2019;s sales are to
 wholesalers in the pharmaceutical industry. The Company monitors
 the creditworthiness of customers to whom it grants credit terms
 and has not experienced any credit losses. The Company does not
 require collateral or any other security to support credit sales.
 The Company&amp;#x2019;s top three customers accounted for 95% of gross
 product sales for each of the six months ending June&amp;#xA0;30, 2016
 and 2015 and represented 94% and 96% of the gross accounts
 receivable balance as of June&amp;#xA0;30, 2016 and 2015, respectively.
 The Company has not experienced any write-offs of its accounts
 receivable.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Concentration of Suppliers&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company has contractual freedom to source the API for Vascepa
 and has entered into supply agreements with multiple suppliers. The
 Company&amp;#x2019;s supply of product for commercial sale and clinical
 trials is dependent upon relationships with third-party
 manufacturers and key suppliers, in particular three suppliers of
 API for Vascepa.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company cannot provide assurance that its efforts to procure
 uninterrupted supply of Vascepa API to meet market demand will
 continue to be successful or that it will be able to renew current
 API supply agreements on favorable terms or at all. Significant
 alteration to or termination of the Company&amp;#x2019;s current API
 supply chain or its failure to enter into new and similar
 agreements, if needed, could have a material adverse effect on its
 business, condition (financial and other), prospects or results of
 operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company currently has manufacturing agreements with three
 FDA-approved commercial API encapsulators for Vascepa
 manufacturing. Each of these companies has qualified its
 manufacturing processes and is capable of manufacturing Vascepa.
 There can be no guarantee that these or other suppliers with which
 the Company may contract in the future to encapsulate API will
 continue to be qualified to manufacture the product to its
 specifications or that these and any future suppliers will have the
 manufacturing capacity to meet anticipated demand for Vascepa.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Foreign Currency&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 All subsidiaries use the U.S. dollar as the functional currency.
 Monetary assets and liabilities denominated in a foreign currency
 are remeasured into U.S. dollars at period-end exchange rates.
 Gains and losses from the remeasurement are included in other
 (expense) income, net in the condensed consolidated statements of
 operations. For transactions settled during the applicable period,
 gains and losses are included in other (expense) income, net in the
 condensed consolidated statements of operations. Certain amounts
 payable pursuant to supply contracts are denominated in currencies
 other than the U.S. dollar.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Debt Issuance Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Prior to January 2016, debt issuance costs were initially recorded
 as a deferred cost and amortized to interest expense using the
 effective interest method over the expected term of the related
 debt. Effective January 2016, the Company adopted ASU
 No.&amp;#xA0;2015-03, &lt;i&gt;Interest&amp;#x2014;Imputation of Interest
 (Subtopic 835-30): Simplifying the Presentation of Debt Issuance
 Costs&lt;/i&gt;, and as such began recording debt issuance costs related
 to a recognized debt liability in the condensed consolidated
 balance sheet as a direct deduction from the carrying amount of
 that debt liability and amortized to interest expense using the
 effective interest method over the expected term of the related
 debt. As the standard is required to be adopted on a retrospective
 basis, the Company reclassified $1.9 million of underwriters&amp;#x2019;
 fees and offering costs related to the 2014 and 2015 exchangeable
 notes from other long-term assets to exchangeable senior notes, net
 of discount, within the condensed consolidated balance sheet as of
 December&amp;#xA0;31, 2015. Unamortized debt issuance costs related to
 the extinguishment of debt are expensed at the time the debt is
 extinguished and recorded in other (expense) income, net in the
 condensed consolidated statements of operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Fair Value of Financial Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company provides disclosure of financial assets and financial
 liabilities that are carried at fair value based on the price that
 would be received upon sale of an asset or paid to transfer a
 liability in an orderly transaction between market participants at
 the measurement date.&amp;#xA0;Fair value measurements may be
 classified based on the amount of subjectivity associated with the
 inputs to fair valuation of these assets and liabilities using the
 following three levels:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Level 1&amp;#x2014;Inputs are unadjusted quoted prices in active markets
 for identical assets or liabilities that the Company has the
 ability to access at the measurement date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Level 2&amp;#x2014;Inputs include quoted prices for similar assets and
 liabilities in active markets, quoted prices for identical or
 similar assets or liabilities in markets that are not active,
 inputs other than quoted prices that are observable for the asset
 or liability (i.e., interest rates, yield curves, etc.) and inputs
 that are derived principally from or corroborated by observable
 market data by correlation or other means (market corroborated
 inputs).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Level 3&amp;#x2014;Unobservable inputs that reflect the Company&amp;#x2019;s
 estimates of the assumptions that market participants would use in
 pricing the asset or liability.&amp;#xA0;The Company develops these
 inputs based on the best information available, including its own
 data.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following tables present information about the Company&amp;#x2019;s
 assets and liabilities as of June&amp;#xA0;30, 2016 and
 December&amp;#xA0;31, 2015 that are measured at fair value on a
 recurring basis and indicate the fair value hierarchy of the
 valuation techniques the Company utilized to determine such fair
 value:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;June&amp;#xA0;30, 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Asset:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash equivalents&amp;#x2014;money markets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Liabilities:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Long-term debt derivative liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,610&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,610&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;December&amp;#xA0;31, 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Asset:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash equivalents&amp;#x2014;money markets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,184&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,184&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Liabilities:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Long-term debt derivative liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,170&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,170&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The carrying amounts of cash, cash equivalents, accounts payable
 and accrued liabilities approximate fair value because of their
 short-term nature. The carrying amounts and the estimated fair
 values of debt instruments as of June&amp;#xA0;30, 2016 and
 December&amp;#xA0;31, 2015 are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;June&amp;#xA0;30, 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31, 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Carrying&lt;br /&gt;
 Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Estimated&lt;br /&gt;
 Fair&amp;#xA0;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Carrying&lt;br /&gt;
 Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Estimated&lt;br /&gt;
 Fair&amp;#xA0;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Long-term debt&amp;#x2014;December 2012 financing&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;92,533&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;89,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;91,512&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;87,700&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2012 Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,107&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,686&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,107&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,637&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2014 Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;97,994&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;122,959&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;94,599&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;108,034&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2015 Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32,378&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,028&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,448&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The estimated fair value of the long-term debt pursuant to the
 December 2012 financing is calculated utilizing the same Level 3
 inputs utilized in valuing the related derivative liability (see
 Long-Term Debt Redemption Features below).&amp;#xA0;The estimated fair
 value of the 2012 Notes and 2014 Notes is calculated based on Level
 1 quoted bond prices, while the estimated fair value of the 2015
 Notes is calculated based on Level 2 quoted bond prices for the
 2014 Notes.&amp;#xA0;The carrying value of the 2012 Notes as of
 June&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015 does not include a
 debt discount, as it had been fully amortized as non-cash interest
 expense over the expected term of the 2012 Notes, which was
 calculated to be a period of twenty-four months. The carrying value
 of the 2014 Notes as of June&amp;#xA0;30, 2016 and December&amp;#xA0;31,
 2015 includes a debt discount of $20.7 million and $24.1 million,
 respectively, which is being amortized as non-cash interest expense
 over the expected term of the 2014 Notes, through January 2019. The
 carrying value of the 2015 Notes as of June&amp;#xA0;30, 2016 and
 December&amp;#xA0;31, 2015 includes a debt discount of $3.6 million and
 $4.2 million, respectively, which is being amortized as non-cash
 interest expense over the expected term of the 2015 Notes, through
 January 2019. The carrying values and related debt discounts of the
 2014 Notes and 2015 Notes as of December&amp;#xA0;31, 2015 reflect the
 retroactive reclassification of debt issuance costs per adoption of
 ASU No.&amp;#xA0;2015-03 as described in Note 6&amp;#x2014;Debt. The change
 in the estimated fair values of these liabilities from
 December&amp;#xA0;31, 2015 to June&amp;#xA0;30, 2016 is largely related to
 changes in the quoted bond prices.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Derivative Liabilities&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 &lt;i&gt;Warrant Derivative Liability&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company&amp;#x2019;s warrant derivative liability (discussed in Note
 5&amp;#x2014;Warrants and Warrant Derivative Liability) was carried at
 fair value and was classified as Level 3 in the fair value
 hierarchy due to the use of significant unobservable inputs. During
 the six months ended June&amp;#xA0;30, 2015, of the 8,087,388 warrants
 outstanding as of December&amp;#xA0;31, 2014, 1,844,585 warrants were
 exercised while the remaining 6,242,803 warrants expired, and the
 related derivative liability was extinguished. As such, no warrants
 were outstanding as of June&amp;#xA0;30, 2016 and December&amp;#xA0;31,
 2015.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Long-Term Debt Redemption Features&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company&amp;#x2019;s December 2012 financing agreement with
 BioPharma Secured Debt Fund II Holdings Cayman LP (discussed in
 Note&amp;#xA0;6&amp;#x2014;Debt) contains a redemption feature whereby, upon
 a change of control, the Company would be required to repay $150
 million, less any previously repaid amount. The Company determined
 this redemption feature to be an embedded derivative, which is
 carried at fair value and is classified as Level 3 in the fair
 value hierarchy due to the use of significant unobservable
 inputs.&amp;#xA0;The fair value of the embedded derivative was
 calculated using a probability-weighted model incorporating
 management estimates of future revenues and for a potential change
 in control, and by determining the fair value of the debt with and
 without the change in control provision included. The difference
 between the two was determined to be the fair value of the embedded
 derivative. As of June&amp;#xA0;30, 2016, the fair value of the
 derivative was determined to be $2.8 million, and the debt was
 valued by comparing debt issues of similar companies with
 (i)&amp;#xA0;remaining terms of between 1.6 and 5.9 years,
 (ii)&amp;#xA0;coupon rates of between 6.6% and 12.5% and
 (iii)&amp;#xA0;market yields of between 11.0% and 27.7%. As of
 December&amp;#xA0;31, 2015, the fair value of the derivative was
 determined to be $5.5 million, and the debt was valued by comparing
 debt issues of similar companies with (i)&amp;#xA0;remaining terms of
 between 2.0 and 7.3 years, (ii)&amp;#xA0;coupon rates of between 6.6%
 and 12.5% and (iii)&amp;#xA0;market yields of between 13.0% and 30.7%.
 As such, the Company recognized a $2.7 million gain on change in
 fair value of derivative liability for the six months ended
 June&amp;#xA0;30, 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company&amp;#x2019;s 2014 Notes and 2015 Notes each contain a
 redemption feature whereby, upon occurrence of a change in control,
 the Company would be required to repurchase the notes. The Company
 determined these redemption features to be embedded derivatives,
 requiring bifurcation in accordance with ASC 815. The derivatives
 are carried at fair value and are classified as Level 3 in the fair
 value hierarchy due to the use of significant unobservable
 inputs.&amp;#xA0;The fair value of each embedded derivative was
 calculated using a probability-weighted model incorporating
 management estimates of the probability of a change in control
 occurring, and by determining the fair value of the debt with and
 without the change in control provision included. The difference
 between the two was determined to be the fair value of the embedded
 derivative. As of June&amp;#xA0;30, 2016, the fair values of the
 derivatives related to the 2014 Notes and 2015 Notes were
 determined to be $0.6 million and $0.2 million, respectively, and
 the debts were valued by using (i)&amp;#xA0;the estimated remaining
 term of the notes, (ii)&amp;#xA0;a bond yield of 20.6%, (iii)&amp;#xA0;a
 risk-free interest rate of 2.0% and (iv)&amp;#xA0;volatility of 86.0%.
 As of December&amp;#xA0;31, 2015, the fair values of the derivatives
 related to the 2014 Notes and 2015 Notes were determined to be $2.1
 million and $0.6 million, respectively, and the debts were valued
 by using (i)&amp;#xA0;the estimated remaining term of the notes,
 (ii)&amp;#xA0;a bond yield of 25.6%, (iii)&amp;#xA0;a risk-free interest
 rate of 2.9% and (iv)&amp;#xA0;volatility of 89.0%. As such, the
 Company recognized a $1.5 million gain and $0.4 million gain on
 change in fair value of derivative liability for the 2014 Notes and
 2015 Notes, respectively, for the six months ended June&amp;#xA0;30,
 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Preferred Stock Purchase Option Derivative Liability&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Pursuant to a pre-existing contractual right to participate in
 certain private placement transactions effected by the Company in
 connection with the subscription agreement executed on
 March&amp;#xA0;5, 2015, the Company determined that such right
 represented a derivative liability (see Note 8). This preferred
 stock purchase option derivative liability was carried at fair
 value and classified as Level 3 in the fair value hierarchy due to
 the use of significant unobservable inputs. The fair value of this
 liability was calculated using a Black-Scholes model and was
 determined to be $0.9 million at inception. On March&amp;#xA0;30, 2015,
 this right was exercised and the liability was marked to fair value
 through such date. The liability was then reclassified to permanent
 equity on such date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Any changes in the assumptions used to value the derivative
 liabilities, including the probability of a change in control,
 could result in a material change to the carrying value of such
 liabilities.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The change in the fair value of derivative liabilities for the six
 months ended June&amp;#xA0;30, 2016 and 2015 is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;October&lt;br /&gt;
 2009&lt;br /&gt;
 Warrants&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Long-Term&amp;#xA0;Debt&lt;/font&gt;&lt;br /&gt;
 Derivative&lt;br /&gt;
 Liabilities&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Preferred&amp;#xA0;Stock&lt;br /&gt;
 Purchase&amp;#xA0;Option&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Totals&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Balance as of December&amp;#xA0;31, 2015&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;8,170&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;8,170&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Gain on change in fair value of derivative liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,560&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,560&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Balance as of June&amp;#xA0;30, 2016&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;3,610&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;3,610&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;October&lt;br /&gt;
 2009&lt;br /&gt;
 Warrants&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Long-Term&amp;#xA0;Debt&lt;/font&gt;&lt;br /&gt;
 Derivative&lt;br /&gt;
 Liabilities&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Preferred&amp;#xA0;Stock&lt;br /&gt;
 Purchase&amp;#xA0;Option&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Totals&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Balance as of December&amp;#xA0;31, 2014&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;119&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#xA0;7,400&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;7,519&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Record derivative liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;868&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;868&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 (Gain) loss on change in fair value of derivative liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(110&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(700&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;946&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;136&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Compensation income for change in fair value of warrants issued to
 former employees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Transfer derivative liability to equity&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,814&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,814&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Balance as of June&amp;#xA0;30, 2015&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;6,700&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;6,700&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Segment and Geographical Information&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Operating segments are defined as components of an enterprise about
 which separate financial information is available that is evaluated
 on a regular basis by the chief operating decision-maker, or
 decision making group, in deciding how to allocate resources to an
 individual segment and in assessing performance of the segment. The
 Company currently operates in one business segment, which is the
 development and commercialization of Vascepa. A single management
 team that reports to the Company&amp;#x2019;s chief decision-maker, who
 is the Chief Executive Officer, comprehensively manages the
 business. Accordingly, the Company does not have separately
 reportable segments.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Recent Accounting Pronouncements&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 From time to time, new accounting pronouncements are issued by the
 Financial Accounting Standards Board, or FASB, and are early
 adopted by the Company or adopted as of the specified effective
 date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In January 2016, the Company adopted ASU No.&amp;#xA0;2015-03,
 &lt;i&gt;Interest&amp;#x2014;Imputation of Interest (Subtopic 835-30):
 Simplifying the Presentation of Debt Issuance Costs&lt;/i&gt;, which
 provides guidance on simplifying the presentation of debt issuance
 costs on the balance sheet. To simplify presentation of debt
 issuance costs, the amendments in ASU No.&amp;#xA0;2015-03 require that
 debt issuance costs related to a recognized debt liability be
 presented in the balance sheet as a direct deduction from the
 carrying amount of that debt liability, consistent with the
 treatment of debt discounts. The recognition and measurement
 guidance for debt issuance costs are not affected by the amendments
 in this update. In accordance with ASU No.&amp;#xA0;2015-03, the
 Company applied the new guidance on a retrospective basis, wherein
 the condensed consolidated balance sheet of each individual period
 presented was adjusted to reflect the period-specific effects of
 applying the new guidance. See Note 6&lt;i&gt;&amp;#x2014;&lt;/i&gt;Debt.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In April 2016, the Company adopted ASU No.&amp;#xA0;2015-11,
 &lt;i&gt;Inventory (Topic 330): Simplifying the Measurement of
 Inventory&lt;/i&gt;, which simplifies the subsequent measurement of
 inventories by replacing the lower of cost or market test with a
 lower of cost or net realizable value test. When evidence exists
 that the net realizable value of inventory is less than its cost
 (due to damage, physical deterioration, obsolescence, changes in
 price levels or other causes), the Company will recognize the
 difference as a component of cost of goods sold in the period in
 which it occurs. In accordance with ASU No.&amp;#xA0;2015-11, the
 Company applied the new guidance on a prospective basis with no
 impact on the carrying amount of inventory.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Also in April 2016, the Company adopted ASU No.&amp;#xA0;2016-09,
 &lt;i&gt;Compensation&amp;#x2014;Stock Compensation (Topic 718): Improvements
 to Employee Share-Based Payment Accounting,&lt;/i&gt; which changes the
 accounting for certain aspects of share-based payments to
 employees. One aspect of the standard requires that excess tax
 benefits and deficiencies that arise upon vesting or exercise of
 share-based payments be recognized as an income tax benefit and
 expense in the income statement. Previously, such amounts were
 recognized as an increase and decrease in additional paid-in
 capital. This aspect of the standard was adopted prospectively, and
 accordingly, the benefit from income taxes for the three and six
 months ended June&amp;#xA0;30, 2016, includes $0.1 million and $0.2
 million, respectively, of excess tax deficiencies arising from
 share-based payments. Additionally, the new standard requires that
 historical excess tax benefits that were not previously recognized
 because the related tax deduction had not reduced current taxes
 payable should be recognized on a modified retrospective basis as a
 cumulative-effect adjustment to retained earnings as of the
 beginning of the annual period of adoption. Consequently, the
 Company recognized deferred tax assets of approximately $1.6
 million relating to excess tax benefits on stock-based compensation
 outstanding as of December&amp;#xA0;31, 2015, with a corresponding
 cumulative-effect adjustment to accumulated deficit. The new
 standard also amends the presentation of employee share-based
 payment-related items in the statement of cash flows by requiring
 that: (i)&amp;#xA0;excess income tax benefits and deficiencies be
 classified in cash flows from operating activities, and
 (ii)&amp;#xA0;cash paid to taxing authorities arising from the
 withholding of shares from employees be classified as cash flows
 from financing activities. The Company adopted the aspects of the
 standard affecting cash flow presentation retrospectively and,
 accordingly, reclassified $0.6 million of excess tax provision from
 cash flows provided by financing activities to cash flows used in
 operating activities in the condensed consolidated statement of
 cash flows for the six months ended June&amp;#xA0;30, 2015 to conform
 to the current year presentation. The presentation requirement for
 cash flows related to taxes paid for withheld shares had no impact
 to any of the periods presented in the condensed consolidated
 statement of cash flows since such payments have historically been
 presented as a financing activity.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company also considered the following recent accounting
 pronouncements which were not yet adopted as of June&amp;#xA0;30,
 2016:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In May 2014, the FASB issued ASU No.&amp;#xA0;2014-09, &lt;i&gt;Revenue from
 Contracts with Customers (Topic 606)&lt;/i&gt;. This amendment provides
 principles for recognizing revenue for the transfer of promised
 goods or services to customers with the consideration to which the
 entity expects to be entitled in exchange for those goods or
 services, and is effective for annual periods beginning after
 December&amp;#xA0;15, 2016 (the original effective date). In April
 2015, the FASB issued a proposal, which was subsequently adopted in
 July 2015, to defer the original effective date of this standard by
 one year, such that the amendment is effective for the
 Company&amp;#x2019;s fiscal year beginning January&amp;#xA0;1, 2018. Early
 adoption is permitted, but not before the original effective date.
 The Company is currently evaluating the accounting, transition and
 disclosure requirements of the standard and cannot currently
 estimate the financial statement impact of adoption.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In August 2014, the FASB issued ASU No.&amp;#xA0;2014-15,
 &lt;i&gt;Presentation of Financial Statements&amp;#x2014;Going Concern
 (Subtopic 205-40): Disclosure of Uncertainties about an
 Entity&amp;#x2019;s Ability to Continue as a Going Concern&lt;/i&gt;. ASU
 2014-15 requires management to assess an entity&amp;#x2019;s ability to
 continue as a going concern by incorporating and expanding upon
 certain principles that are currently in U.S. auditing standards.
 Specifically, the ASU (i)&amp;#xA0;provides a definition of the term
 substantial doubt, (ii)&amp;#xA0;requires an evaluation every reporting
 period including interim periods, (iii)&amp;#xA0;provides principles
 for considering the mitigating effect of management&amp;#x2019;s plans,
 (iv)&amp;#xA0;requires certain disclosures when substantial doubt is
 alleviated as a result of consideration of management&amp;#x2019;s
 plans, (v)&amp;#xA0;requires an express statement and other disclosures
 when substantial doubt is not alleviated and (vi)&amp;#xA0;requires an
 assessment for a period of one year after the date that the
 financial statements are issued (or available to be issued). This
 standard is effective for fiscal years ending after
 December&amp;#xA0;15, 2016, and for annual and interim periods
 thereafter. Early application is permitted. The Company has
 determined that this standard would not have a material impact on
 its condensed consolidated financial statements based on the
 assessment of its ability to continue as a going concern as of
 June&amp;#xA0;30, 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In January 2016, the FASB issued ASU No.&amp;#xA0;2016-01, &lt;i&gt;Financial
 Instruments&amp;#x2014;Overall (Subtopic 825-10): Recognition and
 Measurement of Financial Assets and Financial Liabilities&lt;/i&gt;. The
 new guidance is intended to improve the recognition and measurement
 of financial instruments by requiring separate presentation of
 financial assets and financial liabilities by measurement category
 and form of financial asset (i.e., securities or loans and
 receivables) within the balance sheet or the accompanying notes to
 the financial statements, eliminating the requirement for public
 business entities to disclose the method(s) and significant
 assumptions used to estimate the fair value that is required to be
 disclosed for financial instruments measured at amortized cost
 within the balance sheet, requiring public business entities to use
 the exit price notion when measuring the fair value of financial
 instruments for disclosure purposes, requiring equity investments
 (except those accounted for under the equity method of accounting,
 or those that result in consolidation of the investee) to be
 measured at fair value with changes in fair value recognized in net
 income, and requiring a reporting organization to present
 separately in other comprehensive income the portion of the total
 change in the fair value of a liability resulting from a change in
 the instrument-specific credit risk (also referred to as &amp;#x201C;own
 credit&amp;#x201D;) when the organization has elected to measure the
 liability at fair value in accordance with the fair value option
 for financial instruments, among others. The new guidance is
 effective for fiscal years beginning after December&amp;#xA0;15, 2017,
 including interim periods within those fiscal years. The new
 guidance permits early adoption of the own credit provision. The
 Company is currently evaluating the accounting, transition and
 disclosure requirements of the standard and cannot currently
 estimate the financial statement impact of adoption.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In February 2016, the FASB issued ASU No.&amp;#xA0;2016-02, &lt;i&gt;Leases
 (Topic 842)&lt;/i&gt;. The new guidance will require lessees to recognize
 a right-of-use asset and a lease liability for virtually all of
 their leases (other than leases that meet the definition of a
 short-term lease). The liability will be equal to the present value
 of lease payments. The asset will be based on the liability,
 subject to adjustment, such as for initial direct costs. Under the
 new guidance, lessor accounting is largely unchanged but certain
 targeted improvements were made to align, where necessary, lessor
 accounting with the lessee accounting model and Topic 606, Revenue
 from Contracts with Customers. The new lease guidance also
 simplified the accounting for sale and leaseback transactions
 primarily because lessees must recognize lease assets and lease
 liabilities and therefore, will no longer be provided with a source
 of off-balance sheet financing. The new guidance is effective for
 fiscal years beginning after December&amp;#xA0;15, 2018, including
 interim periods within those fiscal years. Early adoption is
 permitted. The Company is currently evaluating the accounting,
 transition and disclosure requirements of the standard and cannot
 currently estimate the financial statement impact of adoption.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In March 2016, the FASB issued ASU No.&amp;#xA0;2016-08, &lt;i&gt;Revenue
 from Contracts with Customers (Topic 606): Principal versus Agent
 Considerations (Reporting Revenue Gross versus Net)&lt;/i&gt;, which
 clarifies that an entity is a principal when it controls the
 specified good or service before that good or service is
 transferred to the customer, and is an agent when it does not
 control the specified good or service before it is transferred to
 the customer. The new guidance is intended to improve the
 operability and understandability of the implementation guidance on
 principal versus agent considerations. In April 2016, the FASB
 issued ASU No.&amp;#xA0;2016-10&lt;i&gt;, Revenue from Contracts with
 Customers (Topic 606): Identifying Performance Obligations and
 Licensing,&lt;/i&gt; which clarifies the following two aspects of Topic
 606: (a)&amp;#xA0;identifying performance obligations; and (b)&amp;#xA0;the
 licensing implementation guidance. Further, in May 2016, the FASB
 issued ASU No.&amp;#xA0;2016-12, &lt;i&gt;Revenue from Contracts with
 Customers (Topic 606): Narrow-Scope Improvements and Practical
 Expedients,&lt;/i&gt; which provides clarifying guidance in certain
 narrow areas and adds some practical expedients. The amendments do
 not change the core principles of the guidance in Topic 606 and are
 effective for the Company&amp;#x2019;s fiscal year beginning
 January&amp;#xA0;1, 2018. Early application is permitted only as of
 annual reporting periods beginning after December&amp;#xA0;15, 2016,
 including interim reporting periods within that reporting period.
 The Company is currently evaluating the accounting, transition and
 disclosure requirements of these standards and cannot currently
 estimate the financial statement impact of adoption.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company believes that the impact of other recently issued but
 not yet adopted accounting pronouncements will not have a material
 impact on the Company&amp;#x2019;s consolidated financial position,
 results of operations, and cash flows, or do not apply to the
 Company&amp;#x2019;s operations.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <dei:TradingSymbol contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_7122CAB9-2953-466D-BF94-16FD51A80C1D_1_400000">AMRN</dei:TradingSymbol>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_3_24" unitRef="shares">184262000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_3_23" unitRef="shares">184262000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <dei:AmendmentFlag contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_BA3A6215-CFF4-4E66-9004-D121F0B695FC_1_1">false</dei:AmendmentFlag>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_CEBB1C1D-66F0-47E5-8621-AB0CDDF85CFB_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Concentration of Credit Risk&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Financial instruments that potentially subject the Company to
 credit risk consist primarily of cash and cash equivalents and
 accounts receivable. The Company maintains substantially all of its
 cash and cash equivalents in financial institutions believed to be
 of high-credit quality.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 A significant portion of the Company&amp;#x2019;s sales are to
 wholesalers in the pharmaceutical industry. The Company monitors
 the creditworthiness of customers to whom it grants credit terms
 and has not experienced any credit losses. The Company does not
 require collateral or any other security to support credit sales.
 The Company&amp;#x2019;s top three customers accounted for 95% of gross
 product sales for each of the six months ending June&amp;#xA0;30, 2016
 and 2015 and represented 94% and 96% of the gross accounts
 receivable balance as of June&amp;#xA0;30, 2016 and 2015, respectively.
 The Company has not experienced any write-offs of its accounts
 receivable.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_E15891FF-1E94-4AEE-9B91-CAC719E61DE8_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Principles of Consolidation&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The condensed consolidated financial statements include the
 accounts of the Company and its wholly-owned subsidiaries. All
 intercompany accounts and transactions have been eliminated in
 consolidation.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_4810D818-ACB0-4B09-9B61-6E64A19D9749_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Derivative Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Derivative financial liabilities are recorded at fair value, with
 gains and losses arising for changes in fair value recognized in
 the condensed consolidated statement of operations at each period
 end while such instruments are outstanding. If the Company issues
 shares to discharge the liability, the derivative financial
 liability is derecognized and common stock and additional paid-in
 capital are recognized on the issuance of those shares. Warrants
 are valued using a Black-Scholes option pricing model. The
 long-term debt redemption features are valued using
 probability-weighted models incorporating management estimates for
 potential change in control, and by determining the fair value of
 the debt with and without the change in control provision
 included.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 If the terms of warrants that initially require the warrant to be
 classified as a derivative financial liability lapse, the
 derivative financial liability is reclassified out of financial
 liabilities into equity at its fair value on that date. The cash
 proceeds received from exercises of warrants are recorded in common
 stock and additional paid-in capital.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_3BEFE39F-8AE6-4B05-9883-04D942B93097_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Foreign Currency&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 All subsidiaries use the U.S. dollar as the functional currency.
 Monetary assets and liabilities denominated in a foreign currency
 are remeasured into U.S. dollars at period-end exchange rates.
 Gains and losses from the remeasurement are included in other
 (expense) income, net in the condensed consolidated statements of
 operations. For transactions settled during the applicable period,
 gains and losses are included in other (expense) income, net in the
 condensed consolidated statements of operations. Certain amounts
 payable pursuant to supply contracts are denominated in currencies
 other than the U.S. dollar.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_57600314-1C54-46E5-80B7-421AD76CC8D3_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Intangible Asset, net&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Intangible asset, net consists of a milestone payment paid to the
 former shareholders of Laxdale Limited related to the 2004
 acquisition of the rights to Vascepa, which is the result of
 Vascepa receiving marketing approval for the first indication and
 is amortized over its estimated useful life on a straight-line
 basis. See Note 7&amp;#x2014;Commitments and Contingencies for further
 information regarding other obligations related to the acquisition
 of Laxdale Limited.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_AAEB2F01-3408-4D31-AE19-6E6003A2112B_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;(1)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Nature of Business and Basis of
 Presentation&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Nature of Business&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Amarin Corporation plc (&amp;#x201C;Amarin&amp;#x201D; or the
 &amp;#x201C;Company&amp;#x201D;) is a biopharmaceutical company with
 expertise in lipid science focused on the commercialization and
 development of therapeutics to improve cardiovascular health.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company&amp;#x2019;s lead product, Vascepa&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt; (icosapent
 ethyl) capsules, is approved by the U.S. Food and Drug
 Administration, or FDA, for use as an adjunct to diet to reduce
 triglyceride levels in adult patients with severe (TG
 &lt;u&gt;&amp;gt;&lt;/u&gt;500 mg/dL) hypertriglyceridemia. Vascepa is available in
 the United States by prescription only. In January 2013, the
 Company began selling and marketing Vascepa in the United States.
 In August 2015, in addition to marketing Vascepa for severe
 hypertriglyceridemia, the Company commenced marketing Vascepa for
 use in adult patients with mixed dyslipidemia, as an adjunct to
 diet and an add-on to statin therapy in patients who despite statin
 therapy have high triglycerides (TGs &lt;u&gt;&amp;gt;&lt;/u&gt;200 mg/dL and
 &amp;lt;500 mg/dL), which the Company also refers to as persistently
 high triglycerides. This expanded promotion of Vascepa commenced
 pursuant to a federal court order and is continuing pursuant to an
 agreement among the Company, the FDA and the U.S. government. The
 Company sells Vascepa principally to a limited number of major
 wholesalers, as well as selected regional wholesalers and specialty
 pharmacy providers, or collectively, its Distributors or its
 customers, that in turn resell Vascepa to retail pharmacies for
 subsequent resale to patients and healthcare providers. The Company
 markets Vascepa through its sales force of approximately 150 sales
 professionals, including sales representatives and their managers.
 In May 2014, Kowa Pharmaceuticals America, Inc. commenced
 co-promotion of Vascepa in accordance with a co-promotion agreement
 with the Company. Kowa Pharmaceuticals America, Inc. co-promotes
 Vascepa through its no less than 250 sales representatives who now
 devote a substantial portion of their time to promoting Vascepa in
 conjunction with the promotion of Kowa Pharmaceutical America,
 Inc.&amp;#x2019;s primary product, a branded statin for patients with
 high cholesterol. The Company operates in one business segment.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company is also developing Vascepa for FDA approval of
 potential additional indications for use. In particular, the
 Company is conducting a cardiovascular outcomes study of Vascepa,
 titled REDUCE-IT (Reduction of Cardiovascular Events with
 EPA&amp;#x2014;Intervention Trial). The REDUCE-IT study, which commenced
 in 2011 and reached its approximately 8,000 patient enrollment
 target in March 2016, is designed to evaluate the efficacy of
 Vascepa in reducing major cardiovascular events in a high-risk
 patient population on statin therapy.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Basis of Presentation&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The condensed consolidated financial statements included herein
 have been prepared by the Company, without audit, in accordance
 with accounting principles generally accepted in the United States
 of America (the &amp;#x201C;U.S.&amp;#x201D; or the &amp;#x201C;United
 States&amp;#x201D;) and pursuant to the rules and regulations of the
 Securities and Exchange Commission, or the SEC. Certain information
 in the footnote disclosures of the financial statements has been
 condensed or omitted where it substantially duplicates information
 provided in the Company&amp;#x2019;s latest audited consolidated
 financial statements, in accordance with the rules and regulations
 of the SEC. These condensed consolidated financial statements
 should be read in conjunction with the Company&amp;#x2019;s audited
 consolidated financial statements and notes included in its Annual
 Report on Form 10-K for the fiscal year ended December&amp;#xA0;31,
 2015, or the 2015 Form 10-K, filed with the SEC. The consolidated
 balance sheet amounts at December&amp;#xA0;31, 2015 in this report were
 derived from the Company&amp;#x2019;s audited 2015 consolidated
 financial statements included in the 2015 Form 10-K.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The condensed consolidated financial statements reflect all
 adjustments of a normal and recurring nature that, in the opinion
 of management, are necessary to present fairly the Company&amp;#x2019;s
 financial position, results of operations and cash flows for the
 periods indicated. The preparation of the Company&amp;#x2019;s condensed
 consolidated financial statements in conformity with U.S. Generally
 Accepted Accounting Principles (&amp;#x201C;GAAP&amp;#x201D;) requires
 management to make estimates and assumptions that affect the
 reported amounts of assets and liabilities, disclosure of
 contingent assets and liabilities at the date of the financial
 statements, and the reported amounts of revenues and expenses
 during the reporting period. The results of operations for the
 three and six months ended June&amp;#xA0;30, 2016 and June&amp;#xA0;30,
 2015, respectively, are not necessarily indicative of the results
 for the entire fiscal year or any future period. Certain numbers
 presented throughout this document may not add precisely to the
 totals provided due to rounding. Absolute and percentage changes
 are calculated using the underlying amounts in thousands. Certain
 prior year balances have been reclassified to conform to current
 year presentation.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The accompanying consolidated financial statements of the Company
 and subsidiaries have been prepared on a basis which assumes that
 the Company will continue as a going concern, which contemplates
 the realization of assets and the satisfaction of liabilities and
 commitments in the normal course of business.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 As of June&amp;#xA0;30, 2016, the Company had current assets of $116.5
 million, including cash and cash equivalents of $72.5&amp;#xA0;million.
 The Company&amp;#x2019;s condensed consolidated balance sheets also
 include derivative liabilities as well as long-term debt and
 exchangeable senior notes. The outstanding January 2012
 exchangeable senior notes, or the 2012 Notes, may be redeemed by
 the Company on or after January&amp;#xA0;19, 2017 and may be put back
 to the Company by the holders on each of January&amp;#xA0;19, 2017,
 2022 and 2027 for cash equal to 100% of the principal amount of
 $15.1 million plus any accrued and unpaid interest. The outstanding
 May 2014 exchangeable senior notes, or the 2014 Notes, and the
 outstanding November 2015 exchangeable senior notes, or the 2015
 Notes, may be redeemed by the Company on or after January&amp;#xA0;19,
 2019 at the option of the holders and are not puttable by the
 holders prior to this date except upon the occurrence of certain
 contingent events. The 2012 Notes are exchangeable under certain
 circumstances into cash, American Depository Shares, or ADSs, or a
 combination of cash and ADSs, at the Company&amp;#x2019;s election. The
 2014 Notes and 2015 Notes are exchangeable under certain
 circumstances into ADSs. Accordingly, the 2012 Notes represent a
 short-term obligation while the long-term debt, 2014 Notes, and
 2015 Notes do not represent a short-term claim on the liquid assets
 of the Company.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company believes its cash and cash equivalents will be
 sufficient to fund its projected operations for at least the next
 twelve months. Depending on the level of cash generated from
 operations, additional capital will likely be required to sustain
 operations. The Company anticipates that quarterly net cash
 outflows in future periods will be variable.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_84ECC7D2-A9AE-4A55-9575-00FFD1C80380_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company sells Vascepa principally to a limited number of major
 wholesalers, as well as selected regional wholesalers and specialty
 pharmacy providers, or collectively, its Distributors or its
 customers, that in turn resell Vascepa to retail pharmacies for
 subsequent resale to patients and healthcare providers. Patients
 are required to have a prescription in order to purchase Vascepa.
 In accordance with GAAP, the Company&amp;#x2019;s revenue recognition
 policy requires that: (i)&amp;#xA0;there is persuasive evidence that an
 arrangement exists between the Company and the Distributor,
 (ii)&amp;#xA0;delivery has occurred, (iii)&amp;#xA0;collectability is
 reasonably assured and (iv)&amp;#xA0;the price is fixed or
 determinable.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company has contracts with its primary Distributors and
 delivery generally occurs when a Distributor receives Vascepa. The
 Company evaluates the creditworthiness of each of its Distributors
 to determine whether revenues can be recognized upon delivery,
 subject to satisfaction of the other requirements, or whether
 recognition is required to be delayed until receipt of payment. In
 order to conclude that the price is fixed or determinable, the
 Company must be able to (i)&amp;#xA0;calculate its gross product
 revenues from the sales to Distributors and (ii)&amp;#xA0;reasonably
 estimate its net product revenues. The Company calculates gross
 product revenues generally based on the wholesale acquisition cost
 that the Company charges its Distributors for Vascepa. The Company
 estimates its net product revenues by deducting from its gross
 product revenues (a)&amp;#xA0;trade allowances, such as invoice
 discounts for prompt payment and distributor fees,
 (b)&amp;#xA0;estimated government and private payor rebates,
 chargebacks and discounts, such as Medicaid reimbursements,
 (c)&amp;#xA0;reserves for expected product returns and
 (d)&amp;#xA0;estimated costs of incentives offered to certain indirect
 customers, including patients.&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Trade Allowances:&lt;/i&gt; The Company generally provides invoice
 discounts on Vascepa sales to its Distributors for prompt payment
 and pays fees for distribution services, such as fees for certain
 data that Distributors provide to the Company. The payment terms
 for sales to Distributors generally include a 2% discount for
 payment within 30&amp;#xA0;days while the fees for distribution
 services are based on contractual rates agreed with the respective
 Distributors. Based on judgment and experience, the Company expects
 its Distributors to earn these discounts and fees, and deducts the
 full amount of these discounts and fees from its gross product
 revenues and accounts receivable at the time such revenues are
 recognized.&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Rebates, Chargebacks and Discounts:&lt;/i&gt; The Company contracts
 with Medicaid, other government agencies and various private
 organizations, or collectively, Third-party Payors, so that Vascepa
 will be eligible for purchase by, or partial or full reimbursement
 from, such Third-party Payors. The Company estimates the rebates,
 chargebacks and discounts it will provide to Third-party Payors and
 deducts these estimated amounts from its gross product revenues at
 the time the revenues are recognized. The Company estimates the
 rebates, chargebacks and discounts that it will provide to
 Third-party Payors based upon (i)&amp;#xA0;the Company&amp;#x2019;s
 contracts with these Third-party Payors, (ii)&amp;#xA0;the
 government-mandated discounts applicable to government-funded
 programs, (iii)&amp;#xA0;information obtained from the Company&amp;#x2019;s
 Distributors and (iv)&amp;#xA0;information obtained from other third
 parties regarding the payor mix for Vascepa.&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Product Returns:&lt;/i&gt; The Company&amp;#x2019;s Distributors have the
 right to return unopened unprescribed Vascepa during the 18-month
 period beginning six months prior to the labeled expiration date
 and ending twelve months after the labeled expiration date. The
 expiration date for Vascepa is three years after it has been
 converted into capsule form, which is the last step in the
 manufacturing process for Vascepa and generally occurs within a few
 months before Vascepa is delivered to Distributors. The Company
 estimates future product returns on sales of Vascepa based on:
 (i)&amp;#xA0;data provided to the Company by its Distributors
 (including weekly reporting of Distributors&amp;#x2019; sales and
 inventory held by Distributors that provided the Company with
 visibility into the distribution channel in order to determine what
 quantities were sold to retail pharmacies and other providers),
 (ii)&amp;#xA0;information provided to the Company from retail
 pharmacies, (iii)&amp;#xA0;data provided to the Company by a third
 party data provider which collects and publishes prescription data,
 and other third parties, (iv)&amp;#xA0;historical industry information
 regarding return rates for similar pharmaceutical products,
 (v)&amp;#xA0;the estimated remaining shelf life of Vascepa previously
 shipped and currently being shipped to Distributors and
 (vi)&amp;#xA0;contractual agreements intended to limit the amount of
 inventory maintained by the Company&amp;#x2019;s Distributors.&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Other Incentives:&lt;/i&gt; Other incentives that the Company offers
 to indirect customers include co-pay mitigation rebates provided by
 the Company to commercially insured patients who have coverage for
 Vascepa and who reside in states that permit co-pay mitigation
 programs. The Company&amp;#x2019;s co-pay mitigation program is intended
 to reduce each participating patient&amp;#x2019;s portion of the
 financial responsibility for Vascepa&amp;#x2019;s purchase price to a
 specified dollar amount. Based upon the terms of the program and
 information regarding programs provided for similar specialty
 pharmaceutical products, the Company estimates the average co-pay
 mitigation amounts and the percentage of patients that it expects
 to participate in the program in order to establish its accruals
 for co-pay mitigation rebates and deducts these estimated amounts
 from its gross product revenues at the time the revenues are
 recognized. The Company adjusts its accruals for co-pay mitigation
 rebates based on actual redemption activity and estimates regarding
 the portion of issued co-pay mitigation rebates that it estimates
 will be redeemed.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The following tables summarize activity in each of the net product
 revenue allowance and reserve categories described above for the
 six months ended June&amp;#xA0;30, 2016 and 2015:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Trade&lt;br /&gt;
 Allowances&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Rebates,&lt;br /&gt;
 Chargebacks&lt;br /&gt;
 and&amp;#xA0;Discounts&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Product&lt;br /&gt;
 Returns&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Other&lt;br /&gt;
 Incentives&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Balance as of December&amp;#xA0;31, 2015&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;4,296&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;9,881&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;535&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,084&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;15,796&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Provision related to current period sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,048&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,945&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;257&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,614&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44,864&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Provision related to prior period sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(87&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(466&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(553&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Credits/payments made for current period sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,415&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10,750&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,910&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(20,075&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Credits/payments made for prior period sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,180&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,497&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(226&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,284&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(14,187&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Balance as of June&amp;#xA0;30, 2016&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;3,662&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;19,113&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;566&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,504&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;25,845&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Trade&lt;br /&gt;
 Allowances&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Rebates,&lt;br /&gt;
 Chargebacks&lt;br /&gt;
 and&amp;#xA0;Discounts&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Product&lt;br /&gt;
 Returns&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Other&lt;br /&gt;
 Incentives&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Balance as of December&amp;#xA0;31, 2014&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,207&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;3,610&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#xA0;481&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;792&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;7,090&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Provision related to current period sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,044&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,957&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;276&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,691&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,968&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Provision related to prior period sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(113&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(44&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(157&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Credits/payments made for current period sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,810&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,243&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,149&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12,202&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Credits/payments made for prior period sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,039&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,531&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(14&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(792&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,376&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Balance as of June&amp;#xA0;30, 2015&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,289&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;5,749&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;743&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,542&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;10,323&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Such net product revenue allowances and reserves are included
 within accrued expenses and other current liabilities within the
 condensed consolidated balance sheets, with the exception of trade
 allowances and chargebacks, which are included within accounts
 receivable, net as discussed below.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Multiple-Element Arrangements and Licensing Revenue&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 When evaluating multiple-element arrangements, the Company
 identifies the deliverables included within the agreement and
 evaluates which deliverables represent separate units of accounting
 based on whether the delivered element has stand-alone value to the
 customer or if the arrangement includes a general right of return
 for delivered items.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The consideration received is allocated between each of the
 separable elements in the arrangement using the relative selling
 price method. The selling price used for each separable element
 will be based on vendor specific objective evidence
 (&amp;#x201C;VSOE&amp;#x201D;) if available, third-party evidence if VSOE is
 not available, or estimated selling price if neither VSOE nor
 third-party evidence is available. Revenue is then recognized as
 each of the separable elements to which the revenue has been
 allocated is delivered.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company may receive up-front, non-refundable payments when
 licensing its intellectual property in conjunction with research,
 development and commercialization agreements. In determining the
 units of accounting, management evaluates whether the license has
 stand-alone value from the undelivered elements to the
 collaborative partner based on the consideration of the relevant
 facts and circumstances for each arrangement. Factors considered in
 this determination include the stage of development of the license
 delivered, research and development capabilities of the partner and
 the ability of partners to develop and commercialize Vascepa
 independent of the Company.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 When management believes the license to its intellectual property
 does not have stand-alone value from the other deliverables to be
 provided in the arrangement, the Company generally recognizes
 revenue attributable to the license over the Company&amp;#x2019;s
 contractual or estimated performance period. Any unrecognized
 portion of license revenue is classified within deferred revenue in
 the accompanying condensed consolidated balance sheets. When
 management believes the license to its intellectual property has
 stand-alone value, the Company recognizes revenue attributed to the
 license upon delivery. The periods over which revenue is recognized
 is subject to estimates by management and may change over the
 course of the agreement. Such a change could have a material impact
 on the amount of revenue the Company records in future periods.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Milestones&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Contingent consideration from activities that is earned upon the
 achievement of a substantive milestone is recognized in its
 entirety in the period in which the milestone is achieved. At the
 inception of each arrangement that includes milestone payments, the
 Company evaluates whether each milestone is substantive. This
 evaluation includes an assessment of whether: (a)&amp;#xA0;the
 consideration is commensurate with either (1)&amp;#xA0;the
 entity&amp;#x2019;s performance to achieve the milestone, or
 (2)&amp;#xA0;the enhancement of the value of the delivered item(s) as a
 result of a specific outcome resulting from the entity&amp;#x2019;s
 performance to achieve the milestone, (b)&amp;#xA0;the consideration
 relates solely to past performance and (c)&amp;#xA0;the consideration
 is reasonable relative to all of the deliverables and payment terms
 within the arrangement. The Company evaluates factors such as the
 scientific, clinical, regulatory, commercial and other risks that
 must be overcome to achieve the respective milestone, the level of
 effort and investment required and whether the milestone
 consideration is reasonable relative to all deliverables and
 payment terms in the arrangement in making this assessment.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 See Note 10&amp;#x2014;Development, Commercialization and Supply
 Agreement for further information regarding licensing revenue and
 milestones related to the Company&amp;#x2019;s multiple-element
 arrangement with Eddingpharm (Asia) Macao Commercial Offshore
 Limited.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_AC2CDF15-5BAD-461C-915E-153262D1375D_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The calculation of net loss and the number of shares used to
 compute basic and diluted net loss per share for the three and six
 months ended June&amp;#xA0;30, 2016 and 2015 are as follows:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Six&amp;#xA0;months&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(13,354&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(31,512&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(43,125&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(62,638&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Preferred stock purchase option (see Note 8)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(868&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Preferred stock beneficial conversion feature (see Note 8)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(31,341&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(31,341&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Net loss applicable to common shareholders&amp;#x2014;basic&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(13,354&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(62,853&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(43,125&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(94,847&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Gain on warrant derivative liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(119&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Net loss&amp;#x2014;diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(13,354&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(62,853&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(43,125&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(94,966&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Net loss per share&amp;#x2014;basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.07&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.35&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.23&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.53&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Weighted average shares outstanding&amp;#x2014;basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;184,471&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,464&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;184,262&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;178,036&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_13817BF0-DA7A-4D92-9BA6-92220CA59356_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Inventories as of June&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015
 consist of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&amp;#xA0;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Raw materials&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,596&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,096&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Work in process&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,748&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,640&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Finished goods&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,962&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,249&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total inventory&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,306&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,985&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_355FA83B-6BFD-4FE5-982F-B2B0E64592E3_1_0">&lt;div&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Stock-Based Compensation&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Stock-based compensation cost is generally measured at the grant
 date, based on the fair value of the award, and is recognized as
 compensation expense over the requisite service period. For awards
 with performance conditions, if the achievement of the performance
 conditions is deemed probable, the Company recognizes compensation
 expense based on the fair value of the award over the estimated
 service period. The Company reassesses the probability of
 achievement of the performance conditions for such awards each
 reporting period.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_938BD5E9-A023-4494-BBD9-FDB4D35A3605_3_8" unitRef="shares">184262000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_7122CAB9-2953-466D-BF94-16FD51A80C1D_1_400003">--12-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:DebtDisclosureTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_4EA8682A-F1B4-4C3E-BDBB-3F5E2DE0BD17_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;b&gt;(6)&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;b&gt;Debt&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;&lt;u&gt;Long-Term Debt&amp;#x2014;December 2012 Financing&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 On December&amp;#xA0;6, 2012, the Company entered into an agreement
 with BioPharma Secured Debt Fund II Holdings Cayman LP, or
 BioPharma. Under this agreement, the Company granted to BioPharma a
 security interest in future receivables associated with the Vascepa
 patent rights, in exchange for $100 million received at the closing
 of the agreement which occurred in December 2012. Under these
 terms, the Company continues to own all Vascepa intellectual
 property rights, however, such rights, as described below, could be
 used by BioPharma as collateral for repayment of the remaining
 unpaid balance under this agreement if the Company defaults on
 making required payments. In the agreement, the Company agreed to
 repay BioPharma up to $150&amp;#xA0;million with such repayment based
 on a portion of revenues and receivables generated from
 Vascepa.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 As of June&amp;#xA0;30, 2016, the remaining amount to be repaid to
 BioPharma is $132.1 million. During the three and six months ended
 June&amp;#xA0;30, 2016, the Company made repayments under the agreement
 of $2.5 million and $5.2 million, respectively, to BioPharma and an
 additional $3.3 million is scheduled to be paid in August 2016 for
 the second quarter of 2016. These payments were calculated based on
 the threshold limitation, as described below, as opposed to the
 scheduled quarterly repayments. Additional quarterly repayments,
 subject to the threshold limitation, are scheduled to be paid.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The maximum quarterly amounts which could be due for payment,
 except upon a change of control and subject each quarter to the
 threshold limitation, are as follows: $15.0 million in the fourth
 quarter of 2016 and first quarter of 2017, and a payment of $13.0
 million scheduled for payment in May 2017. All such payments reduce
 the remainder of the $150 million in aggregate payments to
 BioPharma. These quarterly payments are subject to a quarterly
 threshold amount whereby, if a calculated threshold, based on
 quarterly Vascepa revenues, is not achieved, the quarterly payment
 payable in that quarter can at the Company&amp;#x2019;s election be
 reduced, with the reduction carried forward without interest for
 payment in a future period. The payment of any carried forward
 amount is subject to similarly calculated threshold repayment
 amounts based on Vascepa revenue levels. Except upon a change of
 control in Amarin, the agreement does not expire until $150 million
 in aggregate has been repaid. Except in the event of the
 Company&amp;#x2019;s default, there is no compounding of interest and no
 scheduled cliff payment due under this agreement. Rather, payment
 will be made, subject to the threshold limitation, until $150
 million in aggregate has been repaid, including payments made
 previously. The Company can prepay an amount equal to $150 million
 less any previously repaid amount.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company currently estimates that its Vascepa revenue levels
 will not be high enough in each quarter to support repayment to
 BioPharma in accordance with the maximum quarterly amounts in the
 repayment schedule. For each quarterly period since the inception
 of the debt, revenues were below the contractual threshold amount
 such that cash payments were calculated for each period reflecting
 the optional reduction amount as opposed to the contractual
 threshold payment due for each quarterly period. In accordance with
 the agreement with BioPharma, quarterly differences between the
 calculated optional reduction amounts and the repayment schedule
 amounts are rescheduled for payment beginning in the second quarter
 of 2017. Any such deferred repayments will remain subject to
 continued application of the quarterly ceiling in amounts due
 established by the calculated threshold limitation based on
 quarterly Vascepa revenues. No additional interest expense or
 liability is incurred as a result of such deferred repayments.
 These estimates will be reevaluated each reporting period by the
 Company and adjusted if necessary, prospectively.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company determined the redemption feature upon a change of
 control to be an embedded derivative requiring bifurcation. The
 fair value of the embedded derivative was calculated by determining
 the fair value of the debt with the change in control provision
 included and also without the change in control provision. The
 difference between the two fair values of the debt was determined
 to be the fair value of the embedded derivative, and upon closing
 the Company recorded a derivative liability of $14.6 million as a
 reduction to the note payable. The fair value of this derivative
 liability is remeasured at each reporting period, with changes in
 fair value recognized in the condensed consolidated statement of
 operations and any changes in the assumptions used in measuring the
 fair value of the derivative liability could result in a material
 increase or decrease in its carrying value. The Company recognized
 a $2.7 million gain and a $0.8 million loss on change in fair value
 of derivative liability during the six months ended June&amp;#xA0;30,
 2016 and 2015, respectively.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 As of June&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015, the carrying
 value of the BioPharma debt, net of the unamortized debt discount
 and issuance costs, was $92.5 million and $91.5 million,
 respectively. During the six months ended June&amp;#xA0;30, 2016, the
 Company recorded cash and non-cash interest expense of $3.4 million
 and $1.0 million, respectively, in connection with the BioPharma
 debt. During the six months ended June&amp;#xA0;30, 2015, the Company
 recorded cash and non-cash interest expense of $3.2 million and
 $0.9 million, respectively, in connection with the BioPharma debt.
 The Company will periodically evaluate the remaining term of the
 agreement and the effective interest rate is recalculated each
 period based on the Company&amp;#x2019;s most current estimate of
 repayment.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 To secure the obligations under the agreement with BioPharma, the
 Company granted BioPharma a security interest in the
 Company&amp;#x2019;s patents, trademarks, trade names, domain names,
 copyrights, know-how and regulatory approvals related to the
 covered products, all books and records relating to the foregoing
 and all proceeds of the foregoing, referred to collectively as the
 collateral. If the Company (i)&amp;#xA0;fails to deliver a payment when
 due and does not remedy that failure within a specific notice
 period, (ii)&amp;#xA0;fails to maintain a first-priority perfected
 security interest in the collateral in the United States and does
 not remedy that failure after receiving notice of such failure or
 (iii)&amp;#xA0;becomes subject to an event of bankruptcy, then
 BioPharma may attempt to collect the maximum amount payable by the
 Company under this agreement (after deducting any payments the
 Company has already made).&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Under the Purchase and Sale Agreement with BioPharma, the Company
 is restricted from paying dividends on its common shares, unless it
 has cash and cash equivalents in excess of a specified amount after
 such payment.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;&lt;u&gt;January 2012 Exchangeable Senior Notes&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 In January 2012, the Company issued $150.0 million in principal
 amount of 3.5% exchangeable senior notes due 2032 (the &amp;#x201C;2012
 Notes&amp;#x201D;), a portion of which was subsequently exchanged and a
 portion of which was extinguished (see discussion of May 2014 and
 November 2015 Exchangeable Senior Notes below). The 2012 Notes were
 issued by Corsicanto Limited, an Irish limited company acquired by
 Amarin in January 2012. Corsicanto Limited is a wholly-owned
 subsidiary of Amarin. The general, unsecured, senior obligations
 are fully and unconditionally guaranteed by Amarin but not by any
 of the Company&amp;#x2019;s other subsidiaries. Corsicanto Limited has
 no assets, operations, revenues or cash flows other than those
 related to the issuance, administration and repayment of the 2012
 Notes and 2014 Notes.&amp;#xA0;There are no significant restrictions on
 the ability of Amarin to obtain funds from Corsicanto Limited in
 the form of cash dividends, loans, or advances.&amp;#xA0;Net proceeds
 to the Company, after payment of underwriting fees and expenses,
 were approximately $144.3 million.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The 2012 Notes have a stated interest rate of 3.5%&amp;#xA0;per year,
 payable semiannually in arrears on January&amp;#xA0;15 and July&amp;#xA0;15
 of each year beginning on July&amp;#xA0;15, 2012, and ending upon the
 2012 Notes&amp;#x2019; maturity on January&amp;#xA0;15, 2032. The 2012 Notes
 are subject to repurchase by the Company at the option of the
 holders on each of January&amp;#xA0;19, 2017,&amp;#xA0;January&amp;#xA0;19,
 2022, and January&amp;#xA0;19, 2027, at a price equal to 100% of the
 principal amount of the 2012 Notes to be repurchased, plus accrued
 and unpaid interest to, but excluding, the repurchase date. The
 2012 Notes are exchangeable under certain circumstances into cash,
 ADSs, or a combination of cash and ADSs, at the Company&amp;#x2019;s
 election, with an initial exchange rate of 113.4752 ADSs per $1,000
 principal amount of 2012 Notes (equivalent to an initial exchange
 price of approximately $8.8125 per ADS), subject to adjustment in
 certain circumstances, including adjustment if the Company pays
 cash dividends. If the Company elected physical settlement, the net
 remaining outstanding portion of the 2012 Notes would be
 exchangeable into 1,714,270 ADSs. Based on the closing price of the
 Company&amp;#x2019;s stock as of June&amp;#xA0;30, 2016, the principal
 amount of the 2012 Notes would exceed the value of the shares if
 converted on that date by $11.4 million.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Additional covenants include: (i)&amp;#xA0;limitations on future
 indebtedness under certain circumstances, (ii)&amp;#xA0;the timely
 filing of documents and reports pursuant to Section&amp;#xA0;13 or
 15(d) of the Securities Exchange Act of 1934 with both the SEC and
 the Trustee and (iii)&amp;#xA0;maintaining the tradability of the 2012
 Notes. The Company is required to use commercially reasonable
 efforts to maintain the listing of the 2012 Notes on the Global
 Exchange Market operated under the supervision of the Irish Stock
 Exchange (or other recognized stock exchange as defined in the 2012
 Notes indenture). If the 2012 Notes are not freely tradable, as a
 result of restrictions pursuant to U.S. securities law or the terms
 of the 2012 Notes indenture or the 2012 Notes, the Company shall
 pay additional interest on the 2012 Notes at the rate of
 0.50%&amp;#xA0;per annum of the principal amount of 2012 Notes
 outstanding for each day during such period for which the
 Company&amp;#x2019;s failure to file has occurred and is continuing or
 for which the 2012 Notes are not freely tradable.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company may not redeem the 2012 Notes prior to January&amp;#xA0;19,
 2017, other than in connection with certain changes in the tax law
 of a relevant taxing jurisdiction that results in additional
 amounts becoming due with respect to payments and/or deliveries on
 the 2012 Notes. On or after January&amp;#xA0;19, 2017 and prior to the
 maturity date, the Company may redeem for cash all or part of the
 2012 Notes at a redemption price equal to 100% of the principal
 amount of the 2012 Notes to be redeemed, plus accrued and unpaid
 interest to, but excluding, the redemption date. There is no
 prepayment penalty or sinking fund provided for the 2012 Notes. If
 the Company undergoes a change in control, holders may require the
 Company to repurchase for cash all or part of their 2012 Notes at a
 repurchase price equal to 100% of the principal amount of the 2012
 Notes to be repurchased, plus accrued and unpaid interest to, but
 excluding, the change in control repurchase date. The 2012 Notes
 are the Company&amp;#x2019;s senior unsecured obligations and rank
 senior in right of payment to the Company&amp;#x2019;s future
 indebtedness that is expressly subordinated in right of payment to
 the 2012 Notes and equal in right of payment to the Company&amp;#x2019;s
 future unsecured indebtedness that is not so subordinated. The 2012
 Notes are effectively junior in right of payment to future secured
 indebtedness to the extent of the value of the assets securing such
 indebtedness.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The 2012 Notes are exchangeable under certain circumstances. At the
 time of issuance, the Company calculated the fair value of the
 liability component of the outstanding 2012 Notes to be $126.2
 million, and the excess of the principal amount of the debt over
 the liability component of $23.8 million was allocated to the
 conversion option resulting in a discount on the debt and
 corresponding increase in equity as a result of the cash settlement
 feature. The discount created from allocating proceeds to the
 conversion option was amortized to interest expense using the
 effective interest method over the 2012 Notes&amp;#x2019; estimated
 remaining life, which was calculated to be a period of twenty-four
 months. As of both June&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015,
 the discount created from the allocation of the proceeds to the
 conversion option was fully amortized and the carrying amount of
 the conversion option was $11.5 million. The conversion option will
 not be subsequently remeasured as long as it continues to meet the
 criteria for equity classification.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company also recorded a debt discount to reflect the value of
 the underwriter&amp;#x2019;s discounts and offering costs. A portion of
 the debt discount from underwriter&amp;#x2019;s discounts and offering
 costs was allocated to the equity and liability components of the
 2012 Notes in proportion to the proceeds allocated to each
 component. The portion of the debt discount from
 underwriter&amp;#x2019;s discounts and offering costs allocated to the
 liability component was amortized as interest expense over the
 estimated life of the 2012 Notes of twenty-four months. As of both
 June&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015, the debt discount
 was fully amortized and the carrying value of the 2012 Notes was
 $15.1 million after an exchange and repayment of a portion of the
 2012 Notes (see below for further discussion of the May 2014 Notes
 and November 2015 Notes). The outstanding 2012 Notes may be put to
 the Company (at the holders&amp;#x2019; option, upon fundamental change
 or an event of default), or converted by holders and the holders
 have the option to put the 2012 Notes back to the Company on each
 of January&amp;#xA0;19, 2017, 2022 and 2027 for cash equal to 100% of
 the principal amount plus accrued and unpaid interest. As a result,
 the carrying value of the 2012 Notes of $15.1 million is classified
 as a current liability as of June&amp;#xA0;30, 2016.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;&lt;u&gt;May 2014 Exchangeable Senior Notes&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 In May 2014, the Company entered into separate, privately
 negotiated exchange agreements with certain holders of the 2012
 Notes pursuant to which Corsicanto exchanged $118.7 million in
 aggregate principal amount of the existing 2012 Notes for $118.7
 million in aggregate principal amount of new 3.5%&amp;#xA0;May 2014
 Exchangeable Senior Notes due 2032 (the &amp;#x201C;2014 Notes&amp;#x201D;),
 following which $31.3 million in aggregate principal amount of the
 2012 Notes remained outstanding with terms unchanged (the 2012
 Notes and 2014 Notes are referred to collectively as the
 &amp;#x201C;Notes&amp;#x201D;).&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The 2014 Notes have a stated interest rate of 3.5%&amp;#xA0;per year,
 payable semiannually in arrears on January&amp;#xA0;15 and July&amp;#xA0;15
 of each year beginning on July&amp;#xA0;15, 2014, and ending upon the
 2014 Notes&amp;#x2019; maturity on January&amp;#xA0;15, 2032, unless earlier
 repurchased or redeemed by Corsicanto or exchanged by the holders.
 At any time after the issuance of the 2014 Notes and prior to the
 close of business on the second business day immediately preceding
 January&amp;#xA0;15, 2032, holders may exchange the 2014 Notes at their
 option. If prior to January&amp;#xA0;15, 2018, a make-whole fundamental
 change (as defined in the 2014 Notes indenture) occurs or the
 Company elects to redeem the 2014 Notes in connection with certain
 changes in tax law, in each case as described in the 2014 Notes
 indenture, and a holder elects to exchange its 2014 Notes in
 connection with such make-whole fundamental change or election, as
 the case may be, such holder may be entitled to an increase in the
 exchange rate as described in the 2014 Notes indenture. In the
 event of physical settlement, the 2014 Notes would be exchangeable
 into 45,666,925 ADSs. The initial exchange rate is 384.6154 ADSs
 per $1,000 principal amount of the 2014 Notes (equivalent to an
 initial exchange price of approximately $2.60 per ADS, or the
 Exchange Price), subject to adjustment in certain circumstances.
 The exchange rate is subject to adjustment from time to time upon
 the occurrence of certain events, including, but not limited to,
 the payment of cash dividends. Based on the closing price of the
 Company&amp;#x2019;s stock as of June&amp;#xA0;30, 2016, the principal
 amount of the 2014 Notes would exceed the value of the shares if
 converted on that date by $20.1 million.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Prior to January&amp;#xA0;19, 2018, the Company may not redeem the 2014
 Notes at its option other than in connection with certain changes
 in the tax law of a relevant taxing jurisdiction that results in
 additional amounts (as defined in the 2014 Notes indenture)
 becoming due with respect to payments and/or deliveries on the 2014
 Notes. On or after January&amp;#xA0;19, 2018, the Company may redeem
 for cash all or a portion of the 2014 Notes at a redemption price
 of 100% of the aggregate principal amount of the 2014 Notes to be
 redeemed, plus accrued and unpaid interest to, but not including,
 the redemption date. If a fundamental change (as defined in the
 2014 Notes indenture) occurs, holders may require the Company to
 repurchase all or part of their 2014 Notes for cash at a
 fundamental change repurchase price equal to 100% of the aggregate
 principal amount of the 2014 Notes to be repurchased, plus accrued
 and unpaid interest to, but not including, the fundamental change
 repurchase date. In addition, holders of the 2014 Notes may require
 the Company to repurchase all or any portion of the 2014 Notes on
 each of January&amp;#xA0;19, 2019,&amp;#xA0;January&amp;#xA0;19, 2024 and
 January&amp;#xA0;19, 2029 for cash at a price equal to 100% of the
 aggregate principal amount of the 2014 Notes to be repurchased,
 plus accrued and unpaid interest to, but not including, the
 repurchase date.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company may elect at its option to cause all or any portion of
 the 2014 Notes to be mandatorily exchanged in whole or in part at
 any time prior to the close of business on the business day
 preceding January&amp;#xA0;15, 2032 if the Daily VWAP (as defined in
 the 2014 Notes indenture) equals or exceeds 110% of the Exchange
 Price then in effect for at least 20 VWAP Trading Days (as defined
 in the 2014 Notes indenture) in any 30 VWAP Trading Day period. The
 Company may only exercise its optional exchange rights upon
 satisfaction of specified equity conditions, including that the
 ADSs issuable upon exchange of the 2014 Notes be eligible for
 resale without registration by non-affiliates and listed on The
 NASDAQ Global Market, its related exchanges or the New York Stock
 Exchange. If Corsicanto elects to exercise its optional exchange
 rights on or prior to January&amp;#xA0;15, 2018, each holder whose 2014
 Notes are exchanged will upon exchange receive a specified number
 of additional ADSs as set forth in the 2014 Notes indenture. Upon
 such a declaration of acceleration, such principal and accrued and
 unpaid interest, if any, will be due and payable immediately. Upon
 the occurrence of certain events of bankruptcy, insolvency or
 reorganization involving Corsicanto, 100% of the principal of and
 accrued and unpaid interest, if any, on all of the 2014 Notes will
 become due and payable automatically. Notwithstanding the
 foregoing, the 2014 Notes indenture provides that, to the extent
 Corsicanto elects and for up to 360 days, the sole remedy for an
 event of default relating to certain failures by Corsicanto or the
 Company, as the case may be, to comply with certain reporting
 covenants in the 2014 Notes indenture consists exclusively of the
 right to receive additional interest on the 2014 Notes. Additional
 covenants pertaining to the 2012 Notes (as described above for the
 January 2012 Exchangeable Senior Notes) are also applicable to the
 May 2014 Notes.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 As a result of the note exchange (as described above), the Company
 assessed both quantitative and qualitative aspects of the features
 of the 2014 Notes as compared to the 2012 Notes. Such assessment
 resulted in the conclusion that the features of the 2014 Notes
 represent a substantive modification from the 2012 Notes as the
 terms of the exchange resulted in a substantive modification to the
 embedded conversion feature within the 2012 Notes, and as such
 should be accounted for as an extinguishment of debt. In accordance
 with ASC 470-20, the Company extinguished the 2012 Notes by
 recording a gain on extinguishment of the liability component of
 $38.0 million and repurchase of the conversion option in equity
 through a reduction to additional paid-in capital of $10.1 million.
 The 2014 Notes were recorded at fair value of $90.8 million
 representing a $27.9 million discount to par. In addition, the
 Company recognized $2.5 million in underwriter&amp;#x2019;s fees and
 offering costs and initially recognized those costs as deferred
 assets. Effective January 2016, the Company adopted ASU
 No.&amp;#xA0;2015-03, &lt;i&gt;Interest&amp;#x2014;Imputation of Interest
 (Subtopic 835-30): Simplifying the Presentation of Debt Issuance
 Costs&lt;/i&gt;, which requires that debt issuance costs related to a
 recognized debt liability be presented in the balance sheet as a
 direct deduction from the carrying amount of that debt liability,
 consistent with the treatment of debt discounts. As the standard is
 required to be adopted on a retrospective basis, the Company
 reclassified $1.8 million of underwriters&amp;#x2019; fees and offering
 costs related to the 2014 Notes from other long-term assets to
 exchangeable senior notes, net of discount, within the condensed
 consolidated balance sheet as of December&amp;#xA0;31, 2015.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company further allocated $3.5 million of the $90.8 million
 fair value of the 2014 Notes to the derivative liability related to
 the fundamental change redemption feature (as described above). The
 fair value of this derivative liability is remeasured at each
 reporting period, with changes in fair value recognized in the
 condensed consolidated statement of operations and any changes in
 the assumptions used in measuring the fair value of the derivative
 liability could result in a material increase or decrease in its
 carrying value. The Company recognized a $1.5 million gain on the
 change in fair value of the redemption feature in each of the six
 months ended June&amp;#xA0;30, 2016 and 2015.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Because the conversion option in the 2014 Notes receives an
 exception from derivative accounting and only requires gross
 physical settlement in shares, the embedded option does not require
 separate accounting and is therefore accounted for as part of the
 debt host at amortized cost. The debt discount is being amortized
 as interest expense over the estimated life of the 2014 Notes and
 recognized in the condensed consolidated statement of operations as
 interest expense. As of June&amp;#xA0;30, 2016 and December&amp;#xA0;31,
 2015, the carrying value of the 2014 Notes, net of the unamortized
 debt discount and issuance costs, was $98.0 million and $94.6
 million, respectively. During the six months ended June&amp;#xA0;30,
 2016, the Company recognized aggregate interest expense of $5.7
 million related to the Notes, of which $3.4 million represents
 non-cash interest and $2.3 million represents contractual coupon
 interest. During the six months ended June&amp;#xA0;30, 2015, the
 Company recognized aggregate interest expense of $5.6 million
 related to the Notes, of which $3.0 million represents non-cash
 interest and $2.6 million represents contractual coupon
 interest.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;&lt;u&gt;November 2015 Exchangeable Senior Notes&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 In November 2015, the Company entered into a privately negotiated
 subscription agreement with one of its existing investors (the
 &amp;#x201C;Investor&amp;#x201D;), pursuant to which the Investor agreed to
 purchase approximately $31.3 million in aggregate principal amount
 of new 3.5%&amp;#xA0;November 2015 Exchangeable Senior Notes due 2032
 (the &amp;#x201C;2015 Notes&amp;#x201D;) for approximately $27.5 million.
 Approximately $15.9 million of such proceeds were used to finance
 the repayment of a portion of the 2012 Notes and the remainder will
 be used for working capital and general corporate purposes. The
 2015 Notes have substantially identical terms to the 2014 Notes,
 except that the 2015 Notes were issued by Amarin Corporation plc
 and are not guaranteed by any entity. In the event of physical
 settlement, the 2015 Notes would be exchangeable into 12,025,385
 ADSs. The initial exchange rate is 384.6154 ADSs per $1,000
 principal amount of 2015 Notes (equivalent to an initial exchange
 price of approximately $2.60 per ADS), provided that exchanges will
 be prohibited if, as a result, the holder of such 2015 Notes and
 its affiliates would beneficially own more than 4.99% of the total
 number of the Company&amp;#x2019;s ordinary shares or ADSs outstanding
 following such exchange (the &amp;#x201C;Beneficial Ownership
 Limitation&amp;#x201D;). By written notice to the Company, a holder may
 from time to time increase or decrease the Beneficial Ownership
 Limitation to any other percentage not in excess of 19.9% (the
 &amp;#x201C;Beneficial Ownership Cap&amp;#x201D;) specified in such notice;
 provided that any such increase will not be effective until the
 sixty-first (61st)&amp;#xA0;day after such notice is delivered to the
 Company. The exchange rate is subject to adjustment from time to
 time upon the occurrence of certain events, including, but not
 limited to, the payment of cash dividends. Based on the closing
 price of the Company&amp;#x2019;s stock as of June&amp;#xA0;30, 2016, the
 principal amount of the 2015 Notes would exceed the value of the
 shares if converted on that date by $5.3 million.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The 2015 Notes are the senior unsecured obligations of the Company.
 The 2015 Notes bear interest at a rate of 3.5%&amp;#xA0;per annum from,
 and including, November&amp;#xA0;24, 2015, payable semi-annually in
 arrears on January&amp;#xA0;15 and July&amp;#xA0;15 of each year, beginning
 on January&amp;#xA0;15, 2016. The 2015 Notes mature on January&amp;#xA0;15,
 2032, unless earlier repurchased or redeemed by the Company or
 exchanged by the holders.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The 2015 Notes were recorded at fair value of $27.5 million
 representing a $3.8 million discount to par. In addition, the
 Company recognized $0.1 million in offering costs and initially
 recognized those costs as deferred assets. As described for the
 2014 Notes above, effective January 2016, the Company adopted ASU
 No.&amp;#xA0;2015-03, &lt;i&gt;Interest&amp;#x2014;Imputation of Interest
 (Subtopic 835-30): Simplifying the Presentation of Debt Issuance
 Costs.&lt;/i&gt; As the standard is required to be adopted on a
 retrospective basis, the Company reclassified $0.1 million of
 underwriters&amp;#x2019; fees and offering costs related to the 2015
 Notes from other long-term assets to exchangeable senior notes, net
 of discount, within the condensed consolidated balance sheet as of
 December&amp;#xA0;31, 2015.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company further allocated $0.5 million of the $27.5 million
 fair value of the 2015 Notes to the derivative liability related to
 the fundamental change redemption feature (as described under the
 2014 Notes above). The fair value of this derivative liability is
 remeasured at each reporting period, with changes in fair value
 recognized in the condensed consolidated statement of operations
 and any changes in the assumptions used in measuring the fair value
 of the derivative liability could result in a material increase or
 decrease in its carrying value. During the six months ended
 June&amp;#xA0;30, 2016, the Company recognized a gain on the change in
 fair value of the redemption feature of $0.4 million.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Because the conversion option in the 2015 Notes receives an
 exception from derivative accounting and only requires gross
 physical settlement in shares, the embedded option does not require
 separate accounting and is therefore accounted for as part of the
 debt host at amortized cost. The debt discount is being amortized
 as interest expense over the estimated life of the 2015 Notes and
 recognized in the condensed consolidated statement of operations as
 interest expense. As of June&amp;#xA0;30, 2016 and December&amp;#xA0;31,
 2015, the carrying value of the 2015 Notes, net of the unamortized
 debt discount and issuance costs, was $27.6 million and $27.0
 million, respectively. During the six months ended June&amp;#xA0;30,
 2016, the Company recognized aggregate interest expense of $1.2
 million related to the 2015 Notes, of which $0.6 million represents
 non-cash interest and $0.6 million represents contractual coupon
 interest.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Concurrent with the issuance of the 2015 Notes, Corsicanto Limited
 and the Company entered into separate, privately negotiated
 purchase agreements with certain holders of the 2012 Notes pursuant
 to which the Company purchased (the &amp;#x201C;2012 Notes
 Purchase&amp;#x201D;) approximately $16.2 million in aggregate principal
 amount of the 2012 Notes for $15.9 million, which included accrued
 but unpaid interest on such 2012 Notes. The 2012 Notes Purchase was
 funded by the issuance of the 2015 Notes. Following the closing of
 the 2012 Notes Purchase, Corsicanto had approximately $15.1 million
 in aggregate principal amount of 2012 Notes outstanding. The 2012
 Notes Purchase was accounted for as an extinguishment of debt and
 the Company recorded a gain of $1.3 million upon extinguishment
 during the fourth quarter of 2015, which represents the
 reacquisition of the conversion option at fair value and a
 negotiated discount on the purchase of the notes partially offset
 by legal and transaction advisory costs incurred.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 As of June&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015, the Company
 had total accrued interest on the notes of $2.7 million and $2.3
 million, respectively, which is included in current portion of
 long-term debt. The Company made the contractual interest payments
 due on the notes during the six months ended June&amp;#xA0;30, 2016 and
 2015 of $2.5 million and $2.6 million, respectively.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:DebtPolicyTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_64FFBD9F-64A1-4551-B46E-FBCE95942486_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Debt Instruments&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Debt instruments are initially recorded at fair value, with coupon
 interest and amortization of debt issuance discounts recognized in
 the condensed consolidated statement of operations as interest
 expense each period in which such instruments are outstanding. If
 the Company issues shares to discharge the liability, the debt
 obligation is derecognized and common stock and additional paid-in
 capital are recognized on the issuance of those shares. The
 conversion features in the 2012 Notes, 2014 Notes, and 2015 Notes
 qualify for the exception from derivative accounting in accordance
 with ASC 815-40. The 2012 Notes may be settled, at the
 Company&amp;#x2019;s discretion, in any combination of ADSs or cash upon
 conversion and have been accounted for in accordance with ASC
 470-20. Under ASC 470-20, the fair value of the liability component
 of the 2012 Notes was determined and deducted from the initial
 proceeds to determine the proceeds allocated to the conversion
 option, which has been recorded in equity. The difference between
 the initial fair value of the liability component and the amount
 repayable was amortized over the expected term of the instrument.
 The conversion features in the 2014 Notes and 2015 Notes may only
 be settled in ADSs upon conversion and have been accounted for as
 part of the debt host.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The conversion options in the 2012 Notes, 2014 Notes, and 2015
 Notes continue to be evaluated on a quarterly basis to determine if
 they still receive an exception from derivative accounting in
 accordance with ASC 815-40. The 2014 Notes were recognized
 initially at fair value as part of an extinguishment of a portion
 of the 2012 Notes. As a result, the 2014 Notes were initially
 recognized at a discount of $27.9 million. The 2015 Notes were
 recognized initially at fair value as part of the issuance of new
 debt in November 2015. As a result, the 2015 Notes were initially
 recognized at a discount of $3.8 million. These discounts are being
 amortized through interest expense over the expected terms of the
 2014 Notes and 2015 Notes, which is through January 2019 for each.
 See Note 6&amp;#x2014;Debt for further discussion.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
  <dei:DocumentPeriodEndDate contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_BA3A6215-CFF4-4E66-9004-D121F0B695FC_1_2">2016-06-30</dei:DocumentPeriodEndDate>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="2" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_3_20" unitRef="iso4217_USD_per_shares">-0.23</us-gaap:EarningsPerShareBasic>
  <dei:EntityFilerCategory contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_7122CAB9-2953-466D-BF94-16FD51A80C1D_1_400004">Accelerated Filer</dei:EntityFilerCategory>
  <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_007DEDC2-1FB7-49CE-B651-78435323F49E_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;(3)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Intangible Assets&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Intangible assets consist of the historical acquisition cost of
 certain technology rights for Vascepa and have an estimated
 remaining useful life of 14.1 years. The carrying value as of
 June&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015 is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&amp;#xA0;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Technology rights&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,624&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,624&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accumulated amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,529&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,207&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,095&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,417&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
  <us-gaap:LegalCostsPolicyTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_28F63792-F142-4983-9E05-D9DD4FBD57AC_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Costs for Patent Litigation and Legal
 Proceedings&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Costs for patent litigation or other legal proceedings are expensed
 as incurred and included in selling, general and administrative
 expenses.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:LegalCostsPolicyTextBlock>
  <us-gaap:NumberOfOperatingSegments contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="INF" id="id_6038951_692848A1-A21C-4442-9758-7D1FF923CF1F_1_2" unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:ReceivablesPolicyTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_547E1F11-FA94-4906-A428-197C063EFA22_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Accounts Receivable, net&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Accounts receivable, net, comprised of trade receivables, are
 generally due within 30 days and are stated at amounts due from
 customers. The Company does not currently maintain an allowance for
 doubtful accounts and has not historically experienced any credit
 losses.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The following table summarizes the impact of accounts receivable
 reserves on the gross trade accounts receivable balances as of
 June&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;June&amp;#xA0;30,&amp;#xA0;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Gross trade accounts receivable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,528&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,270&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Trade allowances&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,662&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,296&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Chargebacks&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(227&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(148&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accounts receivable, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,639&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,826&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_4132E426-D7D7-4FD9-BEAC-8C634B4A926B_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Research and Development Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company charges research and development costs to operations as
 incurred. Research and development expenses are comprised of costs
 incurred by the Company in performing research and development
 activities, including: salary and benefits; stock-based
 compensation expense; laboratory supplies and other direct
 expenses; contractual services, including clinical trial and
 pharmaceutical development costs; commercial supply investment in
 its drug candidates; and infrastructure costs, including facilities
 costs and depreciation expense. In addition, research and
 development costs include the costs of product supply received from
 suppliers when such receipt by the Company is prior to regulatory
 approval of the supplier.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_58B813E0-DDFA-40E6-B421-19B60FB52CAD_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Segment and Geographical Information&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Operating segments are defined as components of an enterprise about
 which separate financial information is available that is evaluated
 on a regular basis by the chief operating decision-maker, or
 decision making group, in deciding how to allocate resources to an
 individual segment and in assessing performance of the segment. The
 Company currently operates in one business segment, which is the
 development and commercialization of Vascepa. A single management
 team that reports to the Company&amp;#x2019;s chief decision-maker, who
 is the Chief Executive Officer, comprehensively manages the
 business. Accordingly, the Company does not have separately
 reportable segments.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:ShippingAndHandlingCostPolicyTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_166F7138-942F-4AC8-A2B5-616EDD7CC3A7_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Distribution Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company records distribution costs related to shipping product
 to its customers, primarily through the use of common carriers or
 external distribution services, in cost of goods sold.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ShippingAndHandlingCostPolicyTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_1AAEB11C-7141-4D97-B398-4A64D0B5869E_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;b&gt;(8)&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;b&gt;Equity&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;&lt;u&gt;Warrants&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 During the six months ended June&amp;#xA0;30, 2015, the Company issued
 1,844,585 shares upon the exercise of warrants, resulting in gross
 and net proceeds of $2.8 million and $2.7 million, respectively.
 There was no warrant activity during the six months ended
 June&amp;#xA0;30, 2016 and no warrants remained outstanding as of
 June&amp;#xA0;30, 2016.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;&lt;u&gt;Incentive Equity Awards&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 In June 2014, the FASB issued guidance for accounting for
 share-based payments when the terms of an award provide that a
 performance target could be achieved after the requisite service
 period. The standard states that a performance target in a
 share-based payment that affects vesting and that could be achieved
 after the requisite service period should be accounted for as a
 performance condition. As such, the performance target should not
 be reflected in estimating the grant-date fair value of the award.
 The guidance became effective for all entities during the first
 quarter of fiscal 2016. The Company previously accounted for awards
 in a manner consistent with the new guidance and as such, adoption
 of the guidance did not have any impact on the Company&amp;#x2019;s
 condensed consolidated financial statements.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 In March 2016, the FASB issued ASU No.&amp;#xA0;2016-09,
 &lt;i&gt;Compensation&amp;#x2014;Stock Compensation (Topic 718): Improvements
 to Employee Share-Based Payment Accounting&lt;/i&gt;. The Company early
 adopted this standard during the quarter ended June&amp;#xA0;30, 2016,
 without electing to change its existing accounting policy of
 accounting for forfeitures based on expected vesting. The new
 standard requires that excess tax benefits and deficiencies that
 arise upon vesting or exercise of share-based payments be
 recognized as an income tax benefit and expense in the income
 statement, and also that historical excess tax benefits that were
 not previously recognized because the related tax deduction had not
 reduced current taxes payable should be recognized on a modified
 retrospective basis as a cumulative-effect adjustment to retained
 earnings as of the beginning of the annual period of adoption.
 Further, the new standard amends the presentation of employee
 share-based payment-related items in the statement of cash flows by
 requiring that: (i)&amp;#xA0;excess income tax benefits and
 deficiencies be classified in cash flows from operating activities,
 and (ii)&amp;#xA0;cash paid to taxing authorities arising from the
 withholding of shares from employees be classified as cash flows
 from financing activities. Refer to Note 2 above for additional
 discussion on the Company&amp;#x2019;s adoption of the new standard.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 As of June&amp;#xA0;30, 2016, there were an aggregate of 20,641,123
 stock options and 10,361,147 restricted stock units
 (&amp;#x201C;RSUs&amp;#x201D;) outstanding, representing approximately 8% and
 4%, respectively, of outstanding shares (including common and
 preferred shares) on a fully diluted basis.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 During the six months ended June&amp;#xA0;30, 2016 and 2015, the
 Company issued 83,020 and 18,020 shares, respectively, as a result
 of the exercise of stock options, resulting in gross and net
 proceeds of $0.1 million during the six months ended June&amp;#xA0;30,
 2016 and $31 thousand during the six months ended June&amp;#xA0;30,
 2015.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 On February&amp;#xA0;1, 2016, the Company granted a total of 1,607,500
 RSUs and 2,442,000 stock options to employees under the Amarin
 Corporation plc Stock Incentive Plan (the &amp;#x201C;2011 Plan&amp;#x201D;).
 The RSUs vest annually over a three year period and the stock
 options vest monthly over a four year period.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 On July&amp;#xA0;6, 2015, the Company granted a total of 1,455,000 RSUs
 and 5,470,000 stock options to employees under the 2011 Plan. The
 RSUs granted vest over a four year period. Of the total stock
 options granted, 3,670,000 stock options vest over a four year
 period while the remaining 1,800,000 stock options vest upon the
 achievement of certain performance conditions. During the six
 months ended June&amp;#xA0;30, 2016, the Company issued 181,874 common
 shares related to the vesting of these RSUs, of which 77,405 shares
 were retained as treasury shares as settlement of employee tax
 obligations.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Also on July&amp;#xA0;6, 2015, the Company granted a total of 413,500
 RSUs and 288,657 stock options to members of the Company&amp;#x2019;s
 Board of Directors under the 2011 Plan. Of the total awards
 granted, 283,500 RSUs and 121,506 stock options vest in equal
 installments over a three year period upon the earlier of the
 one-year anniversary of the grant date or the Company&amp;#x2019;s
 annual general meeting of shareholders in such anniversary year,
 while the remaining 130,000 RSUs and 167,151 stock options vest in
 full upon the earlier of the one-year anniversary of the grant date
 or the Company&amp;#x2019;s annual general meeting of shareholders in
 such anniversary year. Upon termination of service to the Company
 or upon a change of control, each Director shall be entitled to a
 payment equal to the fair market value of one share of Amarin
 common stock, which is required to be made in shares.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 On January&amp;#xA0;29, 2015, the Company granted a total of 2,564,251
 RSUs and 1,622,500 stock options to employees under the 2011 Plan.
 The RSUs vest annually over a three year period and the stock
 options vest monthly over a four year period. Also on
 January&amp;#xA0;29, 2015, the Company granted 5,455,500 RSUs to
 employees under the 2011 Plan that vest upon the achievement of
 certain performance conditions. The issuance of these performance
 RSUs was contingent upon shareholder approval to increase the
 aggregate number of shares authorized for issuance under the 2011
 Plan, which was obtained at the Company&amp;#x2019;s Annual General
 Meeting of Shareholders held on July&amp;#xA0;6, 2015. During the six
 months ended June&amp;#xA0;30, 2016, the Company issued 818,352 common
 shares related to the vesting of these RSUs, of which 270,329
 shares were retained as treasury shares as settlement of employee
 tax obligations.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;&lt;u&gt;Preferred Stock&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 On March&amp;#xA0;5, 2015, the Company entered into a subscription
 agreement with four institutional investors (the
 &amp;#x201C;Purchasers&amp;#x201D;), including both existing and new
 investors, for the private placement of 352,150,790 restricted
 American Depositary Shares, each representing one (1)&amp;#xA0;share of
 Amarin&amp;#x2019;s Series A Convertible Preference Shares, par value
 &amp;#xA3;0.05&amp;#xA0;per share, in the capital of the Company
 (&amp;#x201C;Series A Preference Shares&amp;#x201D;), resulting in gross
 proceeds to the Company of $52.8 million. The closing of the
 private placement occurred on March&amp;#xA0;30, 2015.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 For each restricted American Depositary Share, the Purchasers paid
 a negotiated price of $0.15 (equating to $1.50 on an
 as-if-converted-to-ordinary-shares basis), resulting in $52.8
 million in aggregate gross proceeds to the Company, before
 deducting estimated offering expenses of approximately $0.7
 million. The net proceeds are reflected as preferred stock in the
 accompanying condensed consolidated balance sheets.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Each ten (10)&amp;#xA0;Series A Preference Shares may be consolidated
 and redesignated as one (1)&amp;#xA0;ordinary share, par value
 &amp;#xA3;0.50&amp;#xA0;per share, in the capital of the Company, each
 ordinary share to be represented by American Depositary Shares
 (&amp;#x201C;ADSs&amp;#x201D;), provided that consolidation will be
 prohibited if, as a result, the holder of such Series A Preference
 Shares and its affiliates would beneficially own more than 4.99% of
 the total number of Amarin ordinary shares or ADSs outstanding
 following such redesignation (the &amp;#x201C;Beneficial Ownership
 Limitation&amp;#x201D;). By written notice to the Company, a holder may
 from time to time increase or decrease the Beneficial Ownership
 Limitation to any other percentage not in excess of 19.9% specified
 in such notice; provided that any such increase will not be
 effective until the sixty-first (61st)&amp;#xA0;day after such notice
 is delivered to the Company. This consolidation and redesignation
 may be effected by a holder of Series A Preference Shares following
 the first to occur of the resale of the ADSs representing the
 ordinary shares being registered for resale under the Securities
 Act pursuant to an effective registration statement, following any
 sale of the ADSs representing the ordinary shares pursuant to Rule
 144 under the Securities Act, or if such ADSs representing the
 ordinary shares are eligible for sale under Rule 144, following the
 expiration of the one-year holding requirement under Rule 144.
 Subsequently, at the request of the holders, a portion of the
 Series A Preference Shares were consolidated and redesignated
 during the three months ended June&amp;#xA0;30, 2015, resulting in the
 issuance of 6,283,333 ADSs such that a maximum of 32,818,464
 ordinary shares remain issuable upon future consolidation and
 redesignation of the remaining Series A Preference Shares as of
 June&amp;#xA0;30, 2016, inclusive of the shares issued in July 2015 as
 discussed below, subject to certain adjustments for dilutive
 events.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Except as otherwise provided in the Series A Preference Share Terms
 or as required by applicable law, the Series A Preference Shares
 have no voting rights. However, as long as any Series A Preference
 Shares are outstanding, the Company cannot, without the approval of
 the holders of seventy-five percent (75%)&amp;#xA0;of the then
 outstanding Series A Preference Shares, alter or change adversely
 the powers, preferences or rights attaching to the Series A
 Preference Shares or enter into any agreement with respect to the
 foregoing.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Holders of the Series A Preference Shares are entitled to receive,
 and the Company is required to pay, dividends (other than dividends
 in the form of ordinary shares) on the Series A Preference Shares
 equal (on an as-if-converted-to-ordinary-shares basis) to and in
 the same form as dividends (other than dividends in the form of
 ordinary shares) actually paid on ordinary shares when, as and if
 such dividends (other than dividends in the form of ordinary
 shares) are paid on the ordinary shares.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The restricted American Depositary Shares and Series A Preference
 Shares were sold in a transaction exempt from the registration
 requirements under the Securities Act of 1933, as amended (the
 &amp;#x201C;Securities Act&amp;#x201D;). The Company filed a registration
 statement with the SEC covering the resale of the restricted
 American Depositary Shares and the ADSs representing ordinary
 shares created by the consolidation and redesignation of the Series
 A Preference Shares (the &amp;#x201C;Registrable Securities&amp;#x201D;) on
 April&amp;#xA0;9, 2015, which was declared effective by the SEC on
 May&amp;#xA0;1, 2015. In addition, the Company agreed to use its
 commercially reasonable best efforts to keep the registration, and
 any qualification, exemption or compliance under state securities
 laws which the Company determines to obtain, continuously
 effective, and to keep the Registration Statement free of any
 material misstatements or omissions, until the earlier of
 (a)&amp;#xA0;March 11, 2017 or (b)&amp;#xA0;the date on which all
 Registrable Securities held by Purchasers may be sold or
 transferred in compliance with Rule 144 under the Securities Act,
 without any volume or manner of sale restrictions.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Series A Preference Shares contain a contingent beneficial
 conversion feature (&amp;#x201C;BCF&amp;#x201D;) because they contain a
 conversion feature at a fixed rate that was in-the-money when
 issued. The BCF was recorded in the three months ended
 June&amp;#xA0;30, 2015 as a result of the related Form S-3 Registration
 Statement being declared effective, which represents the resolution
 of the contingency to convert the Series A Preference Shares. The
 BCF was recognized in stockholders&amp;#x2019; deficit and was measured
 by allocating a portion of the proceeds equal to the intrinsic
 value of that feature to additional paid-in capital. The effective
 purchase price of the ordinary shares into which the preferred
 shares are convertible was $1.50, which was used to compute the
 intrinsic value. The intrinsic value was calculated as the
 difference between the effective purchase price of the ordinary
 shares and the market value ($2.39 per share) on the date the
 preferred shares were issued, multiplied by the number of shares
 into which the preferred shares are convertible. The BCF resulting
 from the issuance of the Series A Preference Shares was determined
 to be $31.3 million. The BCF was recorded as a non-cash dividend to
 preferred shareholders through accumulated deficit, and was
 therefore reflected as an adjustment to net loss applicable to
 common shareholders for earnings per common share purposes in
 accordance with GAAP for the three months ended June&amp;#xA0;30,
 2015.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 On March&amp;#xA0;30, 2015, in connection with the closing of the
 private placement, and pursuant to a pre-existing contractual right
 to participate in certain private placement transactions effected
 by the Company, the Company entered into a separate subscription
 agreement with an existing investor, Sofinnova Venture Partners VII
 L.P. (Sofinnova), for the purchase of an additional $5.8 million of
 restricted American Depositary Shares, each representing one
 (1)&amp;#xA0;share of the Company&amp;#x2019;s Series A Preference Shares,
 at the same price per share and otherwise on substantially the same
 terms as the initial private placement (the &amp;#x201C;Second Private
 Placement&amp;#x201D;). In accordance with applicable marketplace rules
 of the NASDAQ Stock Market, the consummation of the Second Private
 Placement was conditioned upon approval by the Company&amp;#x2019;s
 shareholders at a future meeting of the Company&amp;#x2019;s
 shareholders. Such approval was received at the Company&amp;#x2019;s
 Annual General Meeting of Shareholders on July&amp;#xA0;6, 2015 and as
 a result, the closing of the Second Private Placement occurred on
 July&amp;#xA0;10, 2015. The Company issued 38,867,180 restricted ADSs
 at that time, each representing one Series A Preference Share,
 which may be consolidated and redesignated from time to time up to
 a maximum of 3,886,718 ordinary shares, each ordinary share to be
 represented by one ADS. For each restricted ADS, Sofinnova paid a
 negotiated price of $0.15 (equating to $1.50 on an
 as-if-converted-to-ordinary-shares basis) resulting in gross
 proceeds to the Company of $5.8 million. Dr.&amp;#xA0;James Healy, a
 member of the Company&amp;#x2019;s Board, is a managing general partner
 of Sofinnova Management VII, L.L.C., which is the general partner
 of Sofinnova.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company filed another registration statement with the SEC
 covering the resale of these restricted American Depositary Shares
 and the ADSs representing ordinary shares created by the
 consolidation and redesignation of the Series A Preference Shares
 (the &amp;#x201C;Sofinnova Registrable Securities&amp;#x201D;) on
 July&amp;#xA0;24, 2015, which was declared effective by the SEC on
 August&amp;#xA0;7, 2015. In addition, the Company agreed to use its
 commercially reasonable best efforts to keep the registration, and
 any qualification, exemption or compliance under state securities
 laws which the Company determines to obtain, continuously
 effective, and to keep the registration statement free of any
 material misstatements or omissions, until the earlier of
 (a)&amp;#xA0;July 10, 2017 or (b)&amp;#xA0;the date on which all Sofinnova
 Registrable Securities held by Sofinnova may be sold or transferred
 in compliance with Rule 144 under the Securities Act, without any
 volume or manner of sale restrictions.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The existence of this preferred stock purchase option was
 determined to be a derivative liability effective March&amp;#xA0;5,
 2015, the date on which the private placement was initially
 subscribed. The fair value of this liability was calculated using a
 Black-Scholes model and was determined to be $0.9 million at
 inception and was charged to accumulated deficit as a deemed
 non-cash dividend to Sofinnova. The liability was then marked to
 fair value as of March&amp;#xA0;30, 2015, the date on which the Company
 executed a subscription agreement with Sofinnova, resulting in a
 charge of $0.9 million through gain (loss) on change in fair value
 of derivatives. The liability of $1.8 million was reclassified to
 permanent equity (additional paid-in capital) on such date.
 Subsequent to approval of the Second Private Placement at the
 Company&amp;#x2019;s Annual General Meeting of Shareholders in July
 2015, the Company recorded the remaining value of the BCF related
 to this share issuance as a non-cash dividend to preferred
 shareholders through accumulated deficit. The value of the BCF was
 determined on the same basis as the first private placement and
 amounted to $3.4 million less $1.8 million previously recorded for
 the preferred stock purchase option for a net non-cash charge of
 $1.6 million in the third quarter of 2015.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="INF" id="id_6038951_736EEF89-CDFA-4A38-9059-1DA96B98CDB3_1_0" unitRef="shares">83020</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:UseOfEstimates contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_B892700F-CC79-4389-B128-70B7590119E9_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Use of Estimates&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Accounting estimates are based on historical experience and other
 factors that are considered reasonable under the circumstances.
 Estimates are used in determining such items as provisions for
 sales returns, rebates and incentives, chargebacks, and other sales
 allowances; depreciable/amortizable lives; asset impairments;
 valuation allowance on deferred taxes; probabilities of achievement
 of performance conditions for certain equity awards; amounts
 recorded for licensing revenue; contingencies and accruals; and
 valuations of derivative and long-term debt instruments. Because of
 the uncertainties inherent in such estimates, actual results may
 differ from these estimates. Management periodically evaluates
 estimates used in the preparation of the condensed consolidated
 financial statements for continued reasonableness.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:DerivativesPolicyTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_56AC169B-53C0-4385-BC04-77F179DBBC86_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Derivative Liabilities&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Warrant Derivative Liability&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company&amp;#x2019;s warrant derivative liability (discussed in Note
 5&amp;#x2014;Warrants and Warrant Derivative Liability) was carried at
 fair value and was classified as Level 3 in the fair value
 hierarchy due to the use of significant unobservable inputs. During
 the six months ended June&amp;#xA0;30, 2015, of the 8,087,388 warrants
 outstanding as of December&amp;#xA0;31, 2014, 1,844,585 warrants were
 exercised while the remaining 6,242,803 warrants expired, and the
 related derivative liability was extinguished. As such, no warrants
 were outstanding as of June&amp;#xA0;30, 2016 and December&amp;#xA0;31,
 2015.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Long-Term Debt Redemption Features&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company&amp;#x2019;s December 2012 financing agreement with
 BioPharma Secured Debt Fund II Holdings Cayman LP (discussed in
 Note&amp;#xA0;6&amp;#x2014;Debt) contains a redemption feature whereby, upon
 a change of control, the Company would be required to repay $150
 million, less any previously repaid amount. The Company determined
 this redemption feature to be an embedded derivative, which is
 carried at fair value and is classified as Level 3 in the fair
 value hierarchy due to the use of significant unobservable
 inputs.&amp;#xA0;The fair value of the embedded derivative was
 calculated using a probability-weighted model incorporating
 management estimates of future revenues and for a potential change
 in control, and by determining the fair value of the debt with and
 without the change in control provision included. The difference
 between the two was determined to be the fair value of the embedded
 derivative. As of June&amp;#xA0;30, 2016, the fair value of the
 derivative was determined to be $2.8 million, and the debt was
 valued by comparing debt issues of similar companies with
 (i)&amp;#xA0;remaining terms of between 1.6 and 5.9 years,
 (ii)&amp;#xA0;coupon rates of between 6.6% and 12.5% and
 (iii)&amp;#xA0;market yields of between 11.0% and 27.7%. As of
 December&amp;#xA0;31, 2015, the fair value of the derivative was
 determined to be $5.5 million, and the debt was valued by comparing
 debt issues of similar companies with (i)&amp;#xA0;remaining terms of
 between 2.0 and 7.3 years, (ii)&amp;#xA0;coupon rates of between 6.6%
 and 12.5% and (iii)&amp;#xA0;market yields of between 13.0% and 30.7%.
 As such, the Company recognized a $2.7 million gain on change in
 fair value of derivative liability for the six months ended
 June&amp;#xA0;30, 2016.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company&amp;#x2019;s 2014 Notes and 2015 Notes each contain a
 redemption feature whereby, upon occurrence of a change in control,
 the Company would be required to repurchase the notes. The Company
 determined these redemption features to be embedded derivatives,
 requiring bifurcation in accordance with ASC 815. The derivatives
 are carried at fair value and are classified as Level 3 in the fair
 value hierarchy due to the use of significant unobservable
 inputs.&amp;#xA0;The fair value of each embedded derivative was
 calculated using a probability-weighted model incorporating
 management estimates of the probability of a change in control
 occurring, and by determining the fair value of the debt with and
 without the change in control provision included. The difference
 between the two was determined to be the fair value of the embedded
 derivative. As of June&amp;#xA0;30, 2016, the fair values of the
 derivatives related to the 2014 Notes and 2015 Notes were
 determined to be $0.6 million and $0.2 million, respectively, and
 the debts were valued by using (i)&amp;#xA0;the estimated remaining
 term of the notes, (ii)&amp;#xA0;a bond yield of 20.6%, (iii)&amp;#xA0;a
 risk-free interest rate of 2.0% and (iv)&amp;#xA0;volatility of 86.0%.
 As of December&amp;#xA0;31, 2015, the fair values of the derivatives
 related to the 2014 Notes and 2015 Notes were determined to be $2.1
 million and $0.6 million, respectively, and the debts were valued
 by using (i)&amp;#xA0;the estimated remaining term of the notes,
 (ii)&amp;#xA0;a bond yield of 25.6%, (iii)&amp;#xA0;a risk-free interest
 rate of 2.9% and (iv)&amp;#xA0;volatility of 89.0%. As such, the
 Company recognized a $1.5 million gain and $0.4 million gain on
 change in fair value of derivative liability for the 2014 Notes and
 2015 Notes, respectively, for the six months ended June&amp;#xA0;30,
 2016.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;i&gt;Preferred Stock Purchase Option Derivative Liability&lt;/i&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Pursuant to a pre-existing contractual right to participate in
 certain private placement transactions effected by the Company in
 connection with the subscription agreement executed on
 March&amp;#xA0;5, 2015, the Company determined that such right
 represented a derivative liability (see Note 8). This preferred
 stock purchase option derivative liability was carried at fair
 value and classified as Level 3 in the fair value hierarchy due to
 the use of significant unobservable inputs. The fair value of this
 liability was calculated using a Black-Scholes model and was
 determined to be $0.9 million at inception. On March&amp;#xA0;30, 2015,
 this right was exercised and the liability was marked to fair value
 through such date. The liability was then reclassified to permanent
 equity on such date.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Any changes in the assumptions used to value the derivative
 liabilities, including the probability of a change in control,
 could result in a material change to the carrying value of such
 liabilities.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:18px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The change in the fair value of derivative liabilities for the six
 months ended June&amp;#xA0;30, 2016 and 2015 is as follows:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;October&lt;br /&gt;
 2009&lt;br /&gt;
 Warrants&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;&lt;font style="white-space:nowrap"&gt;Long-Term&amp;#xA0;Debt&lt;/font&gt;&lt;br /&gt;
 Derivative&lt;br /&gt;
 Liabilities&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Preferred&amp;#xA0;Stock&lt;br /&gt;
 Purchase&amp;#xA0;Option&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Totals&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Balance as of December&amp;#xA0;31, 2015&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;8,170&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;8,170&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Gain on change in fair value of derivative liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,560&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,560&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Balance as of June&amp;#xA0;30, 2016&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;3,610&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;3,610&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;October&lt;br /&gt;
 2009&lt;br /&gt;
 Warrants&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;&lt;font style="white-space:nowrap"&gt;Long-Term&amp;#xA0;Debt&lt;/font&gt;&lt;br /&gt;
 Derivative&lt;br /&gt;
 Liabilities&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Preferred&amp;#xA0;Stock&lt;br /&gt;
 Purchase&amp;#xA0;Option&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Totals&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Balance as of December&amp;#xA0;31, 2014&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;119&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#xA0;7,400&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;7,519&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Record derivative liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;868&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;868&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 (Gain) loss on change in fair value of derivative liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(110&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(700&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;946&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;136&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Compensation income for change in fair value of warrants issued to
 former employees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(9&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(9&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Transfer derivative liability to equity&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,814&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,814&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Balance as of June&amp;#xA0;30, 2015&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;6,700&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;6,700&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="2" id="id_6038951_938BD5E9-A023-4494-BBD9-FDB4D35A3605_3_7" unitRef="iso4217_USD_per_shares">-0.23</us-gaap:EarningsPerShareBasicAndDiluted>
  <dei:EntityRegistrantName contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_7122CAB9-2953-466D-BF94-16FD51A80C1D_1_400001">AMARIN CORP PLC\UK</dei:EntityRegistrantName>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_303296E7-4744-4C08-94DE-9E859DEA8929_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following tables present information about the Company&amp;#x2019;s
 assets and liabilities as of June&amp;#xA0;30, 2016 and
 December&amp;#xA0;31, 2015 that are measured at fair value on a
 recurring basis and indicate the fair value hierarchy of the
 valuation techniques the Company utilized to determine such fair
 value:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;June&amp;#xA0;30, 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Asset:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash equivalents&amp;#x2014;money markets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Liabilities:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Long-term debt derivative liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,610&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,610&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;December&amp;#xA0;31, 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level&amp;#xA0;3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Asset:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash equivalents&amp;#x2014;money markets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,184&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,184&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Liabilities:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Long-term debt derivative liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,170&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,170&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_3A758A4F-35C5-4895-981C-39EA61739767_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Long-Lived Asset Impairment&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company reviews its long-lived assets for impairment whenever
 events or changes in circumstances indicate that the carrying
 amount of such assets may not be recoverable. Recoverability of
 these assets is determined by comparing the forecasted undiscounted
 net cash flows of the operation to which the assets relate to their
 carrying amount. If impairment is indicated, the assets are written
 down to fair value. Fair value is determined based on discounted
 forecasted cash flows or appraised values, depending on the nature
 of the assets.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_EA8A0972-3924-4C46-AFAA-39B8270D3C22_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Income Taxes&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Deferred tax assets and liabilities are recognized for the future
 tax consequences of differences between the carrying amounts and
 tax bases of assets and liabilities and operating loss
 carryforwards and other attributes using enacted rates expected to
 be in effect when those differences reverse. Valuation allowances
 are provided against deferred tax assets that are not more likely
 than not to be realized.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company provides reserves for potential payments of tax to
 various tax authorities or does not recognize tax benefits related
 to uncertain tax positions and other issues. Tax benefits for
 uncertain tax positions are based on a determination of whether a
 tax benefit taken by the Company in its tax filings or positions is
 more likely than not to be realized, assuming that the matter in
 question will be decided based on its technical merits. The
 Company&amp;#x2019;s policy is to record interest and penalties in the
 provision for income taxes.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company regularly assesses its ability to realize deferred tax
 assets. Changes in historical earnings performance and future
 earnings projections, among other factors, may cause the Company to
 adjust its valuation allowance on deferred tax assets, which would
 impact the Company&amp;#x2019;s income tax expense in the period in
 which it is determined that these factors have changed.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In April 2016, the Company adopted ASU No.&amp;#xA0;2016-09,
 &lt;i&gt;Compensation&amp;#x2014;Stock Compensation (Topic 718): Improvements
 to Employee Share-Based Payment Accounting,&lt;/i&gt; which changes the
 accounting for certain aspects of share-based payments to
 employees. One aspect of the standard requires that excess tax
 benefits and deficiencies that arise upon vesting or exercise of
 share-based payments be recognized as an income tax benefit and
 expense in the income statement. Previously, such amounts were
 recognized as an increase and decrease in additional paid-in
 capital. This aspect of the standard was adopted prospectively, and
 accordingly, the benefit from income taxes for the three and six
 months ended June&amp;#xA0;30, 2016, includes $0.1 million and $0.2
 million, respectively, of excess tax deficiencies arising from
 share-based payments. Additionally, the new standard requires that
 historical excess tax benefits that were not previously recognized
 because the related tax deduction had not reduced current taxes
 payable should be recognized on a modified retrospective basis as a
 cumulative-effect adjustment to retained earnings as of the
 beginning of the annual period of adoption. Consequently, the
 Company recognized deferred tax assets of approximately $1.6
 million relating to excess tax benefits of stock-based compensation
 outstanding as of December&amp;#xA0;31, 2015, with a corresponding
 cumulative-effect adjustment to accumulated deficit. The new
 standard also amends the presentation of employee share-based
 payment-related items in the statement of cash flows by requiring
 that: (i)&amp;#xA0;excess income tax benefits and deficiencies be
 classified in cash flows from operating activities, and
 (ii)&amp;#xA0;cash paid to taxing authorities arising from the
 withholding of shares from employees be classified as cash flows
 from financing activities. The Company adopted the aspects of the
 standard affecting cash flow presentation retrospectively and,
 accordingly, reclassified $0.6 million of excess tax provision from
 cash flows provided by financing activities to cash flows used in
 operating activities in the condensed consolidated statement of
 cash flows for the six months ended June&amp;#xA0;30, 2015 to conform
 to the current year presentation. The presentation requirement for
 cash flows related to taxes paid for withheld shares had no impact
 to any of the periods presented in the condensed consolidated
 statement of cash flows since such payments have historically been
 presented as a financing activity.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company&amp;#x2019;s and its subsidiaries&amp;#x2019; income tax returns
 are periodically examined by various tax authorities. The Company
 is currently under audit by the United States Internal Revenue
 Service (IRS) for the years 2012 to 2013. Although the outcome of
 tax audits is always uncertain and could result in significant cash
 tax payments, the Company does not believe the outcome of these
 audits will have a material adverse effect on the Company&amp;#x2019;s
 consolidated financial position or results of operations.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_34555C53-9817-48EE-B043-7C09D38EAA59_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Property, Plant and Equipment&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company provides for depreciation and amortization using the
 straight-line method by charges to operations in amounts that
 depreciate the cost of the fixed asset over its estimated useful
 life. The estimated useful lives, by asset classification, are as
 follows:&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:66.30pt; font-size:8pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Asset Classification&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Useful&amp;#xA0;Lives&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Computer equipment and software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;3&amp;#xA0;-&amp;#xA0;5&amp;#xA0;years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Furniture and fixtures&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5&amp;#xA0;years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 Lesser&amp;#xA0;of&amp;#xA0;useful&amp;#xA0;life&amp;#xA0;or&amp;#xA0;lease&amp;#xA0;term&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Upon retirement or sale of assets, the cost of the assets disposed
 and the related accumulated depreciation are removed from the
 condensed consolidated balance sheet and any resulting gain or loss
 is credited or expensed to operations. Repairs and maintenance
 costs are expensed as incurred.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_13786F86-E216-4523-8496-CC4123603175_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The following table summarizes the impact of accounts receivable
 reserves on the gross trade accounts receivable balances as of
 June&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;June&amp;#xA0;30,&amp;#xA0;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Gross trade accounts receivable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,528&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,270&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Trade allowances&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,662&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,296&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Chargebacks&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(227&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(148&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accounts receivable, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,639&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,826&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
  <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_E2EDCD91-D6A3-4C18-B74E-53E1644CBA4D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The carrying amounts and the estimated fair values of debt
 instruments as of June&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015 are
 as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;June&amp;#xA0;30, 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;December&amp;#xA0;31, 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Carrying&lt;br /&gt;
 Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Estimated&lt;br /&gt;
 Fair&amp;#xA0;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Carrying&lt;br /&gt;
 Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Estimated&lt;br /&gt;
 Fair&amp;#xA0;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Long-term debt&amp;#x2014;December 2012 financing&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;92,533&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;89,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;91,512&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;87,700&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2012 Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,107&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,686&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,107&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,637&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2014 Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;97,994&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;122,959&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;94,599&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;108,034&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2015 Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;32,378&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,028&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,448&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
  <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_A90F35AB-FB91-4A64-A5BA-F5D06E2622A1_1_0">&lt;div&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The change in the fair value of derivative liabilities for the six
 months ended June&amp;#xA0;30, 2016 and 2015 is as follows:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;October&lt;br /&gt;
 2009&lt;br /&gt;
 Warrants&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;&lt;font style="white-space:nowrap"&gt;Long-Term&amp;#xA0;Debt&lt;/font&gt;&lt;br /&gt;
 Derivative&lt;br /&gt;
 Liabilities&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Preferred&amp;#xA0;Stock&lt;br /&gt;
 Purchase&amp;#xA0;Option&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Totals&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Balance as of December&amp;#xA0;31, 2015&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;8,170&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;8,170&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Gain on change in fair value of derivative liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,560&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,560&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Balance as of June&amp;#xA0;30, 2016&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;3,610&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;3,610&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;October&lt;br /&gt;
 2009&lt;br /&gt;
 Warrants&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;&lt;font style="white-space:nowrap"&gt;Long-Term&amp;#xA0;Debt&lt;/font&gt;&lt;br /&gt;
 Derivative&lt;br /&gt;
 Liabilities&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Preferred&amp;#xA0;Stock&lt;br /&gt;
 Purchase&amp;#xA0;Option&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Totals&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Balance as of December&amp;#xA0;31, 2014&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;119&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#xA0;7,400&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;7,519&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Record derivative liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;868&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;868&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 (Gain) loss on change in fair value of derivative liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(110&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(700&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;946&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;136&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Compensation income for change in fair value of warrants issued to
 former employees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(9&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(9&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Transfer derivative liability to equity&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,814&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,814&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Balance as of June&amp;#xA0;30, 2015&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;6,700&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;6,700&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_2C660218-5573-451F-BE42-1F39C182655D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The carrying value as of June&amp;#xA0;30, 2016 and December&amp;#xA0;31,
 2015 is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&amp;#xA0;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Technology rights&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,624&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,624&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accumulated amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,529&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,207&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,095&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,417&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_C4532379-610C-4905-9B08-21A09538DB64_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;b&gt;(11)&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;b&gt;Subsequent Events&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company has evaluated subsequent events from June&amp;#xA0;30, 2016
 through the date of the issuance of these condensed consolidated
 financial statements.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_9005_2" unitRef="iso4217_USD">44864000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_7009_1200005" unitRef="iso4217_USD">-793000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:Revenues contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_3_2" unitRef="iso4217_USD">58654000</us-gaap:Revenues>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_1_22" unitRef="iso4217_USD">21000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_3_11" unitRef="iso4217_USD">-11202000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_1_4" unitRef="iso4217_USD">-48000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_3_0" unitRef="iso4217_USD">58122000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_3_9" unitRef="iso4217_USD">-37497000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_3_15" unitRef="iso4217_USD">-43125000</us-gaap:NetIncomeLoss>
  <us-gaap:InterestPaid contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_1_36" unitRef="iso4217_USD">7668000</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_1_13" unitRef="iso4217_USD">1321000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_1_12" unitRef="iso4217_USD">3813000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_7009_1200006" unitRef="iso4217_USD">6930000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_1_28" unitRef="iso4217_USD">793000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:LicensesRevenue contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_3_1" unitRef="iso4217_USD">532000</us-gaap:LicensesRevenue>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_1_37" unitRef="iso4217_USD">767000</us-gaap:IncomeTaxesPaid>
  <us-gaap:GrossProfit contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_3_4" unitRef="iso4217_USD">42897000</us-gaap:GrossProfit>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_3_10" unitRef="iso4217_USD">4560000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_7009_1200004" unitRef="iso4217_USD">124000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_3_12" unitRef="iso4217_USD">-303000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_3_18" unitRef="iso4217_USD">-43125000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_938BD5E9-A023-4494-BBD9-FDB4D35A3605_3_6" unitRef="iso4217_USD">-43125000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_1_14" unitRef="iso4217_USD">2324000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_3_13" unitRef="iso4217_USD">-44442000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_1_10" unitRef="iso4217_USD">-1846000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:Depreciation contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_1_3" unitRef="iso4217_USD">79000</us-gaap:Depreciation>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_3_14" unitRef="iso4217_USD">-1317000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_1_23" unitRef="iso4217_USD">-21000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_1_5" unitRef="iso4217_USD">6962000</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_1_17" unitRef="iso4217_USD">1470000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_1_19" unitRef="iso4217_USD">-67000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_3_6" unitRef="iso4217_USD">54086000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_9005_4" unitRef="iso4217_USD">20075000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_1_7" unitRef="iso4217_USD">5038000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_1_18" unitRef="iso4217_USD">10773000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_1_16" unitRef="iso4217_USD">-1416000</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_1_30" unitRef="iso4217_USD">-669000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_3_7" unitRef="iso4217_USD">26308000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_1_8" unitRef="iso4217_USD">322000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_1_31" unitRef="iso4217_USD">-34470000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_3_3" unitRef="iso4217_USD">15757000</us-gaap:CostOfGoodsSold>
  <us-gaap:OperatingExpenses contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_3_8" unitRef="iso4217_USD">80394000</us-gaap:OperatingExpenses>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_089CAFE4-D431-49BC-9DD5-AF057834DB24_1_26" unitRef="iso4217_USD">124000</us-gaap:ProceedsFromStockOptionsExercised>
  <amrn:PropertyPlantAndEquipmentUsefulLifeTableTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_17907398-4470-48A4-9D5A-5B500BD7D2E5_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The estimated useful lives, by asset classification, are as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 66.3pt; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Asset Classification&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;Useful&amp;#xA0;Lives&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Computer equipment and software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;3&amp;#xA0;-&amp;#xA0;5&amp;#xA0;years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Furniture and fixtures&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5&amp;#xA0;years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 Lesser&amp;#xA0;of&amp;#xA0;useful&amp;#xA0;life&amp;#xA0;or&amp;#xA0;lease&amp;#xA0;term&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</amrn:PropertyPlantAndEquipmentUsefulLifeTableTextBlock>
  <amrn:DebtIssuanceCostsPolicyTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_399A3306-3858-4423-A67D-C11EA6348BE3_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Debt Issuance Costs&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Prior to January 2016, debt issuance costs were initially recorded
 as a deferred cost and amortized to interest expense using the
 effective interest method over the expected term of the related
 debt. Effective January 2016, the Company adopted ASU
 No.&amp;#xA0;2015-03, &lt;i&gt;Interest&amp;#x2014;Imputation of Interest
 (Subtopic 835-30): Simplifying the Presentation of Debt Issuance
 Costs&lt;/i&gt;, and as such began recording debt issuance costs related
 to a recognized debt liability in the condensed consolidated
 balance sheet as a direct deduction from the carrying amount of
 that debt liability and amortized to interest expense using the
 effective interest method over the expected term of the related
 debt. As the standard is required to be adopted on a retrospective
 basis, the Company reclassified $1.9 million of underwriters&amp;#x2019;
 fees and offering costs related to the 2014 and 2015 exchangeable
 notes from other long-term assets to exchangeable senior notes, net
 of discount, within the condensed consolidated balance sheet as of
 December&amp;#xA0;31, 2015. Unamortized debt issuance costs related to
 the extinguishment of debt are expensed at the time the debt is
 extinguished and recorded in other (expense) income, net in the
 condensed consolidated statements of operations.&lt;/p&gt;
 &lt;/div&gt;</amrn:DebtIssuanceCostsPolicyTextBlock>
  <amrn:CoPromotionAgreementDisclosureTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_7998374A-7A51-4838-A689-05DB191BA047_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;b&gt;(9)&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;b&gt;Co-Promotion Agreement&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 On March&amp;#xA0;31, 2014, the Company entered into a Co-Promotion
 Agreement (the Agreement) with Kowa Pharmaceuticals America, Inc.
 related to the commercialization of Vascepa&lt;sup style="font-size:85%; vertical-align:top"&gt;&amp;#xAE;&lt;/sup&gt; (icosapent ethyl)
 capsules in the United States. Under the terms of the Agreement,
 Amarin granted to Kowa Pharmaceuticals America, Inc. the right to
 be the sole co-promoter, together with the Company, of Vascepa in
 the United States during the term. The initial term of the
 Agreement extends through 2018.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 During the term, Kowa Pharmaceuticals America, Inc. and Amarin have
 agreed to use commercially reasonable efforts to promote, detail
 and optimize sales of Vascepa in the United States. The performance
 requirements include a negotiated minimum number of details to be
 delivered by each party in the first and second position, and the
 use of a negotiated number of minimum sales representatives from
 each party, including no less than 250 Kowa Pharmaceuticals
 America, Inc. sales representatives. Kowa Pharmaceuticals America,
 Inc. has agreed to continue to bear the costs incurred for its
 sales force associated with the commercialization of Vascepa and to
 pay for certain incremental costs associated with the use of its
 sales force, such as sample costs and costs for promotional and
 marketing materials. Amarin will continue to recognize all revenue
 from sales of Vascepa and will use commercially reasonable efforts
 to maintain a minimum amount of inventory of Vascepa for use in the
 United States.&lt;/p&gt;
 &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 In exchange for Kowa Pharmaceuticals America, Inc.&amp;#x2019;s
 co-promotional services, Kowa Pharmaceuticals America, Inc. is
 entitled to a quarterly co-promotion fee based on aggregate Vascepa
 gross margin that increases during the term. The percentage of
 aggregate Vascepa gross margin earned by Kowa Pharmaceuticals
 America, Inc. was fifteen percent (15%)&amp;#xA0;in 2015, is nineteen
 percent (19%)&amp;#xA0;in 2016, and is scheduled to increase to low
 twenty percent levels in 2017 and 2018, subject to certain
 adjustments. The co-promotion fee also varies based on sales levels
 and whether the FDA has approved an ANCHOR indication labeling
 expansion for Vascepa or has permitted the use of data generated to
 support obtaining FDA approval of the ANCHOR indication in the
 promotion of Vascepa, in which case the co-promotion fee would be
 decreased if specified requirements are met. In certain
 circumstances, upon the earlier of the expiration or termination of
 the Agreement in accordance with its terms, Kowa Pharmaceuticals
 America, Inc. may be eligible for a co-promotion tail fee equal to
 declining fractions of the co-promotion fee in effect prior to such
 expiration or termination for periods ranging from one to three
 years following such expiration or termination.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 As of June&amp;#xA0;30, 2016 and December&amp;#xA0;31, 2015,&amp;#xA0;the
 Company had a net payable of $2.7 million and $2.5 million,
 respectively, to Kowa Pharmaceuticals America, Inc. representing
 co-promotion fees payable to Kowa Pharmaceuticals America, Inc. net
 of reimbursable amounts incurred for samples and other marketing
 expenses.&lt;/p&gt;
 &lt;/div&gt;</amrn:CoPromotionAgreementDisclosureTextBlock>
  <amrn:ProvisionRelatedToPriorPeriodSales contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_9005_3" unitRef="iso4217_USD">-553000</amrn:ProvisionRelatedToPriorPeriodSales>
  <amrn:BeneficialConversionFeaturePolicyTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_5CE1E93B-90E6-49B3-8404-2C9FD605FB8E_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Beneficial Conversion Features&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company issued Series A preference shares in a private
 placement transaction executed in two tranches that each contain a
 conversion feature whereby such shares are convertible into
 ordinary shares at a fixed rate. The conversion price on the date
 of issuance was less than the market price of the Company&amp;#x2019;s
 ordinary shares. It was determined that these discounts represent
 contingent beneficial conversion features, which were valued based
 on the difference between the conversion price and the market price
 of the ordinary shares on the date of issuance, which is the
 commitment date. These features are analogous to preference
 dividends and were each recorded as a non-cash return to preferred
 shareholders through accumulated deficit upon the earliest possible
 date of conversion, which occurred in the three months ended
 June&amp;#xA0;30, 2015 upon effectiveness of the related resale
 Registration Statement on Form S-3 and in the three months ended
 September&amp;#xA0;30, 2015 upon shareholder approval received at the
 Company&amp;#x2019;s Annual General Meeting of Shareholders. See Note
 8&amp;#x2014;Equity for further discussion.&lt;/p&gt;
 &lt;/div&gt;</amrn:BeneficialConversionFeaturePolicyTextBlock>
  <amrn:CreditsPaymentsMadeForPriorPeriodSales contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_9005_5" unitRef="iso4217_USD">14187000</amrn:CreditsPaymentsMadeForPriorPeriodSales>
  <amrn:CashDiscountInvoiceTerms contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_74F636D7-EA93-4F41-BB3E-B115FE6B03DA_1_1">P30D</amrn:CashDiscountInvoiceTerms>
  <amrn:ConcentrationOfSuppliersPolicyTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_82EE712C-144F-4D71-B2BD-D0203F97A354_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Concentration of Suppliers&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company has contractual freedom to source the API for Vascepa
 and has entered into supply agreements with multiple suppliers. The
 Company&amp;#x2019;s supply of product for commercial sale and clinical
 trials is dependent upon relationships with third-party
 manufacturers and key suppliers, in particular three suppliers of
 API for Vascepa.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company cannot provide assurance that its efforts to procure
 uninterrupted supply of Vascepa API to meet market demand will
 continue to be successful or that it will be able to renew current
 API supply agreements on favorable terms or at all. Significant
 alteration to or termination of the Company&amp;#x2019;s current API
 supply chain or its failure to enter into new and similar
 agreements, if needed, could have a material adverse effect on its
 business, condition (financial and other), prospects or results of
 operations.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company currently has manufacturing agreements with three
 FDA-approved commercial API encapsulators for Vascepa
 manufacturing. Each of these companies has qualified its
 manufacturing processes and is capable of manufacturing Vascepa.
 There can be no guarantee that these or other suppliers with which
 the Company may contract in the future to encapsulate API will
 continue to be qualified to manufacture the product to its
 specifications or that these and any future suppliers will have the
 manufacturing capacity to meet anticipated demand for Vascepa.&lt;/p&gt;
 &lt;/div&gt;</amrn:ConcentrationOfSuppliersPolicyTextBlock>
  <amrn:UseOfForecastedFinancialInformationInAccountingEstimatesPolicyTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_85D80E60-FCBD-4267-9B7A-C359B5769312_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;&lt;u&gt;Use of Forecasted Financial Information in Accounting
 Estimates&lt;/u&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The use of forecasted financial information is inherent in many of
 the Company&amp;#x2019;s accounting estimates including, but not limited
 to, determining the estimated fair values of derivatives, debt
 instruments and intangible assets, and evaluating the need for
 valuation allowances for deferred tax assets. Such forecasted
 financial information is comprised of numerous assumptions
 regarding the Company&amp;#x2019;s future revenues, cash flows, and
 operational results. Management believes that its financial
 forecasts are reasonable and appropriate based upon current facts
 and circumstances. Because of the inherent nature of forecasts,
 however, actual results may differ from these forecasts. Management
 regularly reviews the information related to these forecasts and
 adjusts the carrying amounts of the applicable assets
 prospectively, if and when actual results differ from previous
 estimates.&lt;/p&gt;
 &lt;/div&gt;</amrn:UseOfForecastedFinancialInformationInAccountingEstimatesPolicyTextBlock>
  <amrn:AccountsReceivableCreditPeriod contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_D1481062-FBC7-46E0-B790-9528B4B0BC0E_1_0">P30D</amrn:AccountsReceivableCreditPeriod>
  <amrn:SummaryOfNetProductRevenueValuationAllowancesTableTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0" id="id_6038951_CF03C8B8-03E9-4890-90B5-856EC87E5490_1_0">&lt;div&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The following tables summarize activity in each of the net product
 revenue allowance and reserve categories described above for the
 six months ended June&amp;#xA0;30, 2016 and 2015:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Trade&lt;br /&gt;
 Allowances&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Rebates,&lt;br /&gt;
 Chargebacks&lt;br /&gt;
 and&amp;#xA0;Discounts&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Product&lt;br /&gt;
 Returns&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Other&lt;br /&gt;
 Incentives&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Balance as of December&amp;#xA0;31, 2015&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;4,296&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;9,881&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;535&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,084&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;15,796&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Provision related to current period sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,048&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,945&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;257&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,614&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44,864&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Provision related to prior period sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(87&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(466&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(553&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Credits/payments made for current period sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,415&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10,750&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,910&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(20,075&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Credits/payments made for prior period sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,180&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(8,497&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(226&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,284&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(14,187&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Balance as of June&amp;#xA0;30, 2016&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;3,662&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;19,113&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;566&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,504&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;25,845&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;In thousands&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Trade&lt;br /&gt;
 Allowances&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Rebates,&lt;br /&gt;
 Chargebacks&lt;br /&gt;
 and&amp;#xA0;Discounts&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Product&lt;br /&gt;
 Returns&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Other&lt;br /&gt;
 Incentives&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Balance as of December&amp;#xA0;31, 2014&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,207&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;3,610&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#xA0;481&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;792&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;7,090&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Provision related to current period sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,044&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,957&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;276&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,691&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,968&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Provision related to prior period sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(113&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(44&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(157&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Credits/payments made for current period sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,810&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,243&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,149&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12,202&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Credits/payments made for prior period sales&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,039&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,531&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(14&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(792&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,376&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Balance as of June&amp;#xA0;30, 2015&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,289&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;5,749&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;743&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,542&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;10,323&lt;/b&gt;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</amrn:SummaryOfNetProductRevenueValuationAllowancesTableTextBlock>
  <us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1 contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324093x1528669" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_8009_1200002" unitRef="iso4217_USD">1639000</us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1>
  <amrn:ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324093x1528669" decimals="-5" id="id_6038951_3F6849BD-D7D4-4677-A197-16E5D7F62D46_1002_0" unitRef="iso4217_USD">200000</amrn:ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities>
  <us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1 contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324093x1528669_1330097x1326044" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_8008_1100002" unitRef="iso4217_USD">1639000</us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1>
  <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324199x1335583_1325804x1405848_1336123x1429469" decimals="INF" id="id_6038951_A8FD6E71-FE9D-4C45-B45C-593469947C43_4002_7" unitRef="shares">77405</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324199x1335583_1325804x1405848_1336123x1429469" decimals="INF" id="id_6038951_A8FD6E71-FE9D-4C45-B45C-593469947C43_4002_6" unitRef="shares">181874</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324199x1335583_1325804x1405848_1336123x1454011" decimals="INF" id="id_6038951_4EE230FA-CF6D-4C64-9E39-A1088A62EA42_3002_6" unitRef="shares">270329</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324199x1335583_1325804x1405848_1336123x1454011" decimals="INF" id="id_6038951_4EE230FA-CF6D-4C64-9E39-A1088A62EA42_3002_5" unitRef="shares">818352</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:DebtInstrumentCallDateEarliest contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324529x1375482_1328615x1333865" id="id_6038951_3C66D491-3A39-4445-8C9A-AA1BE3334369_1002_2">2019-01-19</us-gaap:DebtInstrumentCallDateEarliest>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6038951_D7D9551B-0EB9-45F8-A623-ED5904725C48_1001_1" unitRef="iso4217_USD">1500000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324529x1410374_1328615x1333865" decimals="3" id="id_6038951_6D4583B3-AC09-464C-9701-513739DFDEAF_2001_2" unitRef="pure">0.206</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324529x1410374_1328615x1333865" decimals="3" id="id_6038951_6D4583B3-AC09-464C-9701-513739DFDEAF_2001_4" unitRef="pure">0.860</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324529x1410374_1328615x1333865" decimals="3" id="id_6038951_6D4583B3-AC09-464C-9701-513739DFDEAF_2001_3" unitRef="pure">0.020</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:DebtInstrumentCallDateLatest contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324529x1435611_1328615x1333865" id="id_6038951_3C66D491-3A39-4445-8C9A-AA1BE3334369_2002_5">2022-01-19</us-gaap:DebtInstrumentCallDateLatest>
  <us-gaap:DebtInstrumentCallDateEarliest contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324529x1461424_1328615x1333865" id="id_6038951_3C66D491-3A39-4445-8C9A-AA1BE3334369_3002_1">2017-01-19</us-gaap:DebtInstrumentCallDateEarliest>
  <us-gaap:DebtInstrumentCallDateLatest contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324529x1482079_1328615x1333865" id="id_6038951_3C66D491-3A39-4445-8C9A-AA1BE3334369_4002_4">2017-01-19</us-gaap:DebtInstrumentCallDateLatest>
  <us-gaap:DebtInstrumentCallDateEarliest contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324529x1486557_1328615x1333865" id="id_6038951_3C66D491-3A39-4445-8C9A-AA1BE3334369_5002_3">2019-01-19</us-gaap:DebtInstrumentCallDateEarliest>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6038951_E743A84A-72A8-4DA5-B7B1-38F582C13171_1002_1" unitRef="iso4217_USD">400000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6038951_FD305EA1-2595-400A-922D-829A38A62F3E_1003_3" unitRef="iso4217_USD">600000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6038951_FD305EA1-2595-400A-922D-829A38A62F3E_1003_1" unitRef="iso4217_USD">1200000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324529x1486557_1328615x1333865_1333245x1345793" decimals="-5" id="id_6038951_FD305EA1-2595-400A-922D-829A38A62F3E_2003_2" unitRef="iso4217_USD">600000</us-gaap:InterestExpenseDebt>
  <us-gaap:DebtInstrumentCallDateLatest contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324529x1511434_1328615x1333865" id="id_6038951_3C66D491-3A39-4445-8C9A-AA1BE3334369_6002_6">2027-01-19</us-gaap:DebtInstrumentCallDateLatest>
  <amrn:RangeOfPercentageOfGrossMarginPayableForCoPromotionAgreement contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1327036x1498782" id="id_6038951_91EFBC58-FCE3-4F75-8011-E75832648346_1003_1">Scheduled to increase to low twenty percent levels in 2017 and  2018, subject to certain adjustments.</amrn:RangeOfPercentageOfGrossMarginPayableForCoPromotionAgreement>
  <amrn:NumberOfSalesProfessionals contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1327036x1498782_1328480x1458944" decimals="INF" id="id_6038951_692848A1-A21C-4442-9758-7D1FF923CF1F_1001_0" unitRef="Employee">150</amrn:NumberOfSalesProfessionals>
  <amrn:NumberOfSalesRepresentative contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1327036x1498782_1328480x1458944_1335482x1331874" decimals="INF" id="id_6038951_692848A1-A21C-4442-9758-7D1FF923CF1F_2001_1" unitRef="Employee">250</amrn:NumberOfSalesRepresentative>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1327091x1327216" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_9003_2" unitRef="iso4217_USD">257000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <amrn:CreditsPaymentsMadeForPriorPeriodSales contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1327091x1327216" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_9003_5" unitRef="iso4217_USD">226000</amrn:CreditsPaymentsMadeForPriorPeriodSales>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1327091x1327217" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_9001_2" unitRef="iso4217_USD">10048000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1327091x1327217" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_9001_4" unitRef="iso4217_USD">6415000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <amrn:ProvisionRelatedToPriorPeriodSales contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1327091x1327217" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_9001_3" unitRef="iso4217_USD">-87000</amrn:ProvisionRelatedToPriorPeriodSales>
  <amrn:CreditsPaymentsMadeForPriorPeriodSales contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1327091x1327217" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_9001_5" unitRef="iso4217_USD">4180000</amrn:CreditsPaymentsMadeForPriorPeriodSales>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1327091x1368196" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_9004_2" unitRef="iso4217_USD">5614000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1327091x1368196" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_9004_4" unitRef="iso4217_USD">2910000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <amrn:CreditsPaymentsMadeForPriorPeriodSales contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1327091x1368196" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_9004_5" unitRef="iso4217_USD">1284000</amrn:CreditsPaymentsMadeForPriorPeriodSales>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1327091x1397499" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_9002_2" unitRef="iso4217_USD">28945000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1327091x1397499" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_9002_4" unitRef="iso4217_USD">10750000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <amrn:ProvisionRelatedToPriorPeriodSales contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1327091x1397499" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_9002_3" unitRef="iso4217_USD">-466000</amrn:ProvisionRelatedToPriorPeriodSales>
  <amrn:CreditsPaymentsMadeForPriorPeriodSales contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1327091x1397499" decimals="-3" id="id_6038951_4EBEF23E-2BAA-4250-BCDD-FE36643C97AC_9002_5" unitRef="iso4217_USD">8497000</amrn:CreditsPaymentsMadeForPriorPeriodSales>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1328615x1333865" decimals="-3" id="id_6038951_5BDFD6F6-6DE1-4246-B761-5D351FDA9212_1003_2" unitRef="shares">59407000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1328615x1333865" decimals="-5" id="id_6038951_E80A76F1-63CB-46EA-9296-5170BC68CB70_1003_3" unitRef="iso4217_USD">2300000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1328615x1333865" decimals="-5" id="id_6038951_E80A76F1-63CB-46EA-9296-5170BC68CB70_1003_1" unitRef="iso4217_USD">5700000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestPaid contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1328615x1333865_1333110x1404455" decimals="-5" id="id_6038951_E36B50A5-038F-45C3-9A4D-31D5B08AD71A_1001_1" unitRef="iso4217_USD">2500000</us-gaap:InterestPaid>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1328615x1333865_1333245x1345793" decimals="-5" id="id_6038951_E80A76F1-63CB-46EA-9296-5170BC68CB70_2003_2" unitRef="iso4217_USD">3400000</us-gaap:InterestExpenseDebt>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330097x1326044" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_7008_1100007" unitRef="iso4217_USD">-43125000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330097x1327190" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_7006_900005" unitRef="iso4217_USD">-1152000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330097x1327190" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_7006_900006" unitRef="iso4217_USD">6930000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330097x1327190" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_7006_900004" unitRef="iso4217_USD">64000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330097x1330220" decimals="INF" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_7003_600005" unitRef="shares">-548845</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330097x1330220" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_7003_1000005" unitRef="iso4217_USD">-786000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330097x1333806" decimals="INF" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_7002_500005" unitRef="shares">1613726</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330097x1333806" decimals="INF" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_7002_500004" unitRef="shares">83020</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330097x1333806" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_7002_800005" unitRef="iso4217_USD">1145000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330097x1333806" decimals="-3" id="id_6038951_46B2BD98-9CD3-4711-B5D3-4AB1349E615A_7002_800004" unitRef="iso4217_USD">60000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:EmbeddedDerivativeDescriptionOfHostContract contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330125x1468605_1333769x1451741" id="id_6038951_E5C838E3-B79F-4EA5-9874-E54D2758BA20_1001_0">The warrants issued in connection with the October 2009 financing contained a pricing variability feature which provided for an increase to the exercise price if the exchange rate between the U.S. dollar and British pound adjusts such that the warrants could be exercised at a price less than the &#xA3;0.5 par value of the common stock-that is, if the exchange rate exceeded U.S. $3.00 per &#xA3;1.0 sterling. Due to the potential variable nature of the exercise price, the warrants were not considered to be indexed to the Company&#x2019;s common stock. Accordingly, the warrants did not qualify for the exception to classify the warrants within equity and were classified as a derivative liability.</us-gaap:EmbeddedDerivativeDescriptionOfHostContract>
  <us-gaap:PreferredStockConversionsInducements contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330125x1482162_1330926x1353534" decimals="-5" id="id_6038951_62CE8781-0CA8-4BF2-BBA3-8742054E9C6E_1002_3" unitRef="iso4217_USD">3400000</us-gaap:PreferredStockConversionsInducements>
  <amrn:DerivativeLiabilitiesTransferredToStockholdersEquity contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330125x1482162_1330926x1353534" decimals="-5" id="id_6038951_62CE8781-0CA8-4BF2-BBA3-8742054E9C6E_1002_2" unitRef="iso4217_USD">1800000</amrn:DerivativeLiabilitiesTransferredToStockholdersEquity>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330926x1327893" decimals="-3" id="id_6038951_E2DC3566-84DC-4350-9A4A-417787BC4F4E_10002_2" unitRef="iso4217_USD">4560000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330926x1327893_1333242x1356609" decimals="-5" id="id_6038951_DB4BC3CD-3A87-41FF-AE0F-2D181F3A62CA_1003_8" unitRef="iso4217_USD">2700000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330926x1327893_1333242x1356609_1335482x1328677" id="id_6038951_DB4BC3CD-3A87-41FF-AE0F-2D181F3A62CA_2003_2">P5Y10M24D</us-gaap:FairValueAssumptionsExpectedTerm>
  <amrn:FairValueAssumptionsComparableYieldToMaturity contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330926x1327893_1333242x1356609_1335482x1328677" decimals="INF" id="id_6038951_DB4BC3CD-3A87-41FF-AE0F-2D181F3A62CA_2003_6" unitRef="pure">0.277</amrn:FairValueAssumptionsComparableYieldToMaturity>
  <amrn:FairValueAssumptionsCouponRate contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330926x1327893_1333242x1356609_1335482x1328677" decimals="INF" id="id_6038951_DB4BC3CD-3A87-41FF-AE0F-2D181F3A62CA_2003_4" unitRef="pure">0.125</amrn:FairValueAssumptionsCouponRate>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330926x1327893_1333242x1356609_1335482x1331874" id="id_6038951_DB4BC3CD-3A87-41FF-AE0F-2D181F3A62CA_3003_1">P1Y7M6D</us-gaap:FairValueAssumptionsExpectedTerm>
  <amrn:FairValueAssumptionsComparableYieldToMaturity contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330926x1327893_1333242x1356609_1335482x1331874" decimals="INF" id="id_6038951_DB4BC3CD-3A87-41FF-AE0F-2D181F3A62CA_3003_5" unitRef="pure">0.110</amrn:FairValueAssumptionsComparableYieldToMaturity>
  <amrn:FairValueAssumptionsCouponRate contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330926x1327893_1333242x1356609_1335482x1331874" decimals="INF" id="id_6038951_DB4BC3CD-3A87-41FF-AE0F-2D181F3A62CA_3003_3" unitRef="pure">0.066</amrn:FairValueAssumptionsCouponRate>
  <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1331645x1336129" id="id_6038951_88BA03FD-6E54-47A7-AB0F-6D9B79E79955_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;(5)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Warrants and Warrant Derivative
 Liability&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 On October&amp;#xA0;16, 2009, the Company completed a $70.0 million
 private placement with both existing and new investors resulting in
 $62.3 million in net proceeds and an additional $3.6 million from
 bridge notes converted in conjunction with the private placement.
 In consideration for the $62.3 million in net cash proceeds Amarin
 issued 66.4&amp;#xA0;million units, each unit consisting of
 (i)&amp;#xA0;one ADS (representing one ordinary share) at a purchase
 price of $1.00 and (ii)&amp;#xA0;a warrant with a five year term to
 purchase 0.5 (one half) of an ADS at an exercise price of $1.50 per
 ADS. In consideration for the conversion of $3.6 million of
 convertible bridge notes, Amarin issued 4.0&amp;#xA0;million units,
 each unit consisting of (i)&amp;#xA0;one ADS (representing one ordinary
 share) at a purchase price of $0.90 and (ii)&amp;#xA0;a warrant with a
 five year term to purchase 0.5 (one half) of an ADS at an exercise
 price of $1.50 per ADS. The total number of warrants issued in
 conjunction with the financing was 35.2&amp;#xA0;million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In conjunction with the October 2009 financing, the Company issued
 an additional 0.9&amp;#xA0;million warrants to three former officers.
 The warrants issued in connection with the October 2009 financing
 contained a pricing variability feature which provided for an
 increase to the exercise price if the exchange rate between the
 U.S. dollar and British pound adjusts such that the warrants could
 be exercised at a price less than the &amp;#xA3;0.5 par value of the
 common stock&amp;#x2014;that is, if the exchange rate exceeded U.S.
 $3.00 per &amp;#xA3;1.0 sterling. Due to the potential variable nature
 of the exercise price, the warrants were not considered to be
 indexed to the Company&amp;#x2019;s common stock. Accordingly, the
 warrants did not qualify for the exception to classify the warrants
 within equity and were classified as a derivative liability.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The fair value of this warrant derivative liability was remeasured
 at each reporting period, with changes in fair value recognized in
 the condensed consolidated statement of operations. Upon exercise,
 the fair value of the warrants exercised was remeasured and
 reclassified from warrant derivative liability to additional
 paid-in-capital. Although the warrants contained a pricing
 variability feature, the number of warrants issuable remained
 fixed. Therefore, the maximum number of common shares issuable as a
 result of the October 2009 private placement was 36.1 million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In October 2014, the Company and the holders of the remaining
 October 2009 warrants mutually agreed to extend the expiration date
 of such warrants from October&amp;#xA0;16, 2014 to February&amp;#xA0;27,
 2015. During the six months ended June&amp;#xA0;30, 2015, of the
 8,087,388 warrants outstanding as of December&amp;#xA0;31, 2014,
 1,844,585 warrants were exercised, resulting in net proceeds to the
 Company of $2.7 million, the remaining 6,242,803 warrants expired,
 and the related derivative liability was extinguished. As such, no
 warrants were outstanding as of June&amp;#xA0;30, 2016 and
 December&amp;#xA0;31, 2015.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1333242x1356609" decimals="-5" id="id_6038951_F7F2EBF9-0A3F-445D-B3F5-C5AC806D4324_1002_1" unitRef="iso4217_USD">2700000</us-gaap:UnrealizedGainLossOnDerivatives>
  <amrn:GuaranteePayments contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1333242x1356609" decimals="-5" id="id_6038951_48EB9B53-53EA-46D5-8390-75FBDA9FAE94_1003_1" unitRef="iso4217_USD">5200000</amrn:GuaranteePayments>
  <us-gaap:InterestExpenseDebt contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1333242x1356609_1333245x1345793" decimals="-5" id="id_6038951_BBD88633-2BB4-4D8C-A7DD-A310C02B9223_1003_2" unitRef="iso4217_USD">1000000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1333242x1356609_1333245x1417215" decimals="-5" id="id_6038951_BBD88633-2BB4-4D8C-A7DD-A310C02B9223_2003_1" unitRef="iso4217_USD">3400000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1333589x1330112" decimals="-3" id="id_6038951_5BDFD6F6-6DE1-4246-B761-5D351FDA9212_2003_0" unitRef="shares">20641000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1333589x1335583" decimals="-3" id="id_6038951_5BDFD6F6-6DE1-4246-B761-5D351FDA9212_3003_1" unitRef="shares">10361000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1333817x1329312_1333818x1324536_1334994x1501282" decimals="2" id="id_6038951_DA538F2D-9B24-45F9-BA03-48BAF678A727_1001_0" unitRef="pure">0.95</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1333817x1333518_1333818x1324536_1334994x1501282" decimals="2" id="id_6038951_DA538F2D-9B24-45F9-BA03-48BAF678A727_2001_1" unitRef="pure">0.94</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1334996x1325837" decimals="-3" id="id_6038951_5BDFD6F6-6DE1-4246-B761-5D351FDA9212_4003_3" unitRef="shares">32818000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1335427x1328146" id="id_6038951_D7B4FC09-B17E-4408-809D-B58255EDA217_1001_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1335427x1331682" id="id_6038951_D7B4FC09-B17E-4408-809D-B58255EDA217_2001_3">Lesser of useful life or lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1335427x1443526_1335482x1328677" id="id_6038951_D7B4FC09-B17E-4408-809D-B58255EDA217_3001_1">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1335427x1443526_1335482x1331874" id="id_6038951_D7B4FC09-B17E-4408-809D-B58255EDA217_4001_0">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <amrn:EligibleMilestonePayment contextRef="eol_PE46938---1610-Q0007_STD_182_20160630_0_1335482x1328677_1512983x1440366" decimals="INF" id="id_6038951_737588EE-5959-493F-81A7-F4EF4906F4A1_1001_0" unitRef="iso4217_USD">153000000</amrn:EligibleMilestonePayment>
  <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="eol_PE46938---1610-Q0007_STD_273_20150930_0_1330125x1482162_1330926x1353534" decimals="-5" id="id_6038951_62CE8781-0CA8-4BF2-BBA3-8742054E9C6E_1003_5" unitRef="iso4217_USD">-1600000</us-gaap:DerivativeGainLossOnDerivativeNet>
  <us-gaap:RepaymentsOfConvertibleDebt contextRef="eol_PE46938---1610-Q0007_STD_29_20151130_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6038951_60A62C0D-177A-4669-86C4-DEF1FAF41842_1001_4" unitRef="iso4217_USD">15900000</us-gaap:RepaymentsOfConvertibleDebt>
  <us-gaap:DebtInstrumentDateOfFirstRequiredPayment1 contextRef="eol_PE46938---1610-Q0007_STD_29_20151130_0_1324529x1486557_1328615x1333865" id="id_6038951_C0C20A68-6B67-4DE7-A7DD-96ED490FFF2A_1001_0">2016-01-15</us-gaap:DebtInstrumentDateOfFirstRequiredPayment1>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE46938---1610-Q0007_STD_29_20151130_0_1324529x1486557_1328615x1333865" id="id_6038951_C0C20A68-6B67-4DE7-A7DD-96ED490FFF2A_1001_1">2032-01-15</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE46938---1610-Q0007_STD_29_20151130_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6038951_60A62C0D-177A-4669-86C4-DEF1FAF41842_2001_3" unitRef="iso4217_USD">27500000</us-gaap:ProceedsFromConvertibleDebt>
  <amrn:DebtInstrumentMaturityDateYear contextRef="eol_PE46938---1610-Q0007_STD_29_20151130_0_1324529x1486557_1328615x1333865" id="id_6038951_60A62C0D-177A-4669-86C4-DEF1FAF41842_2001_2">2032</amrn:DebtInstrumentMaturityDateYear>
  <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments contextRef="eol_PE46938---1610-Q0007_STD_29_20151130_0_1324529x1486557_1328615x1333865_1330096x1403450" decimals="INF" id="id_6038951_60A62C0D-177A-4669-86C4-DEF1FAF41842_3001_6" unitRef="shares">12025385</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="eol_PE46938---1610-Q0007_STD_29_20151130_0_1324529x1486557_1328615x1333865_1330096x1403450" decimals="4" id="id_6038951_60A62C0D-177A-4669-86C4-DEF1FAF41842_3001_5" unitRef="pure">384.6154</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <amrn:BeneficialOwnershipLimitationPercentage contextRef="eol_PE46938---1610-Q0007_STD_29_20151130_0_1324529x1486557_1328615x1333865_1335482x1328677" decimals="INF" id="id_6038951_60A62C0D-177A-4669-86C4-DEF1FAF41842_4001_9" unitRef="pure">0.199</amrn:BeneficialOwnershipLimitationPercentage>
  <amrn:BeneficialOwnershipLimitationPercentage contextRef="eol_PE46938---1610-Q0007_STD_29_20151130_0_1324529x1486557_1328615x1333865_1335482x1331874" decimals="INF" id="id_6038951_60A62C0D-177A-4669-86C4-DEF1FAF41842_5001_8" unitRef="pure">0.0499</amrn:BeneficialOwnershipLimitationPercentage>
  <us-gaap:DebtInstrumentDateOfFirstRequiredPayment1 contextRef="eol_PE46938---1610-Q0007_STD_31_20120131_0_1324529x1461424_1328615x1333865" id="id_6038951_AA371BFA-143A-4DAA-A51B-AE6F15E09FD4_1001_3">2012-07-15</us-gaap:DebtInstrumentDateOfFirstRequiredPayment1>
  <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="eol_PE46938---1610-Q0007_STD_31_20120131_0_1324529x1461424_1328615x1333865" decimals="INF" id="id_6038951_3C66D491-3A39-4445-8C9A-AA1BE3334369_3003_8" unitRef="pure">1.00</us-gaap:DebtInstrumentRedemptionPricePercentage>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE46938---1610-Q0007_STD_31_20120131_0_1324529x1461424_1328615x1333865" id="id_6038951_AA371BFA-143A-4DAA-A51B-AE6F15E09FD4_1001_4">2032-01-15</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentTerm contextRef="eol_PE46938---1610-Q0007_STD_31_20120131_0_1324529x1461424_1328615x1333865" id="id_6038951_2DB18CD9-77CA-4B94-9785-9A7F990D70CC_1003_1">P24M</us-gaap:DebtInstrumentTerm>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE46938---1610-Q0007_STD_31_20120131_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6038951_32D75A08-FD12-43FC-9ABE-3343C6704FC9_1001_3" unitRef="iso4217_USD">144300000</us-gaap:ProceedsFromConvertibleDebt>
  <amrn:DebtInstrumentMaturityDateYear contextRef="eol_PE46938---1610-Q0007_STD_31_20120131_0_1324529x1461424_1328615x1333865" id="id_6038951_32D75A08-FD12-43FC-9ABE-3343C6704FC9_1001_2">2032</amrn:DebtInstrumentMaturityDateYear>
  <amrn:AdditionalPercentageInterestRatePenalty contextRef="eol_PE46938---1610-Q0007_STD_31_20120131_0_1324529x1461424_1328615x1333865" decimals="4" id="id_6038951_886D2C4E-486B-4717-814E-AB4ED9898D84_1001_0" unitRef="pure">0.0050</amrn:AdditionalPercentageInterestRatePenalty>
  <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments contextRef="eol_PE46938---1610-Q0007_STD_31_20120131_0_1324529x1461424_1328615x1333865_1330096x1403450" decimals="INF" id="id_6038951_AA371BFA-143A-4DAA-A51B-AE6F15E09FD4_2001_1" unitRef="shares">1714270</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="eol_PE46938---1610-Q0007_STD_31_20120131_0_1324529x1461424_1328615x1333865_1330096x1403450" decimals="4" id="id_6038951_AA371BFA-143A-4DAA-A51B-AE6F15E09FD4_2001_0" unitRef="pure">113.4752</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <us-gaap:DebtInstrumentDateOfFirstRequiredPayment1 contextRef="eol_PE46938---1610-Q0007_STD_31_20140531_0_1324529x1375482_1328615x1333865" id="id_6038951_DCD753F6-986B-4B11-945C-7651F17A6D7C_1001_3">2014-07-15</us-gaap:DebtInstrumentDateOfFirstRequiredPayment1>
  <us-gaap:DebtInstrumentRedemptionPeriodEndDate contextRef="eol_PE46938---1610-Q0007_STD_31_20140531_0_1324529x1375482_1328615x1333865" id="id_6038951_96AF6A6D-464E-4216-8CC8-4B910728F508_1001_0">2032-01-15</us-gaap:DebtInstrumentRedemptionPeriodEndDate>
  <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="eol_PE46938---1610-Q0007_STD_31_20140531_0_1324529x1375482_1328615x1333865" decimals="INF" id="id_6038951_67A1C822-3A95-4FF8-908C-4CD834DE8398_1001_0" unitRef="pure">1.00</us-gaap:DebtInstrumentRedemptionPricePercentage>
  <us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="eol_PE46938---1610-Q0007_STD_31_20140531_0_1324529x1375482_1328615x1333865" decimals="INF" id="id_6038951_96AF6A6D-464E-4216-8CC8-4B910728F508_1001_3" unitRef="D">30</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE46938---1610-Q0007_STD_31_20140531_0_1324529x1375482_1328615x1333865" id="id_6038951_DCD753F6-986B-4B11-945C-7651F17A6D7C_1001_4">2032-01-15</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="eol_PE46938---1610-Q0007_STD_31_20140531_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6038951_1F250133-B467-41B8-BB19-11E3049DC435_1001_4" unitRef="iso4217_USD">38000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="eol_PE46938---1610-Q0007_STD_31_20140531_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6038951_1F250133-B467-41B8-BB19-11E3049DC435_1001_0" unitRef="iso4217_USD">-10100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
  <amrn:DebtInstrumentMaturityDateYear contextRef="eol_PE46938---1610-Q0007_STD_31_20140531_0_1324529x1375482_1328615x1333865" id="id_6038951_10BF13B3-4BC9-49C5-B079-5403CE1F4BC4_1001_2">2032</amrn:DebtInstrumentMaturityDateYear>
  <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments contextRef="eol_PE46938---1610-Q0007_STD_31_20140531_0_1324529x1375482_1328615x1333865_1330096x1403450" decimals="INF" id="id_6038951_DCD753F6-986B-4B11-945C-7651F17A6D7C_2001_0" unitRef="shares">45666925</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="eol_PE46938---1610-Q0007_STD_31_20140531_0_1324529x1375482_1328615x1333865_1330096x1403450" decimals="4" id="id_6038951_DCD753F6-986B-4B11-945C-7651F17A6D7C_2001_1" unitRef="pure">384.6154</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays contextRef="eol_PE46938---1610-Q0007_STD_31_20140531_0_1324529x1375482_1328615x1333865_1335482x1331874" id="id_6038951_96AF6A6D-464E-4216-8CC8-4B910728F508_2001_2">P20D</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays>
  <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="eol_PE46938---1610-Q0007_STD_31_20140531_0_1324529x1375482_1328615x1333865_1335482x1331874" decimals="INF" id="id_6038951_96AF6A6D-464E-4216-8CC8-4B910728F508_2001_1" unitRef="pure">1.10</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-Q0007_STD_365_20151231_0_1324529x1375482_1328615x1333865" decimals="-5" id="id_6038951_6D4583B3-AC09-464C-9701-513739DFDEAF_1002_5" unitRef="iso4217_USD">1500000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE46938---1610-Q0007_STD_365_20151231_0_1324529x1410374_1328615x1333865" decimals="3" id="id_6038951_6D4583B3-AC09-464C-9701-513739DFDEAF_2002_2" unitRef="pure">0.256</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE46938---1610-Q0007_STD_365_20151231_0_1324529x1410374_1328615x1333865" decimals="3" id="id_6038951_6D4583B3-AC09-464C-9701-513739DFDEAF_2002_4" unitRef="pure">0.890</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE46938---1610-Q0007_STD_365_20151231_0_1324529x1410374_1328615x1333865" decimals="3" id="id_6038951_6D4583B3-AC09-464C-9701-513739DFDEAF_2002_3" unitRef="pure">0.029</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-Q0007_STD_365_20151231_0_1324529x1486557_1328615x1333865" decimals="-5" id="id_6038951_6D4583B3-AC09-464C-9701-513739DFDEAF_3002_6" unitRef="iso4217_USD">400000</us-gaap:UnrealizedGainLossOnDerivatives>
  <amrn:PercentageOfGrossMarginPayableForPromotionAgreement contextRef="eol_PE46938---1610-Q0007_STD_365_20151231_0_1327036x1498782" decimals="2" id="id_6038951_91EFBC58-FCE3-4F75-8011-E75832648346_1001_0" unitRef="pure">0.15</amrn:PercentageOfGrossMarginPayableForPromotionAgreement>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1610-Q0007_STD_365_20151231_0_1330926x1327893_1333242x1356609_1335482x1328677" id="id_6038951_DB4BC3CD-3A87-41FF-AE0F-2D181F3A62CA_2001_2">P7Y3M18D</us-gaap:FairValueAssumptionsExpectedTerm>
  <amrn:FairValueAssumptionsComparableYieldToMaturity contextRef="eol_PE46938---1610-Q0007_STD_365_20151231_0_1330926x1327893_1333242x1356609_1335482x1328677" decimals="INF" id="id_6038951_DB4BC3CD-3A87-41FF-AE0F-2D181F3A62CA_2001_6" unitRef="pure">0.307</amrn:FairValueAssumptionsComparableYieldToMaturity>
  <amrn:FairValueAssumptionsCouponRate contextRef="eol_PE46938---1610-Q0007_STD_365_20151231_0_1330926x1327893_1333242x1356609_1335482x1328677" decimals="INF" id="id_6038951_DB4BC3CD-3A87-41FF-AE0F-2D181F3A62CA_2001_4" unitRef="pure">0.125</amrn:FairValueAssumptionsCouponRate>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE46938---1610-Q0007_STD_365_20151231_0_1330926x1327893_1333242x1356609_1335482x1331874" id="id_6038951_DB4BC3CD-3A87-41FF-AE0F-2D181F3A62CA_3001_1">P2Y</us-gaap:FairValueAssumptionsExpectedTerm>
  <amrn:FairValueAssumptionsComparableYieldToMaturity contextRef="eol_PE46938---1610-Q0007_STD_365_20151231_0_1330926x1327893_1333242x1356609_1335482x1331874" decimals="INF" id="id_6038951_DB4BC3CD-3A87-41FF-AE0F-2D181F3A62CA_3001_5" unitRef="pure">0.130</amrn:FairValueAssumptionsComparableYieldToMaturity>
  <amrn:FairValueAssumptionsCouponRate contextRef="eol_PE46938---1610-Q0007_STD_365_20151231_0_1330926x1327893_1333242x1356609_1335482x1331874" decimals="INF" id="id_6038951_DB4BC3CD-3A87-41FF-AE0F-2D181F3A62CA_3001_3" unitRef="pure">0.066</amrn:FairValueAssumptionsCouponRate>
  <amrn:PercentageOfGrossMarginPayableForPromotionAgreement contextRef="eol_PE46938---1610-Q0007_STD_366_20161231_0_1327036x1498782_1333245x1326102" decimals="2" id="id_6038951_91EFBC58-FCE3-4F75-8011-E75832648346_1002_0" unitRef="pure">0.19</amrn:PercentageOfGrossMarginPayableForPromotionAgreement>
  <amrn:NumberOfPatientsEnrolledInStudy contextRef="eol_PE46938---1610-Q0007_STD_40_20160331_0" decimals="-3" id="id_6038951_E7D662A1-FD74-40D5-82EE-38DFB5CB5999_1_0" unitRef="Patient">8000</amrn:NumberOfPatientsEnrolledInStudy>
  <amrn:LicensingAgreementTerm contextRef="eol_PE46938---1610-Q0007_STD_40_20160331_0_1333954x1528901_1512983x1440366" id="id_6038951_B573A080-6791-486C-B846-3A3BFE474F7A_1003_3">P4Y</amrn:LicensingAgreementTerm>
  <amrn:NonrefundableMilestonePayment contextRef="eol_PE46938---1610-Q0007_STD_40_20160331_0_1333954x1528901_1512983x1440366" decimals="-5" id="id_6038951_B573A080-6791-486C-B846-3A3BFE474F7A_1003_2" unitRef="iso4217_USD">1000000</amrn:NonrefundableMilestonePayment>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE46938---1610-Q0007_STD_90_20150331_0" decimals="-5" id="id_6038951_44DABF76-3C5D-49AB-B8C7-A78855E86E67_2_2" unitRef="iso4217_USD">52800000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <amrn:EquityOfferingCosts contextRef="eol_PE46938---1610-Q0007_STD_90_20150331_0" decimals="-5" id="id_6038951_44DABF76-3C5D-49AB-B8C7-A78855E86E67_2_3" unitRef="iso4217_USD">700000</amrn:EquityOfferingCosts>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0" decimals="2" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_2_21" unitRef="iso4217_USD_per_shares">-0.35</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_2_24" unitRef="shares">180464000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_2_23" unitRef="shares">180464000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0" decimals="-3" id="id_6038951_938BD5E9-A023-4494-BBD9-FDB4D35A3605_2_8" unitRef="shares">180464000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0" decimals="2" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_2_20" unitRef="iso4217_USD_per_shares">-0.35</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0" decimals="2" id="id_6038951_938BD5E9-A023-4494-BBD9-FDB4D35A3605_2_7" unitRef="iso4217_USD_per_shares">-0.35</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:Revenues contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_2_2" unitRef="iso4217_USD">17707000</us-gaap:Revenues>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_2_11" unitRef="iso4217_USD">-4807000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_2_0" unitRef="iso4217_USD">17707000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_2_9" unitRef="iso4217_USD">-26737000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_2_15" unitRef="iso4217_USD">-31512000</us-gaap:NetIncomeLoss>
  <us-gaap:GrossProfit contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_2_4" unitRef="iso4217_USD">11326000</us-gaap:GrossProfit>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_2_10" unitRef="iso4217_USD">-600000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_2_12" unitRef="iso4217_USD">95000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_2_18" unitRef="iso4217_USD">-62853000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0" decimals="-3" id="id_6038951_938BD5E9-A023-4494-BBD9-FDB4D35A3605_2_6" unitRef="iso4217_USD">-62853000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_2_13" unitRef="iso4217_USD">-32049000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_2_14" unitRef="iso4217_USD">-537000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_2_6" unitRef="iso4217_USD">26054000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:PreferredStockConversionsInducements contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_2_17" unitRef="iso4217_USD">31341000</us-gaap:PreferredStockConversionsInducements>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_2_7" unitRef="iso4217_USD">12009000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_2_3" unitRef="iso4217_USD">6381000</us-gaap:CostOfGoodsSold>
  <us-gaap:OperatingExpenses contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_2_8" unitRef="iso4217_USD">38063000</us-gaap:OperatingExpenses>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0_1328615x1333865" decimals="-3" id="id_6038951_5BDFD6F6-6DE1-4246-B761-5D351FDA9212_1002_2" unitRef="shares">49215000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0_1330096x1433040" decimals="INF" id="id_6038951_34A17C75-E862-47A6-82B8-4BBCB04A527A_3003_4" unitRef="shares">6283333</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0_1333589x1330112" decimals="-3" id="id_6038951_5BDFD6F6-6DE1-4246-B761-5D351FDA9212_2002_0" unitRef="shares">11750000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0_1333589x1335583" decimals="-3" id="id_6038951_5BDFD6F6-6DE1-4246-B761-5D351FDA9212_3002_1" unitRef="shares">4046000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-Q0007_STD_91_20150630_0_1334996x1325837" decimals="-3" id="id_6038951_5BDFD6F6-6DE1-4246-B761-5D351FDA9212_4002_3" unitRef="shares">28932000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0" decimals="2" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_1_21" unitRef="iso4217_USD_per_shares">-0.07</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_1_24" unitRef="shares">184471000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_1_23" unitRef="shares">184471000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0" decimals="-3" id="id_6038951_938BD5E9-A023-4494-BBD9-FDB4D35A3605_1_8" unitRef="shares">184471000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0" decimals="2" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_1_20" unitRef="iso4217_USD_per_shares">-0.07</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0" decimals="2" id="id_6038951_938BD5E9-A023-4494-BBD9-FDB4D35A3605_1_7" unitRef="iso4217_USD_per_shares">-0.07</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:Revenues contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_1_2" unitRef="iso4217_USD">33111000</us-gaap:Revenues>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_1_11" unitRef="iso4217_USD">-5616000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_1_0" unitRef="iso4217_USD">32815000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_1_9" unitRef="iso4217_USD">-14394000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_1_15" unitRef="iso4217_USD">-13354000</us-gaap:NetIncomeLoss>
  <us-gaap:LicensesRevenue contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_1_1" unitRef="iso4217_USD">296000</us-gaap:LicensesRevenue>
  <us-gaap:GrossProfit contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_1_4" unitRef="iso4217_USD">24250000</us-gaap:GrossProfit>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_1_10" unitRef="iso4217_USD">5810000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_1_12" unitRef="iso4217_USD">-182000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_1_18" unitRef="iso4217_USD">-13354000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0" decimals="-3" id="id_6038951_938BD5E9-A023-4494-BBD9-FDB4D35A3605_1_6" unitRef="iso4217_USD">-13354000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_1_13" unitRef="iso4217_USD">-14382000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_1_14" unitRef="iso4217_USD">-1028000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_1_6" unitRef="iso4217_USD">26066000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_1_7" unitRef="iso4217_USD">12578000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_1_3" unitRef="iso4217_USD">8861000</us-gaap:CostOfGoodsSold>
  <us-gaap:OperatingExpenses contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0" decimals="-3" id="id_6038951_37B2EE84-5032-4757-B329-3963A0A52929_1_8" unitRef="iso4217_USD">38644000</us-gaap:OperatingExpenses>
  <amrn:ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0_1324093x1528669" decimals="-5" id="id_6038951_3F6849BD-D7D4-4677-A197-16E5D7F62D46_1001_0" unitRef="iso4217_USD">100000</amrn:ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0_1328615x1333865" decimals="-3" id="id_6038951_5BDFD6F6-6DE1-4246-B761-5D351FDA9212_1001_2" unitRef="shares">59407000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <amrn:GuaranteePayments contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0_1333242x1356609" decimals="-5" id="id_6038951_48EB9B53-53EA-46D5-8390-75FBDA9FAE94_1002_1" unitRef="iso4217_USD">2500000</amrn:GuaranteePayments>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0_1333589x1330112" decimals="-3" id="id_6038951_5BDFD6F6-6DE1-4246-B761-5D351FDA9212_2001_0" unitRef="shares">20641000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0_1333589x1335583" decimals="-3" id="id_6038951_5BDFD6F6-6DE1-4246-B761-5D351FDA9212_3001_1" unitRef="shares">10361000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE46938---1610-Q0007_STD_91_20160630_0_1334996x1325837" decimals="-3" id="id_6038951_5BDFD6F6-6DE1-4246-B761-5D351FDA9212_4001_3" unitRef="shares">32818000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="eol_PE46938---1610-Q0007_STD_92_20151231_0_1324529x1461424_1328615x1333865" decimals="-5" id="id_6038951_0B66086E-A0DF-4566-8C35-FD6CF3551219_1002_3" unitRef="iso4217_USD">1300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <context id="eol_PE46938---1610-Q0007_STD_92_20151231_0_1324529x1461424_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-10-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_91_20160630_0_1334996x1325837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_91_20160630_0_1333589x1335583">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_91_20160630_0_1333589x1330112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_91_20160630_0_1333242x1356609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_91_20160630_0_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_91_20160630_0_1324093x1528669">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">amrn:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_91_20160630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_91_20150630_0_1334996x1325837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_91_20150630_0_1333589x1335583">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_91_20150630_0_1333589x1330112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_91_20150630_0_1330096x1433040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:OrdinarySharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_91_20150630_0_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_91_20150630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_90_20150331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_40_20160331_0_1333954x1528901_1512983x1440366">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:EddingpharmMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">amrn:ClinicalTrialApplicationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-21</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_40_20160331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2016-02-21</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_366_20161231_0_1327036x1498782_1333245x1326102">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrn:CoPromotionAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_365_20151231_0_1330926x1327893_1333242x1356609_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_365_20151231_0_1330926x1327893_1333242x1356609_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_365_20151231_0_1327036x1498782">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrn:CoPromotionAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_365_20151231_0_1324529x1486557_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_365_20151231_0_1324529x1410374_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoAndThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_365_20151231_0_1324529x1375482_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_31_20140531_0_1324529x1375482_1328615x1333865_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-05-01</startDate>
      <endDate>2014-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_31_20140531_0_1324529x1375482_1328615x1333865_1330096x1403450">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-05-01</startDate>
      <endDate>2014-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_31_20140531_0_1324529x1375482_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-05-01</startDate>
      <endDate>2014-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_31_20120131_0_1324529x1461424_1328615x1333865_1330096x1403450">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_31_20120131_0_1324529x1461424_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_29_20151130_0_1324529x1486557_1328615x1333865_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-11-02</startDate>
      <endDate>2015-11-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_29_20151130_0_1324529x1486557_1328615x1333865_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-11-02</startDate>
      <endDate>2015-11-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_29_20151130_0_1324529x1486557_1328615x1333865_1330096x1403450">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-11-02</startDate>
      <endDate>2015-11-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_29_20151130_0_1324529x1486557_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-11-02</startDate>
      <endDate>2015-11-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_29_20151130_0_1324529x1461424_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-11-02</startDate>
      <endDate>2015-11-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_273_20150930_0_1330125x1482162_1330926x1353534">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:PreferredStockPurchaseOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:SecondPrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1335482x1328677_1512983x1440366">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:EddingpharmMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1335427x1443526_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amrn:ComputerEquipmentAndCapitalizedSoftwareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1335427x1443526_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amrn:ComputerEquipmentAndCapitalizedSoftwareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1335427x1331682">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1335427x1328146">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1334996x1325837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1333817x1333518_1333818x1324536_1334994x1501282">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">amrn:TopThreeCustomerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1333817x1329312_1333818x1324536_1334994x1501282">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">amrn:TopThreeCustomerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1333589x1335583">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1333589x1330112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1333242x1356609_1333245x1417215">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:ChargesCashMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1333242x1356609_1333245x1345793">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:NonCashMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1333242x1356609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1331645x1336129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330926x1327893_1333242x1356609_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330926x1327893_1333242x1356609_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330926x1327893_1333242x1356609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330926x1327893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330125x1482162_1330926x1353534">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:PreferredStockPurchaseOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:SecondPrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330125x1468605_1333769x1451741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330097x1333806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330097x1330220">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330097x1327190">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1330097x1326044">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1328615x1333865_1333245x1345793">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:NonCashMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1328615x1333865_1333110x1404455">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">amrn:FinanceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1327091x1397499">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:RebatesChargebacksAndDiscountsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1327091x1368196">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:OtherIncentiveProgramsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1327091x1327217">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForTradeReceivablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1327091x1327216">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForSalesReturnsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1327036x1498782_1328480x1458944_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">amrn:KowaPharmaceuticalsAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrn:CoPromotionAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1327036x1498782_1328480x1458944">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">amrn:KowaPharmaceuticalsAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrn:CoPromotionAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1327036x1498782">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrn:CoPromotionAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324529x1511434_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:DateThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324529x1486557_1328615x1333865_1333245x1345793">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:NonCashMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324529x1486557_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324529x1482079_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:DateOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324529x1461424_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324529x1435611_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:DateTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324529x1410374_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoAndThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324529x1375482_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324199x1335583_1325804x1405848_1336123x1454011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">amrn:VestingPeriodOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324199x1335583_1325804x1405848_1336123x1429469">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">amrn:VestingPeriodThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324093x1528669_1330097x1326044">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">amrn:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0_1324093x1528669">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">amrn:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_182_20160630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_181_20150630_0_1334996x1325837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_181_20150630_0_1333817x1333518_1333818x1324536_1334994x1501282">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">amrn:TopThreeCustomerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_181_20150630_0_1333817x1329312_1333818x1324536_1334994x1501282">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">amrn:TopThreeCustomerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_181_20150630_0_1333769x1451741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_181_20150630_0_1333589x1335583">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_181_20150630_0_1333589x1330112">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_181_20150630_0_1333242x1356609_1333245x1417215">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:ChargesCashMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_181_20150630_0_1333242x1356609_1333245x1345793">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:NonCashMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_181_20150630_0_1333242x1356609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_181_20150630_0_1331645x1336129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_181_20150630_0_1330926x1451741_1331645x1336129">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_181_20150630_0_1330926x1451741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_181_20150630_0_1330926x1353534">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:PreferredStockPurchaseOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_181_20150630_0_1330926x1327893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_181_20150630_0_1328615x1333865_1333245x1345793">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:NonCashMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_181_20150630_0_1328615x1333865_1333110x1404455">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SecuritiesFinancingTransactionAxis">amrn:FinanceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_181_20150630_0_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_181_20150630_0_1327091x1397499">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:RebatesChargebacksAndDiscountsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_181_20150630_0_1327091x1368196">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:OtherIncentiveProgramsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_181_20150630_0_1327091x1327217">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForTradeReceivablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_181_20150630_0_1327091x1327216">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForSalesReturnsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_181_20150630_0_1324529x1375482_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_181_20150630_0_1324093x1528669_1333245x1335616">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">amrn:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_181_20150630_0_1324093x1528669_1333245x1332387">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">amrn:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_181_20150630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20150129_0_1324199x1423313_1325804x1405848">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amrn:PerformanceBasedRestrictedStockUnitMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-29</startDate>
      <endDate>2015-01-29</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20150129_0_1324199x1335583_1325804x1405848">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-29</startDate>
      <endDate>2015-01-29</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20150129_0_1324199x1331109_1325804x1405848">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-29</startDate>
      <endDate>2015-01-29</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20121206_0_1333242x1356609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-12-06</startDate>
      <endDate>2012-12-06</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20091016_0_1330125x1468605">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-10-16</startDate>
      <endDate>2009-10-16</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20091016_0_1328615x1330534_1330125x1468605">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-10-16</startDate>
      <endDate>2009-10-16</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20091016_0_1324828x1419380_1330125x1468605_1333769x1451741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EnergyAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-10-16</startDate>
      <endDate>2009-10-16</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20091016_0_1324828x1419380_1328615x1330534_1330125x1468605_1333769x1451741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EnergyAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-10-16</startDate>
      <endDate>2009-10-16</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20150710_0_1330096x1335797_1330097x1403450_1330125x1482162">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:SecondPrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-10</startDate>
      <endDate>2015-07-10</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20150706_0_1324199x1456480_1325804x1405848_1336123x1425353">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amrn:PerformanceBasedOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">amrn:VestingPeriodFourMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-06</startDate>
      <endDate>2015-07-06</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20150706_0_1324199x1335583_1325804x1405848_1330194x1334098_1336123x1487759">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">amrn:VestingPeriodTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-06</startDate>
      <endDate>2015-07-06</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20150706_0_1324199x1335583_1325804x1405848_1330194x1334098_1336123x1454011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">amrn:VestingPeriodOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-06</startDate>
      <endDate>2015-07-06</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20150706_0_1324199x1335583_1325804x1405848_1330194x1334098">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-06</startDate>
      <endDate>2015-07-06</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20150706_0_1324199x1335583_1325804x1405848">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-06</startDate>
      <endDate>2015-07-06</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20150706_0_1324199x1331109_1325804x1405848_1336123x1429469">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">amrn:VestingPeriodThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-06</startDate>
      <endDate>2015-07-06</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20150706_0_1324199x1331109_1325804x1405848_1330194x1334098_1336123x1487759">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">amrn:VestingPeriodTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-06</startDate>
      <endDate>2015-07-06</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20150706_0_1324199x1331109_1325804x1405848_1330194x1334098_1336123x1454011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">amrn:VestingPeriodOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-06</startDate>
      <endDate>2015-07-06</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20150706_0_1324199x1331109_1325804x1405848_1330194x1334098">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-06</startDate>
      <endDate>2015-07-06</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20150706_0_1324199x1331109_1325804x1405848">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-06</startDate>
      <endDate>2015-07-06</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20150305_0_1330125x1482162_1330926x1353534">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:PreferredStockPurchaseOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:SecondPrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-03-05</startDate>
      <endDate>2015-03-05</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20150305_0_1330096x1335797_1335482x1331874">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-03-05</startDate>
      <endDate>2015-03-05</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20150305_0_1330096x1335797_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-03-05</startDate>
      <endDate>2015-03-05</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20150305_0_1330096x1335797_1330097x1403450">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-03-05</startDate>
      <endDate>2015-03-05</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20150305_0_1330096x1335797">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-03-05</startDate>
      <endDate>2015-03-05</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20150305_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <startDate>2015-03-05</startDate>
      <endDate>2015-03-05</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20160201_0_1324199x1335583_1325804x1405848">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-01</startDate>
      <endDate>2016-02-01</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20160201_0_1324199x1331109_1325804x1405848">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">amrn:StockIncentivePlanTwentyElevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-01</startDate>
      <endDate>2016-02-01</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_1_20150226_0_1512983x1440366">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:EddingpharmMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-02-26</startDate>
      <endDate>2015-02-26</endDate>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1333769x1451741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1333245x1335616">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1333242x1356609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1331211x1328015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330926x1327893_1333242x1356609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330926x1327893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1333806_1333245x1335616">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1333806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1330220_1333245x1335616">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1330220">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1327190_1333245x1335616">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1327190">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1326044_1333245x1335616">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1326044">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1325837_1333245x1335616">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1330097x1325837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1327091x1397499">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:RebatesChargebacksAndDiscountsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1327091x1368196">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:OtherIncentiveProgramsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1327091x1366356">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:AllowanceForEstimatedChargebacksMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1327091x1327217">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForTradeReceivablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1327091x1327216">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForSalesReturnsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1327036x1498782_1328480x1458944">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">amrn:KowaPharmaceuticalsAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrn:CoPromotionAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324896x1327983_1331211x1328015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324896x1324925_1331211x1328015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324529x1486557_1328615x1333865_1333245x1345793">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:NonCashMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324529x1486557_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324529x1461424_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324529x1375482_1328615x1333865_1333245x1345793">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:NonCashMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324529x1375482_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324093x1330360_1333245x1332467">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201503Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324093x1330360_1324529x1486557_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201503Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324093x1330360_1324529x1486557">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201503Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324093x1330360_1324529x1375482_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201503Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0_1324093x1330360_1324529x1375482">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201503Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20141231_0_1333769x1451741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20141231_0_1330926x1451741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20141231_0_1330926x1327893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20141231_0_1327091x1397499">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:RebatesChargebacksAndDiscountsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20141231_0_1327091x1368196">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:OtherIncentiveProgramsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20141231_0_1327091x1327217">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForTradeReceivablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20141231_0_1327091x1327216">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForSalesReturnsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20121231_0_1330926x1327893_1333242x1356609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20121206_0_1333242x1356609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-12-06</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1333769x1451741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1333245x1506247_1512983x1493724">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:PotentialMarketingApprovalOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:FurtherIndicationForAmrOneZeroOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1333245x1506247_1512983x1410232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:MarketingApprovalInEuropeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:FurtherIndicationForAmrOneZeroOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1333245x1506247_1512983x1364380">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:BusinessDevelopmentsAxis">amrn:PotentialMarketingApprovalTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:FurtherIndicationForAmrOneZeroOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1333245x1506247_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:FurtherIndicationForAmrOneZeroOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1333242x1356609_1367440x1517729">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:PeriodAxis">amrn:PeriodThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1333242x1356609_1367440x1358031">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:PeriodAxis">amrn:PeriodTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1333242x1356609_1367440x1347115">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="amrn:PeriodAxis">amrn:PeriodOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1333242x1356609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1331211x1328015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1330926x1327893_1333242x1356609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amrn:BiopharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1330926x1327893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1330125x1482162_1330926x1353534">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:PreferredStockPurchaseOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:SecondPrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1330097x1400959">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amrn:OrdinarySharesBasisMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1330097x1333806">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1330097x1330220">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1330097x1327190">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1330097x1326044">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1330097x1325837">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1330096x1433040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:OrdinarySharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1327091x1397499">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:RebatesChargebacksAndDiscountsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1327091x1368196">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:OtherIncentiveProgramsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1327091x1366356">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:AllowanceForEstimatedChargebacksMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1327091x1327217">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForTradeReceivablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1327091x1327216">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForSalesReturnsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1327036x1498782_1328480x1458944">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">amrn:KowaPharmaceuticalsAmericaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">amrn:CoPromotionAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324896x1327983_1331211x1328015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324896x1324925_1331211x1328015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324529x1486557_1328615x1333865_1333245x1345793">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:NonCashMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324529x1486557_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324529x1461424_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324529x1461424">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324529x1375482_1328615x1333865_1333245x1345793">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">amrn:NonCashMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324529x1375482_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324199x1335583">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324199x1331109">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0_1324093x1528669">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">amrn:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20150630_0_1330926x1327893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20150630_0_1327091x1397499">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:RebatesChargebacksAndDiscountsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20150630_0_1327091x1368196">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amrn:OtherIncentiveProgramsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20150630_0_1327091x1327217">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForTradeReceivablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20150630_0_1327091x1327216">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForSalesReturnsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20150630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20091016_0_1330125x1468605_1333769x1451741_1335482x1328677">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20091016_0_1330125x1468605_1333769x1451741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20091016_0_1328615x1330534_1330125x1468605">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20091016_0_1326002x1332009_1330125x1468605">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OfficerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20091016_0_1324828x1419380_1330125x1468605_1333769x1451741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EnergyAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20091016_0_1324828x1419380_1328615x1330534_1330125x1468605_1333769x1451741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">amrn:WarrantsIssuedOctoberTwentyZeroNineMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:EnergyAxis">amrn:AmericanDepositaryShareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:OctoberTwentyZeroNinePrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-10-16</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160801_0_1330096x1433040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:OrdinarySharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-08-01</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20160801_0_1330096x1403450">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-08-01</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20150710_0_1330096x1335797_1330125x1482162">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:SecondPrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-07-10</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20150710_0_1330096x1335797_1330097x1400959_1330125x1482162">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amrn:OrdinarySharesBasisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:SecondPrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-07-10</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20150710_0_1330096x1335797_1330097x1393080_1330125x1482162">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amrn:PreferredSharesBasisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:SecondPrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-07-10</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20140531_0_1324529x1461424_1328615x1333865_1330788x1464257">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">amrn:DebtExchangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-05-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20140531_0_1324529x1461424_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-05-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20140531_0_1324529x1375482_1328615x1333865_1330096x1403450">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-05-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20140531_0_1324529x1375482_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-05-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20150305_0_1330926x1353534">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:PreferredStockPurchaseOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-05</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20150305_0_1330125x1482162_1330926x1353534">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">amrn:PreferredStockPurchaseOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">amrn:SecondPrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-05</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20150305_0_1330097x1400959">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amrn:OrdinarySharesBasisMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-05</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20150305_0_1330097x1393080">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">amrn:PreferredSharesBasisMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-05</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20150305_0_1330096x1335797">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-05</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20150305_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
    </entity>
    <period>
      <instant>2015-03-05</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151130_0_1324529x1486557_1328615x1333865_1330096x1403450">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-11-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151130_0_1324529x1486557_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesThreeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-11-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20151130_0_1324529x1461424_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-11-30</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20120131_0_1324529x1461424_1328615x1333865_1334996x1364094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">amrn:OtherDebtObligationsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-01-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20120131_0_1324529x1461424_1328615x1333865_1330096x1403450">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amrn:AmericanDepositorySharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-01-31</instant>
    </period>
  </context>
  <context id="eol_PE46938---1610-Q0007_STD_0_20120131_0_1324529x1461424_1328615x1333865">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amrn:SeniorNotesOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-01-31</instant>
    </period>
  </context>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="iso4217_GBP_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:GBP</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="Tranche">
    <measure>amrn:Tranche</measure>
  </unit>
  <unit id="iso4217_GBP">
    <measure>iso4217:GBP</measure>
  </unit>
  <unit id="Segment">
    <measure>amrn:Segment</measure>
  </unit>
  <unit id="Employee">
    <measure>amrn:Employee</measure>
  </unit>
  <unit id="D">
    <measure>utr:D</measure>
  </unit>
  <unit id="Patient">
    <measure>amrn:Patient</measure>
  </unit>

</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>amrn-20160630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Schema, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 3 -->
<!-- Creation date: 2016-08-03T22:03:39Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31"
  xmlns:us-types="http://fasb.org/us-types/2016-01-31"
  xmlns:amrn="http://www.amarincorp.com/20160630"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2016-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
  targetNamespace="http://www.amarincorp.com/20160630"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DocumentandEntityInformation" id="DocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfIncomeAlternative" id="Role_StatementOfIncomeAlternative">
        <link:definition>105 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" id="Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome">
        <link:definition>106 - Statement - Condensed Consolidated Statements Of Stockholders' Deficit</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>107 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <link:definition>108 - Disclosure - Nature of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
        <link:definition>109 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock" id="Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock">
        <link:definition>110 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock" id="Role_NotesToFinancialStatementsInventoryDisclosureTextBlock">
        <link:definition>111 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="Role_NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
        <link:definition>112 - Disclosure - Warrants and Warrant Derivative Liability</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock" id="Role_NotesToFinancialStatementsDebtDisclosureTextBlock">
        <link:definition>113 - Disclosure - Debt</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
        <link:definition>114 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
        <link:definition>115 - Disclosure - Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCoPromotionAgreementDisclosureTextBlock" id="Role_NotesToFinancialStatementsCoPromotionAgreementDisclosureTextBlock">
        <link:definition>116 - Disclosure - Co-Promotion Agreement</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" id="Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
        <link:definition>117 - Disclosure - Development, Commercialization and Supply Agreement</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock" id="Role_NotesToFinancialStatementsSubsequentEventsTextBlock">
        <link:definition>118 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
        <link:definition>119 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
        <link:definition>120 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables">
        <link:definition>121 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsInventoryDisclosureTextBlockTables">
        <link:definition>122 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation" id="DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation">
        <link:definition>123 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation" id="DisclosureSignificantAccountingPoliciesAdditionalInformation">
        <link:definition>124 - Disclosure - Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureSummarizesActivityOfTheNetProductRevenueAllowanceAndReserveCategories" id="DisclosureSummarizesActivityOfTheNetProductRevenueAllowanceAndReserveCategories">
        <link:definition>125 - Disclosure - Summarizes Activity of the Net Product Revenue Allowance and Reserve Categories (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureSummarizesTheImpactOfAccountsReceivableReservesOnGrossTradeAccountsReceivable" id="DisclosureSummarizesTheImpactOfAccountsReceivableReservesOnGrossTradeAccountsReceivable">
        <link:definition>126 - Disclosure - Summarizes the Impact of Accounts Receivable Reserves on Gross Trade Accounts Receivable (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureEstimatedUsefulLives" id="DisclosureEstimatedUsefulLives">
        <link:definition>127 - Disclosure - Estimated Useful Lives (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureNetLossAndTheNumberOfSharesUsedToComputeBasicAndDilutedLossPerShare" id="DisclosureNetLossAndTheNumberOfSharesUsedToComputeBasicAndDilutedLossPerShare">
        <link:definition>128 - Disclosure - Net Loss and the Number of Shares Used to Compute Basic and Diluted Loss per Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureAntiDilutiveSecuritiesNotIncludedInTheComputationOfNetLossPerShare" id="DisclosureAntiDilutiveSecuritiesNotIncludedInTheComputationOfNetLossPerShare">
        <link:definition>129 - Disclosure - Anti-Dilutive Securities Not Included in the Computation of Net Loss per Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureAssetsAndLiabilityMeasuredAtFairValueOnRecurringBasis" id="DisclosureAssetsAndLiabilityMeasuredAtFairValueOnRecurringBasis">
        <link:definition>130 - Disclosure - Assets and Liability Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureCarryingAmountsAndEstimatedFairValuesOfDebtInstruments" id="DisclosureCarryingAmountsAndEstimatedFairValuesOfDebtInstruments">
        <link:definition>131 - Disclosure - Carrying Amounts and Estimated Fair Values of Debt Instruments (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureChangeInFairValueOfDerivativeLiabilities" id="DisclosureChangeInFairValueOfDerivativeLiabilities">
        <link:definition>132 - Disclosure - Change in Fair Value of Derivative Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation" id="DisclosureIntangibleAssetsAdditionalInformation">
        <link:definition>133 - Disclosure - Intangible Assets - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureIntangibleAssets" id="DisclosureIntangibleAssets">
        <link:definition>134 - Disclosure - Intangible Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureInventory" id="DisclosureInventory">
        <link:definition>135 - Disclosure - Inventory (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureWarrantsAndWarrantDerivativeLiabilityAdditionalInformation" id="DisclosureWarrantsAndWarrantDerivativeLiabilityAdditionalInformation">
        <link:definition>136 - Disclosure - Warrants and Warrant Derivative Liability - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureDebtAdditionalInformation" id="DisclosureDebtAdditionalInformation">
        <link:definition>137 - Disclosure - Debt - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation" id="DisclosureCommitmentsAndContingenciesAdditionalInformation">
        <link:definition>138 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureEquityAdditionalInformation" id="DisclosureEquityAdditionalInformation">
        <link:definition>139 - Disclosure - Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureCoPromotionAgreementAdditionalInformation" id="DisclosureCoPromotionAgreementAdditionalInformation">
        <link:definition>140 - Disclosure - Co-Promotion Agreement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureDevelopmentCommercializationAndSupplyAgreementAdditionalInformation" id="DisclosureDevelopmentCommercializationAndSupplyAgreementAdditionalInformation">
        <link:definition>141 - Disclosure - Development, Commercialization and Supply Agreement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="amrn-20160630_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="amrn-20160630_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="amrn-20160630_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="amrn-20160630_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <element name="AccountingStandardsUpdate201609Member" id="amrn_AccountingStandardsUpdate201609Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AccountsReceivableCreditPeriod" id="amrn_AccountsReceivableCreditPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalPercentageInterestRatePenalty" id="amrn_AdditionalPercentageInterestRatePenalty" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AllowanceForEstimatedChargebacksMember" id="amrn_AllowanceForEstimatedChargebacksMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmericanDepositaryShareMember" id="amrn_AmericanDepositaryShareMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmericanDepositorySharesMember" id="amrn_AmericanDepositorySharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmericanDepositorySharesToSharesRatio" id="amrn_AmericanDepositorySharesToSharesRatio" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BeneficialConversionFeaturePolicyTextBlock" id="amrn_BeneficialConversionFeaturePolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BeneficialOwnershipLimitationPercentage" id="amrn_BeneficialOwnershipLimitationPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BiopharmaceuticalMember" id="amrn_BiopharmaceuticalMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessDevelopmentDomain" id="amrn_BusinessDevelopmentDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BusinessDevelopmentsAxis" id="amrn_BusinessDevelopmentsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
  <element name="CashDiscountInvoiceTerms" id="amrn_CashDiscountInvoiceTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CashDiscountPercent" id="amrn_CashDiscountPercent" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CashPaidDuringPeriodForAbstract" id="amrn_CashPaidDuringPeriodForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ChargesCashMember" id="amrn_ChargesCashMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightExercisedInPeriod" id="amrn_ClassOfWarrantOrRightExercisedInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightExpiredInPeriod" id="amrn_ClassOfWarrantOrRightExpiredInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightIssued" id="amrn_ClassOfWarrantOrRightIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightTerm" id="amrn_ClassOfWarrantOrRightTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClinicalTrialApplicationMember" id="amrn_ClinicalTrialApplicationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommitmentsAndContingenciesDisclosureLineItems" id="amrn_CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommitmentsAndContingenciesDisclosureTable" id="amrn_CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="ComputerEquipmentAndCapitalizedSoftwareMember" id="amrn_ComputerEquipmentAndCapitalizedSoftwareMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConcentrationOfSuppliersPolicyTextBlock" id="amrn_ConcentrationOfSuppliersPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConversionPricePerShare" id="amrn_ConversionPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CoPromotionAgreementDisclosureTextBlock" id="amrn_CoPromotionAgreementDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CoPromotionAgreementLineItems" id="amrn_CoPromotionAgreementLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CoPromotionAgreementMember" id="amrn_CoPromotionAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CoPromotionAgreementTable" id="amrn_CoPromotionAgreementTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="CreditsPaymentsMadeForPriorPeriodSales" id="amrn_CreditsPaymentsMadeForPriorPeriodSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DateOneMember" id="amrn_DateOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DateThreeMember" id="amrn_DateThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DateTwoMember" id="amrn_DateTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtDisclosureLineItems" id="amrn_DebtDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtDisclosureTable" id="amrn_DebtDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="DebtExchangeMember" id="amrn_DebtExchangeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtInstrumentMaturityDateYear" id="amrn_DebtInstrumentMaturityDateYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtIssuanceCostsPolicyTextBlock" id="amrn_DebtIssuanceCostsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DerivativeLiabilitiesTransferredToEquityClassifications" id="amrn_DerivativeLiabilitiesTransferredToEquityClassifications" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DerivativeLiabilitiesTransferredToStockholdersEquity" id="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentAndEntityInformationAbstract" id="amrn_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EarningsLossPerShareLineItems" id="amrn_EarningsLossPerShareLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EarningsLossPerShareTable" id="amrn_EarningsLossPerShareTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="EddingpharmMember" id="amrn_EddingpharmMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EligibleMilestonePayment" id="amrn_EligibleMilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EquityIssuancePerShareAmount1" id="amrn_EquityIssuancePerShareAmount1" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EquityOfferingCosts" id="amrn_EquityOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ExcessPrincipalValueOverFairValue" id="amrn_ExcessPrincipalValueOverFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities" id="amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationOperatingActivities" id="amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationOperatingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairValueAssumptionsComparableYieldToMaturity" id="amrn_FairValueAssumptionsComparableYieldToMaturity" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairValueAssumptionsCouponRate" id="amrn_FairValueAssumptionsCouponRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FinanceMember" id="amrn_FinanceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FurtherIndicationForAmrOneZeroOneMember" id="amrn_FurtherIndicationForAmrOneZeroOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FutureMinimumGuaranteePayments" id="amrn_FutureMinimumGuaranteePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GuaranteePayments" id="amrn_GuaranteePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="KowaPharmaceuticalsAmericaMember" id="amrn_KowaPharmaceuticalsAmericaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAndCollaborationAgreementsLineItems" id="amrn_LicenseAndCollaborationAgreementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAndCollaborationAgreementsTable" id="amrn_LicenseAndCollaborationAgreementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="LicensingAgreementTerm" id="amrn_LicensingAgreementTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MarketingApprovalInEuropeMember" id="amrn_MarketingApprovalInEuropeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonCashMember" id="amrn_NonCashMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonrefundableMilestonePayment" id="amrn_NonrefundableMilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonRefundableUpfrontPaymentsReceived" id="amrn_NonRefundableUpfrontPaymentsReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfPatientsEnrolledInStudy" id="amrn_NumberOfPatientsEnrolledInStudy" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfSalesProfessionals" id="amrn_NumberOfSalesProfessionals" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfSalesRepresentative" id="amrn_NumberOfSalesRepresentative" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OctoberTwentyZeroNinePrivatePlacementMember" id="amrn_OctoberTwentyZeroNinePrivatePlacementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OrdinarySharesBasisMember" id="amrn_OrdinarySharesBasisMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OrdinarySharesMember" id="amrn_OrdinarySharesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" id="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" id="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="OtherDebtObligationsMember" id="amrn_OtherDebtObligationsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OtherIncentiveProgramsMember" id="amrn_OtherIncentiveProgramsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfGrossMarginPayableForPromotionAgreement" id="amrn_PercentageOfGrossMarginPayableForPromotionAgreement" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis" id="amrn_PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PerformanceBasedOptionsMember" id="amrn_PerformanceBasedOptionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PerformanceBasedRestrictedStockUnitMember" id="amrn_PerformanceBasedRestrictedStockUnitMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeriodAxis" id="amrn_PeriodAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
  <element name="PeriodDomain" id="amrn_PeriodDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeriodOneMember" id="amrn_PeriodOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeriodThreeMember" id="amrn_PeriodThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeriodTwoMember" id="amrn_PeriodTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PotentialMarketingApprovalOneMember" id="amrn_PotentialMarketingApprovalOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PotentialMarketingApprovalTwoMember" id="amrn_PotentialMarketingApprovalTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PreferredSharesBasisMember" id="amrn_PreferredSharesBasisMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding" id="amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PreferredStockPurchaseOptionMember" id="amrn_PreferredStockPurchaseOptionMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PrivatePlacementClosingDate" id="amrn_PrivatePlacementClosingDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PrivatePlacementIssuanceNumberOfTranches" id="amrn_PrivatePlacementIssuanceNumberOfTranches" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromWarrantExercisesGross" id="amrn_ProceedsFromWarrantExercisesGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PropertyPlantAndEquipmentUsefulLifeTableTextBlock" id="amrn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProvisionRelatedToPriorPeriodSales" id="amrn_ProvisionRelatedToPriorPeriodSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RangeOfPercentageOfGrossMarginPayableForCoPromotionAgreement" id="amrn_RangeOfPercentageOfGrossMarginPayableForCoPromotionAgreement" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RebatesChargebacksAndDiscountsMember" id="amrn_RebatesChargebacksAndDiscountsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SecondPrivatePlacementMember" id="amrn_SecondPrivatePlacementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeniorNotesOneMember" id="amrn_SeniorNotesOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeniorNotesThreeMember" id="amrn_SeniorNotesThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeniorNotesTwoAndThreeMember" id="amrn_SeniorNotesTwoAndThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeniorNotesTwoMember" id="amrn_SeniorNotesTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationNet" id="amrn_ShareBasedCompensationNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SignificantAccountingPoliciesLineItems" id="amrn_SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SignificantAccountingPoliciesTable" id="amrn_SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="StockholdersEquityNoteLineItems" id="amrn_StockholdersEquityNoteLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockholdersEquityNoteTable" id="amrn_StockholdersEquityNoteTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="StockIncentivePlanTwentyElevenMember" id="amrn_StockIncentivePlanTwentyElevenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesStockWarrantsExercised" id="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SummaryOfNetProductRevenueValuationAllowancesTableTextBlock" id="amrn_SummaryOfNetProductRevenueValuationAllowancesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TopThreeCustomerMember" id="amrn_TopThreeCustomerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UseOfForecastedFinancialInformationInAccountingEstimatesPolicyTextBlock" id="amrn_UseOfForecastedFinancialInformationInAccountingEstimatesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="VestingPeriodFourMember" id="amrn_VestingPeriodFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="VestingPeriodOneMember" id="amrn_VestingPeriodOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="VestingPeriodThreeMember" id="amrn_VestingPeriodThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="VestingPeriodTwoMember" id="amrn_VestingPeriodTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantsIssuedOctoberTwentyZeroNineMember" id="amrn_WarrantsIssuedOctoberTwentyZeroNineMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WriteOffsOfAccountsReceivables" id="amrn_WriteOffsOfAccountsReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>amrn-20160630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 3 -->
<!-- Creation date: 2016-08-03T22:03:39Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DocumentandEntityInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureSummarizesActivityOfTheNetProductRevenueAllowanceAndReserveCategories" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureSummarizesActivityOfTheNetProductRevenueAllowanceAndReserveCategories"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureSummarizesTheImpactOfAccountsReceivableReservesOnGrossTradeAccountsReceivable" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureSummarizesTheImpactOfAccountsReceivableReservesOnGrossTradeAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureEstimatedUsefulLives" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureEstimatedUsefulLives"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureNetLossAndTheNumberOfSharesUsedToComputeBasicAndDilutedLossPerShare" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureNetLossAndTheNumberOfSharesUsedToComputeBasicAndDilutedLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureAntiDilutiveSecuritiesNotIncludedInTheComputationOfNetLossPerShare" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureAntiDilutiveSecuritiesNotIncludedInTheComputationOfNetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureAssetsAndLiabilityMeasuredAtFairValueOnRecurringBasis" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureAssetsAndLiabilityMeasuredAtFairValueOnRecurringBasis"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureCarryingAmountsAndEstimatedFairValuesOfDebtInstruments" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureCarryingAmountsAndEstimatedFairValuesOfDebtInstruments"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureChangeInFairValueOfDerivativeLiabilities" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureChangeInFairValueOfDerivativeLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureIntangibleAssetsAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureIntangibleAssets" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureIntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureInventory" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureInventory"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureWarrantsAndWarrantDerivativeLiabilityAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureWarrantsAndWarrantDerivativeLiabilityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureDebtAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureDebtAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureEquityAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureCoPromotionAgreementAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureCoPromotionAgreementAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureDevelopmentCommercializationAndSupplyAgreementAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureDevelopmentCommercializationAndSupplyAgreementAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlockTables" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsCoPromotionAgreementDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCoPromotionAgreementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="us-gaap_SeniorLongTermNotes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredTaxAssetsNetNoncurrent" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_SeniorLongTermNotes" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.2800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtCurrent" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1.2300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.2400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockValue" order="1.2600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2700" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockConversionsInducements" xlink:label="us-gaap_PreferredStockConversionsInducements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfGoodsSold" order="1.0400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" order="1.1600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_PreferredStockConversionsInducements" order="1.1700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_SalesRevenueGoodsNet" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_LicensesRevenue" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ShareBasedCompensationNet" xlink:label="amrn_ShareBasedCompensationNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="1.2300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="1.2400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_Depreciation" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1.0300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="1.0700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.1000" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.1100" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1.1200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="amrn_ShareBasedCompensationNet" order="1.2800" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureSummarizesActivityOfTheNetProductRevenueAllowanceAndReserveCategories">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureSummarizesTheImpactOfAccountsReceivableReservesOnGrossTradeAccountsReceivable">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance" order="1.0200" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureEstimatedUsefulLives">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureNetLossAndTheNumberOfSharesUsedToComputeBasicAndDilutedLossPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" order="1.0500" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureAntiDilutiveSecuritiesNotIncludedInTheComputationOfNetLossPerShare">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureAssetsAndLiabilityMeasuredAtFairValueOnRecurringBasis">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureCarryingAmountsAndEstimatedFairValuesOfDebtInstruments">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureChangeInFairValueOfDerivativeLiabilities">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureIntangibleAssets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0200" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureInventory">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="1.0300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureWarrantsAndWarrantDerivativeLiabilityAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureDebtAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureEquityAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureCoPromotionAgreementAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureDevelopmentCommercializationAndSupplyAgreementAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCoPromotionAgreementDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>amrn-20160630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Definition Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 3 -->
<!-- Creation date: 2016-08-03T22:03:39Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DocumentandEntityInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureSummarizesActivityOfTheNetProductRevenueAllowanceAndReserveCategories" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureSummarizesActivityOfTheNetProductRevenueAllowanceAndReserveCategories"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureSummarizesTheImpactOfAccountsReceivableReservesOnGrossTradeAccountsReceivable" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureSummarizesTheImpactOfAccountsReceivableReservesOnGrossTradeAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureEstimatedUsefulLives" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureEstimatedUsefulLives"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureNetLossAndTheNumberOfSharesUsedToComputeBasicAndDilutedLossPerShare" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureNetLossAndTheNumberOfSharesUsedToComputeBasicAndDilutedLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureAntiDilutiveSecuritiesNotIncludedInTheComputationOfNetLossPerShare" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureAntiDilutiveSecuritiesNotIncludedInTheComputationOfNetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureAssetsAndLiabilityMeasuredAtFairValueOnRecurringBasis" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureAssetsAndLiabilityMeasuredAtFairValueOnRecurringBasis"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureCarryingAmountsAndEstimatedFairValuesOfDebtInstruments" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureCarryingAmountsAndEstimatedFairValuesOfDebtInstruments"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureChangeInFairValueOfDerivativeLiabilities" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureChangeInFairValueOfDerivativeLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureIntangibleAssetsAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureIntangibleAssets" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureIntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureInventory" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureInventory"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureWarrantsAndWarrantDerivativeLiabilityAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureWarrantsAndWarrantDerivativeLiabilityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureDebtAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureDebtAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureEquityAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureCoPromotionAgreementAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureCoPromotionAgreementAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureDevelopmentCommercializationAndSupplyAgreementAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureDevelopmentCommercializationAndSupplyAgreementAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlockTables" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsCoPromotionAgreementDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCoPromotionAgreementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_AmericanDepositorySharesMember" xlink:label="amrn_AmericanDepositorySharesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_OrdinarySharesMember" xlink:label="amrn_OrdinarySharesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amrn_OrdinarySharesMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amrn_AmericanDepositorySharesMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="us-gaap_SeniorLongTermNotes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetNoncurrent" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_SeniorLongTermNotes" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.2100" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding" xlink:label="amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockShares" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockConversionsInducements" xlink:label="us-gaap_PreferredStockConversionsInducements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfGoodsSold" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConversionsInducements" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_AccountingStandardsUpdate201609Member" xlink:label="amrn_AccountingStandardsUpdate201609Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:label="us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="us-gaap_ScenarioPreviouslyReportedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPreviouslyReportedMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="amrn_AccountingStandardsUpdate201609Member" order="1.0100" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_CashPaidDuringPeriodForAbstract" xlink:label="amrn_CashPaidDuringPeriodForAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_DerivativeLiabilitiesTransferredToEquityClassifications" xlink:label="amrn_DerivativeLiabilitiesTransferredToEquityClassifications"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockConversionsInducements" xlink:label="us-gaap_PreferredStockConversionsInducements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ShareBasedCompensationNet" xlink:label="amrn_ShareBasedCompensationNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="amrn_ShareBasedCompensationNet" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="amrn_DerivativeLiabilitiesTransferredToEquityClassifications" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_PreferredStockConversionsInducements" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_CashPaidDuringPeriodForAbstract" xlink:to="us-gaap_InterestPaid" order="1.4300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_CashPaidDuringPeriodForAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.4400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_WarrantMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="amrn_CashPaidDuringPeriodForAbstract" order="1.0300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_CoPromotionAgreementMember" xlink:label="amrn_CoPromotionAgreementMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_DateOneMember" xlink:label="amrn_DateOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_DateThreeMember" xlink:label="amrn_DateThreeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_DateTwoMember" xlink:label="amrn_DateTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCallDateEarliest" xlink:label="us-gaap_DebtInstrumentCallDateEarliest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCallDateLatest" xlink:label="us-gaap_DebtInstrumentCallDateLatest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_KowaPharmaceuticalsAmericaMember" xlink:label="amrn_KowaPharmaceuticalsAmericaMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_NumberOfPatientsEnrolledInStudy" xlink:label="amrn_NumberOfPatientsEnrolledInStudy"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_NumberOfSalesProfessionals" xlink:label="amrn_NumberOfSalesProfessionals"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_NumberOfSalesRepresentative" xlink:label="amrn_NumberOfSalesRepresentative"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesOneMember" xlink:label="amrn_SeniorNotesOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesThreeMember" xlink:label="amrn_SeniorNotesThreeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesTwoMember" xlink:label="amrn_SeniorNotesTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="amrn_CoPromotionAgreementMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesOneMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesTwoMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesThreeMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_DateOneMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_DateTwoMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_DateThreeMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="amrn_KowaPharmaceuticalsAmericaMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="amrn_NumberOfSalesProfessionals" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="amrn_NumberOfSalesRepresentative" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="amrn_NumberOfPatientsEnrolledInStudy" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentCallDateEarliest" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentCallDateLatest" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_AssetsCurrent" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ConvertibleDebt" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="dei_LegalEntityAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_RangeAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingStandardsUpdate201503Member" xlink:label="us-gaap_AccountingStandardsUpdate201503Member"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_AccountingStandardsUpdate201609Member" xlink:label="amrn_AccountingStandardsUpdate201609Member"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_AccountsReceivableCreditPeriod" xlink:label="amrn_AccountsReceivableCreditPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_BiopharmaceuticalMember" xlink:label="amrn_BiopharmaceuticalMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_CashDiscountInvoiceTerms" xlink:label="amrn_CashDiscountInvoiceTerms"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_CashDiscountPercent" xlink:label="amrn_CashDiscountPercent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_2"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ClassOfWarrantOrRightExercisedInPeriod" xlink:label="amrn_ClassOfWarrantOrRightExercisedInPeriod"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ClassOfWarrantOrRightExpiredInPeriod" xlink:label="amrn_ClassOfWarrantOrRightExpiredInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities" xlink:label="amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationOperatingActivities" xlink:label="amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_FairValueAssumptionsComparableYieldToMaturity" xlink:label="amrn_FairValueAssumptionsComparableYieldToMaturity"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_FairValueAssumptionsCouponRate" xlink:label="amrn_FairValueAssumptionsCouponRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain_2"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_NonCashMember" xlink:label="amrn_NonCashMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PreferredStockPurchaseOptionMember" xlink:label="amrn_PreferredStockPurchaseOptionMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PrivatePlacementIssuanceNumberOfTranches" xlink:label="amrn_PrivatePlacementIssuanceNumberOfTranches"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="us-gaap_RestatementAdjustmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioAdjustmentMember" xlink:label="us-gaap_ScenarioAdjustmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="us-gaap_ScenarioPreviouslyReportedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesOneMember" xlink:label="amrn_SeniorNotesOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesThreeMember" xlink:label="amrn_SeniorNotesThreeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesTwoAndThreeMember" xlink:label="amrn_SeniorNotesTwoAndThreeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesTwoMember" xlink:label="amrn_SeniorNotesTwoMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SignificantAccountingPoliciesLineItems" xlink:label="amrn_SignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SignificantAccountingPoliciesTable" xlink:label="amrn_SignificantAccountingPoliciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_TopThreeCustomerMember" xlink:label="amrn_TopThreeCustomerMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_WarrantsIssuedOctoberTwentyZeroNineMember" xlink:label="amrn_WarrantsIssuedOctoberTwentyZeroNineMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_WriteOffsOfAccountsReceivables" xlink:label="amrn_WriteOffsOfAccountsReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amrn_WarrantsIssuedOctoberTwentyZeroNineMember" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesTwoMember" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesThreeMember" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesTwoAndThreeMember" order="1.4700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesOneMember" order="1.4900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="amrn_PreferredStockPurchaseOptionMember" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" order="1.4400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="amrn_TopThreeCustomerMember" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.4500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioAdjustmentMember" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_NonCashMember" order="1.4300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPreviouslyReportedMember" order="1.4600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_RestatementAdjustmentMember" order="1.4800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="amrn_BiopharmaceuticalMember" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_SignificantAccountingPoliciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_CashDiscountPercent" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_CashDiscountInvoiceTerms" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_AccountsReceivableCreditPeriod" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_PrivatePlacementIssuanceNumberOfTranches" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationOperatingActivities" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_WriteOffsOfAccountsReceivables" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_ClassOfWarrantOrRightExercisedInPeriod" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_ClassOfWarrantOrRightExpiredInPeriod" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherCommitment" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_FairValueAssumptionsCouponRate" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_FairValueAssumptionsComparableYieldToMaturity" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_RangeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementScenarioAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" order="7.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_MajorCustomersAxis" order="8.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="9.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="11.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="12.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201503Member" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="amrn_AccountingStandardsUpdate201609Member" order="1.4000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureSummarizesActivityOfTheNetProductRevenueAllowanceAndReserveCategories">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForSalesReturnsMember" xlink:label="us-gaap_AllowanceForSalesReturnsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForTradeReceivablesMember" xlink:label="us-gaap_AllowanceForTradeReceivablesMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_CreditsPaymentsMadeForPriorPeriodSales" xlink:label="amrn_CreditsPaymentsMadeForPriorPeriodSales"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_OtherIncentiveProgramsMember" xlink:label="amrn_OtherIncentiveProgramsMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ProvisionRelatedToPriorPeriodSales" xlink:label="amrn_ProvisionRelatedToPriorPeriodSales"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_RebatesChargebacksAndDiscountsMember" xlink:label="amrn_RebatesChargebacksAndDiscountsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_AllowanceForTradeReceivablesMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="amrn_RebatesChargebacksAndDiscountsMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_AllowanceForSalesReturnsMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="amrn_OtherIncentiveProgramsMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="amrn_ProvisionRelatedToPriorPeriodSales" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="amrn_CreditsPaymentsMadeForPriorPeriodSales" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureSummarizesTheImpactOfAccountsReceivableReservesOnGrossTradeAccountsReceivable">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_AllowanceForEstimatedChargebacksMember" xlink:label="amrn_AllowanceForEstimatedChargebacksMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForTradeReceivablesMember" xlink:label="us-gaap_AllowanceForTradeReceivablesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_AllowanceForTradeReceivablesMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="amrn_AllowanceForEstimatedChargebacksMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureEstimatedUsefulLives">
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ComputerEquipmentAndCapitalizedSoftwareMember" xlink:label="amrn_ComputerEquipmentAndCapitalizedSoftwareMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="amrn_ComputerEquipmentAndCapitalizedSoftwareMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RangeAxis" order="3.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureNetLossAndTheNumberOfSharesUsedToComputeBasicAndDilutedLossPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_EarningsLossPerShareLineItems" xlink:label="amrn_EarningsLossPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_EarningsLossPerShareTable" xlink:label="amrn_EarningsLossPerShareTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockConversionsInducements" xlink:label="us-gaap_PreferredStockConversionsInducements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="amrn_EarningsLossPerShareLineItems" xlink:to="amrn_EarningsLossPerShareTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_EarningsLossPerShareLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_EarningsLossPerShareTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_PreferredStockConversionsInducements" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureAntiDilutiveSecuritiesNotIncludedInTheComputationOfNetLossPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_PreferredStockMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="4.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureAssetsAndLiabilityMeasuredAtFairValueOnRecurringBasis">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="1.0800" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureCarryingAmountsAndEstimatedFairValuesOfDebtInstruments">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorNotes" xlink:label="us-gaap_SeniorNotes"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesOneMember" xlink:label="amrn_SeniorNotesOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesThreeMember" xlink:label="amrn_SeniorNotesThreeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesTwoMember" xlink:label="amrn_SeniorNotesTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SeniorNotes" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtFairValue" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesOneMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesTwoMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesThreeMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="1.0500" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureChangeInFairValueOfDerivativeLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_DerivativeLiabilitiesTransferredToStockholdersEquity" xlink:label="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="us-gaap_DerivativesFairValueLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PreferredStockPurchaseOptionMember" xlink:label="amrn_PreferredStockPurchaseOptionMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ShareBasedCompensationNet" xlink:label="amrn_ShareBasedCompensationNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_WarrantsIssuedOctoberTwentyZeroNineMember" xlink:label="amrn_WarrantsIssuedOctoberTwentyZeroNineMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="amrn_WarrantsIssuedOctoberTwentyZeroNineMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="amrn_PreferredStockPurchaseOptionMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="amrn_ShareBasedCompensationNet" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="us-gaap_InvestmentTypeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_WarrantMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureIntangibleAssets">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureInventory">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryCurrentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryNet" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureWarrantsAndWarrantDerivativeLiabilityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_AmericanDepositaryShareMember" xlink:label="amrn_AmericanDepositaryShareMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_AmericanDepositorySharesToSharesRatio" xlink:label="amrn_AmericanDepositorySharesToSharesRatio"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="us-gaap_BridgeLoanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ClassOfWarrantOrRightExercisedInPeriod" xlink:label="amrn_ClassOfWarrantOrRightExercisedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ClassOfWarrantOrRightExpiredInPeriod" xlink:label="amrn_ClassOfWarrantOrRightExpiredInPeriod"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ClassOfWarrantOrRightIssued" xlink:label="amrn_ClassOfWarrantOrRightIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ClassOfWarrantOrRightTerm" xlink:label="amrn_ClassOfWarrantOrRightTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="us-gaap_DerivativeLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeTable" xlink:label="us-gaap_DerivativeTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeDescriptionOfHostContract" xlink:label="us-gaap_EmbeddedDerivativeDescriptionOfHostContract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EnergyAxis" xlink:label="us-gaap_EnergyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EnergyDomain" xlink:label="us-gaap_EnergyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EnergyDomain" xlink:label="us-gaap_EnergyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_EquityIssuancePerShareAmount1" xlink:label="amrn_EquityIssuancePerShareAmount1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_OctoberTwentyZeroNinePrivatePlacementMember" xlink:label="amrn_OctoberTwentyZeroNinePrivatePlacementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficerMember" xlink:label="us-gaap_OfficerMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_WarrantsIssuedOctoberTwentyZeroNineMember" xlink:label="amrn_WarrantsIssuedOctoberTwentyZeroNineMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amrn_WarrantsIssuedOctoberTwentyZeroNineMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DerivativeTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="amrn_AmericanDepositorySharesToSharesRatio" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="amrn_EquityIssuancePerShareAmount1" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="amrn_ClassOfWarrantOrRightTerm" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="amrn_ClassOfWarrantOrRightIssued" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_EmbeddedDerivativeDescriptionOfHostContract" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="amrn_ClassOfWarrantOrRightExercisedInPeriod" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLineItems" xlink:to="amrn_ClassOfWarrantOrRightExpiredInPeriod" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DerivativeTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_EnergyAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_RangeAxis" order="7.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EnergyAxis" xlink:to="us-gaap_EnergyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EnergyAxis" xlink:to="us-gaap_EnergyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EnergyDomain" xlink:to="amrn_AmericanDepositaryShareMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_BridgeLoanMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_OfficerMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="amrn_OctoberTwentyZeroNinePrivatePlacementMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureDebtAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingStandardsUpdate201503Member" xlink:label="us-gaap_AccountingStandardsUpdate201503Member"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_AdditionalPercentageInterestRatePenalty" xlink:label="amrn_AdditionalPercentageInterestRatePenalty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_AmericanDepositorySharesMember" xlink:label="amrn_AmericanDepositorySharesMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_BeneficialOwnershipLimitationPercentage" xlink:label="amrn_BeneficialOwnershipLimitationPercentage"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_BiopharmaceuticalMember" xlink:label="amrn_BiopharmaceuticalMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ChargesCashMember" xlink:label="amrn_ChargesCashMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_DebtDisclosureLineItems" xlink:label="amrn_DebtDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_DebtDisclosureTable" xlink:label="amrn_DebtDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_DebtExchangeMember" xlink:label="amrn_DebtExchangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_DebtInstrumentMaturityDateYear" xlink:label="amrn_DebtInstrumentMaturityDateYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodEndDate" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ExcessPrincipalValueOverFairValue" xlink:label="amrn_ExcessPrincipalValueOverFairValue"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_FinanceMember" xlink:label="amrn_FinanceMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_FutureMinimumGuaranteePayments" xlink:label="amrn_FutureMinimumGuaranteePayments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_GuaranteePayments" xlink:label="amrn_GuaranteePayments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_NonCashMember" xlink:label="amrn_NonCashMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_OtherDebtObligationsMember" xlink:label="amrn_OtherDebtObligationsMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PeriodAxis" xlink:label="amrn_PeriodAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PeriodDomain" xlink:label="amrn_PeriodDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PeriodDomain" xlink:label="amrn_PeriodDomain_2"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PeriodOneMember" xlink:label="amrn_PeriodOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PeriodThreeMember" xlink:label="amrn_PeriodThreeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PeriodTwoMember" xlink:label="amrn_PeriodTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuritiesFinancingTransactionAxis" xlink:label="us-gaap_SecuritiesFinancingTransactionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="us-gaap_SecuritiesFinancingTransactionTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="us-gaap_SecuritiesFinancingTransactionTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="us-gaap_SeniorLongTermNotes"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesOneMember" xlink:label="amrn_SeniorNotesOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesThreeMember" xlink:label="amrn_SeniorNotesThreeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesTwoMember" xlink:label="amrn_SeniorNotesTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amrn_AmericanDepositorySharesMember" order="1.4800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="amrn_DebtExchangeMember" order="1.5000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_DebtDisclosureTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_OtherCommitment" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_GuaranteePayments" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_FutureMinimumGuaranteePayments" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_ConvertibleDebt" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_DebtInstrumentMaturityDateYear" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_ExcessPrincipalValueOverFairValue" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_AdditionalPercentageInterestRatePenalty" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_LongTermDebtCurrent" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodEndDate" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_SeniorLongTermNotes" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_BeneficialOwnershipLimitationPercentage" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentRepurchasedFaceAmount" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_InterestPayableCurrent" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_InterestPaid" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_DebtDisclosureTable" xlink:to="amrn_PeriodAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_StatementScenarioAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_DebtInstrumentAxis" order="7.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_RangeAxis" order="8.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" order="9.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_DebtDisclosureTable" xlink:to="dei_LegalEntityAxis" order="11.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_SecuritiesFinancingTransactionAxis" order="12.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesOneMember" order="1.4600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesTwoMember" order="1.5600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesThreeMember" order="1.5900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="1.4700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="amrn_OtherDebtObligationsMember" order="1.4900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="amrn_PeriodAxis" xlink:to="amrn_PeriodDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="amrn_PeriodAxis" xlink:to="amrn_PeriodDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_PeriodDomain" xlink:to="amrn_PeriodOneMember" order="1.4400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_PeriodDomain" xlink:to="amrn_PeriodTwoMember" order="1.5400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_PeriodDomain" xlink:to="amrn_PeriodThreeMember" order="1.5800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.5100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.5700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_ChargesCashMember" order="1.4500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_NonCashMember" order="1.5500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SecuritiesFinancingTransactionAxis" xlink:to="us-gaap_SecuritiesFinancingTransactionTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SecuritiesFinancingTransactionAxis" xlink:to="us-gaap_SecuritiesFinancingTransactionTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:to="amrn_FinanceMember" order="1.5300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="amrn_BiopharmaceuticalMember" order="1.4300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201503Member" order="1.5200" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_BusinessDevelopmentDomain" xlink:label="amrn_BusinessDevelopmentDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_BusinessDevelopmentDomain" xlink:label="amrn_BusinessDevelopmentDomain_2"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_BusinessDevelopmentsAxis" xlink:label="amrn_BusinessDevelopmentsAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="amrn_CommitmentsAndContingenciesDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_CommitmentsAndContingenciesDisclosureTable" xlink:label="amrn_CommitmentsAndContingenciesDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_FurtherIndicationForAmrOneZeroOneMember" xlink:label="amrn_FurtherIndicationForAmrOneZeroOneMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_MarketingApprovalInEuropeMember" xlink:label="amrn_MarketingApprovalInEuropeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PotentialMarketingApprovalOneMember" xlink:label="amrn_PotentialMarketingApprovalOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PotentialMarketingApprovalTwoMember" xlink:label="amrn_PotentialMarketingApprovalTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_BusinessDevelopmentDomain" xlink:to="amrn_MarketingApprovalInEuropeMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_BusinessDevelopmentDomain" xlink:to="amrn_PotentialMarketingApprovalOneMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_BusinessDevelopmentDomain" xlink:to="amrn_PotentialMarketingApprovalTwoMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="amrn_BusinessDevelopmentsAxis" xlink:to="amrn_BusinessDevelopmentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="amrn_BusinessDevelopmentsAxis" xlink:to="amrn_BusinessDevelopmentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="amrn_CommitmentsAndContingenciesDisclosureTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_CommitmentsAndContingenciesDisclosureTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_StatementScenarioAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_RangeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_CommitmentsAndContingenciesDisclosureTable" xlink:to="amrn_BusinessDevelopmentsAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_FurtherIndicationForAmrOneZeroOneMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureEquityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_AmericanDepositorySharesMember" xlink:label="amrn_AmericanDepositorySharesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_BeneficialOwnershipLimitationPercentage" xlink:label="amrn_BeneficialOwnershipLimitationPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ConversionPricePerShare" xlink:label="amrn_ConversionPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_DerivativeLiabilitiesTransferredToStockholdersEquity" xlink:label="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DirectorMember" xlink:label="us-gaap_DirectorMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_EquityOfferingCosts" xlink:label="amrn_EquityOfferingCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_OrdinarySharesBasisMember" xlink:label="amrn_OrdinarySharesBasisMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_OrdinarySharesMember" xlink:label="amrn_OrdinarySharesMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis" xlink:label="amrn_PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PerformanceBasedOptionsMember" xlink:label="amrn_PerformanceBasedOptionsMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PerformanceBasedRestrictedStockUnitMember" xlink:label="amrn_PerformanceBasedRestrictedStockUnitMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PreferredSharesBasisMember" xlink:label="amrn_PreferredSharesBasisMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="us-gaap_PreferredStockConversionBasis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockConversionsInducements" xlink:label="us-gaap_PreferredStockConversionsInducements"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding" xlink:label="amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PreferredStockPurchaseOptionMember" xlink:label="amrn_PreferredStockPurchaseOptionMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PrivatePlacementClosingDate" xlink:label="amrn_PrivatePlacementClosingDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ProceedsFromWarrantExercisesGross" xlink:label="amrn_ProceedsFromWarrantExercisesGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SecondPrivatePlacementMember" xlink:label="amrn_SecondPrivatePlacementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_StockholdersEquityNoteLineItems" xlink:label="amrn_StockholdersEquityNoteLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_StockholdersEquityNoteTable" xlink:label="amrn_StockholdersEquityNoteTable"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_StockIncentivePlanTwentyElevenMember" xlink:label="amrn_StockIncentivePlanTwentyElevenMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_2"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_VestingPeriodFourMember" xlink:label="amrn_VestingPeriodFourMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_VestingPeriodOneMember" xlink:label="amrn_VestingPeriodOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_VestingPeriodThreeMember" xlink:label="amrn_VestingPeriodThreeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_VestingPeriodTwoMember" xlink:label="amrn_VestingPeriodTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amrn_OrdinarySharesMember" order="1.4700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="amrn_PreferredStockPurchaseOptionMember" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="amrn_AmericanDepositorySharesMember" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="amrn_PreferredSharesBasisMember" order="1.4500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="amrn_OrdinarySharesBasisMember" order="1.5000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="amrn_StockIncentivePlanTwentyElevenMember" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.4600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="amrn_SecondPrivatePlacementMember" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.4300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="amrn_PerformanceBasedOptionsMember" order="1.4900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="amrn_PerformanceBasedRestrictedStockUnitMember" order="1.5200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_StockholdersEquityNoteTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_ProceedsFromWarrantExercisesGross" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_PreferredStockConversionBasis" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_PrivatePlacementClosingDate" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_ConversionPricePerShare" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_EquityOfferingCosts" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_BeneficialOwnershipLimitationPercentage" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_SharePrice" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_PreferredStockConversionsInducements" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_AwardTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_PlanNameAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_VestingAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="7.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="8.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_RangeAxis" order="9.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="10.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_DirectorMember" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="amrn_VestingPeriodOneMember" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="amrn_VestingPeriodTwoMember" order="1.4400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="amrn_VestingPeriodThreeMember" order="1.4800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="amrn_VestingPeriodFourMember" order="1.5100" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureCoPromotionAgreementAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_CoPromotionAgreementLineItems" xlink:label="amrn_CoPromotionAgreementLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_CoPromotionAgreementMember" xlink:label="amrn_CoPromotionAgreementMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_CoPromotionAgreementTable" xlink:label="amrn_CoPromotionAgreementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_KowaPharmaceuticalsAmericaMember" xlink:label="amrn_KowaPharmaceuticalsAmericaMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_NumberOfSalesRepresentative" xlink:label="amrn_NumberOfSalesRepresentative"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PercentageOfGrossMarginPayableForPromotionAgreement" xlink:label="amrn_PercentageOfGrossMarginPayableForPromotionAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_RangeOfPercentageOfGrossMarginPayableForCoPromotionAgreement" xlink:label="amrn_RangeOfPercentageOfGrossMarginPayableForCoPromotionAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="amrn_CoPromotionAgreementMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="amrn_CoPromotionAgreementLineItems" xlink:to="amrn_CoPromotionAgreementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_CoPromotionAgreementLineItems" xlink:to="amrn_NumberOfSalesRepresentative" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_CoPromotionAgreementLineItems" xlink:to="amrn_PercentageOfGrossMarginPayableForPromotionAgreement" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_CoPromotionAgreementLineItems" xlink:to="amrn_RangeOfPercentageOfGrossMarginPayableForCoPromotionAgreement" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_CoPromotionAgreementLineItems" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_CoPromotionAgreementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_CoPromotionAgreementTable" xlink:to="dei_LegalEntityAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_CoPromotionAgreementTable" xlink:to="us-gaap_StatementScenarioAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_CoPromotionAgreementTable" xlink:to="us-gaap_RangeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="amrn_KowaPharmaceuticalsAmericaMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureDevelopmentCommercializationAndSupplyAgreementAdditionalInformation">
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_BusinessDevelopmentDomain" xlink:label="amrn_BusinessDevelopmentDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_BusinessDevelopmentsAxis" xlink:label="amrn_BusinessDevelopmentsAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ClinicalTrialApplicationMember" xlink:label="amrn_ClinicalTrialApplicationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_EddingpharmMember" xlink:label="amrn_EddingpharmMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_EligibleMilestonePayment" xlink:label="amrn_EligibleMilestonePayment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_LicenseAndCollaborationAgreementsLineItems" xlink:label="amrn_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_LicenseAndCollaborationAgreementsTable" xlink:label="amrn_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_LicensingAgreementTerm" xlink:label="amrn_LicensingAgreementTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_NonrefundableMilestonePayment" xlink:label="amrn_NonrefundableMilestonePayment"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_NonRefundableUpfrontPaymentsReceived" xlink:label="amrn_NonRefundableUpfrontPaymentsReceived"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_BusinessDevelopmentDomain" xlink:to="amrn_EddingpharmMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="amrn_BusinessDevelopmentsAxis" xlink:to="amrn_BusinessDevelopmentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="amrn_ClinicalTrialApplicationMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="amrn_LicenseAndCollaborationAgreementsLineItems" xlink:to="amrn_LicenseAndCollaborationAgreementsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_LicenseAndCollaborationAgreementsLineItems" xlink:to="amrn_NonRefundableUpfrontPaymentsReceived" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_LicenseAndCollaborationAgreementsLineItems" xlink:to="amrn_LicensingAgreementTerm" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_LicenseAndCollaborationAgreementsLineItems" xlink:to="amrn_NonrefundableMilestonePayment" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_LicenseAndCollaborationAgreementsLineItems" xlink:to="amrn_EligibleMilestonePayment" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amrn_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_LicenseAndCollaborationAgreementsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_LicenseAndCollaborationAgreementsTable" xlink:to="amrn_BusinessDevelopmentsAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amrn_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_RangeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.1000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_BeneficialConversionFeaturePolicyTextBlock" xlink:label="amrn_BeneficialConversionFeaturePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ConcentrationOfSuppliersPolicyTextBlock" xlink:label="amrn_ConcentrationOfSuppliersPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_DebtIssuanceCostsPolicyTextBlock" xlink:label="amrn_DebtIssuanceCostsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_UseOfForecastedFinancialInformationInAccountingEstimatesPolicyTextBlock" xlink:label="amrn_UseOfForecastedFinancialInformationInAccountingEstimatesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UseOfEstimates" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_UseOfForecastedFinancialInformationInAccountingEstimatesPolicyTextBlock" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryPolicyTextBlock" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_BeneficialConversionFeaturePolicyTextBlock" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LegalCostsPolicyTextBlock" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtPolicyTextBlock" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_ConcentrationOfSuppliersPolicyTextBlock" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_DebtIssuanceCostsPolicyTextBlock" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="amrn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SummaryOfNetProductRevenueValuationAllowancesTableTextBlock" xlink:label="amrn_SummaryOfNetProductRevenueValuationAllowancesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_SummaryOfNetProductRevenueValuationAllowancesTableTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_WarrantMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCoPromotionAgreementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_CoPromotionAgreementDisclosureTextBlock" xlink:label="amrn_CoPromotionAgreementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_CoPromotionAgreementDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>amrn-20160630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no" ?>
<!-- RR Donnelley Xcelerate Taxonomy Labels Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 3 -->
<!-- Creation date: 2016-08-03T22:03:39Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <label id="id_6038951_1324050_1_1" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label id="id_6038951_1324050_2_1" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingStandardsUpdate201503Member" xlink:label="us-gaap_AccountingStandardsUpdate201503Member" xlink:type="locator"/>
    <label id="id_6038951_1330360_1_1" xlink:label="us-gaap_AccountingStandardsUpdate201503Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2015-03 [Member]</label>
    <label id="id_6038951_1330360_2_1" xlink:label="us-gaap_AccountingStandardsUpdate201503Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2015-03</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201503Member" xlink:to="us-gaap_AccountingStandardsUpdate201503Member_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_AccountingStandardsUpdate201609Member" xlink:label="amrn_AccountingStandardsUpdate201609Member" xlink:type="locator"/>
    <label id="id_6038951_1528669_3_1" xlink:label="amrn_AccountingStandardsUpdate201609Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-09 [Member]</label>
    <label id="id_6038951_1528669_1_1" xlink:label="amrn_AccountingStandardsUpdate201609Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-09 [Member]</label>
    <label id="id_6038951_1528669_2_1" xlink:label="amrn_AccountingStandardsUpdate201609Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASU No. 2016-09</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_AccountingStandardsUpdate201609Member" xlink:to="amrn_AccountingStandardsUpdate201609Member_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="locator"/>
    <label id="id_6038951_1330363_1_1" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</label>
    <label id="id_6038951_1330363_2_1" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <label id="id_6038951_1337522_1_1" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</label>
    <label id="id_6038951_1337522_2_1" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_AccountsReceivableCreditPeriod" xlink:label="amrn_AccountsReceivableCreditPeriod" xlink:type="locator"/>
    <label id="id_6038951_1495157_3_1" xlink:label="amrn_AccountsReceivableCreditPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable Credit Period</label>
    <label id="id_6038951_1495157_1_1" xlink:label="amrn_AccountsReceivableCreditPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable Credit Period</label>
    <label id="id_6038951_1495157_2_1" xlink:label="amrn_AccountsReceivableCreditPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables, credit period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_AccountsReceivableCreditPeriod" xlink:to="amrn_AccountsReceivableCreditPeriod_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent" xlink:type="locator"/>
    <label id="id_6038951_1342963_1_1" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Gross, Current</label>
    <label id="id_6038951_1342963_2_1" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross trade accounts receivable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <label id="id_6038951_1333518_1_1" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</label>
    <label id="id_6038951_1333518_2_1" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <label id="id_6038951_1341977_1_1" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</label>
    <label id="id_6038951_1341977_2_1" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</label>
    <label id="id_6038951_1341977_6_1" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator"/>
    <label id="id_6038951_1339200_1_1" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities and Other Liabilities</label>
    <label id="id_6038951_1339200_2_1" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <label id="id_6038951_1338333_1_1" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <label id="id_6038951_1338333_2_1" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <label id="id_6038951_1327190_1_1" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <label id="id_6038951_1327190_2_1" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_AdditionalPercentageInterestRatePenalty" xlink:label="amrn_AdditionalPercentageInterestRatePenalty" xlink:type="locator"/>
    <label id="id_6038951_1520822_3_1" xlink:label="amrn_AdditionalPercentageInterestRatePenalty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Percentage Interest Rate Penalty</label>
    <label id="id_6038951_1520822_1_1" xlink:label="amrn_AdditionalPercentageInterestRatePenalty_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Percentage Interest Rate Penalty</label>
    <label id="id_6038951_1520822_2_1" xlink:label="amrn_AdditionalPercentageInterestRatePenalty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional interest rate on notes per annum</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_AdditionalPercentageInterestRatePenalty" xlink:to="amrn_AdditionalPercentageInterestRatePenalty_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator"/>
    <label id="id_6038951_1324093_1_1" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</label>
    <label id="id_6038951_1324093_2_1" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="locator"/>
    <label id="id_6038951_1337491_1_1" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature</label>
    <label id="id_6038951_1337491_14_1" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Decrease to additional paid-in capital for repurchase of conversion option in convertible notes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <label id="id_6038951_1338330_1_1" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label id="id_6038951_1338330_2_1" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <label id="id_6038951_1333553_1_1" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label id="id_6038951_1333553_2_1" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_AllowanceForEstimatedChargebacksMember" xlink:label="amrn_AllowanceForEstimatedChargebacksMember" xlink:type="locator"/>
    <label id="id_6038951_1366356_3_1" xlink:label="amrn_AllowanceForEstimatedChargebacksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allowance for Estimated Chargebacks [Member]</label>
    <label id="id_6038951_1366356_1_1" xlink:label="amrn_AllowanceForEstimatedChargebacksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance for Estimated Chargebacks [Member]</label>
    <label id="id_6038951_1366356_2_1" xlink:label="amrn_AllowanceForEstimatedChargebacksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chargebacks</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_AllowanceForEstimatedChargebacksMember" xlink:to="amrn_AllowanceForEstimatedChargebacksMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForSalesReturnsMember" xlink:label="us-gaap_AllowanceForSalesReturnsMember" xlink:type="locator"/>
    <label id="id_6038951_1327216_1_1" xlink:label="us-gaap_AllowanceForSalesReturnsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance for Sales Returns [Member]</label>
    <label id="id_6038951_1327216_2_1" xlink:label="us-gaap_AllowanceForSalesReturnsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for Sales Returns</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForSalesReturnsMember" xlink:to="us-gaap_AllowanceForSalesReturnsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForTradeReceivablesMember" xlink:label="us-gaap_AllowanceForTradeReceivablesMember" xlink:type="locator"/>
    <label id="id_6038951_1327217_1_1" xlink:label="us-gaap_AllowanceForTradeReceivablesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance for Trade Receivables [Member]</label>
    <label id="id_6038951_1327217_2_1" xlink:label="us-gaap_AllowanceForTradeReceivablesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade Receivables</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForTradeReceivablesMember" xlink:to="us-gaap_AllowanceForTradeReceivablesMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <label id="id_6038951_1327225_1_1" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</label>
    <label id="id_6038951_1327225_2_1" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_AmericanDepositaryShareMember" xlink:label="amrn_AmericanDepositaryShareMember" xlink:type="locator"/>
    <label id="id_6038951_1419380_3_1" xlink:label="amrn_AmericanDepositaryShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">American Depositary Share</label>
    <label id="id_6038951_1419380_1_1" xlink:label="amrn_AmericanDepositaryShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">American Depositary Share [Member]</label>
    <label id="id_6038951_1419380_2_1" xlink:label="amrn_AmericanDepositaryShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">American Depositary Share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_AmericanDepositaryShareMember" xlink:to="amrn_AmericanDepositaryShareMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_AmericanDepositorySharesMember" xlink:label="amrn_AmericanDepositorySharesMember" xlink:type="locator"/>
    <label id="id_6038951_1403450_3_1" xlink:label="amrn_AmericanDepositorySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">American Depository Shares [Member]</label>
    <label id="id_6038951_1403450_1_1" xlink:label="amrn_AmericanDepositorySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">American Depository Shares [Member]</label>
    <label id="id_6038951_1403450_2_1" xlink:label="amrn_AmericanDepositorySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">American Depository Shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_AmericanDepositorySharesMember" xlink:to="amrn_AmericanDepositorySharesMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_AmericanDepositorySharesToSharesRatio" xlink:label="amrn_AmericanDepositorySharesToSharesRatio" xlink:type="locator"/>
    <label id="id_6038951_1371112_3_1" xlink:label="amrn_AmericanDepositorySharesToSharesRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">American Depository Shares to Shares Ratio</label>
    <label id="id_6038951_1371112_1_1" xlink:label="amrn_AmericanDepositorySharesToSharesRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">American Depository Shares to Shares Ratio</label>
    <label id="id_6038951_1371112_2_1" xlink:label="amrn_AmericanDepositorySharesToSharesRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares that each ADS represents</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_AmericanDepositorySharesToSharesRatio" xlink:to="amrn_AmericanDepositorySharesToSharesRatio_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="locator"/>
    <label id="id_6038951_1342009_1_1" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
    <label id="id_6038951_1342009_2_1" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount and debt issuance costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <label id="id_6038951_1342987_1_1" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</label>
    <label id="id_6038951_1342987_2_1" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible asset</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <label id="id_6038951_1324144_1_1" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label id="id_6038951_1324144_2_1" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive securities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <label id="id_6038951_1333589_1_1" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <label id="id_6038951_1333589_2_1" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator"/>
    <label id="id_6038951_1327231_1_1" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label id="id_6038951_1327231_2_1" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <label id="id_6038951_1333590_1_1" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <label id="id_6038951_1333590_2_1" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <label id="id_6038951_1330434_1_1" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <label id="id_6038951_1330434_2_1" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <label id="id_6038951_1342997_1_1" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</label>
    <label id="id_6038951_1342997_6_1" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <label id="id_6038951_1324158_1_1" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</label>
    <label id="id_6038951_1324158_2_1" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <label id="id_6038951_1340155_1_1" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</label>
    <label id="id_6038951_1340155_2_1" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total current assets</label>
    <label id="id_6038951_1340155_6_1" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <label id="id_6038951_1333606_1_1" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label id="id_6038951_1333606_2_1" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Assets:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator"/>
    <label id="id_6038951_1333608_1_1" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</label>
    <label id="id_6038951_1333608_2_1" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <label id="id_6038951_1324199_1_1" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</label>
    <label id="id_6038951_1324199_2_1" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_BeneficialConversionFeaturePolicyTextBlock" xlink:label="amrn_BeneficialConversionFeaturePolicyTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1442317_3_1" xlink:label="amrn_BeneficialConversionFeaturePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Beneficial Conversion Feature [Policy Text Block]</label>
    <label id="id_6038951_1442317_1_1" xlink:label="amrn_BeneficialConversionFeaturePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Beneficial Conversion Feature [Policy Text Block]</label>
    <label id="id_6038951_1442317_2_1" xlink:label="amrn_BeneficialConversionFeaturePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beneficial Conversion Features</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_BeneficialConversionFeaturePolicyTextBlock" xlink:to="amrn_BeneficialConversionFeaturePolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_BeneficialOwnershipLimitationPercentage" xlink:label="amrn_BeneficialOwnershipLimitationPercentage" xlink:type="locator"/>
    <label id="id_6038951_1366888_3_1" xlink:label="amrn_BeneficialOwnershipLimitationPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Beneficial Ownership Limitation Percentage</label>
    <label id="id_6038951_1366888_1_1" xlink:label="amrn_BeneficialOwnershipLimitationPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Beneficial Ownership Limitation Percentage</label>
    <label id="id_6038951_1366888_2_1" xlink:label="amrn_BeneficialOwnershipLimitationPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beneficial ownership limitation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_BeneficialOwnershipLimitationPercentage" xlink:to="amrn_BeneficialOwnershipLimitationPercentage_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_BiopharmaceuticalMember" xlink:label="amrn_BiopharmaceuticalMember" xlink:type="locator"/>
    <label id="id_6038951_1356609_3_1" xlink:label="amrn_BiopharmaceuticalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biopharmaceutical [Member]</label>
    <label id="id_6038951_1356609_1_1" xlink:label="amrn_BiopharmaceuticalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biopharmaceutical [Member]</label>
    <label id="id_6038951_1356609_2_1" xlink:label="amrn_BiopharmaceuticalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioPharma Debt</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_BiopharmaceuticalMember" xlink:to="amrn_BiopharmaceuticalMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="us-gaap_BridgeLoanMember" xlink:type="locator"/>
    <label id="id_6038951_1330534_1_1" xlink:label="us-gaap_BridgeLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bridge Loan [Member]</label>
    <label id="id_6038951_1330534_2_1" xlink:label="us-gaap_BridgeLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridge Loan</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BridgeLoanMember" xlink:to="us-gaap_BridgeLoanMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_BusinessDevelopmentDomain" xlink:label="amrn_BusinessDevelopmentDomain" xlink:type="locator"/>
    <label id="id_6038951_1458042_3_1" xlink:label="amrn_BusinessDevelopmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Development [Domain]</label>
    <label id="id_6038951_1458042_1_1" xlink:label="amrn_BusinessDevelopmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Development [Domain]</label>
    <label id="id_6038951_1458042_2_1" xlink:label="amrn_BusinessDevelopmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Development [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_BusinessDevelopmentDomain" xlink:to="amrn_BusinessDevelopmentDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_BusinessDevelopmentsAxis" xlink:label="amrn_BusinessDevelopmentsAxis" xlink:type="locator"/>
    <label id="id_6038951_1512983_3_1" xlink:label="amrn_BusinessDevelopmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Developments [Axis]</label>
    <label id="id_6038951_1512983_1_1" xlink:label="amrn_BusinessDevelopmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Developments [Axis]</label>
    <label id="id_6038951_1512983_2_1" xlink:label="amrn_BusinessDevelopmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Developments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_BusinessDevelopmentsAxis" xlink:to="amrn_BusinessDevelopmentsAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <label id="id_6038951_1341134_1_1" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label id="id_6038951_1341134_4_1" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF PERIOD</label>
    <label id="id_6038951_1341134_5_1" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</label>
    <label id="id_6038951_1341134_2_1" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <label id="id_6038951_1343059_1_1" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label id="id_6038951_1343059_2_1" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents-money markets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <label id="id_6038951_1343060_1_1" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label id="id_6038951_1343060_6_1" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1324323_1_1" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label id="id_6038951_1324323_2_1" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents and Restricted Cash</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_CashDiscountInvoiceTerms" xlink:label="amrn_CashDiscountInvoiceTerms" xlink:type="locator"/>
    <label id="id_6038951_1454506_3_1" xlink:label="amrn_CashDiscountInvoiceTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Discount Invoice Terms</label>
    <label id="id_6038951_1454506_1_1" xlink:label="amrn_CashDiscountInvoiceTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Discount Invoice Terms</label>
    <label id="id_6038951_1454506_2_1" xlink:label="amrn_CashDiscountInvoiceTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales discount term</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_CashDiscountInvoiceTerms" xlink:to="amrn_CashDiscountInvoiceTerms_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_CashDiscountPercent" xlink:label="amrn_CashDiscountPercent" xlink:type="locator"/>
    <label id="id_6038951_1503862_3_1" xlink:label="amrn_CashDiscountPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Discount Percent</label>
    <label id="id_6038951_1503862_1_1" xlink:label="amrn_CashDiscountPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Discount Percent</label>
    <label id="id_6038951_1503862_2_1" xlink:label="amrn_CashDiscountPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales discount percentage</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_CashDiscountPercent" xlink:to="amrn_CashDiscountPercent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <label id="id_6038951_1330625_1_1" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label id="id_6038951_1330625_2_1" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash transactions:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_CashPaidDuringPeriodForAbstract" xlink:label="amrn_CashPaidDuringPeriodForAbstract" xlink:type="locator"/>
    <label id="id_6038951_1396763_3_1" xlink:label="amrn_CashPaidDuringPeriodForAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Paid During Period For [Abstract]</label>
    <label id="id_6038951_1396763_1_1" xlink:label="amrn_CashPaidDuringPeriodForAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Paid During Period For [Abstract]</label>
    <label id="id_6038951_1396763_2_1" xlink:label="amrn_CashPaidDuringPeriodForAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid during the year for:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_CashPaidDuringPeriodForAbstract" xlink:to="amrn_CashPaidDuringPeriodForAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_ChargesCashMember" xlink:label="amrn_ChargesCashMember" xlink:type="locator"/>
    <label id="id_6038951_1417215_3_1" xlink:label="amrn_ChargesCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Charges Cash [Member]</label>
    <label id="id_6038951_1417215_1_1" xlink:label="amrn_ChargesCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Charges Cash [Member]</label>
    <label id="id_6038951_1417215_2_1" xlink:label="amrn_ChargesCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ChargesCashMember" xlink:to="amrn_ChargesCashMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <label id="id_6038951_1324361_1_1" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</label>
    <label id="id_6038951_1324361_2_1" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <label id="id_6038951_1333769_1_1" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <label id="id_6038951_1333769_2_1" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <label id="id_6038951_1327448_1_1" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <label id="id_6038951_1327448_2_1" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_ClassOfWarrantOrRightExercisedInPeriod" xlink:label="amrn_ClassOfWarrantOrRightExercisedInPeriod" xlink:type="locator"/>
    <label id="id_6038951_1391384_3_1" xlink:label="amrn_ClassOfWarrantOrRightExercisedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercised in Period</label>
    <label id="id_6038951_1391384_1_1" xlink:label="amrn_ClassOfWarrantOrRightExercisedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercised in Period</label>
    <label id="id_6038951_1391384_2_1" xlink:label="amrn_ClassOfWarrantOrRightExercisedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ClassOfWarrantOrRightExercisedInPeriod" xlink:to="amrn_ClassOfWarrantOrRightExercisedInPeriod_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <label id="id_6038951_1324362_1_1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label id="id_6038951_1324362_2_1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of the warrants</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_ClassOfWarrantOrRightExpiredInPeriod" xlink:label="amrn_ClassOfWarrantOrRightExpiredInPeriod" xlink:type="locator"/>
    <label id="id_6038951_1494775_3_1" xlink:label="amrn_ClassOfWarrantOrRightExpiredInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Expired in Period</label>
    <label id="id_6038951_1494775_1_1" xlink:label="amrn_ClassOfWarrantOrRightExpiredInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Expired in Period</label>
    <label id="id_6038951_1494775_2_1" xlink:label="amrn_ClassOfWarrantOrRightExpiredInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants expired</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ClassOfWarrantOrRightExpiredInPeriod" xlink:to="amrn_ClassOfWarrantOrRightExpiredInPeriod_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_ClassOfWarrantOrRightIssued" xlink:label="amrn_ClassOfWarrantOrRightIssued" xlink:type="locator"/>
    <label id="id_6038951_1394781_3_1" xlink:label="amrn_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Issued</label>
    <label id="id_6038951_1394781_1_1" xlink:label="amrn_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Issued</label>
    <label id="id_6038951_1394781_2_1" xlink:label="amrn_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants issued</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ClassOfWarrantOrRightIssued" xlink:to="amrn_ClassOfWarrantOrRightIssued_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <label id="id_6038951_1327450_1_1" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label id="id_6038951_1327450_2_1" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued, number of shares called by a warrant</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <label id="id_6038951_1330670_1_1" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label id="id_6038951_1330670_2_1" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued, number of shares called by the warrant</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <label id="id_6038951_1333772_1_1" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <label id="id_6038951_1333772_2_1" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_ClassOfWarrantOrRightTerm" xlink:label="amrn_ClassOfWarrantOrRightTerm" xlink:type="locator"/>
    <label id="id_6038951_1461542_3_1" xlink:label="amrn_ClassOfWarrantOrRightTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Term</label>
    <label id="id_6038951_1461542_1_1" xlink:label="amrn_ClassOfWarrantOrRightTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Term</label>
    <label id="id_6038951_1461542_2_1" xlink:label="amrn_ClassOfWarrantOrRightTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant term</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ClassOfWarrantOrRightTerm" xlink:to="amrn_ClassOfWarrantOrRightTerm_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_ClinicalTrialApplicationMember" xlink:label="amrn_ClinicalTrialApplicationMember" xlink:type="locator"/>
    <label id="id_6038951_1528901_3_1" xlink:label="amrn_ClinicalTrialApplicationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Trial Application</label>
    <label id="id_6038951_1528901_1_1" xlink:label="amrn_ClinicalTrialApplicationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Trial Application [Member]</label>
    <label id="id_6038951_1528901_2_1" xlink:label="amrn_ClinicalTrialApplicationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Trial Application</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ClinicalTrialApplicationMember" xlink:to="amrn_ClinicalTrialApplicationMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1324386_1_1" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>
    <label id="id_6038951_1324386_2_1" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development, Commercialization and Supply Agreement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <label id="id_6038951_1339112_1_1" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</label>
    <label id="id_6038951_1339112_2_1" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 7)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator"/>
    <label id="id_6038951_1333796_1_1" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <label id="id_6038951_1333796_2_1" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="locator"/>
    <label id="id_6038951_1425378_3_1" xlink:label="amrn_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Line Items]</label>
    <label id="id_6038951_1425378_1_1" xlink:label="amrn_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Line Items]</label>
    <label id="id_6038951_1425378_2_1" xlink:label="amrn_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="amrn_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_CommitmentsAndContingenciesDisclosureTable" xlink:label="amrn_CommitmentsAndContingenciesDisclosureTable" xlink:type="locator"/>
    <label id="id_6038951_1381024_3_1" xlink:label="amrn_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Table]</label>
    <label id="id_6038951_1381024_1_1" xlink:label="amrn_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Table]</label>
    <label id="id_6038951_1381024_2_1" xlink:label="amrn_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_CommitmentsAndContingenciesDisclosureTable" xlink:to="amrn_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1324400_1_1" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label id="id_6038951_1324400_2_1" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <label id="id_6038951_1333806_1_1" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</label>
    <label id="id_6038951_1333806_2_1" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <label id="id_6038951_1330695_1_1" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label id="id_6038951_1330695_2_1" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <label id="id_6038951_1330697_1_1" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label id="id_6038951_1330697_2_1" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, issued</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <label id="id_6038951_1327484_1_1" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label id="id_6038951_1327484_2_1" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <label id="id_6038951_1338248_1_1" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label id="id_6038951_1338248_2_1" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, &#xA3;0.50 par, unlimited authorized; 185,274,511 issued, 184,551,164 outstanding as of June 30, 2016; 183,577,765 issued, 183,403,263 outstanding as of December 31, 2015</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_ComputerEquipmentAndCapitalizedSoftwareMember" xlink:label="amrn_ComputerEquipmentAndCapitalizedSoftwareMember" xlink:type="locator"/>
    <label id="id_6038951_1443526_3_1" xlink:label="amrn_ComputerEquipmentAndCapitalizedSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer Equipment and Capitalized Software [Member]</label>
    <label id="id_6038951_1443526_1_1" xlink:label="amrn_ComputerEquipmentAndCapitalizedSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment and Capitalized Software [Member]</label>
    <label id="id_6038951_1443526_2_1" xlink:label="amrn_ComputerEquipmentAndCapitalizedSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ComputerEquipmentAndCapitalizedSoftwareMember" xlink:to="amrn_ComputerEquipmentAndCapitalizedSoftwareMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_ConcentrationOfSuppliersPolicyTextBlock" xlink:label="amrn_ConcentrationOfSuppliersPolicyTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1483961_3_1" xlink:label="amrn_ConcentrationOfSuppliersPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration Of Suppliers [Policy Text Block]</label>
    <label id="id_6038951_1483961_1_1" xlink:label="amrn_ConcentrationOfSuppliersPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Of Suppliers [Policy Text Block]</label>
    <label id="id_6038951_1483961_2_1" xlink:label="amrn_ConcentrationOfSuppliersPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Suppliers</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ConcentrationOfSuppliersPolicyTextBlock" xlink:to="amrn_ConcentrationOfSuppliersPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <label id="id_6038951_1327497_1_1" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <label id="id_6038951_1327497_2_1" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <label id="id_6038951_1333817_1_1" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <label id="id_6038951_1333817_2_1" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <label id="id_6038951_1333818_1_1" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <label id="id_6038951_1333818_2_1" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <label id="id_6038951_1327498_1_1" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label id="id_6038951_1327498_2_1" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <label id="id_6038951_1333825_1_1" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</label>
    <label id="id_6038951_1333825_2_1" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk percentage</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <label id="id_6038951_1324453_1_1" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <label id="id_6038951_1324453_2_1" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1327525_1_1" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <label id="id_6038951_1327525_2_1" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator"/>
    <label id="id_6038951_1340254_1_1" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Amount Converted</label>
    <label id="id_6038951_1340254_2_1" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Series A Convertible Preferred Stock into common stock</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_ConversionPricePerShare" xlink:label="amrn_ConversionPricePerShare" xlink:type="locator"/>
    <label id="id_6038951_1365020_3_1" xlink:label="amrn_ConversionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion Price Per Share</label>
    <label id="id_6038951_1365020_1_1" xlink:label="amrn_ConversionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Price Per Share</label>
    <label id="id_6038951_1365020_2_1" xlink:label="amrn_ConversionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share conversion price</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ConversionPricePerShare" xlink:to="amrn_ConversionPricePerShare_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" xlink:type="locator"/>
    <label id="id_6038951_1339091_1_1" xlink:label="us-gaap_ConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt</label>
    <label id="id_6038951_1339091_2_1" xlink:label="us-gaap_ConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes, carrying amount net of unamortized discount</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" xlink:type="locator"/>
    <label id="id_6038951_1333865_1_1" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</label>
    <label id="id_6038951_1333865_2_1" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator"/>
    <label id="id_6038951_1330744_1_1" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <label id="id_6038951_1330744_2_1" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued for each preference shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_CoPromotionAgreementDisclosureTextBlock" xlink:label="amrn_CoPromotionAgreementDisclosureTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1373541_3_1" xlink:label="amrn_CoPromotionAgreementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co Promotion Agreement Disclosure [Text Block]</label>
    <label id="id_6038951_1373541_1_1" xlink:label="amrn_CoPromotionAgreementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co Promotion Agreement Disclosure [Text Block]</label>
    <label id="id_6038951_1373541_2_1" xlink:label="amrn_CoPromotionAgreementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Co-Promotion Agreement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_CoPromotionAgreementDisclosureTextBlock" xlink:to="amrn_CoPromotionAgreementDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_CoPromotionAgreementLineItems" xlink:label="amrn_CoPromotionAgreementLineItems" xlink:type="locator"/>
    <label id="id_6038951_1496799_3_1" xlink:label="amrn_CoPromotionAgreementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co-Promotion Agreement [Line Items]</label>
    <label id="id_6038951_1496799_1_1" xlink:label="amrn_CoPromotionAgreementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co-Promotion Agreement [Line Items]</label>
    <label id="id_6038951_1496799_2_1" xlink:label="amrn_CoPromotionAgreementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Co-Promotion Agreement [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_CoPromotionAgreementLineItems" xlink:to="amrn_CoPromotionAgreementLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_CoPromotionAgreementMember" xlink:label="amrn_CoPromotionAgreementMember" xlink:type="locator"/>
    <label id="id_6038951_1498782_3_1" xlink:label="amrn_CoPromotionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co Promotion Agreement [Member]</label>
    <label id="id_6038951_1498782_1_1" xlink:label="amrn_CoPromotionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co Promotion Agreement [Member]</label>
    <label id="id_6038951_1498782_2_1" xlink:label="amrn_CoPromotionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Co-Promotion Agreement (the Agreement)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_CoPromotionAgreementMember" xlink:to="amrn_CoPromotionAgreementMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_CoPromotionAgreementTable" xlink:label="amrn_CoPromotionAgreementTable" xlink:type="locator"/>
    <label id="id_6038951_1457869_3_1" xlink:label="amrn_CoPromotionAgreementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co-Promotion Agreement [Table]</label>
    <label id="id_6038951_1457869_1_1" xlink:label="amrn_CoPromotionAgreementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co-Promotion Agreement [Table]</label>
    <label id="id_6038951_1457869_2_1" xlink:label="amrn_CoPromotionAgreementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Co-Promotion Agreement [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_CoPromotionAgreementTable" xlink:to="amrn_CoPromotionAgreementTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <label id="id_6038951_1343106_1_1" xlink:label="us-gaap_CostOfGoodsSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods Sold</label>
    <label id="id_6038951_1343106_2_1" xlink:label="us-gaap_CostOfGoodsSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Cost of goods sold</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_CreditsPaymentsMadeForPriorPeriodSales" xlink:label="amrn_CreditsPaymentsMadeForPriorPeriodSales" xlink:type="locator"/>
    <label id="id_6038951_1443718_3_1" xlink:label="amrn_CreditsPaymentsMadeForPriorPeriodSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credits/payments Made for Prior Period Sales</label>
    <label id="id_6038951_1443718_1_1" xlink:label="amrn_CreditsPaymentsMadeForPriorPeriodSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credits/payments Made for Prior Period Sales</label>
    <label id="id_6038951_1443718_14_1" xlink:label="amrn_CreditsPaymentsMadeForPriorPeriodSales_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Credits/payments made for prior period sales</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_CreditsPaymentsMadeForPriorPeriodSales" xlink:to="amrn_CreditsPaymentsMadeForPriorPeriodSales_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:label="us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:type="locator"/>
    <label id="id_6038951_1338237_1_1" xlink:label="us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect on Retained Earnings, Net of Tax</label>
    <label id="id_6038951_1338237_2_1" xlink:label="us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative-effect adjustment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:to="us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <label id="id_6038951_1330780_1_1" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label id="id_6038951_1330780_2_1" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <label id="id_6038951_1324536_1_1" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <label id="id_6038951_1324536_2_1" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_DateOneMember" xlink:label="amrn_DateOneMember" xlink:type="locator"/>
    <label id="id_6038951_1482079_3_1" xlink:label="amrn_DateOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Date One [Member]</label>
    <label id="id_6038951_1482079_1_1" xlink:label="amrn_DateOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Date One [Member]</label>
    <label id="id_6038951_1482079_2_1" xlink:label="amrn_DateOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Date One</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_DateOneMember" xlink:to="amrn_DateOneMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_DateThreeMember" xlink:label="amrn_DateThreeMember" xlink:type="locator"/>
    <label id="id_6038951_1511434_3_1" xlink:label="amrn_DateThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Date Three [Member]</label>
    <label id="id_6038951_1511434_1_1" xlink:label="amrn_DateThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Date Three [Member]</label>
    <label id="id_6038951_1511434_2_1" xlink:label="amrn_DateThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Date Three</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_DateThreeMember" xlink:to="amrn_DateThreeMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_DateTwoMember" xlink:label="amrn_DateTwoMember" xlink:type="locator"/>
    <label id="id_6038951_1435611_3_1" xlink:label="amrn_DateTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Date Two [Member]</label>
    <label id="id_6038951_1435611_1_1" xlink:label="amrn_DateTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Date Two [Member]</label>
    <label id="id_6038951_1435611_2_1" xlink:label="amrn_DateTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Date Two</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_DateTwoMember" xlink:to="amrn_DateTwoMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <label id="id_6038951_1330788_1_1" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Description [Axis]</label>
    <label id="id_6038951_1330788_2_1" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion by Unique Description</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <label id="id_6038951_1330793_1_1" xlink:label="us-gaap_DebtConversionNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Name [Domain]</label>
    <label id="id_6038951_1330793_2_1" xlink:label="us-gaap_DebtConversionNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion, Name [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="us-gaap_DebtConversionNameDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <label id="id_6038951_1337391_1_1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Original Debt, Amount</label>
    <label id="id_6038951_1337391_2_1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridge notes converted in conjunction with the private placement, amount</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:type="locator"/>
    <label id="id_6038951_1330799_1_1" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <label id="id_6038951_1330799_2_1" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_DebtDisclosureLineItems" xlink:label="amrn_DebtDisclosureLineItems" xlink:type="locator"/>
    <label id="id_6038951_1441123_3_1" xlink:label="amrn_DebtDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Line Items]</label>
    <label id="id_6038951_1441123_1_1" xlink:label="amrn_DebtDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Line Items]</label>
    <label id="id_6038951_1441123_2_1" xlink:label="amrn_DebtDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_DebtDisclosureLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_DebtDisclosureTable" xlink:label="amrn_DebtDisclosureTable" xlink:type="locator"/>
    <label id="id_6038951_1351658_3_1" xlink:label="amrn_DebtDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Table]</label>
    <label id="id_6038951_1351658_1_1" xlink:label="amrn_DebtDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Table]</label>
    <label id="id_6038951_1351658_2_1" xlink:label="amrn_DebtDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_DebtDisclosureTable" xlink:to="amrn_DebtDisclosureTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1330800_1_1" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <label id="id_6038951_1330800_2_1" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_DebtExchangeMember" xlink:label="amrn_DebtExchangeMember" xlink:type="locator"/>
    <label id="id_6038951_1464257_3_1" xlink:label="amrn_DebtExchangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Exchange [Member]</label>
    <label id="id_6038951_1464257_1_1" xlink:label="amrn_DebtExchangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Exchange [Member]</label>
    <label id="id_6038951_1464257_2_1" xlink:label="amrn_DebtExchangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchanged Debt</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_DebtExchangeMember" xlink:to="amrn_DebtExchangeMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <label id="id_6038951_1324529_1_1" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</label>
    <label id="id_6038951_1324529_2_1" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCallDateEarliest" xlink:label="us-gaap_DebtInstrumentCallDateEarliest" xlink:type="locator"/>
    <label id="id_6038951_1333911_1_1" xlink:label="us-gaap_DebtInstrumentCallDateEarliest_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Call Date, Earliest</label>
    <label id="id_6038951_1333911_2_1" xlink:label="us-gaap_DebtInstrumentCallDateEarliest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, earliest redemption date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCallDateEarliest" xlink:to="us-gaap_DebtInstrumentCallDateEarliest_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCallDateLatest" xlink:label="us-gaap_DebtInstrumentCallDateLatest" xlink:type="locator"/>
    <label id="id_6038951_1324531_1_1" xlink:label="us-gaap_DebtInstrumentCallDateLatest_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Call Date, Latest</label>
    <label id="id_6038951_1324531_2_1" xlink:label="us-gaap_DebtInstrumentCallDateLatest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, latest redemption date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCallDateLatest" xlink:to="us-gaap_DebtInstrumentCallDateLatest_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="locator"/>
    <label id="id_6038951_1339076_1_1" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</label>
    <label id="id_6038951_1339076_2_1" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount of debt conversion option over the liability component</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator"/>
    <label id="id_6038951_1333928_1_1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <label id="id_6038951_1333928_2_1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridge notes converted in conjunction with the private placement, price per share</label>
    <label id="id_6038951_1333928_12_1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, initial exchange price</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="locator"/>
    <label id="id_6038951_1330801_1_1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</label>
    <label id="id_6038951_1330801_2_1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, exchange rate of ADS per $1,000 principal amount of notes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="locator"/>
    <label id="id_6038951_1324539_1_1" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Number of Equity Instruments</label>
    <label id="id_6038951_1324539_2_1" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, total ADS into which the debt is exchangeable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays" xlink:type="locator"/>
    <label id="id_6038951_1327604_1_1" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</label>
    <label id="id_6038951_1327604_2_1" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, mandatory exchange in whole or in part if daily VWAP equals or exceeds percentage of exchange price, at least number of VWAP Trading days</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="locator"/>
    <label id="id_6038951_1333932_1_1" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</label>
    <label id="id_6038951_1333932_2_1" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, mandatory exchange in whole or in part if daily VWAP equals or exceeds percentage of exchange price</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="locator"/>
    <label id="id_6038951_1330803_1_1" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</label>
    <label id="id_6038951_1330803_2_1" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, mandatory exchange in whole or in part if daily VWAP equals or exceeds percentage of exchange price, in any number of VWAP Trading days</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:type="locator"/>
    <label id="id_6038951_1324543_1_1" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Date of First Required Payment</label>
    <label id="id_6038951_1324543_2_1" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, payment start date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:to="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <label id="id_6038951_1338229_1_1" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <label id="id_6038951_1338229_2_1" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, principal amount</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" xlink:type="locator"/>
    <label id="id_6038951_1338230_1_1" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</label>
    <label id="id_6038951_1338230_2_1" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, fair value</label>
    <label id="id_6038951_1338230_12_1" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exchangeable senior notes, estimated fair value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <label id="id_6038951_1327611_1_1" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label id="id_6038951_1327611_2_1" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, stated interest rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:type="locator"/>
    <label id="id_6038951_1333918_1_1" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</label>
    <label id="id_6038951_1333918_2_1" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:type="locator"/>
    <label id="id_6038951_1333919_1_1" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <label id="id_6038951_1333919_2_1" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, maturity date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_DebtInstrumentMaturityDateYear" xlink:label="amrn_DebtInstrumentMaturityDateYear" xlink:type="locator"/>
    <label id="id_6038951_1517274_3_1" xlink:label="amrn_DebtInstrumentMaturityDateYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument Maturity Date Year</label>
    <label id="id_6038951_1517274_1_1" xlink:label="amrn_DebtInstrumentMaturityDateYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Maturity Date Year</label>
    <label id="id_6038951_1517274_2_1" xlink:label="amrn_DebtInstrumentMaturityDateYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, due date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_DebtInstrumentMaturityDateYear" xlink:to="amrn_DebtInstrumentMaturityDateYear_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <label id="id_6038951_1330814_1_1" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <label id="id_6038951_1330814_2_1" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodEndDate" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodEndDate" xlink:type="locator"/>
    <label id="id_6038951_1324554_1_1" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Period, End Date</label>
    <label id="id_6038951_1324554_2_1" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes redemption, end date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodEndDate" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodEndDate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="locator"/>
    <label id="id_6038951_1327618_1_1" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</label>
    <label id="id_6038951_1327618_2_1" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, repurchase price at option of the issuer</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="locator"/>
    <label id="id_6038951_1341222_1_1" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</label>
    <label id="id_6038951_1341222_2_1" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, principal amount purchase</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xlink:type="locator"/>
    <label id="id_6038951_1333926_1_1" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
    <label id="id_6038951_1333926_2_1" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <label id="id_6038951_1333927_1_1" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</label>
    <label id="id_6038951_1333927_2_1" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note, estimated remaining life</label>
    <label id="id_6038951_1333927_12_1" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Note, expected term</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator"/>
    <label id="id_6038951_1342170_1_1" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
    <label id="id_6038951_1342170_2_1" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, discount</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_DebtIssuanceCostsPolicyTextBlock" xlink:label="amrn_DebtIssuanceCostsPolicyTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1373341_3_1" xlink:label="amrn_DebtIssuanceCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs [Policy Text Block]</label>
    <label id="id_6038951_1373341_1_1" xlink:label="amrn_DebtIssuanceCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs [Policy Text Block]</label>
    <label id="id_6038951_1373341_2_1" xlink:label="amrn_DebtIssuanceCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_DebtIssuanceCostsPolicyTextBlock" xlink:to="amrn_DebtIssuanceCostsPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1330819_1_1" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
    <label id="id_6038951_1330819_2_1" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instruments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" xlink:type="locator"/>
    <label id="id_6038951_1341235_1_1" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</label>
    <label id="id_6038951_1341235_2_1" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <label id="id_6038951_1340298_1_1" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <label id="id_6038951_1340298_2_1" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" xlink:type="locator"/>
    <label id="id_6038951_1338207_1_1" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue</label>
    <label id="id_6038951_1338207_2_1" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:type="locator"/>
    <label id="id_6038951_1333954_1_1" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</label>
    <label id="id_6038951_1333954_2_1" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:type="locator"/>
    <label id="id_6038951_1330841_1_1" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue [Domain]</label>
    <label id="id_6038951_1330841_2_1" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <label id="id_6038951_1337375_1_1" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</label>
    <label id="id_6038951_1337375_2_1" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, current</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <label id="id_6038951_1338204_1_1" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Noncurrent</label>
    <label id="id_6038951_1338204_2_1" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, long-term</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <label id="id_6038951_1341269_1_1" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <label id="id_6038951_1341269_2_1" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:type="locator"/>
    <label id="id_6038951_1341272_1_1" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance, Noncurrent</label>
    <label id="id_6038951_1341272_2_1" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:to="us-gaap_DeferredTaxAssetsNetNoncurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <label id="id_6038951_1340335_1_1" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</label>
    <label id="id_6038951_1340335_2_1" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <label id="id_6038951_1327709_1_1" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</label>
    <label id="id_6038951_1327709_2_1" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="locator"/>
    <label id="id_6038951_1338174_1_1" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</label>
    <label id="id_6038951_1338174_2_1" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability at fair value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="locator"/>
    <label id="id_6038951_1337343_1_1" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</label>
    <label id="id_6038951_1337343_2_1" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on change in fair value of derivatives</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <label id="id_6038951_1330926_1_1" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <label id="id_6038951_1330926_2_1" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, by Nature</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <label id="id_6038951_1327773_1_1" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</label>
    <label id="id_6038951_1327773_2_1" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1327776_1_1" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</label>
    <label id="id_6038951_1327776_2_1" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Warrant Derivative Liability</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" xlink:type="locator"/>
    <label id="id_6038951_1338172_1_1" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability</label>
    <label id="id_6038951_1338172_4_1" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</label>
    <label id="id_6038951_1338172_5_1" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="locator"/>
    <label id="id_6038951_1337338_1_1" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Noncurrent</label>
    <label id="id_6038951_1337338_2_1" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt derivative liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_DerivativeLiabilitiesTransferredToEquityClassifications" xlink:label="amrn_DerivativeLiabilitiesTransferredToEquityClassifications" xlink:type="locator"/>
    <label id="id_6038951_1365299_3_1" xlink:label="amrn_DerivativeLiabilitiesTransferredToEquityClassifications_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Liabilities Transferred To Equity Classifications</label>
    <label id="id_6038951_1365299_1_1" xlink:label="amrn_DerivativeLiabilitiesTransferredToEquityClassifications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liabilities Transferred To Equity Classifications</label>
    <label id="id_6038951_1365299_2_1" xlink:label="amrn_DerivativeLiabilitiesTransferredToEquityClassifications_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfer of preferred stock purchase option derivative liability to equity</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_DerivativeLiabilitiesTransferredToEquityClassifications" xlink:to="amrn_DerivativeLiabilitiesTransferredToEquityClassifications_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_DerivativeLiabilitiesTransferredToStockholdersEquity" xlink:label="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity" xlink:type="locator"/>
    <label id="id_6038951_1355330_3_1" xlink:label="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Liabilities Transferred to Stockholders' Equity</label>
    <label id="id_6038951_1355330_1_1" xlink:label="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liabilities Transferred to Stockholders' Equity</label>
    <label id="id_6038951_1355330_2_1" xlink:label="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfer derivative liability to equity</label>
    <label id="id_6038951_1355330_14_1" xlink:label="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Transfer derivative liability to equity</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity" xlink:to="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="us-gaap_DerivativeLineItems" xlink:type="locator"/>
    <label id="id_6038951_1324653_1_1" xlink:label="us-gaap_DerivativeLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</label>
    <label id="id_6038951_1324653_2_1" xlink:label="us-gaap_DerivativeLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DerivativeLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="us-gaap_DerivativesFairValueLineItems" xlink:type="locator"/>
    <label id="id_6038951_1330941_1_1" xlink:label="us-gaap_DerivativesFairValueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</label>
    <label id="id_6038951_1330941_2_1" xlink:label="us-gaap_DerivativesFairValueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_DerivativesFairValueLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1334097_1_1" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
    <label id="id_6038951_1334097_2_1" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeTable" xlink:label="us-gaap_DerivativeTable" xlink:type="locator"/>
    <label id="id_6038951_1334049_1_1" xlink:label="us-gaap_DerivativeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Table]</label>
    <label id="id_6038951_1334049_2_1" xlink:label="us-gaap_DerivativeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_DerivativeTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:type="locator"/>
    <label id="id_6038951_1339915_1_1" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities</label>
    <label id="id_6038951_1339915_2_1" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on warrant derivative liability</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:to="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DirectorMember" xlink:label="us-gaap_DirectorMember" xlink:type="locator"/>
    <label id="id_6038951_1334098_1_1" xlink:label="us-gaap_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</label>
    <label id="id_6038951_1334098_2_1" xlink:label="us-gaap_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Director</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectorMember" xlink:to="us-gaap_DirectorMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_DocumentAndEntityInformationAbstract" xlink:label="amrn_DocumentAndEntityInformationAbstract" xlink:type="locator"/>
    <label id="id_6038951_1386744_3_1" xlink:label="amrn_DocumentAndEntityInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</label>
    <label id="id_6038951_1386744_1_1" xlink:label="amrn_DocumentAndEntityInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</label>
    <label id="id_6038951_1386744_2_1" xlink:label="amrn_DocumentAndEntityInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_DocumentAndEntityInformationAbstract" xlink:to="amrn_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <label id="id_6038951_1324767_1_1" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label id="id_6038951_1324767_2_1" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <label id="id_6038951_1324768_1_1" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label id="id_6038951_1324768_2_1" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <label id="id_6038951_1324770_1_1" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</label>
    <label id="id_6038951_1324770_2_1" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <label id="id_6038951_1327843_1_1" xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</label>
    <label id="id_6038951_1327843_2_1" xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <label id="id_6038951_1331044_1_1" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</label>
    <label id="id_6038951_1331044_2_1" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <label id="id_6038951_1324772_1_1" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</label>
    <label id="id_6038951_1324772_2_1" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_EarningsLossPerShareLineItems" xlink:label="amrn_EarningsLossPerShareLineItems" xlink:type="locator"/>
    <label id="id_6038951_1351295_3_1" xlink:label="amrn_EarningsLossPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings Loss Per Share [Line Items]</label>
    <label id="id_6038951_1351295_1_1" xlink:label="amrn_EarningsLossPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Loss Per Share [Line Items]</label>
    <label id="id_6038951_1351295_2_1" xlink:label="amrn_EarningsLossPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Loss Per Share [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_EarningsLossPerShareLineItems" xlink:to="amrn_EarningsLossPerShareLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_EarningsLossPerShareTable" xlink:label="amrn_EarningsLossPerShareTable" xlink:type="locator"/>
    <label id="id_6038951_1451732_3_1" xlink:label="amrn_EarningsLossPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings Loss Per Share [Table]</label>
    <label id="id_6038951_1451732_1_1" xlink:label="amrn_EarningsLossPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Loss Per Share [Table]</label>
    <label id="id_6038951_1451732_2_1" xlink:label="amrn_EarningsLossPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Loss Per Share [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_EarningsLossPerShareTable" xlink:to="amrn_EarningsLossPerShareTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <label id="id_6038951_1331060_1_1" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <label id="id_6038951_1331060_2_1" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <label id="id_6038951_1331061_1_1" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label id="id_6038951_1331061_2_1" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <label id="id_6038951_1334165_1_1" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label id="id_6038951_1334165_2_1" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share-basic and diluted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="locator"/>
    <label id="id_6038951_1324780_1_1" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>
    <label id="id_6038951_1324780_2_1" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per share:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <label id="id_6038951_1324782_1_1" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label id="id_6038951_1324782_2_1" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1324786_1_1" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label id="id_6038951_1324786_2_1" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per Share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_EddingpharmMember" xlink:label="amrn_EddingpharmMember" xlink:type="locator"/>
    <label id="id_6038951_1440366_3_1" xlink:label="amrn_EddingpharmMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eddingpharm [Member]</label>
    <label id="id_6038951_1440366_1_1" xlink:label="amrn_EddingpharmMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eddingpharm [Member]</label>
    <label id="id_6038951_1440366_2_1" xlink:label="amrn_EddingpharmMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eddingpharm</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_EddingpharmMember" xlink:to="amrn_EddingpharmMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_EligibleMilestonePayment" xlink:label="amrn_EligibleMilestonePayment" xlink:type="locator"/>
    <label id="id_6038951_1499821_3_1" xlink:label="amrn_EligibleMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eligible Milestone Payment</label>
    <label id="id_6038951_1499821_1_1" xlink:label="amrn_EligibleMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eligible Milestone Payment</label>
    <label id="id_6038951_1499821_2_1" xlink:label="amrn_EligibleMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional upfront payment eligible to receive based on development, regulatory and sales Milestone</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_EligibleMilestonePayment" xlink:to="amrn_EligibleMilestonePayment_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeDescriptionOfHostContract" xlink:label="us-gaap_EmbeddedDerivativeDescriptionOfHostContract" xlink:type="locator"/>
    <label id="id_6038951_1334216_1_1" xlink:label="us-gaap_EmbeddedDerivativeDescriptionOfHostContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Embedded Derivative, Description of Host Contract</label>
    <label id="id_6038951_1334216_2_1" xlink:label="us-gaap_EmbeddedDerivativeDescriptionOfHostContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of pricing variability feature and classification of warrants</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeDescriptionOfHostContract" xlink:to="us-gaap_EmbeddedDerivativeDescriptionOfHostContract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:type="locator"/>
    <label id="id_6038951_1337310_1_1" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Embedded Derivative, Fair Value of Embedded Derivative Liability</label>
    <label id="id_6038951_1337310_2_1" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of embedded derivative liability</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:type="locator"/>
    <label id="id_6038951_1327893_1_1" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Embedded Derivative Financial Instruments [Member]</label>
    <label id="id_6038951_1327893_2_1" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Embedded Derivative Financial Instruments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:to="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <label id="id_6038951_1331109_1_1" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</label>
    <label id="id_6038951_1331109_2_1" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EnergyAxis" xlink:label="us-gaap_EnergyAxis" xlink:type="locator"/>
    <label id="id_6038951_1324828_1_1" xlink:label="us-gaap_EnergyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Energy [Axis]</label>
    <label id="id_6038951_1324828_2_1" xlink:label="us-gaap_EnergyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instrument</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EnergyAxis" xlink:to="us-gaap_EnergyAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EnergyDomain" xlink:label="us-gaap_EnergyDomain" xlink:type="locator"/>
    <label id="id_6038951_1324829_1_1" xlink:label="us-gaap_EnergyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Energy [Domain]</label>
    <label id="id_6038951_1324829_2_1" xlink:label="us-gaap_EnergyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Energy [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EnergyDomain" xlink:to="us-gaap_EnergyDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <label id="id_6038951_1324832_1_1" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</label>
    <label id="id_6038951_1324832_2_1" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <label id="id_6038951_1331127_1_1" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label id="id_6038951_1331127_2_1" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <label id="id_6038951_1331131_1_1" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</label>
    <label id="id_6038951_1331131_2_1" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <label id="id_6038951_1331132_1_1" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</label>
    <label id="id_6038951_1331132_2_1" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <label id="id_6038951_1334246_1_1" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</label>
    <label id="id_6038951_1334246_2_1" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xlink:type="locator"/>
    <label id="id_6038951_1327926_1_1" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</label>
    <label id="id_6038951_1327926_2_1" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <label id="id_6038951_1334257_1_1" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</label>
    <label id="id_6038951_1334257_2_1" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_EquityIssuancePerShareAmount1" xlink:label="amrn_EquityIssuancePerShareAmount1" xlink:type="locator"/>
    <label id="id_6038951_1443319_3_1" xlink:label="amrn_EquityIssuancePerShareAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount per share or per unit assigned to the consideration received of equity securities issued for development stage entities.</label>
    <label id="id_6038951_1443319_1_1" xlink:label="amrn_EquityIssuancePerShareAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Stage Entities, Equity Issuance, Per Share Amount</label>
    <label id="id_6038951_1443319_2_1" xlink:label="amrn_EquityIssuancePerShareAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued under private placement, price per share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_EquityIssuancePerShareAmount1" xlink:to="amrn_EquityIssuancePerShareAmount1_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_EquityOfferingCosts" xlink:label="amrn_EquityOfferingCosts" xlink:type="locator"/>
    <label id="id_6038951_1387219_3_1" xlink:label="amrn_EquityOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Offering Costs</label>
    <label id="id_6038951_1387219_1_1" xlink:label="amrn_EquityOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Offering Costs</label>
    <label id="id_6038951_1387219_2_1" xlink:label="amrn_EquityOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated offering expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_EquityOfferingCosts" xlink:to="amrn_EquityOfferingCosts_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_ExcessPrincipalValueOverFairValue" xlink:label="amrn_ExcessPrincipalValueOverFairValue" xlink:type="locator"/>
    <label id="id_6038951_1478798_3_1" xlink:label="amrn_ExcessPrincipalValueOverFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Excess Principal Value Over Fair Value</label>
    <label id="id_6038951_1478798_1_1" xlink:label="amrn_ExcessPrincipalValueOverFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Excess Principal Value Over Fair Value</label>
    <label id="id_6038951_1478798_2_1" xlink:label="amrn_ExcessPrincipalValueOverFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of shares in excess of principal amount of Notes based on closing price</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ExcessPrincipalValueOverFairValue" xlink:to="amrn_ExcessPrincipalValueOverFairValue_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities" xlink:label="amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities" xlink:type="locator"/>
    <label id="id_6038951_1436016_3_1" xlink:label="amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Excess Tax Benefit (Tax Deficiency) From Share Based Compensation Financing Activities</label>
    <label id="id_6038951_1436016_1_1" xlink:label="amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Excess Tax Benefit Tax Deficiency From Share Based Compensation Financing Activities</label>
    <label id="id_6038951_1436016_2_1" xlink:label="amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excess tax provision on stock-based awards</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities" xlink:to="amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationOperatingActivities" xlink:label="amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationOperatingActivities" xlink:type="locator"/>
    <label id="id_6038951_1418154_3_1" xlink:label="amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Excess Tax Benefit (Tax Deficiency) From Share Based Compensation Operating Activities</label>
    <label id="id_6038951_1418154_1_1" xlink:label="amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Excess Tax Benefit Tax Deficiency From Share Based Compensation Operating Activities</label>
    <label id="id_6038951_1418154_2_1" xlink:label="amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excess tax provision on stock-based awards</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationOperatingActivities" xlink:to="amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationOperatingActivities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator"/>
    <label id="id_6038951_1324893_1_1" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label id="id_6038951_1324893_2_1" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator"/>
    <label id="id_6038951_1324894_1_1" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <label id="id_6038951_1324894_2_1" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1334308_1_1" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</label>
    <label id="id_6038951_1334308_2_1" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and Liability Measured at Fair Value on a Recurring Basis</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_FairValueAssumptionsComparableYieldToMaturity" xlink:label="amrn_FairValueAssumptionsComparableYieldToMaturity" xlink:type="locator"/>
    <label id="id_6038951_1370451_3_1" xlink:label="amrn_FairValueAssumptionsComparableYieldToMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Comparable Yield to Maturity</label>
    <label id="id_6038951_1370451_1_1" xlink:label="amrn_FairValueAssumptionsComparableYieldToMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Comparable Yield to Maturity</label>
    <label id="id_6038951_1370451_2_1" xlink:label="amrn_FairValueAssumptionsComparableYieldToMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability fair value assumptions, market yields</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_FairValueAssumptionsComparableYieldToMaturity" xlink:to="amrn_FairValueAssumptionsComparableYieldToMaturity_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_FairValueAssumptionsCouponRate" xlink:label="amrn_FairValueAssumptionsCouponRate" xlink:type="locator"/>
    <label id="id_6038951_1383368_3_1" xlink:label="amrn_FairValueAssumptionsCouponRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions Coupon Rate</label>
    <label id="id_6038951_1383368_1_1" xlink:label="amrn_FairValueAssumptionsCouponRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions Coupon Rate</label>
    <label id="id_6038951_1383368_2_1" xlink:label="amrn_FairValueAssumptionsCouponRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability fair value assumption, coupon rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_FairValueAssumptionsCouponRate" xlink:to="amrn_FairValueAssumptionsCouponRate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <label id="id_6038951_1327975_1_1" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</label>
    <label id="id_6038951_1327975_2_1" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability fair value assumptions, dividend yield</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" xlink:type="locator"/>
    <label id="id_6038951_1334314_1_1" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Term</label>
    <label id="id_6038951_1334314_2_1" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability fair value assumptions, term</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <label id="id_6038951_1331206_1_1" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</label>
    <label id="id_6038951_1331206_2_1" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability fair value assumptions, volatility rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <label id="id_6038951_1331207_1_1" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</label>
    <label id="id_6038951_1331207_2_1" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability fair value assumptions, risk-free rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <label id="id_6038951_1324896_1_1" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
    <label id="id_6038951_1324896_2_1" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <label id="id_6038951_1331211_1_1" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <label id="id_6038951_1331211_2_1" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Measurement Frequency</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:type="locator"/>
    <label id="id_6038951_1324909_1_1" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <label id="id_6038951_1324909_2_1" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <label id="id_6038951_1327983_1_1" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <label id="id_6038951_1327983_2_1" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <label id="id_6038951_1324925_1_1" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <label id="id_6038951_1324925_2_1" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <label id="id_6038951_1331258_1_1" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</label>
    <label id="id_6038951_1331258_2_1" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1328014_1_1" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label id="id_6038951_1328014_2_1" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <label id="id_6038951_1324950_1_1" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</label>
    <label id="id_6038951_1324950_2_1" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <label id="id_6038951_1328015_1_1" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</label>
    <label id="id_6038951_1328015_2_1" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <label id="id_6038951_1324959_1_1" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label id="id_6038951_1324959_2_1" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="locator"/>
    <label id="id_6038951_1328034_1_1" xlink:label="us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</label>
    <label id="id_6038951_1328034_2_1" xlink:label="us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_FinanceMember" xlink:label="amrn_FinanceMember" xlink:type="locator"/>
    <label id="id_6038951_1404455_3_1" xlink:label="amrn_FinanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance [Member]</label>
    <label id="id_6038951_1404455_1_1" xlink:label="amrn_FinanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance [Member]</label>
    <label id="id_6038951_1404455_2_1" xlink:label="amrn_FinanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_FinanceMember" xlink:to="amrn_FinanceMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <label id="id_6038951_1338925_1_1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <label id="id_6038951_1338925_14_1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <label id="id_6038951_1343316_1_1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
    <label id="id_6038951_1343316_2_1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technology rights</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator"/>
    <label id="id_6038951_1331353_1_1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
    <label id="id_6038951_1331353_2_1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <label id="id_6038951_1343314_1_1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <label id="id_6038951_1343314_2_1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset, net</label>
    <label id="id_6038951_1343314_6_1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible asset, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator"/>
    <label id="id_6038951_1325051_1_1" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <label id="id_6038951_1325051_2_1" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets estimated remaining useful life</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1328127_1_1" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label id="id_6038951_1328127_2_1" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <label id="id_6038951_1328146_1_1" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <label id="id_6038951_1328146_2_1" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_FurtherIndicationForAmrOneZeroOneMember" xlink:label="amrn_FurtherIndicationForAmrOneZeroOneMember" xlink:type="locator"/>
    <label id="id_6038951_1506247_3_1" xlink:label="amrn_FurtherIndicationForAmrOneZeroOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Further Indication for AMR101 [Member]</label>
    <label id="id_6038951_1506247_1_1" xlink:label="amrn_FurtherIndicationForAmrOneZeroOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Further Indication for AMR101 [Member]</label>
    <label id="id_6038951_1506247_2_1" xlink:label="amrn_FurtherIndicationForAmrOneZeroOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Further Indication for AMR101</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_FurtherIndicationForAmrOneZeroOneMember" xlink:to="amrn_FurtherIndicationForAmrOneZeroOneMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_FutureMinimumGuaranteePayments" xlink:label="amrn_FutureMinimumGuaranteePayments" xlink:type="locator"/>
    <label id="id_6038951_1422160_3_1" xlink:label="amrn_FutureMinimumGuaranteePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Minimum Guarantee Payments</label>
    <label id="id_6038951_1422160_1_1" xlink:label="amrn_FutureMinimumGuaranteePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Guarantee Payments</label>
    <label id="id_6038951_1422160_2_1" xlink:label="amrn_FutureMinimumGuaranteePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum repayment under agreement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_FutureMinimumGuaranteePayments" xlink:to="amrn_FutureMinimumGuaranteePayments_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator"/>
    <label id="id_6038951_1337199_1_1" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label id="id_6038951_1337199_14_1" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on sale of fixed assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <label id="id_6038951_1337190_1_1" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <label id="id_6038951_1337190_2_1" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on extinguishment of debt</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator"/>
    <label id="id_6038951_1328176_1_1" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>
    <label id="id_6038951_1328176_2_1" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xlink:type="locator"/>
    <label id="id_6038951_1338871_1_1" xlink:label="us-gaap_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</label>
    <label id="id_6038951_1338871_6_1" xlink:label="us-gaap_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross margin</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_GuaranteePayments" xlink:label="amrn_GuaranteePayments" xlink:type="locator"/>
    <label id="id_6038951_1499969_3_1" xlink:label="amrn_GuaranteePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Guarantee Payments</label>
    <label id="id_6038951_1499969_1_1" xlink:label="amrn_GuaranteePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantee Payments</label>
    <label id="id_6038951_1499969_2_1" xlink:label="amrn_GuaranteePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment under agreement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_GuaranteePayments" xlink:to="amrn_GuaranteePayments_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1334658_1_1" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label id="id_6038951_1334658_2_1" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Asset Impairment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <label id="id_6038951_1339760_1_1" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label id="id_6038951_1339760_6_1" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations before taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <label id="id_6038951_1325223_1_1" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</label>
    <label id="id_6038951_1325223_2_1" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xlink:type="locator"/>
    <label id="id_6038951_1338851_1_1" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</label>
    <label id="id_6038951_1338851_2_1" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <label id="id_6038951_1340505_1_1" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label id="id_6038951_1340505_14_1" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Benefit from income taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1334674_1_1" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label id="id_6038951_1334674_2_1" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:type="locator"/>
    <label id="id_6038951_1342443_1_1" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Other Operating Liabilities</label>
    <label id="id_6038951_1342443_2_1" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and other current liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <label id="id_6038951_1337998_1_1" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label id="id_6038951_1337998_14_1" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <label id="id_6038951_1341503_1_1" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <label id="id_6038951_1341503_2_1" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:type="locator"/>
    <label id="id_6038951_1340530_1_1" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</label>
    <label id="id_6038951_1340530_2_1" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Record derivative liability</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <label id="id_6038951_1342454_1_1" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Interest Payable, Net</label>
    <label id="id_6038951_1342454_2_1" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest payable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <label id="id_6038951_1337978_1_1" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <label id="id_6038951_1337978_14_1" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <label id="id_6038951_1328317_1_1" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label id="id_6038951_1328317_2_1" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator"/>
    <label id="id_6038951_1337138_1_1" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
    <label id="id_6038951_1337138_14_1" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator"/>
    <label id="id_6038951_1341521_1_1" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <label id="id_6038951_1341521_2_1" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <label id="id_6038951_1339720_1_1" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label id="id_6038951_1339720_14_1" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid and other current assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1331571_1_1" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <label id="id_6038951_1331571_2_1" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <label id="id_6038951_1328340_1_1" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <label id="id_6038951_1328340_2_1" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:type="locator"/>
    <label id="id_6038951_1342485_1_1" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</label>
    <label id="id_6038951_1342485_2_1" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes, interest expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="locator"/>
    <label id="id_6038951_1340571_1_1" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</label>
    <label id="id_6038951_1340571_2_1" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, contractual coupon interest</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <label id="id_6038951_1337111_1_1" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</label>
    <label id="id_6038951_1337111_2_1" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" xlink:type="locator"/>
    <label id="id_6038951_1337940_1_1" xlink:label="us-gaap_InterestPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid</label>
    <label id="id_6038951_1337940_2_1" xlink:label="us-gaap_InterestPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest</label>
    <label id="id_6038951_1337940_12_1" xlink:label="us-gaap_InterestPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest payment on notes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <label id="id_6038951_1337942_1_1" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</label>
    <label id="id_6038951_1337942_2_1" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest on convertible note</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable" xlink:type="locator"/>
    <label id="id_6038951_1331609_1_1" xlink:label="us-gaap_InventoryCurrentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</label>
    <label id="id_6038951_1331609_2_1" xlink:label="us-gaap_InventoryCurrentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryCurrentTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:type="locator"/>
    <label id="id_6038951_1331610_1_1" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</label>
    <label id="id_6038951_1331610_2_1" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1325291_1_1" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <label id="id_6038951_1325291_2_1" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <label id="id_6038951_1343488_1_1" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</label>
    <label id="id_6038951_1343488_2_1" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems" xlink:type="locator"/>
    <label id="id_6038951_1325295_1_1" xlink:label="us-gaap_InventoryLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</label>
    <label id="id_6038951_1325295_2_1" xlink:label="us-gaap_InventoryLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <label id="id_6038951_1341567_1_1" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</label>
    <label id="id_6038951_1341567_2_1" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</label>
    <label id="id_6038951_1341567_6_1" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1325296_1_1" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <label id="id_6038951_1325296_2_1" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>
    <label id="id_6038951_1343483_1_1" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</label>
    <label id="id_6038951_1343483_2_1" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <label id="id_6038951_1340597_1_1" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</label>
    <label id="id_6038951_1340597_2_1" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in process</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <label id="id_6038951_1331645_1_1" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</label>
    <label id="id_6038951_1331645_2_1" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <label id="id_6038951_1328442_1_1" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</label>
    <label id="id_6038951_1328442_2_1" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_KowaPharmaceuticalsAmericaMember" xlink:label="amrn_KowaPharmaceuticalsAmericaMember" xlink:type="locator"/>
    <label id="id_6038951_1458944_3_1" xlink:label="amrn_KowaPharmaceuticalsAmericaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kowa Pharmaceuticals America [Member]</label>
    <label id="id_6038951_1458944_1_1" xlink:label="amrn_KowaPharmaceuticalsAmericaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kowa Pharmaceuticals America [Member]</label>
    <label id="id_6038951_1458944_2_1" xlink:label="amrn_KowaPharmaceuticalsAmericaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kowa Pharmaceuticals America</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_KowaPharmaceuticalsAmericaMember" xlink:to="amrn_KowaPharmaceuticalsAmericaMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <label id="id_6038951_1331682_1_1" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <label id="id_6038951_1331682_2_1" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1331687_1_1" xlink:label="us-gaap_LegalCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</label>
    <label id="id_6038951_1331687_2_1" xlink:label="us-gaap_LegalCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs for Patent Litigation and Legal Proceedings</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalCostsPolicyTextBlock" xlink:to="us-gaap_LegalCostsPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <label id="id_6038951_1328480_1_1" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</label>
    <label id="id_6038951_1328480_2_1" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <label id="id_6038951_1337090_1_1" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</label>
    <label id="id_6038951_1337090_6_1" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <label id="id_6038951_1337091_1_1" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</label>
    <label id="id_6038951_1337091_6_1" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <label id="id_6038951_1328488_1_1" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label id="id_6038951_1328488_2_1" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' DEFICIT</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <label id="id_6038951_1339671_1_1" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</label>
    <label id="id_6038951_1339671_6_1" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <label id="id_6038951_1334857_1_1" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label id="id_6038951_1334857_2_1" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Liabilities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="locator"/>
    <label id="id_6038951_1334858_1_1" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</label>
    <label id="id_6038951_1334858_2_1" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <label id="id_6038951_1328492_1_1" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label id="id_6038951_1328492_2_1" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Liabilities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_LicenseAndCollaborationAgreementsLineItems" xlink:label="amrn_LicenseAndCollaborationAgreementsLineItems" xlink:type="locator"/>
    <label id="id_6038951_1407313_3_1" xlink:label="amrn_LicenseAndCollaborationAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Line Items]</label>
    <label id="id_6038951_1407313_1_1" xlink:label="amrn_LicenseAndCollaborationAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Line Items]</label>
    <label id="id_6038951_1407313_2_1" xlink:label="amrn_LicenseAndCollaborationAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_LicenseAndCollaborationAgreementsLineItems" xlink:to="amrn_LicenseAndCollaborationAgreementsLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_LicenseAndCollaborationAgreementsTable" xlink:label="amrn_LicenseAndCollaborationAgreementsTable" xlink:type="locator"/>
    <label id="id_6038951_1358426_3_1" xlink:label="amrn_LicenseAndCollaborationAgreementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Table]</label>
    <label id="id_6038951_1358426_1_1" xlink:label="amrn_LicenseAndCollaborationAgreementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Table]</label>
    <label id="id_6038951_1358426_2_1" xlink:label="amrn_LicenseAndCollaborationAgreementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_LicenseAndCollaborationAgreementsTable" xlink:to="amrn_LicenseAndCollaborationAgreementsTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue" xlink:type="locator"/>
    <label id="id_6038951_1338733_1_1" xlink:label="us-gaap_LicensesRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licenses Revenue</label>
    <label id="id_6038951_1338733_2_1" xlink:label="us-gaap_LicensesRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing revenue</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensesRevenue" xlink:to="us-gaap_LicensesRevenue_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_LicensingAgreementTerm" xlink:label="amrn_LicensingAgreementTerm" xlink:type="locator"/>
    <label id="id_6038951_1444999_3_1" xlink:label="amrn_LicensingAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Licensing Agreement Term</label>
    <label id="id_6038951_1444999_1_1" xlink:label="amrn_LicensingAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreement Term</label>
    <label id="id_6038951_1444999_2_1" xlink:label="amrn_LicensingAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing agreement term</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_LicensingAgreementTerm" xlink:to="amrn_LicensingAgreementTerm_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <label id="id_6038951_1339643_1_1" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</label>
    <label id="id_6038951_1339643_2_1" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long term debt-December 2012 financing, carrying value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:type="locator"/>
    <label id="id_6038951_1339631_1_1" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</label>
    <label id="id_6038951_1339631_2_1" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue" xlink:type="locator"/>
    <label id="id_6038951_1337041_1_1" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Fair Value</label>
    <label id="id_6038951_1337041_2_1" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long term debt-December 2012 financing, estimated fair value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtFairValue" xlink:to="us-gaap_LongTermDebtFairValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <label id="id_6038951_1337872_1_1" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</label>
    <label id="id_6038951_1337872_2_1" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <label id="id_6038951_1328615_1_1" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</label>
    <label id="id_6038951_1328615_2_1" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <label id="id_6038951_1331802_1_1" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</label>
    <label id="id_6038951_1331802_2_1" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" xlink:type="locator"/>
    <label id="id_6038951_1334994_1_1" xlink:label="us-gaap_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</label>
    <label id="id_6038951_1334994_2_1" xlink:label="us-gaap_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_MajorCustomersAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator"/>
    <label id="id_6038951_1334996_1_1" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</label>
    <label id="id_6038951_1334996_2_1" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator"/>
    <label id="id_6038951_1325523_1_1" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</label>
    <label id="id_6038951_1325523_2_1" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_MarketingApprovalInEuropeMember" xlink:label="amrn_MarketingApprovalInEuropeMember" xlink:type="locator"/>
    <label id="id_6038951_1410232_3_1" xlink:label="amrn_MarketingApprovalInEuropeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marketing Approval In Europe [Member]</label>
    <label id="id_6038951_1410232_1_1" xlink:label="amrn_MarketingApprovalInEuropeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketing Approval In Europe [Member]</label>
    <label id="id_6038951_1410232_2_1" xlink:label="amrn_MarketingApprovalInEuropeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketing Approval In Europe</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_MarketingApprovalInEuropeMember" xlink:to="amrn_MarketingApprovalInEuropeMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <label id="id_6038951_1328677_1_1" xlink:label="us-gaap_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</label>
    <label id="id_6038951_1328677_2_1" xlink:label="us-gaap_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <label id="id_6038951_1331874_1_1" xlink:label="us-gaap_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</label>
    <label id="id_6038951_1331874_2_1" xlink:label="us-gaap_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <label id="id_6038951_1328762_1_1" xlink:label="us-gaap_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</label>
    <label id="id_6038951_1328762_2_1" xlink:label="us-gaap_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="us-gaap_NameOfMajorCustomerDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <label id="id_6038951_1331946_1_1" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label id="id_6038951_1331946_2_1" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
    <label id="id_6038951_1342613_1_1" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label id="id_6038951_1342613_6_1" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by financing activities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <label id="id_6038951_1331947_1_1" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label id="id_6038951_1331947_2_1" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
    <label id="id_6038951_1340686_1_1" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <label id="id_6038951_1340686_2_1" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <label id="id_6038951_1328783_1_1" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label id="id_6038951_1328783_2_1" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
    <label id="id_6038951_1325627_1_1" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label id="id_6038951_1325627_6_1" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <label id="id_6038951_1337830_1_1" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label id="id_6038951_1337830_2_1" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss for the period</label>
    <label id="id_6038951_1337830_6_1" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</label>
    <label id="id_6038951_1337830_12_1" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator"/>
    <label id="id_6038951_1339589_1_1" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label id="id_6038951_1339589_2_1" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss applicable to common shareholders-basic</label>
    <label id="id_6038951_1339589_6_1" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss applicable to common shareholders</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="locator"/>
    <label id="id_6038951_1339590_1_1" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</label>
    <label id="id_6038951_1339590_6_1" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss-diluted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1325637_1_1" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label id="id_6038951_1325637_2_1" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_NonCashMember" xlink:label="amrn_NonCashMember" xlink:type="locator"/>
    <label id="id_6038951_1345793_3_1" xlink:label="amrn_NonCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non Cash [Member]</label>
    <label id="id_6038951_1345793_1_1" xlink:label="amrn_NonCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Cash [Member]</label>
    <label id="id_6038951_1345793_2_1" xlink:label="amrn_NonCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non Cash</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_NonCashMember" xlink:to="amrn_NonCashMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_NonrefundableMilestonePayment" xlink:label="amrn_NonrefundableMilestonePayment" xlink:type="locator"/>
    <label id="id_6038951_1528902_3_1" xlink:label="amrn_NonrefundableMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nonrefundable Milestone Payment</label>
    <label id="id_6038951_1528902_1_1" xlink:label="amrn_NonrefundableMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrefundable Milestone Payment</label>
    <label id="id_6038951_1528902_2_1" xlink:label="amrn_NonrefundableMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-refundable milestone payment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_NonrefundableMilestonePayment" xlink:to="amrn_NonrefundableMilestonePayment_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_NonRefundableUpfrontPaymentsReceived" xlink:label="amrn_NonRefundableUpfrontPaymentsReceived" xlink:type="locator"/>
    <label id="id_6038951_1477205_3_1" xlink:label="amrn_NonRefundableUpfrontPaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non Refundable Upfront Payments Received</label>
    <label id="id_6038951_1477205_1_1" xlink:label="amrn_NonRefundableUpfrontPaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Refundable Upfront Payments Received</label>
    <label id="id_6038951_1477205_2_1" xlink:label="amrn_NonRefundableUpfrontPaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-refundable up-front received</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_NonRefundableUpfrontPaymentsReceived" xlink:to="amrn_NonRefundableUpfrontPaymentsReceived_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <label id="id_6038951_1331993_1_1" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</label>
    <label id="id_6038951_1331993_2_1" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_NumberOfPatientsEnrolledInStudy" xlink:label="amrn_NumberOfPatientsEnrolledInStudy" xlink:type="locator"/>
    <label id="id_6038951_1528903_3_1" xlink:label="amrn_NumberOfPatientsEnrolledInStudy_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Patients Enrolled In Study</label>
    <label id="id_6038951_1528903_1_1" xlink:label="amrn_NumberOfPatientsEnrolledInStudy_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Patients Enrolled In Study</label>
    <label id="id_6038951_1528903_2_1" xlink:label="amrn_NumberOfPatientsEnrolledInStudy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">REDUCE-IT study, number of patients enrolled</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_NumberOfPatientsEnrolledInStudy" xlink:to="amrn_NumberOfPatientsEnrolledInStudy_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_NumberOfSalesProfessionals" xlink:label="amrn_NumberOfSalesProfessionals" xlink:type="locator"/>
    <label id="id_6038951_1528904_3_1" xlink:label="amrn_NumberOfSalesProfessionals_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Sales Professionals</label>
    <label id="id_6038951_1528904_1_1" xlink:label="amrn_NumberOfSalesProfessionals_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Sales Professionals</label>
    <label id="id_6038951_1528904_2_1" xlink:label="amrn_NumberOfSalesProfessionals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of sales professionals</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_NumberOfSalesProfessionals" xlink:to="amrn_NumberOfSalesProfessionals_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_NumberOfSalesRepresentative" xlink:label="amrn_NumberOfSalesRepresentative" xlink:type="locator"/>
    <label id="id_6038951_1378047_3_1" xlink:label="amrn_NumberOfSalesRepresentative_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Sales Representative</label>
    <label id="id_6038951_1378047_1_1" xlink:label="amrn_NumberOfSalesRepresentative_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Sales Representative</label>
    <label id="id_6038951_1378047_2_1" xlink:label="amrn_NumberOfSalesRepresentative_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of sales representatives</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_NumberOfSalesRepresentative" xlink:to="amrn_NumberOfSalesRepresentative_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_OctoberTwentyZeroNinePrivatePlacementMember" xlink:label="amrn_OctoberTwentyZeroNinePrivatePlacementMember" xlink:type="locator"/>
    <label id="id_6038951_1468605_3_1" xlink:label="amrn_OctoberTwentyZeroNinePrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">October 2009 Private Placement [Member]</label>
    <label id="id_6038951_1468605_1_1" xlink:label="amrn_OctoberTwentyZeroNinePrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">October 2009 Private Placement [Member]</label>
    <label id="id_6038951_1468605_2_1" xlink:label="amrn_OctoberTwentyZeroNinePrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">October 2009 Private Placement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_OctoberTwentyZeroNinePrivatePlacementMember" xlink:to="amrn_OctoberTwentyZeroNinePrivatePlacementMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficerMember" xlink:label="us-gaap_OfficerMember" xlink:type="locator"/>
    <label id="id_6038951_1332009_1_1" xlink:label="us-gaap_OfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Officer [Member]</label>
    <label id="id_6038951_1332009_2_1" xlink:label="us-gaap_OfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued to three former officers</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficerMember" xlink:to="us-gaap_OfficerMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <label id="id_6038951_1343595_1_1" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</label>
    <label id="id_6038951_1343595_6_1" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <label id="id_6038951_1328869_1_1" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label id="id_6038951_1328869_2_1" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <label id="id_6038951_1337808_1_1" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</label>
    <label id="id_6038951_1337808_6_1" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_OrdinarySharesBasisMember" xlink:label="amrn_OrdinarySharesBasisMember" xlink:type="locator"/>
    <label id="id_6038951_1400959_3_1" xlink:label="amrn_OrdinarySharesBasisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ordinary Shares Basis [Member]</label>
    <label id="id_6038951_1400959_1_1" xlink:label="amrn_OrdinarySharesBasisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary Shares Basis [Member]</label>
    <label id="id_6038951_1400959_2_1" xlink:label="amrn_OrdinarySharesBasisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary Shares Basis</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_OrdinarySharesBasisMember" xlink:to="amrn_OrdinarySharesBasisMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_OrdinarySharesMember" xlink:label="amrn_OrdinarySharesMember" xlink:type="locator"/>
    <label id="id_6038951_1433040_3_1" xlink:label="amrn_OrdinarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ordinary Shares</label>
    <label id="id_6038951_1433040_1_1" xlink:label="amrn_OrdinarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary Shares [Member]</label>
    <label id="id_6038951_1433040_2_1" xlink:label="amrn_OrdinarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary Shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_OrdinarySharesMember" xlink:to="amrn_OrdinarySharesMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator"/>
    <label id="id_6038951_1328883_1_1" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <label id="id_6038951_1328883_2_1" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:type="locator"/>
    <label id="id_6038951_1478147_3_1" xlink:label="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</label>
    <label id="id_6038951_1478147_1_1" xlink:label="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</label>
    <label id="id_6038951_1478147_2_1" xlink:label="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:type="locator"/>
    <label id="id_6038951_1354085_3_1" xlink:label="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Table]</label>
    <label id="id_6038951_1354085_1_1" xlink:label="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Table]</label>
    <label id="id_6038951_1354085_2_1" xlink:label="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1328884_1_1" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label id="id_6038951_1328884_2_1" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature of Business and Basis of Presentation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <label id="id_6038951_1343602_1_1" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</label>
    <label id="id_6038951_1343602_2_1" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</label>
    <label id="id_6038951_1343602_12_1" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" xlink:type="locator"/>
    <label id="id_6038951_1338643_1_1" xlink:label="us-gaap_OtherCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment</label>
    <label id="id_6038951_1338643_2_1" xlink:label="us-gaap_OtherCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum repayment of future revenue and receivables</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_OtherDebtObligationsMember" xlink:label="amrn_OtherDebtObligationsMember" xlink:type="locator"/>
    <label id="id_6038951_1364094_3_1" xlink:label="amrn_OtherDebtObligationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Debt Obligations [Member]</label>
    <label id="id_6038951_1364094_1_1" xlink:label="amrn_OtherDebtObligationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Debt Obligations [Member]</label>
    <label id="id_6038951_1364094_2_1" xlink:label="amrn_OtherDebtObligationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other debt outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_OtherDebtObligationsMember" xlink:to="amrn_OtherDebtObligationsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_OtherIncentiveProgramsMember" xlink:label="amrn_OtherIncentiveProgramsMember" xlink:type="locator"/>
    <label id="id_6038951_1368196_3_1" xlink:label="amrn_OtherIncentiveProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Incentive Programs [Member]</label>
    <label id="id_6038951_1368196_1_1" xlink:label="amrn_OtherIncentiveProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Incentive Programs [Member]</label>
    <label id="id_6038951_1368196_2_1" xlink:label="amrn_OtherIncentiveProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Incentive Programs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_OtherIncentiveProgramsMember" xlink:to="amrn_OtherIncentiveProgramsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <label id="id_6038951_1336939_1_1" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <label id="id_6038951_1336939_2_1" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <label id="id_6038951_1339526_1_1" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <label id="id_6038951_1339526_2_1" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (expense) income, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator"/>
    <label id="id_6038951_1338563_1_1" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</label>
    <label id="id_6038951_1338563_14_1" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to stock-based awards</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <label id="id_6038951_1336880_1_1" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label id="id_6038951_1336880_14_1" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_PercentageOfGrossMarginPayableForPromotionAgreement" xlink:label="amrn_PercentageOfGrossMarginPayableForPromotionAgreement" xlink:type="locator"/>
    <label id="id_6038951_1516442_3_1" xlink:label="amrn_PercentageOfGrossMarginPayableForPromotionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of Gross Margin, Payable for Promotion Agreement</label>
    <label id="id_6038951_1516442_1_1" xlink:label="amrn_PercentageOfGrossMarginPayableForPromotionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Gross Margin, Payable for Promotion Agreement</label>
    <label id="id_6038951_1516442_2_1" xlink:label="amrn_PercentageOfGrossMarginPayableForPromotionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Promotion fee as a percentage of gross margin</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PercentageOfGrossMarginPayableForPromotionAgreement" xlink:to="amrn_PercentageOfGrossMarginPayableForPromotionAgreement_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis" xlink:label="amrn_PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis" xlink:type="locator"/>
    <label id="id_6038951_1516921_3_1" xlink:label="amrn_PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of Outstanding Common Shares and Preferred Shares on Fully Diluted Basis</label>
    <label id="id_6038951_1516921_1_1" xlink:label="amrn_PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Outstanding Common Shares and Preferred Shares on Fully Diluted Basis</label>
    <label id="id_6038951_1516921_2_1" xlink:label="amrn_PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of outstanding shares on a fully diluted basis</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis" xlink:to="amrn_PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_PerformanceBasedOptionsMember" xlink:label="amrn_PerformanceBasedOptionsMember" xlink:type="locator"/>
    <label id="id_6038951_1456480_3_1" xlink:label="amrn_PerformanceBasedOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Based Options [Member]</label>
    <label id="id_6038951_1456480_1_1" xlink:label="amrn_PerformanceBasedOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Based Options [Member]</label>
    <label id="id_6038951_1456480_2_1" xlink:label="amrn_PerformanceBasedOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Based Options</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PerformanceBasedOptionsMember" xlink:to="amrn_PerformanceBasedOptionsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_PerformanceBasedRestrictedStockUnitMember" xlink:label="amrn_PerformanceBasedRestrictedStockUnitMember" xlink:type="locator"/>
    <label id="id_6038951_1423313_3_1" xlink:label="amrn_PerformanceBasedRestrictedStockUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Based Restricted Stock Unit [Member]</label>
    <label id="id_6038951_1423313_1_1" xlink:label="amrn_PerformanceBasedRestrictedStockUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Based Restricted Stock Unit [Member]</label>
    <label id="id_6038951_1423313_2_1" xlink:label="amrn_PerformanceBasedRestrictedStockUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Based Restricted Stock Unit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PerformanceBasedRestrictedStockUnitMember" xlink:to="amrn_PerformanceBasedRestrictedStockUnitMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_PeriodAxis" xlink:label="amrn_PeriodAxis" xlink:type="locator"/>
    <label id="id_6038951_1367440_3_1" xlink:label="amrn_PeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period [Axis]</label>
    <label id="id_6038951_1367440_1_1" xlink:label="amrn_PeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period [Axis]</label>
    <label id="id_6038951_1367440_2_1" xlink:label="amrn_PeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PeriodAxis" xlink:to="amrn_PeriodAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_PeriodDomain" xlink:label="amrn_PeriodDomain" xlink:type="locator"/>
    <label id="id_6038951_1386517_3_1" xlink:label="amrn_PeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period [Domain]</label>
    <label id="id_6038951_1386517_1_1" xlink:label="amrn_PeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period [Domain]</label>
    <label id="id_6038951_1386517_2_1" xlink:label="amrn_PeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PeriodDomain" xlink:to="amrn_PeriodDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_PeriodOneMember" xlink:label="amrn_PeriodOneMember" xlink:type="locator"/>
    <label id="id_6038951_1347115_3_1" xlink:label="amrn_PeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period 1</label>
    <label id="id_6038951_1347115_1_1" xlink:label="amrn_PeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period 1 [Member]</label>
    <label id="id_6038951_1347115_2_1" xlink:label="amrn_PeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">August 2016</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PeriodOneMember" xlink:to="amrn_PeriodOneMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_PeriodThreeMember" xlink:label="amrn_PeriodThreeMember" xlink:type="locator"/>
    <label id="id_6038951_1517729_3_1" xlink:label="amrn_PeriodThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period 3 [Member]</label>
    <label id="id_6038951_1517729_1_1" xlink:label="amrn_PeriodThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period 3 [Member]</label>
    <label id="id_6038951_1517729_2_1" xlink:label="amrn_PeriodThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">May 2017</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PeriodThreeMember" xlink:to="amrn_PeriodThreeMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_PeriodTwoMember" xlink:label="amrn_PeriodTwoMember" xlink:type="locator"/>
    <label id="id_6038951_1358031_3_1" xlink:label="amrn_PeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period 2 [Member]</label>
    <label id="id_6038951_1358031_1_1" xlink:label="amrn_PeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period 2 [Member]</label>
    <label id="id_6038951_1358031_2_1" xlink:label="amrn_PeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fourth quarter of 2016 and first quarter of 2017</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PeriodTwoMember" xlink:to="amrn_PeriodTwoMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <label id="id_6038951_1325804_1_1" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</label>
    <label id="id_6038951_1325804_2_1" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <label id="id_6038951_1335326_1_1" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</label>
    <label id="id_6038951_1335326_2_1" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_PotentialMarketingApprovalOneMember" xlink:label="amrn_PotentialMarketingApprovalOneMember" xlink:type="locator"/>
    <label id="id_6038951_1493724_3_1" xlink:label="amrn_PotentialMarketingApprovalOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Marketing Approval 1 [Member]</label>
    <label id="id_6038951_1493724_1_1" xlink:label="amrn_PotentialMarketingApprovalOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Marketing Approval 1 [Member]</label>
    <label id="id_6038951_1493724_2_1" xlink:label="amrn_PotentialMarketingApprovalOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Marketing Approval 1</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PotentialMarketingApprovalOneMember" xlink:to="amrn_PotentialMarketingApprovalOneMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_PotentialMarketingApprovalTwoMember" xlink:label="amrn_PotentialMarketingApprovalTwoMember" xlink:type="locator"/>
    <label id="id_6038951_1364380_3_1" xlink:label="amrn_PotentialMarketingApprovalTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Marketing Approval 2 [Member]</label>
    <label id="id_6038951_1364380_1_1" xlink:label="amrn_PotentialMarketingApprovalTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Marketing Approval 2 [Member]</label>
    <label id="id_6038951_1364380_2_1" xlink:label="amrn_PotentialMarketingApprovalTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Marketing Approval 2</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PotentialMarketingApprovalTwoMember" xlink:to="amrn_PotentialMarketingApprovalTwoMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_PreferredSharesBasisMember" xlink:label="amrn_PreferredSharesBasisMember" xlink:type="locator"/>
    <label id="id_6038951_1393080_3_1" xlink:label="amrn_PreferredSharesBasisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Shares Basis [Member]</label>
    <label id="id_6038951_1393080_1_1" xlink:label="amrn_PreferredSharesBasisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Shares Basis [Member]</label>
    <label id="id_6038951_1393080_2_1" xlink:label="amrn_PreferredSharesBasisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Shares Basis</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PreferredSharesBasisMember" xlink:to="amrn_PreferredSharesBasisMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="us-gaap_PreferredStockConversionBasis" xlink:type="locator"/>
    <label id="id_6038951_1329044_1_1" xlink:label="us-gaap_PreferredStockConversionBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Conversion Basis</label>
    <label id="id_6038951_1329044_2_1" xlink:label="us-gaap_PreferredStockConversionBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">American depositary shares conversion rate to preference shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConversionBasis" xlink:to="us-gaap_PreferredStockConversionBasis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockConversionsInducements" xlink:label="us-gaap_PreferredStockConversionsInducements" xlink:type="locator"/>
    <label id="id_6038951_1342723_1_1" xlink:label="us-gaap_PreferredStockConversionsInducements_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Conversions, Inducements</label>
    <label id="id_6038951_1342723_2_1" xlink:label="us-gaap_PreferredStockConversionsInducements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accretion of preferred stock beneficial conversion feature</label>
    <label id="id_6038951_1342723_12_1" xlink:label="us-gaap_PreferredStockConversionsInducements_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">BCF resulting from issuance of Series A Preference Shares</label>
    <label id="id_6038951_1342723_14_1" xlink:label="us-gaap_PreferredStockConversionsInducements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Preferred stock beneficial conversion feature</label>
    <label id="id_6038951_1342723_18_1" xlink:label="us-gaap_PreferredStockConversionsInducements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock beneficial conversion feature (see Note 8)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConversionsInducements" xlink:to="us-gaap_PreferredStockConversionsInducements_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="locator"/>
    <label id="id_6038951_1343680_1_1" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Dividends and Other Adjustments</label>
    <label id="id_6038951_1343680_14_1" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Preferred stock purchase option</label>
    <label id="id_6038951_1343680_18_1" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock purchase option (see Note 8)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding" xlink:label="amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding" xlink:type="locator"/>
    <label id="id_6038951_1528905_3_1" xlink:label="amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred stock, equivalent ordinary shares upon future conversion outstanding</label>
    <label id="id_6038951_1528905_1_1" xlink:label="amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Equivalent Ordinary Shares Upon Future Conversion Outstanding</label>
    <label id="id_6038951_1528905_2_1" xlink:label="amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, equivalent ordinary shares upon future consolidation outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding" xlink:to="amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <label id="id_6038951_1325837_1_1" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</label>
    <label id="id_6038951_1325837_2_1" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Shares</label>
    <label id="id_6038951_1325837_12_1" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <label id="id_6038951_1335367_1_1" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <label id="id_6038951_1335367_2_1" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_PreferredStockPurchaseOptionMember" xlink:label="amrn_PreferredStockPurchaseOptionMember" xlink:type="locator"/>
    <label id="id_6038951_1353534_3_1" xlink:label="amrn_PreferredStockPurchaseOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Stock Purchase Option [Member]</label>
    <label id="id_6038951_1353534_1_1" xlink:label="amrn_PreferredStockPurchaseOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Purchase Option [Member]</label>
    <label id="id_6038951_1353534_2_1" xlink:label="amrn_PreferredStockPurchaseOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock Purchase Option</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PreferredStockPurchaseOptionMember" xlink:to="amrn_PreferredStockPurchaseOptionMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <label id="id_6038951_1332188_1_1" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <label id="id_6038951_1332188_2_1" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, issued</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <label id="id_6038951_1325830_1_1" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <label id="id_6038951_1325830_2_1" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <label id="id_6038951_1336848_1_1" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label id="id_6038951_1336848_2_1" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock, &#xA3;0.05 par, unlimited authorized; 328,184,640 shares issued and outstanding as of June 30, 2016 and December 31, 2015 (equivalent to 32,818,464 ordinary shares upon future consolidation and redesignation at a 10:1 ratio)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <label id="id_6038951_1343684_1_1" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label id="id_6038951_1343684_2_1" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid and other current assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_PrivatePlacementClosingDate" xlink:label="amrn_PrivatePlacementClosingDate" xlink:type="locator"/>
    <label id="id_6038951_1511384_3_1" xlink:label="amrn_PrivatePlacementClosingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private Placement Closing Date</label>
    <label id="id_6038951_1511384_1_1" xlink:label="amrn_PrivatePlacementClosingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement Closing Date</label>
    <label id="id_6038951_1511384_2_1" xlink:label="amrn_PrivatePlacementClosingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private placement, closing date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PrivatePlacementClosingDate" xlink:to="amrn_PrivatePlacementClosingDate_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_PrivatePlacementIssuanceNumberOfTranches" xlink:label="amrn_PrivatePlacementIssuanceNumberOfTranches" xlink:type="locator"/>
    <label id="id_6038951_1404100_3_1" xlink:label="amrn_PrivatePlacementIssuanceNumberOfTranches_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private Placement Issuance Number Of Tranches</label>
    <label id="id_6038951_1404100_1_1" xlink:label="amrn_PrivatePlacementIssuanceNumberOfTranches_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement Issuance Number Of Tranches</label>
    <label id="id_6038951_1404100_2_1" xlink:label="amrn_PrivatePlacementIssuanceNumberOfTranches_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of tranches for private placement transaction</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PrivatePlacementIssuanceNumberOfTranches" xlink:to="amrn_PrivatePlacementIssuanceNumberOfTranches_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <label id="id_6038951_1341847_1_1" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Convertible Debt</label>
    <label id="id_6038951_1341847_2_1" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of convertible debt, net of transaction costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator"/>
    <label id="id_6038951_1343719_1_1" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</label>
    <label id="id_6038951_1343719_2_1" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount received at the closing of the agreement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator"/>
    <label id="id_6038951_1341829_1_1" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
    <label id="id_6038951_1341829_2_1" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of preferred stock, net of transaction costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <label id="id_6038951_1341831_1_1" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
    <label id="id_6038951_1341831_2_1" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate gross proceeds</label>
    <label id="id_6038951_1341831_12_1" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued under private placement, net proceeds</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <label id="id_6038951_1343736_1_1" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <label id="id_6038951_1343736_2_1" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options, net of transaction costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <label id="id_6038951_1342792_1_1" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <label id="id_6038951_1342792_2_1" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <label id="id_6038951_1342792_12_1" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants, net of transaction costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_ProceedsFromWarrantExercisesGross" xlink:label="amrn_ProceedsFromWarrantExercisesGross" xlink:type="locator"/>
    <label id="id_6038951_1522591_3_1" xlink:label="amrn_ProceedsFromWarrantExercisesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises Gross</label>
    <label id="id_6038951_1522591_1_1" xlink:label="amrn_ProceedsFromWarrantExercisesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises Gross</label>
    <label id="id_6038951_1522591_2_1" xlink:label="amrn_ProceedsFromWarrantExercisesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants, gross of transaction costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ProceedsFromWarrantExercisesGross" xlink:to="amrn_ProceedsFromWarrantExercisesGross_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator"/>
    <label id="id_6038951_1329107_1_1" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <label id="id_6038951_1329107_2_1" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <label id="id_6038951_1335427_1_1" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <label id="id_6038951_1335427_2_1" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment by Type</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator"/>
    <label id="id_6038951_1329110_1_1" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
    <label id="id_6038951_1329110_2_1" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property Plant and Equipment Useful Life</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator"/>
    <label id="id_6038951_1332242_1_1" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label id="id_6038951_1332242_2_1" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <label id="id_6038951_1340873_1_1" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label id="id_6038951_1340873_2_1" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1335441_1_1" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label id="id_6038951_1335441_2_1" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <label id="id_6038951_1332245_1_1" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <label id="id_6038951_1332245_2_1" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <label id="id_6038951_1332246_1_1" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <label id="id_6038951_1332246_2_1" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property Plant and Equipment Useful Life</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="amrn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1370861_3_1" xlink:label="amrn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life [Table Text Block]</label>
    <label id="id_6038951_1370861_1_1" xlink:label="amrn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life [Table Text Block]</label>
    <label id="id_6038951_1370861_2_1" xlink:label="amrn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Useful Lives</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="amrn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_ProvisionRelatedToPriorPeriodSales" xlink:label="amrn_ProvisionRelatedToPriorPeriodSales" xlink:type="locator"/>
    <label id="id_6038951_1435577_3_1" xlink:label="amrn_ProvisionRelatedToPriorPeriodSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provision Related to Prior Period Sales</label>
    <label id="id_6038951_1435577_1_1" xlink:label="amrn_ProvisionRelatedToPriorPeriodSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision Related to Prior Period Sales</label>
    <label id="id_6038951_1435577_2_1" xlink:label="amrn_ProvisionRelatedToPriorPeriodSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision related to prior period sales</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ProvisionRelatedToPriorPeriodSales" xlink:to="amrn_ProvisionRelatedToPriorPeriodSales_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <label id="id_6038951_1335482_1_1" xlink:label="us-gaap_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</label>
    <label id="id_6038951_1335482_2_1" xlink:label="us-gaap_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <label id="id_6038951_1325933_1_1" xlink:label="us-gaap_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</label>
    <label id="id_6038951_1325933_2_1" xlink:label="us-gaap_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_RangeOfPercentageOfGrossMarginPayableForCoPromotionAgreement" xlink:label="amrn_RangeOfPercentageOfGrossMarginPayableForCoPromotionAgreement" xlink:type="locator"/>
    <label id="id_6038951_1443355_3_1" xlink:label="amrn_RangeOfPercentageOfGrossMarginPayableForCoPromotionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Range of Percentage of Gross Margin Payable for Co-Promotion Agreement</label>
    <label id="id_6038951_1443355_1_1" xlink:label="amrn_RangeOfPercentageOfGrossMarginPayableForCoPromotionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range of Percentage of Gross Margin Payable for Co-Promotion Agreement</label>
    <label id="id_6038951_1443355_2_1" xlink:label="amrn_RangeOfPercentageOfGrossMarginPayableForCoPromotionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Promotion fee as a percentage gross margin</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_RangeOfPercentageOfGrossMarginPayableForCoPromotionAgreement" xlink:to="amrn_RangeOfPercentageOfGrossMarginPayableForCoPromotionAgreement_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_RebatesChargebacksAndDiscountsMember" xlink:label="amrn_RebatesChargebacksAndDiscountsMember" xlink:type="locator"/>
    <label id="id_6038951_1397499_3_1" xlink:label="amrn_RebatesChargebacksAndDiscountsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rebates Chargebacks And Discounts [Member]</label>
    <label id="id_6038951_1397499_1_1" xlink:label="amrn_RebatesChargebacksAndDiscountsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rebates Chargebacks And Discounts [Member]</label>
    <label id="id_6038951_1397499_2_1" xlink:label="amrn_RebatesChargebacksAndDiscountsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebates Chargebacks And Discounts</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_RebatesChargebacksAndDiscountsMember" xlink:to="amrn_RebatesChargebacksAndDiscountsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1332308_1_1" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Policy [Policy Text Block]</label>
    <label id="id_6038951_1332308_2_1" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <label id="id_6038951_1326001_1_1" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</label>
    <label id="id_6038951_1326001_2_1" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator"/>
    <label id="id_6038951_1332351_1_1" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <label id="id_6038951_1332351_2_1" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <label id="id_6038951_1326002_1_1" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</label>
    <label id="id_6038951_1326002_2_1" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions, by Related Party</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:type="locator"/>
    <label id="id_6038951_1339372_1_1" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Convertible Debt</label>
    <label id="id_6038951_1339372_2_1" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, repayment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:type="locator"/>
    <label id="id_6038951_1336804_1_1" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</label>
    <label id="id_6038951_1336804_14_1" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments under capital leases</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <label id="id_6038951_1342850_1_1" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</label>
    <label id="id_6038951_1342850_2_1" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <label id="id_6038951_1332400_1_1" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label id="id_6038951_1332400_2_1" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="us-gaap_RestatementAdjustmentMember" xlink:type="locator"/>
    <label id="id_6038951_1332387_1_1" xlink:label="us-gaap_RestatementAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Adjustment [Member]</label>
    <label id="id_6038951_1332387_2_1" xlink:label="us-gaap_RestatementAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Adjustment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestatementAdjustmentMember" xlink:to="us-gaap_RestatementAdjustmentMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <label id="id_6038951_1342852_1_1" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
    <label id="id_6038951_1342852_2_1" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <label id="id_6038951_1335583_1_1" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <label id="id_6038951_1335583_2_1" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <label id="id_6038951_1336790_1_1" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label id="id_6038951_1336790_2_1" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <label id="id_6038951_1326044_1_1" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</label>
    <label id="id_6038951_1326044_2_1" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1329294_1_1" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label id="id_6038951_1329294_2_1" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <label id="id_6038951_1336776_1_1" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</label>
    <label id="id_6038951_1336776_6_1" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenue, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:type="locator"/>
    <label id="id_6038951_1337610_1_1" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Guarantees, Commitments, Amount</label>
    <label id="id_6038951_1337610_2_1" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential aggregate stock or cash payment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <label id="id_6038951_1326203_1_1" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</label>
    <label id="id_6038951_1326203_2_1" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <label id="id_6038951_1337615_1_1" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net</label>
    <label id="id_6038951_1337615_2_1" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenue, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xlink:type="locator"/>
    <label id="id_6038951_1329312_1_1" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Net [Member]</label>
    <label id="id_6038951_1329312_2_1" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Product Sales</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioAdjustmentMember" xlink:label="us-gaap_ScenarioAdjustmentMember" xlink:type="locator"/>
    <label id="id_6038951_1332467_1_1" xlink:label="us-gaap_ScenarioAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Adjustment [Member]</label>
    <label id="id_6038951_1332467_2_1" xlink:label="us-gaap_ScenarioAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Adjustment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioAdjustmentMember" xlink:to="us-gaap_ScenarioAdjustmentMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <label id="id_6038951_1326102_1_1" xlink:label="us-gaap_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Forecast [Member]</label>
    <label id="id_6038951_1326102_2_1" xlink:label="us-gaap_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Forecast</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioForecastMember" xlink:to="us-gaap_ScenarioForecastMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="us-gaap_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <label id="id_6038951_1335616_1_1" xlink:label="us-gaap_ScenarioPreviouslyReportedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Previously Reported [Member]</label>
    <label id="id_6038951_1335616_2_1" xlink:label="us-gaap_ScenarioPreviouslyReportedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Previously Reported</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioPreviouslyReportedMember" xlink:to="us-gaap_ScenarioPreviouslyReportedMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <label id="id_6038951_1329317_1_1" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <label id="id_6038951_1329317_2_1" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="locator"/>
    <label id="id_6038951_1326103_1_1" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</label>
    <label id="id_6038951_1326103_2_1" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1335617_1_1" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
    <label id="id_6038951_1335617_2_1" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summarizes the Impact of Accounts Receivable Reserves on Gross Trade Accounts Receivable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator"/>
    <label id="id_6038951_1332472_1_1" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <label id="id_6038951_1332472_2_1" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1326109_1_1" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label id="id_6038951_1326109_2_1" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-Dilutive Securities Not Included in the Computation of Net Loss or Earnings per Share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1335632_1_1" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</label>
    <label id="id_6038951_1335632_2_1" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Amounts and Estimated Fair Values of Debt Instruments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1335649_1_1" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</label>
    <label id="id_6038951_1335649_2_1" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value of Derivative Liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1329350_1_1" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label id="id_6038951_1329350_2_1" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss and the Number of Shares Used to Compute Basic and Diluted Net Loss per Share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator"/>
    <label id="id_6038951_1332517_1_1" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <label id="id_6038951_1332517_2_1" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1335671_1_1" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <label id="id_6038951_1335671_2_1" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Value of Intangible Asset</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1329882_1_1" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <label id="id_6038951_1329882_2_1" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
    <label id="id_6038951_1326167_1_1" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <label id="id_6038951_1326167_2_1" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_SecondPrivatePlacementMember" xlink:label="amrn_SecondPrivatePlacementMember" xlink:type="locator"/>
    <label id="id_6038951_1482162_3_1" xlink:label="amrn_SecondPrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Second Private Placement [Member]</label>
    <label id="id_6038951_1482162_1_1" xlink:label="amrn_SecondPrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second Private Placement [Member]</label>
    <label id="id_6038951_1482162_2_1" xlink:label="amrn_SecondPrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second Private Placement</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_SecondPrivatePlacementMember" xlink:to="amrn_SecondPrivatePlacementMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuritiesFinancingTransactionAxis" xlink:label="us-gaap_SecuritiesFinancingTransactionAxis" xlink:type="locator"/>
    <label id="id_6038951_1333110_1_1" xlink:label="us-gaap_SecuritiesFinancingTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Financing Transaction [Axis]</label>
    <label id="id_6038951_1333110_2_1" xlink:label="us-gaap_SecuritiesFinancingTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities Financing Transaction [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuritiesFinancingTransactionAxis" xlink:to="us-gaap_SecuritiesFinancingTransactionAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:type="locator"/>
    <label id="id_6038951_1329954_1_1" xlink:label="us-gaap_SecuritiesFinancingTransactionTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Financing Transaction [Domain]</label>
    <label id="id_6038951_1329954_2_1" xlink:label="us-gaap_SecuritiesFinancingTransactionTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities Financing Transaction [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:to="us-gaap_SecuritiesFinancingTransactionTypeDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:type="locator"/>
    <label id="id_6038951_1326222_1_1" xlink:label="us-gaap_SegmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</label>
    <label id="id_6038951_1326222_2_1" xlink:label="us-gaap_SegmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1333124_1_1" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <label id="id_6038951_1333124_2_1" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment and Geographical Information</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <label id="id_6038951_1341923_1_1" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <label id="id_6038951_1341923_2_1" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1326229_1_1" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</label>
    <label id="id_6038951_1326229_2_1" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="us-gaap_SeniorLongTermNotes" xlink:type="locator"/>
    <label id="id_6038951_1336755_1_1" xlink:label="us-gaap_SeniorLongTermNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes, Noncurrent</label>
    <label id="id_6038951_1336755_2_1" xlink:label="us-gaap_SeniorLongTermNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchangeable senior notes, net of discount</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorLongTermNotes" xlink:to="us-gaap_SeniorLongTermNotes_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorNotes" xlink:label="us-gaap_SeniorNotes" xlink:type="locator"/>
    <label id="id_6038951_1339316_1_1" xlink:label="us-gaap_SeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes</label>
    <label id="id_6038951_1339316_2_1" xlink:label="us-gaap_SeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchangeable senior notes, carrying value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorNotes" xlink:to="us-gaap_SeniorNotes_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_SeniorNotesOneMember" xlink:label="amrn_SeniorNotesOneMember" xlink:type="locator"/>
    <label id="id_6038951_1461424_3_1" xlink:label="amrn_SeniorNotesOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes One [Member]</label>
    <label id="id_6038951_1461424_1_1" xlink:label="amrn_SeniorNotesOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes One [Member]</label>
    <label id="id_6038951_1461424_2_1" xlink:label="amrn_SeniorNotesOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2012 Notes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_SeniorNotesOneMember" xlink:to="amrn_SeniorNotesOneMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_SeniorNotesThreeMember" xlink:label="amrn_SeniorNotesThreeMember" xlink:type="locator"/>
    <label id="id_6038951_1486557_3_1" xlink:label="amrn_SeniorNotesThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Three [Member]</label>
    <label id="id_6038951_1486557_1_1" xlink:label="amrn_SeniorNotesThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Three [Member]</label>
    <label id="id_6038951_1486557_2_1" xlink:label="amrn_SeniorNotesThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 Notes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_SeniorNotesThreeMember" xlink:to="amrn_SeniorNotesThreeMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_SeniorNotesTwoAndThreeMember" xlink:label="amrn_SeniorNotesTwoAndThreeMember" xlink:type="locator"/>
    <label id="id_6038951_1410374_3_1" xlink:label="amrn_SeniorNotesTwoAndThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Two and Three [Member]</label>
    <label id="id_6038951_1410374_1_1" xlink:label="amrn_SeniorNotesTwoAndThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Two and Three [Member]</label>
    <label id="id_6038951_1410374_2_1" xlink:label="amrn_SeniorNotesTwoAndThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2014 Notes and 2015 Notes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_SeniorNotesTwoAndThreeMember" xlink:to="amrn_SeniorNotesTwoAndThreeMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_SeniorNotesTwoMember" xlink:label="amrn_SeniorNotesTwoMember" xlink:type="locator"/>
    <label id="id_6038951_1375482_3_1" xlink:label="amrn_SeniorNotesTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Two [Member]</label>
    <label id="id_6038951_1375482_1_1" xlink:label="amrn_SeniorNotesTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Two [Member]</label>
    <label id="id_6038951_1375482_2_1" xlink:label="amrn_SeniorNotesTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2014 Notes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_SeniorNotesTwoMember" xlink:to="amrn_SeniorNotesTwoMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <label id="id_6038951_1335797_1_1" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <label id="id_6038951_1335797_2_1" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <label id="id_6038951_1340955_1_1" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</label>
    <label id="id_6038951_1340955_2_1" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <label id="id_6038951_1335813_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label id="id_6038951_1335813_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock units, Vesting Period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <label id="id_6038951_1335841_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label id="id_6038951_1335841_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock units, Granted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator"/>
    <label id="id_6038951_1333159_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</label>
    <label id="id_6038951_1333159_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units, outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <label id="id_6038951_1335831_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
    <label id="id_6038951_1335831_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, Granted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <label id="id_6038951_1333167_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label id="id_6038951_1333167_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <label id="id_6038951_1326835_1_1" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</label>
    <label id="id_6038951_1326835_2_1" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_ShareBasedCompensationNet" xlink:label="amrn_ShareBasedCompensationNet" xlink:type="locator"/>
    <label id="id_6038951_1348582_3_1" xlink:label="amrn_ShareBasedCompensationNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based compensation net.</label>
    <label id="id_6038951_1348582_1_1" xlink:label="amrn_ShareBasedCompensationNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Net</label>
    <label id="id_6038951_1348582_2_1" xlink:label="amrn_ShareBasedCompensationNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation income for change in fair value of warrants issued to former employees</label>
    <label id="id_6038951_1348582_12_1" xlink:label="amrn_ShareBasedCompensationNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_ShareBasedCompensationNet" xlink:to="amrn_ShareBasedCompensationNet_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <label id="id_6038951_1330025_1_1" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label id="id_6038951_1330025_2_1" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <label id="id_6038951_1335856_1_1" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</label>
    <label id="id_6038951_1335856_2_1" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market value, per share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <label id="id_6038951_1335859_1_1" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</label>
    <label id="id_6038951_1335859_4_1" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance (in shares)</label>
    <label id="id_6038951_1335859_5_1" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance (in shares)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator"/>
    <label id="id_6038951_1326850_1_1" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Paid for Tax Withholding for Share Based Compensation</label>
    <label id="id_6038951_1326850_2_1" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares for settlement of employee tax obligations</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1333188_1_1" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shipping and Handling Cost, Policy [Policy Text Block]</label>
    <label id="id_6038951_1333188_2_1" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distribution Costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_SignificantAccountingPoliciesLineItems" xlink:label="amrn_SignificantAccountingPoliciesLineItems" xlink:type="locator"/>
    <label id="id_6038951_1401236_3_1" xlink:label="amrn_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <label id="id_6038951_1401236_1_1" xlink:label="amrn_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <label id="id_6038951_1401236_2_1" xlink:label="amrn_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_SignificantAccountingPoliciesLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_SignificantAccountingPoliciesTable" xlink:label="amrn_SignificantAccountingPoliciesTable" xlink:type="locator"/>
    <label id="id_6038951_1391952_3_1" xlink:label="amrn_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <label id="id_6038951_1391952_1_1" xlink:label="amrn_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <label id="id_6038951_1391952_2_1" xlink:label="amrn_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="amrn_SignificantAccountingPoliciesTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1326904_1_1" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label id="id_6038951_1326904_2_1" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator"/>
    <label id="id_6038951_1333242_1_1" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</label>
    <label id="id_6038951_1333242_2_1" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <label id="id_6038951_1330096_1_1" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</label>
    <label id="id_6038951_1330096_2_1" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <label id="id_6038951_1330097_1_1" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</label>
    <label id="id_6038951_1330097_2_1" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement, Equity Components</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <label id="id_6038951_1330099_1_1" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</label>
    <label id="id_6038951_1330099_2_1" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <label id="id_6038951_1326913_1_1" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label id="id_6038951_1326913_2_1" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <label id="id_6038951_1333243_1_1" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <label id="id_6038951_1333243_2_1" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <label id="id_6038951_1330100_1_1" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
    <label id="id_6038951_1330100_2_1" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <label id="id_6038951_1333245_1_1" xlink:label="us-gaap_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</label>
    <label id="id_6038951_1333245_2_1" xlink:label="us-gaap_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement, Scenario</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <label id="id_6038951_1335914_1_1" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</label>
    <label id="id_6038951_1335914_2_1" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <label id="id_6038951_1337582_1_1" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label id="id_6038951_1337582_4_1" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</label>
    <label id="id_6038951_1337582_5_1" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</label>
    <label id="id_6038951_1337582_6_1" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' deficit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <label id="id_6038951_1333273_1_1" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label id="id_6038951_1333273_2_1" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Deficit:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1333259_1_1" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label id="id_6038951_1333259_2_1" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_StockholdersEquityNoteLineItems" xlink:label="amrn_StockholdersEquityNoteLineItems" xlink:type="locator"/>
    <label id="id_6038951_1350133_3_1" xlink:label="amrn_StockholdersEquityNoteLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stockholders Equity Note [Line Items]</label>
    <label id="id_6038951_1350133_1_1" xlink:label="amrn_StockholdersEquityNoteLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders Equity Note [Line Items]</label>
    <label id="id_6038951_1350133_2_1" xlink:label="amrn_StockholdersEquityNoteLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders Equity Note [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_StockholdersEquityNoteLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_StockholdersEquityNoteTable" xlink:label="amrn_StockholdersEquityNoteTable" xlink:type="locator"/>
    <label id="id_6038951_1443037_3_1" xlink:label="amrn_StockholdersEquityNoteTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stockholders Equity Note [Table]</label>
    <label id="id_6038951_1443037_1_1" xlink:label="amrn_StockholdersEquityNoteTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders Equity Note [Table]</label>
    <label id="id_6038951_1443037_2_1" xlink:label="amrn_StockholdersEquityNoteTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders Equity Note [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="amrn_StockholdersEquityNoteTable_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_StockIncentivePlanTwentyElevenMember" xlink:label="amrn_StockIncentivePlanTwentyElevenMember" xlink:type="locator"/>
    <label id="id_6038951_1405848_3_1" xlink:label="amrn_StockIncentivePlanTwentyElevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan 2011 [Member]</label>
    <label id="id_6038951_1405848_1_1" xlink:label="amrn_StockIncentivePlanTwentyElevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan 2011 [Member]</label>
    <label id="id_6038951_1405848_2_1" xlink:label="amrn_StockIncentivePlanTwentyElevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan 2011</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_StockIncentivePlanTwentyElevenMember" xlink:to="amrn_StockIncentivePlanTwentyElevenMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <label id="id_6038951_1330107_1_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label id="id_6038951_1330107_2_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <label id="id_6038951_1335930_1_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label id="id_6038951_1335930_2_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued under private placement, shares</label>
    <label id="id_6038951_1335930_12_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock issued under private placement, shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <label id="id_6038951_1330109_1_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
    <label id="id_6038951_1330109_2_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted stock units (in shares)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator"/>
    <label id="id_6038951_1333268_1_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</label>
    <label id="id_6038951_1333268_2_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued, related to the vesting of RSUs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <label id="id_6038951_1333270_1_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label id="id_6038951_1333270_2_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</label>
    <label id="id_6038951_1333270_12_1" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issued, exercise of stock options</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:type="locator"/>
    <label id="id_6038951_1354077_3_1" xlink:label="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares issued during the period as a result of the exercise of warrants.</label>
    <label id="id_6038951_1354077_1_1" xlink:label="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</label>
    <label id="id_6038951_1354077_2_1" xlink:label="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued, exercise of warrants</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <label id="id_6038951_1339288_1_1" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label id="id_6038951_1339288_2_1" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued under private placement, value</label>
    <label id="id_6038951_1339288_12_1" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock issued under private placement, value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <label id="id_6038951_1336728_1_1" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</label>
    <label id="id_6038951_1336728_2_1" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted stock units</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <label id="id_6038951_1339284_1_1" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label id="id_6038951_1339284_2_1" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" xlink:type="locator"/>
    <label id="id_6038951_1330112_1_1" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</label>
    <label id="id_6038951_1330112_2_1" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:type="locator"/>
    <label id="id_6038951_1330135_1_1" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <label id="id_6038951_1330135_2_1" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1335954_1_1" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label id="id_6038951_1335954_2_1" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <label id="id_6038951_1330125_1_1" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</label>
    <label id="id_6038951_1330125_2_1" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_SummaryOfNetProductRevenueValuationAllowancesTableTextBlock" xlink:label="amrn_SummaryOfNetProductRevenueValuationAllowancesTableTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1516433_3_1" xlink:label="amrn_SummaryOfNetProductRevenueValuationAllowancesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of Net Product Revenue Valuation Allowances [Table Text Block]</label>
    <label id="id_6038951_1516433_1_1" xlink:label="amrn_SummaryOfNetProductRevenueValuationAllowancesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Net Product Revenue Valuation Allowances [Table Text Block]</label>
    <label id="id_6038951_1516433_2_1" xlink:label="amrn_SummaryOfNetProductRevenueValuationAllowancesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summarize Activity of the Net Product Revenue Allowance and Reserve Categories</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_SummaryOfNetProductRevenueValuationAllowancesTableTextBlock" xlink:to="amrn_SummaryOfNetProductRevenueValuationAllowancesTableTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <label id="id_6038951_1333299_1_1" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label id="id_6038951_1333299_2_1" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract" xlink:type="locator"/>
    <label id="id_6038951_1336003_1_1" xlink:label="us-gaap_TextBlockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Text Block [Abstract]</label>
    <label id="id_6038951_1336003_2_1" xlink:label="us-gaap_TextBlockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Text Block [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <label id="id_6038951_1330194_1_1" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</label>
    <label id="id_6038951_1330194_2_1" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <label id="id_6038951_1330195_1_1" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</label>
    <label id="id_6038951_1330195_2_1" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_TopThreeCustomerMember" xlink:label="amrn_TopThreeCustomerMember" xlink:type="locator"/>
    <label id="id_6038951_1501282_3_1" xlink:label="amrn_TopThreeCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Top 3 Customer [Member]</label>
    <label id="id_6038951_1501282_1_1" xlink:label="amrn_TopThreeCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top 3 Customer [Member]</label>
    <label id="id_6038951_1501282_2_1" xlink:label="amrn_TopThreeCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Top Three Customers</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_TopThreeCustomerMember" xlink:to="amrn_TopThreeCustomerMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <label id="id_6038951_1327017_1_1" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</label>
    <label id="id_6038951_1327017_2_1" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" xlink:type="locator"/>
    <label id="id_6038951_1330220_1_1" xlink:label="us-gaap_TreasuryStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</label>
    <label id="id_6038951_1330220_2_1" xlink:label="us-gaap_TreasuryStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" xlink:type="locator"/>
    <label id="id_6038951_1327050_1_1" xlink:label="us-gaap_TreasuryStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares</label>
    <label id="id_6038951_1327050_2_1" xlink:label="us-gaap_TreasuryStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" xlink:type="locator"/>
    <label id="id_6038951_1343912_1_1" xlink:label="us-gaap_TreasuryStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</label>
    <label id="id_6038951_1343912_14_1" xlink:label="us-gaap_TreasuryStockValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock; 723,347 shares as of June 30, 2016; 174,502 shares as of December 31, 2015</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xlink:type="locator"/>
    <label id="id_6038951_1336059_1_1" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</label>
    <label id="id_6038951_1336059_2_1" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <label id="id_6038951_1327036_1_1" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <label id="id_6038951_1327036_2_1" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="locator"/>
    <label id="id_6038951_1341005_1_1" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unamortized Debt Issuance Expense</label>
    <label id="id_6038951_1341005_2_1" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt issuance cost</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="locator"/>
    <label id="id_6038951_1339233_1_1" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</label>
    <label id="id_6038951_1339233_2_1" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on change in fair value of derivative liabilities</label>
    <label id="id_6038951_1339233_12_1" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on change in fair value of derivative liability</label>
    <label id="id_6038951_1339233_14_1" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on change in fair value of derivative liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <label id="id_6038951_1333430_1_1" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label id="id_6038951_1333430_2_1" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_UseOfForecastedFinancialInformationInAccountingEstimatesPolicyTextBlock" xlink:label="amrn_UseOfForecastedFinancialInformationInAccountingEstimatesPolicyTextBlock" xlink:type="locator"/>
    <label id="id_6038951_1489710_3_1" xlink:label="amrn_UseOfForecastedFinancialInformationInAccountingEstimatesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Use of Forecasted Financial Information in Accounting Estimates [Policy Text Block]</label>
    <label id="id_6038951_1489710_1_1" xlink:label="amrn_UseOfForecastedFinancialInformationInAccountingEstimatesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Forecasted Financial Information in Accounting Estimates [Policy Text Block]</label>
    <label id="id_6038951_1489710_2_1" xlink:label="amrn_UseOfForecastedFinancialInformationInAccountingEstimatesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Forecasted Financial Information in Accounting Estimates</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_UseOfForecastedFinancialInformationInAccountingEstimatesPolicyTextBlock" xlink:to="amrn_UseOfForecastedFinancialInformationInAccountingEstimatesPolicyTextBlock_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="locator"/>
    <label id="id_6038951_1338355_1_1" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves, Balance</label>
    <label id="id_6038951_1338355_4_1" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</label>
    <label id="id_6038951_1338355_5_1" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</label>
    <label id="id_6038951_1338355_14_1" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowances and reserves</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="locator"/>
    <label id="id_6038951_1336677_1_1" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves, Additions for Charges to Cost and Expense</label>
    <label id="id_6038951_1336677_2_1" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision related to current period sales</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="locator"/>
    <label id="id_6038951_1341971_1_1" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves, Deductions</label>
    <label id="id_6038951_1341971_14_1" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Credits/payments made for current period sales</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator"/>
    <label id="id_6038951_1330323_1_1" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</label>
    <label id="id_6038951_1330323_2_1" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator"/>
    <label id="id_6038951_1327091_1_1" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</label>
    <label id="id_6038951_1327091_2_1" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsAbstract" xlink:label="us-gaap_ValuationAndQualifyingAccountsAbstract" xlink:type="locator"/>
    <label id="id_6038951_1330325_1_1" xlink:label="us-gaap_ValuationAndQualifyingAccountsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts [Abstract]</label>
    <label id="id_6038951_1330325_2_1" xlink:label="us-gaap_ValuationAndQualifyingAccountsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAndQualifyingAccountsAbstract" xlink:to="us-gaap_ValuationAndQualifyingAccountsAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="locator"/>
    <label id="id_6038951_1333445_1_1" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</label>
    <label id="id_6038951_1333445_2_1" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="locator"/>
    <label id="id_6038951_1327093_1_1" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</label>
    <label id="id_6038951_1327093_2_1" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ValuationAndQualifyingAccountsDisclosureTable_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <label id="id_6038951_1336123_1_1" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</label>
    <label id="id_6038951_1336123_2_1" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <label id="id_6038951_1336124_1_1" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</label>
    <label id="id_6038951_1336124_2_1" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_VestingPeriodFourMember" xlink:label="amrn_VestingPeriodFourMember" xlink:type="locator"/>
    <label id="id_6038951_1425353_3_1" xlink:label="amrn_VestingPeriodFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Period Four [Member]</label>
    <label id="id_6038951_1425353_1_1" xlink:label="amrn_VestingPeriodFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Period Four [Member]</label>
    <label id="id_6038951_1425353_2_1" xlink:label="amrn_VestingPeriodFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vest upon the achievement of certain performance conditions</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_VestingPeriodFourMember" xlink:to="amrn_VestingPeriodFourMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_VestingPeriodOneMember" xlink:label="amrn_VestingPeriodOneMember" xlink:type="locator"/>
    <label id="id_6038951_1454011_3_1" xlink:label="amrn_VestingPeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Period One [Member]</label>
    <label id="id_6038951_1454011_1_1" xlink:label="amrn_VestingPeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Period One [Member]</label>
    <label id="id_6038951_1454011_2_1" xlink:label="amrn_VestingPeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vest in equal installments over a three year period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_VestingPeriodOneMember" xlink:to="amrn_VestingPeriodOneMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_VestingPeriodThreeMember" xlink:label="amrn_VestingPeriodThreeMember" xlink:type="locator"/>
    <label id="id_6038951_1429469_3_1" xlink:label="amrn_VestingPeriodThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Period Three [Member]</label>
    <label id="id_6038951_1429469_1_1" xlink:label="amrn_VestingPeriodThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Period Three [Member]</label>
    <label id="id_6038951_1429469_2_1" xlink:label="amrn_VestingPeriodThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vest over a four year period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_VestingPeriodThreeMember" xlink:to="amrn_VestingPeriodThreeMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_VestingPeriodTwoMember" xlink:label="amrn_VestingPeriodTwoMember" xlink:type="locator"/>
    <label id="id_6038951_1487759_3_1" xlink:label="amrn_VestingPeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Period Two [Member]</label>
    <label id="id_6038951_1487759_1_1" xlink:label="amrn_VestingPeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Period Two [Member]</label>
    <label id="id_6038951_1487759_2_1" xlink:label="amrn_VestingPeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vest in full</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_VestingPeriodTwoMember" xlink:to="amrn_VestingPeriodTwoMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <label id="id_6038951_1336129_1_1" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</label>
    <label id="id_6038951_1336129_2_1" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_WarrantsIssuedOctoberTwentyZeroNineMember" xlink:label="amrn_WarrantsIssuedOctoberTwentyZeroNineMember" xlink:type="locator"/>
    <label id="id_6038951_1451741_3_1" xlink:label="amrn_WarrantsIssuedOctoberTwentyZeroNineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Issued October 2009 [Member]</label>
    <label id="id_6038951_1451741_1_1" xlink:label="amrn_WarrantsIssuedOctoberTwentyZeroNineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued October 2009 [Member]</label>
    <label id="id_6038951_1451741_2_1" xlink:label="amrn_WarrantsIssuedOctoberTwentyZeroNineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Issued October 2009</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_WarrantsIssuedOctoberTwentyZeroNineMember" xlink:to="amrn_WarrantsIssuedOctoberTwentyZeroNineMember_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <label id="id_6038951_1327121_1_1" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label id="id_6038951_1327121_2_1" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <label id="id_6038951_1330297_1_1" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label id="id_6038951_1330297_2_1" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding-basic and diluted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator"/>
    <label id="id_6038951_1336137_1_1" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <label id="id_6038951_1336137_2_1" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <label id="id_6038951_1327124_1_1" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label id="id_6038951_1327124_2_1" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc"/>
    <loc xlink:href="amrn-20160630.xsd#amrn_WriteOffsOfAccountsReceivables" xlink:label="amrn_WriteOffsOfAccountsReceivables" xlink:type="locator"/>
    <label id="id_6038951_1405734_3_1" xlink:label="amrn_WriteOffsOfAccountsReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Write Offs Of Accounts Receivables</label>
    <label id="id_6038951_1405734_1_1" xlink:label="amrn_WriteOffsOfAccountsReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Write Offs Of Accounts Receivables</label>
    <label id="id_6038951_1405734_2_1" xlink:label="amrn_WriteOffsOfAccountsReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable written off</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amrn_WriteOffsOfAccountsReceivables" xlink:to="amrn_WriteOffsOfAccountsReceivables_lbl" xlink:type="arc"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>amrn-20160630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Presentation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 3 -->
<!-- Creation date: 2016-08-03T22:03:39Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DocumentandEntityInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.amarincorp.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureSummarizesActivityOfTheNetProductRevenueAllowanceAndReserveCategories" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureSummarizesActivityOfTheNetProductRevenueAllowanceAndReserveCategories"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureSummarizesTheImpactOfAccountsReceivableReservesOnGrossTradeAccountsReceivable" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureSummarizesTheImpactOfAccountsReceivableReservesOnGrossTradeAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureEstimatedUsefulLives" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureEstimatedUsefulLives"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureNetLossAndTheNumberOfSharesUsedToComputeBasicAndDilutedLossPerShare" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureNetLossAndTheNumberOfSharesUsedToComputeBasicAndDilutedLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureAntiDilutiveSecuritiesNotIncludedInTheComputationOfNetLossPerShare" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureAntiDilutiveSecuritiesNotIncludedInTheComputationOfNetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureAssetsAndLiabilityMeasuredAtFairValueOnRecurringBasis" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureAssetsAndLiabilityMeasuredAtFairValueOnRecurringBasis"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureCarryingAmountsAndEstimatedFairValuesOfDebtInstruments" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureCarryingAmountsAndEstimatedFairValuesOfDebtInstruments"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureChangeInFairValueOfDerivativeLiabilities" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureChangeInFairValueOfDerivativeLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureIntangibleAssetsAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureIntangibleAssets" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureIntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureInventory" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureInventory"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureWarrantsAndWarrantDerivativeLiabilityAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureWarrantsAndWarrantDerivativeLiabilityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureDebtAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureDebtAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureEquityAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureCoPromotionAgreementAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureCoPromotionAgreementAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#DisclosureDevelopmentCommercializationAndSupplyAgreementAdditionalInformation" roleURI="http://www.amarincorp.com/taxonomy/role/DisclosureDevelopmentCommercializationAndSupplyAgreementAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlockTables" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsCoPromotionAgreementDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCoPromotionAgreementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="amrn-20160630.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_AmericanDepositorySharesMember" xlink:label="amrn_AmericanDepositorySharesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_DocumentAndEntityInformationAbstract" xlink:label="amrn_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_OrdinarySharesMember" xlink:label="amrn_OrdinarySharesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amrn_OrdinarySharesMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amrn_AmericanDepositorySharesMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassified" xlink:title="104000 - Statement - Statement of Financial Position, Classified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="us-gaap_DeferredTaxAssetsNetNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="us-gaap_SeniorLongTermNotes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetNoncurrent" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_SeniorLongTermNotes" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="1.1900" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding" xlink:label="amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockShares" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfIncomeAlternative" xlink:title="124100 - Statement - Statement of Income">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockConversionsInducements" xlink:label="us-gaap_PreferredStockConversionsInducements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfGoodsSold" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" order="1.1700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConversionsInducements" order="1.1800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_AccountingStandardsUpdate201609Member" xlink:label="amrn_AccountingStandardsUpdate201609Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:label="us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="us-gaap_ScenarioPreviouslyReportedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPreviouslyReportedMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_2" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_2" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="amrn_AccountingStandardsUpdate201609Member" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/StatementOfCashFlowsIndirect" xlink:title="152200 - Statement - Statement of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_CashPaidDuringPeriodForAbstract" xlink:label="amrn_CashPaidDuringPeriodForAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_DerivativeLiabilitiesTransferredToEquityClassifications" xlink:label="amrn_DerivativeLiabilitiesTransferredToEquityClassifications"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockConversionsInducements" xlink:label="us-gaap_PreferredStockConversionsInducements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ShareBasedCompensationNet" xlink:label="amrn_ShareBasedCompensationNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1.1600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="amrn_ShareBasedCompensationNet" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="1.2100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="amrn_DerivativeLiabilitiesTransferredToEquityClassifications" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_PreferredStockConversionsInducements" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CashPaidDuringPeriodForAbstract" xlink:to="us-gaap_InterestPaid" order="1.4300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CashPaidDuringPeriodForAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.4400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.2300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.2400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.2500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1.2600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_WarrantMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="1.4000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="1.4100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.3500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="amrn_CashPaidDuringPeriodForAbstract" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_CoPromotionAgreementMember" xlink:label="amrn_CoPromotionAgreementMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_DateOneMember" xlink:label="amrn_DateOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_DateThreeMember" xlink:label="amrn_DateThreeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_DateTwoMember" xlink:label="amrn_DateTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCallDateEarliest" xlink:label="us-gaap_DebtInstrumentCallDateEarliest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentCallDateLatest" xlink:label="us-gaap_DebtInstrumentCallDateLatest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_KowaPharmaceuticalsAmericaMember" xlink:label="amrn_KowaPharmaceuticalsAmericaMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_NumberOfPatientsEnrolledInStudy" xlink:label="amrn_NumberOfPatientsEnrolledInStudy"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_NumberOfSalesProfessionals" xlink:label="amrn_NumberOfSalesProfessionals"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_NumberOfSalesRepresentative" xlink:label="amrn_NumberOfSalesRepresentative"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesOneMember" xlink:label="amrn_SeniorNotesOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesThreeMember" xlink:label="amrn_SeniorNotesThreeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesTwoMember" xlink:label="amrn_SeniorNotesTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="amrn_CoPromotionAgreementMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesOneMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesTwoMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesThreeMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_DateOneMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_DateTwoMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_DateThreeMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="amrn_KowaPharmaceuticalsAmericaMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="amrn_NumberOfSalesProfessionals" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="amrn_NumberOfSalesRepresentative" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="amrn_NumberOfPatientsEnrolledInStudy" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentCallDateEarliest" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentCallDateLatest" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_AssetsCurrent" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ConvertibleDebt" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_DebtInstrumentAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="dei_LegalEntityAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_RangeAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingStandardsUpdate201503Member" xlink:label="us-gaap_AccountingStandardsUpdate201503Member"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_AccountingStandardsUpdate201609Member" xlink:label="amrn_AccountingStandardsUpdate201609Member"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_AccountsReceivableCreditPeriod" xlink:label="amrn_AccountsReceivableCreditPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_BiopharmaceuticalMember" xlink:label="amrn_BiopharmaceuticalMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_CashDiscountInvoiceTerms" xlink:label="amrn_CashDiscountInvoiceTerms"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_CashDiscountPercent" xlink:label="amrn_CashDiscountPercent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ClassOfWarrantOrRightExercisedInPeriod" xlink:label="amrn_ClassOfWarrantOrRightExercisedInPeriod"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ClassOfWarrantOrRightExpiredInPeriod" xlink:label="amrn_ClassOfWarrantOrRightExpiredInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities" xlink:label="amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationOperatingActivities" xlink:label="amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_FairValueAssumptionsComparableYieldToMaturity" xlink:label="amrn_FairValueAssumptionsComparableYieldToMaturity"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_FairValueAssumptionsCouponRate" xlink:label="amrn_FairValueAssumptionsCouponRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_NonCashMember" xlink:label="amrn_NonCashMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PreferredStockPurchaseOptionMember" xlink:label="amrn_PreferredStockPurchaseOptionMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PrivatePlacementIssuanceNumberOfTranches" xlink:label="amrn_PrivatePlacementIssuanceNumberOfTranches"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="us-gaap_RestatementAdjustmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioAdjustmentMember" xlink:label="us-gaap_ScenarioAdjustmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="us-gaap_ScenarioPreviouslyReportedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesOneMember" xlink:label="amrn_SeniorNotesOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesThreeMember" xlink:label="amrn_SeniorNotesThreeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesTwoAndThreeMember" xlink:label="amrn_SeniorNotesTwoAndThreeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesTwoMember" xlink:label="amrn_SeniorNotesTwoMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SignificantAccountingPoliciesLineItems" xlink:label="amrn_SignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SignificantAccountingPoliciesTable" xlink:label="amrn_SignificantAccountingPoliciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_TopThreeCustomerMember" xlink:label="amrn_TopThreeCustomerMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_WarrantsIssuedOctoberTwentyZeroNineMember" xlink:label="amrn_WarrantsIssuedOctoberTwentyZeroNineMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_WriteOffsOfAccountsReceivables" xlink:label="amrn_WriteOffsOfAccountsReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="amrn_SignificantAccountingPoliciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amrn_WarrantsIssuedOctoberTwentyZeroNineMember" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesTwoMember" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesThreeMember" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesTwoAndThreeMember" order="1.4700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesOneMember" order="1.4900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="amrn_PreferredStockPurchaseOptionMember" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" order="1.4400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="amrn_TopThreeCustomerMember" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.4500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioAdjustmentMember" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_NonCashMember" order="1.4300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPreviouslyReportedMember" order="1.4600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_RestatementAdjustmentMember" order="1.4800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="amrn_BiopharmaceuticalMember" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_CashDiscountPercent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_CashDiscountInvoiceTerms" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_AccountsReceivableCreditPeriod" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_PrivatePlacementIssuanceNumberOfTranches" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationOperatingActivities" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_WriteOffsOfAccountsReceivables" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_ClassOfWarrantOrRightExercisedInPeriod" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_ClassOfWarrantOrRightExpiredInPeriod" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherCommitment" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_FairValueAssumptionsCouponRate" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="amrn_FairValueAssumptionsComparableYieldToMaturity" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_RangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementScenarioAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" order="16.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_MajorCustomersAxis" order="17.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="18.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="19.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="20.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="21.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_SignificantAccountingPoliciesTable" xlink:to="amrn_SignificantAccountingPoliciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201503Member" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="amrn_AccountingStandardsUpdate201609Member" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureSummarizesActivityOfTheNetProductRevenueAllowanceAndReserveCategories">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForSalesReturnsMember" xlink:label="us-gaap_AllowanceForSalesReturnsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForTradeReceivablesMember" xlink:label="us-gaap_AllowanceForTradeReceivablesMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_CreditsPaymentsMadeForPriorPeriodSales" xlink:label="amrn_CreditsPaymentsMadeForPriorPeriodSales"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_OtherIncentiveProgramsMember" xlink:label="amrn_OtherIncentiveProgramsMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ProvisionRelatedToPriorPeriodSales" xlink:label="amrn_ProvisionRelatedToPriorPeriodSales"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_RebatesChargebacksAndDiscountsMember" xlink:label="amrn_RebatesChargebacksAndDiscountsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsAbstract" xlink:label="us-gaap_ValuationAndQualifyingAccountsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_AllowanceForTradeReceivablesMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="amrn_RebatesChargebacksAndDiscountsMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_AllowanceForSalesReturnsMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="amrn_OtherIncentiveProgramsMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsAbstract" xlink:to="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="amrn_ProvisionRelatedToPriorPeriodSales" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="amrn_CreditsPaymentsMadeForPriorPeriodSales" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance_2" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="dei_LegalEntityAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureSummarizesTheImpactOfAccountsReceivableReservesOnGrossTradeAccountsReceivable">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_AllowanceForEstimatedChargebacksMember" xlink:label="amrn_AllowanceForEstimatedChargebacksMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForTradeReceivablesMember" xlink:label="us-gaap_AllowanceForTradeReceivablesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="dei_LegalEntityAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_AllowanceForTradeReceivablesMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="amrn_AllowanceForEstimatedChargebacksMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureEstimatedUsefulLives">
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ComputerEquipmentAndCapitalizedSoftwareMember" xlink:label="amrn_ComputerEquipmentAndCapitalizedSoftwareMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="amrn_ComputerEquipmentAndCapitalizedSoftwareMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureNetLossAndTheNumberOfSharesUsedToComputeBasicAndDilutedLossPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_EarningsLossPerShareLineItems" xlink:label="amrn_EarningsLossPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_EarningsLossPerShareTable" xlink:label="amrn_EarningsLossPerShareTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockConversionsInducements" xlink:label="us-gaap_PreferredStockConversionsInducements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_EarningsLossPerShareLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_EarningsLossPerShareTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_EarningsLossPerShareTable" xlink:to="amrn_EarningsLossPerShareLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_PreferredStockConversionsInducements" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="amrn_EarningsLossPerShareTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureAntiDilutiveSecuritiesNotIncludedInTheComputationOfNetLossPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_PreferredStockMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureAssetsAndLiabilityMeasuredAtFairValueOnRecurringBasis">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="dei_LegalEntityAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureCarryingAmountsAndEstimatedFairValuesOfDebtInstruments">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorNotes" xlink:label="us-gaap_SeniorNotes"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesOneMember" xlink:label="amrn_SeniorNotesOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesThreeMember" xlink:label="amrn_SeniorNotesThreeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesTwoMember" xlink:label="amrn_SeniorNotesTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SeniorNotes" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtFairValue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesOneMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesTwoMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesThreeMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="dei_LegalEntityAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureChangeInFairValueOfDerivativeLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities_2"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_DerivativeLiabilitiesTransferredToStockholdersEquity" xlink:label="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="us-gaap_DerivativesFairValueLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PreferredStockPurchaseOptionMember" xlink:label="amrn_PreferredStockPurchaseOptionMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ShareBasedCompensationNet" xlink:label="amrn_ShareBasedCompensationNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_WarrantsIssuedOctoberTwentyZeroNineMember" xlink:label="amrn_WarrantsIssuedOctoberTwentyZeroNineMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="amrn_WarrantsIssuedOctoberTwentyZeroNineMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="amrn_PreferredStockPurchaseOptionMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="amrn_ShareBasedCompensationNet" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_DerivativeLiabilities_2" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="us-gaap_InvestmentTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="us-gaap_DerivativesFairValueLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_WarrantMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureIntangibleAssets">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureInventory">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryCurrentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryNet" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureWarrantsAndWarrantDerivativeLiabilityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_AmericanDepositaryShareMember" xlink:label="amrn_AmericanDepositaryShareMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_AmericanDepositorySharesToSharesRatio" xlink:label="amrn_AmericanDepositorySharesToSharesRatio"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="us-gaap_BridgeLoanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ClassOfWarrantOrRightExercisedInPeriod" xlink:label="amrn_ClassOfWarrantOrRightExercisedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ClassOfWarrantOrRightExpiredInPeriod" xlink:label="amrn_ClassOfWarrantOrRightExpiredInPeriod"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ClassOfWarrantOrRightIssued" xlink:label="amrn_ClassOfWarrantOrRightIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ClassOfWarrantOrRightTerm" xlink:label="amrn_ClassOfWarrantOrRightTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="us-gaap_DerivativeLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeTable" xlink:label="us-gaap_DerivativeTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeDescriptionOfHostContract" xlink:label="us-gaap_EmbeddedDerivativeDescriptionOfHostContract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EnergyAxis" xlink:label="us-gaap_EnergyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EnergyDomain" xlink:label="us-gaap_EnergyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_EquityIssuancePerShareAmount1" xlink:label="amrn_EquityIssuancePerShareAmount1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_OctoberTwentyZeroNinePrivatePlacementMember" xlink:label="amrn_OctoberTwentyZeroNinePrivatePlacementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficerMember" xlink:label="us-gaap_OfficerMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_WarrantsIssuedOctoberTwentyZeroNineMember" xlink:label="amrn_WarrantsIssuedOctoberTwentyZeroNineMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="amrn_WarrantsIssuedOctoberTwentyZeroNineMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="amrn_AmericanDepositorySharesToSharesRatio" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="amrn_EquityIssuancePerShareAmount1" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="amrn_ClassOfWarrantOrRightTerm" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="amrn_ClassOfWarrantOrRightIssued" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_EmbeddedDerivativeDescriptionOfHostContract" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="amrn_ClassOfWarrantOrRightExercisedInPeriod" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLineItems" xlink:to="amrn_ClassOfWarrantOrRightExpiredInPeriod" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable" xlink:to="dei_LegalEntityAxis" order="3.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_EnergyAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_RangeAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeTable" xlink:to="us-gaap_DerivativeLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EnergyAxis" xlink:to="us-gaap_EnergyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EnergyDomain" xlink:to="amrn_AmericanDepositaryShareMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_BridgeLoanMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_OfficerMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="amrn_OctoberTwentyZeroNinePrivatePlacementMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureDebtAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingStandardsUpdate201503Member" xlink:label="us-gaap_AccountingStandardsUpdate201503Member"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_AdditionalPercentageInterestRatePenalty" xlink:label="amrn_AdditionalPercentageInterestRatePenalty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_AmericanDepositorySharesMember" xlink:label="amrn_AmericanDepositorySharesMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_BeneficialOwnershipLimitationPercentage" xlink:label="amrn_BeneficialOwnershipLimitationPercentage"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_BiopharmaceuticalMember" xlink:label="amrn_BiopharmaceuticalMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ChargesCashMember" xlink:label="amrn_ChargesCashMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_DebtDisclosureLineItems" xlink:label="amrn_DebtDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_DebtDisclosureTable" xlink:label="amrn_DebtDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_DebtExchangeMember" xlink:label="amrn_DebtExchangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_DebtInstrumentMaturityDateYear" xlink:label="amrn_DebtInstrumentMaturityDateYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodEndDate" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ExcessPrincipalValueOverFairValue" xlink:label="amrn_ExcessPrincipalValueOverFairValue"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_FinanceMember" xlink:label="amrn_FinanceMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_FutureMinimumGuaranteePayments" xlink:label="amrn_FutureMinimumGuaranteePayments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_GuaranteePayments" xlink:label="amrn_GuaranteePayments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_NonCashMember" xlink:label="amrn_NonCashMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_OtherDebtObligationsMember" xlink:label="amrn_OtherDebtObligationsMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PeriodAxis" xlink:label="amrn_PeriodAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PeriodDomain" xlink:label="amrn_PeriodDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PeriodOneMember" xlink:label="amrn_PeriodOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PeriodThreeMember" xlink:label="amrn_PeriodThreeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PeriodTwoMember" xlink:label="amrn_PeriodTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuritiesFinancingTransactionAxis" xlink:label="us-gaap_SecuritiesFinancingTransactionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:label="us-gaap_SecuritiesFinancingTransactionTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="us-gaap_SeniorLongTermNotes"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesOneMember" xlink:label="amrn_SeniorNotesOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesThreeMember" xlink:label="amrn_SeniorNotesThreeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SeniorNotesTwoMember" xlink:label="amrn_SeniorNotesTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amrn_AmericanDepositorySharesMember" order="1.4800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="amrn_DebtExchangeMember" order="1.5000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="amrn_DebtDisclosureTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_OtherCommitment" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_GuaranteePayments" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_FutureMinimumGuaranteePayments" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_ConvertibleDebt" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_DebtInstrumentMaturityDateYear" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_ExcessPrincipalValueOverFairValue" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_AdditionalPercentageInterestRatePenalty" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_LongTermDebtCurrent" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodEndDate" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" order="1.3100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_SeniorLongTermNotes" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="amrn_BeneficialOwnershipLimitationPercentage" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_DebtInstrumentRepurchasedFaceAmount" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_InterestPayableCurrent" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureLineItems" xlink:to="us-gaap_InterestPaid" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureTable" xlink:to="amrn_PeriodAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_StatementScenarioAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_DebtInstrumentAxis" order="16.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_RangeAxis" order="17.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" order="18.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="19.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureTable" xlink:to="dei_LegalEntityAxis" order="20.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureTable" xlink:to="us-gaap_SecuritiesFinancingTransactionAxis" order="21.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_DebtDisclosureTable" xlink:to="amrn_DebtDisclosureLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesOneMember" order="1.4600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesTwoMember" order="1.5600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="amrn_SeniorNotesThreeMember" order="1.5900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="1.4700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="amrn_OtherDebtObligationsMember" order="1.4900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_PeriodAxis" xlink:to="amrn_PeriodDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_PeriodDomain" xlink:to="amrn_PeriodOneMember" order="1.4400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_PeriodDomain" xlink:to="amrn_PeriodTwoMember" order="1.5400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_PeriodDomain" xlink:to="amrn_PeriodThreeMember" order="1.5800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.5100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.5700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_ChargesCashMember" order="1.4500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_NonCashMember" order="1.5500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SecuritiesFinancingTransactionAxis" xlink:to="us-gaap_SecuritiesFinancingTransactionTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SecuritiesFinancingTransactionTypeDomain" xlink:to="amrn_FinanceMember" order="1.5300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="amrn_BiopharmaceuticalMember" order="1.4300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201503Member" order="1.5200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_BusinessDevelopmentDomain" xlink:label="amrn_BusinessDevelopmentDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_BusinessDevelopmentsAxis" xlink:label="amrn_BusinessDevelopmentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="amrn_CommitmentsAndContingenciesDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_CommitmentsAndContingenciesDisclosureTable" xlink:label="amrn_CommitmentsAndContingenciesDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_FurtherIndicationForAmrOneZeroOneMember" xlink:label="amrn_FurtherIndicationForAmrOneZeroOneMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_MarketingApprovalInEuropeMember" xlink:label="amrn_MarketingApprovalInEuropeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PotentialMarketingApprovalOneMember" xlink:label="amrn_PotentialMarketingApprovalOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PotentialMarketingApprovalTwoMember" xlink:label="amrn_PotentialMarketingApprovalTwoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_BusinessDevelopmentDomain" xlink:to="amrn_MarketingApprovalInEuropeMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_BusinessDevelopmentDomain" xlink:to="amrn_PotentialMarketingApprovalOneMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_BusinessDevelopmentDomain" xlink:to="amrn_PotentialMarketingApprovalTwoMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_BusinessDevelopmentsAxis" xlink:to="amrn_BusinessDevelopmentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="amrn_CommitmentsAndContingenciesDisclosureTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CommitmentsAndContingenciesDisclosureTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_StatementScenarioAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CommitmentsAndContingenciesDisclosureTable" xlink:to="amrn_BusinessDevelopmentsAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CommitmentsAndContingenciesDisclosureTable" xlink:to="amrn_CommitmentsAndContingenciesDisclosureLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="amrn_FurtherIndicationForAmrOneZeroOneMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureEquityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_AmericanDepositorySharesMember" xlink:label="amrn_AmericanDepositorySharesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_BeneficialOwnershipLimitationPercentage" xlink:label="amrn_BeneficialOwnershipLimitationPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ConversionPricePerShare" xlink:label="amrn_ConversionPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_DerivativeLiabilitiesTransferredToStockholdersEquity" xlink:label="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DirectorMember" xlink:label="us-gaap_DirectorMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_EquityOfferingCosts" xlink:label="amrn_EquityOfferingCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_OrdinarySharesBasisMember" xlink:label="amrn_OrdinarySharesBasisMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_OrdinarySharesMember" xlink:label="amrn_OrdinarySharesMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis" xlink:label="amrn_PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PerformanceBasedOptionsMember" xlink:label="amrn_PerformanceBasedOptionsMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PerformanceBasedRestrictedStockUnitMember" xlink:label="amrn_PerformanceBasedRestrictedStockUnitMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PreferredSharesBasisMember" xlink:label="amrn_PreferredSharesBasisMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="us-gaap_PreferredStockConversionBasis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockConversionsInducements" xlink:label="us-gaap_PreferredStockConversionsInducements"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding" xlink:label="amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PreferredStockPurchaseOptionMember" xlink:label="amrn_PreferredStockPurchaseOptionMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PrivatePlacementClosingDate" xlink:label="amrn_PrivatePlacementClosingDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ProceedsFromWarrantExercisesGross" xlink:label="amrn_ProceedsFromWarrantExercisesGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SecondPrivatePlacementMember" xlink:label="amrn_SecondPrivatePlacementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_StockholdersEquityNoteLineItems" xlink:label="amrn_StockholdersEquityNoteLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_StockholdersEquityNoteTable" xlink:label="amrn_StockholdersEquityNoteTable"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_StockIncentivePlanTwentyElevenMember" xlink:label="amrn_StockIncentivePlanTwentyElevenMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_VestingPeriodFourMember" xlink:label="amrn_VestingPeriodFourMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_VestingPeriodOneMember" xlink:label="amrn_VestingPeriodOneMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_VestingPeriodThreeMember" xlink:label="amrn_VestingPeriodThreeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_VestingPeriodTwoMember" xlink:label="amrn_VestingPeriodTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amrn_OrdinarySharesMember" order="1.4700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="amrn_PreferredStockPurchaseOptionMember" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="amrn_StockholdersEquityNoteTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="amrn_AmericanDepositorySharesMember" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="amrn_PreferredSharesBasisMember" order="1.4500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="amrn_OrdinarySharesBasisMember" order="1.5000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="amrn_StockIncentivePlanTwentyElevenMember" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.4600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="amrn_SecondPrivatePlacementMember" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.4300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="amrn_PerformanceBasedOptionsMember" order="1.4900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="amrn_PerformanceBasedRestrictedStockUnitMember" order="1.5200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_ProceedsFromWarrantExercisesGross" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_PreferredStockConversionBasis" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_PrivatePlacementClosingDate" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_ConversionPricePerShare" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_EquityOfferingCosts" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_BeneficialOwnershipLimitationPercentage" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_SharePrice" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_PreferredStockConversionsInducements" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteLineItems" xlink:to="amrn_DerivativeLiabilitiesTransferredToStockholdersEquity" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="dei_LegalEntityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_AwardTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_PlanNameAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_VestingAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="16.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="17.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_RangeAxis" order="18.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="19.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_StockholdersEquityNoteTable" xlink:to="amrn_StockholdersEquityNoteLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_DirectorMember" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="amrn_VestingPeriodOneMember" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="amrn_VestingPeriodTwoMember" order="1.4400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="amrn_VestingPeriodThreeMember" order="1.4800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="amrn_VestingPeriodFourMember" order="1.5100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureCoPromotionAgreementAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_CoPromotionAgreementLineItems" xlink:label="amrn_CoPromotionAgreementLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_CoPromotionAgreementMember" xlink:label="amrn_CoPromotionAgreementMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_CoPromotionAgreementTable" xlink:label="amrn_CoPromotionAgreementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_KowaPharmaceuticalsAmericaMember" xlink:label="amrn_KowaPharmaceuticalsAmericaMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_NumberOfSalesRepresentative" xlink:label="amrn_NumberOfSalesRepresentative"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PercentageOfGrossMarginPayableForPromotionAgreement" xlink:label="amrn_PercentageOfGrossMarginPayableForPromotionAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_RangeOfPercentageOfGrossMarginPayableForCoPromotionAgreement" xlink:label="amrn_RangeOfPercentageOfGrossMarginPayableForCoPromotionAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="amrn_CoPromotionAgreementMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CoPromotionAgreementLineItems" xlink:to="amrn_NumberOfSalesRepresentative" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CoPromotionAgreementLineItems" xlink:to="amrn_PercentageOfGrossMarginPayableForPromotionAgreement" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CoPromotionAgreementLineItems" xlink:to="amrn_RangeOfPercentageOfGrossMarginPayableForCoPromotionAgreement" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CoPromotionAgreementLineItems" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CoPromotionAgreementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CoPromotionAgreementTable" xlink:to="dei_LegalEntityAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CoPromotionAgreementTable" xlink:to="us-gaap_StatementScenarioAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CoPromotionAgreementTable" xlink:to="us-gaap_RangeAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_CoPromotionAgreementTable" xlink:to="amrn_CoPromotionAgreementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="amrn_KowaPharmaceuticalsAmericaMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="amrn_CoPromotionAgreementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/DisclosureDevelopmentCommercializationAndSupplyAgreementAdditionalInformation">
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_BusinessDevelopmentDomain" xlink:label="amrn_BusinessDevelopmentDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_BusinessDevelopmentsAxis" xlink:label="amrn_BusinessDevelopmentsAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ClinicalTrialApplicationMember" xlink:label="amrn_ClinicalTrialApplicationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_EddingpharmMember" xlink:label="amrn_EddingpharmMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_EligibleMilestonePayment" xlink:label="amrn_EligibleMilestonePayment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_LicenseAndCollaborationAgreementsLineItems" xlink:label="amrn_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_LicenseAndCollaborationAgreementsTable" xlink:label="amrn_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_LicensingAgreementTerm" xlink:label="amrn_LicensingAgreementTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_NonrefundableMilestonePayment" xlink:label="amrn_NonrefundableMilestonePayment"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_NonRefundableUpfrontPaymentsReceived" xlink:label="amrn_NonRefundableUpfrontPaymentsReceived"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_BusinessDevelopmentDomain" xlink:to="amrn_EddingpharmMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_BusinessDevelopmentsAxis" xlink:to="amrn_BusinessDevelopmentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="amrn_LicenseAndCollaborationAgreementsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="amrn_ClinicalTrialApplicationMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_LicenseAndCollaborationAgreementsLineItems" xlink:to="amrn_NonRefundableUpfrontPaymentsReceived" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_LicenseAndCollaborationAgreementsLineItems" xlink:to="amrn_LicensingAgreementTerm" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_LicenseAndCollaborationAgreementsLineItems" xlink:to="amrn_NonrefundableMilestonePayment" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_LicenseAndCollaborationAgreementsLineItems" xlink:to="amrn_EligibleMilestonePayment" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_LicenseAndCollaborationAgreementsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_LicenseAndCollaborationAgreementsTable" xlink:to="amrn_BusinessDevelopmentsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_RangeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amrn_LicenseAndCollaborationAgreementsTable" xlink:to="amrn_LicenseAndCollaborationAgreementsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_BeneficialConversionFeaturePolicyTextBlock" xlink:label="amrn_BeneficialConversionFeaturePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_ConcentrationOfSuppliersPolicyTextBlock" xlink:label="amrn_ConcentrationOfSuppliersPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_DebtIssuanceCostsPolicyTextBlock" xlink:label="amrn_DebtIssuanceCostsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_UseOfForecastedFinancialInformationInAccountingEstimatesPolicyTextBlock" xlink:label="amrn_UseOfForecastedFinancialInformationInAccountingEstimatesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UseOfEstimates" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_UseOfForecastedFinancialInformationInAccountingEstimatesPolicyTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryPolicyTextBlock" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_BeneficialConversionFeaturePolicyTextBlock" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LegalCostsPolicyTextBlock" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtPolicyTextBlock" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_ConcentrationOfSuppliersPolicyTextBlock" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_DebtIssuanceCostsPolicyTextBlock" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="amrn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_SummaryOfNetProductRevenueValuationAllowancesTableTextBlock" xlink:label="amrn_SummaryOfNetProductRevenueValuationAllowancesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_SummaryOfNetProductRevenueValuationAllowancesTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_WarrantMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCoPromotionAgreementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="amrn-20160630.xsd#amrn_CoPromotionAgreementDisclosureTextBlock" xlink:label="amrn_CoPromotionAgreementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="amrn_CoPromotionAgreementDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6816695568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Aug. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMRN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AMARIN CORP PLC\UK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000897448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=amrn_OrdinarySharesMember', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,836,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=amrn_AmericanDepositorySharesMember', window );">American Depository Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,448,877<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=amrn_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=amrn_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=amrn_AmericanDepositorySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=amrn_AmericanDepositorySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6817256720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 72,491<span></span>
</td>
<td class="nump">$ 106,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">17,639<span></span>
</td>
<td class="nump">13,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">20,306<span></span>
</td>
<td class="nump">18,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">5,476<span></span>
</td>
<td class="nump">3,152<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">116,512<span></span>
</td>
<td class="nump">143,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetNoncurrent', window );">Deferred tax assets</a></td>
<td class="nump">21,718<span></span>
</td>
<td class="nump">19,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible asset, net</a></td>
<td class="nump">9,095<span></span>
</td>
<td class="nump">9,417<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">147,636<span></span>
</td>
<td class="nump">173,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">14,811<span></span>
</td>
<td class="nump">10,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">31,052<span></span>
</td>
<td class="nump">24,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">30,816<span></span>
</td>
<td class="nump">14,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">1,172<span></span>
</td>
<td class="nump">923<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">77,851<span></span>
</td>
<td class="nump">50,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-Term Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Exchangeable senior notes, net of discount</a></td>
<td class="nump">125,644<span></span>
</td>
<td class="nump">136,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">90,150<span></span>
</td>
<td class="nump">91,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Long-term debt derivative liabilities</a></td>
<td class="nump">3,610<span></span>
</td>
<td class="nump">8,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, long-term</a></td>
<td class="nump">14,529<span></span>
</td>
<td class="nump">13,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">312,052<span></span>
</td>
<td class="nump">300,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series A Convertible Preferred Stock, &#163;0.05 par, unlimited authorized; 328,184,640 shares issued and outstanding as of June 30, 2016 and December 31, 2015 (equivalent to 32,818,464 ordinary shares upon future consolidation and redesignation at a 10:1 ratio)</a></td>
<td class="nump">24,364<span></span>
</td>
<td class="nump">24,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, &#163;0.50 par, unlimited authorized; 185,274,511 issued, 184,551,164 outstanding as of June 30, 2016; 183,577,765 issued, 183,403,263 outstanding as of December 31, 2015</a></td>
<td class="nump">151,183<span></span>
</td>
<td class="nump">149,978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">822,013<span></span>
</td>
<td class="nump">816,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock; 723,347 shares as of June 30, 2016; 174,502 shares as of December 31, 2015</a></td>
<td class="num">(1,197)<span></span>
</td>
<td class="num">(411)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,160,779)<span></span>
</td>
<td class="num">(1,117,654)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(164,416)<span></span>
</td>
<td class="num">(127,552)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT</a></td>
<td class="nump">$ 147,636<span></span>
</td>
<td class="nump">$ 173,230<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31931-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31928-109318<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31958-109318<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorLongTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorLongTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6815598688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - &#163; / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">&#163; 0.05<span></span>
</td>
<td class="nump">&#163; 0.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">328,184,640<span></span>
</td>
<td class="nump">328,184,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">328,184,640<span></span>
</td>
<td class="nump">328,184,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding', window );">Preferred stock, equivalent ordinary shares upon future consolidation outstanding</a></td>
<td class="nump">32,818,464<span></span>
</td>
<td class="nump">32,818,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">&#163; 0.50<span></span>
</td>
<td class="nump">&#163; 0.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="nump">185,274,511<span></span>
</td>
<td class="nump">183,577,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="nump">184,551,164<span></span>
</td>
<td class="nump">183,403,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">723,347<span></span>
</td>
<td class="nump">174,502<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock, equivalent ordinary shares upon future conversion outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6816998464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product revenue, net</a></td>
<td class="nump">$ 32,815<span></span>
</td>
<td class="nump">$ 17,707<span></span>
</td>
<td class="nump">$ 58,122<span></span>
</td>
<td class="nump">$ 33,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licensing revenue</a></td>
<td class="nump">296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">532<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue, net</a></td>
<td class="nump">33,111<span></span>
</td>
<td class="nump">17,707<span></span>
</td>
<td class="nump">58,654<span></span>
</td>
<td class="nump">33,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Less: Cost of goods sold</a></td>
<td class="nump">8,861<span></span>
</td>
<td class="nump">6,381<span></span>
</td>
<td class="nump">15,757<span></span>
</td>
<td class="nump">12,008<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">24,250<span></span>
</td>
<td class="nump">11,326<span></span>
</td>
<td class="nump">42,897<span></span>
</td>
<td class="nump">21,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">26,066<span></span>
</td>
<td class="nump">26,054<span></span>
</td>
<td class="nump">54,086<span></span>
</td>
<td class="nump">50,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">12,578<span></span>
</td>
<td class="nump">12,009<span></span>
</td>
<td class="nump">26,308<span></span>
</td>
<td class="nump">24,623<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">38,644<span></span>
</td>
<td class="nump">38,063<span></span>
</td>
<td class="nump">80,394<span></span>
</td>
<td class="nump">75,418<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(14,394)<span></span>
</td>
<td class="num">(26,737)<span></span>
</td>
<td class="num">(37,497)<span></span>
</td>
<td class="num">(53,786)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain (loss) on change in fair value of derivative liabilities</a></td>
<td class="nump">5,810<span></span>
</td>
<td class="num">(600)<span></span>
</td>
<td class="nump">4,560<span></span>
</td>
<td class="num">(136)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="num">(5,616)<span></span>
</td>
<td class="num">(4,807)<span></span>
</td>
<td class="num">(11,202)<span></span>
</td>
<td class="num">(9,692)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(182)<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="num">(303)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from operations before taxes</a></td>
<td class="num">(14,382)<span></span>
</td>
<td class="num">(32,049)<span></span>
</td>
<td class="num">(44,442)<span></span>
</td>
<td class="num">(63,647)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="nump">1,028<span></span>
</td>
<td class="nump">537<span></span>
</td>
<td class="nump">1,317<span></span>
</td>
<td class="nump">1,009<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(13,354)<span></span>
</td>
<td class="num">(31,512)<span></span>
</td>
<td class="num">(43,125)<span></span>
</td>
<td class="num">(62,638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Preferred stock purchase option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(868)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConversionsInducements', window );">Preferred stock beneficial conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,341)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,341)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss applicable to common shareholders</a></td>
<td class="num">$ (13,354)<span></span>
</td>
<td class="num">$ (62,853)<span></span>
</td>
<td class="num">$ (43,125)<span></span>
</td>
<td class="num">$ (94,847)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">184,471<span></span>
</td>
<td class="nump">180,464<span></span>
</td>
<td class="nump">184,262<span></span>
</td>
<td class="nump">178,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">184,471<span></span>
</td>
<td class="nump">180,464<span></span>
</td>
<td class="nump">184,262<span></span>
</td>
<td class="nump">178,036<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConversionsInducements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The excess of (1) the fair value of all securities and other consideration transferred in transactions by the registrant to the holders of the convertible preferred stock over (2) the fair value of securities issuable pursuant to the original conversion terms, during the accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27010884&amp;loc=d3e42851-122695<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConversionsInducements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6816939440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements Of Stockholders' Deficit - 6 months ended Jun. 30, 2016 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred Shares</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1', window );">Cumulative-effect adjustment | ASU No. 2016-09</a></td>
<td class="nump">$ 1,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,639<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) (Scenario, Previously Reported) at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328,184,640<span></span>
</td>
<td class="nump">183,577,765<span></span>
</td>
<td class="num">(174,502)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328,184,640<span></span>
</td>
<td class="nump">183,577,765<span></span>
</td>
<td class="num">(174,502)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance (Scenario, Previously Reported) at Dec. 31, 2015</a></td>
<td class="num">(129,191)<span></span>
</td>
<td class="nump">$ 24,364<span></span>
</td>
<td class="nump">$ 149,978<span></span>
</td>
<td class="num">$ (411)<span></span>
</td>
<td class="nump">$ 816,171<span></span>
</td>
<td class="num">(1,119,293)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2015</a></td>
<td class="num">$ (127,552)<span></span>
</td>
<td class="nump">$ 24,364<span></span>
</td>
<td class="nump">$ 149,978<span></span>
</td>
<td class="num">$ (411)<span></span>
</td>
<td class="nump">816,171<span></span>
</td>
<td class="num">(1,117,654)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">83,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,613,726<span></span>
</td>
<td class="num">(548,845)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units</a></td>
<td class="num">(793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,145<span></span>
</td>
<td class="num">$ (786)<span></span>
</td>
<td class="num">(1,152)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">6,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the period</a></td>
<td class="num">(43,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,125)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Jun. 30, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328,184,640<span></span>
</td>
<td class="nump">185,274,511<span></span>
</td>
<td class="num">(723,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2016</a></td>
<td class="num">$ (164,416)<span></span>
</td>
<td class="nump">$ 24,364<span></span>
</td>
<td class="nump">$ 151,183<span></span>
</td>
<td class="num">$ (1,197)<span></span>
</td>
<td class="nump">$ 822,013<span></span>
</td>
<td class="num">$ (1,160,779)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66904339&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cumulative effect on retained earnings net of related income tax effect.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=amrn_AccountingStandardsUpdate201609Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=amrn_AccountingStandardsUpdate201609Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6817769536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (43,125)<span></span>
</td>
<td class="num">$ (62,638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on sale of fixed assets</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">6,962<span></span>
</td>
<td class="nump">6,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">5,038<span></span>
</td>
<td class="nump">3,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible asset</a></td>
<td class="nump">322<span></span>
</td>
<td class="nump">323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">(Gain) loss on change in fair value of derivative liabilities</a></td>
<td class="num">(4,560)<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(1,846)<span></span>
</td>
<td class="num">(731)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(3,813)<span></span>
</td>
<td class="num">(2,101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(1,321)<span></span>
</td>
<td class="num">(6,766)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other current assets</a></td>
<td class="num">(2,324)<span></span>
</td>
<td class="nump">1,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest payable</a></td>
<td class="num">(1,416)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">1,470<span></span>
</td>
<td class="nump">14,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities', window );">Accounts payable and other current liabilities</a></td>
<td class="nump">10,773<span></span>
</td>
<td class="nump">6,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="num">(67)<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(33,780)<span></span>
</td>
<td class="num">(38,260)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of equipment</a></td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options, net of transaction costs</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to stock-based awards</a></td>
<td class="num">(793)<span></span>
</td>
<td class="num">(117)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Payments under capital leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(669)<span></span>
</td>
<td class="nump">54,771<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(34,470)<span></span>
</td>
<td class="nump">16,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</a></td>
<td class="nump">106,961<span></span>
</td>
<td class="nump">119,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, END OF PERIOD</a></td>
<td class="nump">72,491<span></span>
</td>
<td class="nump">136,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_CashPaidDuringPeriodForAbstract', window );"><strong>Cash paid during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest</a></td>
<td class="nump">7,668<span></span>
</td>
<td class="nump">5,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="nump">$ 767<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DerivativeLiabilitiesTransferredToEquityClassifications', window );">Transfer of preferred stock purchase option derivative liability to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Series A Convertible Preferred Stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConversionsInducements', window );">Accretion of preferred stock beneficial conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ShareBasedCompensationNet', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_CashPaidDuringPeriodForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Paid During Period For [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_CashPaidDuringPeriodForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_DerivativeLiabilitiesTransferredToEquityClassifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative Liabilities Transferred To Equity Classifications</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_DerivativeLiabilitiesTransferredToEquityClassifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ShareBasedCompensationNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_ShareBasedCompensationNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConversionsInducements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The excess of (1) the fair value of all securities and other consideration transferred in transactions by the registrant to the holders of the convertible preferred stock over (2) the fair value of securities issuable pursuant to the original conversion terms, during the accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27010884&amp;loc=d3e42851-122695<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConversionsInducements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6807601088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Business and Basis of Presentation</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>(1)</b></td>
 <td valign="top" align="left"><b>Nature of Business and Basis of
 Presentation</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 <b><i><u>Nature of Business</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Amarin Corporation plc (&#x201C;Amarin&#x201D; or the
 &#x201C;Company&#x201D;) is a biopharmaceutical company with
 expertise in lipid science focused on the commercialization and
 development of therapeutics to improve cardiovascular health.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company&#x2019;s lead product, Vascepa<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">&#xAE;</sup> (icosapent
 ethyl) capsules, is approved by the U.S. Food and Drug
 Administration, or FDA, for use as an adjunct to diet to reduce
 triglyceride levels in adult patients with severe (TG
 <u>&gt;</u>500 mg/dL) hypertriglyceridemia. Vascepa is available in
 the United States by prescription only. In January 2013, the
 Company began selling and marketing Vascepa in the United States.
 In August 2015, in addition to marketing Vascepa for severe
 hypertriglyceridemia, the Company commenced marketing Vascepa for
 use in adult patients with mixed dyslipidemia, as an adjunct to
 diet and an add-on to statin therapy in patients who despite statin
 therapy have high triglycerides (TGs <u>&gt;</u>200 mg/dL and
 &lt;500 mg/dL), which the Company also refers to as persistently
 high triglycerides. This expanded promotion of Vascepa commenced
 pursuant to a federal court order and is continuing pursuant to an
 agreement among the Company, the FDA and the U.S. government. The
 Company sells Vascepa principally to a limited number of major
 wholesalers, as well as selected regional wholesalers and specialty
 pharmacy providers, or collectively, its Distributors or its
 customers, that in turn resell Vascepa to retail pharmacies for
 subsequent resale to patients and healthcare providers. The Company
 markets Vascepa through its sales force of approximately 150 sales
 professionals, including sales representatives and their managers.
 In May 2014, Kowa Pharmaceuticals America, Inc. commenced
 co-promotion of Vascepa in accordance with a co-promotion agreement
 with the Company. Kowa Pharmaceuticals America, Inc. co-promotes
 Vascepa through its no less than 250 sales representatives who now
 devote a substantial portion of their time to promoting Vascepa in
 conjunction with the promotion of Kowa Pharmaceutical America,
 Inc.&#x2019;s primary product, a branded statin for patients with
 high cholesterol. The Company operates in one business segment.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company is also developing Vascepa for FDA approval of
 potential additional indications for use. In particular, the
 Company is conducting a cardiovascular outcomes study of Vascepa,
 titled REDUCE-IT (Reduction of Cardiovascular Events with
 EPA&#x2014;Intervention Trial). The REDUCE-IT study, which commenced
 in 2011 and reached its approximately 8,000 patient enrollment
 target in March 2016, is designed to evaluate the efficacy of
 Vascepa in reducing major cardiovascular events in a high-risk
 patient population on statin therapy.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Basis of Presentation</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The condensed consolidated financial statements included herein
 have been prepared by the Company, without audit, in accordance
 with accounting principles generally accepted in the United States
 of America (the &#x201C;U.S.&#x201D; or the &#x201C;United
 States&#x201D;) and pursuant to the rules and regulations of the
 Securities and Exchange Commission, or the SEC. Certain information
 in the footnote disclosures of the financial statements has been
 condensed or omitted where it substantially duplicates information
 provided in the Company&#x2019;s latest audited consolidated
 financial statements, in accordance with the rules and regulations
 of the SEC. These condensed consolidated financial statements
 should be read in conjunction with the Company&#x2019;s audited
 consolidated financial statements and notes included in its Annual
 Report on Form 10-K for the fiscal year ended December&#xA0;31,
 2015, or the 2015 Form 10-K, filed with the SEC. The consolidated
 balance sheet amounts at December&#xA0;31, 2015 in this report were
 derived from the Company&#x2019;s audited 2015 consolidated
 financial statements included in the 2015 Form 10-K.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The condensed consolidated financial statements reflect all
 adjustments of a normal and recurring nature that, in the opinion
 of management, are necessary to present fairly the Company&#x2019;s
 financial position, results of operations and cash flows for the
 periods indicated. The preparation of the Company&#x2019;s condensed
 consolidated financial statements in conformity with U.S. Generally
 Accepted Accounting Principles (&#x201C;GAAP&#x201D;) requires
 management to make estimates and assumptions that affect the
 reported amounts of assets and liabilities, disclosure of
 contingent assets and liabilities at the date of the financial
 statements, and the reported amounts of revenues and expenses
 during the reporting period. The results of operations for the
 three and six months ended June&#xA0;30, 2016 and June&#xA0;30,
 2015, respectively, are not necessarily indicative of the results
 for the entire fiscal year or any future period. Certain numbers
 presented throughout this document may not add precisely to the
 totals provided due to rounding. Absolute and percentage changes
 are calculated using the underlying amounts in thousands. Certain
 prior year balances have been reclassified to conform to current
 year presentation.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 The accompanying consolidated financial statements of the Company
 and subsidiaries have been prepared on a basis which assumes that
 the Company will continue as a going concern, which contemplates
 the realization of assets and the satisfaction of liabilities and
 commitments in the normal course of business.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 As of June&#xA0;30, 2016, the Company had current assets of $116.5
 million, including cash and cash equivalents of $72.5&#xA0;million.
 The Company&#x2019;s condensed consolidated balance sheets also
 include derivative liabilities as well as long-term debt and
 exchangeable senior notes. The outstanding January 2012
 exchangeable senior notes, or the 2012 Notes, may be redeemed by
 the Company on or after January&#xA0;19, 2017 and may be put back
 to the Company by the holders on each of January&#xA0;19, 2017,
 2022 and 2027 for cash equal to 100% of the principal amount of
 $15.1 million plus any accrued and unpaid interest. The outstanding
 May 2014 exchangeable senior notes, or the 2014 Notes, and the
 outstanding November 2015 exchangeable senior notes, or the 2015
 Notes, may be redeemed by the Company on or after January&#xA0;19,
 2019 at the option of the holders and are not puttable by the
 holders prior to this date except upon the occurrence of certain
 contingent events. The 2012 Notes are exchangeable under certain
 circumstances into cash, American Depository Shares, or ADSs, or a
 combination of cash and ADSs, at the Company&#x2019;s election. The
 2014 Notes and 2015 Notes are exchangeable under certain
 circumstances into ADSs. Accordingly, the 2012 Notes represent a
 short-term obligation while the long-term debt, 2014 Notes, and
 2015 Notes do not represent a short-term claim on the liquid assets
 of the Company.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company believes its cash and cash equivalents will be
 sufficient to fund its projected operations for at least the next
 twelve months. Depending on the level of cash generated from
 operations, additional capital will likely be required to sustain
 operations. The Company anticipates that quarterly net cash
 outflows in future periods will be variable.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6788972096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>(2)</b></td>
 <td valign="top" align="left"><b>Significant Accounting
 Policies</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 <b><i><u>Principles of Consolidation</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The condensed consolidated financial statements include the
 accounts of the Company and its wholly-owned subsidiaries. All
 intercompany accounts and transactions have been eliminated in
 consolidation.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Use of Estimates</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Accounting estimates are based on historical experience and other
 factors that are considered reasonable under the circumstances.
 Estimates are used in determining such items as provisions for
 sales returns, rebates and incentives, chargebacks, and other sales
 allowances; depreciable/amortizable lives; asset impairments;
 valuation allowance on deferred taxes; probabilities of achievement
 of performance conditions for certain equity awards; amounts
 recorded for licensing revenue; contingencies and accruals; and
 valuations of derivative and long-term debt instruments. Because of
 the uncertainties inherent in such estimates, actual results may
 differ from these estimates. Management periodically evaluates
 estimates used in the preparation of the condensed consolidated
 financial statements for continued reasonableness.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Use of Forecasted Financial Information in Accounting
 Estimates</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The use of forecasted financial information is inherent in many of
 the Company&#x2019;s accounting estimates including, but not limited
 to, determining the estimated fair values of derivatives, debt
 instruments and intangible assets, and evaluating the need for
 valuation allowances for deferred tax assets. Such forecasted
 financial information is comprised of numerous assumptions
 regarding the Company&#x2019;s future revenues, cash flows, and
 operational results. Management believes that its financial
 forecasts are reasonable and appropriate based upon current facts
 and circumstances. Because of the inherent nature of forecasts,
 however, actual results may differ from these forecasts. Management
 regularly reviews the information related to these forecasts and
 adjusts the carrying amounts of the applicable assets
 prospectively, if and when actual results differ from previous
 estimates.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Revenue Recognition</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company sells Vascepa principally to a limited number of major
 wholesalers, as well as selected regional wholesalers and specialty
 pharmacy providers, or collectively, its Distributors or its
 customers, that in turn resell Vascepa to retail pharmacies for
 subsequent resale to patients and healthcare providers. Patients
 are required to have a prescription in order to purchase Vascepa.
 In accordance with GAAP, the Company&#x2019;s revenue recognition
 policy requires that: (i)&#xA0;there is persuasive evidence that an
 arrangement exists between the Company and the Distributor,
 (ii)&#xA0;delivery has occurred, (iii)&#xA0;collectability is
 reasonably assured and (iv)&#xA0;the price is fixed or
 determinable.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company has contracts with its primary Distributors and
 delivery generally occurs when a Distributor receives Vascepa. The
 Company evaluates the creditworthiness of each of its Distributors
 to determine whether revenues can be recognized upon delivery,
 subject to satisfaction of the other requirements, or whether
 recognition is required to be delayed until receipt of payment. In
 order to conclude that the price is fixed or determinable, the
 Company must be able to (i)&#xA0;calculate its gross product
 revenues from the sales to Distributors and (ii)&#xA0;reasonably
 estimate its net product revenues. The Company calculates gross
 product revenues generally based on the wholesale acquisition cost
 that the Company charges its Distributors for Vascepa. The Company
 estimates its net product revenues by deducting from its gross
 product revenues (a)&#xA0;trade allowances, such as invoice
 discounts for prompt payment and distributor fees,
 (b)&#xA0;estimated government and private payor rebates,
 chargebacks and discounts, such as Medicaid reimbursements,
 (c)&#xA0;reserves for expected product returns and
 (d)&#xA0;estimated costs of incentives offered to certain indirect
 customers, including patients.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 <i>Trade Allowances:</i> The Company generally provides invoice
 discounts on Vascepa sales to its Distributors for prompt payment
 and pays fees for distribution services, such as fees for certain
 data that Distributors provide to the Company. The payment terms
 for sales to Distributors generally include a 2% discount for
 payment within 30&#xA0;days while the fees for distribution
 services are based on contractual rates agreed with the respective
 Distributors. Based on judgment and experience, the Company expects
 its Distributors to earn these discounts and fees, and deducts the
 full amount of these discounts and fees from its gross product
 revenues and accounts receivable at the time such revenues are
 recognized.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 <i>Rebates, Chargebacks and Discounts:</i> The Company contracts
 with Medicaid, other government agencies and various private
 organizations, or collectively, Third-party Payors, so that Vascepa
 will be eligible for purchase by, or partial or full reimbursement
 from, such Third-party Payors. The Company estimates the rebates,
 chargebacks and discounts it will provide to Third-party Payors and
 deducts these estimated amounts from its gross product revenues at
 the time the revenues are recognized. The Company estimates the
 rebates, chargebacks and discounts that it will provide to
 Third-party Payors based upon (i)&#xA0;the Company&#x2019;s
 contracts with these Third-party Payors, (ii)&#xA0;the
 government-mandated discounts applicable to government-funded
 programs, (iii)&#xA0;information obtained from the Company&#x2019;s
 Distributors and (iv)&#xA0;information obtained from other third
 parties regarding the payor mix for Vascepa.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 <i>Product Returns:</i> The Company&#x2019;s Distributors have the
 right to return unopened unprescribed Vascepa during the 18-month
 period beginning six months prior to the labeled expiration date
 and ending twelve months after the labeled expiration date. The
 expiration date for Vascepa is three years after it has been
 converted into capsule form, which is the last step in the
 manufacturing process for Vascepa and generally occurs within a few
 months before Vascepa is delivered to Distributors. The Company
 estimates future product returns on sales of Vascepa based on:
 (i)&#xA0;data provided to the Company by its Distributors
 (including weekly reporting of Distributors&#x2019; sales and
 inventory held by Distributors that provided the Company with
 visibility into the distribution channel in order to determine what
 quantities were sold to retail pharmacies and other providers),
 (ii)&#xA0;information provided to the Company from retail
 pharmacies, (iii)&#xA0;data provided to the Company by a third
 party data provider which collects and publishes prescription data,
 and other third parties, (iv)&#xA0;historical industry information
 regarding return rates for similar pharmaceutical products,
 (v)&#xA0;the estimated remaining shelf life of Vascepa previously
 shipped and currently being shipped to Distributors and
 (vi)&#xA0;contractual agreements intended to limit the amount of
 inventory maintained by the Company&#x2019;s Distributors.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 <i>Other Incentives:</i> Other incentives that the Company offers
 to indirect customers include co-pay mitigation rebates provided by
 the Company to commercially insured patients who have coverage for
 Vascepa and who reside in states that permit co-pay mitigation
 programs. The Company&#x2019;s co-pay mitigation program is intended
 to reduce each participating patient&#x2019;s portion of the
 financial responsibility for Vascepa&#x2019;s purchase price to a
 specified dollar amount. Based upon the terms of the program and
 information regarding programs provided for similar specialty
 pharmaceutical products, the Company estimates the average co-pay
 mitigation amounts and the percentage of patients that it expects
 to participate in the program in order to establish its accruals
 for co-pay mitigation rebates and deducts these estimated amounts
 from its gross product revenues at the time the revenues are
 recognized. The Company adjusts its accruals for co-pay mitigation
 rebates based on actual redemption activity and estimates regarding
 the portion of issued co-pay mitigation rebates that it estimates
 will be redeemed.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 The following tables summarize activity in each of the net product
 revenue allowance and reserve categories described above for the
 six months ended June&#xA0;30, 2016 and 2015:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Trade<br />
 Allowances</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Rebates,<br />
 Chargebacks<br />
 and&#xA0;Discounts</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Product<br />
 Returns</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Other<br />
 Incentives</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Balance as of December&#xA0;31, 2015</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>4,296</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>9,881</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>535</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>1,084</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>15,796</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Provision related to current period sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,048</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28,945</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">257</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,614</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">44,864</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Provision related to prior period sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(87</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(466</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(553</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Credits/payments made for current period sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,415</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(10,750</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,910</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(20,075</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Credits/payments made for prior period sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,180</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(8,497</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(226</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,284</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(14,187</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Balance as of June&#xA0;30, 2016</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>3,662</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>19,113</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>566</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>2,504</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>25,845</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="63%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Trade<br />
 Allowances</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Rebates,<br />
 Chargebacks<br />
 and&#xA0;Discounts</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Product<br />
 Returns</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Other<br />
 Incentives</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Balance as of December&#xA0;31, 2014</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>2,207</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>3,610</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>&#xA0;481</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>792</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>7,090</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Provision related to current period sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,044</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,957</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">276</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,691</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,968</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Provision related to prior period sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(113</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(44</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(157</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Credits/payments made for current period sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,810</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,243</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,149</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(12,202</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Credits/payments made for prior period sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,039</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,531</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(14</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(792</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,376</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Balance as of June&#xA0;30, 2015</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>2,289</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>5,749</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>743</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>1,542</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>10,323</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Such net product revenue allowances and reserves are included
 within accrued expenses and other current liabilities within the
 condensed consolidated balance sheets, with the exception of trade
 allowances and chargebacks, which are included within accounts
 receivable, net as discussed below.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <i>Multiple-Element Arrangements and Licensing Revenue</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 When evaluating multiple-element arrangements, the Company
 identifies the deliverables included within the agreement and
 evaluates which deliverables represent separate units of accounting
 based on whether the delivered element has stand-alone value to the
 customer or if the arrangement includes a general right of return
 for delivered items.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The consideration received is allocated between each of the
 separable elements in the arrangement using the relative selling
 price method. The selling price used for each separable element
 will be based on vendor specific objective evidence
 (&#x201C;VSOE&#x201D;) if available, third-party evidence if VSOE is
 not available, or estimated selling price if neither VSOE nor
 third-party evidence is available. Revenue is then recognized as
 each of the separable elements to which the revenue has been
 allocated is delivered.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company may receive up-front, non-refundable payments when
 licensing its intellectual property in conjunction with research,
 development and commercialization agreements. In determining the
 units of accounting, management evaluates whether the license has
 stand-alone value from the undelivered elements to the
 collaborative partner based on the consideration of the relevant
 facts and circumstances for each arrangement. Factors considered in
 this determination include the stage of development of the license
 delivered, research and development capabilities of the partner and
 the ability of partners to develop and commercialize Vascepa
 independent of the Company.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 When management believes the license to its intellectual property
 does not have stand-alone value from the other deliverables to be
 provided in the arrangement, the Company generally recognizes
 revenue attributable to the license over the Company&#x2019;s
 contractual or estimated performance period. Any unrecognized
 portion of license revenue is classified within deferred revenue in
 the accompanying condensed consolidated balance sheets. When
 management believes the license to its intellectual property has
 stand-alone value, the Company recognizes revenue attributed to the
 license upon delivery. The periods over which revenue is recognized
 is subject to estimates by management and may change over the
 course of the agreement. Such a change could have a material impact
 on the amount of revenue the Company records in future periods.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <i>Milestones</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Contingent consideration from activities that is earned upon the
 achievement of a substantive milestone is recognized in its
 entirety in the period in which the milestone is achieved. At the
 inception of each arrangement that includes milestone payments, the
 Company evaluates whether each milestone is substantive. This
 evaluation includes an assessment of whether: (a)&#xA0;the
 consideration is commensurate with either (1)&#xA0;the
 entity&#x2019;s performance to achieve the milestone, or
 (2)&#xA0;the enhancement of the value of the delivered item(s) as a
 result of a specific outcome resulting from the entity&#x2019;s
 performance to achieve the milestone, (b)&#xA0;the consideration
 relates solely to past performance and (c)&#xA0;the consideration
 is reasonable relative to all of the deliverables and payment terms
 within the arrangement. The Company evaluates factors such as the
 scientific, clinical, regulatory, commercial and other risks that
 must be overcome to achieve the respective milestone, the level of
 effort and investment required and whether the milestone
 consideration is reasonable relative to all deliverables and
 payment terms in the arrangement in making this assessment.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 See Note 10&#x2014;Development, Commercialization and Supply
 Agreement for further information regarding licensing revenue and
 milestones related to the Company&#x2019;s multiple-element
 arrangement with Eddingpharm (Asia) Macao Commercial Offshore
 Limited.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Distribution Costs</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company records distribution costs related to shipping product
 to its customers, primarily through the use of common carriers or
 external distribution services, in cost of goods sold.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Cash and Cash Equivalents and Restricted
 Cash</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Cash and cash equivalents consist of cash, deposits with banks and
 short-term highly liquid money market instruments with remaining
 maturities at the date of purchase of 90&#xA0;days or less.
 Restricted cash represents cash and cash equivalents pledged to
 guarantee repayment of certain expenses which may be incurred for
 business travel under corporate credit cards held by employees.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Accounts Receivable, net</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Accounts receivable, net, comprised of trade receivables, are
 generally due within 30 days and are stated at amounts due from
 customers. The Company does not currently maintain an allowance for
 doubtful accounts and has not historically experienced any credit
 losses.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following table summarizes the impact of accounts receivable
 reserves on the gross trade accounts receivable balances as of
 June&#xA0;30, 2016 and December&#xA0;31, 2015:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="68%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,&#xA0;2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Gross trade accounts receivable</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">21,528</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">18,270</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade allowances</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,662</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,296</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Chargebacks</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(227</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(148</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accounts receivable, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">17,639</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">13,826</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Inventory</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Effective April 2016, the Company adopted ASU No.&#xA0;2015-11,
 <i>Inventory (Topic 330)&#x2014;Simplifying the Measurement of
 Inventory</i>, which simplifies the subsequent measurement of
 inventories by replacing the lower of cost or market test with a
 lower of cost and net realizable value test and, as such, began to
 state inventories at the lower of cost or net realizable value.
 Such adoption had no impact on the carrying value of inventory.
 Cost is determined based on actual cost using the average cost
 method. An allowance is established when management determines that
 certain inventories may not be saleable. If inventory cost exceeds
 expected net realizable value due to obsolescence, damage,
 quantities in excess of expected demand, changes in price levels or
 other causes, the Company will reduce the carrying value of such
 inventory to net realizable value and recognize the difference as a
 component of cost of goods sold in the period in which it occurs.
 The Company capitalizes inventory purchases of saleable product
 from approved suppliers while inventory purchases from suppliers
 prior to regulatory approval are included as a component of
 research and development expense. The Company expenses inventory
 identified for use as marketing samples when they are packaged. The
 average cost reflects the actual purchase price of Vascepa active
 pharmaceutical ingredient, or API.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Property, Plant and Equipment</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company provides for depreciation and amortization using the
 straight-line method by charges to operations in amounts that
 depreciate the cost of the fixed asset over its estimated useful
 life. The estimated useful lives, by asset classification, are as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 66.3pt; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt">
 <b>Asset Classification</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>Useful&#xA0;Lives</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Computer equipment and software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">3&#xA0;-&#xA0;5&#xA0;years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Furniture and fixtures</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">5&#xA0;years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 Lesser&#xA0;of&#xA0;useful&#xA0;life&#xA0;or&#xA0;lease&#xA0;term</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Upon retirement or sale of assets, the cost of the assets disposed
 and the related accumulated depreciation are removed from the
 condensed consolidated balance sheet and any resulting gain or loss
 is credited or expensed to operations. Repairs and maintenance
 costs are expensed as incurred.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Long-Lived Asset Impairment</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company reviews its long-lived assets for impairment whenever
 events or changes in circumstances indicate that the carrying
 amount of such assets may not be recoverable. Recoverability of
 these assets is determined by comparing the forecasted undiscounted
 net cash flows of the operation to which the assets relate to their
 carrying amount. If impairment is indicated, the assets are written
 down to fair value. Fair value is determined based on discounted
 forecasted cash flows or appraised values, depending on the nature
 of the assets.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Intangible Asset, net</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Intangible asset, net consists of a milestone payment paid to the
 former shareholders of Laxdale Limited related to the 2004
 acquisition of the rights to Vascepa, which is the result of
 Vascepa receiving marketing approval for the first indication and
 is amortized over its estimated useful life on a straight-line
 basis. See Note 7&#x2014;Commitments and Contingencies for further
 information regarding other obligations related to the acquisition
 of Laxdale Limited.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Beneficial Conversion Features</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company issued Series A preference shares in a private
 placement transaction executed in two tranches that each contain a
 conversion feature whereby such shares are convertible into
 ordinary shares at a fixed rate. The conversion price on the date
 of issuance was less than the market price of the Company&#x2019;s
 ordinary shares. It was determined that these discounts represent
 contingent beneficial conversion features, which were valued based
 on the difference between the conversion price and the market price
 of the ordinary shares on the date of issuance, which is the
 commitment date. These features are analogous to preference
 dividends and were each recorded as a non-cash return to preferred
 shareholders through accumulated deficit upon the earliest possible
 date of conversion, which occurred in the three months ended
 June&#xA0;30, 2015 upon effectiveness of the related resale
 Registration Statement on Form S-3 and in the three months ended
 September&#xA0;30, 2015 upon shareholder approval received at the
 Company&#x2019;s Annual General Meeting of Shareholders. See Note
 8&#x2014;Equity for further discussion.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Costs for Patent Litigation and Legal
 Proceedings</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Costs for patent litigation or other legal proceedings are expensed
 as incurred and included in selling, general and administrative
 expenses.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Research and Development Costs</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company charges research and development costs to operations as
 incurred. Research and development expenses are comprised of costs
 incurred by the Company in performing research and development
 activities, including: salary and benefits; stock-based
 compensation expense; laboratory supplies and other direct
 expenses; contractual services, including clinical trial and
 pharmaceutical development costs; commercial supply investment in
 its drug candidates; and infrastructure costs, including facilities
 costs and depreciation expense. In addition, research and
 development costs include the costs of product supply received from
 suppliers when such receipt by the Company is prior to regulatory
 approval of the supplier.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Selling, General and Administrative Costs</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company charges selling, general and administrative costs to
 operations as incurred. Selling, general and administrative costs
 include costs of salaries, programs and infrastructure necessary
 for the general conduct of the Company&#x2019;s business, including
 those incurred as a result of the commercialization of Vascepa in
 the United States as well as co-promotion fees payable to Kowa
 Pharmaceuticals America, Inc.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt">
 <b><i><u>Income Taxes</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Deferred tax assets and liabilities are recognized for the future
 tax consequences of differences between the carrying amounts and
 tax bases of assets and liabilities and operating loss
 carryforwards and other attributes using enacted rates expected to
 be in effect when those differences reverse. Valuation allowances
 are provided against deferred tax assets that are not more likely
 than not to be realized.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company provides reserves for potential payments of tax to
 various tax authorities or does not recognize tax benefits related
 to uncertain tax positions and other issues. Tax benefits for
 uncertain tax positions are based on a determination of whether a
 tax benefit taken by the Company in its tax filings or positions is
 more likely than not to be realized, assuming that the matter in
 question will be decided based on its technical merits. The
 Company&#x2019;s policy is to record interest and penalties in the
 provision for income taxes.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company regularly assesses its ability to realize deferred tax
 assets. Changes in historical earnings performance and future
 earnings projections, among other factors, may cause the Company to
 adjust its valuation allowance on deferred tax assets, which would
 impact the Company&#x2019;s income tax expense in the period in
 which it is determined that these factors have changed.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In April 2016, the Company adopted ASU No.&#xA0;2016-09,
 <i>Compensation&#x2014;Stock Compensation (Topic 718): Improvements
 to Employee Share-Based Payment Accounting,</i> which changes the
 accounting for certain aspects of share-based payments to
 employees. One aspect of the standard requires that excess tax
 benefits and deficiencies that arise upon vesting or exercise of
 share-based payments be recognized as an income tax benefit and
 expense in the income statement. Previously, such amounts were
 recognized as an increase and decrease in additional paid-in
 capital. This aspect of the standard was adopted prospectively, and
 accordingly, the benefit from income taxes for the three and six
 months ended June&#xA0;30, 2016, includes $0.1 million and $0.2
 million, respectively, of excess tax deficiencies arising from
 share-based payments. Additionally, the new standard requires that
 historical excess tax benefits that were not previously recognized
 because the related tax deduction had not reduced current taxes
 payable should be recognized on a modified retrospective basis as a
 cumulative-effect adjustment to retained earnings as of the
 beginning of the annual period of adoption. Consequently, the
 Company recognized deferred tax assets of approximately $1.6
 million relating to excess tax benefits of stock-based compensation
 outstanding as of December&#xA0;31, 2015, with a corresponding
 cumulative-effect adjustment to accumulated deficit. The new
 standard also amends the presentation of employee share-based
 payment-related items in the statement of cash flows by requiring
 that: (i)&#xA0;excess income tax benefits and deficiencies be
 classified in cash flows from operating activities, and
 (ii)&#xA0;cash paid to taxing authorities arising from the
 withholding of shares from employees be classified as cash flows
 from financing activities. The Company adopted the aspects of the
 standard affecting cash flow presentation retrospectively and,
 accordingly, reclassified $0.6 million of excess tax provision from
 cash flows provided by financing activities to cash flows used in
 operating activities in the condensed consolidated statement of
 cash flows for the six months ended June&#xA0;30, 2015 to conform
 to the current year presentation. The presentation requirement for
 cash flows related to taxes paid for withheld shares had no impact
 to any of the periods presented in the condensed consolidated
 statement of cash flows since such payments have historically been
 presented as a financing activity.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company&#x2019;s and its subsidiaries&#x2019; income tax returns
 are periodically examined by various tax authorities. The Company
 is currently under audit by the United States Internal Revenue
 Service (IRS) for the years 2012 to 2013. Although the outcome of
 tax audits is always uncertain and could result in significant cash
 tax payments, the Company does not believe the outcome of these
 audits will have a material adverse effect on the Company&#x2019;s
 consolidated financial position or results of operations.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Derivative Instruments</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Derivative financial liabilities are recorded at fair value, with
 gains and losses arising for changes in fair value recognized in
 the condensed consolidated statement of operations at each period
 end while such instruments are outstanding. If the Company issues
 shares to discharge the liability, the derivative financial
 liability is derecognized and common stock and additional paid-in
 capital are recognized on the issuance of those shares. Warrants
 are valued using a Black-Scholes option pricing model. The
 long-term debt redemption features are valued using
 probability-weighted models incorporating management estimates for
 potential change in control, and by determining the fair value of
 the debt with and without the change in control provision
 included.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 If the terms of warrants that initially require the warrant to be
 classified as a derivative financial liability lapse, the
 derivative financial liability is reclassified out of financial
 liabilities into equity at its fair value on that date. The cash
 proceeds received from exercises of warrants are recorded in common
 stock and additional paid-in capital.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Loss per Share</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Basic net loss per share is determined by dividing net loss by the
 weighted average shares of common stock outstanding during the
 period. Diluted net loss per share is determined by dividing net
 loss by diluted weighted average shares outstanding. Diluted
 weighted average shares reflects the dilutive effect, if any, of
 potentially dilutive common shares, such as common stock options
 and warrants calculated using the treasury stock method and
 convertible notes using the &#x201C;if-converted&#x201D; method. In
 periods with reported net operating losses, all common stock
 options and warrants are deemed anti-dilutive such that basic net
 loss per share and diluted net loss per share are equal. However,
 in certain periods in which there is a gain recorded pursuant to
 the change in fair value of the warrant derivative liability, for
 diluted net loss per share purposes, the impact of such gains is
 reversed and the treasury stock method is used to determine diluted
 net loss per share.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 The Company&#x2019;s preferred stock is entitled to receive
 dividends on an as-if-converted basis in the same form as dividends
 actually paid on common shares. Accordingly, the preferred stock is
 considered a participating security and the Company is required to
 apply the two-class method to consider the impact of the preferred
 stock on the calculation of basic and diluted earnings per share.
 The Company is currently in a net loss position and is therefore
 not required to present the two-class method, however, in the event
 the Company is in a net income position, the two-class method must
 be applied by allocating all earnings during the period to common
 shares and preferred stock based on their contractual entitlements
 assuming all earnings were distributed.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The calculation of net loss and the number of shares used to
 compute basic and diluted net loss per share for the three and six
 months ended June&#xA0;30, 2016 and 2015 are as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>Three&#xA0;months&#xA0;ended&#xA0;June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>Six&#xA0;months&#xA0;ended&#xA0;June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(13,354</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(31,512</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(43,125</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(62,638</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Preferred stock purchase option (see Note 8)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(868</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Preferred stock beneficial conversion feature (see Note 8)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(31,341</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(31,341</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss applicable to common shareholders&#x2014;basic</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(13,354</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(62,853</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(43,125</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(94,847</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Gain on warrant derivative liability</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(119</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss&#x2014;diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(13,354</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(62,853</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(43,125</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(94,966</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss per share&#x2014;basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(0.07</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(0.35</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(0.23</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(0.53</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Weighted average shares outstanding&#x2014;basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">184,471</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,464</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">184,262</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">178,036</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 For the three and six months ended&#xA0;June 30, 2016 and 2015, the
 following potentially dilutive securities were not included in the
 computation of net loss per share because the effect would be
 anti-dilutive:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="72%"></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>Three months
 ended</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>Six months
 ended</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br />
 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br />
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br />
 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br />
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Stock options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,641</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,750</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,641</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,750</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Restricted stock and restricted stock units</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,361</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,046</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,361</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,046</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exchangeable senior notes (if converted)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">59,407</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">49,215</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">59,407</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">49,215</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Preferred stock (if converted)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">32,818</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28,932</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">32,818</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28,932</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Debt Instruments</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Debt instruments are initially recorded at fair value, with coupon
 interest and amortization of debt issuance discounts recognized in
 the condensed consolidated statement of operations as interest
 expense each period in which such instruments are outstanding. If
 the Company issues shares to discharge the liability, the debt
 obligation is derecognized and common stock and additional paid-in
 capital are recognized on the issuance of those shares. The
 conversion features in the 2012 Notes, 2014 Notes, and 2015 Notes
 qualify for the exception from derivative accounting in accordance
 with ASC 815-40. The 2012 Notes may be settled, at the
 Company&#x2019;s discretion, in any combination of ADSs or cash upon
 conversion and have been accounted for in accordance with ASC
 470-20. Under ASC 470-20, the fair value of the liability component
 of the 2012 Notes was determined and deducted from the initial
 proceeds to determine the proceeds allocated to the conversion
 option, which has been recorded in equity. The difference between
 the initial fair value of the liability component and the amount
 repayable was amortized over the expected term of the instrument.
 The conversion features in the 2014 Notes and 2015 Notes may only
 be settled in ADSs upon conversion and have been accounted for as
 part of the debt host.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The conversion options in the 2012 Notes, 2014 Notes, and 2015
 Notes continue to be evaluated on a quarterly basis to determine if
 they still receive an exception from derivative accounting in
 accordance with ASC 815-40. The 2014 Notes were recognized
 initially at fair value as part of an extinguishment of a portion
 of the 2012 Notes. As a result, the 2014 Notes were initially
 recognized at a discount of $27.9 million. The 2015 Notes were
 recognized initially at fair value as part of the issuance of new
 debt in November 2015. As a result, the 2015 Notes were initially
 recognized at a discount of $3.8 million. These discounts are being
 amortized through interest expense over the expected terms of the
 2014 Notes and 2015 Notes, which is through January 2019 for each.
 See Note 6&#x2014;Debt for further discussion.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt">
 <b><i><u>Stock-Based Compensation</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Stock-based compensation cost is generally measured at the grant
 date, based on the fair value of the award, and is recognized as
 compensation expense over the requisite service period. For awards
 with performance conditions, if the achievement of the performance
 conditions is deemed probable, the Company recognizes compensation
 expense based on the fair value of the award over the estimated
 service period. The Company reassesses the probability of
 achievement of the performance conditions for such awards each
 reporting period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Concentration of Credit Risk</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Financial instruments that potentially subject the Company to
 credit risk consist primarily of cash and cash equivalents and
 accounts receivable. The Company maintains substantially all of its
 cash and cash equivalents in financial institutions believed to be
 of high-credit quality.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 A significant portion of the Company&#x2019;s sales are to
 wholesalers in the pharmaceutical industry. The Company monitors
 the creditworthiness of customers to whom it grants credit terms
 and has not experienced any credit losses. The Company does not
 require collateral or any other security to support credit sales.
 The Company&#x2019;s top three customers accounted for 95% of gross
 product sales for each of the six months ending June&#xA0;30, 2016
 and 2015 and represented 94% and 96% of the gross accounts
 receivable balance as of June&#xA0;30, 2016 and 2015, respectively.
 The Company has not experienced any write-offs of its accounts
 receivable.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Concentration of Suppliers</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company has contractual freedom to source the API for Vascepa
 and has entered into supply agreements with multiple suppliers. The
 Company&#x2019;s supply of product for commercial sale and clinical
 trials is dependent upon relationships with third-party
 manufacturers and key suppliers, in particular three suppliers of
 API for Vascepa.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company cannot provide assurance that its efforts to procure
 uninterrupted supply of Vascepa API to meet market demand will
 continue to be successful or that it will be able to renew current
 API supply agreements on favorable terms or at all. Significant
 alteration to or termination of the Company&#x2019;s current API
 supply chain or its failure to enter into new and similar
 agreements, if needed, could have a material adverse effect on its
 business, condition (financial and other), prospects or results of
 operations.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company currently has manufacturing agreements with three
 FDA-approved commercial API encapsulators for Vascepa
 manufacturing. Each of these companies has qualified its
 manufacturing processes and is capable of manufacturing Vascepa.
 There can be no guarantee that these or other suppliers with which
 the Company may contract in the future to encapsulate API will
 continue to be qualified to manufacture the product to its
 specifications or that these and any future suppliers will have the
 manufacturing capacity to meet anticipated demand for Vascepa.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Foreign Currency</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 All subsidiaries use the U.S. dollar as the functional currency.
 Monetary assets and liabilities denominated in a foreign currency
 are remeasured into U.S. dollars at period-end exchange rates.
 Gains and losses from the remeasurement are included in other
 (expense) income, net in the condensed consolidated statements of
 operations. For transactions settled during the applicable period,
 gains and losses are included in other (expense) income, net in the
 condensed consolidated statements of operations. Certain amounts
 payable pursuant to supply contracts are denominated in currencies
 other than the U.S. dollar.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Debt Issuance Costs</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Prior to January 2016, debt issuance costs were initially recorded
 as a deferred cost and amortized to interest expense using the
 effective interest method over the expected term of the related
 debt. Effective January 2016, the Company adopted ASU
 No.&#xA0;2015-03, <i>Interest&#x2014;Imputation of Interest
 (Subtopic 835-30): Simplifying the Presentation of Debt Issuance
 Costs</i>, and as such began recording debt issuance costs related
 to a recognized debt liability in the condensed consolidated
 balance sheet as a direct deduction from the carrying amount of
 that debt liability and amortized to interest expense using the
 effective interest method over the expected term of the related
 debt. As the standard is required to be adopted on a retrospective
 basis, the Company reclassified $1.9 million of underwriters&#x2019;
 fees and offering costs related to the 2014 and 2015 exchangeable
 notes from other long-term assets to exchangeable senior notes, net
 of discount, within the condensed consolidated balance sheet as of
 December&#xA0;31, 2015. Unamortized debt issuance costs related to
 the extinguishment of debt are expensed at the time the debt is
 extinguished and recorded in other (expense) income, net in the
 condensed consolidated statements of operations.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt">
 <b><i><u>Fair Value of Financial Instruments</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company provides disclosure of financial assets and financial
 liabilities that are carried at fair value based on the price that
 would be received upon sale of an asset or paid to transfer a
 liability in an orderly transaction between market participants at
 the measurement date.&#xA0;Fair value measurements may be
 classified based on the amount of subjectivity associated with the
 inputs to fair valuation of these assets and liabilities using the
 following three levels:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Level 1&#x2014;Inputs are unadjusted quoted prices in active markets
 for identical assets or liabilities that the Company has the
 ability to access at the measurement date.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Level 2&#x2014;Inputs include quoted prices for similar assets and
 liabilities in active markets, quoted prices for identical or
 similar assets or liabilities in markets that are not active,
 inputs other than quoted prices that are observable for the asset
 or liability (i.e., interest rates, yield curves, etc.) and inputs
 that are derived principally from or corroborated by observable
 market data by correlation or other means (market corroborated
 inputs).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Level 3&#x2014;Unobservable inputs that reflect the Company&#x2019;s
 estimates of the assumptions that market participants would use in
 pricing the asset or liability.&#xA0;The Company develops these
 inputs based on the best information available, including its own
 data.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following tables present information about the Company&#x2019;s
 assets and liabilities as of June&#xA0;30, 2016 and
 December&#xA0;31, 2015 that are measured at fair value on a
 recurring basis and indicate the fair value hierarchy of the
 valuation techniques the Company utilized to determine such fair
 value:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>June&#xA0;30, 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Asset:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cash equivalents&#x2014;money markets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14,210</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14,210</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Liabilities:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Long-term debt derivative liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,610</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,610</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>December&#xA0;31, 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Asset:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cash equivalents&#x2014;money markets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14,184</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14,184</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Liabilities:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Long-term debt derivative liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,170</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,170</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The carrying amounts of cash, cash equivalents, accounts payable
 and accrued liabilities approximate fair value because of their
 short-term nature. The carrying amounts and the estimated fair
 values of debt instruments as of June&#xA0;30, 2016 and
 December&#xA0;31, 2015 are as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>June&#xA0;30, 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31, 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Carrying<br />
 Value</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Estimated<br />
 Fair&#xA0;Value</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Carrying<br />
 Value</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Estimated<br />
 Fair&#xA0;Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Long-term debt&#x2014;December 2012 financing</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">92,533</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">89,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">91,512</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">87,700</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2012 Notes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,107</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14,686</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,107</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,637</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2014 Notes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">97,994</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">122,959</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">94,599</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">108,034</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2015 Notes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,650</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">32,378</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,028</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28,448</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The estimated fair value of the long-term debt pursuant to the
 December 2012 financing is calculated utilizing the same Level 3
 inputs utilized in valuing the related derivative liability (see
 Long-Term Debt Redemption Features below).&#xA0;The estimated fair
 value of the 2012 Notes and 2014 Notes is calculated based on Level
 1 quoted bond prices, while the estimated fair value of the 2015
 Notes is calculated based on Level 2 quoted bond prices for the
 2014 Notes.&#xA0;The carrying value of the 2012 Notes as of
 June&#xA0;30, 2016 and December&#xA0;31, 2015 does not include a
 debt discount, as it had been fully amortized as non-cash interest
 expense over the expected term of the 2012 Notes, which was
 calculated to be a period of twenty-four months. The carrying value
 of the 2014 Notes as of June&#xA0;30, 2016 and December&#xA0;31,
 2015 includes a debt discount of $20.7 million and $24.1 million,
 respectively, which is being amortized as non-cash interest expense
 over the expected term of the 2014 Notes, through January 2019. The
 carrying value of the 2015 Notes as of June&#xA0;30, 2016 and
 December&#xA0;31, 2015 includes a debt discount of $3.6 million and
 $4.2 million, respectively, which is being amortized as non-cash
 interest expense over the expected term of the 2015 Notes, through
 January 2019. The carrying values and related debt discounts of the
 2014 Notes and 2015 Notes as of December&#xA0;31, 2015 reflect the
 retroactive reclassification of debt issuance costs per adoption of
 ASU No.&#xA0;2015-03 as described in Note 6&#x2014;Debt. The change
 in the estimated fair values of these liabilities from
 December&#xA0;31, 2015 to June&#xA0;30, 2016 is largely related to
 changes in the quoted bond prices.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Derivative Liabilities</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 <i>Warrant Derivative Liability</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company&#x2019;s warrant derivative liability (discussed in Note
 5&#x2014;Warrants and Warrant Derivative Liability) was carried at
 fair value and was classified as Level 3 in the fair value
 hierarchy due to the use of significant unobservable inputs. During
 the six months ended June&#xA0;30, 2015, of the 8,087,388 warrants
 outstanding as of December&#xA0;31, 2014, 1,844,585 warrants were
 exercised while the remaining 6,242,803 warrants expired, and the
 related derivative liability was extinguished. As such, no warrants
 were outstanding as of June&#xA0;30, 2016 and December&#xA0;31,
 2015.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <i>Long-Term Debt Redemption Features</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company&#x2019;s December 2012 financing agreement with
 BioPharma Secured Debt Fund II Holdings Cayman LP (discussed in
 Note&#xA0;6&#x2014;Debt) contains a redemption feature whereby, upon
 a change of control, the Company would be required to repay $150
 million, less any previously repaid amount. The Company determined
 this redemption feature to be an embedded derivative, which is
 carried at fair value and is classified as Level 3 in the fair
 value hierarchy due to the use of significant unobservable
 inputs.&#xA0;The fair value of the embedded derivative was
 calculated using a probability-weighted model incorporating
 management estimates of future revenues and for a potential change
 in control, and by determining the fair value of the debt with and
 without the change in control provision included. The difference
 between the two was determined to be the fair value of the embedded
 derivative. As of June&#xA0;30, 2016, the fair value of the
 derivative was determined to be $2.8 million, and the debt was
 valued by comparing debt issues of similar companies with
 (i)&#xA0;remaining terms of between 1.6 and 5.9 years,
 (ii)&#xA0;coupon rates of between 6.6% and 12.5% and
 (iii)&#xA0;market yields of between 11.0% and 27.7%. As of
 December&#xA0;31, 2015, the fair value of the derivative was
 determined to be $5.5 million, and the debt was valued by comparing
 debt issues of similar companies with (i)&#xA0;remaining terms of
 between 2.0 and 7.3 years, (ii)&#xA0;coupon rates of between 6.6%
 and 12.5% and (iii)&#xA0;market yields of between 13.0% and 30.7%.
 As such, the Company recognized a $2.7 million gain on change in
 fair value of derivative liability for the six months ended
 June&#xA0;30, 2016.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company&#x2019;s 2014 Notes and 2015 Notes each contain a
 redemption feature whereby, upon occurrence of a change in control,
 the Company would be required to repurchase the notes. The Company
 determined these redemption features to be embedded derivatives,
 requiring bifurcation in accordance with ASC 815. The derivatives
 are carried at fair value and are classified as Level 3 in the fair
 value hierarchy due to the use of significant unobservable
 inputs.&#xA0;The fair value of each embedded derivative was
 calculated using a probability-weighted model incorporating
 management estimates of the probability of a change in control
 occurring, and by determining the fair value of the debt with and
 without the change in control provision included. The difference
 between the two was determined to be the fair value of the embedded
 derivative. As of June&#xA0;30, 2016, the fair values of the
 derivatives related to the 2014 Notes and 2015 Notes were
 determined to be $0.6 million and $0.2 million, respectively, and
 the debts were valued by using (i)&#xA0;the estimated remaining
 term of the notes, (ii)&#xA0;a bond yield of 20.6%, (iii)&#xA0;a
 risk-free interest rate of 2.0% and (iv)&#xA0;volatility of 86.0%.
 As of December&#xA0;31, 2015, the fair values of the derivatives
 related to the 2014 Notes and 2015 Notes were determined to be $2.1
 million and $0.6 million, respectively, and the debts were valued
 by using (i)&#xA0;the estimated remaining term of the notes,
 (ii)&#xA0;a bond yield of 25.6%, (iii)&#xA0;a risk-free interest
 rate of 2.9% and (iv)&#xA0;volatility of 89.0%. As such, the
 Company recognized a $1.5 million gain and $0.4 million gain on
 change in fair value of derivative liability for the 2014 Notes and
 2015 Notes, respectively, for the six months ended June&#xA0;30,
 2016.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <i>Preferred Stock Purchase Option Derivative Liability</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Pursuant to a pre-existing contractual right to participate in
 certain private placement transactions effected by the Company in
 connection with the subscription agreement executed on
 March&#xA0;5, 2015, the Company determined that such right
 represented a derivative liability (see Note 8). This preferred
 stock purchase option derivative liability was carried at fair
 value and classified as Level 3 in the fair value hierarchy due to
 the use of significant unobservable inputs. The fair value of this
 liability was calculated using a Black-Scholes model and was
 determined to be $0.9 million at inception. On March&#xA0;30, 2015,
 this right was exercised and the liability was marked to fair value
 through such date. The liability was then reclassified to permanent
 equity on such date.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Any changes in the assumptions used to value the derivative
 liabilities, including the probability of a change in control,
 could result in a material change to the carrying value of such
 liabilities.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 The change in the fair value of derivative liabilities for the six
 months ended June&#xA0;30, 2016 and 2015 is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>October<br />
 2009<br />
 Warrants</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b><font style="WHITE-SPACE: nowrap">Long-Term&#xA0;Debt</font><br />
 Derivative<br />
 Liabilities</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Preferred&#xA0;Stock<br />
 Purchase&#xA0;Option</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Totals</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Balance as of December&#xA0;31, 2015</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>$</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#xA0;&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>8,170</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>$</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#xA0;&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>8,170</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Gain on change in fair value of derivative liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,560</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,560</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Balance as of June&#xA0;30, 2016</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>$</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>3,610</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>$</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>3,610</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>October<br />
 2009<br />
 Warrants</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b><font style="WHITE-SPACE: nowrap">Long-Term&#xA0;Debt</font><br />
 Derivative<br />
 Liabilities</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Preferred&#xA0;Stock<br />
 Purchase&#xA0;Option</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Totals</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Balance as of December&#xA0;31, 2014</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>119</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>&#xA0;7,400</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>$</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>7,519</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Record derivative liability</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">868</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">868</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 (Gain) loss on change in fair value of derivative liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(110</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(700</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">946</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">136</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Compensation income for change in fair value of warrants issued to
 former employees</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(9</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(9</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Transfer derivative liability to equity</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,814</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,814</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Balance as of June&#xA0;30, 2015</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>$</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>6,700</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>$</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>6,700</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Segment and Geographical Information</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Operating segments are defined as components of an enterprise about
 which separate financial information is available that is evaluated
 on a regular basis by the chief operating decision-maker, or
 decision making group, in deciding how to allocate resources to an
 individual segment and in assessing performance of the segment. The
 Company currently operates in one business segment, which is the
 development and commercialization of Vascepa. A single management
 team that reports to the Company&#x2019;s chief decision-maker, who
 is the Chief Executive Officer, comprehensively manages the
 business. Accordingly, the Company does not have separately
 reportable segments.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Recent Accounting Pronouncements</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 From time to time, new accounting pronouncements are issued by the
 Financial Accounting Standards Board, or FASB, and are early
 adopted by the Company or adopted as of the specified effective
 date.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In January 2016, the Company adopted ASU No.&#xA0;2015-03,
 <i>Interest&#x2014;Imputation of Interest (Subtopic 835-30):
 Simplifying the Presentation of Debt Issuance Costs</i>, which
 provides guidance on simplifying the presentation of debt issuance
 costs on the balance sheet. To simplify presentation of debt
 issuance costs, the amendments in ASU No.&#xA0;2015-03 require that
 debt issuance costs related to a recognized debt liability be
 presented in the balance sheet as a direct deduction from the
 carrying amount of that debt liability, consistent with the
 treatment of debt discounts. The recognition and measurement
 guidance for debt issuance costs are not affected by the amendments
 in this update. In accordance with ASU No.&#xA0;2015-03, the
 Company applied the new guidance on a retrospective basis, wherein
 the condensed consolidated balance sheet of each individual period
 presented was adjusted to reflect the period-specific effects of
 applying the new guidance. See Note 6<i>&#x2014;</i>Debt.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In April 2016, the Company adopted ASU No.&#xA0;2015-11,
 <i>Inventory (Topic 330): Simplifying the Measurement of
 Inventory</i>, which simplifies the subsequent measurement of
 inventories by replacing the lower of cost or market test with a
 lower of cost or net realizable value test. When evidence exists
 that the net realizable value of inventory is less than its cost
 (due to damage, physical deterioration, obsolescence, changes in
 price levels or other causes), the Company will recognize the
 difference as a component of cost of goods sold in the period in
 which it occurs. In accordance with ASU No.&#xA0;2015-11, the
 Company applied the new guidance on a prospective basis with no
 impact on the carrying amount of inventory.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Also in April 2016, the Company adopted ASU No.&#xA0;2016-09,
 <i>Compensation&#x2014;Stock Compensation (Topic 718): Improvements
 to Employee Share-Based Payment Accounting,</i> which changes the
 accounting for certain aspects of share-based payments to
 employees. One aspect of the standard requires that excess tax
 benefits and deficiencies that arise upon vesting or exercise of
 share-based payments be recognized as an income tax benefit and
 expense in the income statement. Previously, such amounts were
 recognized as an increase and decrease in additional paid-in
 capital. This aspect of the standard was adopted prospectively, and
 accordingly, the benefit from income taxes for the three and six
 months ended June&#xA0;30, 2016, includes $0.1 million and $0.2
 million, respectively, of excess tax deficiencies arising from
 share-based payments. Additionally, the new standard requires that
 historical excess tax benefits that were not previously recognized
 because the related tax deduction had not reduced current taxes
 payable should be recognized on a modified retrospective basis as a
 cumulative-effect adjustment to retained earnings as of the
 beginning of the annual period of adoption. Consequently, the
 Company recognized deferred tax assets of approximately $1.6
 million relating to excess tax benefits on stock-based compensation
 outstanding as of December&#xA0;31, 2015, with a corresponding
 cumulative-effect adjustment to accumulated deficit. The new
 standard also amends the presentation of employee share-based
 payment-related items in the statement of cash flows by requiring
 that: (i)&#xA0;excess income tax benefits and deficiencies be
 classified in cash flows from operating activities, and
 (ii)&#xA0;cash paid to taxing authorities arising from the
 withholding of shares from employees be classified as cash flows
 from financing activities. The Company adopted the aspects of the
 standard affecting cash flow presentation retrospectively and,
 accordingly, reclassified $0.6 million of excess tax provision from
 cash flows provided by financing activities to cash flows used in
 operating activities in the condensed consolidated statement of
 cash flows for the six months ended June&#xA0;30, 2015 to conform
 to the current year presentation. The presentation requirement for
 cash flows related to taxes paid for withheld shares had no impact
 to any of the periods presented in the condensed consolidated
 statement of cash flows since such payments have historically been
 presented as a financing activity.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company also considered the following recent accounting
 pronouncements which were not yet adopted as of June&#xA0;30,
 2016:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In May 2014, the FASB issued ASU No.&#xA0;2014-09, <i>Revenue from
 Contracts with Customers (Topic 606)</i>. This amendment provides
 principles for recognizing revenue for the transfer of promised
 goods or services to customers with the consideration to which the
 entity expects to be entitled in exchange for those goods or
 services, and is effective for annual periods beginning after
 December&#xA0;15, 2016 (the original effective date). In April
 2015, the FASB issued a proposal, which was subsequently adopted in
 July 2015, to defer the original effective date of this standard by
 one year, such that the amendment is effective for the
 Company&#x2019;s fiscal year beginning January&#xA0;1, 2018. Early
 adoption is permitted, but not before the original effective date.
 The Company is currently evaluating the accounting, transition and
 disclosure requirements of the standard and cannot currently
 estimate the financial statement impact of adoption.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In August 2014, the FASB issued ASU No.&#xA0;2014-15,
 <i>Presentation of Financial Statements&#x2014;Going Concern
 (Subtopic 205-40): Disclosure of Uncertainties about an
 Entity&#x2019;s Ability to Continue as a Going Concern</i>. ASU
 2014-15 requires management to assess an entity&#x2019;s ability to
 continue as a going concern by incorporating and expanding upon
 certain principles that are currently in U.S. auditing standards.
 Specifically, the ASU (i)&#xA0;provides a definition of the term
 substantial doubt, (ii)&#xA0;requires an evaluation every reporting
 period including interim periods, (iii)&#xA0;provides principles
 for considering the mitigating effect of management&#x2019;s plans,
 (iv)&#xA0;requires certain disclosures when substantial doubt is
 alleviated as a result of consideration of management&#x2019;s
 plans, (v)&#xA0;requires an express statement and other disclosures
 when substantial doubt is not alleviated and (vi)&#xA0;requires an
 assessment for a period of one year after the date that the
 financial statements are issued (or available to be issued). This
 standard is effective for fiscal years ending after
 December&#xA0;15, 2016, and for annual and interim periods
 thereafter. Early application is permitted. The Company has
 determined that this standard would not have a material impact on
 its condensed consolidated financial statements based on the
 assessment of its ability to continue as a going concern as of
 June&#xA0;30, 2016.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In January 2016, the FASB issued ASU No.&#xA0;2016-01, <i>Financial
 Instruments&#x2014;Overall (Subtopic 825-10): Recognition and
 Measurement of Financial Assets and Financial Liabilities</i>. The
 new guidance is intended to improve the recognition and measurement
 of financial instruments by requiring separate presentation of
 financial assets and financial liabilities by measurement category
 and form of financial asset (i.e., securities or loans and
 receivables) within the balance sheet or the accompanying notes to
 the financial statements, eliminating the requirement for public
 business entities to disclose the method(s) and significant
 assumptions used to estimate the fair value that is required to be
 disclosed for financial instruments measured at amortized cost
 within the balance sheet, requiring public business entities to use
 the exit price notion when measuring the fair value of financial
 instruments for disclosure purposes, requiring equity investments
 (except those accounted for under the equity method of accounting,
 or those that result in consolidation of the investee) to be
 measured at fair value with changes in fair value recognized in net
 income, and requiring a reporting organization to present
 separately in other comprehensive income the portion of the total
 change in the fair value of a liability resulting from a change in
 the instrument-specific credit risk (also referred to as &#x201C;own
 credit&#x201D;) when the organization has elected to measure the
 liability at fair value in accordance with the fair value option
 for financial instruments, among others. The new guidance is
 effective for fiscal years beginning after December&#xA0;15, 2017,
 including interim periods within those fiscal years. The new
 guidance permits early adoption of the own credit provision. The
 Company is currently evaluating the accounting, transition and
 disclosure requirements of the standard and cannot currently
 estimate the financial statement impact of adoption.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In February 2016, the FASB issued ASU No.&#xA0;2016-02, <i>Leases
 (Topic 842)</i>. The new guidance will require lessees to recognize
 a right-of-use asset and a lease liability for virtually all of
 their leases (other than leases that meet the definition of a
 short-term lease). The liability will be equal to the present value
 of lease payments. The asset will be based on the liability,
 subject to adjustment, such as for initial direct costs. Under the
 new guidance, lessor accounting is largely unchanged but certain
 targeted improvements were made to align, where necessary, lessor
 accounting with the lessee accounting model and Topic 606, Revenue
 from Contracts with Customers. The new lease guidance also
 simplified the accounting for sale and leaseback transactions
 primarily because lessees must recognize lease assets and lease
 liabilities and therefore, will no longer be provided with a source
 of off-balance sheet financing. The new guidance is effective for
 fiscal years beginning after December&#xA0;15, 2018, including
 interim periods within those fiscal years. Early adoption is
 permitted. The Company is currently evaluating the accounting,
 transition and disclosure requirements of the standard and cannot
 currently estimate the financial statement impact of adoption.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In March 2016, the FASB issued ASU No.&#xA0;2016-08, <i>Revenue
 from Contracts with Customers (Topic 606): Principal versus Agent
 Considerations (Reporting Revenue Gross versus Net)</i>, which
 clarifies that an entity is a principal when it controls the
 specified good or service before that good or service is
 transferred to the customer, and is an agent when it does not
 control the specified good or service before it is transferred to
 the customer. The new guidance is intended to improve the
 operability and understandability of the implementation guidance on
 principal versus agent considerations. In April 2016, the FASB
 issued ASU No.&#xA0;2016-10<i>, Revenue from Contracts with
 Customers (Topic 606): Identifying Performance Obligations and
 Licensing,</i> which clarifies the following two aspects of Topic
 606: (a)&#xA0;identifying performance obligations; and (b)&#xA0;the
 licensing implementation guidance. Further, in May 2016, the FASB
 issued ASU No.&#xA0;2016-12, <i>Revenue from Contracts with
 Customers (Topic 606): Narrow-Scope Improvements and Practical
 Expedients,</i> which provides clarifying guidance in certain
 narrow areas and adds some practical expedients. The amendments do
 not change the core principles of the guidance in Topic 606 and are
 effective for the Company&#x2019;s fiscal year beginning
 January&#xA0;1, 2018. Early application is permitted only as of
 annual reporting periods beginning after December&#xA0;15, 2016,
 including interim reporting periods within that reporting period.
 The Company is currently evaluating the accounting, transition and
 disclosure requirements of these standards and cannot currently
 estimate the financial statement impact of adoption.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company believes that the impact of other recently issued but
 not yet adopted accounting pronouncements will not have a material
 impact on the Company&#x2019;s consolidated financial position,
 results of operations, and cash flows, or do not apply to the
 Company&#x2019;s operations.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6807657552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>(3)</b></td>
 <td valign="top" align="left"><b>Intangible Assets</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Intangible assets consist of the historical acquisition cost of
 certain technology rights for Vascepa and have an estimated
 remaining useful life of 14.1 years. The carrying value as of
 June&#xA0;30, 2016 and December&#xA0;31, 2015 is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="68%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,&#xA0;2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Technology rights</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,624</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,624</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accumulated amortization</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,529</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,207</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,095</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,417</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6788972096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>(4)</b></td>
 <td valign="top" align="left"><b>Inventory</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company capitalizes its purchases of saleable inventory of
 Vascepa from suppliers that have been qualified by the FDA.
 Inventories as of June&#xA0;30, 2016 and December&#xA0;31, 2015
 consist of the following:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="68%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,&#xA0;2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Raw materials</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,596</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,096</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Work in process</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,748</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,640</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Finished goods</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,962</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,249</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total inventory</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">20,306</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">18,985</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6807603264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Warrant Derivative Liability<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Warrants and Warrant Derivative Liability</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr>
 <td valign="top" width="4%" align="left"><b>(5)</b></td>
 <td valign="top" align="left"><b>Warrants and Warrant Derivative
 Liability</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 On October&#xA0;16, 2009, the Company completed a $70.0 million
 private placement with both existing and new investors resulting in
 $62.3 million in net proceeds and an additional $3.6 million from
 bridge notes converted in conjunction with the private placement.
 In consideration for the $62.3 million in net cash proceeds Amarin
 issued 66.4&#xA0;million units, each unit consisting of
 (i)&#xA0;one ADS (representing one ordinary share) at a purchase
 price of $1.00 and (ii)&#xA0;a warrant with a five year term to
 purchase 0.5 (one half) of an ADS at an exercise price of $1.50 per
 ADS. In consideration for the conversion of $3.6 million of
 convertible bridge notes, Amarin issued 4.0&#xA0;million units,
 each unit consisting of (i)&#xA0;one ADS (representing one ordinary
 share) at a purchase price of $0.90 and (ii)&#xA0;a warrant with a
 five year term to purchase 0.5 (one half) of an ADS at an exercise
 price of $1.50 per ADS. The total number of warrants issued in
 conjunction with the financing was 35.2&#xA0;million.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In conjunction with the October 2009 financing, the Company issued
 an additional 0.9&#xA0;million warrants to three former officers.
 The warrants issued in connection with the October 2009 financing
 contained a pricing variability feature which provided for an
 increase to the exercise price if the exchange rate between the
 U.S. dollar and British pound adjusts such that the warrants could
 be exercised at a price less than the &#xA3;0.5 par value of the
 common stock&#x2014;that is, if the exchange rate exceeded U.S.
 $3.00 per &#xA3;1.0 sterling. Due to the potential variable nature
 of the exercise price, the warrants were not considered to be
 indexed to the Company&#x2019;s common stock. Accordingly, the
 warrants did not qualify for the exception to classify the warrants
 within equity and were classified as a derivative liability.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The fair value of this warrant derivative liability was remeasured
 at each reporting period, with changes in fair value recognized in
 the condensed consolidated statement of operations. Upon exercise,
 the fair value of the warrants exercised was remeasured and
 reclassified from warrant derivative liability to additional
 paid-in-capital. Although the warrants contained a pricing
 variability feature, the number of warrants issuable remained
 fixed. Therefore, the maximum number of common shares issuable as a
 result of the October 2009 private placement was 36.1 million.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In October 2014, the Company and the holders of the remaining
 October 2009 warrants mutually agreed to extend the expiration date
 of such warrants from October&#xA0;16, 2014 to February&#xA0;27,
 2015. During the six months ended June&#xA0;30, 2015, of the
 8,087,388 warrants outstanding as of December&#xA0;31, 2014,
 1,844,585 warrants were exercised, resulting in net proceeds to the
 Company of $2.7 million, the remaining 6,242,803 warrants expired,
 and the related derivative liability was extinguished. As such, no
 warrants were outstanding as of June&#xA0;30, 2016 and
 December&#xA0;31, 2015.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6441202&amp;loc=d3e80720-113993<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41620-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579240-113959<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624177-113959<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80784-113994<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41641-113959<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579245-113959<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624258-113959<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80748-113994<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5708775-113959<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5708773-113959<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5580258-113959<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624181-113959<br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41638-113959<br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6788969488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><div>
 <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
 <tr>
 <td width="4%" valign="top" align="left"><b>(6)</b></td>
 <td align="left" valign="top"><b>Debt</b></td>
 </tr>
 </table>
 <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <i><u>Long-Term Debt&#x2014;December 2012 Financing</u></i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 On December&#xA0;6, 2012, the Company entered into an agreement
 with BioPharma Secured Debt Fund II Holdings Cayman LP, or
 BioPharma. Under this agreement, the Company granted to BioPharma a
 security interest in future receivables associated with the Vascepa
 patent rights, in exchange for $100 million received at the closing
 of the agreement which occurred in December 2012. Under these
 terms, the Company continues to own all Vascepa intellectual
 property rights, however, such rights, as described below, could be
 used by BioPharma as collateral for repayment of the remaining
 unpaid balance under this agreement if the Company defaults on
 making required payments. In the agreement, the Company agreed to
 repay BioPharma up to $150&#xA0;million with such repayment based
 on a portion of revenues and receivables generated from
 Vascepa.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 As of June&#xA0;30, 2016, the remaining amount to be repaid to
 BioPharma is $132.1 million. During the three and six months ended
 June&#xA0;30, 2016, the Company made repayments under the agreement
 of $2.5 million and $5.2 million, respectively, to BioPharma and an
 additional $3.3 million is scheduled to be paid in August 2016 for
 the second quarter of 2016. These payments were calculated based on
 the threshold limitation, as described below, as opposed to the
 scheduled quarterly repayments. Additional quarterly repayments,
 subject to the threshold limitation, are scheduled to be paid.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The maximum quarterly amounts which could be due for payment,
 except upon a change of control and subject each quarter to the
 threshold limitation, are as follows: $15.0 million in the fourth
 quarter of 2016 and first quarter of 2017, and a payment of $13.0
 million scheduled for payment in May 2017. All such payments reduce
 the remainder of the $150 million in aggregate payments to
 BioPharma. These quarterly payments are subject to a quarterly
 threshold amount whereby, if a calculated threshold, based on
 quarterly Vascepa revenues, is not achieved, the quarterly payment
 payable in that quarter can at the Company&#x2019;s election be
 reduced, with the reduction carried forward without interest for
 payment in a future period. The payment of any carried forward
 amount is subject to similarly calculated threshold repayment
 amounts based on Vascepa revenue levels. Except upon a change of
 control in Amarin, the agreement does not expire until $150 million
 in aggregate has been repaid. Except in the event of the
 Company&#x2019;s default, there is no compounding of interest and no
 scheduled cliff payment due under this agreement. Rather, payment
 will be made, subject to the threshold limitation, until $150
 million in aggregate has been repaid, including payments made
 previously. The Company can prepay an amount equal to $150 million
 less any previously repaid amount.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company currently estimates that its Vascepa revenue levels
 will not be high enough in each quarter to support repayment to
 BioPharma in accordance with the maximum quarterly amounts in the
 repayment schedule. For each quarterly period since the inception
 of the debt, revenues were below the contractual threshold amount
 such that cash payments were calculated for each period reflecting
 the optional reduction amount as opposed to the contractual
 threshold payment due for each quarterly period. In accordance with
 the agreement with BioPharma, quarterly differences between the
 calculated optional reduction amounts and the repayment schedule
 amounts are rescheduled for payment beginning in the second quarter
 of 2017. Any such deferred repayments will remain subject to
 continued application of the quarterly ceiling in amounts due
 established by the calculated threshold limitation based on
 quarterly Vascepa revenues. No additional interest expense or
 liability is incurred as a result of such deferred repayments.
 These estimates will be reevaluated each reporting period by the
 Company and adjusted if necessary, prospectively.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company determined the redemption feature upon a change of
 control to be an embedded derivative requiring bifurcation. The
 fair value of the embedded derivative was calculated by determining
 the fair value of the debt with the change in control provision
 included and also without the change in control provision. The
 difference between the two fair values of the debt was determined
 to be the fair value of the embedded derivative, and upon closing
 the Company recorded a derivative liability of $14.6 million as a
 reduction to the note payable. The fair value of this derivative
 liability is remeasured at each reporting period, with changes in
 fair value recognized in the condensed consolidated statement of
 operations and any changes in the assumptions used in measuring the
 fair value of the derivative liability could result in a material
 increase or decrease in its carrying value. The Company recognized
 a $2.7 million gain and a $0.8 million loss on change in fair value
 of derivative liability during the six months ended June&#xA0;30,
 2016 and 2015, respectively.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 As of June&#xA0;30, 2016 and December&#xA0;31, 2015, the carrying
 value of the BioPharma debt, net of the unamortized debt discount
 and issuance costs, was $92.5 million and $91.5 million,
 respectively. During the six months ended June&#xA0;30, 2016, the
 Company recorded cash and non-cash interest expense of $3.4 million
 and $1.0 million, respectively, in connection with the BioPharma
 debt. During the six months ended June&#xA0;30, 2015, the Company
 recorded cash and non-cash interest expense of $3.2 million and
 $0.9 million, respectively, in connection with the BioPharma debt.
 The Company will periodically evaluate the remaining term of the
 agreement and the effective interest rate is recalculated each
 period based on the Company&#x2019;s most current estimate of
 repayment.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 To secure the obligations under the agreement with BioPharma, the
 Company granted BioPharma a security interest in the
 Company&#x2019;s patents, trademarks, trade names, domain names,
 copyrights, know-how and regulatory approvals related to the
 covered products, all books and records relating to the foregoing
 and all proceeds of the foregoing, referred to collectively as the
 collateral. If the Company (i)&#xA0;fails to deliver a payment when
 due and does not remedy that failure within a specific notice
 period, (ii)&#xA0;fails to maintain a first-priority perfected
 security interest in the collateral in the United States and does
 not remedy that failure after receiving notice of such failure or
 (iii)&#xA0;becomes subject to an event of bankruptcy, then
 BioPharma may attempt to collect the maximum amount payable by the
 Company under this agreement (after deducting any payments the
 Company has already made).</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Under the Purchase and Sale Agreement with BioPharma, the Company
 is restricted from paying dividends on its common shares, unless it
 has cash and cash equivalents in excess of a specified amount after
 such payment.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <i><u>January 2012 Exchangeable Senior Notes</u></i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 In January 2012, the Company issued $150.0 million in principal
 amount of 3.5% exchangeable senior notes due 2032 (the &#x201C;2012
 Notes&#x201D;), a portion of which was subsequently exchanged and a
 portion of which was extinguished (see discussion of May 2014 and
 November 2015 Exchangeable Senior Notes below). The 2012 Notes were
 issued by Corsicanto Limited, an Irish limited company acquired by
 Amarin in January 2012. Corsicanto Limited is a wholly-owned
 subsidiary of Amarin. The general, unsecured, senior obligations
 are fully and unconditionally guaranteed by Amarin but not by any
 of the Company&#x2019;s other subsidiaries. Corsicanto Limited has
 no assets, operations, revenues or cash flows other than those
 related to the issuance, administration and repayment of the 2012
 Notes and 2014 Notes.&#xA0;There are no significant restrictions on
 the ability of Amarin to obtain funds from Corsicanto Limited in
 the form of cash dividends, loans, or advances.&#xA0;Net proceeds
 to the Company, after payment of underwriting fees and expenses,
 were approximately $144.3 million.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The 2012 Notes have a stated interest rate of 3.5%&#xA0;per year,
 payable semiannually in arrears on January&#xA0;15 and July&#xA0;15
 of each year beginning on July&#xA0;15, 2012, and ending upon the
 2012 Notes&#x2019; maturity on January&#xA0;15, 2032. The 2012 Notes
 are subject to repurchase by the Company at the option of the
 holders on each of January&#xA0;19, 2017,&#xA0;January&#xA0;19,
 2022, and January&#xA0;19, 2027, at a price equal to 100% of the
 principal amount of the 2012 Notes to be repurchased, plus accrued
 and unpaid interest to, but excluding, the repurchase date. The
 2012 Notes are exchangeable under certain circumstances into cash,
 ADSs, or a combination of cash and ADSs, at the Company&#x2019;s
 election, with an initial exchange rate of 113.4752 ADSs per $1,000
 principal amount of 2012 Notes (equivalent to an initial exchange
 price of approximately $8.8125 per ADS), subject to adjustment in
 certain circumstances, including adjustment if the Company pays
 cash dividends. If the Company elected physical settlement, the net
 remaining outstanding portion of the 2012 Notes would be
 exchangeable into 1,714,270 ADSs. Based on the closing price of the
 Company&#x2019;s stock as of June&#xA0;30, 2016, the principal
 amount of the 2012 Notes would exceed the value of the shares if
 converted on that date by $11.4 million.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Additional covenants include: (i)&#xA0;limitations on future
 indebtedness under certain circumstances, (ii)&#xA0;the timely
 filing of documents and reports pursuant to Section&#xA0;13 or
 15(d) of the Securities Exchange Act of 1934 with both the SEC and
 the Trustee and (iii)&#xA0;maintaining the tradability of the 2012
 Notes. The Company is required to use commercially reasonable
 efforts to maintain the listing of the 2012 Notes on the Global
 Exchange Market operated under the supervision of the Irish Stock
 Exchange (or other recognized stock exchange as defined in the 2012
 Notes indenture). If the 2012 Notes are not freely tradable, as a
 result of restrictions pursuant to U.S. securities law or the terms
 of the 2012 Notes indenture or the 2012 Notes, the Company shall
 pay additional interest on the 2012 Notes at the rate of
 0.50%&#xA0;per annum of the principal amount of 2012 Notes
 outstanding for each day during such period for which the
 Company&#x2019;s failure to file has occurred and is continuing or
 for which the 2012 Notes are not freely tradable.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company may not redeem the 2012 Notes prior to January&#xA0;19,
 2017, other than in connection with certain changes in the tax law
 of a relevant taxing jurisdiction that results in additional
 amounts becoming due with respect to payments and/or deliveries on
 the 2012 Notes. On or after January&#xA0;19, 2017 and prior to the
 maturity date, the Company may redeem for cash all or part of the
 2012 Notes at a redemption price equal to 100% of the principal
 amount of the 2012 Notes to be redeemed, plus accrued and unpaid
 interest to, but excluding, the redemption date. There is no
 prepayment penalty or sinking fund provided for the 2012 Notes. If
 the Company undergoes a change in control, holders may require the
 Company to repurchase for cash all or part of their 2012 Notes at a
 repurchase price equal to 100% of the principal amount of the 2012
 Notes to be repurchased, plus accrued and unpaid interest to, but
 excluding, the change in control repurchase date. The 2012 Notes
 are the Company&#x2019;s senior unsecured obligations and rank
 senior in right of payment to the Company&#x2019;s future
 indebtedness that is expressly subordinated in right of payment to
 the 2012 Notes and equal in right of payment to the Company&#x2019;s
 future unsecured indebtedness that is not so subordinated. The 2012
 Notes are effectively junior in right of payment to future secured
 indebtedness to the extent of the value of the assets securing such
 indebtedness.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The 2012 Notes are exchangeable under certain circumstances. At the
 time of issuance, the Company calculated the fair value of the
 liability component of the outstanding 2012 Notes to be $126.2
 million, and the excess of the principal amount of the debt over
 the liability component of $23.8 million was allocated to the
 conversion option resulting in a discount on the debt and
 corresponding increase in equity as a result of the cash settlement
 feature. The discount created from allocating proceeds to the
 conversion option was amortized to interest expense using the
 effective interest method over the 2012 Notes&#x2019; estimated
 remaining life, which was calculated to be a period of twenty-four
 months. As of both June&#xA0;30, 2016 and December&#xA0;31, 2015,
 the discount created from the allocation of the proceeds to the
 conversion option was fully amortized and the carrying amount of
 the conversion option was $11.5 million. The conversion option will
 not be subsequently remeasured as long as it continues to meet the
 criteria for equity classification.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company also recorded a debt discount to reflect the value of
 the underwriter&#x2019;s discounts and offering costs. A portion of
 the debt discount from underwriter&#x2019;s discounts and offering
 costs was allocated to the equity and liability components of the
 2012 Notes in proportion to the proceeds allocated to each
 component. The portion of the debt discount from
 underwriter&#x2019;s discounts and offering costs allocated to the
 liability component was amortized as interest expense over the
 estimated life of the 2012 Notes of twenty-four months. As of both
 June&#xA0;30, 2016 and December&#xA0;31, 2015, the debt discount
 was fully amortized and the carrying value of the 2012 Notes was
 $15.1 million after an exchange and repayment of a portion of the
 2012 Notes (see below for further discussion of the May 2014 Notes
 and November 2015 Notes). The outstanding 2012 Notes may be put to
 the Company (at the holders&#x2019; option, upon fundamental change
 or an event of default), or converted by holders and the holders
 have the option to put the 2012 Notes back to the Company on each
 of January&#xA0;19, 2017, 2022 and 2027 for cash equal to 100% of
 the principal amount plus accrued and unpaid interest. As a result,
 the carrying value of the 2012 Notes of $15.1 million is classified
 as a current liability as of June&#xA0;30, 2016.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <i><u>May 2014 Exchangeable Senior Notes</u></i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 In May 2014, the Company entered into separate, privately
 negotiated exchange agreements with certain holders of the 2012
 Notes pursuant to which Corsicanto exchanged $118.7 million in
 aggregate principal amount of the existing 2012 Notes for $118.7
 million in aggregate principal amount of new 3.5%&#xA0;May 2014
 Exchangeable Senior Notes due 2032 (the &#x201C;2014 Notes&#x201D;),
 following which $31.3 million in aggregate principal amount of the
 2012 Notes remained outstanding with terms unchanged (the 2012
 Notes and 2014 Notes are referred to collectively as the
 &#x201C;Notes&#x201D;).</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The 2014 Notes have a stated interest rate of 3.5%&#xA0;per year,
 payable semiannually in arrears on January&#xA0;15 and July&#xA0;15
 of each year beginning on July&#xA0;15, 2014, and ending upon the
 2014 Notes&#x2019; maturity on January&#xA0;15, 2032, unless earlier
 repurchased or redeemed by Corsicanto or exchanged by the holders.
 At any time after the issuance of the 2014 Notes and prior to the
 close of business on the second business day immediately preceding
 January&#xA0;15, 2032, holders may exchange the 2014 Notes at their
 option. If prior to January&#xA0;15, 2018, a make-whole fundamental
 change (as defined in the 2014 Notes indenture) occurs or the
 Company elects to redeem the 2014 Notes in connection with certain
 changes in tax law, in each case as described in the 2014 Notes
 indenture, and a holder elects to exchange its 2014 Notes in
 connection with such make-whole fundamental change or election, as
 the case may be, such holder may be entitled to an increase in the
 exchange rate as described in the 2014 Notes indenture. In the
 event of physical settlement, the 2014 Notes would be exchangeable
 into 45,666,925 ADSs. The initial exchange rate is 384.6154 ADSs
 per $1,000 principal amount of the 2014 Notes (equivalent to an
 initial exchange price of approximately $2.60 per ADS, or the
 Exchange Price), subject to adjustment in certain circumstances.
 The exchange rate is subject to adjustment from time to time upon
 the occurrence of certain events, including, but not limited to,
 the payment of cash dividends. Based on the closing price of the
 Company&#x2019;s stock as of June&#xA0;30, 2016, the principal
 amount of the 2014 Notes would exceed the value of the shares if
 converted on that date by $20.1 million.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Prior to January&#xA0;19, 2018, the Company may not redeem the 2014
 Notes at its option other than in connection with certain changes
 in the tax law of a relevant taxing jurisdiction that results in
 additional amounts (as defined in the 2014 Notes indenture)
 becoming due with respect to payments and/or deliveries on the 2014
 Notes. On or after January&#xA0;19, 2018, the Company may redeem
 for cash all or a portion of the 2014 Notes at a redemption price
 of 100% of the aggregate principal amount of the 2014 Notes to be
 redeemed, plus accrued and unpaid interest to, but not including,
 the redemption date. If a fundamental change (as defined in the
 2014 Notes indenture) occurs, holders may require the Company to
 repurchase all or part of their 2014 Notes for cash at a
 fundamental change repurchase price equal to 100% of the aggregate
 principal amount of the 2014 Notes to be repurchased, plus accrued
 and unpaid interest to, but not including, the fundamental change
 repurchase date. In addition, holders of the 2014 Notes may require
 the Company to repurchase all or any portion of the 2014 Notes on
 each of January&#xA0;19, 2019,&#xA0;January&#xA0;19, 2024 and
 January&#xA0;19, 2029 for cash at a price equal to 100% of the
 aggregate principal amount of the 2014 Notes to be repurchased,
 plus accrued and unpaid interest to, but not including, the
 repurchase date.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company may elect at its option to cause all or any portion of
 the 2014 Notes to be mandatorily exchanged in whole or in part at
 any time prior to the close of business on the business day
 preceding January&#xA0;15, 2032 if the Daily VWAP (as defined in
 the 2014 Notes indenture) equals or exceeds 110% of the Exchange
 Price then in effect for at least 20 VWAP Trading Days (as defined
 in the 2014 Notes indenture) in any 30 VWAP Trading Day period. The
 Company may only exercise its optional exchange rights upon
 satisfaction of specified equity conditions, including that the
 ADSs issuable upon exchange of the 2014 Notes be eligible for
 resale without registration by non-affiliates and listed on The
 NASDAQ Global Market, its related exchanges or the New York Stock
 Exchange. If Corsicanto elects to exercise its optional exchange
 rights on or prior to January&#xA0;15, 2018, each holder whose 2014
 Notes are exchanged will upon exchange receive a specified number
 of additional ADSs as set forth in the 2014 Notes indenture. Upon
 such a declaration of acceleration, such principal and accrued and
 unpaid interest, if any, will be due and payable immediately. Upon
 the occurrence of certain events of bankruptcy, insolvency or
 reorganization involving Corsicanto, 100% of the principal of and
 accrued and unpaid interest, if any, on all of the 2014 Notes will
 become due and payable automatically. Notwithstanding the
 foregoing, the 2014 Notes indenture provides that, to the extent
 Corsicanto elects and for up to 360 days, the sole remedy for an
 event of default relating to certain failures by Corsicanto or the
 Company, as the case may be, to comply with certain reporting
 covenants in the 2014 Notes indenture consists exclusively of the
 right to receive additional interest on the 2014 Notes. Additional
 covenants pertaining to the 2012 Notes (as described above for the
 January 2012 Exchangeable Senior Notes) are also applicable to the
 May 2014 Notes.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 As a result of the note exchange (as described above), the Company
 assessed both quantitative and qualitative aspects of the features
 of the 2014 Notes as compared to the 2012 Notes. Such assessment
 resulted in the conclusion that the features of the 2014 Notes
 represent a substantive modification from the 2012 Notes as the
 terms of the exchange resulted in a substantive modification to the
 embedded conversion feature within the 2012 Notes, and as such
 should be accounted for as an extinguishment of debt. In accordance
 with ASC 470-20, the Company extinguished the 2012 Notes by
 recording a gain on extinguishment of the liability component of
 $38.0 million and repurchase of the conversion option in equity
 through a reduction to additional paid-in capital of $10.1 million.
 The 2014 Notes were recorded at fair value of $90.8 million
 representing a $27.9 million discount to par. In addition, the
 Company recognized $2.5 million in underwriter&#x2019;s fees and
 offering costs and initially recognized those costs as deferred
 assets. Effective January 2016, the Company adopted ASU
 No.&#xA0;2015-03, <i>Interest&#x2014;Imputation of Interest
 (Subtopic 835-30): Simplifying the Presentation of Debt Issuance
 Costs</i>, which requires that debt issuance costs related to a
 recognized debt liability be presented in the balance sheet as a
 direct deduction from the carrying amount of that debt liability,
 consistent with the treatment of debt discounts. As the standard is
 required to be adopted on a retrospective basis, the Company
 reclassified $1.8 million of underwriters&#x2019; fees and offering
 costs related to the 2014 Notes from other long-term assets to
 exchangeable senior notes, net of discount, within the condensed
 consolidated balance sheet as of December&#xA0;31, 2015.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company further allocated $3.5 million of the $90.8 million
 fair value of the 2014 Notes to the derivative liability related to
 the fundamental change redemption feature (as described above). The
 fair value of this derivative liability is remeasured at each
 reporting period, with changes in fair value recognized in the
 condensed consolidated statement of operations and any changes in
 the assumptions used in measuring the fair value of the derivative
 liability could result in a material increase or decrease in its
 carrying value. The Company recognized a $1.5 million gain on the
 change in fair value of the redemption feature in each of the six
 months ended June&#xA0;30, 2016 and 2015.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Because the conversion option in the 2014 Notes receives an
 exception from derivative accounting and only requires gross
 physical settlement in shares, the embedded option does not require
 separate accounting and is therefore accounted for as part of the
 debt host at amortized cost. The debt discount is being amortized
 as interest expense over the estimated life of the 2014 Notes and
 recognized in the condensed consolidated statement of operations as
 interest expense. As of June&#xA0;30, 2016 and December&#xA0;31,
 2015, the carrying value of the 2014 Notes, net of the unamortized
 debt discount and issuance costs, was $98.0 million and $94.6
 million, respectively. During the six months ended June&#xA0;30,
 2016, the Company recognized aggregate interest expense of $5.7
 million related to the Notes, of which $3.4 million represents
 non-cash interest and $2.3 million represents contractual coupon
 interest. During the six months ended June&#xA0;30, 2015, the
 Company recognized aggregate interest expense of $5.6 million
 related to the Notes, of which $3.0 million represents non-cash
 interest and $2.6 million represents contractual coupon
 interest.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <i><u>November 2015 Exchangeable Senior Notes</u></i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 In November 2015, the Company entered into a privately negotiated
 subscription agreement with one of its existing investors (the
 &#x201C;Investor&#x201D;), pursuant to which the Investor agreed to
 purchase approximately $31.3 million in aggregate principal amount
 of new 3.5%&#xA0;November 2015 Exchangeable Senior Notes due 2032
 (the &#x201C;2015 Notes&#x201D;) for approximately $27.5 million.
 Approximately $15.9 million of such proceeds were used to finance
 the repayment of a portion of the 2012 Notes and the remainder will
 be used for working capital and general corporate purposes. The
 2015 Notes have substantially identical terms to the 2014 Notes,
 except that the 2015 Notes were issued by Amarin Corporation plc
 and are not guaranteed by any entity. In the event of physical
 settlement, the 2015 Notes would be exchangeable into 12,025,385
 ADSs. The initial exchange rate is 384.6154 ADSs per $1,000
 principal amount of 2015 Notes (equivalent to an initial exchange
 price of approximately $2.60 per ADS), provided that exchanges will
 be prohibited if, as a result, the holder of such 2015 Notes and
 its affiliates would beneficially own more than 4.99% of the total
 number of the Company&#x2019;s ordinary shares or ADSs outstanding
 following such exchange (the &#x201C;Beneficial Ownership
 Limitation&#x201D;). By written notice to the Company, a holder may
 from time to time increase or decrease the Beneficial Ownership
 Limitation to any other percentage not in excess of 19.9% (the
 &#x201C;Beneficial Ownership Cap&#x201D;) specified in such notice;
 provided that any such increase will not be effective until the
 sixty-first (61st)&#xA0;day after such notice is delivered to the
 Company. The exchange rate is subject to adjustment from time to
 time upon the occurrence of certain events, including, but not
 limited to, the payment of cash dividends. Based on the closing
 price of the Company&#x2019;s stock as of June&#xA0;30, 2016, the
 principal amount of the 2015 Notes would exceed the value of the
 shares if converted on that date by $5.3 million.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The 2015 Notes are the senior unsecured obligations of the Company.
 The 2015 Notes bear interest at a rate of 3.5%&#xA0;per annum from,
 and including, November&#xA0;24, 2015, payable semi-annually in
 arrears on January&#xA0;15 and July&#xA0;15 of each year, beginning
 on January&#xA0;15, 2016. The 2015 Notes mature on January&#xA0;15,
 2032, unless earlier repurchased or redeemed by the Company or
 exchanged by the holders.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The 2015 Notes were recorded at fair value of $27.5 million
 representing a $3.8 million discount to par. In addition, the
 Company recognized $0.1 million in offering costs and initially
 recognized those costs as deferred assets. As described for the
 2014 Notes above, effective January 2016, the Company adopted ASU
 No.&#xA0;2015-03, <i>Interest&#x2014;Imputation of Interest
 (Subtopic 835-30): Simplifying the Presentation of Debt Issuance
 Costs.</i> As the standard is required to be adopted on a
 retrospective basis, the Company reclassified $0.1 million of
 underwriters&#x2019; fees and offering costs related to the 2015
 Notes from other long-term assets to exchangeable senior notes, net
 of discount, within the condensed consolidated balance sheet as of
 December&#xA0;31, 2015.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company further allocated $0.5 million of the $27.5 million
 fair value of the 2015 Notes to the derivative liability related to
 the fundamental change redemption feature (as described under the
 2014 Notes above). The fair value of this derivative liability is
 remeasured at each reporting period, with changes in fair value
 recognized in the condensed consolidated statement of operations
 and any changes in the assumptions used in measuring the fair value
 of the derivative liability could result in a material increase or
 decrease in its carrying value. During the six months ended
 June&#xA0;30, 2016, the Company recognized a gain on the change in
 fair value of the redemption feature of $0.4 million.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Because the conversion option in the 2015 Notes receives an
 exception from derivative accounting and only requires gross
 physical settlement in shares, the embedded option does not require
 separate accounting and is therefore accounted for as part of the
 debt host at amortized cost. The debt discount is being amortized
 as interest expense over the estimated life of the 2015 Notes and
 recognized in the condensed consolidated statement of operations as
 interest expense. As of June&#xA0;30, 2016 and December&#xA0;31,
 2015, the carrying value of the 2015 Notes, net of the unamortized
 debt discount and issuance costs, was $27.6 million and $27.0
 million, respectively. During the six months ended June&#xA0;30,
 2016, the Company recognized aggregate interest expense of $1.2
 million related to the 2015 Notes, of which $0.6 million represents
 non-cash interest and $0.6 million represents contractual coupon
 interest.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Concurrent with the issuance of the 2015 Notes, Corsicanto Limited
 and the Company entered into separate, privately negotiated
 purchase agreements with certain holders of the 2012 Notes pursuant
 to which the Company purchased (the &#x201C;2012 Notes
 Purchase&#x201D;) approximately $16.2 million in aggregate principal
 amount of the 2012 Notes for $15.9 million, which included accrued
 but unpaid interest on such 2012 Notes. The 2012 Notes Purchase was
 funded by the issuance of the 2015 Notes. Following the closing of
 the 2012 Notes Purchase, Corsicanto had approximately $15.1 million
 in aggregate principal amount of 2012 Notes outstanding. The 2012
 Notes Purchase was accounted for as an extinguishment of debt and
 the Company recorded a gain of $1.3 million upon extinguishment
 during the fourth quarter of 2015, which represents the
 reacquisition of the conversion option at fair value and a
 negotiated discount on the purchase of the notes partially offset
 by legal and transaction advisory costs incurred.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 As of June&#xA0;30, 2016 and December&#xA0;31, 2015, the Company
 had total accrued interest on the notes of $2.7 million and $2.3
 million, respectively, which is included in current portion of
 long-term debt. The Company made the contractual interest payments
 due on the notes during the six months ended June&#xA0;30, 2016 and
 2015 of $2.5 million and $2.6 million, respectively.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6636806320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div>
 <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
 <tr>
 <td width="4%" valign="top" align="left"><b>(7)</b></td>
 <td align="left" valign="top"><b>Commitments and
 Contingencies</b></td>
 </tr>
 </table>
 <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <i><u>Litigation</u></i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 In the ordinary course of business, the Company is from time to
 time involved in lawsuits, claims, investigations, proceedings, and
 threats of litigation relating to intellectual property, commercial
 arrangements and other matters. &#x201C;Item 3. Legal
 Proceedings&#x201D; of the Company&#x2019;s Annual Report on Form
 10-K for the fiscal year ended December&#xA0;31, 2015, and
 &#x201C;Item 1. Legal Proceedings&#x201D; of the Company&#x2019;s
 Quarterly Report on Form 10-Q for the quarter ended March&#xA0;31,
 2016, include discussions of the Company&#x2019;s current legal
 proceedings. There have been no material changes to those
 disclosures as of the date of this filing other than as set forth
 below.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 On April&#xA0;26, 2016, the U.S. District Court for the District of
 New Jersey granted a motion to dismiss in favor of the Company and
 related defendants in the putative consolidated class action
 lawsuit captioned&#xA0;<i>In re Amarin Corporation plc, Securities
 Litigation,</i>&#xA0;No.&#xA0;3:13-cv-06663 (D.N.J. Nov. 1, 2013).
 The class action was dismissed without prejudice with leave for
 plaintiffs to file an amended complaint. The lawsuit seeks
 unspecified monetary damages and attorneys&#x2019; fees and costs
 alleging that the Company and certain of its current and former
 officers and directors made misstatements and omissions regarding
 the FDA&#x2019;s willingness to approve Vascepa&#x2019;s ANCHOR
 indication and related contributing factors and the potential
 relevance of data from the ongoing REDUCE-IT trial to that
 potential approval. The April 2016 dismissal was the second motion
 to dismiss granted in favor of the Company and related defendants
 in this litigation. The first motion to dismiss in this litigation
 was granted in June 2015 in response to the original complaint and
 related amendment. On May&#xA0;24, 2016, plaintiffs notified the
 court they would not file another amended complaint and, on
 May&#xA0;26, 2016, filed a notice of appeal of the most recent
 dismissal to the Third Circuit Court of Appeals. The Company plans
 a vigorous defense to this appeal. The Company has insurance
 coverage that is anticipated to cover any significant loss exposure
 that may arise from this action.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 On May&#xA0;31, 2016, FDA granted five-year, new chemical entity
 exclusivity with respect to Vascepa in connection with
 Vascepa&#x2019;s July&#xA0;26, 2012 FDA approval. Following such
 exclusivity grant, on June&#xA0;7, 2016, Watson Laboratories Inc.,
 or Watson, moved for voluntarily dismissal of its own appeal to the
 United States Court of Appeals (case no. 2016-1596) of the
 January&#xA0;22, 2016 U.S. District Court for the District of New
 Jersey order of dismissal of the abbreviated new drug application,
 or ANDA, patent infringement litigation (case no. 14-CV-3259)
 related to Vascepa. The Watson motion for voluntary dismissal, to
 which the Company consented, was granted on June&#xA0;8, 2016.
 There is no pending patent litigation related to Vascepa.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <i><u>Milestone and Supply Purchase Obligations</u></i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company entered into long-term supply agreements with multiple
 FDA-approved API suppliers and encapsulators. Certain supply
 agreements require annual minimum volume commitments by the Company
 and certain volume shortfalls may require payments for such
 shortfalls, as detailed below.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company entered into its initial Vascepa API supply agreement
 with Nisshin Pharma, Inc. (&#x201C;Nisshin&#x201D;) in 2010. In 2011,
 the Company entered into agreements with two additional suppliers,
 Chemport, Inc. (&#x201C;Chemport&#x201D;) and BASF (formerly Equateq
 Limited), for the supply of API. In 2012, the Company agreed to
 terms with a fourth API supplier, a consortium of companies led by
 Slanmhor Pharmaceutical, Inc. (&#x201C;Slanmhor&#x201D;). The API
 supply agreement with BASF terminated in February 2014. In July
 2014, the Company terminated the supply agreement with Slanmhor and
 subsequently, in July 2015, entered into a new supply agreement
 with Finorga SAS (&#x201C;Novasep&#x201D;). These agreements included
 requirements for the suppliers to meet certain product
 specifications and qualify their materials and facilities with
 applicable regulatory authorities including the FDA. The Company
 has incurred certain costs associated with the qualification of
 product produced by these suppliers as described below. Nisshin,
 Chemport and Novasep are currently the three manufacturers from
 which the Company purchases API.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Chemport was approved by the FDA to manufacture API for commercial
 sale in April 2013 and the Company began purchasing commercial
 supply from Chemport in 2013. The agreement with Chemport contains
 a provision requiring the Company to pay Chemport in cash for any
 shortfall in the minimum purchase obligations. The Company began
 purchasing commercial supply from Novasep in 2015. API manufactured
 by Novasep was previously approved by the FDA in July 2014. The
 2015 supply agreement with Novasep includes commitments for the
 Company to fund API purchases and contains a provision requiring
 the Company to pay Novasep a cash remedy for any shortfall in the
 minimum purchase obligations. The Company continues to meet its
 contractual purchase obligations.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Under the 2004 share repurchase agreement with Laxdale Limited
 (&#x201C;Laxdale&#x201D;) upon receipt of marketing approval in
 Europe for the first indication for Vascepa (or first indication of
 any product containing Amarin Neuroscience Limited intellectual
 property acquired from Laxdale in 2004), the Company must make an
 aggregate stock or cash payment to the former shareholders of
 Laxdale (at the sole option of each of the sellers) of
 &#xA3;7.5&#xA0;million (approximately $10.0 million as of
 June&#xA0;30, 2016). Also under the Laxdale agreement, upon receipt
 of a marketing approval in the United States or Europe for a
 further indication of Vascepa (or further indication of any other
 product using Amarin Neuroscience Limited intellectual property),
 the Company must make an aggregate stock or cash payment (at the
 sole option of each of the sellers) of &#xA3;5&#xA0;million
 (approximately $6.7 million as of June&#xA0;30, 2016) for each of
 the two potential market approvals (i.e. &#xA3;10&#xA0;million
 maximum, or approximately $13.4 million as of June&#xA0;30,
 2016).</p>
 <p style="font-size:1px;margin-top:12px;margin-bottom:0px">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company has no provision for any of the obligations above since
 the amounts are either not probable or able to be estimated as of
 June&#xA0;30, 2016.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6807572688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div>
 <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
 <tr>
 <td width="4%" valign="top" align="left"><b>(8)</b></td>
 <td align="left" valign="top"><b>Equity</b></td>
 </tr>
 </table>
 <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <i><u>Warrants</u></i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 During the six months ended June&#xA0;30, 2015, the Company issued
 1,844,585 shares upon the exercise of warrants, resulting in gross
 and net proceeds of $2.8 million and $2.7 million, respectively.
 There was no warrant activity during the six months ended
 June&#xA0;30, 2016 and no warrants remained outstanding as of
 June&#xA0;30, 2016.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <i><u>Incentive Equity Awards</u></i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 In June 2014, the FASB issued guidance for accounting for
 share-based payments when the terms of an award provide that a
 performance target could be achieved after the requisite service
 period. The standard states that a performance target in a
 share-based payment that affects vesting and that could be achieved
 after the requisite service period should be accounted for as a
 performance condition. As such, the performance target should not
 be reflected in estimating the grant-date fair value of the award.
 The guidance became effective for all entities during the first
 quarter of fiscal 2016. The Company previously accounted for awards
 in a manner consistent with the new guidance and as such, adoption
 of the guidance did not have any impact on the Company&#x2019;s
 condensed consolidated financial statements.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 In March 2016, the FASB issued ASU No.&#xA0;2016-09,
 <i>Compensation&#x2014;Stock Compensation (Topic 718): Improvements
 to Employee Share-Based Payment Accounting</i>. The Company early
 adopted this standard during the quarter ended June&#xA0;30, 2016,
 without electing to change its existing accounting policy of
 accounting for forfeitures based on expected vesting. The new
 standard requires that excess tax benefits and deficiencies that
 arise upon vesting or exercise of share-based payments be
 recognized as an income tax benefit and expense in the income
 statement, and also that historical excess tax benefits that were
 not previously recognized because the related tax deduction had not
 reduced current taxes payable should be recognized on a modified
 retrospective basis as a cumulative-effect adjustment to retained
 earnings as of the beginning of the annual period of adoption.
 Further, the new standard amends the presentation of employee
 share-based payment-related items in the statement of cash flows by
 requiring that: (i)&#xA0;excess income tax benefits and
 deficiencies be classified in cash flows from operating activities,
 and (ii)&#xA0;cash paid to taxing authorities arising from the
 withholding of shares from employees be classified as cash flows
 from financing activities. Refer to Note 2 above for additional
 discussion on the Company&#x2019;s adoption of the new standard.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 As of June&#xA0;30, 2016, there were an aggregate of 20,641,123
 stock options and 10,361,147 restricted stock units
 (&#x201C;RSUs&#x201D;) outstanding, representing approximately 8% and
 4%, respectively, of outstanding shares (including common and
 preferred shares) on a fully diluted basis.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 During the six months ended June&#xA0;30, 2016 and 2015, the
 Company issued 83,020 and 18,020 shares, respectively, as a result
 of the exercise of stock options, resulting in gross and net
 proceeds of $0.1 million during the six months ended June&#xA0;30,
 2016 and $31 thousand during the six months ended June&#xA0;30,
 2015.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 On February&#xA0;1, 2016, the Company granted a total of 1,607,500
 RSUs and 2,442,000 stock options to employees under the Amarin
 Corporation plc Stock Incentive Plan (the &#x201C;2011 Plan&#x201D;).
 The RSUs vest annually over a three year period and the stock
 options vest monthly over a four year period.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 On July&#xA0;6, 2015, the Company granted a total of 1,455,000 RSUs
 and 5,470,000 stock options to employees under the 2011 Plan. The
 RSUs granted vest over a four year period. Of the total stock
 options granted, 3,670,000 stock options vest over a four year
 period while the remaining 1,800,000 stock options vest upon the
 achievement of certain performance conditions. During the six
 months ended June&#xA0;30, 2016, the Company issued 181,874 common
 shares related to the vesting of these RSUs, of which 77,405 shares
 were retained as treasury shares as settlement of employee tax
 obligations.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Also on July&#xA0;6, 2015, the Company granted a total of 413,500
 RSUs and 288,657 stock options to members of the Company&#x2019;s
 Board of Directors under the 2011 Plan. Of the total awards
 granted, 283,500 RSUs and 121,506 stock options vest in equal
 installments over a three year period upon the earlier of the
 one-year anniversary of the grant date or the Company&#x2019;s
 annual general meeting of shareholders in such anniversary year,
 while the remaining 130,000 RSUs and 167,151 stock options vest in
 full upon the earlier of the one-year anniversary of the grant date
 or the Company&#x2019;s annual general meeting of shareholders in
 such anniversary year. Upon termination of service to the Company
 or upon a change of control, each Director shall be entitled to a
 payment equal to the fair market value of one share of Amarin
 common stock, which is required to be made in shares.</p>
 <p style="font-size:1px;margin-top:12px;margin-bottom:0px">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 On January&#xA0;29, 2015, the Company granted a total of 2,564,251
 RSUs and 1,622,500 stock options to employees under the 2011 Plan.
 The RSUs vest annually over a three year period and the stock
 options vest monthly over a four year period. Also on
 January&#xA0;29, 2015, the Company granted 5,455,500 RSUs to
 employees under the 2011 Plan that vest upon the achievement of
 certain performance conditions. The issuance of these performance
 RSUs was contingent upon shareholder approval to increase the
 aggregate number of shares authorized for issuance under the 2011
 Plan, which was obtained at the Company&#x2019;s Annual General
 Meeting of Shareholders held on July&#xA0;6, 2015. During the six
 months ended June&#xA0;30, 2016, the Company issued 818,352 common
 shares related to the vesting of these RSUs, of which 270,329
 shares were retained as treasury shares as settlement of employee
 tax obligations.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <i><u>Preferred Stock</u></i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 On March&#xA0;5, 2015, the Company entered into a subscription
 agreement with four institutional investors (the
 &#x201C;Purchasers&#x201D;), including both existing and new
 investors, for the private placement of 352,150,790 restricted
 American Depositary Shares, each representing one (1)&#xA0;share of
 Amarin&#x2019;s Series A Convertible Preference Shares, par value
 &#xA3;0.05&#xA0;per share, in the capital of the Company
 (&#x201C;Series A Preference Shares&#x201D;), resulting in gross
 proceeds to the Company of $52.8 million. The closing of the
 private placement occurred on March&#xA0;30, 2015.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 For each restricted American Depositary Share, the Purchasers paid
 a negotiated price of $0.15 (equating to $1.50 on an
 as-if-converted-to-ordinary-shares basis), resulting in $52.8
 million in aggregate gross proceeds to the Company, before
 deducting estimated offering expenses of approximately $0.7
 million. The net proceeds are reflected as preferred stock in the
 accompanying condensed consolidated balance sheets.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Each ten (10)&#xA0;Series A Preference Shares may be consolidated
 and redesignated as one (1)&#xA0;ordinary share, par value
 &#xA3;0.50&#xA0;per share, in the capital of the Company, each
 ordinary share to be represented by American Depositary Shares
 (&#x201C;ADSs&#x201D;), provided that consolidation will be
 prohibited if, as a result, the holder of such Series A Preference
 Shares and its affiliates would beneficially own more than 4.99% of
 the total number of Amarin ordinary shares or ADSs outstanding
 following such redesignation (the &#x201C;Beneficial Ownership
 Limitation&#x201D;). By written notice to the Company, a holder may
 from time to time increase or decrease the Beneficial Ownership
 Limitation to any other percentage not in excess of 19.9% specified
 in such notice; provided that any such increase will not be
 effective until the sixty-first (61st)&#xA0;day after such notice
 is delivered to the Company. This consolidation and redesignation
 may be effected by a holder of Series A Preference Shares following
 the first to occur of the resale of the ADSs representing the
 ordinary shares being registered for resale under the Securities
 Act pursuant to an effective registration statement, following any
 sale of the ADSs representing the ordinary shares pursuant to Rule
 144 under the Securities Act, or if such ADSs representing the
 ordinary shares are eligible for sale under Rule 144, following the
 expiration of the one-year holding requirement under Rule 144.
 Subsequently, at the request of the holders, a portion of the
 Series A Preference Shares were consolidated and redesignated
 during the three months ended June&#xA0;30, 2015, resulting in the
 issuance of 6,283,333 ADSs such that a maximum of 32,818,464
 ordinary shares remain issuable upon future consolidation and
 redesignation of the remaining Series A Preference Shares as of
 June&#xA0;30, 2016, inclusive of the shares issued in July 2015 as
 discussed below, subject to certain adjustments for dilutive
 events.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Except as otherwise provided in the Series A Preference Share Terms
 or as required by applicable law, the Series A Preference Shares
 have no voting rights. However, as long as any Series A Preference
 Shares are outstanding, the Company cannot, without the approval of
 the holders of seventy-five percent (75%)&#xA0;of the then
 outstanding Series A Preference Shares, alter or change adversely
 the powers, preferences or rights attaching to the Series A
 Preference Shares or enter into any agreement with respect to the
 foregoing.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Holders of the Series A Preference Shares are entitled to receive,
 and the Company is required to pay, dividends (other than dividends
 in the form of ordinary shares) on the Series A Preference Shares
 equal (on an as-if-converted-to-ordinary-shares basis) to and in
 the same form as dividends (other than dividends in the form of
 ordinary shares) actually paid on ordinary shares when, as and if
 such dividends (other than dividends in the form of ordinary
 shares) are paid on the ordinary shares.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The restricted American Depositary Shares and Series A Preference
 Shares were sold in a transaction exempt from the registration
 requirements under the Securities Act of 1933, as amended (the
 &#x201C;Securities Act&#x201D;). The Company filed a registration
 statement with the SEC covering the resale of the restricted
 American Depositary Shares and the ADSs representing ordinary
 shares created by the consolidation and redesignation of the Series
 A Preference Shares (the &#x201C;Registrable Securities&#x201D;) on
 April&#xA0;9, 2015, which was declared effective by the SEC on
 May&#xA0;1, 2015. In addition, the Company agreed to use its
 commercially reasonable best efforts to keep the registration, and
 any qualification, exemption or compliance under state securities
 laws which the Company determines to obtain, continuously
 effective, and to keep the Registration Statement free of any
 material misstatements or omissions, until the earlier of
 (a)&#xA0;March 11, 2017 or (b)&#xA0;the date on which all
 Registrable Securities held by Purchasers may be sold or
 transferred in compliance with Rule 144 under the Securities Act,
 without any volume or manner of sale restrictions.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Series A Preference Shares contain a contingent beneficial
 conversion feature (&#x201C;BCF&#x201D;) because they contain a
 conversion feature at a fixed rate that was in-the-money when
 issued. The BCF was recorded in the three months ended
 June&#xA0;30, 2015 as a result of the related Form S-3 Registration
 Statement being declared effective, which represents the resolution
 of the contingency to convert the Series A Preference Shares. The
 BCF was recognized in stockholders&#x2019; deficit and was measured
 by allocating a portion of the proceeds equal to the intrinsic
 value of that feature to additional paid-in capital. The effective
 purchase price of the ordinary shares into which the preferred
 shares are convertible was $1.50, which was used to compute the
 intrinsic value. The intrinsic value was calculated as the
 difference between the effective purchase price of the ordinary
 shares and the market value ($2.39 per share) on the date the
 preferred shares were issued, multiplied by the number of shares
 into which the preferred shares are convertible. The BCF resulting
 from the issuance of the Series A Preference Shares was determined
 to be $31.3 million. The BCF was recorded as a non-cash dividend to
 preferred shareholders through accumulated deficit, and was
 therefore reflected as an adjustment to net loss applicable to
 common shareholders for earnings per common share purposes in
 accordance with GAAP for the three months ended June&#xA0;30,
 2015.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 On March&#xA0;30, 2015, in connection with the closing of the
 private placement, and pursuant to a pre-existing contractual right
 to participate in certain private placement transactions effected
 by the Company, the Company entered into a separate subscription
 agreement with an existing investor, Sofinnova Venture Partners VII
 L.P. (Sofinnova), for the purchase of an additional $5.8 million of
 restricted American Depositary Shares, each representing one
 (1)&#xA0;share of the Company&#x2019;s Series A Preference Shares,
 at the same price per share and otherwise on substantially the same
 terms as the initial private placement (the &#x201C;Second Private
 Placement&#x201D;). In accordance with applicable marketplace rules
 of the NASDAQ Stock Market, the consummation of the Second Private
 Placement was conditioned upon approval by the Company&#x2019;s
 shareholders at a future meeting of the Company&#x2019;s
 shareholders. Such approval was received at the Company&#x2019;s
 Annual General Meeting of Shareholders on July&#xA0;6, 2015 and as
 a result, the closing of the Second Private Placement occurred on
 July&#xA0;10, 2015. The Company issued 38,867,180 restricted ADSs
 at that time, each representing one Series A Preference Share,
 which may be consolidated and redesignated from time to time up to
 a maximum of 3,886,718 ordinary shares, each ordinary share to be
 represented by one ADS. For each restricted ADS, Sofinnova paid a
 negotiated price of $0.15 (equating to $1.50 on an
 as-if-converted-to-ordinary-shares basis) resulting in gross
 proceeds to the Company of $5.8 million. Dr.&#xA0;James Healy, a
 member of the Company&#x2019;s Board, is a managing general partner
 of Sofinnova Management VII, L.L.C., which is the general partner
 of Sofinnova.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company filed another registration statement with the SEC
 covering the resale of these restricted American Depositary Shares
 and the ADSs representing ordinary shares created by the
 consolidation and redesignation of the Series A Preference Shares
 (the &#x201C;Sofinnova Registrable Securities&#x201D;) on
 July&#xA0;24, 2015, which was declared effective by the SEC on
 August&#xA0;7, 2015. In addition, the Company agreed to use its
 commercially reasonable best efforts to keep the registration, and
 any qualification, exemption or compliance under state securities
 laws which the Company determines to obtain, continuously
 effective, and to keep the registration statement free of any
 material misstatements or omissions, until the earlier of
 (a)&#xA0;July 10, 2017 or (b)&#xA0;the date on which all Sofinnova
 Registrable Securities held by Sofinnova may be sold or transferred
 in compliance with Rule 144 under the Securities Act, without any
 volume or manner of sale restrictions.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The existence of this preferred stock purchase option was
 determined to be a derivative liability effective March&#xA0;5,
 2015, the date on which the private placement was initially
 subscribed. The fair value of this liability was calculated using a
 Black-Scholes model and was determined to be $0.9 million at
 inception and was charged to accumulated deficit as a deemed
 non-cash dividend to Sofinnova. The liability was then marked to
 fair value as of March&#xA0;30, 2015, the date on which the Company
 executed a subscription agreement with Sofinnova, resulting in a
 charge of $0.9 million through gain (loss) on change in fair value
 of derivatives. The liability of $1.8 million was reclassified to
 permanent equity (additional paid-in capital) on such date.
 Subsequent to approval of the Second Private Placement at the
 Company&#x2019;s Annual General Meeting of Shareholders in July
 2015, the Company recorded the remaining value of the BCF related
 to this share issuance as a non-cash dividend to preferred
 shareholders through accumulated deficit. The value of the BCF was
 determined on the same basis as the first private placement and
 amounted to $3.4 million less $1.8 million previously recorded for
 the preferred stock purchase option for a net non-cash charge of
 $1.6 million in the third quarter of 2015.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6807588656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Co-Promotion Agreement<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_CoPromotionAgreementDisclosureTextBlock', window );">Co-Promotion Agreement</a></td>
<td class="text"><div>
 <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
 <tr>
 <td width="4%" valign="top" align="left"><b>(9)</b></td>
 <td align="left" valign="top"><b>Co-Promotion Agreement</b></td>
 </tr>
 </table>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 On March&#xA0;31, 2014, the Company entered into a Co-Promotion
 Agreement (the Agreement) with Kowa Pharmaceuticals America, Inc.
 related to the commercialization of Vascepa<sup style="font-size:85%; vertical-align:top">&#xAE;</sup> (icosapent ethyl)
 capsules in the United States. Under the terms of the Agreement,
 Amarin granted to Kowa Pharmaceuticals America, Inc. the right to
 be the sole co-promoter, together with the Company, of Vascepa in
 the United States during the term. The initial term of the
 Agreement extends through 2018.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 During the term, Kowa Pharmaceuticals America, Inc. and Amarin have
 agreed to use commercially reasonable efforts to promote, detail
 and optimize sales of Vascepa in the United States. The performance
 requirements include a negotiated minimum number of details to be
 delivered by each party in the first and second position, and the
 use of a negotiated number of minimum sales representatives from
 each party, including no less than 250 Kowa Pharmaceuticals
 America, Inc. sales representatives. Kowa Pharmaceuticals America,
 Inc. has agreed to continue to bear the costs incurred for its
 sales force associated with the commercialization of Vascepa and to
 pay for certain incremental costs associated with the use of its
 sales force, such as sample costs and costs for promotional and
 marketing materials. Amarin will continue to recognize all revenue
 from sales of Vascepa and will use commercially reasonable efforts
 to maintain a minimum amount of inventory of Vascepa for use in the
 United States.</p>
 <p style="font-size:1px;margin-top:12px;margin-bottom:0px">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 In exchange for Kowa Pharmaceuticals America, Inc.&#x2019;s
 co-promotional services, Kowa Pharmaceuticals America, Inc. is
 entitled to a quarterly co-promotion fee based on aggregate Vascepa
 gross margin that increases during the term. The percentage of
 aggregate Vascepa gross margin earned by Kowa Pharmaceuticals
 America, Inc. was fifteen percent (15%)&#xA0;in 2015, is nineteen
 percent (19%)&#xA0;in 2016, and is scheduled to increase to low
 twenty percent levels in 2017 and 2018, subject to certain
 adjustments. The co-promotion fee also varies based on sales levels
 and whether the FDA has approved an ANCHOR indication labeling
 expansion for Vascepa or has permitted the use of data generated to
 support obtaining FDA approval of the ANCHOR indication in the
 promotion of Vascepa, in which case the co-promotion fee would be
 decreased if specified requirements are met. In certain
 circumstances, upon the earlier of the expiration or termination of
 the Agreement in accordance with its terms, Kowa Pharmaceuticals
 America, Inc. may be eligible for a co-promotion tail fee equal to
 declining fractions of the co-promotion fee in effect prior to such
 expiration or termination for periods ranging from one to three
 years following such expiration or termination.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 As of June&#xA0;30, 2016 and December&#xA0;31, 2015,&#xA0;the
 Company had a net payable of $2.7 million and $2.5 million,
 respectively, to Kowa Pharmaceuticals America, Inc. representing
 co-promotion fees payable to Kowa Pharmaceuticals America, Inc. net
 of reimbursable amounts incurred for samples and other marketing
 expenses.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_CoPromotionAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co Promotion Agreement Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_CoPromotionAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6807690432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Development, Commercialization and Supply Agreement<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Development, Commercialization and Supply Agreement</a></td>
<td class="text"><div>
 <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
 <tr>
 <td width="4%" valign="top" align="left"><b>(10)</b></td>
 <td align="left" valign="top"><b>Development, Commercialization and
 Supply Agreement</b></td>
 </tr>
 </table>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 On February&#xA0;26, 2015, the Company entered into a Development,
 Commercialization and Supply Agreement (the &#x201C;DCS
 Agreement&#x201D;) with Eddingpharm (Asia) Macao Commercial Offshore
 Limited (&#x201C;Eddingpharm&#x201D;) related to the development and
 commercialization of Vascepa in Mainland China, Hong Kong, Macau
 and Taiwan (the &#x201C;China Territory&#x201D;). Under the terms of
 the DCS Agreement, the Company granted to Eddingpharm an exclusive
 (including as to the Company) license with right to sublicense to
 develop and commercialize Vascepa in the China Territory for uses
 that are currently commercialized and under development by the
 Company based on the Company&#x2019;s MARINE, ANCHOR and ongoing
 REDUCE-IT clinical trials of Vascepa.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Under the DCS Agreement, Eddingpharm will be solely responsible for
 development and commercialization activities in the China Territory
 and associated expenses. The Company will provide development
 assistance and be responsible for supplying finished and later bulk
 drug product at defined prices under negotiated terms. The Company
 will retain all Vascepa manufacturing rights. Eddingpharm has
 agreed to certain restrictions regarding the commercialization of
 competitive products globally and the Company has agreed to certain
 restrictions regarding the commercialization of competitive
 products in the China Territory.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company and Eddingpharm agreed to form a joint development
 committee to oversee regulatory and development activities for
 Vascepa in the China Territory in accordance with a negotiated
 development plan and to form a separate joint commercialization
 committee to oversee Vascepa commercialization activities in the
 China Territory. Development costs will be paid by Eddingpharm to
 the extent such costs are incurred in connection with the
 negotiated development plan or otherwise incurred by Eddingpharm.
 Eddingpharm will be responsible for preparing and filing regulatory
 applications in all countries of the China Territory at
 Eddingpharm&#x2019;s cost with the Company&#x2019;s assistance. The
 DCS Agreement also contains customary provisions regarding
 indemnification, packaging, record keeping, audit rights, reporting
 obligations, and representations and warranties that are customary
 for an arrangement of this type.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The term of the DCS Agreement expires, on a product-by-product
 basis, upon the later of (i)&#xA0;the date on which such product is
 no longer covered by a valid claim under a licensed patent in the
 China Territory, or (ii)&#xA0;the twelfth (12th)&#xA0;anniversary
 of the first commercial sale of such product in Mainland China. The
 DCS Agreement may be terminated by either party in the event of a
 bankruptcy of the other party and for material breach, subject to
 customary cure periods. In addition, at any time following the
 third anniversary of the first commercial sale of a product in
 Mainland China, Eddingpharm has the right to terminate the DCS
 Agreement for convenience with twelve months&#x2019; prior notice.
 Neither party may assign or transfer the DCS Agreement without the
 prior consent of the other party, provided that the Company may
 assign the DCS Agreement in the event of a change of control
 transaction.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Upon closing of the DCS Agreement, the Company received a
 non-refundable $15.0 million up-front payment, which it will
 recognize as revenue over the estimated period in which the Company
 is required to provide initial and on-going regulatory and
 development support and clinical supply for obtaining regulatory
 approvals in the China Territory and through the estimated period
 in which the Company is required to provide commercial supply,
 which is currently estimated to be a period of approximately 16
 years. In March 2016, Eddingpharm submitted its clinical trial
 application (&#x201C;CTA&#x201D;) with respect to the MARINE
 indication for Vascepa to the Chinese regulatory authority.
 Following the CTA submission, the Company received a non-refundable
 $1.0 million milestone payment which it will recognize as revenue
 over the estimated period in which the Company is required to
 provide on-going development support needed to support the
 successful approval for a new drug application, which is currently
 estimated to be a period of approximately four years.</p>
 <p style="font-size:1px;margin-top:12px;margin-bottom:0px">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 In addition to the non-refundable, up-front and regulatory
 milestone payments described above, the Company is entitled to
 receive certain regulatory and sales-based milestone payments of up
 to an additional $153.0 million as well as tiered double-digit
 percentage royalties on net sales of Vascepa in the China Territory
 escalating to the high teens. The regulatory milestone events
 relate to the submission and approval of certain applications to
 the applicable regulatory authority, such as a clinical trial
 application, clinical trial exemption, or import drug license
 application. The sales-based milestone events occur when annual
 aggregate net sales of Vascepa in the territory equals or exceeds
 certain specified thresholds. Each such milestone payment shall be
 payable only once regardless of how many times the sales milestone
 event is achieved. Each such milestone payment is non-refundable
 and non-creditable against any other milestone payments. The
 Company recognizes contingent consideration from activities that is
 earned upon the achievement of a substantive milestone in the
 period in which the milestone is achieved.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Licensing and deferred revenues currently consist of revenue
 attributable to receipt of up-front, non-refundable payments and
 milestone payments related to the DCS Agreement and other licensing
 agreements outside the United States. Up-front and milestone
 payments under such agreements are typically recognized as
 licensing revenue over the estimated period in which we are
 required to provide regulatory and development support and clinical
 and commercial supply pursuant to the agreements. During the six
 months ended June&#xA0;30, 2016 and 2015, the Company recognized
 $0.5 million and $0.4 million of up-front and milestone payments as
 licensing revenue, respectively, and recorded $15.7 million as
 deferred revenue as of June&#xA0;30, 2016.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6585004288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div>
 <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
 <tr>
 <td width="4%" valign="top" align="left"><b>(11)</b></td>
 <td align="left" valign="top"><b>Subsequent Events</b></td>
 </tr>
 </table>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company has evaluated subsequent events from June&#xA0;30, 2016
 through the date of the issuance of these condensed consolidated
 financial statements.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6817177600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <b><i><u>Principles of Consolidation</u></i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The condensed consolidated financial statements include the
 accounts of the Company and its wholly-owned subsidiaries. All
 intercompany accounts and transactions have been eliminated in
 consolidation.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <b><i><u>Use of Estimates</u></i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Accounting estimates are based on historical experience and other
 factors that are considered reasonable under the circumstances.
 Estimates are used in determining such items as provisions for
 sales returns, rebates and incentives, chargebacks, and other sales
 allowances; depreciable/amortizable lives; asset impairments;
 valuation allowance on deferred taxes; probabilities of achievement
 of performance conditions for certain equity awards; amounts
 recorded for licensing revenue; contingencies and accruals; and
 valuations of derivative and long-term debt instruments. Because of
 the uncertainties inherent in such estimates, actual results may
 differ from these estimates. Management periodically evaluates
 estimates used in the preparation of the condensed consolidated
 financial statements for continued reasonableness.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_UseOfForecastedFinancialInformationInAccountingEstimatesPolicyTextBlock', window );">Use of Forecasted Financial Information in Accounting Estimates</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <b><i><u>Use of Forecasted Financial Information in Accounting
 Estimates</u></i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The use of forecasted financial information is inherent in many of
 the Company&#x2019;s accounting estimates including, but not limited
 to, determining the estimated fair values of derivatives, debt
 instruments and intangible assets, and evaluating the need for
 valuation allowances for deferred tax assets. Such forecasted
 financial information is comprised of numerous assumptions
 regarding the Company&#x2019;s future revenues, cash flows, and
 operational results. Management believes that its financial
 forecasts are reasonable and appropriate based upon current facts
 and circumstances. Because of the inherent nature of forecasts,
 however, actual results may differ from these forecasts. Management
 regularly reviews the information related to these forecasts and
 adjusts the carrying amounts of the applicable assets
 prospectively, if and when actual results differ from previous
 estimates.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <b><i><u>Revenue Recognition</u></i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company sells Vascepa principally to a limited number of major
 wholesalers, as well as selected regional wholesalers and specialty
 pharmacy providers, or collectively, its Distributors or its
 customers, that in turn resell Vascepa to retail pharmacies for
 subsequent resale to patients and healthcare providers. Patients
 are required to have a prescription in order to purchase Vascepa.
 In accordance with GAAP, the Company&#x2019;s revenue recognition
 policy requires that: (i)&#xA0;there is persuasive evidence that an
 arrangement exists between the Company and the Distributor,
 (ii)&#xA0;delivery has occurred, (iii)&#xA0;collectability is
 reasonably assured and (iv)&#xA0;the price is fixed or
 determinable.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company has contracts with its primary Distributors and
 delivery generally occurs when a Distributor receives Vascepa. The
 Company evaluates the creditworthiness of each of its Distributors
 to determine whether revenues can be recognized upon delivery,
 subject to satisfaction of the other requirements, or whether
 recognition is required to be delayed until receipt of payment. In
 order to conclude that the price is fixed or determinable, the
 Company must be able to (i)&#xA0;calculate its gross product
 revenues from the sales to Distributors and (ii)&#xA0;reasonably
 estimate its net product revenues. The Company calculates gross
 product revenues generally based on the wholesale acquisition cost
 that the Company charges its Distributors for Vascepa. The Company
 estimates its net product revenues by deducting from its gross
 product revenues (a)&#xA0;trade allowances, such as invoice
 discounts for prompt payment and distributor fees,
 (b)&#xA0;estimated government and private payor rebates,
 chargebacks and discounts, such as Medicaid reimbursements,
 (c)&#xA0;reserves for expected product returns and
 (d)&#xA0;estimated costs of incentives offered to certain indirect
 customers, including patients.</p>
 <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Trade Allowances:</i> The Company generally provides invoice
 discounts on Vascepa sales to its Distributors for prompt payment
 and pays fees for distribution services, such as fees for certain
 data that Distributors provide to the Company. The payment terms
 for sales to Distributors generally include a 2% discount for
 payment within 30&#xA0;days while the fees for distribution
 services are based on contractual rates agreed with the respective
 Distributors. Based on judgment and experience, the Company expects
 its Distributors to earn these discounts and fees, and deducts the
 full amount of these discounts and fees from its gross product
 revenues and accounts receivable at the time such revenues are
 recognized.</p>
 <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Rebates, Chargebacks and Discounts:</i> The Company contracts
 with Medicaid, other government agencies and various private
 organizations, or collectively, Third-party Payors, so that Vascepa
 will be eligible for purchase by, or partial or full reimbursement
 from, such Third-party Payors. The Company estimates the rebates,
 chargebacks and discounts it will provide to Third-party Payors and
 deducts these estimated amounts from its gross product revenues at
 the time the revenues are recognized. The Company estimates the
 rebates, chargebacks and discounts that it will provide to
 Third-party Payors based upon (i)&#xA0;the Company&#x2019;s
 contracts with these Third-party Payors, (ii)&#xA0;the
 government-mandated discounts applicable to government-funded
 programs, (iii)&#xA0;information obtained from the Company&#x2019;s
 Distributors and (iv)&#xA0;information obtained from other third
 parties regarding the payor mix for Vascepa.</p>
 <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Product Returns:</i> The Company&#x2019;s Distributors have the
 right to return unopened unprescribed Vascepa during the 18-month
 period beginning six months prior to the labeled expiration date
 and ending twelve months after the labeled expiration date. The
 expiration date for Vascepa is three years after it has been
 converted into capsule form, which is the last step in the
 manufacturing process for Vascepa and generally occurs within a few
 months before Vascepa is delivered to Distributors. The Company
 estimates future product returns on sales of Vascepa based on:
 (i)&#xA0;data provided to the Company by its Distributors
 (including weekly reporting of Distributors&#x2019; sales and
 inventory held by Distributors that provided the Company with
 visibility into the distribution channel in order to determine what
 quantities were sold to retail pharmacies and other providers),
 (ii)&#xA0;information provided to the Company from retail
 pharmacies, (iii)&#xA0;data provided to the Company by a third
 party data provider which collects and publishes prescription data,
 and other third parties, (iv)&#xA0;historical industry information
 regarding return rates for similar pharmaceutical products,
 (v)&#xA0;the estimated remaining shelf life of Vascepa previously
 shipped and currently being shipped to Distributors and
 (vi)&#xA0;contractual agreements intended to limit the amount of
 inventory maintained by the Company&#x2019;s Distributors.</p>
 <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 <i>Other Incentives:</i> Other incentives that the Company offers
 to indirect customers include co-pay mitigation rebates provided by
 the Company to commercially insured patients who have coverage for
 Vascepa and who reside in states that permit co-pay mitigation
 programs. The Company&#x2019;s co-pay mitigation program is intended
 to reduce each participating patient&#x2019;s portion of the
 financial responsibility for Vascepa&#x2019;s purchase price to a
 specified dollar amount. Based upon the terms of the program and
 information regarding programs provided for similar specialty
 pharmaceutical products, the Company estimates the average co-pay
 mitigation amounts and the percentage of patients that it expects
 to participate in the program in order to establish its accruals
 for co-pay mitigation rebates and deducts these estimated amounts
 from its gross product revenues at the time the revenues are
 recognized. The Company adjusts its accruals for co-pay mitigation
 rebates based on actual redemption activity and estimates regarding
 the portion of issued co-pay mitigation rebates that it estimates
 will be redeemed.</p>
 <p style="font-size:1px;margin-top:12px;margin-bottom:0px">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The following tables summarize activity in each of the net product
 revenue allowance and reserve categories described above for the
 six months ended June&#xA0;30, 2016 and 2015:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Trade<br />
 Allowances</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Rebates,<br />
 Chargebacks<br />
 and&#xA0;Discounts</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Product<br />
 Returns</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Other<br />
 Incentives</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Balance as of December&#xA0;31, 2015</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>4,296</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>9,881</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>535</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>1,084</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>15,796</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Provision related to current period sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,048</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28,945</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">257</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,614</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">44,864</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Provision related to prior period sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(87</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(466</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(553</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Credits/payments made for current period sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,415</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(10,750</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,910</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(20,075</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Credits/payments made for prior period sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,180</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(8,497</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(226</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,284</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(14,187</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Balance as of June&#xA0;30, 2016</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>3,662</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>19,113</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>566</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>2,504</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>25,845</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="63%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Trade<br />
 Allowances</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Rebates,<br />
 Chargebacks<br />
 and&#xA0;Discounts</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Product<br />
 Returns</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Other<br />
 Incentives</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Balance as of December&#xA0;31, 2014</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>2,207</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>3,610</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>&#xA0;481</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>792</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>7,090</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Provision related to current period sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,044</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,957</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">276</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,691</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,968</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Provision related to prior period sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(113</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(44</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(157</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Credits/payments made for current period sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,810</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,243</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,149</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(12,202</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Credits/payments made for prior period sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,039</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,531</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(14</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(792</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,376</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Balance as of June&#xA0;30, 2015</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>2,289</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>5,749</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>743</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>1,542</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>10,323</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Such net product revenue allowances and reserves are included
 within accrued expenses and other current liabilities within the
 condensed consolidated balance sheets, with the exception of trade
 allowances and chargebacks, which are included within accounts
 receivable, net as discussed below.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <i>Multiple-Element Arrangements and Licensing Revenue</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 When evaluating multiple-element arrangements, the Company
 identifies the deliverables included within the agreement and
 evaluates which deliverables represent separate units of accounting
 based on whether the delivered element has stand-alone value to the
 customer or if the arrangement includes a general right of return
 for delivered items.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The consideration received is allocated between each of the
 separable elements in the arrangement using the relative selling
 price method. The selling price used for each separable element
 will be based on vendor specific objective evidence
 (&#x201C;VSOE&#x201D;) if available, third-party evidence if VSOE is
 not available, or estimated selling price if neither VSOE nor
 third-party evidence is available. Revenue is then recognized as
 each of the separable elements to which the revenue has been
 allocated is delivered.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company may receive up-front, non-refundable payments when
 licensing its intellectual property in conjunction with research,
 development and commercialization agreements. In determining the
 units of accounting, management evaluates whether the license has
 stand-alone value from the undelivered elements to the
 collaborative partner based on the consideration of the relevant
 facts and circumstances for each arrangement. Factors considered in
 this determination include the stage of development of the license
 delivered, research and development capabilities of the partner and
 the ability of partners to develop and commercialize Vascepa
 independent of the Company.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 When management believes the license to its intellectual property
 does not have stand-alone value from the other deliverables to be
 provided in the arrangement, the Company generally recognizes
 revenue attributable to the license over the Company&#x2019;s
 contractual or estimated performance period. Any unrecognized
 portion of license revenue is classified within deferred revenue in
 the accompanying condensed consolidated balance sheets. When
 management believes the license to its intellectual property has
 stand-alone value, the Company recognizes revenue attributed to the
 license upon delivery. The periods over which revenue is recognized
 is subject to estimates by management and may change over the
 course of the agreement. Such a change could have a material impact
 on the amount of revenue the Company records in future periods.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <i>Milestones</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Contingent consideration from activities that is earned upon the
 achievement of a substantive milestone is recognized in its
 entirety in the period in which the milestone is achieved. At the
 inception of each arrangement that includes milestone payments, the
 Company evaluates whether each milestone is substantive. This
 evaluation includes an assessment of whether: (a)&#xA0;the
 consideration is commensurate with either (1)&#xA0;the
 entity&#x2019;s performance to achieve the milestone, or
 (2)&#xA0;the enhancement of the value of the delivered item(s) as a
 result of a specific outcome resulting from the entity&#x2019;s
 performance to achieve the milestone, (b)&#xA0;the consideration
 relates solely to past performance and (c)&#xA0;the consideration
 is reasonable relative to all of the deliverables and payment terms
 within the arrangement. The Company evaluates factors such as the
 scientific, clinical, regulatory, commercial and other risks that
 must be overcome to achieve the respective milestone, the level of
 effort and investment required and whether the milestone
 consideration is reasonable relative to all deliverables and
 payment terms in the arrangement in making this assessment.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 See Note 10&#x2014;Development, Commercialization and Supply
 Agreement for further information regarding licensing revenue and
 milestones related to the Company&#x2019;s multiple-element
 arrangement with Eddingpharm (Asia) Macao Commercial Offshore
 Limited.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock', window );">Distribution Costs</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <b><i><u>Distribution Costs</u></i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company records distribution costs related to shipping product
 to its customers, primarily through the use of common carriers or
 external distribution services, in cost of goods sold.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <b><i><u>Cash and Cash Equivalents and Restricted
 Cash</u></i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Cash and cash equivalents consist of cash, deposits with banks and
 short-term highly liquid money market instruments with remaining
 maturities at the date of purchase of 90&#xA0;days or less.
 Restricted cash represents cash and cash equivalents pledged to
 guarantee repayment of certain expenses which may be incurred for
 business travel under corporate credit cards held by employees.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable, net</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <b><i><u>Accounts Receivable, net</u></i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Accounts receivable, net, comprised of trade receivables, are
 generally due within 30 days and are stated at amounts due from
 customers. The Company does not currently maintain an allowance for
 doubtful accounts and has not historically experienced any credit
 losses.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The following table summarizes the impact of accounts receivable
 reserves on the gross trade accounts receivable balances as of
 June&#xA0;30, 2016 and December&#xA0;31, 2015:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="68%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">
 <b>June&#xA0;30,&#xA0;2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">
 <b>December&#xA0;31,&#xA0;2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Gross trade accounts receivable</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">21,528</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">18,270</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Trade allowances</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,662</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,296</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Chargebacks</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(227</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(148</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accounts receivable, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">17,639</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">13,826</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Inventory</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Effective April 2016, the Company adopted ASU No.&#xA0;2015-11,
 <i>Inventory (Topic 330)&#x2014;Simplifying the Measurement of
 Inventory</i>, which simplifies the subsequent measurement of
 inventories by replacing the lower of cost or market test with a
 lower of cost and net realizable value test and, as such, began to
 state inventories at the lower of cost or net realizable value.
 Such adoption had no impact on the carrying value of inventory.
 Cost is determined based on actual cost using the average cost
 method. An allowance is established when management determines that
 certain inventories may not be saleable. If inventory cost exceeds
 expected net realizable value due to obsolescence, damage,
 quantities in excess of expected demand, changes in price levels or
 other causes, the Company will reduce the carrying value of such
 inventory to net realizable value and recognize the difference as a
 component of cost of goods sold in the period in which it occurs.
 The Company capitalizes inventory purchases of saleable product
 from approved suppliers while inventory purchases from suppliers
 prior to regulatory approval are included as a component of
 research and development expense. The Company expenses inventory
 identified for use as marketing samples when they are packaged. The
 average cost reflects the actual purchase price of Vascepa active
 pharmaceutical ingredient, or API.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <b><i><u>Property, Plant and Equipment</u></i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company provides for depreciation and amortization using the
 straight-line method by charges to operations in amounts that
 depreciate the cost of the fixed asset over its estimated useful
 life. The estimated useful lives, by asset classification, are as
 follows:</p>
 <p style="font-size:1px;margin-top:12px;margin-bottom:0px">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:66.30pt; font-size:8pt; font-family:Times New Roman">
 <b>Asset Classification</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center" style="border-bottom:1.00pt solid #000000"><b>Useful&#xA0;Lives</b></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Computer equipment and software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">3&#xA0;-&#xA0;5&#xA0;years</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Furniture and fixtures</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">5&#xA0;years</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 Lesser&#xA0;of&#xA0;useful&#xA0;life&#xA0;or&#xA0;lease&#xA0;term</td>
 </tr>
 </table>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Upon retirement or sale of assets, the cost of the assets disposed
 and the related accumulated depreciation are removed from the
 condensed consolidated balance sheet and any resulting gain or loss
 is credited or expensed to operations. Repairs and maintenance
 costs are expensed as incurred.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Asset Impairment</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <b><i><u>Long-Lived Asset Impairment</u></i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company reviews its long-lived assets for impairment whenever
 events or changes in circumstances indicate that the carrying
 amount of such assets may not be recoverable. Recoverability of
 these assets is determined by comparing the forecasted undiscounted
 net cash flows of the operation to which the assets relate to their
 carrying amount. If impairment is indicated, the assets are written
 down to fair value. Fair value is determined based on discounted
 forecasted cash flows or appraised values, depending on the nature
 of the assets.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Asset, net</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <b><i><u>Intangible Asset, net</u></i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Intangible asset, net consists of a milestone payment paid to the
 former shareholders of Laxdale Limited related to the 2004
 acquisition of the rights to Vascepa, which is the result of
 Vascepa receiving marketing approval for the first indication and
 is amortized over its estimated useful life on a straight-line
 basis. See Note 7&#x2014;Commitments and Contingencies for further
 information regarding other obligations related to the acquisition
 of Laxdale Limited.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_BeneficialConversionFeaturePolicyTextBlock', window );">Beneficial Conversion Features</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <b><i><u>Beneficial Conversion Features</u></i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company issued Series A preference shares in a private
 placement transaction executed in two tranches that each contain a
 conversion feature whereby such shares are convertible into
 ordinary shares at a fixed rate. The conversion price on the date
 of issuance was less than the market price of the Company&#x2019;s
 ordinary shares. It was determined that these discounts represent
 contingent beneficial conversion features, which were valued based
 on the difference between the conversion price and the market price
 of the ordinary shares on the date of issuance, which is the
 commitment date. These features are analogous to preference
 dividends and were each recorded as a non-cash return to preferred
 shareholders through accumulated deficit upon the earliest possible
 date of conversion, which occurred in the three months ended
 June&#xA0;30, 2015 upon effectiveness of the related resale
 Registration Statement on Form S-3 and in the three months ended
 September&#xA0;30, 2015 upon shareholder approval received at the
 Company&#x2019;s Annual General Meeting of Shareholders. See Note
 8&#x2014;Equity for further discussion.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Costs for Patent Litigation and Legal Proceedings</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <b><i><u>Costs for Patent Litigation and Legal
 Proceedings</u></i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Costs for patent litigation or other legal proceedings are expensed
 as incurred and included in selling, general and administrative
 expenses.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <b><i><u>Research and Development Costs</u></i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company charges research and development costs to operations as
 incurred. Research and development expenses are comprised of costs
 incurred by the Company in performing research and development
 activities, including: salary and benefits; stock-based
 compensation expense; laboratory supplies and other direct
 expenses; contractual services, including clinical trial and
 pharmaceutical development costs; commercial supply investment in
 its drug candidates; and infrastructure costs, including facilities
 costs and depreciation expense. In addition, research and
 development costs include the costs of product supply received from
 suppliers when such receipt by the Company is prior to regulatory
 approval of the supplier.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Costs</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <b><i><u>Selling, General and Administrative Costs</u></i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company charges selling, general and administrative costs to
 operations as incurred. Selling, general and administrative costs
 include costs of salaries, programs and infrastructure necessary
 for the general conduct of the Company&#x2019;s business, including
 those incurred as a result of the commercialization of Vascepa in
 the United States as well as co-promotion fees payable to Kowa
 Pharmaceuticals America, Inc.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt">
 <b><i><u>Income Taxes</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Deferred tax assets and liabilities are recognized for the future
 tax consequences of differences between the carrying amounts and
 tax bases of assets and liabilities and operating loss
 carryforwards and other attributes using enacted rates expected to
 be in effect when those differences reverse. Valuation allowances
 are provided against deferred tax assets that are not more likely
 than not to be realized.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company provides reserves for potential payments of tax to
 various tax authorities or does not recognize tax benefits related
 to uncertain tax positions and other issues. Tax benefits for
 uncertain tax positions are based on a determination of whether a
 tax benefit taken by the Company in its tax filings or positions is
 more likely than not to be realized, assuming that the matter in
 question will be decided based on its technical merits. The
 Company&#x2019;s policy is to record interest and penalties in the
 provision for income taxes.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company regularly assesses its ability to realize deferred tax
 assets. Changes in historical earnings performance and future
 earnings projections, among other factors, may cause the Company to
 adjust its valuation allowance on deferred tax assets, which would
 impact the Company&#x2019;s income tax expense in the period in
 which it is determined that these factors have changed.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In April 2016, the Company adopted ASU No.&#xA0;2016-09,
 <i>Compensation&#x2014;Stock Compensation (Topic 718): Improvements
 to Employee Share-Based Payment Accounting,</i> which changes the
 accounting for certain aspects of share-based payments to
 employees. One aspect of the standard requires that excess tax
 benefits and deficiencies that arise upon vesting or exercise of
 share-based payments be recognized as an income tax benefit and
 expense in the income statement. Previously, such amounts were
 recognized as an increase and decrease in additional paid-in
 capital. This aspect of the standard was adopted prospectively, and
 accordingly, the benefit from income taxes for the three and six
 months ended June&#xA0;30, 2016, includes $0.1 million and $0.2
 million, respectively, of excess tax deficiencies arising from
 share-based payments. Additionally, the new standard requires that
 historical excess tax benefits that were not previously recognized
 because the related tax deduction had not reduced current taxes
 payable should be recognized on a modified retrospective basis as a
 cumulative-effect adjustment to retained earnings as of the
 beginning of the annual period of adoption. Consequently, the
 Company recognized deferred tax assets of approximately $1.6
 million relating to excess tax benefits of stock-based compensation
 outstanding as of December&#xA0;31, 2015, with a corresponding
 cumulative-effect adjustment to accumulated deficit. The new
 standard also amends the presentation of employee share-based
 payment-related items in the statement of cash flows by requiring
 that: (i)&#xA0;excess income tax benefits and deficiencies be
 classified in cash flows from operating activities, and
 (ii)&#xA0;cash paid to taxing authorities arising from the
 withholding of shares from employees be classified as cash flows
 from financing activities. The Company adopted the aspects of the
 standard affecting cash flow presentation retrospectively and,
 accordingly, reclassified $0.6 million of excess tax provision from
 cash flows provided by financing activities to cash flows used in
 operating activities in the condensed consolidated statement of
 cash flows for the six months ended June&#xA0;30, 2015 to conform
 to the current year presentation. The presentation requirement for
 cash flows related to taxes paid for withheld shares had no impact
 to any of the periods presented in the condensed consolidated
 statement of cash flows since such payments have historically been
 presented as a financing activity.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company&#x2019;s and its subsidiaries&#x2019; income tax returns
 are periodically examined by various tax authorities. The Company
 is currently under audit by the United States Internal Revenue
 Service (IRS) for the years 2012 to 2013. Although the outcome of
 tax audits is always uncertain and could result in significant cash
 tax payments, the Company does not believe the outcome of these
 audits will have a material adverse effect on the Company&#x2019;s
 consolidated financial position or results of operations.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <b><i><u>Derivative Instruments</u></i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Derivative financial liabilities are recorded at fair value, with
 gains and losses arising for changes in fair value recognized in
 the condensed consolidated statement of operations at each period
 end while such instruments are outstanding. If the Company issues
 shares to discharge the liability, the derivative financial
 liability is derecognized and common stock and additional paid-in
 capital are recognized on the issuance of those shares. Warrants
 are valued using a Black-Scholes option pricing model. The
 long-term debt redemption features are valued using
 probability-weighted models incorporating management estimates for
 potential change in control, and by determining the fair value of
 the debt with and without the change in control provision
 included.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 If the terms of warrants that initially require the warrant to be
 classified as a derivative financial liability lapse, the
 derivative financial liability is reclassified out of financial
 liabilities into equity at its fair value on that date. The cash
 proceeds received from exercises of warrants are recorded in common
 stock and additional paid-in capital.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per Share</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <b><i><u>Loss per Share</u></i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Basic net loss per share is determined by dividing net loss by the
 weighted average shares of common stock outstanding during the
 period. Diluted net loss per share is determined by dividing net
 loss by diluted weighted average shares outstanding. Diluted
 weighted average shares reflects the dilutive effect, if any, of
 potentially dilutive common shares, such as common stock options
 and warrants calculated using the treasury stock method and
 convertible notes using the &#x201C;if-converted&#x201D; method. In
 periods with reported net operating losses, all common stock
 options and warrants are deemed anti-dilutive such that basic net
 loss per share and diluted net loss per share are equal. However,
 in certain periods in which there is a gain recorded pursuant to
 the change in fair value of the warrant derivative liability, for
 diluted net loss per share purposes, the impact of such gains is
 reversed and the treasury stock method is used to determine diluted
 net loss per share.</p>
 <p style="font-size:1px;margin-top:12px;margin-bottom:0px">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company&#x2019;s preferred stock is entitled to receive
 dividends on an as-if-converted basis in the same form as dividends
 actually paid on common shares. Accordingly, the preferred stock is
 considered a participating security and the Company is required to
 apply the two-class method to consider the impact of the preferred
 stock on the calculation of basic and diluted earnings per share.
 The Company is currently in a net loss position and is therefore
 not required to present the two-class method, however, in the event
 the Company is in a net income position, the two-class method must
 be applied by allocating all earnings during the period to common
 shares and preferred stock based on their contractual entitlements
 assuming all earnings were distributed.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The calculation of net loss and the number of shares used to
 compute basic and diluted net loss per share for the three and six
 months ended June&#xA0;30, 2016 and 2015 are as follows:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>Three&#xA0;months&#xA0;ended&#xA0;June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>Six&#xA0;months&#xA0;ended&#xA0;June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Net loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(13,354</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(31,512</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(43,125</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(62,638</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Preferred stock purchase option (see Note 8)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(868</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Preferred stock beneficial conversion feature (see Note 8)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(31,341</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(31,341</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Net loss applicable to common shareholders&#x2014;basic</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(13,354</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(62,853</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(43,125</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(94,847</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Gain on warrant derivative liability</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(119</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Net loss&#x2014;diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(13,354</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(62,853</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(43,125</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(94,966</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Net loss per share&#x2014;basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(0.07</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(0.35</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(0.23</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(0.53</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Weighted average shares outstanding&#x2014;basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">184,471</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,464</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">184,262</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">178,036</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 </table>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 For the three and six months ended&#xA0;June 30, 2016 and 2015, the
 following potentially dilutive securities were not included in the
 computation of net loss per share because the effect would be
 anti-dilutive:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="72%"></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>Three months
 ended</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>Six months
 ended</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>June&#xA0;30,<br />
 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>June&#xA0;30,<br />
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>June&#xA0;30,<br />
 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>June&#xA0;30,<br />
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Stock options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,641</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,750</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,641</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,750</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Restricted stock and restricted stock units</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,361</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,046</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,361</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,046</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Exchangeable senior notes (if converted)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">59,407</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">49,215</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">59,407</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">49,215</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Preferred stock (if converted)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">32,818</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28,932</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">32,818</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28,932</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Instruments</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <b><i><u>Debt Instruments</u></i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Debt instruments are initially recorded at fair value, with coupon
 interest and amortization of debt issuance discounts recognized in
 the condensed consolidated statement of operations as interest
 expense each period in which such instruments are outstanding. If
 the Company issues shares to discharge the liability, the debt
 obligation is derecognized and common stock and additional paid-in
 capital are recognized on the issuance of those shares. The
 conversion features in the 2012 Notes, 2014 Notes, and 2015 Notes
 qualify for the exception from derivative accounting in accordance
 with ASC 815-40. The 2012 Notes may be settled, at the
 Company&#x2019;s discretion, in any combination of ADSs or cash upon
 conversion and have been accounted for in accordance with ASC
 470-20. Under ASC 470-20, the fair value of the liability component
 of the 2012 Notes was determined and deducted from the initial
 proceeds to determine the proceeds allocated to the conversion
 option, which has been recorded in equity. The difference between
 the initial fair value of the liability component and the amount
 repayable was amortized over the expected term of the instrument.
 The conversion features in the 2014 Notes and 2015 Notes may only
 be settled in ADSs upon conversion and have been accounted for as
 part of the debt host.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The conversion options in the 2012 Notes, 2014 Notes, and 2015
 Notes continue to be evaluated on a quarterly basis to determine if
 they still receive an exception from derivative accounting in
 accordance with ASC 815-40. The 2014 Notes were recognized
 initially at fair value as part of an extinguishment of a portion
 of the 2012 Notes. As a result, the 2014 Notes were initially
 recognized at a discount of $27.9 million. The 2015 Notes were
 recognized initially at fair value as part of the issuance of new
 debt in November 2015. As a result, the 2015 Notes were initially
 recognized at a discount of $3.8 million. These discounts are being
 amortized through interest expense over the expected terms of the
 2014 Notes and 2015 Notes, which is through January 2019 for each.
 See Note 6&#x2014;Debt for further discussion.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div>
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <b><i><u>Stock-Based Compensation</u></i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Stock-based compensation cost is generally measured at the grant
 date, based on the fair value of the award, and is recognized as
 compensation expense over the requisite service period. For awards
 with performance conditions, if the achievement of the performance
 conditions is deemed probable, the Company recognizes compensation
 expense based on the fair value of the award over the estimated
 service period. The Company reassesses the probability of
 achievement of the performance conditions for such awards each
 reporting period.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <b><i><u>Concentration of Credit Risk</u></i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Financial instruments that potentially subject the Company to
 credit risk consist primarily of cash and cash equivalents and
 accounts receivable. The Company maintains substantially all of its
 cash and cash equivalents in financial institutions believed to be
 of high-credit quality.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 A significant portion of the Company&#x2019;s sales are to
 wholesalers in the pharmaceutical industry. The Company monitors
 the creditworthiness of customers to whom it grants credit terms
 and has not experienced any credit losses. The Company does not
 require collateral or any other security to support credit sales.
 The Company&#x2019;s top three customers accounted for 95% of gross
 product sales for each of the six months ending June&#xA0;30, 2016
 and 2015 and represented 94% and 96% of the gross accounts
 receivable balance as of June&#xA0;30, 2016 and 2015, respectively.
 The Company has not experienced any write-offs of its accounts
 receivable.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ConcentrationOfSuppliersPolicyTextBlock', window );">Concentration of Suppliers</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <b><i><u>Concentration of Suppliers</u></i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company has contractual freedom to source the API for Vascepa
 and has entered into supply agreements with multiple suppliers. The
 Company&#x2019;s supply of product for commercial sale and clinical
 trials is dependent upon relationships with third-party
 manufacturers and key suppliers, in particular three suppliers of
 API for Vascepa.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company cannot provide assurance that its efforts to procure
 uninterrupted supply of Vascepa API to meet market demand will
 continue to be successful or that it will be able to renew current
 API supply agreements on favorable terms or at all. Significant
 alteration to or termination of the Company&#x2019;s current API
 supply chain or its failure to enter into new and similar
 agreements, if needed, could have a material adverse effect on its
 business, condition (financial and other), prospects or results of
 operations.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company currently has manufacturing agreements with three
 FDA-approved commercial API encapsulators for Vascepa
 manufacturing. Each of these companies has qualified its
 manufacturing processes and is capable of manufacturing Vascepa.
 There can be no guarantee that these or other suppliers with which
 the Company may contract in the future to encapsulate API will
 continue to be qualified to manufacture the product to its
 specifications or that these and any future suppliers will have the
 manufacturing capacity to meet anticipated demand for Vascepa.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <b><i><u>Foreign Currency</u></i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 All subsidiaries use the U.S. dollar as the functional currency.
 Monetary assets and liabilities denominated in a foreign currency
 are remeasured into U.S. dollars at period-end exchange rates.
 Gains and losses from the remeasurement are included in other
 (expense) income, net in the condensed consolidated statements of
 operations. For transactions settled during the applicable period,
 gains and losses are included in other (expense) income, net in the
 condensed consolidated statements of operations. Certain amounts
 payable pursuant to supply contracts are denominated in currencies
 other than the U.S. dollar.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtIssuanceCostsPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <b><i><u>Debt Issuance Costs</u></i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Prior to January 2016, debt issuance costs were initially recorded
 as a deferred cost and amortized to interest expense using the
 effective interest method over the expected term of the related
 debt. Effective January 2016, the Company adopted ASU
 No.&#xA0;2015-03, <i>Interest&#x2014;Imputation of Interest
 (Subtopic 835-30): Simplifying the Presentation of Debt Issuance
 Costs</i>, and as such began recording debt issuance costs related
 to a recognized debt liability in the condensed consolidated
 balance sheet as a direct deduction from the carrying amount of
 that debt liability and amortized to interest expense using the
 effective interest method over the expected term of the related
 debt. As the standard is required to be adopted on a retrospective
 basis, the Company reclassified $1.9 million of underwriters&#x2019;
 fees and offering costs related to the 2014 and 2015 exchangeable
 notes from other long-term assets to exchangeable senior notes, net
 of discount, within the condensed consolidated balance sheet as of
 December&#xA0;31, 2015. Unamortized debt issuance costs related to
 the extinguishment of debt are expensed at the time the debt is
 extinguished and recorded in other (expense) income, net in the
 condensed consolidated statements of operations.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div>
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <b><i><u>Fair Value of Financial Instruments</u></i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company provides disclosure of financial assets and financial
 liabilities that are carried at fair value based on the price that
 would be received upon sale of an asset or paid to transfer a
 liability in an orderly transaction between market participants at
 the measurement date.&#xA0;Fair value measurements may be
 classified based on the amount of subjectivity associated with the
 inputs to fair valuation of these assets and liabilities using the
 following three levels:</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Level 1&#x2014;Inputs are unadjusted quoted prices in active markets
 for identical assets or liabilities that the Company has the
 ability to access at the measurement date.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Level 2&#x2014;Inputs include quoted prices for similar assets and
 liabilities in active markets, quoted prices for identical or
 similar assets or liabilities in markets that are not active,
 inputs other than quoted prices that are observable for the asset
 or liability (i.e., interest rates, yield curves, etc.) and inputs
 that are derived principally from or corroborated by observable
 market data by correlation or other means (market corroborated
 inputs).</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Level 3&#x2014;Unobservable inputs that reflect the Company&#x2019;s
 estimates of the assumptions that market participants would use in
 pricing the asset or liability.&#xA0;The Company develops these
 inputs based on the best information available, including its own
 data.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The following tables present information about the Company&#x2019;s
 assets and liabilities as of June&#xA0;30, 2016 and
 December&#xA0;31, 2015 that are measured at fair value on a
 recurring basis and indicate the fair value hierarchy of the
 valuation techniques the Company utilized to determine such fair
 value:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center" style="border-bottom:1.00pt solid #000000"><b>June&#xA0;30, 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Level&#xA0;1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Level&#xA0;2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Level&#xA0;3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Asset:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Cash equivalents&#x2014;money markets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14,210</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14,210</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Liabilities:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Long-term debt derivative liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,610</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,610</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center" style="border-bottom:1.00pt solid #000000"><b>December&#xA0;31,
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Level&#xA0;1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Level&#xA0;2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Level&#xA0;3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Asset:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Cash equivalents&#x2014;money markets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14,184</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14,184</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Liabilities:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Long-term debt derivative liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,170</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">$</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,170</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The carrying amounts of cash, cash equivalents, accounts payable
 and accrued liabilities approximate fair value because of their
 short-term nature. The carrying amounts and the estimated fair
 values of debt instruments as of June&#xA0;30, 2016 and
 December&#xA0;31, 2015 are as follows:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"><b>June&#xA0;30, 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"><b>December&#xA0;31,
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Carrying<br />
 Value</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Estimated<br />
 Fair&#xA0;Value</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Carrying<br />
 Value</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Estimated<br />
 Fair&#xA0;Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Long-term debt&#x2014;December 2012 financing</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">92,533</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">89,000</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">91,512</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">87,700</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 2012 Notes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,107</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14,686</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,107</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,637</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 2014 Notes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">97,994</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">122,959</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">94,599</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">108,034</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 2015 Notes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,650</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">32,378</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,028</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28,448</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 </table>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The estimated fair value of the long-term debt pursuant to the
 December 2012 financing is calculated utilizing the same Level 3
 inputs utilized in valuing the related derivative liability (see
 Long-Term Debt Redemption Features below).&#xA0;The estimated fair
 value of the 2012 Notes and 2014 Notes is calculated based on Level
 1 quoted bond prices, while the estimated fair value of the 2015
 Notes is calculated based on Level 2 quoted bond prices for the
 2014 Notes.&#xA0;The carrying value of the 2012 Notes as of
 June&#xA0;30, 2016 and December&#xA0;31, 2015 does not include a
 debt discount, as it had been fully amortized as non-cash interest
 expense over the expected term of the 2012 Notes, which was
 calculated to be a period of twenty-four months. The carrying value
 of the 2014 Notes as of June&#xA0;30, 2016 and December&#xA0;31,
 2015 includes a debt discount of $20.7 million and $24.1 million,
 respectively, which is being amortized as non-cash interest expense
 over the expected term of the 2014 Notes, through January 2019. The
 carrying value of the 2015 Notes as of June&#xA0;30, 2016 and
 December&#xA0;31, 2015 includes a debt discount of $3.6 million and
 $4.2 million, respectively, which is being amortized as non-cash
 interest expense over the expected term of the 2015 Notes, through
 January 2019. The carrying values and related debt discounts of the
 2014 Notes and 2015 Notes as of December&#xA0;31, 2015 reflect the
 retroactive reclassification of debt issuance costs per adoption of
 ASU No.&#xA0;2015-03 as described in Note 6&#x2014;Debt. The change
 in the estimated fair values of these liabilities from
 December&#xA0;31, 2015 to June&#xA0;30, 2016 is largely related to
 changes in the quoted bond prices.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Liabilities</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <b><i><u>Derivative Liabilities</u></i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <i>Warrant Derivative Liability</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company&#x2019;s warrant derivative liability (discussed in Note
 5&#x2014;Warrants and Warrant Derivative Liability) was carried at
 fair value and was classified as Level 3 in the fair value
 hierarchy due to the use of significant unobservable inputs. During
 the six months ended June&#xA0;30, 2015, of the 8,087,388 warrants
 outstanding as of December&#xA0;31, 2014, 1,844,585 warrants were
 exercised while the remaining 6,242,803 warrants expired, and the
 related derivative liability was extinguished. As such, no warrants
 were outstanding as of June&#xA0;30, 2016 and December&#xA0;31,
 2015.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <i>Long-Term Debt Redemption Features</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company&#x2019;s December 2012 financing agreement with
 BioPharma Secured Debt Fund II Holdings Cayman LP (discussed in
 Note&#xA0;6&#x2014;Debt) contains a redemption feature whereby, upon
 a change of control, the Company would be required to repay $150
 million, less any previously repaid amount. The Company determined
 this redemption feature to be an embedded derivative, which is
 carried at fair value and is classified as Level 3 in the fair
 value hierarchy due to the use of significant unobservable
 inputs.&#xA0;The fair value of the embedded derivative was
 calculated using a probability-weighted model incorporating
 management estimates of future revenues and for a potential change
 in control, and by determining the fair value of the debt with and
 without the change in control provision included. The difference
 between the two was determined to be the fair value of the embedded
 derivative. As of June&#xA0;30, 2016, the fair value of the
 derivative was determined to be $2.8 million, and the debt was
 valued by comparing debt issues of similar companies with
 (i)&#xA0;remaining terms of between 1.6 and 5.9 years,
 (ii)&#xA0;coupon rates of between 6.6% and 12.5% and
 (iii)&#xA0;market yields of between 11.0% and 27.7%. As of
 December&#xA0;31, 2015, the fair value of the derivative was
 determined to be $5.5 million, and the debt was valued by comparing
 debt issues of similar companies with (i)&#xA0;remaining terms of
 between 2.0 and 7.3 years, (ii)&#xA0;coupon rates of between 6.6%
 and 12.5% and (iii)&#xA0;market yields of between 13.0% and 30.7%.
 As such, the Company recognized a $2.7 million gain on change in
 fair value of derivative liability for the six months ended
 June&#xA0;30, 2016.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company&#x2019;s 2014 Notes and 2015 Notes each contain a
 redemption feature whereby, upon occurrence of a change in control,
 the Company would be required to repurchase the notes. The Company
 determined these redemption features to be embedded derivatives,
 requiring bifurcation in accordance with ASC 815. The derivatives
 are carried at fair value and are classified as Level 3 in the fair
 value hierarchy due to the use of significant unobservable
 inputs.&#xA0;The fair value of each embedded derivative was
 calculated using a probability-weighted model incorporating
 management estimates of the probability of a change in control
 occurring, and by determining the fair value of the debt with and
 without the change in control provision included. The difference
 between the two was determined to be the fair value of the embedded
 derivative. As of June&#xA0;30, 2016, the fair values of the
 derivatives related to the 2014 Notes and 2015 Notes were
 determined to be $0.6 million and $0.2 million, respectively, and
 the debts were valued by using (i)&#xA0;the estimated remaining
 term of the notes, (ii)&#xA0;a bond yield of 20.6%, (iii)&#xA0;a
 risk-free interest rate of 2.0% and (iv)&#xA0;volatility of 86.0%.
 As of December&#xA0;31, 2015, the fair values of the derivatives
 related to the 2014 Notes and 2015 Notes were determined to be $2.1
 million and $0.6 million, respectively, and the debts were valued
 by using (i)&#xA0;the estimated remaining term of the notes,
 (ii)&#xA0;a bond yield of 25.6%, (iii)&#xA0;a risk-free interest
 rate of 2.9% and (iv)&#xA0;volatility of 89.0%. As such, the
 Company recognized a $1.5 million gain and $0.4 million gain on
 change in fair value of derivative liability for the 2014 Notes and
 2015 Notes, respectively, for the six months ended June&#xA0;30,
 2016.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <i>Preferred Stock Purchase Option Derivative Liability</i></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Pursuant to a pre-existing contractual right to participate in
 certain private placement transactions effected by the Company in
 connection with the subscription agreement executed on
 March&#xA0;5, 2015, the Company determined that such right
 represented a derivative liability (see Note 8). This preferred
 stock purchase option derivative liability was carried at fair
 value and classified as Level 3 in the fair value hierarchy due to
 the use of significant unobservable inputs. The fair value of this
 liability was calculated using a Black-Scholes model and was
 determined to be $0.9 million at inception. On March&#xA0;30, 2015,
 this right was exercised and the liability was marked to fair value
 through such date. The liability was then reclassified to permanent
 equity on such date.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Any changes in the assumptions used to value the derivative
 liabilities, including the probability of a change in control,
 could result in a material change to the carrying value of such
 liabilities.</p>
 <p style="font-size:1px;margin-top:18px;margin-bottom:0px">
 &#xA0;</p>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The change in the fair value of derivative liabilities for the six
 months ended June&#xA0;30, 2016 and 2015 is as follows:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>October<br />
 2009<br />
 Warrants</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b><font style="white-space:nowrap">Long-Term&#xA0;Debt</font><br />
 Derivative<br />
 Liabilities</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Preferred&#xA0;Stock<br />
 Purchase&#xA0;Option</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Totals</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Balance as of December&#xA0;31, 2015</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom"><b>$</b></td>
 <td nowrap="nowrap" valign="bottom" align="right">
 <b>&#xA0;&#x2014;&#xA0;&#xA0;</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>8,170</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom"><b>$</b></td>
 <td nowrap="nowrap" valign="bottom" align="right">
 <b>&#xA0;&#x2014;&#xA0;&#xA0;</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>8,170</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Gain on change in fair value of derivative liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,560</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,560</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Balance as of June&#xA0;30, 2016</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom"><b>$</b></td>
 <td nowrap="nowrap" valign="bottom" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>3,610</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom"><b>$</b></td>
 <td nowrap="nowrap" valign="bottom" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>3,610</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>October<br />
 2009<br />
 Warrants</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b><font style="white-space:nowrap">Long-Term&#xA0;Debt</font><br />
 Derivative<br />
 Liabilities</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Preferred&#xA0;Stock<br />
 Purchase&#xA0;Option</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Totals</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Balance as of December&#xA0;31, 2014</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>119</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>&#xA0;7,400</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom"><b>$</b></td>
 <td nowrap="nowrap" valign="bottom" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>7,519</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Record derivative liability</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">868</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">868</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 (Gain) loss on change in fair value of derivative liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(110</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(700</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">946</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">136</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Compensation income for change in fair value of warrants issued to
 former employees</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(9</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(9</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Transfer derivative liability to equity</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,814</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,814</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Balance as of June&#xA0;30, 2015</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom"><b>$</b></td>
 <td nowrap="nowrap" valign="bottom" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>6,700</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom"><b>$</b></td>
 <td nowrap="nowrap" valign="bottom" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>6,700</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and Geographical Information</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
 <b><i><u>Segment and Geographical Information</u></i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Operating segments are defined as components of an enterprise about
 which separate financial information is available that is evaluated
 on a regular basis by the chief operating decision-maker, or
 decision making group, in deciding how to allocate resources to an
 individual segment and in assessing performance of the segment. The
 Company currently operates in one business segment, which is the
 development and commercialization of Vascepa. A single management
 team that reports to the Company&#x2019;s chief decision-maker, who
 is the Chief Executive Officer, comprehensively manages the
 business. Accordingly, the Company does not have separately
 reportable segments.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i><u>Recent Accounting Pronouncements</u></i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 From time to time, new accounting pronouncements are issued by the
 Financial Accounting Standards Board, or FASB, and are early
 adopted by the Company or adopted as of the specified effective
 date.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In January 2016, the Company adopted ASU No.&#xA0;2015-03,
 <i>Interest&#x2014;Imputation of Interest (Subtopic 835-30):
 Simplifying the Presentation of Debt Issuance Costs</i>, which
 provides guidance on simplifying the presentation of debt issuance
 costs on the balance sheet. To simplify presentation of debt
 issuance costs, the amendments in ASU No.&#xA0;2015-03 require that
 debt issuance costs related to a recognized debt liability be
 presented in the balance sheet as a direct deduction from the
 carrying amount of that debt liability, consistent with the
 treatment of debt discounts. The recognition and measurement
 guidance for debt issuance costs are not affected by the amendments
 in this update. In accordance with ASU No.&#xA0;2015-03, the
 Company applied the new guidance on a retrospective basis, wherein
 the condensed consolidated balance sheet of each individual period
 presented was adjusted to reflect the period-specific effects of
 applying the new guidance. See Note 6<i>&#x2014;</i>Debt.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In April 2016, the Company adopted ASU No.&#xA0;2015-11,
 <i>Inventory (Topic 330): Simplifying the Measurement of
 Inventory</i>, which simplifies the subsequent measurement of
 inventories by replacing the lower of cost or market test with a
 lower of cost or net realizable value test. When evidence exists
 that the net realizable value of inventory is less than its cost
 (due to damage, physical deterioration, obsolescence, changes in
 price levels or other causes), the Company will recognize the
 difference as a component of cost of goods sold in the period in
 which it occurs. In accordance with ASU No.&#xA0;2015-11, the
 Company applied the new guidance on a prospective basis with no
 impact on the carrying amount of inventory.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Also in April 2016, the Company adopted ASU No.&#xA0;2016-09,
 <i>Compensation&#x2014;Stock Compensation (Topic 718): Improvements
 to Employee Share-Based Payment Accounting,</i> which changes the
 accounting for certain aspects of share-based payments to
 employees. One aspect of the standard requires that excess tax
 benefits and deficiencies that arise upon vesting or exercise of
 share-based payments be recognized as an income tax benefit and
 expense in the income statement. Previously, such amounts were
 recognized as an increase and decrease in additional paid-in
 capital. This aspect of the standard was adopted prospectively, and
 accordingly, the benefit from income taxes for the three and six
 months ended June&#xA0;30, 2016, includes $0.1 million and $0.2
 million, respectively, of excess tax deficiencies arising from
 share-based payments. Additionally, the new standard requires that
 historical excess tax benefits that were not previously recognized
 because the related tax deduction had not reduced current taxes
 payable should be recognized on a modified retrospective basis as a
 cumulative-effect adjustment to retained earnings as of the
 beginning of the annual period of adoption. Consequently, the
 Company recognized deferred tax assets of approximately $1.6
 million relating to excess tax benefits on stock-based compensation
 outstanding as of December&#xA0;31, 2015, with a corresponding
 cumulative-effect adjustment to accumulated deficit. The new
 standard also amends the presentation of employee share-based
 payment-related items in the statement of cash flows by requiring
 that: (i)&#xA0;excess income tax benefits and deficiencies be
 classified in cash flows from operating activities, and
 (ii)&#xA0;cash paid to taxing authorities arising from the
 withholding of shares from employees be classified as cash flows
 from financing activities. The Company adopted the aspects of the
 standard affecting cash flow presentation retrospectively and,
 accordingly, reclassified $0.6 million of excess tax provision from
 cash flows provided by financing activities to cash flows used in
 operating activities in the condensed consolidated statement of
 cash flows for the six months ended June&#xA0;30, 2015 to conform
 to the current year presentation. The presentation requirement for
 cash flows related to taxes paid for withheld shares had no impact
 to any of the periods presented in the condensed consolidated
 statement of cash flows since such payments have historically been
 presented as a financing activity.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company also considered the following recent accounting
 pronouncements which were not yet adopted as of June&#xA0;30,
 2016:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In May 2014, the FASB issued ASU No.&#xA0;2014-09, <i>Revenue from
 Contracts with Customers (Topic 606)</i>. This amendment provides
 principles for recognizing revenue for the transfer of promised
 goods or services to customers with the consideration to which the
 entity expects to be entitled in exchange for those goods or
 services, and is effective for annual periods beginning after
 December&#xA0;15, 2016 (the original effective date). In April
 2015, the FASB issued a proposal, which was subsequently adopted in
 July 2015, to defer the original effective date of this standard by
 one year, such that the amendment is effective for the
 Company&#x2019;s fiscal year beginning January&#xA0;1, 2018. Early
 adoption is permitted, but not before the original effective date.
 The Company is currently evaluating the accounting, transition and
 disclosure requirements of the standard and cannot currently
 estimate the financial statement impact of adoption.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In August 2014, the FASB issued ASU No.&#xA0;2014-15,
 <i>Presentation of Financial Statements&#x2014;Going Concern
 (Subtopic 205-40): Disclosure of Uncertainties about an
 Entity&#x2019;s Ability to Continue as a Going Concern</i>. ASU
 2014-15 requires management to assess an entity&#x2019;s ability to
 continue as a going concern by incorporating and expanding upon
 certain principles that are currently in U.S. auditing standards.
 Specifically, the ASU (i)&#xA0;provides a definition of the term
 substantial doubt, (ii)&#xA0;requires an evaluation every reporting
 period including interim periods, (iii)&#xA0;provides principles
 for considering the mitigating effect of management&#x2019;s plans,
 (iv)&#xA0;requires certain disclosures when substantial doubt is
 alleviated as a result of consideration of management&#x2019;s
 plans, (v)&#xA0;requires an express statement and other disclosures
 when substantial doubt is not alleviated and (vi)&#xA0;requires an
 assessment for a period of one year after the date that the
 financial statements are issued (or available to be issued). This
 standard is effective for fiscal years ending after
 December&#xA0;15, 2016, and for annual and interim periods
 thereafter. Early application is permitted. The Company has
 determined that this standard would not have a material impact on
 its condensed consolidated financial statements based on the
 assessment of its ability to continue as a going concern as of
 June&#xA0;30, 2016.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In January 2016, the FASB issued ASU No.&#xA0;2016-01, <i>Financial
 Instruments&#x2014;Overall (Subtopic 825-10): Recognition and
 Measurement of Financial Assets and Financial Liabilities</i>. The
 new guidance is intended to improve the recognition and measurement
 of financial instruments by requiring separate presentation of
 financial assets and financial liabilities by measurement category
 and form of financial asset (i.e., securities or loans and
 receivables) within the balance sheet or the accompanying notes to
 the financial statements, eliminating the requirement for public
 business entities to disclose the method(s) and significant
 assumptions used to estimate the fair value that is required to be
 disclosed for financial instruments measured at amortized cost
 within the balance sheet, requiring public business entities to use
 the exit price notion when measuring the fair value of financial
 instruments for disclosure purposes, requiring equity investments
 (except those accounted for under the equity method of accounting,
 or those that result in consolidation of the investee) to be
 measured at fair value with changes in fair value recognized in net
 income, and requiring a reporting organization to present
 separately in other comprehensive income the portion of the total
 change in the fair value of a liability resulting from a change in
 the instrument-specific credit risk (also referred to as &#x201C;own
 credit&#x201D;) when the organization has elected to measure the
 liability at fair value in accordance with the fair value option
 for financial instruments, among others. The new guidance is
 effective for fiscal years beginning after December&#xA0;15, 2017,
 including interim periods within those fiscal years. The new
 guidance permits early adoption of the own credit provision. The
 Company is currently evaluating the accounting, transition and
 disclosure requirements of the standard and cannot currently
 estimate the financial statement impact of adoption.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In February 2016, the FASB issued ASU No.&#xA0;2016-02, <i>Leases
 (Topic 842)</i>. The new guidance will require lessees to recognize
 a right-of-use asset and a lease liability for virtually all of
 their leases (other than leases that meet the definition of a
 short-term lease). The liability will be equal to the present value
 of lease payments. The asset will be based on the liability,
 subject to adjustment, such as for initial direct costs. Under the
 new guidance, lessor accounting is largely unchanged but certain
 targeted improvements were made to align, where necessary, lessor
 accounting with the lessee accounting model and Topic 606, Revenue
 from Contracts with Customers. The new lease guidance also
 simplified the accounting for sale and leaseback transactions
 primarily because lessees must recognize lease assets and lease
 liabilities and therefore, will no longer be provided with a source
 of off-balance sheet financing. The new guidance is effective for
 fiscal years beginning after December&#xA0;15, 2018, including
 interim periods within those fiscal years. Early adoption is
 permitted. The Company is currently evaluating the accounting,
 transition and disclosure requirements of the standard and cannot
 currently estimate the financial statement impact of adoption.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In March 2016, the FASB issued ASU No.&#xA0;2016-08, <i>Revenue
 from Contracts with Customers (Topic 606): Principal versus Agent
 Considerations (Reporting Revenue Gross versus Net)</i>, which
 clarifies that an entity is a principal when it controls the
 specified good or service before that good or service is
 transferred to the customer, and is an agent when it does not
 control the specified good or service before it is transferred to
 the customer. The new guidance is intended to improve the
 operability and understandability of the implementation guidance on
 principal versus agent considerations. In April 2016, the FASB
 issued ASU No.&#xA0;2016-10<i>, Revenue from Contracts with
 Customers (Topic 606): Identifying Performance Obligations and
 Licensing,</i> which clarifies the following two aspects of Topic
 606: (a)&#xA0;identifying performance obligations; and (b)&#xA0;the
 licensing implementation guidance. Further, in May 2016, the FASB
 issued ASU No.&#xA0;2016-12, <i>Revenue from Contracts with
 Customers (Topic 606): Narrow-Scope Improvements and Practical
 Expedients,</i> which provides clarifying guidance in certain
 narrow areas and adds some practical expedients. The amendments do
 not change the core principles of the guidance in Topic 606 and are
 effective for the Company&#x2019;s fiscal year beginning
 January&#xA0;1, 2018. Early application is permitted only as of
 annual reporting periods beginning after December&#xA0;15, 2016,
 including interim reporting periods within that reporting period.
 The Company is currently evaluating the accounting, transition and
 disclosure requirements of these standards and cannot currently
 estimate the financial statement impact of adoption.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company believes that the impact of other recently issued but
 not yet adopted accounting pronouncements will not have a material
 impact on the Company&#x2019;s consolidated financial position,
 results of operations, and cash flows, or do not apply to the
 Company&#x2019;s operations.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_BeneficialConversionFeaturePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Beneficial Conversion Feature [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_BeneficialConversionFeaturePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ConcentrationOfSuppliersPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Of Suppliers [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_ConcentrationOfSuppliersPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_DebtIssuanceCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Issuance Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_DebtIssuanceCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_UseOfForecastedFinancialInformationInAccountingEstimatesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Use of Forecasted Financial Information in Accounting Estimates [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_UseOfForecastedFinancialInformationInAccountingEstimatesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41620-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579240-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579245-113959<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41675-113959<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41638-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64802544&amp;loc=d3e202-110218<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149975-122751<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65890831&amp;loc=d3e10133-111534<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=d3e4975-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Shipping Costs<br> -URI http://asc.fasb.org/extlink&amp;oid=51575562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 45<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6408413&amp;loc=d3e221937-122793<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 45<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68075638&amp;loc=d3e60635-111653<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 45<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68080631&amp;loc=d3e61069-111654<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Handling Costs<br> -URI http://asc.fasb.org/extlink&amp;oid=51575068<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShippingAndHandlingCostPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6789237760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SummaryOfNetProductRevenueValuationAllowancesTableTextBlock', window );">Summarize Activity of the Net Product Revenue Allowance and Reserve Categories</a></td>
<td class="text"><div>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The following tables summarize activity in each of the net product
 revenue allowance and reserve categories described above for the
 six months ended June&#xA0;30, 2016 and 2015:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Trade<br />
 Allowances</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Rebates,<br />
 Chargebacks<br />
 and&#xA0;Discounts</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Product<br />
 Returns</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Other<br />
 Incentives</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Balance as of December&#xA0;31, 2015</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>4,296</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>9,881</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>535</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>1,084</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>15,796</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Provision related to current period sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,048</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28,945</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">257</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,614</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">44,864</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Provision related to prior period sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(87</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(466</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(553</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Credits/payments made for current period sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,415</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(10,750</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,910</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(20,075</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Credits/payments made for prior period sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,180</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(8,497</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(226</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,284</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(14,187</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Balance as of June&#xA0;30, 2016</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>3,662</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>19,113</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>566</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>2,504</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>25,845</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="63%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Trade<br />
 Allowances</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Rebates,<br />
 Chargebacks<br />
 and&#xA0;Discounts</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Product<br />
 Returns</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Other<br />
 Incentives</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Balance as of December&#xA0;31, 2014</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>2,207</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>3,610</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>&#xA0;481</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>792</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>7,090</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Provision related to current period sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,044</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,957</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">276</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,691</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,968</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Provision related to prior period sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(113</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(44</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(157</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Credits/payments made for current period sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,810</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,243</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,149</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(12,202</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Credits/payments made for prior period sales</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,039</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,531</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(14</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(792</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,376</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Balance as of June&#xA0;30, 2015</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>2,289</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>5,749</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>743</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>1,542</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>10,323</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Summarizes the Impact of Accounts Receivable Reserves on Gross Trade Accounts Receivable</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The following table summarizes the impact of accounts receivable
 reserves on the gross trade accounts receivable balances as of
 June&#xA0;30, 2016 and December&#xA0;31, 2015:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="68%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">
 <b>June&#xA0;30,&#xA0;2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">
 <b>December&#xA0;31,&#xA0;2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Gross trade accounts receivable</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">21,528</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">18,270</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Trade allowances</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,662</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,296</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Chargebacks</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(227</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(148</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accounts receivable, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">17,639</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">13,826</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Estimated Useful Lives</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The estimated useful lives, by asset classification, are as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 66.3pt; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt">
 <b>Asset Classification</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>Useful&#xA0;Lives</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Computer equipment and software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">3&#xA0;-&#xA0;5&#xA0;years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Furniture and fixtures</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">5&#xA0;years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">
 Lesser&#xA0;of&#xA0;useful&#xA0;life&#xA0;or&#xA0;lease&#xA0;term</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Net Loss and the Number of Shares Used to Compute Basic and Diluted Net Loss per Share</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The calculation of net loss and the number of shares used to
 compute basic and diluted net loss per share for the three and six
 months ended June&#xA0;30, 2016 and 2015 are as follows:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>Three&#xA0;months&#xA0;ended&#xA0;June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>Six&#xA0;months&#xA0;ended&#xA0;June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Net loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(13,354</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(31,512</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(43,125</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(62,638</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Preferred stock purchase option (see Note 8)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(868</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Preferred stock beneficial conversion feature (see Note 8)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(31,341</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(31,341</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Net loss applicable to common shareholders&#x2014;basic</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(13,354</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(62,853</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(43,125</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(94,847</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Gain on warrant derivative liability</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(119</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Net loss&#x2014;diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(13,354</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(62,853</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(43,125</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(94,966</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Net loss per share&#x2014;basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(0.07</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(0.35</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(0.23</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(0.53</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Weighted average shares outstanding&#x2014;basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">184,471</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,464</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">184,262</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">178,036</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Anti-Dilutive Securities Not Included in the Computation of Net Loss or Earnings per Share</a></td>
<td class="text"><div>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 For the three and six months ended&#xA0;June 30, 2016 and 2015, the
 following potentially dilutive securities were not included in the
 computation of net loss per share because the effect would be
 anti-dilutive:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="72%"></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>Three months
 ended</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>Six months
 ended</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>June&#xA0;30,<br />
 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>June&#xA0;30,<br />
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>June&#xA0;30,<br />
 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>June&#xA0;30,<br />
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Stock options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,641</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,750</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,641</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,750</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Restricted stock and restricted stock units</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,361</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,046</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,361</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,046</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Exchangeable senior notes (if converted)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">59,407</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">49,215</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">59,407</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">49,215</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Preferred stock (if converted)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">32,818</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28,932</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">32,818</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28,932</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Assets and Liability Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following tables present information about the Company&#x2019;s
 assets and liabilities as of June&#xA0;30, 2016 and
 December&#xA0;31, 2015 that are measured at fair value on a
 recurring basis and indicate the fair value hierarchy of the
 valuation techniques the Company utilized to determine such fair
 value:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>June&#xA0;30, 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Asset:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cash equivalents&#x2014;money markets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14,210</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14,210</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Liabilities:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Long-term debt derivative liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,610</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,610</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>December&#xA0;31, 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level&#xA0;3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Asset:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cash equivalents&#x2014;money markets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14,184</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14,184</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Liabilities:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Long-term debt derivative liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,170</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,170</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Carrying Amounts and Estimated Fair Values of Debt Instruments</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The carrying amounts and the estimated fair values of debt
 instruments as of June&#xA0;30, 2016 and December&#xA0;31, 2015 are
 as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>June&#xA0;30, 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31, 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Carrying<br />
 Value</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Estimated<br />
 Fair&#xA0;Value</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Carrying<br />
 Value</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Estimated<br />
 Fair&#xA0;Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Long-term debt&#x2014;December 2012 financing</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">92,533</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">89,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">91,512</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">87,700</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2012 Notes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,107</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14,686</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,107</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,637</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2014 Notes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">97,994</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">122,959</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">94,599</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">108,034</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2015 Notes</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,650</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">32,378</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,028</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28,448</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Change in Fair Value of Derivative Liabilities</a></td>
<td class="text"><div>
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The change in the fair value of derivative liabilities for the six
 months ended June&#xA0;30, 2016 and 2015 is as follows:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>October<br />
 2009<br />
 Warrants</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b><font style="white-space:nowrap">Long-Term&#xA0;Debt</font><br />
 Derivative<br />
 Liabilities</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Preferred&#xA0;Stock<br />
 Purchase&#xA0;Option</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Totals</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Balance as of December&#xA0;31, 2015</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom"><b>$</b></td>
 <td nowrap="nowrap" valign="bottom" align="right">
 <b>&#xA0;&#x2014;&#xA0;&#xA0;</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>8,170</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom"><b>$</b></td>
 <td nowrap="nowrap" valign="bottom" align="right">
 <b>&#xA0;&#x2014;&#xA0;&#xA0;</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>8,170</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Gain on change in fair value of derivative liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,560</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,560</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Balance as of June&#xA0;30, 2016</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom"><b>$</b></td>
 <td nowrap="nowrap" valign="bottom" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>3,610</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom"><b>$</b></td>
 <td nowrap="nowrap" valign="bottom" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>3,610</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:8pt">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>October<br />
 2009<br />
 Warrants</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b><font style="white-space:nowrap">Long-Term&#xA0;Debt</font><br />
 Derivative<br />
 Liabilities</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Preferred&#xA0;Stock<br />
 Purchase&#xA0;Option</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>Totals</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Balance as of December&#xA0;31, 2014</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>119</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>&#xA0;7,400</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom"><b>$</b></td>
 <td nowrap="nowrap" valign="bottom" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>7,519</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Record derivative liability</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">868</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">868</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 (Gain) loss on change in fair value of derivative liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(110</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(700</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">946</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">136</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Compensation income for change in fair value of warrants issued to
 former employees</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(9</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(9</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Transfer derivative liability to equity</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,814</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,814</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 <b>Balance as of June&#xA0;30, 2015</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td nowrap="nowrap" valign="bottom"><b>$</b></td>
 <td nowrap="nowrap" valign="bottom" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>6,700</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td nowrap="nowrap" valign="bottom"><b>$</b></td>
 <td nowrap="nowrap" valign="bottom" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>6,700</b></td>
 <td nowrap="nowrap" valign="bottom"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant and Equipment, Useful Life [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_PropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_SummaryOfNetProductRevenueValuationAllowancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Net Product Revenue Valuation Allowances [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_SummaryOfNetProductRevenueValuationAllowancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=SL7498348-110258<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6807669072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Carrying Value of Intangible Asset</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The carrying value as of June&#xA0;30, 2016 and December&#xA0;31,
 2015 is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="68%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,&#xA0;2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Technology rights</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,624</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">11,624</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accumulated amortization</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,529</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,207</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,095</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,417</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6807539808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Inventories as of June&#xA0;30, 2016 and December&#xA0;31, 2015
 consist of the following:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="68%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom" nowrap="nowrap"><b>In thousands</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,&#xA0;2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Raw materials</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,596</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,096</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Work in process</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,748</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,640</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Finished goods</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,962</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,249</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total inventory</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">20,306</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">18,985</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818195808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation - Additional Information (Detail)<br> Patient in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>Patient</div>
</th>
<th class="th"><div>May 31, 2014</div></th>
<th class="th"><div>Jan. 31, 2012</div></th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>Employee</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_NumberOfPatientsEnrolledInStudy', window );">REDUCE-IT study, number of patients enrolled | Patient</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,491<span></span>
</td>
<td class="nump">$ 106,961<span></span>
</td>
<td class="nump">$ 136,050<span></span>
</td>
<td class="nump">$ 119,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,512<span></span>
</td>
<td class="nump">143,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amrn_CoPromotionAgreementMember', window );">Co-Promotion Agreement (the Agreement) | Kowa Pharmaceuticals America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_NumberOfSalesProfessionals', window );">Number of sales professionals | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amrn_CoPromotionAgreementMember', window );">Co-Promotion Agreement (the Agreement) | Kowa Pharmaceuticals America | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_NumberOfSalesRepresentative', window );">Number of sales representatives | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 2012 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCallDateEarliest', window );">Convertible senior notes, earliest redemption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 19,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Convertible senior notes, repurchase price at option of the issuer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible notes, carrying amount net of unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,100<span></span>
</td>
<td class="nump">15,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 2014 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCallDateEarliest', window );">Convertible senior notes, earliest redemption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 19,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Convertible senior notes, repurchase price at option of the issuer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible notes, carrying amount net of unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,000<span></span>
</td>
<td class="nump">94,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 2015 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCallDateEarliest', window );">Convertible senior notes, earliest redemption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 19,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible notes, carrying amount net of unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,600<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Date One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCallDateLatest', window );">Convertible senior notes, latest redemption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 19,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Date Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCallDateLatest', window );">Convertible senior notes, latest redemption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 19,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Date Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCallDateLatest', window );">Convertible senior notes, latest redemption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 19,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_NumberOfPatientsEnrolledInStudy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Patients Enrolled In Study</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_NumberOfPatientsEnrolledInStudy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_NumberOfSalesProfessionals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Sales Professionals</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_NumberOfSalesProfessionals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_NumberOfSalesRepresentative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Sales Representative</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_NumberOfSalesRepresentative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCallDateEarliest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earliest date before maturity when the issuer can call the outstanding debt instrument for repayment or conversion to equity, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCallDateEarliest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCallDateLatest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Latest date before maturity which the issuer can call the outstanding debt instrument for repayment or conversion to equity, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCallDateLatest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=amrn_CoPromotionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=amrn_CoPromotionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=amrn_KowaPharmaceuticalsAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=amrn_KowaPharmaceuticalsAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrn_SeniorNotesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrn_SeniorNotesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrn_SeniorNotesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrn_SeniorNotesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrn_SeniorNotesThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrn_SeniorNotesThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrn_DateOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrn_DateOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrn_DateTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrn_DateTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrn_DateThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrn_DateThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6825039328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2012</div></th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>Tranche</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>Tranche </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 05, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 06, 2012 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_CashDiscountPercent', window );">Sales discount percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_CashDiscountInvoiceTerms', window );">Sales discount term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_AccountsReceivableCreditPeriod', window );">Trade receivables, credit period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_PrivatePlacementIssuanceNumberOfTranches', window );">Number of tranches for private placement transaction | Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_WriteOffsOfAccountsReceivables', window );">Accounts receivable written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain (loss) on change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,810,000<span></span>
</td>
<td class="num">$ (600,000)<span></span>
</td>
<td class="nump">$ 4,560,000<span></span>
</td>
<td class="num">$ (136,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amrn_BiopharmaceuticalMember', window );">BioPharma Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Maximum repayment of future revenue and receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair value of embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain (loss) on change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="num">(800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=amrn_PreferredStockPurchaseOptionMember', window );">Preferred Stock Purchase Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain (loss) on change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(946,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember', window );">Embedded Derivative Financial Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain (loss) on change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,560,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember', window );">Embedded Derivative Financial Instruments | BioPharma Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Maximum repayment of future revenue and receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair value of embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain (loss) on change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=amrn_TopThreeCustomerMember', window );">Top Three Customers | Gross Product Sales | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=amrn_TopThreeCustomerMember', window );">Top Three Customers | Accounts Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.00%<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 2014 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Convertible senior notes, discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair value of embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain (loss) on change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 2015 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Convertible senior notes, discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair value of embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain (loss) on change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 2014 Notes and 2015 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Derivative liability fair value assumptions, dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Derivative liability fair value assumptions, risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Derivative liability fair value assumptions, volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 2012 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Convertible senior notes, discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Note, expected term</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=amrn_NonCashMember', window );">Non Cash | Convertible Debt | 2014 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Convertible senior notes, discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=amrn_NonCashMember', window );">Non Cash | Convertible Debt | 2015 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Convertible senior notes, discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amrn_WarrantsIssuedOctoberTwentyZeroNineMember', window );">Warrants Issued October 2009</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,087,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ClassOfWarrantOrRightExercisedInPeriod', window );">Warrants exercised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,844,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ClassOfWarrantOrRightExpiredInPeriod', window );">Warrants expired | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,242,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201503Member', window );">Accounting Standards Update 2015-03 | Convertible Debt | 2014 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201503Member', window );">Accounting Standards Update 2015-03 | Convertible Debt | 2015 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201503Member', window );">Accounting Standards Update 2015-03 | Scenario, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=amrn_AccountingStandardsUpdate201609Member', window );">ASU No. 2016-09</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities', window );">Excess tax provision on stock-based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=amrn_AccountingStandardsUpdate201609Member', window );">ASU No. 2016-09 | Scenario, Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities', window );">Excess tax provision on stock-based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=amrn_AccountingStandardsUpdate201609Member', window );">ASU No. 2016-09 | Restatement Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationOperatingActivities', window );">Excess tax provision on stock-based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Embedded Derivative Financial Instruments | BioPharma Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Derivative liability fair value assumptions, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_FairValueAssumptionsCouponRate', window );">Derivative liability fair value assumption, coupon rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_FairValueAssumptionsComparableYieldToMaturity', window );">Derivative liability fair value assumptions, market yields</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Embedded Derivative Financial Instruments | BioPharma Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Derivative liability fair value assumptions, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_FairValueAssumptionsCouponRate', window );">Derivative liability fair value assumption, coupon rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_FairValueAssumptionsComparableYieldToMaturity', window );">Derivative liability fair value assumptions, market yields</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_AccountsReceivableCreditPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable Credit Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_AccountsReceivableCreditPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_CashDiscountInvoiceTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Discount Invoice Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_CashDiscountInvoiceTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_CashDiscountPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Discount Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_CashDiscountPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ClassOfWarrantOrRightExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercised in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_ClassOfWarrantOrRightExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ClassOfWarrantOrRightExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Expired in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_ClassOfWarrantOrRightExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess Tax Benefit (Tax Deficiency) From Share Based Compensation Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess Tax Benefit (Tax Deficiency) From Share Based Compensation Operating Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_ExcessTaxBenefitTaxDeficiencyFromShareBasedCompensationOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_FairValueAssumptionsComparableYieldToMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Assumptions, Comparable Yield to Maturity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_FairValueAssumptionsComparableYieldToMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_FairValueAssumptionsCouponRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Assumptions Coupon Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_FairValueAssumptionsCouponRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_PrivatePlacementIssuanceNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Private Placement Issuance Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_PrivatePlacementIssuanceNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_WriteOffsOfAccountsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write Offs Of Accounts Receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_WriteOffsOfAccountsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64830801&amp;loc=SL51823488-111719<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amrn_BiopharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amrn_BiopharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amrn_PreferredStockPurchaseOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amrn_PreferredStockPurchaseOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=amrn_TopThreeCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=amrn_TopThreeCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrn_SeniorNotesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrn_SeniorNotesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrn_SeniorNotesThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrn_SeniorNotesThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrn_SeniorNotesTwoAndThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrn_SeniorNotesTwoAndThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrn_SeniorNotesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrn_SeniorNotesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=amrn_NonCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=amrn_NonCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amrn_WarrantsIssuedOctoberTwentyZeroNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amrn_WarrantsIssuedOctoberTwentyZeroNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201503Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201503Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=amrn_AccountingStandardsUpdate201609Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=amrn_AccountingStandardsUpdate201609Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6817960064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summarizes Activity of the Net Product Revenue Allowance and Reserve Categories (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">$ 15,796<span></span>
</td>
<td class="nump">$ 7,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Provision related to current period sales</a></td>
<td class="nump">44,864<span></span>
</td>
<td class="nump">21,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ProvisionRelatedToPriorPeriodSales', window );">Provision related to prior period sales</a></td>
<td class="num">(553)<span></span>
</td>
<td class="num">(157)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits/payments made for current period sales</a></td>
<td class="num">(20,075)<span></span>
</td>
<td class="num">(12,202)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_CreditsPaymentsMadeForPriorPeriodSales', window );">Credits/payments made for prior period sales</a></td>
<td class="num">(14,187)<span></span>
</td>
<td class="num">(6,376)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">25,845<span></span>
</td>
<td class="nump">10,323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForTradeReceivablesMember', window );">Trade Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">4,296<span></span>
</td>
<td class="nump">2,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Provision related to current period sales</a></td>
<td class="nump">10,048<span></span>
</td>
<td class="nump">6,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ProvisionRelatedToPriorPeriodSales', window );">Provision related to prior period sales</a></td>
<td class="num">(87)<span></span>
</td>
<td class="num">(113)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits/payments made for current period sales</a></td>
<td class="num">(6,415)<span></span>
</td>
<td class="num">(3,810)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_CreditsPaymentsMadeForPriorPeriodSales', window );">Credits/payments made for prior period sales</a></td>
<td class="num">(4,180)<span></span>
</td>
<td class="num">(2,039)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">3,662<span></span>
</td>
<td class="nump">2,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=amrn_RebatesChargebacksAndDiscountsMember', window );">Rebates Chargebacks And Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">9,881<span></span>
</td>
<td class="nump">3,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Provision related to current period sales</a></td>
<td class="nump">28,945<span></span>
</td>
<td class="nump">11,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ProvisionRelatedToPriorPeriodSales', window );">Provision related to prior period sales</a></td>
<td class="num">(466)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits/payments made for current period sales</a></td>
<td class="num">(10,750)<span></span>
</td>
<td class="num">(6,243)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_CreditsPaymentsMadeForPriorPeriodSales', window );">Credits/payments made for prior period sales</a></td>
<td class="num">(8,497)<span></span>
</td>
<td class="num">(3,531)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">19,113<span></span>
</td>
<td class="nump">5,749<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForSalesReturnsMember', window );">Allowance for Sales Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Provision related to current period sales</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_CreditsPaymentsMadeForPriorPeriodSales', window );">Credits/payments made for prior period sales</a></td>
<td class="num">(226)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">566<span></span>
</td>
<td class="nump">743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=amrn_OtherIncentiveProgramsMember', window );">Other Incentive Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">1,084<span></span>
</td>
<td class="nump">792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Provision related to current period sales</a></td>
<td class="nump">5,614<span></span>
</td>
<td class="nump">3,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits/payments made for current period sales</a></td>
<td class="num">(2,910)<span></span>
</td>
<td class="num">(2,149)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_CreditsPaymentsMadeForPriorPeriodSales', window );">Credits/payments made for prior period sales</a></td>
<td class="num">(1,284)<span></span>
</td>
<td class="num">(792)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">$ 2,504<span></span>
</td>
<td class="nump">$ 1,542<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_CreditsPaymentsMadeForPriorPeriodSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Credits/payments Made for Prior Period Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_CreditsPaymentsMadeForPriorPeriodSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ProvisionRelatedToPriorPeriodSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision Related to Prior Period Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_ProvisionRelatedToPriorPeriodSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the allowances and reserves, which consist of the valuation and qualifying accounts that are either netted against the cost of an asset or that reflect a liability established to represent expected future costs, from charges to costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the deductions in a given period to allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, representing receivables written off as uncollectible and portions of the reserves utilized, respectively.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForTradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForTradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=amrn_RebatesChargebacksAndDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=amrn_RebatesChargebacksAndDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForSalesReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForSalesReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=amrn_OtherIncentiveProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=amrn_OtherIncentiveProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6817319056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summarizes the Impact of Accounts Receivable Reserves on Gross Trade Accounts Receivable (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Gross trade accounts receivable</a></td>
<td class="nump">$ 21,528<span></span>
</td>
<td class="nump">$ 18,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Valuation allowances and reserves</a></td>
<td class="num">(25,845)<span></span>
</td>
<td class="num">(15,796)<span></span>
</td>
<td class="num">$ (10,323)<span></span>
</td>
<td class="num">$ (7,090)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">17,639<span></span>
</td>
<td class="nump">13,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForTradeReceivablesMember', window );">Trade Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Valuation allowances and reserves</a></td>
<td class="num">(3,662)<span></span>
</td>
<td class="num">(4,296)<span></span>
</td>
<td class="num">$ (2,289)<span></span>
</td>
<td class="num">$ (2,207)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=amrn_AllowanceForEstimatedChargebacksMember', window );">Chargebacks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Valuation allowances and reserves</a></td>
<td class="num">$ (227)<span></span>
</td>
<td class="num">$ (148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForTradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForTradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=amrn_AllowanceForEstimatedChargebacksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=amrn_AllowanceForEstimatedChargebacksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6817137216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Estimated Useful Lives (Detail)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amrn_ComputerEquipmentAndCapitalizedSoftwareMember', window );">Computer equipment and software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property Plant and Equipment Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amrn_ComputerEquipmentAndCapitalizedSoftwareMember', window );">Computer equipment and software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property Plant and Equipment Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property Plant and Equipment Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property Plant and Equipment Useful Life</a></td>
<td class="text">Lesser of useful life or lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amrn_ComputerEquipmentAndCapitalizedSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=amrn_ComputerEquipmentAndCapitalizedSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6817140544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss and the Number of Shares Used to Compute Basic and Diluted Loss per Share (Detail) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,354)<span></span>
</td>
<td class="num">$ (31,512)<span></span>
</td>
<td class="num">$ (43,125)<span></span>
</td>
<td class="num">$ (62,638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Preferred stock purchase option (see Note 8)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(868)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConversionsInducements', window );">Preferred stock beneficial conversion feature (see Note 8)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,341)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,341)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss applicable to common shareholders-basic</a></td>
<td class="num">(13,354)<span></span>
</td>
<td class="num">(62,853)<span></span>
</td>
<td class="num">(43,125)<span></span>
</td>
<td class="num">(94,847)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther', window );">Gain on warrant derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss-diluted</a></td>
<td class="num">$ (13,354)<span></span>
</td>
<td class="num">$ (62,853)<span></span>
</td>
<td class="num">$ (43,125)<span></span>
</td>
<td class="num">$ (94,966)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share-basic and diluted</a></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding-basic and diluted</a></td>
<td class="nump">184,471<span></span>
</td>
<td class="nump">180,464<span></span>
</td>
<td class="nump">184,262<span></span>
</td>
<td class="nump">178,036<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConversionsInducements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The excess of (1) the fair value of all securities and other consideration transferred in transactions by the registrant to the holders of the convertible preferred stock over (2) the fair value of securities issuable pursuant to the original conversion terms, during the accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27010884&amp;loc=d3e42851-122695<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConversionsInducements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6817491728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Anti-Dilutive Securities Not Included in the Computation of Net Loss per Share (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">32,818<span></span>
</td>
<td class="nump">28,932<span></span>
</td>
<td class="nump">32,818<span></span>
</td>
<td class="nump">28,932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">59,407<span></span>
</td>
<td class="nump">49,215<span></span>
</td>
<td class="nump">59,407<span></span>
</td>
<td class="nump">49,215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">20,641<span></span>
</td>
<td class="nump">11,750<span></span>
</td>
<td class="nump">20,641<span></span>
</td>
<td class="nump">11,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">10,361<span></span>
</td>
<td class="nump">4,046<span></span>
</td>
<td class="nump">10,361<span></span>
</td>
<td class="nump">4,046<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6817189088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Assets and Liability Measured at Fair Value on Recurring Basis (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Long-term debt derivative liabilities</a></td>
<td class="nump">$ 3,610<span></span>
</td>
<td class="nump">$ 8,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Asset:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents-money markets</a></td>
<td class="nump">14,210<span></span>
</td>
<td class="nump">14,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Long-term debt derivative liabilities</a></td>
<td class="nump">3,610<span></span>
</td>
<td class="nump">8,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Asset:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents-money markets</a></td>
<td class="nump">14,210<span></span>
</td>
<td class="nump">14,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Long-term debt derivative liabilities</a></td>
<td class="nump">$ 3,610<span></span>
</td>
<td class="nump">$ 8,170<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6814852448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Carrying Amounts and Estimated Fair Values of Debt Instruments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Nov. 30, 2015</div></th>
<th class="th"><div>May 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt-December 2012 financing, carrying value</a></td>
<td class="nump">$ 92,533<span></span>
</td>
<td class="nump">$ 91,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long term debt-December 2012 financing, estimated fair value</a></td>
<td class="nump">89,000<span></span>
</td>
<td class="nump">87,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 2012 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Exchangeable senior notes, carrying value</a></td>
<td class="nump">15,107<span></span>
</td>
<td class="nump">15,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Exchangeable senior notes, estimated fair value</a></td>
<td class="nump">14,686<span></span>
</td>
<td class="nump">13,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 2014 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Exchangeable senior notes, carrying value</a></td>
<td class="nump">97,994<span></span>
</td>
<td class="nump">94,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Exchangeable senior notes, estimated fair value</a></td>
<td class="nump">122,959<span></span>
</td>
<td class="nump">108,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 2015 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Exchangeable senior notes, carrying value</a></td>
<td class="nump">27,650<span></span>
</td>
<td class="nump">27,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Exchangeable senior notes, estimated fair value</a></td>
<td class="nump">$ 32,378<span></span>
</td>
<td class="nump">$ 28,448<span></span>
</td>
<td class="nump">$ 27,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13476-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrn_SeniorNotesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrn_SeniorNotesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrn_SeniorNotesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrn_SeniorNotesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrn_SeniorNotesThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrn_SeniorNotesThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6825196976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Change in Fair Value of Derivative Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,170<span></span>
</td>
<td class="nump">$ 7,519<span></span>
</td>
<td class="nump">$ 7,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Record derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">(Gain) loss on change in fair value of derivative liabilities</a></td>
<td class="num">$ (5,810)<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="num">(4,560)<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DerivativeLiabilitiesTransferredToStockholdersEquity', window );">Transfer derivative liability to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,814)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Ending Balance</a></td>
<td class="nump">3,610<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">3,610<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">8,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ShareBasedCompensationNet', window );">Compensation income for change in fair value of warrants issued to former employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=amrn_WarrantsIssuedOctoberTwentyZeroNineMember', window );">Warrants Issued October 2009</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">(Gain) loss on change in fair value of derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(110)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=amrn_WarrantsIssuedOctoberTwentyZeroNineMember', window );">Warrants Issued October 2009 | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ShareBasedCompensationNet', window );">Compensation income for change in fair value of warrants issued to former employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember', window );">Embedded Derivative Financial Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,170<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">(Gain) loss on change in fair value of derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,560)<span></span>
</td>
<td class="num">(700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Ending Balance</a></td>
<td class="nump">$ 3,610<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="nump">$ 3,610<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">$ 8,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=amrn_PreferredStockPurchaseOptionMember', window );">Preferred Stock Purchase Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Record derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">(Gain) loss on change in fair value of derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DerivativeLiabilitiesTransferredToStockholdersEquity', window );">Transfer derivative liability to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,814)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_DerivativeLiabilitiesTransferredToStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative Liabilities Transferred to Stockholders' Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_DerivativeLiabilitiesTransferredToStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ShareBasedCompensationNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_ShareBasedCompensationNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13495-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amrn_WarrantsIssuedOctoberTwentyZeroNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amrn_WarrantsIssuedOctoberTwentyZeroNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amrn_PreferredStockPurchaseOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amrn_PreferredStockPurchaseOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6692175728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets estimated remaining useful life</a></td>
<td class="text">14 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6788958592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Technology rights</a></td>
<td class="nump">$ 11,624<span></span>
</td>
<td class="nump">$ 11,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(2,529)<span></span>
</td>
<td class="num">(2,207)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible asset, net</a></td>
<td class="nump">$ 9,095<span></span>
</td>
<td class="nump">$ 9,417<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6692476912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 8,596<span></span>
</td>
<td class="nump">$ 9,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">2,748<span></span>
</td>
<td class="nump">1,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">8,962<span></span>
</td>
<td class="nump">8,249<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 20,306<span></span>
</td>
<td class="nump">$ 18,985<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6804447264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Warrant Derivative Liability - Additional Information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 16, 2009 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Common stock issued under private placement, net proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=amrn_WarrantsIssuedOctoberTwentyZeroNineMember', window );">Warrants Issued October 2009</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,087,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ClassOfWarrantOrRightExercisedInPeriod', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,844,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ClassOfWarrantOrRightExpiredInPeriod', window );">Warrants expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,242,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=amrn_OctoberTwentyZeroNinePrivatePlacementMember', window );">October 2009 Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued under private placement, value | $</a></td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Common stock issued under private placement, net proceeds | $</a></td>
<td class="nump">$ 62,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued under private placement, shares</a></td>
<td class="nump">66,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_AmericanDepositorySharesToSharesRatio', window );">Number of shares that each ADS represents</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_EquityIssuancePerShareAmount1', window );">Common stock issued under private placement, price per share | $ / shares</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=amrn_OctoberTwentyZeroNinePrivatePlacementMember', window );">October 2009 Private Placement | Warrants issued to three former officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ClassOfWarrantOrRightIssued', window );">Number of warrants issued</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=amrn_OctoberTwentyZeroNinePrivatePlacementMember', window );">October 2009 Private Placement | Bridge Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Bridge notes converted in conjunction with the private placement, amount | $</a></td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued under private placement, shares</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_AmericanDepositorySharesToSharesRatio', window );">Number of shares that each ADS represents</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Bridge notes converted in conjunction with the private placement, price per share | $ / shares</a></td>
<td class="nump">$ 0.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=amrn_OctoberTwentyZeroNinePrivatePlacementMember', window );">October 2009 Private Placement | Warrants Issued October 2009</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ClassOfWarrantOrRightIssued', window );">Number of warrants issued</a></td>
<td class="nump">35,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeDescriptionOfHostContract', window );">Description of pricing variability feature and classification of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The warrants issued in connection with the October 2009 financing contained a pricing variability feature which provided for an increase to the exercise price if the exchange rate between the U.S. dollar and British pound adjusts such that the warrants could be exercised at a price less than the &#163;0.5 par value of the common stock-that is, if the exchange rate exceeded U.S. $3.00 per &#163;1.0 sterling. Due to the potential variable nature of the exercise price, the warrants were not considered to be indexed to the Company&#8217;s common stock. Accordingly, the warrants did not qualify for the exception to classify the warrants within equity and were classified as a derivative liability.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=amrn_OctoberTwentyZeroNinePrivatePlacementMember', window );">October 2009 Private Placement | Warrants Issued October 2009 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued, number of shares called by the warrant</a></td>
<td class="nump">36,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=amrn_OctoberTwentyZeroNinePrivatePlacementMember', window );">October 2009 Private Placement | Warrants Issued October 2009 | American Depositary Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ClassOfWarrantOrRightTerm', window );">Warrant term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants issued, number of shares called by a warrant</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of the warrants | $ / shares</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=amrn_OctoberTwentyZeroNinePrivatePlacementMember', window );">October 2009 Private Placement | Warrants Issued October 2009 | Bridge Loan | American Depositary Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ClassOfWarrantOrRightTerm', window );">Warrant term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants issued, number of shares called by a warrant</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of the warrants | $ / shares</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_AmericanDepositorySharesToSharesRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>American Depository Shares to Shares Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_AmericanDepositorySharesToSharesRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ClassOfWarrantOrRightExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercised in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_ClassOfWarrantOrRightExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ClassOfWarrantOrRightExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Expired in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_ClassOfWarrantOrRightExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ClassOfWarrantOrRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_ClassOfWarrantOrRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_EquityIssuancePerShareAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount per share or per unit assigned to the consideration received of equity securities issued for development stage entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_EquityIssuancePerShareAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeDescriptionOfHostContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identification of the host contract (such as a debt instrument, lease, an agreement to settle payments in other than the functional currency), description of the terms of the contract, and discussion of a hybrid instrument with an embedded feature which is separated from the host contract and accounted for as a derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64798853&amp;loc=d3e48542-113965<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -Section 25<br> -Paragraph 54<br> -URI http://asc.fasb.org/extlink&amp;oid=64798853&amp;loc=d3e49467-113965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeDescriptionOfHostContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=amrn_WarrantsIssuedOctoberTwentyZeroNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=amrn_WarrantsIssuedOctoberTwentyZeroNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=amrn_OctoberTwentyZeroNinePrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=amrn_OctoberTwentyZeroNinePrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EnergyAxis=amrn_AmericanDepositaryShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EnergyAxis=amrn_AmericanDepositaryShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6828586704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 06, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2015 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 31, 2014 </div>
<div>USD ($) </div>
<div>shares </div>
<div>d </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 31, 2012 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain (loss) on change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (600,000)<span></span>
</td>
<td class="nump">$ 4,560,000<span></span>
</td>
<td class="num">$ (136,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying amount of debt conversion option over the liability component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="nump">$ 11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,816,000<span></span>
</td>
<td class="nump">14,742,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,816,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,742,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,000<span></span>
</td>
<td class="nump">174,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Exchangeable senior notes, net of discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,644,000<span></span>
</td>
<td class="nump">136,734,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,644,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,734,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest payment on notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,668,000<span></span>
</td>
<td class="nump">5,829,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amrn_SeniorNotesOneMember', window );">2012 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201503Member', window );">Accounting Standards Update 2015-03 | 2014 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Exchangeable senior notes, net of discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201503Member', window );">Accounting Standards Update 2015-03 | 2015 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Exchangeable senior notes, net of discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest expense, contractual coupon interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Convertible notes, interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest on convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Finance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest payment on notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 2012 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible notes, carrying amount net of unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,100,000<span></span>
</td>
<td class="nump">15,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible senior notes, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,100,000<span></span>
</td>
<td class="nump">$ 31,300,000<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible senior notes, stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtInstrumentMaturityDateYear', window );">Convertible senior notes, due date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible debt, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1', window );">Convertible senior notes, payment start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 15,  2012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Convertible senior notes, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 15,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ExcessPrincipalValueOverFairValue', window );">Value of shares in excess of principal amount of Notes based on closing price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_AdditionalPercentageInterestRatePenalty', window );">Additional interest rate on notes per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Convertible senior notes, repurchase price at option of the issuer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying amount of debt conversion option over the liability component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,686,000<span></span>
</td>
<td class="nump">13,637,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,686,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,637,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Note, estimated remaining life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Convertible senior notes, discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Convertible senior notes, repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Convertible senior notes, principal amount purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 2012 Notes | American Depository Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Convertible senior notes, exchange rate of ADS per $1,000 principal amount of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113.4752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Convertible senior notes, total ADS into which the debt is exchangeable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,714,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Convertible senior notes, initial exchange price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.8125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 2012 Notes | Exchanged Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible senior notes, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 2014 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair value of embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain (loss) on change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible notes, carrying amount net of unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,000,000<span></span>
</td>
<td class="nump">94,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible senior notes, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible senior notes, stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtInstrumentMaturityDateYear', window );">Convertible senior notes, due date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1', window );">Convertible senior notes, payment start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 15,  2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Convertible senior notes, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 15,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ExcessPrincipalValueOverFairValue', window );">Value of shares in excess of principal amount of Notes based on closing price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Convertible senior notes, repurchase price at option of the issuer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,959,000<span></span>
</td>
<td class="nump">108,034,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,959,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,034,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodEndDate', window );">Convertible senior notes redemption, end date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 15,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Convertible senior notes, mandatory exchange in whole or in part if daily VWAP equals or exceeds percentage of exchange price, in any number of VWAP Trading days | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Decrease to additional paid-in capital for repurchase of conversion option in convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Convertible senior notes, discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 2014 Notes | American Depository Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Convertible senior notes, exchange rate of ADS per $1,000 principal amount of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384.6154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Convertible senior notes, total ADS into which the debt is exchangeable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,666,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Convertible senior notes, initial exchange price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 2014 Notes | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Convertible senior notes, mandatory exchange in whole or in part if daily VWAP equals or exceeds percentage of exchange price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays', window );">Convertible senior notes, mandatory exchange in whole or in part if daily VWAP equals or exceeds percentage of exchange price, at least number of VWAP Trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 2015 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair value of embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain (loss) on change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible notes, carrying amount net of unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,600,000<span></span>
</td>
<td class="nump">27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest expense, contractual coupon interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Convertible notes, interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible senior notes, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible senior notes, stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtInstrumentMaturityDateYear', window );">Convertible senior notes, due date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible debt, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1', window );">Convertible senior notes, payment start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 15,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Convertible senior notes, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 15,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ExcessPrincipalValueOverFairValue', window );">Value of shares in excess of principal amount of Notes based on closing price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,378,000<span></span>
</td>
<td class="nump">28,448,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,448,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Convertible senior notes, discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 2015 Notes | American Depository Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Convertible senior notes, exchange rate of ADS per $1,000 principal amount of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384.6154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Convertible senior notes, total ADS into which the debt is exchangeable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,025,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Convertible senior notes, initial exchange price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 2015 Notes | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_BeneficialOwnershipLimitationPercentage', window );">Beneficial ownership limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 2015 Notes | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_BeneficialOwnershipLimitationPercentage', window );">Beneficial ownership limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Other debt outstanding | 2012 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Non Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Convertible notes, interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Non Cash | 2014 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Convertible senior notes, discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,700,000<span></span>
</td>
<td class="nump">24,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Non Cash | 2015 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Convertible notes, interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Convertible senior notes, discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Accounting Standards Update 2015-03 | 2014 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,800,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Accounting Standards Update 2015-03 | 2015 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amrn_BiopharmaceuticalMember', window );">BioPharma Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Amount received at the closing of the agreement</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Maximum repayment of future revenue and receivables</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_GuaranteePayments', window );">Repayment under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair value of embedded derivative liability</a></td>
<td class="nump">$ 14,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain (loss) on change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="num">(800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible notes, carrying amount net of unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,500,000<span></span>
</td>
<td class="nump">$ 91,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amrn_BiopharmaceuticalMember', window );">BioPharma Debt | Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest expense, contractual coupon interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amrn_BiopharmaceuticalMember', window );">BioPharma Debt | Non Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Convertible notes, interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amrn_BiopharmaceuticalMember', window );">BioPharma Debt | August 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_FutureMinimumGuaranteePayments', window );">Future minimum repayment under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amrn_BiopharmaceuticalMember', window );">BioPharma Debt | Fourth quarter of 2016 and first quarter of 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_FutureMinimumGuaranteePayments', window );">Future minimum repayment under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amrn_BiopharmaceuticalMember', window );">BioPharma Debt | May 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DebtDisclosureLineItems', window );"><strong>Debt Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_FutureMinimumGuaranteePayments', window );">Future minimum repayment under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_AdditionalPercentageInterestRatePenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Percentage Interest Rate Penalty</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_AdditionalPercentageInterestRatePenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_BeneficialOwnershipLimitationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Beneficial Ownership Limitation Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_BeneficialOwnershipLimitationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_DebtDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_DebtDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_DebtInstrumentMaturityDateYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Maturity Date Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_DebtInstrumentMaturityDateYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ExcessPrincipalValueOverFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess Principal Value Over Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_ExcessPrincipalValueOverFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_FutureMinimumGuaranteePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future Minimum Guarantee Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_FutureMinimumGuaranteePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_GuaranteePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Guarantee Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_GuaranteePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 51<br> -URI http://asc.fasb.org/extlink&amp;oid=75116239&amp;loc=d3e34017-109320<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Beneficial Conversion Feature<br> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Conversion Rate<br> -URI http://asc.fasb.org/extlink&amp;oid=6509012<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instruments must exceed threshold percentage for a specified number of trading days to trigger conversion feature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the debt agreement requires the first payment to be made, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDateOfFirstRequiredPayment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13476-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of debt instrument redemption period, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64830801&amp;loc=SL51823488-111719<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorLongTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorLongTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrn_SeniorNotesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrn_SeniorNotesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201503Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201503Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrn_SeniorNotesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrn_SeniorNotesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amrn_SeniorNotesThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amrn_SeniorNotesThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesFinancingTransactionAxis=amrn_FinanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesFinancingTransactionAxis=amrn_FinanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=amrn_AmericanDepositorySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=amrn_AmericanDepositorySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=amrn_DebtExchangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=amrn_DebtExchangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=amrn_OtherDebtObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=amrn_OtherDebtObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=amrn_NonCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=amrn_NonCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amrn_BiopharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amrn_BiopharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=amrn_ChargesCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=amrn_ChargesCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_PeriodAxis=amrn_PeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_PeriodAxis=amrn_PeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_PeriodAxis=amrn_PeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_PeriodAxis=amrn_PeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_PeriodAxis=amrn_PeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_PeriodAxis=amrn_PeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6801959888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - Jun. 30, 2016 - Further Indication for AMR101<br> $ in Millions</strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>GBP (&#163;)</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=amrn_FurtherIndicationForAmrOneZeroOneMember', window );">Marketing Approval In Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Potential aggregate stock or cash payment</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="nump">&#163; 7,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=amrn_FurtherIndicationForAmrOneZeroOneMember', window );">Potential Marketing Approval 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Potential aggregate stock or cash payment</a></td>
<td class="nump">6.7<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=amrn_FurtherIndicationForAmrOneZeroOneMember', window );">Potential Marketing Approval 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Potential aggregate stock or cash payment</a></td>
<td class="nump">6.7<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=amrn_FurtherIndicationForAmrOneZeroOneMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Potential aggregate stock or cash payment</a></td>
<td class="nump">$ 13.4<span></span>
</td>
<td class="nump">&#163; 10,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount the entity has committed to make for future royalty guarantees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473578&amp;loc=d3e63223-108013<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=amrn_FurtherIndicationForAmrOneZeroOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=amrn_FurtherIndicationForAmrOneZeroOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_BusinessDevelopmentsAxis=amrn_MarketingApprovalInEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_BusinessDevelopmentsAxis=amrn_MarketingApprovalInEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_BusinessDevelopmentsAxis=amrn_PotentialMarketingApprovalOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_BusinessDevelopmentsAxis=amrn_PotentialMarketingApprovalOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_BusinessDevelopmentsAxis=amrn_PotentialMarketingApprovalTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_BusinessDevelopmentsAxis=amrn_PotentialMarketingApprovalTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821103168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Additional Information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 01, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 10, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 06, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 05, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 29, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>&#163; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 05, 2015 </div>
<div>&#163; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised', window );">Shares issued, exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,844,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ProceedsFromWarrantExercisesGross', window );">Proceeds from exercise of warrants, gross of transaction costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants, net of transaction costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,641,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Restricted stock units, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,361,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued, exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,020<span></span>
</td>
<td class="nump">18,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options, net of transaction costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.05<span></span>
</td>
<td class="nump">&#163; 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_PrivatePlacementClosingDate', window );">Private placement, closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 30,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Aggregate gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_EquityOfferingCosts', window );">Estimated offering expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.50<span></span>
</td>
<td class="nump">&#163; 0.50<span></span>
</td>
<td class="nump">&#163; 0.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of shares issued for each preference shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding', window );">Preferred stock, equivalent ordinary shares upon future consolidation outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,818,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,818,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Market value, per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConversionsInducements', window );">BCF resulting from issuance of Series A Preference Shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DerivativeLiabilitiesTransferredToStockholdersEquity', window );">Transfer derivative liability to equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=amrn_PreferredStockPurchaseOptionMember', window );">Preferred Stock Purchase Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability at fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DerivativeLiabilitiesTransferredToStockholdersEquity', window );">Transfer derivative liability to equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">American depositary shares conversion rate to preference shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">American  Depositary Shares, each representing one (1) share of Amarin's Series A  Convertible Preference Shares<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | &#163; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_BeneficialOwnershipLimitationPercentage', window );">Beneficial ownership limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_BeneficialOwnershipLimitationPercentage', window );">Beneficial ownership limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=amrn_OrdinarySharesMember', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,283,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding', window );">Preferred stock, equivalent ordinary shares upon future consolidation outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,818,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=amrn_SecondPrivatePlacementMember', window );">Second Private Placement | Preferred Stock Purchase Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConversionsInducements', window );">BCF resulting from issuance of Series A Preference Shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability at fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain (loss) on change in fair value of derivatives | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_DerivativeLiabilitiesTransferredToStockholdersEquity', window );">Transfer derivative liability to equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=amrn_SecondPrivatePlacementMember', window );">Second Private Placement | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding', window );">Preferred stock, equivalent ordinary shares upon future consolidation outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,886,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=amrn_AmericanDepositorySharesMember', window );">American Depository Shares | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued under private placement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,150,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued under private placement, value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=amrn_AmericanDepositorySharesMember', window );">American Depository Shares | Second Private Placement | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued under private placement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,867,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued under private placement, value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=amrn_PreferredSharesBasisMember', window );">Preferred Shares Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ConversionPricePerShare', window );">Share conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=amrn_PreferredSharesBasisMember', window );">Preferred Shares Basis | Second Private Placement | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ConversionPricePerShare', window );">Share conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=amrn_OrdinarySharesBasisMember', window );">Ordinary Shares Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ConversionPricePerShare', window );">Share conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=amrn_OrdinarySharesBasisMember', window );">Ordinary Shares Basis | Second Private Placement | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_ConversionPricePerShare', window );">Share conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis', window );">Percentage of outstanding shares on a fully diluted basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Stock Incentive Plan 2011</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options, Granted</a></td>
<td class="nump">2,442,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,622,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock units, Vesting Period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Stock Incentive Plan 2011 | Vest over a four year period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock units, Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Stock Incentive Plan 2011 | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Stock Incentive Plan 2011 | Director | Vest in equal installments over a three year period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock units, Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Stock Incentive Plan 2011 | Director | Vest in full</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis', window );">Percentage of outstanding shares on a fully diluted basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Stock Incentive Plan 2011</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock units, Granted</a></td>
<td class="nump">1,607,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,455,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,564,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock units, Vesting Period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Stock Incentive Plan 2011 | Vest in equal installments over a three year period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued, related to the vesting of RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">818,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Treasury shares for settlement of employee tax obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Stock Incentive Plan 2011 | Vest over a four year period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued, related to the vesting of RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Treasury shares for settlement of employee tax obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Stock Incentive Plan 2011 | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock units, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Stock Incentive Plan 2011 | Director | Vest in equal installments over a three year period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock units, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock units, Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Stock Incentive Plan 2011 | Director | Vest in full</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock units, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amrn_PerformanceBasedOptionsMember', window );">Performance Based Options | Stock Incentive Plan 2011 | Vest upon the achievement of certain performance conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amrn_PerformanceBasedRestrictedStockUnitMember', window );">Performance Based Restricted Stock Unit | Stock Incentive Plan 2011</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_StockholdersEquityNoteLineItems', window );"><strong>Stockholders Equity Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock units, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,455,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_BeneficialOwnershipLimitationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Beneficial Ownership Limitation Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_BeneficialOwnershipLimitationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_ConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_DerivativeLiabilitiesTransferredToStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative Liabilities Transferred to Stockholders' Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_DerivativeLiabilitiesTransferredToStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_EquityOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Offering Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_EquityOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Outstanding Common Shares and Preferred Shares on Fully Diluted Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_PercentageOfOutstandingCommonSharesAndPreferredSharesOnFullyDilutedBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock, equivalent ordinary shares upon future conversion outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_PreferredStockEquivalentOrdinarySharesUponFutureConversionOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_PrivatePlacementClosingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Private Placement Closing Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_PrivatePlacementClosingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_ProceedsFromWarrantExercisesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Warrant Exercises Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_ProceedsFromWarrantExercisesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_StockIssuedDuringPeriodSharesStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_StockholdersEquityNoteLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders Equity Note [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_StockholdersEquityNoteLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64830801&amp;loc=SL51823488-111719<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConversionsInducements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The excess of (1) the fair value of all securities and other consideration transferred in transactions by the registrant to the holders of the convertible preferred stock over (2) the fair value of securities issuable pursuant to the original conversion terms, during the accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27010884&amp;loc=d3e42851-122695<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConversionsInducements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For net-share settlement of share-based awards when the employer settles employees' income tax withholding obligations, this element represents the number of shares the employees use to repay the employer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=amrn_PreferredStockPurchaseOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=amrn_PreferredStockPurchaseOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=amrn_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=amrn_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=amrn_SecondPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=amrn_SecondPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=amrn_AmericanDepositorySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=amrn_AmericanDepositorySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=amrn_PreferredSharesBasisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=amrn_PreferredSharesBasisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=amrn_OrdinarySharesBasisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=amrn_OrdinarySharesBasisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=amrn_StockIncentivePlanTwentyElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=amrn_StockIncentivePlanTwentyElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=amrn_VestingPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=amrn_VestingPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=amrn_VestingPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=amrn_VestingPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=amrn_VestingPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=amrn_VestingPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amrn_PerformanceBasedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amrn_PerformanceBasedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=amrn_VestingPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=amrn_VestingPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amrn_PerformanceBasedRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amrn_PerformanceBasedRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6804839456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Co-Promotion Agreement - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>Employee</div>
</th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_CoPromotionAgreementLineItems', window );"><strong>Co-Promotion Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 31,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amrn_CoPromotionAgreementMember', window );">Co-Promotion Agreement (the Agreement)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_CoPromotionAgreementLineItems', window );"><strong>Co-Promotion Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_PercentageOfGrossMarginPayableForPromotionAgreement', window );">Promotion fee as a percentage of gross margin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_RangeOfPercentageOfGrossMarginPayableForCoPromotionAgreement', window );">Promotion fee as a percentage gross margin</a></td>
<td class="text">Scheduled to increase to low twenty percent levels in 2017 and  2018, subject to certain adjustments.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amrn_CoPromotionAgreementMember', window );">Co-Promotion Agreement (the Agreement) | Scenario, Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_CoPromotionAgreementLineItems', window );"><strong>Co-Promotion Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_PercentageOfGrossMarginPayableForPromotionAgreement', window );">Promotion fee as a percentage of gross margin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amrn_CoPromotionAgreementMember', window );">Co-Promotion Agreement (the Agreement) | Kowa Pharmaceuticals America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_CoPromotionAgreementLineItems', window );"><strong>Co-Promotion Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=amrn_CoPromotionAgreementMember', window );">Co-Promotion Agreement (the Agreement) | Kowa Pharmaceuticals America | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_CoPromotionAgreementLineItems', window );"><strong>Co-Promotion Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_NumberOfSalesRepresentative', window );">Number of sales representatives | Employee</a></td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_CoPromotionAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-Promotion Agreement [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_CoPromotionAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_NumberOfSalesRepresentative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Sales Representative</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_NumberOfSalesRepresentative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_PercentageOfGrossMarginPayableForPromotionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Gross Margin, Payable for Promotion Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_PercentageOfGrossMarginPayableForPromotionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_RangeOfPercentageOfGrossMarginPayableForCoPromotionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Range of Percentage of Gross Margin Payable for Co-Promotion Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_RangeOfPercentageOfGrossMarginPayableForCoPromotionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=amrn_CoPromotionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=amrn_CoPromotionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=amrn_KowaPharmaceuticalsAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=amrn_KowaPharmaceuticalsAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6806196304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Development, Commercialization and Supply Agreement - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 26, 2015</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licensing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 296,000<span></span>
</td>
<td class="nump">$ 532,000<span></span>
</td>
<td class="nump">$ 375,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,700,000<span></span>
</td>
<td class="nump">15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_BusinessDevelopmentsAxis=amrn_EddingpharmMember', window );">Eddingpharm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_NonRefundableUpfrontPaymentsReceived', window );">Non-refundable up-front received</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_LicensingAgreementTerm', window );">Licensing agreement term</a></td>
<td class="text">16 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_BusinessDevelopmentsAxis=amrn_EddingpharmMember', window );">Eddingpharm | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_EligibleMilestonePayment', window );">Additional upfront payment eligible to receive based on development, regulatory and sales Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_BusinessDevelopmentsAxis=amrn_EddingpharmMember', window );">Eddingpharm | Clinical Trial Application</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_LicensingAgreementTerm', window );">Licensing agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amrn_NonrefundableMilestonePayment', window );">Non-refundable milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_EligibleMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_EligibleMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_LicenseAndCollaborationAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License And Collaboration Agreements [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_LicenseAndCollaborationAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_LicensingAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensing Agreement Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_LicensingAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_NonRefundableUpfrontPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Refundable Upfront Payments Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_NonRefundableUpfrontPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_NonrefundableMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_NonrefundableMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amrn_BusinessDevelopmentsAxis=amrn_EddingpharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amrn_BusinessDevelopmentsAxis=amrn_EddingpharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=amrn_ClinicalTrialApplicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=amrn_ClinicalTrialApplicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>51
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M^GH A3&^.R6:E((C-Z."N[_8_ )02P,$%     @ A3$$21.#K'*E 0  ]1@
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M%H[: M@6CML"X!:.W +H%H[= O 6CMX*]%:.W@KT5M*[-GK9YNBM0&_EZ*U
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M7&*4%B:(46_B^U./(<)A%/"2S9DJ0")*KD)XW9B B[\3*0[AT_F;KZ50MV?
MM:.WHY'_='';MY_;@0L('.-C&L+Q] IZ!Z$_OG>IEWX7W(R=UX,]^/0(_&P_
M^^P(>K8'7;EK4AW9"[P^'.C[W5C_E[PW)T[I\*3Z^)E_TG;LWXL>=GR:Z@.2
M>^") 7O5.8V"3/#VN$Z@,T1!\0S6B&I_JR,15$B@]'W0"IPRQ+#SN$.4Q)(8
M8X88H5MGMFGL%:K\&.%"VMPN0S_/I=]FDLLXA'[UO#Q=W-)M8Z9'*-V=GC9$
M08Z4PI+/]0NH^HMMKB?'!<=.I/4[XKV4:#N>7'4";*/SQD*F6#:9Q[ V10'%
MF=(!DBQ7IE4B-]*%4H+I3DK04G!$#;*.J#H:FV!*'\T'ZTNVP]YDP/F8/?8A
M,"KJKEZ(JML> [NH7I?FV%WLU:NX8),U"70TRG.Z_4#)DC/LQ#K37%1OQ_#C
M/?@H0#45K(0DS]K?'(1$&["$8(VE(DG7\DVB?($WJCK!WB;;I_"U4_Z;FO[\
MJK5J]!'\U\OS7Y-W]\9>0]C3\X*MN"]9C.7<?IE/%_9N-E1EIKX8K+3I<*4-
M>$.OAROM9K#29H/]=IC:<+#2)K\IS:NJD$ZILU/H-%80EX0JPFL-R)2F]T8W
MW:E!VB)',]--6]_8485B_?.WDT7#4IRADJH'LA;*#H:P[7\R\L?3QFO1($+8
M]C_CE)3,_GIX[1]F]!-02P,$%     @ A3$$20H0_1<K!   B0T   \   !X
M;"]W;W)K8F]O:RYX;6R5EU%SVC@0@/^*QD^]F<N!;: )4SI# KUC)LUECESZ
M+.P%=BI+5)))DU]_*YLDZZ!CFB=L8WU>2=^NI$]N_&#L]Y4QW\7/2FDWMI-D
MZ_UNW.NY8@N5='^8'6CZ;VUL)3W=VDW/K-=8P,P4=07:][)^?]2SH*1'H]T6
M=RXYT-ROT-S.@BS=%L!7JH55$G7R^9,;KU'!/5A'8"%WNQM9P23YJ1*AI//S
M$CV4DV1 M^8!.@]LO;NL486;87^8] +LN:NW5A2FA!9VMT7W[?!'(DI8RUKY
M.PKV^;N3),T&639J&>&U>X0'QX'A@9"%QSW<R=4DZ2="UMY\0>7!SJ2'/ZVI
M=Z@WQ$K$&JWSR]#=YLT*-5;X%.*F.[<U#W\9BT]&>ZF6A35*-:W"'TTC^H)[
M>4(Q>BPZ+WJY^B?,Q"09]0FX1X<K5.@?)TESK2#TI/>F*\WPOUX)W0S.\Q0+
MJ4LQUYXH8J';R:.A"3'0RXNR^; =(UW819FV0\5!5T:7H!V4@JZ<45C2J)3B
M4BJI"Q ,E#%0]EY0SD Y ^6_#%IZ^J$N,]" @0;O!0T9:,A P_>"1@PT8J#1
M,>A&^MJ",&MQ63O4X%PS?Y?2H:.G#/21@3X>@Y:XT4BI+LF :5&8F@S0&W%+
ML14(CH'.&>C\&+0@F?4FN">FSI%HK.D%:WH1:[HG 8U]Y++UN6W]XT;?I+44
M=-OOPXV8@<6]#$G*41UQ(^;.8.7Y^]S/-"IH5:$/2=-^G>8R#!KH-R.6<C_3
MB*#S'S6E&V_!14RC)I[=6E.9D)IBNK$01.X$SPU,(PK.8 _*[$*SWT7H"=@"
MI<*G)MUYFJ;<P30BX;)>.?A1A^(Q#S/8Z3OW+GVO>.DY1W'STHAZIU$7',5-
M3*,JOK%8?*!BK,#]QNL7=S.+N/DB=+0UUS&+Z'@RM[.,HSJ5-&+JR9')>"G-
MN*M9Q-5E7562%BUP1*(,"^L$A>BW(&[H)8[B$F<1B1DJ-%]4.UI8 ZP-D:.X
MS5G$YKGS6#4U]%\'ZUJ):\I]FK09>(FJ,^S<YBQ64NGJVAP&N^E67:W AKB6
M6VDYBKN=1=R>TC"?S5#5H1*))12U14^U0=P83XLK1W&WLXC;!PM#3-<HVU5>
M? 7I2)%22([B;F<1MZ^H2#Z&Z9]60806^CJ ?%WE@N<1P:^VE"4@4(LO$JVX
MEZINA#W47X[BMN<1VX\S[DQ,2]KE4362JA,5MSV/V!Y)WF,/\LZF(2(Z2]Y(
M:^YV'G'[Y+*4\ZU"SMW.HY5ZY;N#P?9EX@-'<;?SB-LG5RQQQE'<[3SB=KMF
M_6]<',7=SB-NQQ>S%S1'<;?SB-LG5[5!GV_UN-N#_F&C_+HWIN,!U=PRG!Q<
M\QG:>A?A.$$_[>Y@, S+2+C_2D>,21+. ;3EKY6ZHF=_ZVLCF]UR2WX^0'S^
M#U!+ P04    " "%,01)YK$-2X("  !E"0  &    'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;(V6WX[B(!3&7Z7I TP+_6]J$W6SV;W89#(7N]>H:)MIBPNH
MLV^_P,&.3K#MC2WX?>?'H1R@O#+^+FI*I??1M;U8^K64IT40B%U-.R)>V(GV
MZI\#XQV1JLF/@3AQ2O;&U+4!#L,TZ$C3^U5I^EYY5;*S;)N>OG)/G+N.\']K
MVK+KTD?^K>.M.=92=P15&0R^?=/17C2L]S@]+/T56FQ0H25&\;NA5W'W[NG!
M;QE[UXV?^Z4?ZC'0ENZD#D'4XT(WM&UU)$7^:X-^,K7Q_OT6_;M)5PU_2P3=
ML/9/LY>U&FWH>WMZ(.=6OK'K#VIS2'3 '6N%^?5V9R%9=[/X7D<^X-GTYGF%
M?V)D;6X#M@8\&& FGAHB:X@^#;')%$9F\OI&)*E*SJZ>.!']M=%"R;D.HB)[
M*AFAYLG$Y&:FJO)2A65PT6$>%-@HUJ! @R)0L9T [+OLV-CQ<\ &%-$T('H$
M0.<J,O9XVAX_VF.PQ\:>N,8'BC4HTFE X@0DQIZ- $"13P-2)R U]F($  H4
M3A,R)R$#/WI$]$:2 @(D.$0SYBEW0G* .%=* A KF;%4"B>B '\\,E56DDPC
M4.ADF&X5(1V!W#39# IR4VQ5YB.?Q&KR(HOC&8L+83<)RA.-K2^KP3,6&(K<
M%*ABC,8H5H-G4-RUCJ"4\8P%A+X4L]UL4#)WMT'N8D50BSA^_N$V5H/R*,WS
M&?6$W%6+;$W.6<NY.]M\=K;N@D/%C&R+6[9JF>;9UYH([DZUCO*C.>V%MV/G
M7L*A-O0.-XH5-J?BI[PJ3^1(?Q%^;'KA;9E49ZLY @^,2:I&$;ZH+:96=YZA
MT=*#U*^9WGO@%@ -R4ZW2\UPLZK^ U!+ P04    " "%,01)NMBXASH$  "H
M%   &    'AL+W=O<FMS:&5E=',O<VAE970R+GAM;(V876^C.!2&_PK*_0P^
MQS:&*HTT8;7:O5AI-!>[U[1QFF@@9($VL_]^@6-GTHXY\4T#]+%Y_<&#\?K2
M=M_[@[5#\J.I3_WCZC ,YX<T[9\/MJGZS^W9GL;_[-NNJ8;QM'M)^W-GJ]U<
MJ*E3%")+F^IX6FW6\[6OW6;=O@[U\62_=DG_VC15]]_6UNWE<04K?^';\>4P
M3!?2S3J]EML=&WOJC^TIZ>S^<?4%'DJI)V0F_C[:2W]SG$SAG]KV^W3RY^YQ
M):8,MK;/PU1%-?Z\V=+6]533>.=_7:4_[SD5O#WVM?\^-W>,_U3UMFSK?XZ[
MX3"F%:MD9_?5:SU\:R]_6->&.>%S6_?SW^3YM1_:QA=9)4WU@WZ/I_GW0O_)
MA2L6+H"N %X+@&(+2%= ?BB04K*Y7;]50[59=^TEZ<_5--KP,.+=5,E8<S(V
MIA_[::ZSFWMJLW[;8+9.WZ9ZWB$X(UN'+!.E(\P52<?[!T/@^Q!T\0M2^?Q^
M>?F^O*+RDLH7[R.>9L10(P@QJ I8IDJB0&1%!O?#J& 8-=<A1>@V&84A)!,,
M4_[*+.;0P1R:<@2;ZW(0 B:3P:YS21PE\YM9LI@E"V;)* LR60A!(47&9"$*
M\B+7][.88!9#6223A1"M#!?%U0,:[R?)@TERJD$Q20@!R#0PG5<Z3$F-ZGZ:
M(IBFH#2:25.XF6"8*,2@DO=S@ @&F2^/29C.WSH&P4#.A'$8%+F)&"6 <![2
M&]?JK6/ ,(-9!J#E+!C.0JJ43*.WCBE$P8QEZ2D%$=J&L'>!?,G98^L8&!\F
M;D1+SQF),L)Y\$&^[DT"I$T54T-8FT"Z4YPW'0,J!P8K/29R&3/[PNH$4I[B
MW.D8"4)SEG 8*HPQ.83U">0]Q?G3,5+DP ZY\5-#Q?1/6*) [E.<1<%KU+#=
M0U2!,>H*.Q3(?HJ3J&.,R34[>0C3PL3D01%\')#\IR*&&\/R0W*6XN3G&$"=
M<<-0>DYF1D8H$,,*1!*7XA2(7H&@N366Q^#V[;J<)RQ!)'$I3H*.D1FP<8C*
MP43H"\.K3U1NVG!IE'ON='C)[.,X3([/<42>L$Z1',A-]:UC,.->Y0Z2,F+A
MAV&5(OF/<^06O4J1=ZGGA#!YS-P)RQ3=2O.#3&^9K6?4,E/^RBPGR<.F(/GI
MF-X-NP^=L+AE&UY7AQDKBA"V_$T87D9*<I_FS.68\?F'G'FAE9Y316%BOE+#
M+I7D/\V9RS$YH@ VD>,@&Y? $8G"+I4D0,VYRS&?  INW>\Q!3%Q%K[CI?OH
MY>)('R<3QG#^^DF.7[@QCX8,*U6Z3W%.88[Y!.,;D%WS7$$T.N;+48:U*LF&
M65!1?LO#KU*75MY^T\-O P16WNG-GM*Y>K%_5=W+\=0G3^TPM,V\B[1OV\&.
M]8C/>I4<;+6[GM1V/TR'9CSN:".-3H;V[/<%KYN3F_\!4$L#!!0    ( (4Q
M!$GW9S'J,0(  &8'   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULC97=
MCJ,@%(!?Q?@ @P+^M+$F6S>;W8M-)G.Q>TTKK6947*!U]NV7'^VV,T+F1@&_
M<\X'$B@FQE]%0ZD,WOIN$+NPD7+< B".#>V)>&(C'=27$^,]D:K+ST",G)+:
M!/4=@%&4@IZT0U@69NR9EP6[R*X=Z#,/Q*7O"?^[IQV;=F$<+@,O[;F1>@"4
M!;C%U6U/!]&R(>#TM N_Q-MJHPD#_&KI).[:@78_,/:J.S_J71AI!=K1H]09
MB'I=:46[3B=2A?_,.?^7U('W[27[-S-;97\@@E:L^]W6LE&R41C4]$0NG7QA
MTW<Z3R'1"8^L$^89'"]"LGX)"8.>O-EW.YCW9+_DT1RV'@#G '@+B+$W ,T!
MZ%T L&9F7E^))&7!V12(D>B?'6\5SG42E3E0DQ%JG4Q.;E:J+*YEB@IPU7D>
M$&B0O46@FZAF(KLA0-5?E8"/$MA*0"N!'TL,!LFMA$6BIRAQ0]4*Y#1!JR;(
MFJP62:V)11#,XQRG.'*3E8MT.N%5)VR=4H\3_K23BW0Z):M.B77*/$[)0R6/
MD@-T&J6K1JDURCU[*)VWAV\+?62<'MFJ1V8]-IZ5L4B<)S##21Q[EF8A49)E
M6?H)IWS5*3=I,L^^V.=S)9PH(^_O6DB$(P3O#@ZGTV;5:6.=/+/?SPA$"'LV
M6F6Q6*UE!-_9@+LC<21G^I/P<SN(X,"D.EW-(7AB3%*51OWR,&C4I7?K=/0D
M=3-3;6[O =N1;%QNM=O56OX#4$L#!!0    ( (4Q!$GED=9MO 0  $07   8
M    >&PO=V]R:W-H965T<R]S:&5E=#0N>&ULG9A-;^,V$(;_BN![UOPF93@&
MUI*+]E!@L8?VK,1*;*QEN9(2;_]]*<U0<5)JHC:'Q%:>&<[+KY?B^EHW/]I#
M67;)S^IT;N\7AZZ[K);+]O%05D7[I;Z49_^?I[JIBLY_;9Z7[:4IB_T05)V6
M@C&SK(KC>;%9#\^^-9MU_=*=CN?R6Y.T+U55-']ORU-]O5_P17CP_?A\Z/H'
MR\UZ.<;MCU5Y;H_U.6G*I_O%5[[:"=LC _''L;RV-Y^3OOB'NO[1?_EM?[]@
M?0WEJ7SL^A2%__-:9N7IU&?R+?^%2=_:[ -O/X?LOPQR??D/15MF]>G/X[X[
M^&K9(MF73\7+J?M>7W\M48/N$S[6IW;XG3R^M%U=A9!%4A4_X>_Q//R]PG\<
MP[!X@,  ,0:,[<0#) ;(MP!%!B@,4'-;T!B@/[2P!.U#S^5%5VS637U-VDO1
MSR>^\GC3)_&9$]]=K1^)(6<SC,5F_;JQ8KU\[?.\0\2 ;!&1TT@."!^)I6\_
M6H18Q%H00SA10P:$540-GR;9_2O)9)GR?9D*^DI"O'[?Q'E +"@!1 K'"2H#
MBEO+[#25 Z4=%V*:VF&+4AC]N2X5U:5 EXFU8D 7("(EF!P8+:/5 K,#1MH9
MM>IHK1IJC?8;UJJQ1SCGTU2FZ3% 31K'P&A%J HM&L4^UV6BN@SH<H0N0)PS
ME"R C'0$E /$M=6$]AU2WE_<YZIL5)4%52FA"A"AA&:$+* X]].<T 64$BZE
M=&&+W-S,U$E=[KTN";H<#,6,T4ZC_9)"/#%&6T"$8890G(T4-3]SH+1BCLBU
M0XK9=,;JY"PJ;'CLE1%[P!89+C0UW;,18XR8/SEBPDA&9-L%3!DA9ZCC<77@
M<TY2ZH"1SBAB2+(18X;(EH<6F4RI#0@QJQ6?L5:YB*L#?W1$0UMD[K@B"\H"
M)XR5U/X:.&D5N68#IZ6]F</3"N,&SL$L7=2;@\+1=JG]"*D[PP@J1TII0U"[
MD(O+.<KB%L[!6*GUO47F3AM.;2D!4XYTQH!QOT IQP]<:M(9VRV/NSX'AW64
M[2-SQZG-)T,J):9 'C))1BS-W4C-V4_BIL^#I5.RS+CB:&'(2<$4N5\BI_P/
M.6[(&7^JL3,4Q@\ ',S642< 9#@3I!U8/%Z2DQ)324YN)J'!&V.9%N;BPN (
MD!(+>XN,7]B2LN<L<))K3@Q)'C@EO7=2^I SWA3GV$'\C,+A/) 2AY0=,G?.
MS&A'Q(\, IPYI28W,KZ'I*+JB7/3%<5M7H";IM'5CR]ZR$R/+;[J!<X(IXE\
M>> FQQ9?]P*7*C=G68H/5H_G5P%VFLYX%19Q*Q62V$=3[",T-O:%6?;N)SJ&
M*?;8&"6)Y/D;)J+]FF)_C9B>L4^+N+L*\+#XVV\0J_Z76#5/K)HG5OTGL3H^
M-] AY\RNN*T)\ZG';I'A3BE+O<^.'%.&>L5YRR<,96N!L_Y(/>.X)>*V)BPQ
M(8)".U.AG:G0SE1HIQ4N;ZX(J[)Y'BYGV^2Q?CEW<.LU/ATO@+^*_HKQP_,M
M7V4\\CSGJQU<[[ZEWZPOQ7/Y>]$\'\]M\E!W75T-]X]/==V5OF0_71?)H2SV
MXY=3^=3U'VT_"G#)"U^Z^A+NK,>+\\T_4$L#!!0    ( (4Q!$E@P(<J70,
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MKUG]0UV_2AQ#V 3<JZQJ?[W]:U6KO)-,O#QY-\>T:(]7\T\4H,PN("@@O0#
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MS?)1J5KJ2,&#WM^?]1=>?Y')8]V<"GU>FF\><U&K2_<)UW]'+OX"4$L#!!0
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MB83.A?#"QR;M0TH<CH?M7CZQ^A-02P,$%     @ A3$$2>I<.Q.A 0  L0,
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MO/*V21N1'(?]O-_+3U9^ %!+ P04    " "&,01)M- .>94!  !O P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6R%4]M.XS 0_17+'X#3=*&H2B-1
M5@@>D! /\.PFD\3"]F1MIX&_QY<D%%2Q+[%G?,Z9,V.G&-&\V0[ D7<EM=W1
MSKE^RYBM.E#<7F /VI\T:!1W/C0ML[T!7D>2DBS/LBNFN-"T+&+NR90%#DX*
M#4^&V$$I;C[V(''<T16=$\^B[5Q(L+)@"Z\6"K05J(F!9D=O5MO].B BX$7
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M].%BTOPZ1 ^A?'%S2\D0GO\6*.A\W-Z%O<TO(@<>Q_5];S]9_0=02P,$%
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M:_0\TO/_T]=?Z9OD</TOAPESF#';;TW8Q9$H,&V\>4LJ'+1+)[)4E\=U%^^
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M]GLSO(@A<-A.[WO^R?)O4$L#!!0    ( (8Q!$F$M+TF_@(  %8.   9
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MMI\OW7^<!#/<0(*![ WZ>G #!0:J-Y".--!@H%\-/&E@P,#T!DJ3!A8,+-?
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MX*)B(!M1Z&%X]"9"Q J>]A#K&!7/:XR"19%5!I[7F"EYC1DXSXW9""IQH#H
M4<$]CJ1_((2SN,P8D!E%G#Y_Z"%.+!I<.PQHA^+L98W'1\=/&1T\XS&!,SJ0
MH21C9RD;-IE&4K/3'HLKD@4=49R-K\5W-7;*KL;BT6\EU9-P/!NAT>21"Z8
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M=',O<VAE970R-2YX;6R-EDN/FS 4A?\*8C\#-@^3B"!UDE3MHM)H%NW:29R
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M35HL'EA/.O7FR'B+I5KR$Q0])[@RI);"* S7L,5-%Q2YV7OA1<[.DC8=>>%
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MU:LX?>,^!VH$UZ*5]C=:'Z42W1@21QW[<->FM]>3>Y(#'Q8.0#X G0,@F0S
M/@#/#2 ^@,P-H#Z ?@9@6TN7NZW<$U.L*@=QBN2!F?\3?-3X8$2T<J3+)74G
MK.9@>U&5[Q6!M$S>C= 5@RRS= RZ3=2>R&XC3^-"Z6WFV<NDX,PD.I%@-N@Z
M&^RR07Z1[+X OA8@3@![@?S:96^9S)7#,06B&-^F:D]!"M%],R1HAG@S16B9
MU)EQ3%X  &Y3M:>R#,PH+0V:H;[%^+Y &NQ-.K\W6=!!Y@301*)+Q^BB@VRB
M'"'JIID\:";W9N"$&<= DN;IA!E/X13/,%,$S12^-\5] 0B"S;'3,[L#8= $
MA#/ZXZ$B*PHR49,1([28DQ,*&T(S>N0AB%!!)]ZS>N1 #G#0>>:W,,<5FIOQ
MJL'P+@3=YH%R.$."A!M*_J.AX3<>TCD-'?>%E$YM0&<,H'R&H31L*)UJJ-^=
M/801SB8V\=IC*"=D GL:L8S^T\[DXG-[8#O^@PV[II?12BC]Y;8?V*T0BFL9
M\*#SVNLSVWG0\JTRMYE)V)UBW$")PW@H.Y\,J[]02P,$%     @ AC$$20>>
M@=QV P  /A   !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&ULE5A+<YLP
M$/XK#/<$)!["'LQ,_)KVT)E,#^V9V++-!) +<IS^^PJTX"1=0+X$D+_]]J'=
ME3;Q552O]8ES:;T7>5DO[).4Y[GCU+L3+]+Z49QYJ7XYB*I(I?JLCDY]KGBZ
M;X6*W*&N&SI%FI5V$K=KSU42BXO,LY(_5U9]*8JT^KODN;@N;&)W"S^SXTDV
M"TX2.[W</BMX66>BM"I^6-A/9+ZE40-I$;\R?JT_O%N-\2]"O#8?W_<+VVUL
MX#G?R88B58\WON)YWC IS7^ ]*:S$?SXWK%O6W>5^2]IS5<B_YWMY4E9Z]K6
MGA_22RY_BNLW#CX$#>%.Y'7[U]I=:BF*3L2VBO1=/[.R?5[U+Y$+8K@ !0':
M"_1Z< $/!+R;@#\JX(. ;ZHA (' 5$,( N%-(&R#KX/5AGJ=RC2)*W&UZG/:
M)""9*WC5D"AF2\6W5EO7<E;MYB7Q6^)3&CMO#=$G#&TQ2XUAWC!DK2%D&+'5
M"!K->HRCC$0MI39F!=4$PRI6&L'\$3LG23;3)%L@8=.>>)\]\73,/8BY-TW@
M?R;P-8$/!%^,+%L,TYYJ3$28.PS::! +R&P8M$5 @_8&J+T!V!M@6K3@1F.B
M,)I6$J)*0IV"N!+MRE)C'H*(C$1EI5&ABV*T"6M@\H-P!+4!F[QPVBF&.L4@
M<N&($HUY(!'QI]5$J)H(U+!A-4N-\4(\=!JTTJ"0C<;.A&ECPK2-_D_R0<]G
MJ.<SO4.!P0X1%ZWF=MFPG E!C2!=%XY& @*@!X,J)!17HQN7YQG4&,%;%[FC
M=Q&\>9'1[M4YJT$$;TRP^PAHV!B\,Y%@K&MTQ@108<0@S0C>G4@(7IO8RO#8
MLSMBC]<YB4P2+3)/-+RHB*XJCQA4%<6KBMY1512O*DJF$VT-H*%S$D("*.:/
M=B,,-6PT7J.43B?D&D!3IT\'8T;V>+@]7<&C1P,<JP :ZNAPK )JJ*7#O66"
MJW/-A&L+*+/S@>+MBOJ0RP:'*PWP7 [NR&6\?="N?8SU*0 9W:$H?M^@S* ?
M FCFFY0WWHAHUXC0BPW<3@&$W6R<#[-.P:MC.Y;6UDY<2JFOW?UJ/_H^T696
M^K*^)/,50=;79+[1@^V-/HG/Z9'_2*MC5M;6BY!J0FL'J8,0DBN+W4<URIW4
M,-]_Y/P@FU>FWBL]WNH/*<[=M-[_RR#Y!U!+ P04    " "&,01)Q=E0"Z4!
M  "Q P  &0   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6R-4\MNVS 0_!6"
M'Q#*E-P"ABP@3E&TAP)!#NV9EE8/A.2J)&6E?U\^),4.#+07<7<U,SO+1SFC
M>;4]@"-O2FI[I+USXX$Q6_>@A'W $;3_TZ)1POG4=,R.!D0324HRGF6?F!*#
MIE49:\^F*G%R<M#P;(B=E!+FSPDDSD>ZHVOA9>AZ%PJL*MG&:P8%V@ZHB8'V
M2!]WAU,1$!'P<X#97L4D>#\COH;D>W.D6;  $FH7%(1?+O $4@8AW_CWHOG>
M,A"OXU7]:YS6NS\+"T\H?PV-Z[W9C)(&6C%)]X+S-UA&V ?!&J6-7U)/UJ%:
M*90H\9;60<=U3G_V?*'=)_"%P#<"CSO!4J-H\XMPHBH-SL2.(IS=[N#A)HAX
M9>*]63]VU#1Q\*J\5$6>E>P2A&XPB7A*F-V&8%[];@M.[]%YI/-_T_-;>IX<
MYHO#_^A?W H42:!8!/B]$1/FM&+R#TW8U9XJ,%V\.I;4.&F7MG2K;K?S,1XB
M>X=7Y2@Z^"%,-VA+SNC\R<8#:!$=^/;9PYZ2WK^?+9'0NA!^]K%)5RHE#L?U
M@6ROM/H+4$L#!!0    ( (8Q!$FP^]6ISP$  ,H$   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,S+GAM;(V42X^;,!2%_XK%OF,PD#0109JAJMI%I=$LVK43
M+@&-C:GMA.F_KU\PR8BDW> 'WSD^OA@7HY"OJ@70Z(VS7NVB5NMAB[$ZM,"I
M>A #].9-(R2GV@SE$:M! JV=B#-,XGB%.>WZJ"S<W+,L"W'2K.OA62)UXIS*
M/T_ Q+B+DFB:>.F.K;83N"SPK*L[#KWJ1(\D-+OH,=E6N24<\+.#45WTD<V^
M%^+5#K[7NRBV$8#!05L':IHS5,"8-3(+_PZ>[TM:X65_<O_J=FO2[ZF"2K!?
M7:U;$S:.4 T-/3'](L9O$+;@$AX$4^Z)#B>E!9\D$>+TS;==[]K1O\E)D"T+
M2!"069!D=P5I$*0?!-@G<_OZ0C4M"RE&I 9J/W:R-;BT)L89F<TH4R?G*5VE
MRN)<9FE6X+,UNF*(8YX\0VX352#6,X)-@,44Y#J%GWPD(47R;X/TVB#S!FDP
MR*]#]HY9^VUX)DE6)+M-54O4S3#98I@LA%DM+;/R83SSB>1D<YNJ)HK$_U':
M?#%,[BS2SW<*XY%-O+E3O2I 6?(Q";XX=@,]P@\JCUVOT%YH<X+=06N$T&!,
MXH<\0JVY6.8!@T;;[MKTI?_7_$"+8;HYYNNK_ M02P,$%     @ AC$$23#Y
M@='I 0  5 4  !D   !X;"]W;W)K<VAE971S+W-H965T,S0N>&ULA93+;J,P
M&(5?Q>(!:C"&0$206D959S%2U<7,V@DFH!K,V$[HO/WXEI14D&[B"^<<?[\=
MNYBX>)<MI0I\]&R0NZ!5:MQ"* \M[8E\X",=])>&BYXH/11'*$=!26U-/8,H
M#%/8DVX(RL+.O8JRX"?%NH&^"B!/?4_$OR?*^+0+HN R\=8=6V4F8%G JZ_N
M>CK(C@] T&87/$;;*C4**_C=T4G.^L"P[SE_-X.?]2X(#0)E]*!, M'-F5:4
M,1.D%_[K,S^7-,9Y_Y+^;*O5]'LB:<79GZY6K88- U#3AIR8>N/3"_4E)";P
MP)FTO^!PDHKW%TL >O+AVFZP[>2^8.QMRP;D#>AJB.X;8F^(OQB@([-U_2"*
ME(7@$Y C,8<=;;5<F!"=#'0Q4N^3S11VI\KB7.)X4\"S";K1(*MY<AJTKJB\
MXC,$:H!%"G1+X28?D:?(O@^(;P.P"XA]0'X+.5C-QI7A-%F2I^NBRHGR<"9:
M1<&+*-BAX'!IE=2A8+]?.%L754X4I;.D591D$27Q*-$=%*?)\A3=0?$BA//O
M4=)%E-2C+*[B#\AI4!B']T[(J:(LSY(O,'!V 49RI+^(.':#!'NN]%VR?_F&
M<T5U2OB0!*#53]QUP&BC3'>C^\+=>C=0?+R\8=>'M/P/4$L#!!0    ( (8Q
M!$F'XH#PP ,  )03   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;)68
MW7*;/!"&;X7A @+Z08*,XYDZ?^W!-]/IP==C$LLQ4T ND+B]^PJT<I)VP9N3
M&,B[^TJ[>F29U=%V/_J],4/TJZG;_BK>#\/A,DGZQ[UIRO["'DSK_K.S75,.
M[K9[2OI#9\KM%-34"4]3E31EU<;KU?3L:[=>V>>AKEKSM8OZYZ8IN]\;4]OC
M5<SB\.!;];0?Q@?)>I6<XK958]J^LFW4F=U5_(E=WDLY2B;%_Y4Y]F^NHW'P
M#];^&&^^;*_B=!R#J<WC,*8HW<>+N39U/69RSC\AZ:OG&/CV.F2_FZ;KAO]0
M]N;:UM^K[;!WHTWC:&MVY7,]?+/'SP;FD(T)'VW=3W^CQ^=^L$T(B:.F_.4_
MJW;Z//K_Y"F$X0$< O@I0.C%  $!XA3 V6* A !)'5(& =FKP_*0% 2HUX!E
M!PT!^J^ Q%=WZLU-.93K56>/47\HQQ7++IV\&Y.XS)%K2.]Z/>7LIFZO5R]K
M*<4J>1D3O=/P2;,)&CFON0Z:;%YS$S1J7G,;-'I><Q<T^;SFWFMX\9HG<35!
M"\/?%T;XPG P*<XG$.\32)] ^ 19^GZ4[:3Q@==>D_$\3<_;2-1&@@W#;)0O
MO-<0+#+4(@,+/C^36Z_AFHGS+@IU45,&(?+S"33:,4WO6(Z.(">4,O^KE/\H
M[LXJ[KTB3W,M<L)L"W2P!0Q6S!O=>@W+'99Y=MZ(I:C3]/A<_T'$-64E,X8;
M =B97)@3B!27CAK"8F,<]P*^,TI=!+K>F* O.(;#RP*]:KZT&Q"YRI)JBS/,
M L0+V]$&1(H+DA/.,5/@I.>[N &14C(E3DOC9@!]EB^9>1$CN. ; PL[0[%4
MO)SL@A/- &E%* =/T27)4_J2Y#B$'"!4"[O@!D0%L7D<9Y #@XH34N ,\@\P
MR'$&.3"HT)T4F@LBH4C3Q1'D&0&,($JII<4AY(K !8@(*Y;C]'&@3Z$;=@$N
M7I1>4%J$\\>!/T78K'F!+Y3B ^<Y_'M0I 0R0"0R3FR@P#$4 4/TL.Q%-R<1
MX90K< 9%8)!P$!$X@^(## J<01$81#?84-K (*.6%N=0 &*:DD+A4U8?F#+.
MC@!V-)MO\ 9$I&.BP-D1P(Y&3V_C3_;)"$ZM%P3"!/[U)8 PC>ZCL!F B%%\
M)(ZA! RU)*1@:/LDH[=/XMQ(3F@?B$CMD_BO2"DH[0,5J7URYG>D)+0/1/^V
M+WGS[N%0/IG_RNZI:OOHP0Z#;::W#3MK!^.2N$'&T=Z4V]--;7;#>*G==>=?
M&OF;P1[".[#3B[CU'U!+ P04    " "&,01)R*(A'I0*  "D2@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970S-BYX;6R57%USV[@._2N>O#<6^"6QDV3FUDY=
M1W-G=O9A[[/;.$UF[3AKN\WNO[^V!6@3%P"AER9Q#T& % \!\LA7KYOMG[O'
MY7(_^GN]>MY=7SSN]R\?Q^/=M\?E>K&[W+PLGP__\[#9KA?[PY_;[^/=RW:Y
MN#\U6J_&KJK2>+UX>KZXN3I]]MOVYFKS8[]Z>E[^MAWM?JS7B^T_GY:KS>OU
M!5S0![\_?7_<'S\8WUR-^W;W3^OE\^YI\SS:+A^N+_X#'UN([H@Y0?YX6K[N
MWOP^.GK_=;/Y\_C'_/[ZHCHZL5PMO^V/-A:''S^7D^5J=31UZ/HOM/IOI\>&
M;W\GZY]/\1[\_[K8+2>;U?^>[O>/!W>KB]']\F'Q8[7_??/Z98E!Q*/!;YO5
M[O3OZ-N/W7ZSIB87H_7B[^[GT_/IYVOW/TV%S?@&#ANXOH$#M8''!KYOX&NU
M0< &P=H@8H-H;9"P0;+&4&.#VMJ@P0:-M4'&!MG:X#CGW<Q5YB;]9,-9DW'W
ME)R>L>EBO[BYVFY>1[N7Q7'IP<<C?GNT<S ^.CQ9N\-#>S*[/3VV-U<_;T(=
MK\8_CY;>8=P)\ZG#^*J2,1.RDV3,E#"UC+DE3"-C/A,FRYA9AW')RY@OA DR
M9F[HZ\Y@I_W5G_%ADOB9<N]GRG<SY3I/FLI@P;^W$#H+OIM'.)O'YQ.F[L:V
MP\0&JNI\OM_BOG2X#ZG2<?,.%V+2<7=H#WQZBY,C#&R$ <<(N)Y2%V&' 8@%
MUV=E8&=Q;K78"D YRLA&&;LHO1)DQ"7;0%)]GW5 "'5P>I!6BZU@40XRL4&F
MKK]:";*#0!WT$&VPN0W6LC YN)H-KD9648+K(.!B"H7X$.E3[0LAFFVVDDTY
MT(8-M,$%Z12O.DR=4J/Z=-<@-;EL\RBS'F7TR$+$4+%,?/K82L4 K!L Y46,
M&(A08B )J;CE>+=HEPD6&YX?'C]D>'@BAU!<(3/$0%,8G58 *D[QO M(O$VT
MV$C\X*0A@\.S!Y3I8X:8TI/3\CC%)7Z= R[TRC0TF1^:/&!H7,7ZX6AI)F6U
M(,CYPN#<$3!91\?QB]WA8F^4&9LC*-9%KQ!H]XI?ZX[6>J-P$()<R:L9 4N#
M.K=:; 6+2IQ\VNN(C[+%1F"?31>&/)L\?3BB#VTS1) K)9UW!+0_!7R>Y1).
MAZDRJ?G1J8>,#L\@KD$_U*>Q,>Z(,S-R;D:V$E*)E<]!'#)=5HJ%"8(TOSKD
M%)$>Y+77(6][FU5E#<'S1.N1:/-9J?46=-N#G*4CGCL]<F=6,J5;!+G*FWKB
M^= C'^:@C"""( 0S+7FA&D=:RNS1"XT@@9*E(SZ7\LA=F3UWH8X(U%@ZX@G.
M(\'EK"QA! &$TL*4D(I?/,7YCN(B?X!% T @L'3$)V:^1@YC3\&H(P+5EHYX
MLO145[$''?2H(J-Z<][K>;KR&8=&V;@^(PA":@I'#H3TR=>%)\!JLY5L*@=(
M/*^%"F-E#PYQ"A'DO27;#3RO!3Q5=2S;T%E5!])&LPR9ER'M+Q E'IX]@\.!
M4^*9(>A\HU(ZX[DSX#%E%>7.)@B"F,V]":>* 7M3BHH)@B Y<V\\BX:(O5GX
M(?!59AA290:>S$*-?K )&;:]112 OPQUM.R^@:>T@,<[E;)YW"((:@B'^L'2
M&<]H 1F-/PH'O(M 5'/9@+.L],A32D1* <O.$H&=T @#)C3R*S12?J,0P11!
M $UM?8XCOT:CQWW.4G9%ONR*0\JN*)R61\J.M?/R#B1?9]!Q.59=Q:K":+ 5
M#"I1\CE.Q/-R_HDFI]+;]%\I+JW 5@ J[O-D$RDITJH_!.6F*DX3(D-I_.=F
MFZUD4XF59[K8E*N_*8(&K4.>ZR(5FTJE-NU!%@9//,\EJO:4A39%D+%22WSN
ME*@F5$JG*8(BF#KB*3,192JET[0'64JGQ)-EHCI/*YT0Y*HB^TA(Q2\^]4FA
M7-%,>Y E8TD\2R?*>M@: Q<%@G)5.O+_C$AP+L>L<P5!#T9+]V=VJZUH51D9
MX2(4"]/S_>O]%*0ASR#/P0D3/E R^"F"O"D@GO\29GK )N\TU<A_ YY@GOY2
M+M=94P0=<A5K;S7/@37E>DJI,$70^1FOTAE/@S642ZXI@OSY!J?TQG-A[3##
MT*:-0/;0>#ZLL< #"Z74?/)8#TD>:YZ6:J(EK0B:(LHWX3)!M%R=UOQ:K^D0
M2MD&I@@*,:64385)+:@0:,&S1):Q-\S,+BTGD#6_XFM:\19VJOG;P7K([6##
MK\Z&5B>KYD(J)9 S=<2OS 97IM-RKAYD25 :?E$V>$?66&K+AK^O;X;<US=\
MGM $0Y&%(%?8O&>(*^;N1GLM;T^)D>>"A@I)U2<\ R_ZQ.(4GWC":.CV3JN;
M>E"QO.V1I6IH;K;92C:56'FZ:NB64;O;1Y!]K@7=$AVP:S?V" +SB5_#IRB-
MY3JP$2[Y%/T33X+9<',WR4-N[C)/@MEP<S?)@V[N,L^"V7!S-\FD.S#G)IG/
M3;+AXFZ"H.@LU^J9)]5LN+B;Y"$7=YEGMFRYN$-0+ H\!*#B%<]MF9(AI22<
MY,3/*N,_GI Y7^M"PQG9;$+0D7.SS5:RJ8P*SX*Y+M<S$P*9;_XR3X.9$C?M
MYB-3J6;M2Q!F$L$I]<4DTU6DL:^#4VQGW>?']6D2.E;\J7SWN5G-5PF:RXJN
MSK0B8T*P 54&5#R#=9\7ZHP)H0[[FXO>)GJL!#EG%<JEQH10MEH#*D&E62'_
MF$HCJ 2=9C5(J%D)2LT*2RRGG)]-_D59JEVH! EFA8O5678"J 019C6DSH)S
MA72O;JXL<?<HRQ41B$IJH/W&9(5_NP9ZY;/-BK"P@!:6LF?=$@J<_;(8)*$T
MBINCMU2 <*YL[J./@Z+G-VSHQ<U:UDPH7ZJ1[GJDN7( 23&-,N=HRC+A7.3<
MCU(S:)3X?0[ <"+YF5"N*BIO>V@PO"=@M=J*5K5W"@0V0!UU]*:7+LY%U#3Z
M;M!F*XB>H5<]J\\HHLQE) C:8T#Q<6&R"54LT D92H<><[/-5K*I12N0D2,R
M,F4GYSKI?J('D9&@:P97?H-L1J /AI=()*CFFL!&CMC(E*&<"Z;[81K$1H(4
M&4@\K ]3QMC+H\0CM9>(!-) \; WR6;@7#U,@^0'D8:@# 94_4;/UD'=MOZ)
M4%WHUN@%WO#TLJZBN?Q$J%_UW S'$-:7Q2LR5HM$X 1/G*"][4BHXGL/\]Z>
MG:T$N3)X51G4SRJ]T&K?# 0=,GB+2(=0Q1=D[@CYP<Y(@G 9O$5_0ZBLS!*^
M.]U#RV]/VZVVHE4M8J%:0G7TH; U61&J)3^H6A(TQQ L;ZT1RI W$]*^1 21
M,@2JK4P5VKDTF$8I#*JM!,TO!+JG4C,W4OW*A%C3*'5(\Y4_"/)@('UPL%D1
MLIXP*.LY%_[VON"A:="^ H%0OGB6*R$USP2*(3UQ,)5@YRKA?I0&)3V"_!=(
M_UL8I?=O2ZG#)$ 5WP2U,)!<.)B*)4$O#(,$PR HA@'5P,(XX5>&$ K.Z_1?
MH',1VODV?O,5-B^+[\O_+K;?GYYWHZ^;_7ZSOCY^9\W#9K-?'DQ5E_%B]+A<
MW/=_K)8/^^.O]>'W;?<=2MT?^\W+-7XG5/_%5#?_!U!+ P04    " "&,01)
M+=03OAH"   V!P  &0   'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6R5E<N.
MVC 8A5_%R@-@.U= (=(,U:A=5!K-HET;,"0:)\[8ADS?OKXE!<D#*8OXDO-_
M.3[(=CEP\2YK2A7X;%DG-U&M5+^&4.YKVA*YX#WM])LC%RU1>BA.4/:"DH,M
M:AF,$<IA2YHNJDH[]RJJDI\5:SKZ*H \MRT1?YXIX\,FPM$X\=:<:F4F8%7"
MJ>[0M+23#>^ H,=-](376YP8B57\:N@@K_K F-]Q_FX&/PZ;"!D/E-&],@BB
MFPO=4L8,27_YPT/_?=,47O='^HM=KK:_(Y)N.?O='%2MW:(('.B1G)EZX\-W
MZM>0&>">,VF?8'^6BK=C201:\NG:IK/MX-XLD2\+%\2^()X*5G?UB=<GD]XE
M!YTQNZQO1)&J%'P LB?FS\9K+1<&HLE KT7JF"Q3V*"J\E)E:5K"BP'=:&*K
M>1XUV=>:[:C))PW4'H)&XELCJ3,2>T#Q&)#< MSD4^(!R\> -.@@]8#5[3([
MJRE<%$Z#44B"'7SK-$6&S.^QF2QH)G-FLAF /!A'/C^.(NB@N!>'V24F#R?*
M%T5(E+L\/ C-S&,9=+/T>>#'@%4PC]7\/# *6K#3#Q/QJON1C*BYF6 <=N1W
M71;/0,3!6'#\'[DD81?)W5Q2GXM3X621WML\HPP%HX%71UQ/3O0G$:>FDV#'
ME3XM[:%VY%Q134*++ *UOL2F :-'9;J%[@MWK+N!XOUX2TU79?474$L#!!0
M   ( (8Q!$FGL;I8J <  -HQ   9    >&PO=V]R:W-H965T<R]S:&5E=#,X
M+GAM;)5;VU(;.1#]%9??%ZMU5PJH"K>$[(9*Y6'W>0(#N&)[6'L2LG^_,U;+
MF-"26WF(+QSU33K=K9%\_-RMOV\>V[:?_%HN5IN3Z6/?/[V;S3:WC^VRV1QU
M3^UJ^,M]MUXV_?!Q_3#;/*W;YFX[:+F822'L;-G,5]/3X^UW7]:GQ]V/?C%?
MM5_6D\V/Y;)9_W?6+KKGDRE,TQ=?YP^/_?C%[/1XMAMW-U^VJ\V\6TW6[?W)
M]#V\NP$((V8+^7O>/F_VWD]&Z[]UW??QP_7=R52,1K2+]K8?933#R\_VO%TL
M1E&#ZG]1ZHO2<>#^^R3]:NOO8/^W9M.>=XM_YG?]XV"NF$[NVOOFQZ+_VCU_
M;-$),PJ\[1:;[?^3VQ^;OENF(=/)LOD57^>K[>MS_(L7.(P>('& W V0Y0$*
M!ZC= .6* S0.T%P-!@<8K@\6!UBN!H<#W,N L@\>!_B7 5 <$'! X$9IG/,X
M<X)K%.PF&[AF09INV)MO71Z2)ASV9KP<7DA3#OHW+;.X?+>+_Z+IF]/C=?<\
MV3PU8TZ =R-^/<H9A$^&);\9V+05N][RZ?3XYZDQZGCV<Y3T"B.WF+.$T7G,
M><*8/.8B86P><YDP+H^Y2AB?QWR(&*T+<CXF3,'FZZ0KY#&?&+K^1#E6Y#%_
M)0SD,9\31N8Q-PGS,J>S84'0JT*^7A4JK@J)$C1#@GHM(7[Y7J&$WV*[VF)L
MC%O$@!]FP!N&)DUJTJC)4II<U!0QT@O!4&-(-0;5N(*:B)$..)&WI!H;UY*!
M?-RN(X;CBB-U.'3%%W1$C!16 TB..YY4Y5%5**B*&!#* NQQ**\JD*I"5.5$
M057$>"5D ?4IX+K<1^6M 4&:L_UZM(><28?9)8) ZL*J0I "CC% &X,IP4E*
MC\?T$T'B2)"D]9B "%3!'DG;@PG&D65'8RE(($X6 CH- >8A1[KDL X@B)D?
M@,Y#@(G(%1+11P0YGB(Z$P&F(D>FHC29!J>I.)<,T T!*IA,9S6P:#*9<L;F
M;#OAF-B.6"N=SFT0$Q>=IC$+($9)/]0>2U+/8H RR()9=!X$3(2.3(0!_8\@
M>:0"1Q.=!@'SH"<SG,/N*&!*4;I0:#Z1L$(O06="B9G0EU0A"#QPHBSI-"<!
M[67)R+0^-;V/I+..Q(3BR70;Y^ 208&5"B2=<Z0NA1;K!X*XH:63CL2DXUE-
MI:5#:VM"2_-;8O/BR<T(5HX=B).R),U8F1A;*)DW"&(60TDS5B;&6H8,)<C0
M*E'3L=/L4=@D2')_AJ'=@3B-FJ*KOT**>98,13NL:ARFV:,TQ^$$XN1D19-'
MX<: PQU%<T?5<$?1W%&)%H7&_P."K/1J^,=11O-'^<.%&#$5Y571%%*)0IQ)
MTC2%= V%-$TA#8>+[S6"E&9E?DUS2"<.E4H,@O9+S-M)0!#PFE]-5SR-= P%
MQR\1]$?&GHCZ,Z' \@S*/!5@5,9KK:M<I\FML3(&3HND:7;K&G9KFMWZ<.=[
MCACEO77@.;IH<FLLCD%R9 3:YU#ALZ%;2X.<#2KO]"6"E)%@A NL1T TO0W2
M.Q2VZY<)Q'W:1//;(+\#I[$P=(TT-372T#PR^G"$SQ&$RXKE=>8AFSD<X/,$
M8L:7WI$:9%S@-%W&T?%U-?&EF602DTC:XL;0I#836*N!KI$&^18XO+=TC;0U
M-=+2)+)PV.-S"S4>6YI#-G&(TQ58FD.VAD.6YI#5C#E&$-#/8B+HF@ 5K*$Y
M9B-]>-75TO7*UM0K2]<KZSCKP-4X3%/,8B<J. 7:TL7*UA0K1Q<K)] .\NPF
M@JYW($[K[6B&.4 9+&/IQR"NYC&(HYM"I]".PB'0&8*DUE*4^M0+!!KM1!%X
MA4"P4AK6(G<T;9U&\PO;P[,=B#S\TVC16U#!&IJV+M&6D[X=35M70UN7.3QR
MAR?U D'*OIZK@C*:NLX?GH*+'8@57;HXNH R.*7"T\71UQ1'3U/7 R.Z"))#
MNV4X/GNZ//I(<0N<"?)T>?0UY='3//.:XS-6OK&'Y[1LGF:1-XP%A2#%>B#G
MZ?[26PPNI^AXNK_T-?VESQS >DYP\0AVZ-X-RUZ:1#Z22+.(&&@2A1H2!9I$
M(9&H5&@3"#A;V$ S*"0&<8IUH!D4:A@4: 8%9! 4SK+.$ 1#GC3%0IN VIAR
MH46@'&R7K'43:%(&!BG/PEM2OF7N3E*I&A.2"B;3] Z)WIR^--#T#C7T#C2]
M ](;R$/G=.LA@CQX95BK/7/! FLDE![I(D@ZH5A/S$'DKD]@(\QZ3 4"R!#'
M[[DQ!I&YK2 D(\H)!4.<>5<61.;.@E",0">4<YIW$T-DKBV(E#QXTV4R@395
M@<Y<$Q")5H5$=I%0&A2OOP>1N2L@TED'3XK/N.ZK7,\<VXO <AWIY;FNYVXG
M0=IGEM)I0O%2)60O'V&IE;P;3/2&%*!F1PJY^T"@.&%&%"CF]@5R=X+POL^P
M%65)R9 +JLB5NX.#UVO*K6!"C6<B7-\S[$I7<5C'GO#[Q9F=[U7LREV* 0:[
MKA+*#)W/6WK-]NY7/S4/[>=F_3!?;2;?NK[OEB?CA>K[KNO;09(X,M/)8]O<
M[3XLVOM^?#OLXB?K^,N#^*'OGD[PEQ2[GW.<_@]02P,$%     @ AC$$20IJ
M071T @  ^P@  !D   !X;"]W;W)K<VAE971S+W-H965T,SDN>&ULE5;;;J,P
M$/T5BP\HMKDE%4'*1:O=AY6J/NP^.XD34 %3VTFZ?[^^09/*"?0EV,.9,V<F
M'L;YA?$W45(JP4=3MV(1E%)VSV$H=B5MB'AB'6W5FP/C#9%JRX^AZ#@E>^/4
MU"&&, T;4K5!D1O;"R]R=I)UU=(7#L2I:0C_MZ(UNRP"%/2&U^I82FT(BSP<
M_/950UM1L19P>E@$2_2\09F&&,2?BE[$U1IH\5O&WO3FUWX10*V!UG0G-051
MCS-=T[K63"KRNR/]C*D=K]<]^P^3KI*_)8*N6?VWVLM2J84!V-,#.=7RE5U^
M4I=#H@EWK!;F%^Q.0K*F=PE 0S[LLVK-\V+?S*!S\SM@YX"G.D3.(1H<4/K0
M(78.\>" ;6EL*J80&R))D7-V :(C^GB@9P7GFD0Q Y6]4(4UG-R4MLC/18KC
M/#QKHAL,-IB5Q:#[B+5%X-E\P(1*@5<&#GPAL).1/ C28]+[F(W%X#0:%Q+=
M"HEL/2(7)!LGB&\)K'$9&X(8WXIL#22SR5I(A&#R +6Q*!SCJX3O:DF\6A*7
MS&R<(/56(YU>C<RK(',$<]]_9C$;AXG@>)"9-\C,$7A/J,6L>@P>#S+W!ID[
M@@DG"T%O,8UY8C41\HI :+R>ZQX4Q1/B8'^<OH\F-#3R-Q+Z1B<A?RNA";WD
M,#B#\$$O]:@$3CADR-],*'&1T 0*?SNA;_03\C<4RIP*;U%25Y2L3_=+G/!J
M1#24'\VL%6#'3JVTG^;!.LSS)=8CYHM]K>>\&3V?-$7>D2/]3?BQ:@78,JD&
MF)DS!\8D5;K@4Q* 4MU$ADU-#U(O,[7F=C;;C61=?]48[CO%?U!+ P04
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M\J+:\#O\X?X'WX'VU$>.1$!DZRWL1-$"#=8X^G./W]+XLPIU0-(56I07B[)
M*;)K#EFQ7B]!@*)6 5?X3,X]GCJ1\+UT 8KP0QVF^[9HJUE'>ZN6VTWW+/ZA
MK.[NZ;J&V1:P]7S:N];4L^+C_2+K5:= DIQE#RP.2A0'6>1,.=@6)'[?O0&[
MS%$V='O_Z 4GS7N/?O!!](.7_?J!O;5?]5_%+_D!.#\GY6)1@GPKYG_<MJ36
M9O\/&$K?9^_J 1'D9'C996N0/BL\PGH!'U7"(7!LCVY &A9-5>>HE'ZN@'Y+
M='V@=5/.CU&9VVM'[__ZSWC[GSZ?Y]ZX_JEL9E5+DHH/(A_7UJ[DX)?2!W\
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M2U0^7N01WS+63[*_/6=<K9X(Y]@=4($N:3R93^/YU(D*!3SDFUU5[7'*&0U
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M(^E!$_8P\0Y@;&2J>K5\<H&S"!@4V82!'@]CCZ)U:*:$^C:06G#,NE/3J^+
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MBXAK\V9!. T1NN$"%'K0!:@VOU=/.UPK([SX8-I\$>;QI\Z*7F!R_-EXXG]
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MWO^)]WT<,V24Z5V8#K5<;O/%WA%JWN??TO).;I>FGTXZC5)J*?%T&*UPOI;
MNX]#-TC3M*DOP\=GT J*-MO,E 'NKTN\2UZ,AD&]3-#!,\S%0@IJ>D3P&G5
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MGAH>3$,LER#/N03'!%S< T_Z*Y<0+L,F%7$[9FD^'?::?<31-[7]5=QY6G)
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M'>$(?__+O^%P7"KT][_\^W$>1R-\?0Q!@U!707)=R.=%LW:];]A8)(. !QQ
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MVZ<,#:M-N5+,DTXMO4F2<-VH>J^6BA]X9GC>VR<)#L.FS="@X$X_,=K'Z'(
MA%.!V??9[&6Q)OD3'+D$?0A4X45]XV)>*!0^T<_>XGR&]'<&.\61X=[$#%E"
M-3XZ&[6;8TH5XO"N&2DC8X;BPB&%5V@I[8J_/'_!^?R%[#F/;E_^@C/Y"^RG
M_;+\!6?S%[+#\Q?VA4)C<;,C?\'Y_(5L3_["M >EP1]4B0WOK6&*%];YQBTF
MS 6MA*+N:7(>5W?BGG''"+,)X6Z=J))ED_A.3!:?>S:++[-9?'E(XW.=3#P!
M4+<+>6!3+G[4]27M97N2]JR.5#>NW)FU]ZGG8MOC4[**0L>G9(MU?IY+:6CS
M@E>=K'OK.7+/>XXR]1Q=62='MWLW^SUR(U+^)W8P#9[S, U[/$S1MO5W0_^/
M\3#YNO8.^8\/@-J,W$[NYT!M6IS(?]3D=C\7:C,!J]Q)[\/<3NXYJ,T]AN6^
M_A21A\HXI4+!:@\G]3! 32WY##[%H=ZFZ?_V-OTSO4W3_V6\3=-_CK<)A-Y9
M[&V"WPS_/_,VC4*Q;.IMLFL./IAAKU=EE\NI_^G]/IB7]4I+;3Q\:4_"OI];
M%Q3,=]XZM*[&.F:"?^3PNAH%JA ?C(M\,!YFR*M%%L1/'$H*GTBV2(HF=F;P
M7_L],[NQ&+CXQCA+?(]M#[,MJ8.H\J?):_7*&[ ^COPI'L #/V+='=Z^09_;
MO6O8AT!-4&,NF 2V]//1/M\7\PZ13/66V^N^$J>!+_T*=G&G+M^N[0MBQ!X!
MJ <#G.\L.GG!W2;91?9;S@!#<[.<I"7.5#?2G*L-)17:%N8[@\"Q%LV D*:Z
M+"U03Z/**V9XF) X+!8+N+\<;/P2J,Z^,#CBJU9RV8KYYZI%=%O6AQ6+_XO1
MJS6! CF F]IJHE":4K+RA7T6NUL=X?T"-_2?#\<#@]\BCDR:)992GQ >,B<%
M6/67>F@)U;V8\]/35'""PHWF>@@4N"<0>Q+KOE9<QO&=W"=IVS^8,0C, (WU
MDJK"[THX+V7;Z1%X?IPE+[CH!?<6>(XM8R?^0^^, F9JXOS1%"RUQVW!:6.\
M!\OBL=U2Q^O9LJ@>R%N!OFTUQ7-U_L)T.,V#>G\4G#FS]#.+$JEL4[Q,F^+E
M!EC+4?_%NS*0B)U.#XC#"Y8J2O$WH(N .9^]1<9W'\(L0);W>3ZNR&K//I)5
M@!SPNFX>W&AX\CN/4[. TP>/4+T=[W_/<< EZO C&3Y[=GCW>]]1(YY!!C/X
MO9^!RAH>_;L"3K\J2F?J*++0L*DKA-OQ:L4L4<;LCR+YD N<6OZLZF!&J.5"
M>@A"E.(P<$%0(E(16C>()X7,,05[V_AZ$9MUZ:AZ>X!-*Z_@.EAFXS-K7! *
MV*N*,<)@!2!M/2'\K^'08[+JO\"VEP$Q'*R?6GV2,,V'JA6#[G.=>F=%Q]5>
MH L@K<VO8^O\<QFKNE2$G+$0=7(&,." _X8_OT%^WN'ISPUTG3F:.5(!4]J$
MDX &KU]=^05A(_(3=A%AC&=V7SZ0=<*! :=Y?M2Z-"ER":TFTTH=[7M(7$'^
M*-F ,8VMB.=6*Z $+3L:33#GHE.0A><Z^3_ $8=?O@5[O:$<=V"2-ZO9(,?J
M=_YC#IOT6>YMD"APK164"B\;QFE-E$^,33/7ZY++!/ VC<' F37@X2MZJ,V.
M**ERQ2Z7LY/1]/),@0-#YN%8I/:!;(8YT4[8#+4&XJ-HJF3/W]YBYRIB$MRH
M>;.]L]UY:/E7[UY=Y0)2#]NRP/N%#2<C$,,:1I.3ES^<G(ZGE\<V%JM-*^F2
M$W(+UUN*&GIB?JGK:L#(V:B*S]D64I;3+;W0$OI/II'96NJ)91&I((]GZ+ZK
MEACO7 D,^7:-&:Y>BWMO4)OMA1V9!^%F;_GUU YX0""?];)TP+HGS+KH>OOP
MAE^H%$<!+L5BW3*J/Z(WB_G 7W7FJUJ)Q.[<#%&7$<L=Z?K *(]ZY<8^5#)S
MU"J1I]M[D'<+4,GB(B=??X8;IKF/\J#TNH2O8/VJ2,J=Y*E(8G%430^\7_M3
MVN7W'; #9F$J\CL>S.P(B]KY#V3NP-]AWX?DC84?1GFD.\?!]&0OL*N/R5;T
M&Y"[ER"X\'HS8^JOV,8"VGU[=?,Z.T+H:+H/K_^$/2_^Y,2*/,[]Z93%X<'_
M\$;GF<"]AP@[QVX93E=U=\L>.>'T@I ';9*!'1G4G  HR7IR-\MB]0 [)(2;
ME5L*"YO%Z!,<B\/M@B%<N@L"O8_KY/9&BH<6^G,/1Q-:$8IE-^Y 4IC7#"62
M ?QT\8JS $14Z,T"GW26)#,"!5<_X[RN5EA!D-U<W3"_P/T AKM?;6R?J[+N
MA-\#K_LYT[%4K",]--))PVF?"9.Y1RG8"SIO5>-U$\GC+V;H"ZU*WF5G4L9M
M'X\M:"^"*VI+=4J\\R*+@1H8^/9DOJI5(@?=+M0\M]"&S<DZ9#W> &_MVKL-
M;0=Z/,-IR02S!FE-$;#0^)!BS]13^ $N-JQ1 GVL8;6]1]:KP=C2D0D#D"6M
M0E/D&>H !%;KOTOGA6KX@BI.M4F5U^"&H],L]?/<@J*YTJ$Y1!->9SYC''F=
M#8N>4]Z-A*G]0VC&P8:TK@B]QK+01"TZ+53J&WV?L?>Y4"](7=7Z5-@'^SK<
M4;%526MSO6O+[-IT]WAITP&1TI!VCD:Z/H2[83I@]FV,.< 3D\/2+PC"X'0@
MV^CVTAB7(1;!=.($ [O0I284SWHIGI:7(L4]SS*]HV*:IRPENSN<[%V@-$JB
M-99][S=,9Y3Q<#AA=WY4"!L3[FWQTQSY6SV8*//D=W1=D8>(8@YKTA$?J+B.
M//"B/&/HXWJ+-JPQ(QMJ=#/WY1CP![VT$9JY\P#($FZ*RO)$]@&'$1OC70E#
MM&#MHULO]&#HZRWO.W006^H"B2V'D[@>!G0J! HL?D0ER)3D<I* EO(F4)Q\
M;S-E@T_6Z4 *ET7%5:'%0)2*C+-N6M38W=_^:J*1\'+B7;0M7,@$C8-4Q]A=
MNJT-0K9.P_2AMWO(X,.]N\@F:61W  7,UF*M.0=8HYV+=[;W"9\UXV\,1FX\
M='.]C^0XUM'L]F7/;9]LC#ML8[*__34$B=-M.;.>O:XC\3A 8(MC&?7%=8V6
M!(I-)K]IN'54#<H!C#@*C8*ELQ*W5TB8PJ;?QL,[9HI(C<9+'@T:+]!4.LFB
M(VQ<JF&CCKQ<-& ZP)85[2S&_^!;MZ1VX)>D8NW61MMZ6+7C!+RF6J".M^_B
M..._N#^0$PRDWL]K=R<IB6Z47TPF^?1BJIEI/BO)U_1BF$D&RV/(5(Z54JL\
MT[U%_)\7J?_S?(?_4RS+1]X)&8J\*Y^?Z<78@V08OK #$ZR/^ X4^)(+VIBZ
MV14V,^=64OADT,!?7]U\J^F<=]N*&Q(3SX0@+U9M$S5/N)->:.1[KWU/M<P.
M3R;U8I=\-DEG0UP?E*3T=;#B[U ]#F5QW#W>0&?1+=Q6>+JQ X!ORL:W)JT=
M!VE9</$86<\8&*+IF[J\0DDO;48>7@EF<Q/I=&INS]1\9^L]=7[1^GUU/86-
MT4Z6K+?N_.6;F"-'D! +:1""Z71\_)25R,UQ0M[*;FH";0G+";_'M^6L>+"Y
MA#37I?C@JCA20%>X,Z$A\1V'-"ZOD1L]+R8#<Z#D<JQ69:-UO5$,%HTU/T=3
M1IES^E$5VH7[I^8544B ZE 4P%1F/D1CW=([0OV<NTTZK@;]VP$#*#8<ESSK
MGI:KF^^S=^J3&U[FI''"QR5Y]5\):R"SO\R./E$.U/GHXOCK[,T#J<$<I@&1
M>OVP7M9/8/G<$+]RHN,'X=<K?QK[8EDY)V!P"EMT.5(4+S^;C/+1^-3)5;D.
M!NAHF)^>P1\GY[9!'C^W7:$2BCKBQYOO.7_>")X\BW/@HEOKXI=DI$]^F4:^
M,)7"""^1T4?!<I7V>_CVVL,6\F/'5(DOD*WS:KDE6%$P4V"O#N[NZDN_XDP\
MV=.+TWPX'C)E+NA'S9")EV%2L94=[?42T;GOCLGDCG'1'6-3 +^L8^^+TQ%&
M,;8M_N/05Z<4JO ^FE%?)E2(0' <%-.=\[/A>3X=#AVR!=,SGTS&!-H6<Q@"
M$PA7VW:IK BZ))+ X!Q9N+H^+(&531;#B'X3,"II^,^<!2(IJC4W V4/ @6V
M1#BK#4_S<SH_>IGH$]XED&'S*A&);-.S/K6CET"3Z92H@3,D=6*:3\Z'AQ/(
M+Y9-85JH#D1SWC77[+U)WT\6*Q_(L]/\K'<RO5_6'KJ/]]BBA2] 15 '76NX
M\T,>FE/N4)_0K5ZQOANQ39.1]A1Q]O;!'%W I,XG(D8T/SO).=+[GD]NRYQD
MTH_.S_/)4!5()WG!&U:]$%>@H8Q&7_O ,4#-JD,C0R7YIOC)1?8ZF6_U%_+3
M9'2:'+>+B_QL>M[EI0>*WO9%2=VW-2I,F%<+UO*,2KQZ^2UB(+FS/>>,+V@F
MF9_):#R"7YSU[3_7_U-K=!#WRR5KC#L/:%#3)<-;XEOUB@.%>,:Q:*&5%II>
MYY$(;=-9L00ZM%8*O2JRZ9$QKX48]OL,9=O+\J=#?[*9 F?G^6@ZZJ> P[MJ
MU]*RPY;FNDO+#EZ:ZUT:@^]XI[O6MHDZ&]?7.$*3H8LW(#SYAC5D]2I'<2^J
M#DZI4YW;(Z.11EF0PYM,8Z^K8DB-?5BUMNATVH\7Z6LR9VR;,L(>FY<AH95E
MMD9&+P\\9^-\>C;)Q]-1.&EPUXW'Q/)?*+?_(R^H3*2*.VS%4[J>_#'>U&[O
M4M@BBD1Z%HMT]YQ(_]3-TFLC<X<)3DTX--5'1C/\'+Q7E%,3*KF,*R\4K*EL
MYO#(G\4(\;.(%^IPH;87"#>%Y>SZ]/!)9LUO^/"Y[\+AN[&'[[Y<SE-1_X_>
M;A>@E)Y.Q__8[3:&R_]T?*EO__SKS2$$:G2]?? :.P.MO5<+:MK'D$F8SM8J
MN\1Q33R/%TFUV7IPI[1462/PC72K#D8%X1_Y(F?6O1^=_T((P4JN+JBCQ<RO
M%R@.(GZ8GU\.C9'DKA[@^,W@@+PJUW5;46["C5@+6I$1[",4;4>C8R_>I)TT
M<=0-8[1>868<%I$15![3DIRD^M5UH:43?_OK<##DCJ7TP=SGL@<$'2O$*9:K
MHW2^S.3J\80E'6A"6166U!N/F'2,\>FU="I[:*G-_6KE"W7E#=QK]:$:,W0G
MA9F/PGX3@) K3()U@#1&JVI*1;L^(0\Q1X9D3 *CM2?5XL17[YULZA--)SR1
M T F9DH@6G]_IP&V\';0#FOBL%#"S1D+";X6'*F^Z$L;/_?4$ \#<@.3/7)5
M"MJ_N(DX[J9&--U@E2KETN*<;>Y>K\AML219V=Z76$KFKG%[L!#W:#0\SG:S
MDZ*5VX\YAHV:E]BCVSN-Y4S$Q<0IGT^'!_-Y+MU HN\%/%4^C:74K>\ZO718
ML)A9( ^BPMRP)LXZ(WW'?6&A=@_IG)".*CI^9N&V"XI[N <EZ/(SZK7#;I'K
M2NSP_W\5;?MZ;)?48R?;OK<>V_748V>'UF.[GGIL7^D+YYM[H!J>BP\2!X^>
M0E4X<W=A6&[/0?4[[D(@%Z$=44Z'LC9*B9!_$=-$%QL9:0EW<=46([O2NA94
MHTL?"IJ721S%5L<66Z18&<=TA!#K';1YF#TG/3PWR\X9L -^W"Y+-YI,>J>'
MG9@I-%?) 3Z,"A1&,\BWF5D_CI?!>'85&VKAL*X"'&MD)>*.,EE]]E'RL8&[
MB;*BM-<O_J;U93NBH.;=;E1[.(6TQ.AV2 6Z+261#)X]D;OH+L6QK7UPEJ.C
MX?3TE E-))<8CP1*22T;YZ@/3\XF'<JSO9Y %$M#R\YI<K&@\VRO)O\>JO3$
MWD3M1)!2'V<6D #6X6VJ&M822G:[IDM%/2?4L JP"YS?0LYOQ&EC3(4!(AHC
M7@O.!R7?8]6608+)E;ES'=DG;D)-H2IO5]\^69!2:J>R]RO2QFM59Y]KVE@&
M21YDOZT?89I-;GL#HCS==PLV91QJL,HG7-H@.G,/($T&J9J&<@N:ZKF6:(2B
M^'.I-T)V=#[]I>^]#O];12VM=Z\1%K&D"%BCWI!BCIX5[)I%]@.LM:$J$7V1
MKEK!BRXV&[2< [JL#N2ZK(7J,-I'8AVM.DE0)B5^8\&$!^ZW<>G@/OYM8E^-
ME!OGG=+&Q.&R+D"Z>%".[,@41/C?*LHYVOCDVXG/Z+&&Y_8P%#N,CNB89@<K
MZGQ_>+#W%J.<- G,3=P_YRR><RI7CC-.QL*V2UC 6'?U*HR(LP*(,UBP_^W+
M1O7?='Y4RJVN/.Q),B@[FPZQFWA:>PX>B7D0CX*,:VOKRI^PNCU@[=I;.<Z(
MW76%LMIU>LKT>>![08WW^-&0;^S1'BAOO(B'#27:/GY\<_TR0T!G?Q?%^LM!
M]KMWQG7O^61O?!M7265\1E6+CZ3K.Y*J9W^4=3+$F=*&@[ KQ]FIWLT7'%>,
MYPX3"NJ33 T) V]B3<Y(O5$I,$DWS1Q1'"074?- "5R@:.L5S>V6:KT76 !%
MINZ/9;GN\ >7D>&'HZ3B7)B**-,P5'AEW'.TO=)#FM1$+$WJJ7F>E^S*YO1)
M]MWEFE-)N0A!19=FS6:B'ZUZ>>,Y:H$J#&>S.5\TAH4G/D, YUSC;SC*&W3_
MX.=W1\6QN#I&3/5S?.OH]I@>Y-#%2I8$I'7]V\[.Q-LGZ_(0K9\.:]TX.JIB
MZ5-:MZ<E'0U5$7?KMT[O4Z2HU'G4C:9JX$5:+,/Y87_?I_W7BR1V<B&"NG6#
M(6L;&GO(%#0Q7[XF/K\-8!E/X5M];Y%JN*A^*N>,?$3*XB.ENY_ VR>@B<(G
M4#8[UL)8ML! ])0OG-;63AWU-=+QIGWML=4)2T6.-R>G$5NYP%9L&G6/:7^=
M-0Y2+[<V[<63<O;$^/IT(3YSE7(<V:XW0&"07\BT>YW3]G"2/CZM2#.8T6TZ
M>G=@#;T/*HKS@/H"HKBM9LYD)&%9N&S=7B!P 213&@74A CP*[V#26,*4L)[
MP)RQRV;&T\H-L ?3H16D"NN(!VF[X3B#7XM%-4Y^F;82%QSZ>;70';DM-X^E
MY,T%*;U_:7[J<C%%@;,C+#6_#$XRKUK-"YEXFDEC01QS+36KPC66AE'<+I)F
M_20-Q\O;><XK#BE>PSZKDVO&6+C/'3OR(@S1'0>9#JA'"U%-BX!)XZFKH> Q
MZF>S[</65\_B0<CU)* Z*2@WD8NUL 8:\@QZ9)>4Y6.[//A(IAV74X<;-#09
M@](^Y%$]"7K-=P-@B?Z;JZL//FZQQ^ .F3ZQRSWOJ:!E ?.,&Y_I$7EKD"%.
M?'S%EBV0Y>,8"&U3(4 &8<28VJ@T2&!TSM;[M%Q<D[@_CJ0P1?L"2H2JD8#>
MYME-O:C N/Q<9#^4W'KD TP;W8S9#V_>N+>##X/LR#]D2O<L<$6QLA+MQ=0D
M#H-"<)":OB. Y&P J1.7W&.U.JU2*!Y4P'AI$? &R&M 6"P6+5;?DX)#:?.B
MQ9G=_5,%]H8;UW[@!S#"R@^P:A^UMY M"8>%Q1M],VM <_%]2*3W$V>*:>LG
M5;RW#P^)EMT_ PTT\QZ5DGOB70@QJU$J271D6=E@9Y+)O-CWCK9%T2%$5J&M
MW1=B=G&(.=L58DZBRY(NZ^+80WR<$Z)D'_J"<X[!'#4V%]EAXL4ZO<@O,//E
M8A@9GMC"M5#<X.JAW!4)W<FKN13Y]820.A['WA:J*&AC-V%^<7&6GX\N4CU!
MYM87+'))L BG#&M#Y(">*"4VD V2@PSU".7FGQZ*_.)0K8W4OFH&V;_ >6ZS
MWY8%>8D=IXWUR13*&LO1_4-)V\4=CJEI1VN6C7@VP_*_PZ>8HT!DYMG;P=O!
MRX%)W,$A]GTA 7EDLW_%?I/^2$!D_+O=QG][H)/$/6_^9[WFO_LB\[_7Y>6E
MIR?H?D< NY(G/\,1<+6]PWJJ\__M"]@Q4<-@_SQ?@)6L^UT!X40\YQ0(O!+[
M!#+C$W _RR>0&9^ ^P*? *E6I=?QJVX:0E"8>,M1O0Z:OH3LBWYLT,#1FEQD
MD!5C.FYZ<WK8,Z!@NJ(FWJI7H >&-8R=6'=<V%BX;^';/Y[<S+#1:8M-Q,JE
MMY\[RX)K(#05*#8.Z^_67F+0"/=8_L/IDUV#A*T;!CQV?4:.$::THGCZ&.Y@
M#8L,(HO/1C&#U$SHIZIF%L&IG6TYD7)?LPD_HR3T5SA>JUR/@2YJD!&2W1%:
M4V36]G4%PNLC,$J;KKDF&+R@A(ORA9!'#,6.5F&)B8B2I(HO'>UV2AQ[O$)N
MIQMBKK1?(1*U7]^2^M3=F84[U;XJP&@D&77>_HTCF%$M&%OEQ%".= 5$>"?5
MQQOF.ZWGU)=R@/7,N]&907+>Q6%!]@GI.&IG<$Y"]PC3'?(@Y66H1]DJ64(*
MC_;<5*5Y&F%58^+,Z!5-5+Q&-KTGB>=9!Z.<6=1,-L:K9I[B*/:@XIU\ /V5
M$8ZN]+1T"F0O$0ZO[TECT;-G>;+7*K8?<?XC;*WY?Q[S8?U=_5@DF#"MZDL,
M#I,VT0D:@39C-97B?_OOMCP+]SP_8 @2AI*]A)%E%^LANW00HWZL:;UPRS/L
M$*EUN*</U9]+NKE:.\N^DGAF7INH' 6Z%* N2CQ4T(?@0^/AM7M]2/:!JYML
M"=2"GWP0D!@>I]JRY"#E5/4F$AE;\3/84<-H.CXOT&NO+!L91R6,:I-D5S4?
M' I.CL$JZ=LC%^]1[R"#_;OKZ$VL4P\[JO@73*.B$::R()Z<OPW:)X\)_R))
MU<6MV<N+A7@!"X;M4#<4I74IGOM.1!PA?#()Z9.,:=(%*%@>C'\UEY\6U"1:
MSAZCEKJ R>!!?P;*[91:9BGB_?6D%S:8T "W'EF_'38F%8)Z23]_2!S!X50:
MI%'."0"VZ!E;$<R0&8'Z"S/D^B;%KJ.B6=] !)]\_J!+8>Z))9'4HK0'"8JJ
M=5'!B8K>)4:-PF>Q*V=VJ^U#0KJNK,MQVBYLP5TE10^:[!>50J/\\G)!TPL1
MT23]8!9]$)V\?.8/.%:HHBRJQ0;#!#YE980I*X*W0R8YW.TE/N+"(Y?^D;-<
ML=G;V7TYWPIQ0MT$8M ]NLTC)L?X09; 6\M6/G&NM;(7?4E)SB0E2?YW2FSJ
M=/RY(&/7$YXYE@<BD?QX7V[NQ?Y **![B]T$HNCJW<O?OO]H,4:6Q6V)0)R8
M+0<63HHY S_B-U"GPQS4N3V[H+(5XGZ0=@X(,40 I;<*0F/!(GU&86<2POYA
MQ>&(D&N=5>69)JYVB*-IO;Z'P9S2"WV#H.BF*<C7R&V!E?ZSJ@%M"SVU=%!V
M59G9C,(FJ?ERT>U/^GCBE,5<9'+\]I_$A&\U$]4F/1;QTO$JI/5KE!#7OV3"
M+QKU^_M89T*T2O-"427$Y=0*X;EKD21\J4X*[BF02CP.2$[TZ9'V JMW3]35
MIM.P:L='OQ1/VE>9$Z(X)^Q+AYVZ'SG:@]'D+BX\AQD?(!&MS\JE1&S]X(=]
M#,O489I-63W<;IN6N]L+4DQT.?/U%P,8RRWGM*"AHP:_0D%0KSFP]+)S=1N
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M-251Q\"FB&1BF3&P'?+I,X>V1Y6Q]G+$YFNL<I9(@$S7YQ#PO#O$ZI^]SNF
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MAY)E7]6 40T8_P83 2W\&\)%9<_[+066Y+5 )31*)93L-0*$0/X4Q?1SAZA
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MO985_PRGEY9TP&05@Q-\52!YAR?,4/3I/MD5^;L?E^"GG2:9S$J'LPK:NA)
MM)Z$NL2[M-<BYAWSNTT[DT/$,5"E@L( ':20#6TDQ\H3.%7OK+X,.;E/XHWW
MTHG2K2 U*SC]V\U\(9>XCP2A4Q3:Q0:*YQ4&M;#4"%03R5AT\7^[_-\>T5@]
M)S)$Y2"T>TYS& )*J=//NUAF1/Z!4!O\?_/&3Z^5DB'4/H'6@55P94M\,_*[
M8"4,QLY^JQ%UJ$@._^-;1S3..Z/JB/!W#'R+BR$2OV35/9M[ECM68M&[),5
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M_X2J85+9LK"7-((,5-J8!^# L14\3^;J14MNL\'<9B;U99@,7]J0"WBC:,V
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MPW2KF+$=(5,Q7WONB0:P-F9.93D(W4^$GROM%\-/[:![5YFTP2T/-2?0</B
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MY<OLZ-DQX\$$H1"G9E^[]@;\RJYFZY[1[?1KGGFWOITN^9#D$$?E<*+ _IL
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MY>U4**S7M@?N*;:<,73I0X\@HJA4!<6QZ^^ #6\%"7W7IVG9HU>S)Q.Q3RP
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M]NML82U4*''^88VE4BG5.&4:5N;O7MJ/_==_+,O-__B_4$L! A0#%     @
MA3$$22I7CC?% 0  P1D  !,              ( !     %M#;VYT96YT7U1Y
M<&5S72YX;6Q02P$"% ,4    " "%,01)2'4%[L4    K @  "P
M    @ 'V 0  7W)E;',O+G)E;'-02P$"% ,4    " "%,01)$X.L<J4!  #U
M&   &@              @ 'D @  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " "%,01)AAQYG2P#  #I"@  $               @ '!
M!   9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( (4Q!$D.Y8%1/@$  &D#
M   1              "  1L(  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( (4Q!$F97)PC$ 8  )PG   3              "  8@)  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ A3$$29R)UK*/ @  ;@X   T
M         ( !R0\  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "%,01)"A#]
M%RL$  ")#0  #P              @ &#$@  >&PO=V]R:V)O;VLN>&UL4$L!
M A0#%     @ A3$$2>:Q#4N" @  90D  !@              ( !VQ8  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( (4Q!$FZV+B'.@0
M *@4   8              "  9,9  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    " "%,01)]V<QZC$"  !F!P  &               @ $#
M'@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ A3$$2>61
MUFV\!   1!<  !@              ( !:B   'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    ( (4Q!$E@P(<J70,  %,.   8
M  "  5PE  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " "%
M,01)73?ZD(($   ;%P  &               @ 'O*   >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ A3$$2=QZ_9N4 0  < ,  !@
M         ( !IRT  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   ( (4Q!$D52BE6EP$  ' #   8              "  7$O  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    " "%,01)5!9*D9,!  !P P
M&               @ $^,0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ A3$$252[9@&2 0  ;@,  !D              ( !!S,  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " "%,01)ZEP[$Z$!
M  "Q P  &0              @ '0-   >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    ( (4Q!$D>8T_ZDP$  &\#   9              "
M :@V  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ A3$$
M24"&03B6 0  < ,  !D              ( !<C@  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    " "&,01)M- .>94!  !O P  &0
M        @ $_.@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   ( (8Q!$F +KUZEP$  ' #   9              "  0L\  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ AC$$21KTJF"8 0  < ,
M !D              ( !V3T  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    " "&,01)@\2DI90!  !P P  &0              @ &H/P
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( (8Q!$F$M+TF
M_@(  %8.   9              "  7-!  !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ AC$$29PRO1KW 0  -P8  !D
M ( !J$0  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " "&
M,01):B_C-ID!  !P P  &0              @ '61@  >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( (8Q!$DP/K?VF0$  ' #   9
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M970R-2YX;6Q02P$"% ,4    " "&,01)HMZ4MP0"  "T!@  &0
M    @ &17   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M (8Q!$EFD=@:U@(  %T*   9              "  <Q>  !X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ AC$$22^>RH&$ @  U@D  !D
M             ( !V6$  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    " "&,01)'?(ZK"<"  "T!P  &0              @ &49   >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( (8Q!$F8%Y:3F0(
M "4*   9              "  ?)F  !X;"]W;W)K<VAE971S+W-H965T,S N
M>&UL4$L! A0#%     @ AC$$20>>@=QV P  /A   !D              ( !
MPFD  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " "&,01)
MQ=E0"Z4!  "Q P  &0              @ %O;0  >&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;%!+ 0(4 Q0    ( (8Q!$FP^]6ISP$  ,H$   9
M      "  4MO  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%
M  @ AC$$23#Y@='I 0  5 4  !D              ( !47$  'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " "&,01)A^* \, #  "4$P
M&0              @ %Q<P  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+
M 0(4 Q0    ( (8Q!$G(HB$>E H  *1*   9              "  6AW  !X
M;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ AC$$22W4$[X:
M @  -@<  !D              ( !,X(  'AL+W=O<FMS:&5E=',O<VAE970S
M-RYX;6Q02P$"% ,4    " "&,01)I[&Z6*@'  #:,0  &0
M@ &$A   >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( (8Q
M!$D*:D%T= (  /L(   9              "  6.,  !X;"]W;W)K<VAE971S
M+W-H965T,SDN>&UL4$L! A0#%     @ AC$$25J3(T5A @  "0D  !D
M         ( !#H\  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
M    " "&,01)NW6%\BRW  !YO0( %               @ &FD0  >&PO<VAA
D<F5D4W1R:6YG<RYX;6Q02P4&     #$ ,0!)#0  !$D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.5.0.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>253</ContextCount>
  <ElementCount>281</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>82</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/StatementOfIncomeAlternative</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - Condensed Consolidated Statements Of Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements Of Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Disclosure - Nature of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</Role>
      <ShortName>Nature of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - Warrants and Warrant Derivative Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</Role>
      <ShortName>Warrants and Warrant Derivative Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Co-Promotion Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCoPromotionAgreementDisclosureTextBlock</Role>
      <ShortName>Co-Promotion Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Development, Commercialization and Supply Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock</Role>
      <ShortName>Development, Commercialization and Supply Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation</Role>
      <ShortName>Nature of Business and Basis of Presentation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - Summarizes Activity of the Net Product Revenue Allowance and Reserve Categories (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureSummarizesActivityOfTheNetProductRevenueAllowanceAndReserveCategories</Role>
      <ShortName>Summarizes Activity of the Net Product Revenue Allowance and Reserve Categories (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>126 - Disclosure - Summarizes the Impact of Accounts Receivable Reserves on Gross Trade Accounts Receivable (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureSummarizesTheImpactOfAccountsReceivableReservesOnGrossTradeAccountsReceivable</Role>
      <ShortName>Summarizes the Impact of Accounts Receivable Reserves on Gross Trade Accounts Receivable (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>127 - Disclosure - Estimated Useful Lives (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureEstimatedUsefulLives</Role>
      <ShortName>Estimated Useful Lives (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>128 - Disclosure - Net Loss and the Number of Shares Used to Compute Basic and Diluted Loss per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureNetLossAndTheNumberOfSharesUsedToComputeBasicAndDilutedLossPerShare</Role>
      <ShortName>Net Loss and the Number of Shares Used to Compute Basic and Diluted Loss per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>129 - Disclosure - Anti-Dilutive Securities Not Included in the Computation of Net Loss per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureAntiDilutiveSecuritiesNotIncludedInTheComputationOfNetLossPerShare</Role>
      <ShortName>Anti-Dilutive Securities Not Included in the Computation of Net Loss per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>130 - Disclosure - Assets and Liability Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureAssetsAndLiabilityMeasuredAtFairValueOnRecurringBasis</Role>
      <ShortName>Assets and Liability Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>131 - Disclosure - Carrying Amounts and Estimated Fair Values of Debt Instruments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureCarryingAmountsAndEstimatedFairValuesOfDebtInstruments</Role>
      <ShortName>Carrying Amounts and Estimated Fair Values of Debt Instruments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>132 - Disclosure - Change in Fair Value of Derivative Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureChangeInFairValueOfDerivativeLiabilities</Role>
      <ShortName>Change in Fair Value of Derivative Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>133 - Disclosure - Intangible Assets - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformation</Role>
      <ShortName>Intangible Assets - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>134 - Disclosure - Intangible Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureIntangibleAssets</Role>
      <ShortName>Intangible Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlockTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>135 - Disclosure - Inventory (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureInventory</Role>
      <ShortName>Inventory (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amarincorp.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>136 - Disclosure - Warrants and Warrant Derivative Liability - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureWarrantsAndWarrantDerivativeLiabilityAdditionalInformation</Role>
      <ShortName>Warrants and Warrant Derivative Liability - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>137 - Disclosure - Debt - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureDebtAdditionalInformation</Role>
      <ShortName>Debt - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>138 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>139 - Disclosure - Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureEquityAdditionalInformation</Role>
      <ShortName>Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>140 - Disclosure - Co-Promotion Agreement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureCoPromotionAgreementAdditionalInformation</Role>
      <ShortName>Co-Promotion Agreement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="amrn-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>141 - Disclosure - Development, Commercialization and Supply Agreement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com/taxonomy/role/DisclosureDevelopmentCommercializationAndSupplyAgreementAdditionalInformation</Role>
      <ShortName>Development, Commercialization and Supply Agreement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>amrn-20160630.xml</File>
    <File>amrn-20160630.xsd</File>
    <File>amrn-20160630_cal.xml</File>
    <File>amrn-20160630_def.xml</File>
    <File>amrn-20160630_lab.xml</File>
    <File>amrn-20160630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>57
<FILENAME>0001193125-16-670851-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-16-670851-xbrl.zip
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MOU_&2P[0&28_ORA!AE]?1/'U:WB#]#I($?."7?G&6\5AY7)OY<4![$"\IGA
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M+MCNS-($P36M?1:/MDL<?=3.E1_'('&"$-TF.THVR:]QE"1GCH9VO;.#A!8
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MM&::RDNVXO"R88(VU6V--S5=5Q1@ E?5,.+4:E34$$$ $5U0C0XV\*:A&(.
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M=P53#'B U I26]SA'':I-<0'9K-2]=5V5UYE/RJ1SP"F5L(C1%5(C<W*BZZ
M\Q:D:+B)XKM_1O$?;\./<00:.'GO@QC-E/ H0 HB'NBW"2^(.MC!Q"2\:5H
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MD?H+O^!#>+"F)2$_1]VZN(ZI#L5I:D!3<(!3708C#2RHE# T0SL2K-1J,%>
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M3J"I1K5)0A]H:N#/<8BW[_CL7S TT?\HFC*Q":2GI0'2/E19(GH- ;W@J:I
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M(<)E$7:!H<;B]19H!P4-/K/" P6U4_[8(Z>04.9@+"XH]5)9Z)6HK,I?:]
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M<2I@![^A!DT*(#5:"L"+4XEX1LIG*TP"V =VW(X#(P%>T5Q2/RV.@/U)*([
ML4-QPH4X:3OO1:-2V997-QGWEY(=/5?4M)47G)EC+8,.I4HS;4TXP"+J$Y2^
MI9?F9$:I"O>-6DGK?&=+NSC)>UJ7S[NRI6?&((M:;M((&9@OVSA&EJ,XGF3-
MM+$5]G:YJ%$C%8.K:,'<G 8C*8N*;5<81H*O>6:QI 8.Y6UJXB"7HJ?DQ2$@
M,2G<* 3A.@A#RB^,EKPP+"PG_#*+P%Z O E3_9PBN)#E%3L:5$R<8L+#$TCT
M;:6VX(#%/Y$+-:<#ACNJS:/&S4#_ R5>NN7SDMR;<-%V0_>8JH ]!^VFJ3D
MCXB1]B)ZVWX4 M^P*_Q,^*0GY(#")@6)>2CZJ06=-#I)F1 L$_ DHV ^HZ
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M>+/->ZVP'1MW&8M+B<L!@I%*.">4OJW0Z/8,G)K[98-+L7JCLBTJ4'$HX=)
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M#5^)7G#0>ZC9_PJV]^!.=J]@;\I[_R8W-PAZ#_:Z[2J^M[0"\)%H]\6WN9%
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M1%767:+QCIGU65%0\1IG%*,7(5?VU<15?K';Q"*,\T+*=K$..0VI;087EB"
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MT"Q1[)U64+Y'7_VLYUO0OST?QR+%TZ4>F8%C?V7N'\YBLTJ7<70P'"2FB."
M%)I4@[#Q9&3_^.+$'W8.6OTVCW@S /CS$&?,@MU2XE2= $G+'LIM,NEP'@_B
M/8]XW I-,UTB(D=QJ@GL^/2BP+&@-.>6"=)"!&Z0YI'B5%L%=,1#>!VX-=B>
MWS]LM[H ]Q\TSQ5WPK\)5J<-NM1 *2]92D-DY&_6OG'*O362C,=9X\1U->F.
MCIBOGC4-SYG1Q#-WY"\R548&#/,%DGVKL5J!W(!96# &[)EY/*&/SV<23T&M
MBA 1HZB\IA' %CQWV[4>W ),H$(DY)$:%8^;%]: ]'P5*?K"D=2X YPU*2N;
MFRHS@6XF;"'F&BT3F65ILO0L8L.WB%Z03NY*)B%-O,_US"/B:'#[RA<;FV/@
M5L/3[GC-/<$-#@R*TRKBP9%^A =+A(2H0"8 RG2.HZ!IBI5#@3%S2APHAK-^
M92 6CL"Z(Z_PFBY=G5>H,Z7L,L,(/4LT.1()A8$Z(P(%/U;%Q4S)C=#'L71\
M,^HW<]\_QMEN/%<XJ),5@: _Z]EL&4 (M4C#=7_L'NX?J;'I>C,'UDJ>*_AN
MW4R=[:?1M2<R-85EKR*:D(0?:=[%P4-VT=L?.ILH;,'-B7LT\-5<Z'*6TW!J
MK0HH>=Q\T\T$^[7W5W$NFN_%B_]OF )E+O&A([J9*.SW<8BV] 4=V%G8I-G@
M4],JQPEAM(6JP&OSB./LAB\SSJY9)6W?12.E8''K TT00Y$+QT2R=-,T4X:3
M)YV-+3CA'P5JE/YEE((NB+=G3C,.F921UBZQSXI' V8#9U9:@Q@+K\-\$JA1
M<O:U*#SWNRLD38/FBKA$\<)CW-5<4LS#I84+48?@#SC_CVXQJKFD^!4T$I2
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M2W1+B',:A$-\%*;)(UI+)!#[=\?AB@QRK;)96'CL_YZ3DT(P84O4:W*.Z+R
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M^3"_]F@\ZN!PT&[WL.+JY !,UP%Z0]L?#EO];N?X]'!P<C(\[6T\CS+HXGH
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MS^,41R,@O@JKW$,6T-%M\H_J&I8X%Q]V+DS#M&CZO^PZ]#\[(K8 T1YABZT
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M#@N"" 1M:#FIE05D[(Q7;)<VA1N!&CV@WUPH)=-2)P>QV[J&"%T^00:\<T;
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M)U Q=ZC\R41PQ_)\;T;(X2.F!OQG$(,I?<WQ_R,15R:N.@EC.&S4G"U[^GR
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MKT65"? 8^DN#<^I]35X%#I*A]V_4!%JB&UW$&*7]SE-^5V ('%1T^173(:;
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MVSFKW3YLQZQV^[ =L_KQ:^>%F.I&$'%GL._F^Q+F^\(,=L*<Q*"N.PW/\JT
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M*-08\E(:P7HB,O0B3H K^ _F4_RP)[@KPR.@R]/KQ/@O3IN1E64;<QNRLOR
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MQDHT3]D6_ ^'O@;AFQ.19/.HTD_B?.3[CT%>AFX<);%1]X[L!%NMV H)MR[
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M#&C6GX7Z&+YLV^-_+8(YJ_>Y":/'^W KX?D?"VQC=O?T@.5"<.$3#;"? ,R
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M89KU;6TU5C1(3H08*KVV.OJC3-\FQG?$D3^+)TP6X;L*FC5\2#!@-],,7;T
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M#6-'*LV686V EK60HIK\\F?EJ"SMPNR:8&6D5EMO&1TM8XXGUS=BV;&GRV#
MLF<ZUKVM\9JU;VV*YG1Q@J@/ %-7A&*_<NVL[?53BU8[8.V0FO5L[8;:QQS]
M-M>7T?$V=6[1G+5=Z3B@ZA7434'%N8^MF;*@6276?F#M)*E711=5E,'PX,H4
MC_8DMF@U2.Y!J5G9UAY=ZP#^?D0]D)6@C]G*"#8#-NO8$0(XT;WZ#N7B;@[
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M%5-R.<>D[1,:_*YL VV)X)6%&@^&BBN68JIG*A<FF,Z6K1G.8Y&2@E6'OK8
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M%BH,S"FNL9=I%)19A*U(N!7V)6S3W^5)A1>@J3RBN;P<7'YS>)IO@;BN".R
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M !!UKZ&8^=OS]9(]1 A+SA-LQT[129>P5=,) \<F,DA.=:-)_QT#[/!-_P+
MEO.;3X_=X \]V>)N+F+1"(3@[LC8U'>[H*$;],*Y[X),+KS1X! $?5!0)/'L
M@:1S%LRG63:"EM@4:P4026,,N@NE375)Z\@6MT6CVD3D4W3 H/\VK61I[2--
MU!*)XH47!A=O"Q)G9*WM@VA7(#UQ$"4+DN:KVXAE@X@#=ED6B6CDLJ*R"P:&
M.T(/Z=#/2;"/+L9T%!RD.7T,D>#"2V-*2';B^\OY,F)9!5ER?S^4S1F@(XKC
M*XG#)%U?!$68IP2 J"6JJ^ZU)-A$T1"57E&XB:01#IW MXLCKQ7C]XEC+Y*'
MM$C!NM)>O8*&>'[/8GM+W3 ML2&X[%T(!Z>^K%UV+81CU"EE7?8RA*.4/#A<
M=C"$@]/I35WV,30]:=SV)=2<BKN@@ +T!O-G]YSNC3$;/Q\X>O?\\8W1JYUX
M.%37[TT U*8=A$-S_;H$0 ,I)CABUZ].R+J58<.Z.8?F-*J?*U.+37WZ5!8&
MEYW7+6,762?0?=D/![\.UEU)8A^P2C^J/H0:[P->U1H]_OAPJUQBFN<<<%<
MT1N"1;+DMB,[OYS=?? 9(X6XC7/@[KX-S8 +;=(;F%]Z<6$#8,H<,CG27MS-
MD D5N*9PE+VXE.4N'HW+2&1KXDA[<0/#D,J\,#C87ERY,+!:YU>.NA?7+!2U
MU/&:XW7WE6^,5^7JP@$C/?UW,MGHC<7"4-CA9J\Q8\BV[MWE%"]FR. /"O2<
M+]J(;[6'@;NA[*#)-'GI"=W8^./.W5/87)/1C*?B&-VU5IIAA,3-<M3N/F;-
M4(M\03A*=U^N9B@AOG/\O3Z4PTFI>/H,>\0ZF:CAUF/2WS/)0Y\2BAM?2FF9
MI 790;%]>-7P\K/RD%-I3^2(V3+%SE66+?DLRE$T6CM!N3S),:C+4&(?.Z#F
M[Y\'$!\H21S<E.2X"T@S4>SC(HDOEWE1K#9^H><J/9?DZ\WBP/@Q&H8''; S
M/B[ <:?HX K]^D-/UVOTJ!^.1WU#JB^G6D*LJ&7W7C+K4E5U&;>';C(VW7[H
MW8J/:-1FVM7Y06_0X6@Y57<KNEZS4Y3BG*0.QYRHH=H4BOL0G0*;>-##OP]A
M*L9P95O99?5O*XB2E>NRPA>"4R@2HL>ON&)IPE-S7M$V<W(2Y22-"U<&''UF
M1DGY-4F"[#Z)Y%J_9BN,E\U:@[\^;4^]+/0E](K;.D/U21R<A]&2WA^:\&%H
M;Q>0530!D:Q;.Z7E1.'CKVF29;=I,I6F<:BWP,DDQPZJ:TK$)3V92V_V)9W,
M"3W!BWSOV2F9)BDIVSUX;R2[>*,+,ZEDQ>)F8KX[M"<]!"E]LROZXJ/WD#PQ
M77=?Q.,@I;,*U3HE,9'/MZPU#N4EVTJ:*H(H9Y-R)N*9*KL@H&O_K0JV<I?Y
MC#U9Y=HG8>EV*PQ*Z:SQ[2FAL]D&G<J3%R^,F/3XD-2$_LH^KI(C3$=!R0>V
MWD[5#I/-R6X[)ZC52$#R]JC4:W> J"5:MKCZH=LXC67$JSOA6[ZXMBF[BH.E
M7[RH9%,!ZHJ/Z3Q\"0/ZLMS$%)T$_UAF.1R9<@"D#&V$/O=9<H5S>F%%29&U
M1KWTU'UP4!1WK6P.-G]&L4IZT488*%[G<FE,V!0G^ULAC_]*A=K4B^@\GP3S
M,"XJ[C$EB'IY #N/%NWA6+0?XY1X4?@'"7ZE3W1VD4YB'OXC8[*N%P:2WT@X
M>V9J&WH!>3-RLV2:W<FT4H5 O3E,1W$(Z0YQ&N'/>!B7L:K>&69CX!D<#+69
M=2N$1'W;AWP\%E%OE*3X67F^O<PUVK=G,W 8)J;T(2F:$7"-U-Z'-&A&> 7Z
M$_3\9Z,WEET3N/B=U']7':GV>#A^-_SY/23GFBVC^W"<:AK6S.'XT"AN%'1/
M&OL@Z]KM/J3E@\'3*A+ZD((/!A5FM>U#%C[@RM58.?J0<@\ZLQWZ8O0A.Y\)
MFP0.%WU(OP>#N&6'[T?J"7,7>[59K!_)*,Q1RPR<_4A#8;Q\(0X:_<A- 8$.
MUB?V(S$%!+*Y0< T7<5@'=0Q)K6M_:;-E&]O;X<#X3IDB]P(:!H[AQ?04!#?
MS%%3W=GT4%_0/[%=]%*)IF;!#I+4#57J8<JG>\8O+PVRQT5 "2J:_OBU,9?U
MU RPCACF1$DR*B$46!\<%!LA[3));\@K9_AM2E?/,JY$&H%+;KLQD%$^))))
M*#;%DY>1@&T"N@.*5]H=H?LC"W-R3]*7T&<AA&$2W!$_F96[5%6<K?//(B?S
M4:[UW78HU)9)Q)@A<#HE?CZ)MQ.-4?EV,J4/T$\R' 8CC$$RY77"EG(2TW4O
M)%3=MI=4#R+MTK<4=M!\Q2L/,F%3' ?7YKFCI%K2&,6!T2<Q%4P3RLB7,%EF
MT>J.+)*42M%*!-INF%@>XVQ!_"+5H?*TD+?O-?5[G7=[T ]TO73#N7+SXMJZ
M,E2RM+K/Z"YM0.]Z\4*XW6@[.GD/K!!XF1+E?)FR%VGQDBH/"%Y:M&AV\NJE
M02',TV?LE(0L78Y\Y>P[KG/<*/XX*714V<4;2?TPDV8):#&00WB+Q[/]R8</
MZQHO+$R]8AST](I*,5/4$H5B^H')]"0HM<1JDD5->TAS78H\:"++O;2?C91-
M0@;@6XZ4,0.=HG<B228D5D2E\I';^W>GV%TK&!BB0*7;AT208'S"RZ /3N5@
MA!IC5!^\S,%896HP?+?S;R]22ZM0:@1W:/6 ^'[H,+D!I-EI>!*)%S?^%(,$
M!3MPG9 ,QH MRQ$R)O;5X41@J-Q_>A]_H2Q*U?N0BS8ZL.$$8+30 @TG)L."
M,G@XD1?[ZT:'$Z+1O7_8<*(^I.$L6($=AB*[R"PH>J4(GC3HTJNAN-X:JA.B
M^F#]^BT  [[,*JB?!P6UN:HKB%^& -%0(5]!_\YE!9'*0K2I80.,#N ;U_7"
MN&=>]GP9):\L)C!,Z;,8HV)$0ZAA$DGLAQ%I7-\/":.4KBT6NAF<KAZI=',5
M;](+G/CT84]9I4W^V\FG4 (%YDF:AW\4HMVFOG$\8WE LB+P+RM6JC02 MH=
M']M53+?:+*0GT4F6$2"BG4XH+OUT'5%FLO_AY:ZRD_S,2],5Y;8J(@/6UQU4
MY7."[B)FP2+GI/Q?(W"2(; PLF.1I36@_[R*7^@[DVW^.-CL%7X0L-T2)1E]
M:VI.G[V'->.%),2M.-[H@['^F*:WN(1V4!><\)Y-?;AI^?B?LR.K_#DG@31,
M1ML/ \UY9;LWJ^NAZX6#9$$%B; XB*5DUYI86=,\Z\YUZ#V%4;&!'E(OSDH&
M/235NR/RLHR^'_TRLXEHK;<=:@RIXDF06':\R93*4%1JRE>WD5>^^Q:E%4FX
M)H"=46OMD(P=@A( VZV0*&U<GE=Q]6*A)*W88VX=/KT19VMK7(YKCS'=X@*5
M^ G=W'+'=5!7-S"MSWYU?1]]/S?0K%-&56M*50,*T-453)3#]&LF>ZO>QPT4
MFVU=F1<T,J[! ([@JS*]^4NZ*^)<^<B$]G8269NC7C&$&QAO4[)@#Y/J4*OD
MWTUF+[/)! V&@WM]Q"G$CUH3'!K9:[90&]-/*6+9! WQZ3WS<C*CQVZI0%(&
M"  Z#@S/F#2@GC1 I!X6J&\T]V2+@=S&*\H<NC=VX: .\8&K\/:<=]5 ;N/=
M?]ZA@SK$!W/+4XN!W,:[_[Q#!QV3PTB3PWBKPI9Y1R)Z;0</R8/W]EN8/S.?
M6,K#RV23#K3I#"8!U'HX3.P/R8G_SV68DH;&D KM.HVCP0#XB7^&4I\T\0D)
MBDSCS*.37O>%JK=.+F5\^0.A?RQ^D:)L-1@V;I,0=GT_;#2_>6G*%/050?(5
MJ>B"DZ)J46W_R?0ZB6</))U7^JEKI@R8/$7A3'FIF8R EH((>O);.=<EMCGQ
MV+L:7DWC,:70@)+S+!>+,KC,B]9.$5?Q-$GGQ71K1&EH;PQD ZHM6Q[32M51
MLPV>\V:7'H1UO]>F;T,?PDH.Q1FH[;\/X26'XIGLAL:/5,'GD4YRZ$/9DD.M
M([@O<!\JGN!P;=?+N ^E4@[%*WBA.ZS:*@XQ2^O*V8<"S[8\H#=G>6L/S3ZD
M/[+)K<V8>O_F/F1+ZH(UAI7-'*SN:^*(+RK#63J";!!^YU["@_8(MYQM.4AW
M][^YU]P69("_*K\UW)OLKOC0\*#D#/AV%@+,O8USQMU[P#9G)&Z;G!7N'?K=
M[9)=WVG.!W=U"+;YL.,1SYG@KI*@JZL#%/#!&>2N/J#C@T/,CR_X>5-4.6+D
MOK9-['J/4/0<([!,,;8 .Y$O!K3HH<Z\C4J@39,-?NKG;R_/;'O_X.8#MYV?
M##^_W+WU[7-(EP[PB[NWOWUF[#KD<#ZX>\E;XD-K=TBN9!CZT6+D^,39XJY:
MWPY;]HUSX)QR5Z??/H9!M,D@?K?\Z'%7,6&'*_O&2W!.N:NW:!\+ 4G+^:5W
M1XRIP;D3^R/G7^\.'D/^F2@".%?<599;VTY[!>QP3B%IU<="!];3'K<_1#ZZ
M^V[<"[WR-L<OYM(Q>J4L/)Q:%V:9"8=3!@.89W) E3&@X0/#J0BQOQL->D&(
M,4VZ/K&VR,Z!GAL=LHC- GHV7H%:!R'3\HX'3J7--]J-QXJ-3*:GRXSNXXPY
M7I]Z69@5:ON,,:9@Q*9D1XT[*#FWF99X5B5ICP-ZK'C\E\(MD[*?O1"4\3^F
MHZ!DDRX\0\Y*:Z\,1Z.-.UF5>Y\KNG1696[UY^1)FA9YJY4#E"I7O;BMG=S,
M"97=YTEQ5,Q24NPC(2VZUG:RZM+K:A(3.0'-!M:^^4!;:+Y:;V+ONZ^)YJN;
M!CB9E9_RJYC>C$LVT8H,:X*&^/2>>5'$>'CAI1$54>4IK96=W,%Q3?_/$$75
M!1_#C3<GPCS2VN;XM-^1@,P+H>\V+>N8^4RZFLEN1VCO/N?OEIQI_Y6\>K?/
M'A4S?;+,0]^+LI,YE;%]3W[,:?N,F0#+=<6,YSE)YVQ]:3)>"INZ0+/R#) T
MQJ#[*WV]S9=SI536;(.2,VS)/CV9;E3M]Z4Y09H_3-K>RNY?#W]+QV:C7L3T
MR1HQ??!]O@Q6HLVOZV*5+I8H(*,"[)2^EHLGL; <@Z*U?6KN6'Z'ZK'^LGVA
M:)M;H6>2SKRX\O2D#XTLB<*@5!T4_GX;3<(FT-N+-FJEFMYO1YE8!V']&RXA
M%Z6^L3\^2LXJIEE17#/\[VC4*4_H>@L[F:5('";I34*E:N4S5=C.-@6:1ZND
MI74J5$]883N,M<+$B<FTICU4K&IQ6\0T NTTIUSEK5#QX)OH0-$8<D5$,P^"
M[,F);K$!3+/NP<R3U @/(71K6T<0:^=+'U(YM8)8/\C[D(L)#')+G]N''$I&
MV(2+TUVO%C-LPE7I8&XBF:9K@T:OE>*3-P:N'?!:5VFTZA>[3(N$#U._Y]0:
ML-W\.SL60?2DCSO^LIVJ#3:[UN[K?(!>NH>9!I7RS+3L_,"YLZW,PP^'1F0/
M0$=MZFHU*/[ -.8NYZ([V!(R=3=V,#G=P7BE<X%P/D<='I/6_A4NQZ8<C$5;
M3HPN1ZP@+1N%6XC+$2Z'.[6W73'1XU^T;O.=6055C]F^Q!0<A#DB13]Z.((;
MK)&8L"KN?/E&N:,*T/GN&^6)P'Q?<>1[QQ6".PX'.W#<22.G5_T)'!3J>+9\
MS/!#!T%3I+2D-R1(4[.UZ92B15[=A[.X2!A/P9?)+UDH&=V]/HMS=B;@:D,:
M/33BP$N#['%!SQ="VW__\8LZS K4UXHKB>I3/WS\4>Y; NMHD\9:=NRSE-!I
M+L,'%<3)>J"$I>V0!%D"N\U1:.>9;"Z3](:\UO9=2O?H,JZ2\"O<>LS&L+)N
M3L-DT; [RE>SK*F=("\O>UX7Y;F*7Q+Z7&59V(2NFM*VUBFI7LPZ(M;-4(+T
M6&V0R;1*<3A)[\+9L\IU3-[>&>J5'OBJ'KU'\/?/EM:PZ!.;-*!7L?Q6 /;L
MDLI%F+:BL=G/F;4P6>89N_WI(6ZR(.K=D()_V9E6YL2Z"[/?3TGL/U/I\W?U
MXM9U&Q 6X]W:%9K5AC#5P:_KY@@63=R8JH<3"+B6_1,40KV+$QBT<7"J'KU'
M@+>O#YINP1+5],62S$FZPT\U_9I>^"'5?4LET.?P=?9Z U%=-,2G]S'VRD*I
M9%-(%D2^J!\.FJJ^I/=6&M%K!5^*2DD2+.I>.$C6%319)E>6'DM[\"N[X&*X
M],*T\!2:3'=+@VX')QMWQ\56\TJ@Q[SR=%5TP<!P06^D(*!;5L3HW3_JYJOU
M<(Y@7]OY^.RH\Z$9#3' A",7;S[),GIH5K6.Z;_H2<H,,;&_*DJU".MO"#)8
MBG0A%D?'1"O(Q&P1K6AT*V@W.Y=>B,O2TRIC'_929HWXGY!$P4/RE65!W#T/
M6@S0(<W+!96_O5R8)$#3 ^-<$I'$"H'Z.1.M6*+G.!# ,>[N&C:%I*SMYAJ6
MOR81W93L:FLY4UL#N(*/"2N7*2'K$J2&Z(3=QP13)</&!%,'3##E_2-)UXH:
ME=E:T!"'WC=]0JQ&FS%MES1MES>GKY'&Q"J7K;Q]KZFW98^]26+F+R#WK6@V
M^)82M=FAOE;ZG9<QEE N;HM&-17WYV$^U]!;:V5E13;KIMXN4_^9%3HL1!#Y
M,@7TLD0=4Q60V\@K'9[6]5[7BX[Y9OK/XC<BN.^8KNR0Z<HL44@%XLJ]G#O+
MJ2E6],! 4(5AOY!XR>K<*6D7MT6AVB>QEX8)D.G2YIBTT\/K)4R66;2Z(XLD
MI0]($ 9I-TPLCW%&W\#A-"2!4K*1MT>AOA01U!0WVHPI$3M+B7@2!P:T[+3O
M6Y)&&06J0(EK5<)88,_NJ90F=P7T0CD%UO?QNBS0^N6@D(O4?5!1;.XZ /6-
MME96QD.R*';E^MTJWT.2EHBI3H-$_MQ0-L6@N>Z[P9PZJE<%TT7'F4R_J^F$
M@R,E7L0H^I5>L*S \B3FIEG9"M;ULK*6*P?HC+&)!!,_3^AD/[S2?;/Z&TF3
MFU!U><,[VZ$U#7.Z,*<979P[84C"^T+3 S5BLE7PDB#R>VM'XT? <O1DZBVC
M7 Q?&T/32!JA"OAP";%BOFT!_OMG%R#KPYP!03J;A%<&IQ"O$^Y>IJ(-=&#L
M0Z.6K%A'P>&ZETMO'[CRL-,-XN_PDZXJ#S!@2,A6\AL-I_!W-NPPZP"\&P=;
MZ\G?-HTKH==MTBYA-IOREI#=F.@6Y]JN)T$#L2XJ@Y_E^"?;6%7!2LF!S^YE
M<ML+HC"Y^W?NBAXMYW%;#\NANI?;<1^HHB(+W[F\9/61)1N8$&LZ/W'[#WK=
MWBP\@$\[5J9@X)VCCUEIWCXJIN'?0&/=!H5H.-9M*(XD_+E4O7#DGJB--.YR
MKS_\V00MVCUQ]N4MHW7/W-RK,NL67[A.)R(<<T6R*7(O'3<44=.AG(LO[B7O
M!_L'-=2\4J<N/GD]ARKRON;SZ%Y-C[WF4>[@QB&[:Z@P@JST ^5HW3UZA*YP
MFQ4KS<K(-R:2<D!<:<O,BXIK!P!N34.MBM629<+LE,Y7<;( MID4U/FZ3"T1
MZ]+X.E]LJ25N>,"'\R646G+ 9IH(YRLHF?.(*]LTJ8N<+XUTV/4A3*SA?*FD
M?=:'-E&7\Z6/VJ-7)Z-$KV[4T=;0^6)RW.X9#_><<$G<*WZQZ,X0Z_RP\6N4
M'.AL*U/!<+B#$0B53IN-;-KH=:>[>O< T[=S_(.1\PP2PW/T@Y'TI(D!.-;!
M26SZ=%<<_& $-E F-N[9-2QYS3!K'F?#X,2W]JE%.5,&*.%I(M0X]L&)>/"\
MAIP)@Q/\X$GU.!,&(P!"5L)VYD3.AL'(@;O.=;KDV)P)@Q,'%;FY.&HDP1!6
M1Q:>P$!='=;UXM/M<!J&W_:DVG0[7BA"4WM21[H=;DD^B9[4B3;#K*J(C5?_
MN<O9%;LC5Y!_&"1D4>A6!?A/@P0L\MZM /]YD(#U@;<5_!^_%?@[6_O3QT%"
M5X?(K+$/4UC3I*]:@\>3SF"^Z: L7 W<38]%=('<$*8H39?(B5;@?HH/5>]/
MJDJI)<AU(2Q)__W'+[M^INYIEZ"0ZPYU0KP_?/QQUV48-L4_'W.X].G^>_EC
M\[<&#\A;3N* ;.H9-[CP^OKZP:.W9AC[2;KXX"?SX]Q[HP^_^>JXX 9S7HF2
M;)F2^^6<-?R#9)5#SVHR?7AF65KH2S%8^GF5MN4DBI)79A@_B8,[DI'TA9Q1
MU#,*BV3O$/*.;0BB+]PJOTR^3&-U[2A-)XS\:762'E(O(#57$S 624<KF<E*
MA]'LUEN5P;?T2_2+MVQ%EY;3@I%;1)KT['.-+A<KHTCFL; !7Q4B)I6SZ.Z>
MI=Y<O,3T[2UE94]>0G;CWI'(8];9!+*J +VL4'='GNCPV=FSE\[H/_W?,WKT
MK;W^%'P#]<,X:9BRNWA;;$Z.C!_FV:D7L9\DAPVLKWNHREF@:^0LR7+ZNSJ]
M9KNQW$-]3MC-S2P\K8#6NCN(397L&]1U@)B0*HRK2=M.DV"$:],9%U<<_+^E
M%X735>'Q7A[A7'C>,;))(4+'<1FM*"]XNS'&S"2VWJPFYTKCV0YX=;@<U=$6
MOX%DYW)8A\WI%SV>78[LV&OJU8\@_, .6/X:LWNW/O$PIN&??"!=;+=L<"+[
MS4YX_-XBBI@-H)M_@*'S';%3^<!V.;K^@/R0/LU=CL6WPA^P\LOEZ/P#KI2Z
M.L/E<'U[BP.J<T</S-<:QO=Z9.I\NQQV"-@;MZF08^K$Z8#%\>&97,T7GI^+
MXJS7""?QKVF29<4C=;<5BN6QHJ+(0DSGXCKQXAI).J40N#N*-7*'PP7WSY0%
MD#6=W,!Q0W)3%+4N5BQ*]5?W19:'<W;OU[00<IL2L.>W;;\>+<.'F?%[_YD*
M9!'AIW9QE!7G&#W/-AF$^'RJ-,=M1W//WC%,"^H0[6V6+5,'4OF8RAU-;\26
M>W; .I]]^*F3D_J@X]D'O[&JRUU5CMUE4!<S\=4W S.(@E_=>XHH ] [6.!
MUQJ(/A@-V]G+^Z":-#":0M^MZ-I(%\R&YH<$FB9N,Y>/&9DNH^LB&XH5E_%D
MOECF)+WXYS)<%-&:<7#F+<*\3,-RGTSS5R]5%-\V&V H:H+VSYW+94K7"IW2
MXFA_8_]2*U\4'3#HOR9>1IZ3*+B:+]+DA33*? D!J'J,BIJ21UOU1H1\;+9!
MH;)9YT5,9:,-!I6W:4(EKWQU&WG%:;0YF78KQ6[1#NGI%"+AM6"(33B&4RAU
M9AI 1Z?PL+6DU-5!>@X.$9)CO)2R]7:8RM3$D)X8B'9*CVW1S?^.1IWR!JFW
MP#6:R%<MR$JBZ3YJDFPZVAK<^O5W(NA(<XD'BM=R=RQPV\$6+CB([2RZ;3Y@
MPTH[UH'NS#[HV"S#%XOC^+JV/1BQ*]EQST<SU5$?[&R&;(#H=/I@5VL)6ZD*
M<MRB)A66O\4ZO0[6RX(BDM3IQ8J#;&'T@STR!F7GA$,V$FW1K9H'8<5N9F1P
M5EPT\]4-R5DR?XJ/):RJ4EH75>LR*BH5@46%+''J9:%?1/A&]+\"UN>6I$5#
M#/?Q@@PJQ-T3GQ6D"$EV,9T2/Y_$!:$7'KWVX]F&Q")B5:(5:#64%5?F]=!U
M9LHTJH .G=$DTJEH&F-HA[9GZN0IRU//E[FJ2YN[0/O6=@-"V.XU%)ONL"R*
M],B]H@?SG+!M(YG99AMT*D]>O# J_)O8?3!/XOL\\7]G#PR29L6J@^  C.(V
M4O5N-!\'QZI2%>LM"#I+XA=*$ L+O8J#95710&I6 73%Q[0NR<.$FK(4)Z_D
M $*F'  #WV^$U5L@P0EEN#=KBFFUVHNP2Z/E8(=2'<,E(UZ%62ZS#%!!;,8@
MO7"$GJ8&EA=<*YBZ^PX'*%-TLFNC\%!3?NB#]M8$GLEAW@<5;GOLLLL97X';
MX8*&B)I],&"9,*"=-J,/UJMNEL%&P.F#GMR$!5HU +H:W3+@MI(M?EY!7%\>
M-'WQ"25[][BZ2=C6C98!*P7^\$Q*I7$1Y3&95BIF3'4QHSK8/63?2I(OZ9PU
M*-Y9P7,6_"5Y3]D9&R7KQ'Z4GZ[$ R@<'+O\8@\Y*%/V6Q_>'=[<>'.U/[*V
MVX"P(#E6E^^*/*32%:L'J'3Y%;<=#0LN&A;$]2R%TRILZ@+-ROTD:=Q3NI%V
M?U$1DU&1L9K=3VO7AGP%NL&AO1U%IIPF>/]!HT,+]ZGKOI27DK I2L@,H4_;
MT,\K2A[IXRN[NW]4!]$H^R#G(MM/X 2F*+/Q$10^L?F:" H;;D/=:8<;@'.
M=UXCS8=66,:WR( \D!WCF]NA/K:?PI+$:U8.J %:A0\Q#9:T:'TP6$(?_,T:
MU#O70Q_LDVV@:N0>? /EMQEIJU( -,*#)(]7EW J[N7]8#IQC0+VI5K#4,<I
MT>?AVX=AJ]90(=$,,@*_B?&G'+2V#\&,ONP 8XV'W)7&F?2";7)/6GR4N^LD
MYP!C#O+NZV,H7%>,%E_DIK%S0^80^#JHF/:=^PXD64;R(D5TZ#V%$:7Q*_'8
M'X*3_-(+4Y8>E$SB.X8OK5Q_#!-J6K+Y%H1N2*HA4,>5Z?NAV'R][+G( I$]
MLP7TXD7,EU1 I<P.#.Z/@>Z<I)0DMOG6JZIP2HI]9;$:7:^A6+GW2(FZGM^=
M71NR/!KEOJUM5MJ \B]M[-T=E=)V%E6KW^@KEU2F$WOCHW+G=+7YYU]"DM+;
M]GEU35Y(I# W SLCXZKF@*F%+U/RSR6)?9&?B$E/5$17,155LH*]G]09D!4]
M7$'PQ1C!%Q<0B%:&TKX/Z3DX1$B^"B+*LMT#RAB=?(QO J5+L[FY36''AZKK
MZ)]8/?>YU&+^K )V1K2C0=^+#=4]_%F&'NLD-?UW\DIH9/&S)V /V/3?^30
M5CB^Y=<!/D'/N?X8(ZR_< =@A^B$)T:/R_Z8$@[%*Z6" =VN +2'FRE,A)R
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M'G<? 63AXZ^6THQMTX6B-9<LPBA-/OUV_]U_W<LEI6#R>RGZ__TW]38(M&$
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MLM>1E$H2X8NDHJ;@0JFH2%U50^0>4<H"CPH)LQFXWX797$($U_/3SGC93M.
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MRVZ>[G.V^,-8.E3_('9M^L14F/A83,O.+>2)DK=2(J[$H,)B& HWQN+BXF!
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ME1 "F6)!K=V\1@#3Z4[;TSCNSZ8S_;U/6EF=CA50)Q050 3IPRP-^ *&8'O
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ME*K &:F PV9!/H&WW;4O2TO(SKV;:0W(2S63%:BM/P)Y'VBZ=G"?:C/LHL<
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M.79OA0X/QJ. AF>1R_<G?=,]%;62VF9((7)'#?*[% M=H1>(3!3Q@,BIFT/
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M!3R.&OE.9_WQ%$3N0V&A>WI%@T,=0$-@!1!"[V8 F_';&1B$X,V >6!X>J!
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MAVB)SC*P9*C:Y+8>*>25-(4&U:2"XKKU,]Q=ZS-+OJION&Y]KL0L:2ZQ%C?
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M)6):!LLUL3= [I>-^J8R_GIQ;?-K)[=Y]HC$:)AN>,/H4IED4<2+O1:!D[<
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M.S57W-]3CF9Y*Q?O*)>SH-KSM^#G,9P:SX:#DZ'N2GN3M#!7V2L-2*$"V>F
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M3;*#KN/]IS8^C-N%[\_-B_^UHEKFBY#YZ5$()56IL"UV"<A $R^ 7!@B'*Q
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MRWWXC1:KE&N,\C'3@\#Y1^A54Z<:;Z<M9*-RJ\&M=0(3>LGEQ6:8K(I:E@@
M9;L')+S O'*9(?'C%E^'\9'J##*6T&CDN'5D[#.WXZ<HD]A?ZG9;NE#G^AA8
MSLIB<F;^2@U3(LYW*]5Y5+IHVWO)6LV$Q,"NTIY)4I)$+!.VF9SRB-^T/;QI
M?6;7QDX9R_B=*ZBQ_,\1&Y5V0=\NU"M#&#^%!36$^S2PRPFB?B/#49OYL?'
MT[Z?1;<BY)YX][VPR=W%S%R5WT;R<-S]6?5Z@FZ(2]#@V8D;Z-#[X;+M%0 ^
M?';FAC_@;K@.>MPYF8:-_=,PO5W'$)O\[X2#'PN+:*=G,VQ$&_<^>!WL?&^#
M2WOA@L%;V04?1VSPO/&->@-CB"@>]KCZGP.>!9G/P0.U&#Q(J$MJM8 K&F4-
M7$08W=[5.*CONE-C9]NHY%:*=.83]UX'_;(][3W"WY82I71LW9$:DC5;(^DA
ME@L2=);L,&3I=(W79-#9(YJS;V]+^M^MJ$O[)*O1]AS^[KD<ZOIS8U4BC;#
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M8[SOF82*Q\Z9?DQ7&Q-!^_ES;3^.4" PA]K)U&A_OT*J.8.M1.+[(,8*'L1
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M+^0[J"^D,Q).L:CSW"12OY;UL,Z0KZTODQ RY63)N2>DF8#0R;2$%&0ZSUW
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MYRWP4Z):D4XY<<!@1WOZV'@3:,K2:6/CY6\PPA\E.=IZOJF]!<;"'U%6SA.
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MNUS]%:*T2LGF<*&S@A4.8Y"L67<<C 'VZ!,:'ZTAK[EZ-.<D+0K[$/V3U ;
M>G%NB;./(H4)H[X\>\&=-7?:?3FZOWG/X2;;"!TW[3%&OAQF-=/K7!"#Z\CS
M 3G;^7XZG>DV4%VN5ECO2H2HML?8H#*_X@$!.D_@II))R]4^C!SR%2?;YJLT
M7"I_"T^."*?8X.&&-+T1"#[Z=VO4"7=W<X05"D$>7'_M)1R-0##0-KUY(4&L
M=F(]%'W9-?\BVA#J"UC)LO%(X&Q>%9$TJ5RN&C0*WX_"1"O\$((*S^-IEF#K
ML_"*%E<Q5^![_B=N\WJUR2/B*R]+U9.MO;E6N,H>4!B$Y#Z/;B?!Q\0?/U>Z
M5XL.D-ZSM1K<B:ZU7(]C4KC3&]02X).;04T&W(OL,GP3"9\3."=;26-JYX'K
M(72*:*E:5(/"Z%Y)5WLEP!0N=%R/HQOV(784SND4:F?"I1-CU:\>NUM025S8
M@\JP.P*1X+Y\.GV7A++)0!C,='HPZ2,I#SR;3D,FJ3:A&%#A:AGDP8*M"KZC
M $U:H]>*,Z"8N9D=<YCCH!L'2'&<M,HOCR*D0$U7V5<-0*=835+;5[L<I2#-
M^KXX:IXBY;KJKY6S?NR^OY2;K2ZX97*^+Y$"/((K(>=["BG PXYZJY#Y-&%D
MFI&P%1Y3EC,ZL2(57I^GC!>-I:K@^&'"<#!U(/>KJG3CZ;LR9BHQ!ZS8?=[M
MR7[6/ TL<,MS-N(:#G8VB2@,7Z2X3!6?[N=4C>P62* ?D9O8=,*7.^?Q5)HV
M,D*EFUCLY5_0?>&FYY,?EMT$92]]@H+BIEM=/_:;9PU,1?2J1Y/76HU6QA%U
M[KEY&RV-AVZYM13 GD@]JSPPS6P#U?Y![0O?)U$Z8;R^)1="7A*@^VV MS,>
M_\.'8V%ZCMI<,P6O:KRN0>*35[0F?;4 ?E_I#?GX /Y3NF.%NJM.M9%2L C^
MF17-F-$Y3*[ =PKI=8(W3Q87(@4)T@STUK#,Y1ULO XO#"[B$V^+S<.H$6=!
MOH]?P_21QEN< R_%'XX<@&'+'[0TFW*]N/T91JCZ F* U:'0BY;?L=F.'L/M
M9;@)"TE'OPL6>:I3S= 9PBUF?H./TBS%H$1\V'A#S92WP2NO270!>N13T!UD
ML4Q0?K2J5'%K#K1";_M3Y!&[-VH$E K/0O98^^6-ONSNX_#WK!EP)#A+U.;:
MYXJHD,*]SAUNBW:-^D3,P4:D6GOM3O!"4[;QAAZ #E:5(.XP8\\_>_8?N0GH
MO%'V"WQ)/MZ]@?;I;<;/>DFR(UEU>5X M@ ?09$X< (W6QCSJT0,67%<"+A1
MDDU*79X:,X"[<OZHN*M"3\M<%YHNJLLF?Z%1\7N'GX(>813@WQ#PL_PV./%(
MR.BIM]/F6K;<.'FGYDVI-^??W5T2KM=<37#HJN-$PL2K']?[/O72O M?@M(;
M@+_%A+B_=^0O:I)+--\^=^?8+"Z.125F&L/'0'N8Y+GABJ17H^U3WO0KWJ;Y
MC0K/M])C ?O\?2..,A*]@"E3XJ<UP9CNSE[_?X#'U>,%,^RCJF3-,H?;I_T&
M!&"S+5V!(0S.XD!Y<_#FCHHK<C1K?L3\V6/@;)LEV*9%(- \(M@S[7/$*#HN
M&&B?WOO8*YJU@X X-Y3Q9\VSPTUQ*WL>QB3;_P2B%'U-(.+KA;SQ=HM3UWK#
M<L7H)\1E1G'Z.,I9-XCL_E'&:^_E7"S2_$SZV%V3Z_UPZT4%"-C X:FJBI.,
MT%9^6'Q'9GN F6=FY,;T6QB3N+.OF4>2<0 H[1^F0UDRP\;W\A5O#W2))1%
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ME^R>YWU7,5*!FK5;.C<?):$*$PY&$[\RMF#TP:CA=MKA#^Z_+Q'PWZWAT_L
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M\,%# /_'_P=02P$"% ,4    " "&,01) _5DR2J@ 0#.;@X $0
M    @ $     86UR;BTR,#$V,#8S,"YX;6Q02P$"% ,4    " "&,01)<O=H
M[SX3  "XQ0  $0              @ %9H $ 86UR;BTR,#$V,#8S,"YX<V10
M2P$"% ,4    " "&,01)Q'2F%*H0   'VP  %0              @ '&LP$
M86UR;BTR,#$V,#8S,%]C86PN>&UL4$L! A0#%     @ AC$$27^7_R^)30
MWGD% !4              ( !H\0! &%M<FXM,C Q-C V,S!?9&5F+GAM;%!+
M 0(4 Q0    ( (8Q!$GR7?MKG(H  *A1!P 5              "  5\2 @!A
M;7)N+3(P,38P-C,P7VQA8BYX;6Q02P$"% ,4    " "&,01)X-VLM@)0  #H
M.08 %0              @ $NG0( 86UR;BTR,#$V,#8S,%]P<F4N>&UL4$L%
3!@     &  8 B@$  &/M @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
